AADI,"{'Contentsour', 'LLC', 'Aadi Bioscience', 'Physician Payments Sunshine Act', 'Condensed Consolidated Statements of Operations and Comprehensive LossRevenueProduct Sales', 'Mirati Therapeutics, Inc. (&', 'Contractual Obligations', 'Aerpio Pharmaceuticals', 'Hedging &#8211', 'Contracts with Customers (&#', 'The BMS License Agreement', 'Aerpio 32Table of Contentsimmediately', 'EMA', 'non-European Union', 'Restricted Stock Unit Award Agreement', 'ContentsOther', 'this Quarterly Report on Form 10-Q', 'Bioscience, Inc. 2023', 'FYARRO', 'ActivitiesOur', 'Principal Executive Officer Pursuant', 'BioScience', 'BMS License AgreementWe', 'the Sarbanes-Oxley Act of', 'NSCLC', 'FDA&#8217;s Oncology Center of Excellence', 'ProceduresUnder', 'SOX', 'The Nasdaq Stock Market LLC', 'the Securities Exchange Act', 'Aspen Merger Subsidiary, Inc.', 'NOL', 'NetOther', 'COVID-19', 'Principal Financial Officer Pursuant', 'the Aadi Bioscience', 'the Pacific Palisades Lease', 'FASB', 'Hong Kong Special Administration Region', 'Anti-Kickback Statute', 'EOC Pharma', 'Medicaid', 'Medicare', 'Congress', 'the Securities and Exchange Commission', 'the EOC License Agreement', 'The Gossamer License Agreement', 'GDPR', 'ContentsComparison', 'FDA', 'the CVR Agreement', 'the Federal Deposit Insurance Corporation', 'ContentsThe', 'Risks Related', 'HIPAA', 'REMS', 'Silicon Valley Bank', 'Company', 'USPTO', 'Adopted Pursuant to Section 302', 'Concentration of Credit RiskFinancial', 'Cowen', 'PartiesWe', 'the Delaware General Corporation Law', 'ContentsThere', 'ASU', 'Significant Accounting Policies Basis of PresentationThe', 'CMS', 'BMS', 'Celgene Corporation', '2023).10.2#Executive Employment Agreement', 'License AgreementsBristol Myers Squibb Company License AgreementOn', 'Gossamer Bio, Inc.', 'FCPA', 'the U.S. Department of Health and Human Services', 'NetOur', 'Aadi Bioscience, Inc.', 'the International Chamber of Commerce&#8217;s International Court of Arbitration', 'Contentscommon', 'Bristol Myers Squibb Company', 'Aadi Subsidiary, Inc.', 'the Children&#8217;s Health Insurance Program', 'NDA', 'Share-Based Compensation The Company', 'ContentsOur', 'the Fresenius Agreement', 'DOJ', 'TSC1 &amp', 'NetFYARRO', 'the Sarbanes-Oxley Act', 'the General Data Protection Regulation', 'us;&#8226;a', 'the EOC Territory', 'PGR', 'Cowen and Company', 'Form S-3', 'treasury', 'the Form S-3', 'the BMS License Agreement', 'this Quarterly Report', 'Contracts', 'Bristol Myers Squibb Company (&#8220;BMS&#8221', 'FDA&#8217;s', 'the &#8220;Shelf Registration', 'European Union', 'U.S. Securities and Exchange Commission', 'the Federal Food, Drug and Cosmetic Act', 'LDTs', 'Medicaid Services', 'Pre-Funded Warrants', 'November&#160;8', 'Healthcare', 'United', 'SEC', 'the Shelf Registration Statement', 'Administrative ExpensesSelling', 'The EOC License Agreement', 'the Gossamer License Agreement', 'EOC', 'ContentsPatent', 'the Centers for Medicare &', 'ASC Topic', 'the European Union'}"
ABCL,"{'Bruker Cellular', 'Schrader', 'OverviewWe', 'the University of British Columbia', 'Form S-3', 'RevenueThe', 'BCBCA', 'Critical Accounting Policies', 'this Quarterly Report', 'the International Data Transfer Agreement and International Data', 'Adopted Pursuant to Section 906', 'Dayhu JV Loan', 'XBRL Taxonomy Extension Definition', 'the U.S. Internal Revenue Service', 'the &', 'FCPA', 'InformationDuring', 'this Quarterly Report on Form 10-Q to &#8220;AbCellera,&#8221', 'the EU Commission', 'the Governments of Canada', 'EEA', 'this Quarterly Report on Form 10-Q', 'GDPR', 'Strategic Innovation Fund', ': &', 'Passive Foreign Investment Company', 'Lilly', 'EU', 'FDA', 'the &#', 'the Interactive Data File', 'Dayhu Investments', 'GMP', ': &#', 'Principal Executive Officer Pursuant', 'Court', 'AbCellera Biologics Inc.', 'Percent Shareholders', 'the Government of Canada', 'the Sarbanes-Oxley Act of', 'Columbia) Ltd.', 'Bruker Cellular Analysis', 'Upfront', 'the Coronavirus Treatment Acceleration Program', 'U.S. Treasury Regulations', 'Registrant', 'HIPAA', 'Delaware General Corporation Law', 'September&#160;30', 'SEC', 'the Minister of Industry', 'SIF', 'Company', 'the Securities Exchange Act', 'the Strategic Innovation Fund', 'Item 408 of', 'September&#160;30, 2023', 'the Government of British Columbia', 'COVID-19', 'Regulation S-K).72Item 6', 'Adopted Pursuant to Section 302', 'Biologics Inc.', 'Principal Financial Officer Pursuant', 'the Sarbanes-Oxley Act', 'Eli Lilly and Company', 'CapitalAccumulated', 'F', 'the California Consumer Privacy Act', 'the Ministry of Jobs, Economic Development and Innovation'}"
ABEO,
ABIO,"{'API', 'Treasury Regulations', 'Good Laboratory Practices', 'The Funicular Fund', 'HF', 'U.S. Department of Justice', 'the Nasdaq Capital Market; &#x2022;general', 'EEA', 'EU', 'GCP;\\n  &#x2022;unforeseen', 'Indicate', 'care;\\n  &#x2022;Reduction', 'and\\n  &#x2022;an', 'the University Medical Center Mainz', 'COVID-19', 'Swiss-U.S. Privacy Shield', '\\n  &#x2022;the board', 'or\\n  &#x2022;on', 'and\\n  &#x2022;the FDA', 'x2022;a court', 'x2022;if', 'Recent Accounting PronouncementsThe Company', 'EF &#x2265', 'Medicaid', 'Medicare', '\\n  &#x2022;general', 'all;\\n  &#x2022;long', 'FDA', '\\n  &#x2022;collaborations', 'and\\n  &#', 'the World Health Organization', ': &#x2022;the', 'Scientific', 'Company', 'GLP', 'the Nasdaq Capital Market', 'operations;\\n  &#', 'CCPA', '\\n  &#x2022;the', 'the Sales Agreement', 'LabCorp', '\\n  &#x2022;infringement', 'AF', 'Cable Car Capital', '\\n  &#', 'Our Business and Financial Condition \\n', '\\n  &#x2022;collaborators', 'NDA', 'the Center for Thrombosis and Hemostasis', '\\n  &#x2022;our', 'Form S-3', 'Phase', 'operations;\\n  &#x2022;spend', 'bradycardia;\\n  &#x2022;Reduction', '\\n  &#x2022;pursue', 'SPA', 'health care &#', 'Good Clinical Practices', '\\n  &#x2022;delays', 'ROU', 'ARCA', 'x2022;refuse', 'AF;\\n  &#x2022;One', 'products;\\n  &#x2022;seize', 'us;\\n  &#x2022;suspend', '\\n  &#x2022;obtain', 'treatment;\\n  &#x2022;difficulty', 'CTH', 'Medtronic', 'products;\\n  &#x2022;assume', '\\n  &#x2022;successfully', 'the University of Colorado', 'the University Medical Center of Johannes', 'GCP', 'prosecutions;\\n  &#x2022;close', 'letters;\\n  &#x2022;suspend', 'or\\n  &#x2022;merge', 'Item 408 of Regulation S-K. \\n', 'the European Union-U.S.'}"
ABOS,"{'agreements$1,534&#160;$1,077&#160;Prepaid insurance1,216&#160;1,106&#160;Dues', 'Condensed Financial Statements', 'BofA Securities, Inc.', 'LLC', 'CRO', 'Company, Incorporated', 'Form S-3', 'the Wall Street Journal', 'the Loan Agreement', 'this Quarterly Report on Form 10-Q.', 'Loan Agreement', 'Ankura Trust Company', 'the SEC.29Table of ContentsItem 6', 'ATM', 'the Securities and Exchange Commission', 'Development ExpensesResearch', ': &', 'Company, Incorporated (&#8220;Stifel&#8221', 'Halozyme, Inc. (&#8220;Halozyme&#8221;).Under', 'ContentsAcumen Pharmaceuticals', 'Lonza Sales AG', 'ContentsOperating Activities Net', 'BofA Securities, Inc. (&#8220;BofA&#8221', 'the Public Company Accounting Oversight Board', 'ACU193', 'Loan', 'Lenders', 'Indicate', 'the Halozyme License Agreement', 'Stifel, Nicolaus &amp', 'SEC', 'Common Stock', 'Company', 'Financial Information', 'Restated Certificate of Incorporation', 'Halozyme, Inc.', 'the Securities Exchange Act', 'Swiss Francs', 'the Prime Rate', 'the heading &#8220;Special Note Regarding Forward-Looking', 'November&#160;1', 'Halozyme', 'IPO', 'November&#160;10', 'Restated Bylaws', ': &#8226;the', 'the Registration Statement'}"
ABSI,"{'LLC', 'Cowen and Company', 'Form S-3', 'TrademarksThis Quarterly Report on Form 10-Q', 'this Quarterly Report', 'The Shelf Registration Statement', 'this Quarterly Report on Form 10-Q.', 'CLD Active Programs', 'the Securities and Exchange Commission', 'PhaseBio', 'the U.S. Food and Drug Administration', 'FDA', 'the Public Company Accounting Oversight Board', 'all Active Programs', 'Change% ChangeRevenuesTechnology development revenue$5,380&#160;$3,094&#160;$2,286&#160;74&#160;%Collaboration', 'this Quarterly Report on Form 10-Q to &#8220;Absci,&#8221', 'the Form S-1', 'development$35,798&#160;$47,593&#160;$(11,795)(25)%Selling', 'the Sarbanes-Oxley Act of', 'Registrant', 'OperationsThe', 'Form S-1', 'Goodwill', 'SEC', 'the Shelf Registration Statement', 'Integrated Drug Creation', 'Absci Corporation', 'Company', 'Change% ChangeRevenuesTechnology development revenue$744&#160;$2,004&#160;$(1,260)(63)%Collaboration', 'the Securities Exchange Act', 'Cumulative', 'SFJ Pharmaceuticals, Inc.', 'the Sarbanes-Oxley Act', 'Equity Securities', 'IPO', 'Capital', 'netGoodwill'}"
ABUS,"{'ASC', 'MaximumMember2023', 'RNA', 'OMERS.Genevant Sciences, Ltd.', 'NA', 'EMA', 'AssemblyBiosciencesIncMember2023-01-012023-09-300001447028abus', 'Financial Instruments', 'Jefferies LLC', 'OtherMilestoneandRoyaltyPaymentsMember2023', 'FairValueInputsLevel1Member2022-12-310001447028us-gaap', 'X-Chem', 'the &#', 'Acuitas', 'DEL', 'AssemblyBiosciencesIncMember2022-07-012022-09-300001447028abus', 'the Cross-License Agreement', 'liabilities&#8212;&#160;6&#160;Total', 'Genevant Sciences Ltd.', 'Court', 'NonCashRoyaltyMember2022-01-012022-09-3000014470282023-07-012023-09-3000014470282022-07-012022-09-3000014470282022-01-012022-09-30iso4217:USDxbrli:', 'Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;).ONPATTRO', 'ArbutusPlansMember2022-07-012022-09-300001447028abus', 'The Company and Assembly', 'the Financial Accounting Standards Board', 'X-Chem, Inc. (&', 'COVID-19', 'Acuitas Therapeutics, Inc. (', 'the Share Purchase Agreement', 'loss$(19,520)$(18,474)(51,933)(50,193)See', 'the LNP License Agreement', 'Roivant Sciences Ltd.', 'USTreasuryBillSecuritiesMember2023', 'QiluPharmaceuticalCoLTDMember2021', 'InvestmentsInMarketableSecuritiesNoncurrentMemberabus', 'the Open Market Sale Agreement3,832,717&#160;8,973&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;8,973&#160;Issuance', 'NonCashRoyaltyMember2022', 'Alnylam', 'ONPATTROGlobalNetSalesMember2023-01-012023-09-300001447028abus', 'CommonStockMemberabus', 'ArbutusInc', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'the Securities and Exchange Commission', 'OMERS', 'LNP', 'FDA', 'Oct2020RegistrationStmtMember2023-10-220001447028us-gaap', 'Prospectus Supplement', 'Alnylam LNP', 'InvestmentsInMarketableSecuritiesCurrentMember2023-09-300001447028abus', 'InvestmentsInMarketableSecuritiesNoncurrentMember2022-12-310001447028abus', 'the Ontario Municipal Employees Retirement System', 'the American Society of Clinical Oncology', 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR', 'Company', 'SharesShare', 'LicenseMember2023-01-012023-09-300001447028abus', 'nsp5', 'Assembly', 'AssemblyBiosciencesIncMember2023-07-012023-09-300001447028abus', 'Arbutus Biopharma, Inc.', 'Purchase Agreement', 'OVERVIEWArbutus Biopharma Corporation', 'X-Chem, Inc.', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001447028us-gaap', 'October2021ProspectusSupplementMemberabus', 'ArbutusPlansMember2022-01-012022-09-300001447028us-gaap', 'HBV', 'CandidatesOur', 'the Sale Agreement', 'Enantigen Therapeutics, Inc. (&#8220;Enantigen&#8221', 'USCorporateBondsMember2023', 'Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221', 'Peg-IFN&#945;-2a', 'Proteros', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001447028us-gaap', 'USTreasuryBillSecuritiesMember2022-12-310001447028abus', 'MinimumMemberabus', 'MaximumMemberabus', 'ONPATTRO', 'FairValueMeasurementsRecurringMember2023', 'Qilu Pharmaceutical Co., Ltd.', 'QiluPharmaceuticalCoLTDMember2021-12-130001447028abus', 'Member2014-10-310001447028us', 'the Open Market Sale', 'Inc.$714&#160;$1,256&#160;$2,980&#160;$4,339&#160;Qilu Pharmaceutical Co.', 'AssemblyBiosciencesIncMember2022-01-012022-09-300001447028abus', 'Form S-3', 'the License Agreement', 'Acuitas Therapeutics Inc.', 'Contracts with Customers (&', '2022.The Company', 'Arbutus', 'Arbutus Biopharma Corporation', 'VaccitechMember2022', 'LicenseMember2023-07-012023-09-300001447028abus', 'Arbutus Inc.', 'Columbia', 'compensationThe', 'ArbutusPlansMember2023-01-012023-09-300001447028abus', 'Financial Instruments - Credit Losses', 'the U.S. District Court', 'SEC', 'NonCashRoyaltyMember2023', 'ArbutusPlansMember2023-07-012023-09-300001447028abus', 'GenevantSciencesCorporationMember2023-01-012023-09-300001447028srt', 'agreementsCollaborationsQilu Pharmaceutical Co., Ltd.', 'the District Court of New Jersey', 'ONPATTROGlobalNetSalesMember2014-01-012014-', 'ASC Topic', 'the Securities and Exchange Commission &', 'LicenseMemberabus'}"
ABVC,"{'ASC', 'API', 'LLC', 'the Collaborative Agreement', 'warrants\\nto', 'the BioFirst Collaborative Agreement', 'BioFirst', 'ABV-1601', 'ABVC', 'Euro-Asia Investment &', 'the Lind Securities Purchase Agreement,\\nthe Note', 'Transaction', 'NSCLC', '\\n    Research', 'the Co-Dev Agreement', 'Form S-1', 'Operations &', 'the BHK Agreement', 'Co-Development', 'Principal Executive', 'BioLite', 'the Securities Exchange Act', 'Thalia Media Ltd.', 'Securities Purchase Agreement', 'the Agreement.\\n\\n&#160;\\n\\nThe Company', 'MDD', 'ADHD (Attention Deficit\\nHyperactivity Disorder', 'COVID-19', 'CNS', 'the Co-Dev Agreement\\nwas', 'Unaudited)&#160;&#160;\\n    &', 'Company&#8217;s\\nentry', 'Holdings', 'The Common Stock', 'LLC (&#8220;Allele&#8221', 'profit&#160;\\n    &', 'Company\\nalso', 'the ticker symbol &#', 'Critical Accounting', 'the Securities and Exchange Commission', 'ABV-2001 Intraocular Irrigation Solution\\nand ABV-2002 Corneal Storage Solution', 'the Current Report on Form 8-K', 'Rgene&#8217;s Common Stock', 'the Company (See Note 8)', 'Principal Financial', 'FDA', 'Company&#8217;s\\ncommon', 'AIBL', 'Lucidaim Co., Ltd.', 'Non-Small Cell Lung', 'the securities of &#8220;penny', 'GMP', 'the Licensed Products', 'ABVC BioPharma, Inc.', 'Restated American BriVision (Holding) Corporation', 'BioPharma', 'collaboration\\npartners.\\n\\n&#160;&#160;\\n\\nAs\\npart', 'Company\\nare', 'the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'the Note and Loan Agreement', 'the Rgene Agreement', 'Central Nervous Systems', 'Co-Dev Agreement', 'Barlew Holdings', 'Non-Small Cell Lung Cancer', 'Biolite JP', 'Common Stock', 'the BioFirst Collaborative Agreement\\nwas', 'Company', 'the Nasdaq Listing\\nQualifications Department', 'BioLite BVI', 'the Cathay United Loan', 'Shareholders', 'Internal Control over', 'BioKey, Inc.', 'Report', 'income&#160;\\n    &', 'Joint Venture Agreement', 'the Service Agreement', 'Financial Reporting\\n\\n&#160;\\n\\nThere\\nhas', 'ASU', 'the Original Registration Statement,\\nthe &#8220;Registration', 'the Nasdaq Capital Market', 'the &#8220;Placement', 'BioLite Japan', 'the Quarterly Report on Form 10-Q', 'the Company receives.\\n\\n&#160;\\n\\nCollaborative\\nRevenues &#', 'Stock Purchase Agreement (&', 'Grantor', 'Purchase / Exchange', 'Plant and Equipment (&', 'IND/NDA', 'the Intellectual Property\\nOffice', 'Chengdu) Group Co., Ltd.', 'Report.\\n\\n&#160;\\n\\nThere\\nare', 'Articles of Incorporation', 'The Loan Agreement', 'TCD', 'the U.S. FDA IND', 'K.K.', 'Common Stock and ii', 'RGC', 'tax&#160;\\n    &', 'BioKey', 'Wilmington Capital Securities', 'The Financial Industry\\nRegulatory Authority (&#8220;FINRA&#8221', 'BriVision', 'the BioLite Agreement', 'Lind Global Fund II', 'BioLite Taiwan\\nhas', 'the BHK Co-Development Agreement', 'the Transaction Documents', 'Registrant', 'the Mandatory Default Amount', 'NDA', 'Inverlew Advisors', 'channels.\\n\\n&#160;\\n\\nBusiness\\nObjectives\\n\\n&#160;\\n\\nThe\\nCompany', 'Cathay Bank', 'The BHK Co-Development Agreement', 'a Patent Security Agreement', 'BioLite Taiwan', 'BioFirst Collaborative', 'Zhonghui United Technology', 'NT$31,649,000', 'BioFirst granted\\nthe Company', 'BioLite, Inc. (&#8220;BioLite&#8221', 'Property', 'BioLite Inc.', 'the Cathay United Loan Agreement', 'which\\nthe Mandatory Default Amount', 'the Lind Offering', 'Form S-3', 'a\\nClinical Development Service Agreement', 'Bank', 'the Loan Agreement', 'Board', 'Oncology/ Hematology', 'SPA', 'BioLite JP', 'schedule:\\n\\n&#160;\\n\\n  &#160', 'the BioFirst Agreement', 'Lucidaim', 'YuanGene Corporation', 'Finance', 'the Lind Securities Purchase Agreement', 'LionGeneCorporationtheLionGeneMember\\n    \\n', 'Purchase Agreement 2', 'the obligations\\nof the Company', 'BioFirst in\\na', 'Incorporation of the Company', 'the &#8220;Reserved', 'American BriVision Corporation', 'BHK Co-Development', 'Lind', 'JP', 'BioFirst\\n(Australia', 'CTBC Bank', 'Accounting Standards Codification', 'Securities Purchase Agreement&#160;(27)\\n', 'Ophthalmology, Oncology', 'share:&#160;\\n    &', 'BHK Co-Development\\nAgreement', 'SEC', 'upfront\\npayments\\n\\n&#160;\\n\\nIf\\na', 'Zhonghui United Technology\\n(Chengdu) Group Co., Ltd.', 'U.S. FDA IND', 'the Board of Directors of the Company', 'compensation&#160;\\n    &', 'American BriVision (Holding) Corporation', 'BHK', 'recognition.\\n\\n&#160;\\n\\n(i', '\\n    &', 'the Loan Agreement and Note'}"
ABVX,
ACAD,"{'API', 'EU Clinical Trials Regulation', 'regulators;\\n  &#x2022;costs', 'candidates.\\n  &#x2022;If', 'commercialization.\\n  Delays', 'candidates;\\n  &#x2022;the', 'Item 408 of Regulation S-K', 'MSN', 'the Baker Entities', 'PRV', 'EU', 'and\\n  &#x2022;provide', 'will:\\n  &#', 'matters;\\n  &#x2022;disruptions', 'x2022;a', 'they:\\n  &#x2022;do', 'label;\\n  &#x2022;requirement', 'ACA', 'Rare Pediatric Disease Priority Review', 'the Securities Exchange Act', 'COVID-19', 'CNS', '\\n  &#x2022;obtaining', 'candidates;\\n  &#x2022;may', 'and\\n  &', 'compensation\\n    &', 'management&#x2019;s', 'letters;\\n  &#x2022;suspension', 'HHS', 'Hetero', 'PDP', 'Medicaid', 'Medicare', 'the Company&#x2019;s Orange Book', 'marketing;\\n  &#', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'targets;\\n  &#x2022;preclinical', '\\n  &#x2022;may', 'and\\n  &#', 'the Medicaid Drug Rebate Program', 'Regulation S-K Item', 'Fragile X', '\\n  Commission File Number', 'Company', 'and\\n  &#x2022;the', 'x2022;fail', 'profitably.\\n  &#x2022;If', '\\n    &#', 'NNZ-2591', 'Purchase Common Stock', 'DAYBUE', 'ADP', 'Neuren', 'revenue;\\n  &#x2022;exhaustion', 'Teva', '\\n  &#x2022;the', 'the Registrant&#x2019;s Annual Report', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'recognized.7\\n     &', 'the HHS Office of Inspector General', 'License', '\\n  &#', 'Investigational New Drug', 'if:\\n  &#x2022;these third', 'Upfront', 'Licence Agreement', 'Registrant', 'Q3false0001070494--12-31http://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#ProductMemberhttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent0001070494us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001070494stpr:CAacad:CorporateOfficeSpaceLeaseAgreementMember2018-12-310001070494us-gaap:CashMemberacad:CashAwardsMember2023-09-300001070494us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001070494acad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-04-300001070494srt:NorthAmericaMemberacad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-01-012023-03-310001070494us-gaap:CostOfSalesMember2023-01-012023-09-300001070494us-gaap:RetainedEarningsMember2022-09-300001070494acad:NuplazidMember2022-01-012022-09-300001070494us-gaap:LetterOfCreditMemberacad:FleetProgramMember2023-09-300001070494us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryNotesSecuritiesMember2023-09-300001070494acad:MarkCSchneyerMember2023-09-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001070494us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001070494srt:NorthAmericaMemberacad:LicenseAgreementsMembersrt:MaximumMemberacad:NeurenPharmaceuticalsLimitedMember2018-08-310001070494us-gaap:CashMemberacad:CashAwardsMember2022-12-310001070494us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-3000010704942020-09-3000010704942022-09-300001070494us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-09-300001070494us-gaap:FairValueInputsLevel1Member2023-09-300001070494us-gaap:RetainedEarningsMember2022-07-012022-09-300001070494us-gaap:FairValueInputsLevel1Member2022-12-3100010704942021-03-310001070494acad:NuplazidMember2022-07-012022-09-300001070494acad:DaybueMember2022-07-012022-09-300001070494us-gaap:CostOfSalesMember2022-01-012022-09-300001070494us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023-09-300001070494us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001070494acad:DaybueMember2023-07-012023-09-300001070494srt:NorthAmericaMemberacad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-07-012023-07-310001070494us-gaap:CashMemberus-gaap:FairValueInputsLevel3Memberacad:CashAwardsMember2022-12-310001070494acad:LicenseAgreementsMember2023-09-300001070494us-gaap:RetainedEarningsMember2023-09-300001070494us-gaap:FairValueInputsLevel2Member2022-12-310001070494us-gaap:MoneyMarketFundsMember2023-09-300001070494us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001070494us-gaap:USTreasurySecuritiesMember2022-12-310001070494us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001070494us-gaap:CashMemberus-gaap:FairValueInputsLevel3Memberacad:CashAwardsMember2023-09-300001070494srt:NorthAmericaMemberacad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2018-08-012018-08-310001070494us-gaap:RetainedEarningsMember2021-12-310001070494us-gaap:USTreasuryNotesSecuritiesMember2022-12-3100010704942023-01-012023-09-300001070494us-gaap:RetainedEarningsMember2022-06-300001070494acad:LicenseAgreementsMember2023-04-300001070494us-gaap:FairValueInputsLevel2Member2023-09-300001070494srt:MinimumMemberacad:SanDiegoMember2023-01-012023-09-300001070494acad:NuplazidMember2023-01-012023-09-300001070494acad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-07-012023-09-300001070494acad:DevelopmentCommercializationAndSalesMilestonesMemberacad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-07-012023-07-310001070494us-gaap:MunicipalBondsMember2022-12-310001070494acad:DaybueMember2023-01-012023-09-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001070494us-gaap:MoneyMarketFundsMember2022-12-310001070494acad:DaybueMember2022-01-012022-09-300001070494us-gaap:USTreasurySecuritiesMember2023-09-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001070494srt:NorthAmericaMemberacad:LicenseAgreementsMember2023-03-310001070494us-gaap:EquitySecuritiesMember2022-12-310001070494us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMember2022-12-3100010704942022-06-300001070494us-gaap:RetainedEarningsMember2022-01-012022-09-300001070494us-gaap:RetainedEarningsMember2023-06-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001070494us-gaap:USTreasuryNotesSecuritiesMember2023-09-300001070494srt:NorthAmericaMemberacad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMemberus-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001070494acad:TwoThousandAndTwentyThreeInducementPlanMember2023-09-300001070494acad:CorporateOfficeSpaceLeaseAgreementMember2018-12-310001070494acad:BrendanPTeehanMember2023-09-300001070494acad:LicenseAgreementsMember2023-01-012023-09-300001070494us-gaap:AdditionalPaidInCapitalMember2023-06-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001070494us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-3100010704942023-01-012023-03-310001070494us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2023-09-300001070494us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2022-12-310001070494stpr:CAacad:CorporateOfficeSpaceLeaseAgreementMember2020-02-290001070494us-gaap:RetainedEarningsMember2023-07-012023-09-300001070494us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryNotesSecuritiesMember2022-12-310001070494acad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-04-012023-04-300001070494us-gaap:DomesticCorporateDebtSecuritiesMember2022-12-310001070494us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001070494us-gaap:CommonStockMember2022-12-310001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001070494acad:BrendanPTeehanMember2023-01-012023-09-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-3000010704942023-10-250001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001070494stpr:CAacad:CorporateOfficeSpaceLeaseAgreementMember2021-01-012021-03-310001070494us-gaap:AdditionalPaidInCapitalMember2022-09-300001070494stpr:CAacad:CorporateOfficeSpaceLeaseAgreementMember2020-03-3100010704942021-11-020001070494us-gaap:AdditionalPaidInCapitalMember2022-06-300001070494us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001070494us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2022-12-310001070494srt:NorthAmericaMemberacad:LicenseAgreementsMembersrt:MaximumMemberacad:NeurenPharmaceuticalsLimitedMember2023-07-310001070494us-gaap:CostOfSalesMember2022-07-012022-09-300001070494acad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-09-3000010704942022-07-012022-09-300001070494us-gaap:RetainedEarningsMember2022-12-310001070494us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001070494us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001070494acad:StokeTherapeuticsIncMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-01-310001070494us-gaap:CommonStockMember2022-09-300001070494us-gaap:CommonStockMember2021-12-3100010704942021-11-012021-11-300001070494us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember2022-12-310001070494us-gaap:LetterOfCreditMemberacad:CorporateOfficeSpaceLeaseAgreementMember2021-03-310001070494us-gaap:CostOfSalesMember2023-07-012023-09-300001070494us-gaap:CommonStockMember2023-09-300001070494us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001070494acad:MarkCSchneyerMember2023-01-012023-09-300001070494acad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMember2023-01-012023-09-3000010704942022-01-012022-09-300001070494us-gaap:AdditionalPaidInCapitalMember2022-12-310001070494us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001070494us-gaap:FairValueInputsLevel3Member2023-09-300001070494acad:StokeTherapeuticsIncMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-310001070494acad:SanDiegoMember2023-09-300001070494srt:MaximumMember2023-09-300001070494us-gaap:CommonStockMember2022-06-3000010704942021-12-310001070494us-gaap:RetainedEarningsMember2023-01-012023-09-300001070494us-gaap:FairValueInputsLevel3Member2022-12-310001070494us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001070494us-gaap:LetterOfCreditMemberacad:CorporateCreditCardProgramMember2023-09-3000010704942023-09-3000010704942023-06-3000010704942022-12-310001070494srt:MinimumMember2023-09-300001070494us-gaap:CommonStockMember2023-06-300001070494us-gaap:AdditionalPaidInCapitalMember2021-12-310001070494us-gaap:AdditionalPaidInCapitalMember2023-09-3000010704942023-07-012023-09-300001070494srt:NorthAmericaMemberacad:LicenseAgreementsMemberacad:NeurenPharmaceuticalsLimitedMemberus-gaap:ResearchAndDevelopmentExpenseMember2018-07-012018-09-300001070494us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001070494acad:LicenseAgreementsMember2023-07-012023-09-300001070494acad:NuplazidMember2023-07-012023-09-300001070494acad:TwoThousandAndTwentyThreeInducementPlanMembersrt:MaximumMember2023-09-30xbrli:purexbrli:sharesacad:Termiso4217:USDxbrli:sharesacad:Securityiso4217:USD\\n  &', 'capabilities;\\n  &#x2022;the', 'NDA', 'candidates.\\n  &#x2022;Our', 'Aurobindo', 'DOJ', 'the Sarbanes-Oxley Act', 'the U.S.;\\n  &#x2022;any', 'AMP', 'Comparison', 'rights.\\n  &#x2022;Healthcare', 'Patheon Pharmaceuticals Inc.', 'ENHANCE', 'Merger AgreementsThe Company', 'DRP', 'this Quarterly Report', 'the U.S.;\\n  &#x2022;our', '\\n  &#x2022;obtaining FDA', 'including:\\n  &#x2022;the', 'Rett syndrome;\\n  &#x2022;the', 'China&#x2019;s Personal Information Protection Law', 'the Registrant&#x2019;s Quarterly Report on Form 10-Q', 'Stoke', '\\n    &#160;&#160;10.1*\\n    &', 'results;\\n  &#x2022;changes', 'Neuren Pharmaceuticals Limited', 'benefits;\\n  &#x2022;voluntary', 'the Registrant&#x2019;s Current Report', '\\n  &#x2022;If', 'ACADIA', 'including:\\n  &#x2022;withdrawal', 'decline.\\n  &#x2022;The', 'Significant Accounting Policies', 'SEC', 'CRL', 'Marechal v. Acadia Pharmaceuticals, Inc.', 'AG', 'the U.S. PTO', 'development programs;\\n  &#x2022;the', 'EXHIBITS\\n  &#160;\\n', 'Registration Statement No', 'Medicare&#x2019;s', 'Neuren Pharmaceuticals Ltd', 'recalls;\\n  &#x2022;warning', 'Nasdaq', '\\n    &'}"
ACB,
ACCD,"{'ASC', 'the Option Counterparties', 'Adopted Accounting PronouncementsNone.&#8203;Item&#160;3', 'PlushCare', ': &#9679;Plus and Connect &#8211', 'Item&#160;601&#160;of&#160;Regulation S-K.', 'healthcare', 'the Board of Directors', 'revenue&#8203;&#8203', 'contractThe Company', 'Adopted Pursuant', 'the Securities and Exchange Commission', 'this Quarterly Report on Form 10-Q', 'ESPP', '29,115)&#160;&#8203;Adjusted Gross Profit', 'Innovation Specialists', 'SubsidiariesNotes', 'Indenture', 'ContentsAccolade, Inc.', 'Effectiveness of ControlsOur', 'source:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Three Months Ended August 31,&#8203;Six Months Ended August', 'ERP', 'disclosure.&#160;&#8203;Our', 'Company', 'Interactive Data Files  &', 'the Securities Exchange Act', 'Robbins v. PlushCare, Inc.', 'the Sarbanes-Oxley Act', 'COVID-19', 'IPO', 'Page Interactive Data File', 'ObligationsThe Company', 'Condensed Consolidated Financial Statements'}"
ACET,"{'EC&#x2019;s', 'years)\\n        &', 'regulators;\\n  &#x2022;costs', 'candidates.\\n  &#x2022;If', '\\n    Interest income\\n    &', 'Period\\n        &', 'products.\\n  Specifically', 'the EU Commission', 'the Federal Reserve', 'this Quarterly Report on Form 10-Q', 'Adicet Therapeutics', 'results;\\n  &#x2022;uncertainties', 'protocols;\\n  &#x2022;changes', 'ContingenciesOperating LeasesThe Company', 'Non-Formula Ancillary Services', 'EU', 'x2022;a', '\\n  &#x2022;differing', 'controls;\\n  &#x2022;potential', 'investigators;\\n  &#x2022;failure', 'PacWest', '\\n    Research', 'liability;\\n  &#', 'manner;\\n  &#x2022;inability', 'the Financial Accounting Standards Board', 'Regeneron Pharmaceuticals Inc', '\\n  &#x2022;establishing', 'COVID-19', 'the Registration Statement on Form S-3', 'the Twist Agreement', 'and\\n  &#x2022;collaborations', 'FASB', 'x2022;if', 'the Sublease Agreement', 'ICP', 'candidates;\\n  &#x2022;collaborators', 'candidates.\\n  Clinical', 'x201c;Risk', 'WeWork', 'countries;\\n  &#x2022;challenges', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'x2014;\\n        &', 'restrictions;\\n  &#x2022;economic', 'GDPR', 'future.\\n', 'FDA', 'Regeneron&#x2019;s', '\\n  Liquidity and Capital Resources\\n  Sources', 'GMP', 'Loan', '\\n        Laboratory equipment\\n', 'the Regeneron Agreement', 'and\\n  &#', 'EGC', 'candidates;\\n  &#x2022;injury', 'including:\\n  &#x2022;identifying', 'standards;\\n  &#x2022;We', 'the Shelf Registration Statements', 'REMS', 'Capital On', 'Company', 'the Department of the Treasury', 'stock.\\n  &#x2022;If', 'the Prime Rate', 'and\\n  42\\n  \\n  &#', 'and\\n  &#x2022;the', 'payroll taxes;\\n  &#x2022;foreign', 'SRC', '\\n    Interest expense\\n    &', 'Significant Accounting', 'candidates;\\n  &#x2022;delays', 'and\\n  &#x2022;business', 'the U.S. Securities and Exchange Commission', 'SVB', 'Signature Bank', 'liability;\\n  &#x2022;collaborators', 'CRO', '\\n  ', 'premiums.\\n  Interest Income\\n  ', 'the treatment;\\n  &#x2022;conditioning', 'regulation;\\n  &#x2022;the', '40,986\\n', 'Restated Certificate of Incorporation of resTORbio', 'operations.\\n  General Risk Factors\\n', 'Loan Agreement', 'candidates;\\n  &#x2022;continued', 'the 2021 Shelf Registration Statement', 'Pacific Western Bank', 'harmed.\\n  &#', 'market.\\n  &#x2022;We', 'revenue;\\n  &#x2022;exhaustion', 'CAR', 'candidates;\\n  &#x2022;understanding', 'products;\\n  &#x2022;disagreements', '\\n  &#x2022;Failure', 'IRB', '\\n  &#', 'TCR', 'design;\\n  &#x2022;establishing', 'TCA', 'FDIC', 'Adicet Bio, Inc.', 'CFO', 'Comparison', 'employees.\\n  Issued', 'design;\\n  &#x2022;significant', 'operations.\\n  &#', 'candidates;\\n  &#x2022;achieving', 'companies&#x2019', 'ASU No', 'property.\\n', 'challenges;\\n  &#x2022;increases', 'employees.\\n  Risks Related to Ownership of Our Common Stock\\n  Risks Related', 'Sales Agreement (Sales Agreement', 'Form S-3', 'treasury', 'the Loan Agreement', 'the United States;\\n  &#x2022;production', 'markets;\\n  &#x2022;compliance', 'Regeneron', 'ATM', 'JonesTrading Institutional Services', 'and\\n  &#x2022;retention', '9\\n     &#160;and', 'Regeneron Pharmaceuticals, Inc.', 'Risks Related to', 'product;\\n  &#x2022;collaborators', 'benefits;\\n  &#x2022;changes', 'RFS OPCO', 'the Registrant&#x2019;s Current Report', '\\n    ', 'Adopted Accounting Pronouncements\\n', 'expensive;\\n  &#x2022;collaborators', '\\n        &', 'SEC', 'BLA', 'the Redwood City Lease', 'Twist', 'Nasdaq', '\\n    &', 'The Boston Lease', 'operations.\\n  Risks Related to Marketing Our Product Candidates\\n', 'collaborator&#x2019;s'}"
ACHC,"{'LLC', 'the Company&#x2019;s Quarterly Report on Form 10-Q', 'ASU', 'the Company&#x2019;s Current Report on Form 8-K', 'Accounting for Government Grants and Disclosure of Government Assistance', 'deemed &#x201c;filed&#x201d', 'Medicare', '\\n    Legal', 'FamilyWorks', 'the London Interbank Offered Rate (&#', 'x2014;\\n        &', 'the PHSSE Fund', 'The Credit Facility', 'Acadia Healthcare Company', 'Acadia Healthcare &', 'Credit Facility\\n', 'the Company&#x2019;s Annual Report on Form 10-K', 'the Coronavirus Aid, Relief and Economic Security Act', 'the Inman Litigation', 'Acadia Management Company', '\\n  &#', 'Credit Facility', 'Healthcare', 'Rule 10b5-1', 'the District Court', '\\n    Management', 'Accounting Standards Codification', 'Welfare Benefit', '26\\n', 'Acadia Management Company, Inc.', 'ShareThe', '\\n        &', 'Youth', 'Family Centered Services of', 'Company', 'the Securities Exchange Act', 'Cases', 'revenue.\\n  Professional', 'Item 408 of Regulation S-K).\\n  31\\n', '\\n    &', 'District Court&#x2019;s', '\\n       &'}"
ACHL,
ACHV,
ACIU,
ACLX,"{'ASC', 'Leases &', 'Arcellx, Inc.', 'Gilead Sciences, Inc.', 'the Lonza Manufacturing Services Agreement', 'and\\n  &#x2022;The', 'our control.\\n  &#', '\\n  &#x2022;Obtain', 'any.\\n  &#', 'reputation.\\n', ': &#x2022;Expected Time to', 'components.\\n  &#x2022;Raw', '\\n    Research', 'the U.S. Congress of the', 'Form S-1', 'Development Expenses &', 'candidates;\\n  &#x2022;Our', 'Contingencies &#160;From', 'the Securities Exchange Act', 'Research', 'COVID-19', 'the trial;\\n  &#', 'Condensed Consolidated Financial Statements\\n    10\\n', 'Kite;\\n  &#x2022;Pursue', 'Credit Risk &', 'Adopted Accounting Pronouncements', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prepaid', 'date.&#160;The Company', 'products;\\n  &#x2022;Sufficiency', 'compensation\\n    &', 'FASB', 'position.&#160;The Company', 'the General Services Administration', 'ARCELLX', 'Becerra', 'financial standing.\\n  &#x2022;We', 'manufacturers&#x2019', 'S\\n  &#160;\\n', 'Medicaid', 'candidate;\\n  &#', 'Medicare', 'Award End Date &', 'Congress', 'x2014;\\n        &', 'FDA', 'Kite', 'candidates.\\n  &#', 'regulators;\\n  &#', 'GMP', 'and\\n  &#', 'EGC', '30\\n', '77\\n', 'liability.\\n  &', 'candidates;\\n  &#x2022;The', 'CONDENSED CONSOLIDATED', 'REMS', 'ASH', 'activities\\n    &', 'Kite Pharma, Inc (Kite', 'Company', 'management&#x2019;s attention', 'design;\\n  &#x2022;Delays', 'USPTO', 'Customer', '56,763\\n          &', '\\n    &#', 'Condensed Consolidated Financial Statements', 'ASU', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;Income', 'FCPA', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Stockholders&#x2019', 'including:\\n  &#', 'the Federal Supply Schedule', 'Procedures\\n  &', 'candidates;\\n  &#x2022;A', '\\n  &#', 'Material Definitive Agreement):\\n  &', 'the Organization for Economic Cooperation and Development', 'Lonza', 'others.\\n  Third', 'any.\\n  &', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes', 'Registrant', 'U.S. losses.\\n  &', 'Gilead Stock', 'candidates.\\n  Risks Related', 'CMO', 'the Sarbanes-Oxley Act', 'Gilead', 'the Co-Promote Products', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;Interest', 'Comparison', 'This Quarterly Report on Form 10-Q', 'ASU No', '\\n  &#x2022;Determine', 'product;\\n  &#x2022;Disagreements', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accounts', '4,929\\n          &', '\\n  &', 'the year\\n    &', 'Data Safety Monitoring Boards', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Receivable', 'appropriately.\\n  &', 'the Company&#x2019;s Annual Report', 'Indemnification Agreements &', 'Risks Related to Government Regulation\\n  &#x2022;We', '\\n    ', 'the American Society of Hematology', '\\n        &', 'Stifel, Nicolaus &amp', 'SEC', 'Recognition&#160;The Company', 'Collaboration and License Agreement', 'candidates.\\n  &', 'BLA', 'ARC-SparX', 'acceptance.\\n  Government', 'otherwise;\\n  &#x2022;The', 'the European Union', 'Nasdaq', '\\n    &', '\\n    &#160;&#160;Interest', 'x2022;A'}"
ACON,"{'Form of Option Grant Notice and Stock Option Agreement\\n    &', 'LLC', 'the Nasdaq Capital Market', 'Unsecured Non-Convertible Notes\\n    &', 'Condensed Financial Statements\\n    &', 'Cover Page Interactive Data File', 'the Common Stock Purchase', 'Procedures\\n    &', 'B-1', 'White Lion Capital', 'UCSF the Regents of the University of California\\n    &', 'the Common Stock Purchase\\nAgreement', 'White Lion', 'Exchange Act', 'Internal Control', 'Principal Executive Officer', 'the Securities and Exchange Commission', 'Incentive Plan &#8211', 'the Bid Price', 'Administrative', 'Notice', 'this Quarterly Report on Form 10-Q', 'Jeffrey Thramann\\n    &', 'the Interactive Data File', 'receive\\nin exchange', 'Company&#8217;s\\ncommon', 'RSU', 'agreement\\nwith the Regents of the University of California', '\\n&#160;\\n\\n\\n\\n\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'Nocimed, Inc. 2015 Stock Plan &#8211', 'below.\\n\\n&#160;\\n\\nOn October 23, 2023', 'Aclarion', 'The Nasdaq Capital Market', 'Nocimed, Inc. 2015', 'Aclarion, Inc.', 'the\\nCommon Stock Purchase Agreement', 'UCSF', 'Regulation S-K.', 'the Regents of\\nthe University of California&#8217;s', 'SEC', 'Company', 'the Common Stock Purchase Agreement', 'UC License Agreement\\n    &', 'Risks and Uncertainties', 'Form\\n    &', 'IPO', 'Nasdaq', 'the White Lion RRA', '\\n    &'}"
ACOR,"{'ASC', 'the &#x201c;New', 'Inbrija of $18 million', 'API', 'Civitas Therapeutics, Inc.', 'Alkermes', 'Civitas Therapeutics, Inc. (&', 'ex-U.S. Inbrija', 'Contracts', 'HCRP', 'Alkermes plc (&#x201c;Alkermes&#x201d;)', '\\n  &', 'Healthcare Products Regulatory Agency', 'the Consolidated Financial Statements', 'MS', 'Qutenza', 'S.A. (&#x201c;Esteve', 'LiabilityThe', 'Biopas', 'x2014;\\n        &', 'Wilmington Trust', 'Patheon', 'Esteve Pharmaceuticals GmbH', 'Catalent Pharma Solutions', 'EU', 'FDA', 'Hangzhou Chance Pharmaceuticals Co., Ltd (&#x201c;Chance&#x201d;)', 'National Association', 'Indenture', '\\n  &#', 'Alkermes Plc (&#x201c;Alkermes&#x201d;)', 'Civitas', 'the District Court', 'Pharma Consulting Group', 'Accounting Standards Update', 'Accounts Payable', '4,496\\n        &', 'Accounting for Convertible Instruments', 'Company', 'the Financial Accounting Standards Board', 'Hangzhou Chance Pharmaceuticals Co., Ltd.', 'Chelsea', 'Catalent', 'UK&#x2019;s', 'HealthCare Royalty Partners', 'reporting.\\n', 'Esteve Pharmaceuticals', 'Biogen', 'ARCUS'}"
ACRS,"{'LLC', 'Cantor Fitzgerald &amp', 'treasury', 'KINect', 'Fair Value of Financial Assets', 'Consideration&#8203;The Company', 'consideration&#8203;$ &#8212;&#8203;$ &#', 'Unaudited Condensed Consolidated Financial', 'Aclaris Life Sciences, Inc.', 'Condensed Consolidated Statements of Operations and Comprehensive Loss', 'this Quarterly Report on Form 10-Q.', 'Plan of Merger &#8211', '92)&#8203;Total revenue&#8203;&#8203', 'revenue&#8203;&#8203', 'the Securities and Exchange Commission', 'Intellectual Property&#8203;License Agreement &#8211', 'Confluence', 'Aclaris Therapeutics, Inc.', 'Confluence Life Sciences, Inc.', 'SVB Securities', 'Common Stock Pursuant', '32,500&#8203;$ 32,500&#8203;9\\nTable', 'Lilly', '32,500&#8203;$ 32,500Total liabilities&#8203;$ &#8212;&#8203;$ &', 'the &#8220;Consolidated Securities Action&#8221;)', 'ContentsAsset Purchase Agreement', 'EPI Health', 'License', 'EPI', 'Board of Directors', '7,168)&#8203;Other &#8203;&#8203; &#8212;&#8203;&#8203', 'Eli Lilly and Company (&#8220;Lilly&#8221', 'Office and Laboratory Space&#8203;The Company', 'Accounting Standards Codification', 'Merger Sub', 'Pediatrix Therapeutics, Inc.', 'consideration&#8203;$ &', 'LLC (&#8220;EPI', 'class.&#160;The', 'Development &#8203;Research', 'Months Ended &#', 'Condensed Consolidated Statements', 'SEC', 'Eli Lilly', 'RHOFADE', 'Company', 'ContentsOur', 'InformationWe', 'ContentsOther Income', 'Condensed Consolidated Statements of Cash Flows', 'the Securities Exchange Act', 'Significant Accounting Policies&#8203;Unaudited', 'Fortis Advisors LLC', 'the Confluence Agreement', '6,211&#8203;Licensing &', 'Pediatrix Therapeutics, Inc. (&#8220;Pediatrix&#8221;)', 'Purchase Agreement &', 'Fulcher &#', 'Disposition'}"
ACRV,"{'MaximumMember2023', '\\n  &#x2022;injury', 'UnderwritersMember2022-12-162022-12-160001781174country', '\\n  &#149;\\temployee', 'the Accelerated Approval Program', 'AP3', 'Mayo Collaborative Services', '\\n', 'MaximumMember2022-01-012022-09-300001781174us-gaap', 'Incentive Plan', 'THERAPEUTICS', 'RestrictedStockUnitsRSUMember2023-09-3000017811742022-07-012022-09-300001781174acrv', 'EEA', '42\\n  \\n  &#160;\\n', '\\n  &#149;\\tcosts', 'SE2023', 'Lilly', 'EU', 'TwoThousandTwentyTwoEquityIncentivePlanMember2023-09-300001781174srt', '\\n  &#149;\\tour', 'MaximumMember2023-01-012023-09-300001781174acrv', '\\n    Research', '\\n  Remediation Actions Completed', 'the Securities Exchange Act', 'compensation)\\n    &', 'Research', 'COVID-19', '\\n  &#149;\\texternal', 'costs.\\n  Funding Requirements \\n', 'Stock-Based Compensation 2022 Equity Incentive PlanIn', 'material misstatement;\\n  &#x2022;Established', 'the Lilly Agreement', 'the Series A-1 Preferred Stock', 'Try&#x201d', '\\n  &#x2022;significant', '\\n  &#x2022;publicity', '\\n  &#x2022;substantial', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'USGovernmentSponsoredEnterprisesDebtSecuritiesMember2023', 'OncoSignature', 'Medicare', 'Congress', 'Medicaid', '\\n  &#x2022;allow', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001781174us', 'x2014;\\n        &', 'GDPR', 'Arsenal Way Lease', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Fed', 'The America Invents Act', 'MaximumMember2023-07-012023-09-300001781174us', 'Series A-1 Preferred Stock', 'and\\n  &#', 'the UK Government', 'the Court of Justice', '\\n  &#x2022;loss', 'REMS', 'Eli Lilly and Company (&#x201c;Lilly&#x201d;)', 'TwoThousandTwentyTwoEquityIncentivePlanMember2022', 'activities\\n    &', '\\n  Commission File Number', 'environment:\\n  &#x2022;Continued', 'Company', 'MaximumMember2022', 'RestrictedStockUnitsRSUMember2023-01-012023-09-30iso4217:USDxbrli', 'ACR-2316\\n    &#160;\\n    &#160;\\n    1,748\\n    &', '\\n  &#x2022;limitations', 'Charter)\\n  &#', '\\n  &#x2022;whether', 'and\\n  &#x2022;Continued', '\\n    &#', 'Akoya', 'GLP', 'the Delaware General Corporation Law', 'CRO', 'the European Commission', '\\n  ', 'CMS', 'Public Offering of Common Stock\\n', 'CCPA', 'MaximumMember2022-01-012022-12-310001781174acrv', 'FCPA', 'entries;\\n  &#', 'Contractual Obligations \\n', '\\n  &#x2022;the', 'TwoThousandTwentyTwoEmployeeStockPurchasePlanMember2023-01-012023-09-300001781174us', 'SE2023-09-012023-09-3000017811742023-06-300001781174us', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'the &#x201c;Arsenal Way', '\\n  &#', 'and\\n  &#x2022;Designed', '\\n  &#x2022;diversion', 'Registrant', 'UnderwritersMember2022-12-142022-12-140001781174us-gaap', '\\n  &#x2022;decreased', '\\n  &#x2022;require', 'NDA', 'CMO', 'UnderwritersMember2022-11-172022-11-170001781174us-gaap', 'FairValueMeasurementsRecurringMember2023', 'Research and Development Expenses \\n', 'IPO', 'LillyAgreementMember2021-01-012021-01-3100017811742023-03-310001781174acrv', 'Comparison', '\\n  &#x2022;our', 'LillyAgreementMember2021-01-310001781174acrv', '\\n  &#x2022;limit', 'Board', '\\n  &#x2022;support', 'the International Data Transfer Agreement and International Data', 'Accelerated Approval', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001781174us', '\\n  &', 'European Union', 'LillyAgreementMember2021-11-300001781174us-gaap', 'ESPP', 'GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001781174us-gaap', 'TwoThousandTwentyTwoEmployeeStockPurchasePlanMember2022', 'stock)\\n        &', '\\n  &#149;\\texpenses', 'Medicaid Services', '\\n  &#149;\\tdirect', 'institute a &#x201c;poison pill&#x201d', 'LillyAgreementMember2021-01-012021-01-310001781174us', '\\n  &#x2022;withdrawal', '\\n  &#x2022;authorize', 'Akoya Biosciences, Inc.', 'U.S. Treasury', 'SEC', 'GCP', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001781174us-gaap', 'the Akoya Agreement', 'LillyAgreementMember2021-01-012021-01-310001781174acrv', 'Stock-Based Compensation Expense Stock', 'Capital Resources.&#x201d', 'the Centers for Medicare', 'Equity Securities', 'Fair Value Measurement', 'Athena Diagnostics', '4,420\\n        &', '\\n  &#x2022;reduced', 'the European Union', 'Nasdaq', '\\n    &', '\\n  &#149;\\tfacilities'}"
ACRX,
ACST,"{'ASC', 'LLC', 'the year\\n        &', 'CRO', 'the Nasdaq Capital Market', '\\n  ', 'ODD', 'Form S-3', 'the Black-Scholes', 'structure.\\n  &', 'LeasesThe Corporation', 'Intangible Assets\\n  &#', 'measures.\\n  &#', 'the Accounting Standards Codification', 'the Board of Directors', 'Co. Inc.', 'ATM', 'study drug administration', 'DCI', 'outstanding.&#160;&#160;12\\n     &', 'the Corporation&#x2019;s Annual Report', 'the &#x201c;Reverse Stock', 'TSXV', 'realized.\\n  &#', 'Articles of Incorporation', 'the U.S. Food and Drug Administration', 'Purchasers', 'the &#x201c;Sales Agreement&#x201d', 'Corporation', 'Future Accounting', 'B. Riley', 'the Corporation&#x2019;s Board of Directors', 'AUC', 'Board of Directors', 'table:&#160;\\n      \\n       \\n        \\n        \\n        \\n       \\n       \\n        &', 'IM', 'x201c;FASB&#x201d;).&#160;The', 'Restructuring Costs\\n  &', '\\n  &#', 'funding.\\n', 'Indicate', 'Registration Statement on Form S-3', 'agreements:\\n  &#160;\\n', 'The Notification Letter', 'business.&#160;The Corporation', 'H.C. Wainwright &amp', 'x201c;Common', 'SEC', '\\n        &', 'Critical Accounting Policies\\n  &', 'Commission', 'Acasti Pharma Inc.', 'the TSX Venture Exchange', 'the Financial Accounting Standards Board', 'CMO', 'Sherbrooke, Qu&#xe9;bec', '1-for-6', 'the &#x201c;Purchase', 'the Pre-Funded Warrant Shares', 'Research', 'Contractual Obligations and Commitments \\n  &', 'CaPre', 'AKBM', 'the median percent', 'Form S-8 (File No', 'consolidation.\\n  &#', 'Agents', 'Corporation&#x2019;s', 'the FDA&#x2019;s Division of Neurology', '\\n    &', 'Oppenheimer &amp', 'the International Cooperative Ataxia Rating Scale (&#', 'the Purchase Agreement'}"
ACXP,"{'the Delaware General Corporation Law', 'LLC', 'Months Ended &', 'Form S-3', 'the United States Securities Exchange Commission', 'HHS', 'Critical Accounting Policies', 'this Quarterly Report on Form 10-Q.', 'the World Health Organization (&#8220;WHO&#8221;)', 'Acurx Pharmaceuticals', 'ContentsThe Securities', 'healthcare', 'EMA', 'the U.S. Congress', 'Health Insurance Portability', 'the 2023 Offerings', 'the Court of Chancery of the State of Delaware', 'Contentsvalue', 'the 2023 Registered Offering', 'OverviewAcurx Pharmaceuticals, Inc.', 'EstimatesOur', 'ContentsITEM&#160;3', 'Congress', 'Maxim Group', 'Medicare', 'this Quarterly Report on Form 10-Q', 'SAB', 'the U.S. Food and Drug Administration', 'this Quarterly Report on Form&#160;10-Q', 'Development ExpensesResearch', ': &', 'FDA', 'the Federal Healthcare Anti-Kickback Statute', 'the Public Company Accounting Oversight Board', 'Placement Agent Agreement', ': &#', 'the U.S. Centers for Disease Control and Prevention (&', 'Our BusinessThe World Health Organization (&#8220;WHO&#8221', 'Administrative ExpensesGeneral', 'Existing Warrants', 'Recent Accounting PronouncementsThe Financial Accounting Standards Board', 'ContentsNet LossNet', 'HIPAA', 'ACX-362E', 'SEC', 'ContentsWe', 'ACA', 'Medicaid', 'Company', ': &#9679;our', 'the heading &#8220;Special Note Regarding Forward-Looking', 'COVID-19', 'HMOs', 'IPO', 'Ended &#8203;&#8203;&#160;&#8203;&#8203;September&#160;30,&#160;&#8203;Percentage&#8203;&#8203;&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;Change&#160;&#8203;&#8203;(in&#160;thousands)&#8203;&#8203;&#160;OPERATING', 'ContentsComponents', 'the Health Information Technology for Economic and Clinical Health Act', 'ContentsIn', 'Membership Interests', 'The Series D Warrants', 'SHARE-BASED PAYMENTS TO', 'Nasdaq', 'groups; &', 'the Placement Agents'}"
ADAG,
ADAP,"{'ASC', 'Fair', 'FASB', 'ASU', 'PRAME', '8,817&#8203;$ &', 'Adaptimmune', 'American Depositary Shares', 'this Quarterly Report', 'Accrued', 'Contingencies', '47,694&#8203;&#8203', 'Contracts with Customers', 'the initial &#8220;off', 'Total Liquidity', 'ActivitiesNet', 'the initial &#', 'Genentech Inc.', 'expenditure&#8203;&#8203', 'NY', 'Adaptimmune Limited', 'The University of Texas', 'ESMO', 'the GSK Collaboration and License Agreement', 'Administrative ExpensesGeneral', 'ContentsThe', '7,979&#8203;$ &', 'TCR2', 'Universal Cells, Inc. (&', 'expenses&#8203;&#8203', 'OperationsThe', 'IGNYTE', 'Goodwill', 'SEC', 'CTOS', 'FlowsThe', 'TCR2 Therapeutics Inc.', 'Company', 'GSK Collaboration and License Agreement', 'the Condensed Consolidated Statement of Operations.15\\nTable of', 'on&#8203;other&#8203;&#160;&#160;&#160;&#160;translation &', 'Genentech', 'ContentsThe Company', 'Anderson Cancer Center (&#8220;MD', 'Results of Operations', 'GSK', 'The Genentech Collaboration and License AgreementThe', 'SME', 'additional &#8220;off', 'Cells Research, Collaboration and License Agreement and Co-development', 'additional &'}"
ADIL,
ADMA,"{'The Plasma Supply Agreement', 'the Delaware General Corporation Law', 'The Wall Street Journal', 'and\\n          ', '\\n                  Office', 'Anti-Kickback Statute', 'HHS', 'the Plasma Purchase Agreement to Grifols', 'Board', 'CMS', 'ADMA BioCenters.\\n          ', 'The Plasma Collection Centers', 'Corporate Integrity Agreements', 'Plasma Supply Agreement', 'the Biotest Transaction', 'Plasma Purchase Agreement&#8221;),\\n', 'the U.S. Congress', 'see &#8220;Liquidity', 'BIVIGAM', 'U.S. Food and Drug Administration', 'and\\n              ', 'RSV', 'Medicare', 'the Federal Food, Drug', 'Medicaid', 'post&#8209;FDA', 'ADMA', 'the adjusted Term Secured Overnight Financing Rate (&#8220;SOFR&#8221', 'the Maturity Date', 'ADMA BioCenters', 'the Hayfin Credit Facility', 'FDA', 'Restricted Payments', 'the Perceptive Credit Facility', 'IRB', 'ASCENIV', 'Investments', 'the Hayfin Credit Agreement).\\n\\n        \\n        \\n\\n        ', 'The Hayfin Credit Facility', 'not\\n', 'CMC', 'the HHS Office of Inspector\\n              ', 'NSP', 'Omicron', 'the Hayfin Credit Agreement.\\n\\n        \\n        \\n\\n        \\n', 'the\\n          U.S. Government', 'the\\n          Korean Ministry of Food and Drug Safety (&#8220;MFDS&#8221', 'the Hayfin Credit Agreement', 'Grifols', 'Immune Globulin Intravenous', 'Rate&#8221', 'PI', 'Associates, Inc.', 'SEC', 'Inborn Errors of Immunity', 'Company', 'Nabi-HB', 'the United States.\\n\\n', 'ADMA BioManufacturing', 'ADMA BIOLOGICS', 'and\\n              \\n\\n  ', 'The Hayfin Warrants', 'Plasma Purchase Agreement', 'the Hayfin Warrants', 'Certificate of Incorporation', 'the Sarbanes-Oxley Act', 'COVID-19', 'Results of Operations', 'the Hayfin Credit', 'Human &', '\\n               ', 'Biotest', 'Raymond James &amp', 'Nasdaq', 'Primary Humoral Immunodeficiency'}"
ADPT,
ADTX,"{'ASC', 'Amro Albanna', 'tissues.&#160;In', 'LLC', 'Cellvera Global\\nHoldings', 'Stanford', 'Security Agreement', 'the July Lender', 'Agility, Inc. (&#8220;Agility&#8221;).\\nAdditionally', 'MCA Agreement,\\nthe Company', 'the First Tranche Securities\\nPurchase Agreement', 'Conceptually', 'the July Loan Agreement', 'Governmental Bodies', 'H.C. Wainwright &amp', 'the LLU License Agreement', 'Tranche Securities', 'the August Loan Agreement', 'the First Tranche Securities Purchase Agreement', 'Subsequent Quarterly Bonus', 'First Tranche Shareholder Approval', 'Cellvera Global Holdings', 'the Second Tranche Securities\\nPurchase Agreement', 'the Share Exchange Agreement', 'GRA', 'defined\\nin', 'Revere Securities LLC', 'the Company&#8217;s Series C Preferred Stock', 'investors,\\nemployees and/or business partners.\\n\\n&#160;\\n\\nIn\\naddition', 'Internal Control Over Financial Reporting\\n\\n&#160;\\n\\nNo\\nchange', 'Agility;\\n', 'the Assignment Agreement', 'GRA;\\n  &#160;\\n\\n\\n\\n\\n\\n', 'Licensed Products', 'Original', 'pursuant\\nto', 'Company', 'successfully\\n&#8220;reversing&#8221', 'Tranche Shareholder', 'the U.S. Securities and Exchange Commission', 'the LLU Patent and Technology Rights', 'AditxtScore', 'the Preferred Stock', 'Collateral', 'Business Loan', 'the Aditx Therapeutics, Inc. 2017', 'the Second Tranche Note', 'Loan Agreement', 'Consents', 'Mayo Clinic', 'below.\\n\\n&#160;\\n\\nOn', 'the Asset Purchase Agreement', 'INTANGIBLE ASSETS\\n\\n&#160;\\n\\nThe\\nCompany&#8217;s', '8220;Initial Payment&#8221;).\\nThe Company', 'Board of Directors', 'the April Lender', 'Agility, Inc. (&#8220;Agility&#8221;).\\n\\n&#160;\\n\\nAdditionally,\\nupon', '\\n    &', 'Preferred Stock', 'Loma Linda University', 'the Certificate of Incorporation\\nimplementing', 'MCA', 'Form S-3', 'ADI', 'The Market Offering Agreement', 'the Board of Directors', 'the Acquired Assets', 'consultants.&#160;The Company', 'the Second Tranche Securities', 'The LLU License Agreement', 'Statements of Operations', 'the Public Float', 'Pre-Funded Warrants', 'Cellvera', 'LLU', 'the Second Tranche Securities Purchase Agreement', 'Tranche Note&#8221', 'SEC', 'and\\n  \\n    &', 'anti-dilutive.\\n\\n&#160;\\n\\nRecent\\nAccounting Pronouncements\\n\\n&#160;\\n\\nThe\\nFASB', 'Nasdaq', 'Tranche Security', 'Use\\nin the Licensed Territory'}"
ADUS,"{'LLC', 'Credit Agreement', 'ASU', 'amortization:\\n        &', 'Holdings', 'stakeholders.\\n  Components', '\\n    Business Metrics', 'EXHIBIT INDEX\\n  &', 'Management&#x2019;s', 'operations.\\n  &#160;\\n', 'the Tennessee Quality Care', 'the Company&#x2019;s Consolidated Statements of Income', 'Tri-County Home Health and Hospice', 'Capital One', 'See &#x201c;Liquidity', 'SharesThe', 'Medicare', 'the &#x201c;Credit Agreement,&#x201d', 'ServiceRevenues\\n        &', 'the Private Securities Litigation Reform Act', 'x201c;expects,&#x201d', 'x2014;\\n        &', 'this Quarterly Report on Form 10-Q', '\\n    &#160;-', 'National Association', 'Credit', '\\n  &#', '\\n          &#160;\\n', 'the Federal Reserve Bank', 'Restated Senior Secured Credit FacilityOn', 'the Credit Agreement', 'the Illinois Department on Aging', 'the Company&#x2019;s Unaudited', '26\\n', '\\n    ', '80\\n          &', 'Homecare', 'American Home Care', 'Home Health', 'Goodwill', '\\n        &', 'Restricted', 'SEC', 'AHC', 'Company', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'the Unaudited Condensed Consolidated Statements of Income', 'shares:&#160;\\n        \\n         \\n', 'Ambercare', 'OAS', 'the Sarbanes-Oxley Act', 'TQC &#', 'COVID-19', '\\n    Interest expense\\n    &', 'reporting.\\n', 'Significant Accounting', 'Home Health &', '47\\n          &#', 'PayorsThe', 'Adopted Pursuant to Section 302', 'Coastal Nursecare', 'respectively.\\n  Net', '\\n    &', 'ASU No', 'Results of Operations &', 'Internal Control Over Financial Reporting\\n', '\\n  Interest', 'ARPA'}"
ADVM,"{'Consolidated Statements of Operations', 'ContentsIntellectual', 'REGENXBIO', 'Regents of the University of California and Virovek', 'EYLEA', 'AMD', 'North CarolinaThe Company', 'the European Commission', 'HHS', 'Exhibit 32.1', 'Consolidated Statements', 'LUNA', 'the U.S. Congress', 'EMA', 'INFINITY', 'the Court of Chancery of the State of Delaware', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'EEA', 'ContentsSome', 'Annex', 'Consolidated Statements of Cash Flows', 'EU', 'FDA', 'Our Business OperationsNegative', 'AVA-101', 'NetProperty', 'FDA&#8217;s GMP', 'GMP', 'Cooperation Agreement', 'Principal Accounting Officer)68\\n\\n\\n', 'ContentsDurham', 'AVA&#8209;101', 'Risks Related', 'HIPAA', 'Basis of Presentation &#8212', 'SEC', 'ContentsAccrued Expenses and Other Current LiabilitiesAccrued', 'ContentsWe', 'ContentsResearch', 'ContentsAlthough', 'Company', 'the Securities Exchange Act', 'Party', 'CST', 'NetOther', 'ContentsHealthcare', 'the European Economic Area', 'USPTO', '*&', 'the NC Premises', 'ContentsIn', 'ContentsFor', 'Adverum Biotechnologies, Inc.', 'DME', 'Condensed Consolidated Financial Statements'}"
ADXN,
AEMD,
AEZS,
AFIB,"{'Consolidated Statements of Operations', 'ASC', 'L.P.', 'FASB', 'Credit Agreement', 'The Preferred Stock', 'Form S-3', 'inception.&#160;The Company', 'Restructuring', 'the Distribution Agreement', 'ii)&#160;the Condensed Consolidated Statements of Operations and Comprehensive Loss', 'deemed &#8220;filed&#8221', 'the Bi-Lateral Distribution Agreements', 'Critical Accounting Policies', 'Consolidated Statements', 'CommitmentsThe', 'Business Combinations (&', 'Deerfield Partners', 'State', 'Qualitative Disclosures', 'Intangible AssetsThe', 'Item 10 of Regulation S-K', 'Director(Principal Executive', 'Business CombinationsThe Company', 'Restricted CashThe Company', 'the Condensed Consolidated Balance Sheets', 'Transseptal Dilator/Needle', 'the ""2022 Credit Agreement', 'Restricted Stock Units', 'the Asset Purchase Agreement', 'the Registration Rights Agreement', 'the State of Delaware', 'Consolidated Statements of Cash Flows', 'ImpairmentGoodwill', 'the Condensed Consolidated Financial Statements', 'the Exchange Agreements', 'RSU', 'RestructuringThere', 'Lenders', 'the Bid Price Requirement', 'Medtronic', 'Acutus Medical', 'the Qubic Force Device', 'The Nasdaq Capital Market', 'EquitySeries A Common Equivalent Preferred Stock', 'Nasdaq\\', 'Distribution Agreement', 'Inline Extensible Business Reporting Language', 'Deerfield Private Design Fund III', 'Lease PropertyThe Company', 'SEC', 'ContentsSelling', 'Company', 'the Securities Exchange Act', 'Takeo', 'NetOther', 'the ""Preferred Stock""', ""Credit AgreementsThe Company\\'s"", 'the 2022 Warrants', 'the Sarbanes-Oxley Act', 'Consolidated Balance Sheets', 'Fair Value of Warrant LiabilityWarrants', 'the Company&#8217;s Board of Directors', 'RestructuringRestructuring', 'Page Interactive Data File', 'Deerfield Private Design Fund II', 'ASU No', 'Fair Value of Contingent ConsiderationFor', 'Products', 'Condensed Consolidated Financial Statements'}"
AFMD,
AGEN,
AGIO,
AGRX,
AHCO,"{'ASC', 'FASB', 'ASU', 'Financial ReportingExcept', 'Letter Agreement', 'ContentsEXHIBIT INDEXExhibitNumberDescription3.1Third Amended and Restated Certificate of Incorporation', 'ContentsGoodwill Impairment', 'this Quarterly Report', 'General Information - Recently Adopted Accounting Pronouncements', 'AdaptHealth Corp.', 'Item 408 of Regulation S-K', 'CPAP', 'Third Amended', 'AdaptHealth Holdings', 'Internal Control', 'the Board of the Company and Interim Chief Executive Officer', 'Medicare', 'Medicaid', 'InformationDuring', 'Treasury Stock', 'CompensationThe Company', 'EDPA', 'Complaint', 'stock2,0571082,057221Total17,88314,68817,88313,095(12)&#160;&#160;&#160;&#160;LeasesThe Company', 'the Derivative Complaint', 'AdaptHealth', 'AdaptHealth\\', 'agreements2 yearsDeveloped technology5 yearsThe Company', 'the Share Repurchase Program', 'Tax Receivable AgreementAdaptHealth Corp.', 'InflationCurrent', '2022AssetsInterest', 'Allegheny County Complaint', 'AeroCare', 'the Sarbanes-Oxley Act of', 'Compensation Stock Compensation', 'Interim Consolidated Financial Statements', 'ProceduresUnder', 'Goodwill', 'SEC', 'Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock', 'the Consolidated Complaint', 'the Consolidated Class Action', 'Company', 'Pursuant', 'Restated Certificate of Incorporation', 'the Securities Exchange Act', 'FASB ASC Topic', 'Exhibit 3.2', 'the Sarbanes-Oxley Act', 'Identifiable Intangible Assets', 'Preferred Stock', 'Acquisitions', 'Restated Bylaws', 'Rate SwapsThe Company', 'ASU No', 'Equity', 'ContentsADAPTHEALTH CORP.'}"
AHG,
AIH,
AIMD,"{'COVID19AntigenRapidTestKitsSalesMember2023', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001014763us', 'LiKuoLeeMember2023-01-012023-09-300001014763aimd', 'FASB', 'COVID19AntigenRapidTestKitsSalesMember2023-01-012023-09-300001014763aimd', 'the Nasdaq Capital Market', 'ASU', 'PreferredStockMember2022-09-300001014763us', 'QUARTERLY REPORT PURSUANT TO', 'Regulation S of the Securities Act', 'Registration Statement', 'SPA', 'PrivatePlacementMember2023-04-012023-04-260001014763aimd', 'VeldonaPetcytoproteinMember2023-09-300001014763aimd', 'ASE Test, Inc.', 'Ainos COVID-19 Antigen Rapid Test Kits', 'StockOptionAndWarrantsMember2023-01-012023-09-300001014763us', 'The United States Food and Drug Administration', 'COVID-19 Test Kits', 'Maxim Group', 'Yes &#9744', 'Maxim Partners', 'March2025ConvertibleNotesMember2022-01-012022-09-300001014763aimd', 'COVID19AntigenRapidTestKitsSalesMember2022-07-012022-09-300001014763aimd', 'THE SECURITIES EXCHANGE ACT OF 1934&#160;For', 'THE SECURITIES EXCHANGE ACT OF', 'NISD Inabata Codevelopment Agreement - August 9, 2023', 'PrivatePlacementMember2023-01-012023-09-300001014763us', 'TCNT', 'PreferredStockMember2022-01-012022-09-3000010147632021-12-310001014763us-gaap', 'Global Fund II LP Financing10.5&#160;Securities Purchase Agreement', 'LiKuoLeeMember2023-09-300001014763aimd', 'the Product Co-Development Agreement', 'COVID19AntigenRapidTestKitsSalesMember2022-12-310001014763aimd', 'COVID19AntigenRapidTestKitsSalesMember2022-01-012022-09-300001014763aimd', 'Product Co-Development Agreement', 'the Company.&#160;&#160;12Table of Contents&#160;March 2025 Convertible Notes &', 'POCT', 'March2025ConvertibleNotesMember2022-07-012022-09-300001014763aimd', 'Ainos KY', 'Warrant Agency', 'Orphan Drug Designation', 'Company', 'the Financial Accounting Standards Board', 'Taiwan Carbon Nano Technology Corporation', 'the Company adopted Accounting Standards Update', 'March2025ConvertibleNotesMember2022-12-310001014763aimd', 'Lind Global Fund II LP', 'Restated Bylaws of the Company', 'the Ainos COVID-19 Antigen Rapid Test Kit', 'Operations', 'PreferredStockMember2022-06-3000010147632022-09-300001014763us', 'RestrictedStockUnitsRSUMember2023-01-012023-03', 'RestrictedStockUnitsRSUMember2023-04-012023-06-300001014763us', 'COVID-19 Antigen Rapid Test Kits', 'PreferredStockMember2022-12-310001014763us-gaap', 'COVID-19', 'AinosKyMember2023-01-012023-09-300001014763aimd', 'the KY Note', 'VeldonaPetcytoproteinMember2022', 'AinosKyMember2023-09-300001014763aimd', 'Restated Bylaws', 'Partners Placement Agency', 'PreferredStockMember2022-07-012022-09-3000010147632022-06-300001014763us'}"
AIRS,
AKAN,
AKBA,"{'ASC', 'Vifor (International) Ltd.', 'ContentsAkebia Therapeutics, Inc.', 'the Working Capital Fund', 'EP Patent', 'ReturnsMember2022-12-310001517022akba', 'BostonMember2023', 'Reliance', 'THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS6.FAIR VALUE OF FINANCIAL', 'the Taiwan Food and Drug Administration', 'Fresenius Medical Care North America', 'Assignment of Supply Agreement', 'License Performance Obligation', 'the Otsuka International Agreement', 'this Quarterly Report on Form 10', 'the Transitional Drug Add-on Payment Adjustment', 'BostonMember2022', 'IDA', 'EMA', 'the Panion Letter Agreement', 'The Sarbanes-Oxley Act', 'CostOfSalesMember2022', 'MMA', 'Principal Executive Officer', 'the Otsuka U.S. Agreement', 'Zydus Lifesciences Limited', 'EEA', 'this Quarterly Report on Form 10-Q', 'Revenue RecognitionThe Company', 'Akebia Against', 'ProductMember2023', 'Jefferies LLC', 'Page 71Table', 'ContentsRISK FACTORS SUMMARYInvesting', 'EU', 'the License Deliverable', 'Averoa License Agreement  ', 'Otsuka U.S. Agreement', 'Therapeutics, Inc.', 'the Averoa License Agreement', 'the Boston Lease', 'the Condensed Consolidated Financial Statements', 'Page 44Table', 'the Internal Revenue Code', 'ours;&#8226;a', 'Page 10Table', 'Nasdaq\\', 'ComponentsProduct', 'CPRA', 'CambridgeMember2017-01-012017-01', 'FlowsThe', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001517022us-gaap', 'Astellas Pharma Inc.', 'CSL Limited', 'the Securities Exchange Act', 'the heading &#8220;Risk Factors&#8221', 'the European Economic Area', 'BioVectra Termination Agreement', 'NOL', 'ContentsDirector', 'Panion Amended License Agreement', 'DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember2023-07-012023-09-300001517022akba:', 'JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2023-07-012023-09-300001517022akba:LicenseAgreementMemberakba', 'Jefferies', 'Cardinal Health, Inc.', 'COVID-19', 'First Investment Agreement', 'PMR', 'Goods Sold - Product', 'Contentscoordinate', 'ContentsIn', 'MTPC', 'Akebia Therapeutics, Inc.', 'Fair', 'Particulars of Claim', 'Anti-Kickback Statute', 'Otsuka\\', 'HHS', 'Chamber', 'Principal Executive Officer Required Under Rule', 'Fresenius Kidney Care Group', 'Medice', 'SublicenseAgreementMember2022-07-012022-09-300001517022akba:', 'Foundation', 'the Department of Justice', 'THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSYears', 'OperatingLease', 'FDCA', 'MEDICEArzneimittelPutterGmbHCoKGMember2023-04-012023-06-300001517022us-gaap', 'THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS606', 'the Termination Agreement', 'NDD', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'Medicare', 'Medicaid', 'the U.S. Department of Justice', 'Congress', 'the Supply Group', 'Torii Sublicense Agreement', 'GDPR', 'the European Patent Office', 'the Manufacture and Supply Agreement', 'the Panion License Agreement', 'FDA', 'the Patheon Agreement', 'AccountsPayableMember2022-01-012022-09-300001517022us-gaap', 'Panion', 'FibroGen', 'ContentsAny', 'GXP', 'Otsuka', 'DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember2023-01-012023-09-300001517022akba:', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001517022us', 'the Termination and Settlement Agreement', 'Averoa License Agreement', 'MaximumMember2022-04-072022-04-070001517022akba:AtTheMarketEquityOfferingProgramMembersrt:MaximumMember2020-03-122020-03-120001517022srt', 'Nicole R. Hadas.10.4&#8224;Separation Agreement', 'Second Amendment Effective Date', 'Mitsubishi Tanabe Pharma Corporation', 'CKD', ""Unconditional Purchase Commitment AgreementsThe Company\\'s"", 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR', 'ReturnsMember2022-01-012022-09-300001517022akba:', 'Page 25Table', 'Registration Statement on', 'Risks Related', 'Financial ArrangementsOur', 'HIPAA', 'Jefferies LLC.Sales', 'FTC', 'Siegfried Evionnaz SA', 'Company', 'the Second Amended and Restated License Agreement', 'Cyclerion', 'ProceduresThe Company', 'KeryxBiopharmaceuticalsIncMember2022-07-012022-09-300001517022akba:', 'SegmentsWe', 'Future Lease Commitments Future', 'USPTO', 'THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSanemia', 'Pharmakon Advisors LP', 'BostonMember2023-01-012023-06-300001517022akba:', 'the Panion License Agreement, Panion', 'the Esteve Agreement', 'Vafseo', 'FibroGen Inc.', 'JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2022', 'The Averoa License Agreement', 'ASC606', 'the Panion License Akebia Therapeutics, Inc.', 'the Merger Sub', 'Cantor Fitzgerald &amp', 'European Patent', 'the National Institute of Allergy and Infectious Disease Ordinal Scale', 'the Nasdaq Capital Market', 'Principal Financial Officer Required Under Rule 13a-14(b', 'Medice\\', 'BioPharma Credit Investments V', 'Collateral', 'the Medice Effective Date', 'CMS', 'The Siegfried Agreement', 'the U.S. Patent and Trademark Office', 'Loan Agreement', 'Japan Tobacco International', 'Principal Financial Officer Required Under Rule', 'Cyclerion Agreement', 'MaximumMemberakba', 'Panion of approximately $3.1 million and $9.3 million', 'the License Performance Obligation', 'CSL Vifor', 'Loper Action', 'Bayer', 'the Cyclerion Agreement', 'ActivitiesNet', 'the U.S. Department of Health and Human Services', 'Page 88Table', 'Esteve', 'Torii Sublicense AgreementThe Company', 'Auryxia;Akebia Therapeutics, Inc.', 'BioVectra', 'AgreementThe Company', 'Panion&#160;&amp', 'LicenseCollaborationAndOtherRevenueMember2022-01-012022-09-300001517022akba:', 'the GDPR.The GDPR', 'the Nasdaq Stock Market', 'License', 'Sales Agreement', 'MEDICE Arzneimittel P&#252;tter GmbH &amp', 'Stockholder Litigation Relating', 'FMCNA', 'THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSOn', 'Alpha Therapeutics Merger Sub, Inc.', 'ReturnsMember2023', 'Otsuka International Agreement', 'Board of Directors', 'McKesson Corporation', 'the Medice Territory', 'ProductMember2022', 'DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember2022-07-012022-09-300001517022akba:', 'ReturnsMember2022', 'ASC Akebia Therapeutics, Inc.', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001517022us-gaap', 'DD-CKD', 'the Otsuka International Territory', 'NDA', 'The Nasdaq Capital Market', 'Esteve Agreement', 'IRA', 'Page 92Table', 'AstraZeneca PLC', 'the IDA Indication', 'FairValueMeasurementsRecurringMember2023', 'the Sarbanes-Oxley Act', 'the Master Manufacturing Services', 'The Medice License Agreement', 'Regulation S-K', 'JapanTobaccoIncorporationAndToriiPharmaceuticalCompanyLimitedMember2023-01-012023-09-300001517022akba:LicenseAgreementMemberakba', 'SublicenseAgreementMember2022-01-012022-09-300001517022akba:AveroaSASMember2022-12-222022-12-220001517022us-gaap', 'Recent Accounting', 'the Esteve Assignment Agreement', 'ContentsAgreement', 'the Second Investment Agreement', 'Amended and Restated Sublicense Agreement', 'Intellectual Property High Court', 'the U.S. Federal Food, Drug', 'LicenseCollaborationAndOtherRevenueMember2022-07-012022-09-300001517022akba:', 'the FDA&#8217;s Orange Book', 'BF Biotech, Inc.', 'Keryx Biopharmaceuticals, Inc.', 'BioPharma Credit PLC', 'the Clinical Development Program', 'the Loan Agreement', 'Cyclerion Therapeutics Inc.', 'Foundation Medicine, Inc.', 'Pharmakon', '2022.The Company', 'Amerisource Bergen Drug Corporation', 'the Packaging Validation Transfer Agreement', 'the U.S. Federal Trade Commission', 'ATM', 'Esteve Assignment Agreement', 'andAkebia Therapeutics, Inc.', 'the Consolidated Financial Statements', 'KeryxBiopharmaceuticalsIncMember2022-01-012022-09-300001517022srt', 'Therapeutic Goods Administration', 'NET', 'Pharmakon Loan Agreement See Debt Financing and Covenants Below', 'Royalty Agreement', 'HCR', 'Patheon', 'Amendment of Ninth Amended', 'the MODIFY Study', 'Otsuka Pharmaceutical Co. Ltd.', 'Medicaid Services', 'DevelopmentAndCommercializeInternationalCollaborationAndLicenseAgreementMember2022-01-012022-09-300001517022akba:', 'CambridgeMember2016', 'Second Investment Agreement', 'InflationWe', 'International Collaboration and License Agreement', 'the OTC Markets', 'Contentsunderwritten', 'The First Investment Agreement', 'Vadadustat', 'the Medicare Prescription Drug', 'the Vifor Agreement', 'Panion License Agreement', 'Zydus Pharmaceuticals (USA) Inc.', 'SEC', 'the Pharmakon Loan Agreement', 'SOFR', 'CRL', 'the Office of General Counsel', 'Bayer HealthCare AG', 'Collaboration and License Agreement', 'the Delaware District Court', 'Termination Agreement', ""Australia\\'s"", 'Fresenius Medical Care Rx', 'ContentsFailure', 'the Centers for Medicare &', 'the Patents Court', '2022 Annual Report', 'the Medice License Agreement', 'the MTPC Supply Agreement', 'Nasdaq', 'the BioVectra Termination Agreement', 'the First Investment Agreement', 'the Panion Amended License Agreement'}"
AKLI,"{'ASC', 'Good Manufacturing Practices', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001850266us', 'Fair Value of Financial Assets', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001850266akli', '\\n', 'Security Agreement', 'the Annual Report', '2022\\n         \\n         \\n          ', 'ProductMember2023', 'LoanAndSecurityAgreementMember2023-01-012023-09-300001850266us', 'LoanAndSecurityAgreementMember2023-07-012023-09-300001850266us', 'EU', 'the &#', 'the Company&#x2019;s Common Stock', 'Note Payable Amended and Restated Loan', 'Nasdaq Staff', 'discount\\n        &#160;\\n        ', 'CashAndCashEquivalentsMember2023-01-012023-09-300001850266us', 'adults;\\n  &#x2022;our', 'the European Economic Area', 'COVID-19', 'SVB Innovation Credit Fund VIII', 'the &#x201c;SVB Term Loan&#x201d;)', 'ARPU', '\\n  &#x2022;expenses', 'the University of California San Francisco', 'and\\n  &', 'First-Citizens Bank &amp', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001850266us', '\\n  &#x2022;amount', 'WarrantMember2023-07-012023-09-300001850266us-gaap', 'FASB', 'Earn-Out Service Providers', '\\n  &#x2022;product', 'Amended and Restated Loan', 'x201c;Risk', '\\n  &#x2022;refusal', 'Medicaid', 'Medicare', 'EndeavorRx', '27\\n', 'GDPR', 'EndeavorRx revenue\\n          &#160;\\n          149\\n          &#160;\\n', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Shionogi &amp', '\\n  &#x2022;clinical', 'CollaborationRevenueMember2022', '\\n  &#x2022;Our', 'and\\n  &#', 'candidates;\\n  &#x2022;our', 'the Consolidated Statements of Operations and Comprehensive Income', 'Risks Related', 'Social Capital Suvretta Holdings Corp.', 'Interactive Labs, Inc.', '\\n  &#x2022;fines', 'activities\\n    &', '\\n  Commission File Number', 'Company', 'PII', '2023;\\n  &#', '\\n  &#x2022;facilities', 'Legal Matters \\n', 'the Nasdaq Capital Market (&#x201c;Nasdaq&#x201d;)', '\\n  &#x2022;injunctions', 'the Listing Qualifications Staff', 'the Apple Store', 'Charter)\\n  &#', 'Boston Office Space', 'SVB', '\\n  &#x2022;whether', 'tROC\\n  &#', '\\n    &#', 'Signature Bank', 'x2014;\\n          &', 'L.P.', 'the U.S. Federal Reserve', 'Akili, Inc.', 'SVBB', '\\n  ', 'See &#x201c;Cautionary Statement Regarding Forward-Looking', 'the Earn-Out Shares', 'Nasdaq (the &#', '\\n  &#x2022;the', 'Contractual Obligations \\n', 'First Citizens BancShares, Inc.', 'LoanAndSecurityAgreementMember2023-09-300001850266akli', 'see &#x201c;Business &', 'Improve Electronic Data Security Act', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', '\\n  Acquisitions', 'Trust Company', '\\n  &#', 'UnvestedPhantomShareUnitsPsusMember2023-01-012023-09-300001850266us', 'License, Development and Commercialization Agreement', 'RestrictedStockUnitsRSUMember2023-09-300001850266us', 'agreement.\\n  &', 'FDIC', '\\n  &#x2022;cost', 'FairValueMeasurementsRecurringMember2023', 'the COVID-19 Transition Guidance', 'ASU No', '\\n  &#x2022;our', 'the U.S. Department of Treasury', 'this Quarterly Report', 'WarrantMember2022-01-012022-09-300001850266us', 'Silvergate Capital', 'candidate.\\n  &#x2022;Clinical', 'treat.\\n  &#x2022;If', '\\n  Collaboration Revenue \\n', '\\n  &', 'Nasdaq&#x2019;s', 'Earn-Out Shareholders', '\\n  &#x2022;restrictions', '\\n  Inherent Limitations on Effectiveness of Controls\\n', 'authorization.\\n  &#x2022;We', 'MaximumMember2023-06-012023-06-300001850266akli', '\\n          &#160;\\n', 'Corporate Bond\\n        &', 'Digital', 'Healthcare', 'administrative&#x2014;SG&amp;A', 'PMA', 'Significant Accounting Policies', 'UnvestedPhantomShareUnitsPsusMember2023-07-012023-09-300001850266akli', '\\n        \\n         \\n', 'SEC', 'future products;\\n  &#x2022;our', 'Google PlayTM', 'the &#x201c;Company&#x201d;)', 'the Business Combination', 'the &#x201c;Collaboration', 'WarrantMember2023-01-012023-09-300001850266us', 'Co., Ltd (&#x201c;Shionogi&#x201d', 'United States Treasuries', 'SCS', 'THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n  (dollars', 'investment:\\n  &#x2022;We', 'Digital Limited', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001850266us', 'Nasdaq', 'Apple App', '\\n    &', 'Government Regulation &'}"
AKRO,"{'ASC', 'API', 'EC&#x2019;s', 'protocols;\\n  &#x2022;inspection', 'LLC', 'and\\n  &#x2022;reliance', 'may:\\n  &#x2022;issue', 'the future;\\n  &#x2022;negotiate', 'the EU Commission', 'EEA', 'this Quarterly Report on Form 10-Q', 'the Patient Protection', 'others.\\n  &', 'Jefferies LLC', 'EU', 'criteria;\\n  &#', 'Akero Securities Corporation', 'Lender', 'the Term Loan', 'and\\n  &#x2022;analogous', 'Amgen, Inc. (&#x201c;Amgen&#x201d', 'SYNCHRONY', 'x2022;a', 'countries;\\n  &#x2022;developments', '\\n    Research', 'Office of Inspector General', 'California Consumer Privacy Act', 'ACA', 'the Amgen Agreement', 'technologies.\\n  Depending', 'Research', '\\n  Research', 'operations;\\n  &#x2022;the', 'EFX', 'and\\n  &#x2022;payments', 'and\\n  &', 'our shares;\\n  &#x2022;announcement', 'Warrants', 'the Department of Health and Human Services&#x2019', 'accrualsThe Company', 'Company&#x2019;s 2018 Stock Option', 'HHS', 'the Department of Justice', 'Restated Certificate of Incorporation of the Registrant', 'x201c;Risk', 'Internal Control', 'Amgen;\\n  &#x2022;the', 'property.\\n  &', 'Grant Plan', 'Medicare', 'Congress', 'Medicaid', 'technologies.\\n', 'The Executive Order', 'products;\\n  &#', 'GDPR', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Consolidated Financial', 'Exhibit 3.1', 'reporting.\\n  &', 'agreements.\\n  &', 'and\\n  &#x2022;intellectual', 'and\\n  &#', 'HIPAA', 'others:\\n  &#x2022;failure', 'capital commitments;\\n  &#x2022;regulatory', 'BALANCED', 'personnel.\\n  &#', 'Company', 'and\\n  &#x2022;attract', 'analysts;\\n  &#x2022;variations', 'conditions.\\n  &', 'ContentsAkero Therapeutics', 'and\\n  &#x2022;the', 'USPTO', '\\n    Interest expense\\n    &', 'SYMMETRY', 'Results of Operations', 'Grant Plan\\n        &', '\\n    &#', 'healthcare practitioners;\\n  &#x2022;require', 'Loan Payable', 'supply;\\n  &#x2022;launch', 'CMS', 'candidates;\\n  &#', 'Loan Agreement', 'J.P. Morgan Securities', 'HARMONY', 'all;\\n  &#x2022;an', 'the Unaudited Condensed Consolidated Financial Statements', 'Boehringer Ingelheim', 'technologies;\\n  &#x2022;regulatory', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'impracticable.\\n  &', 'Pfizer, Inc.', 'License', '\\n  &#', 'CMC', 'Unaudited Condensed Consolidated Financial Statements(Amounts', 'Loan Agreement\\n        &', 'the Health Care and Education Reconciliation Act', ""Management\\'s Discussion and Analysis of Financial Condition"", 'Amgen', 'Medicare Advantage', 'patentable;\\n  &#x2022;the', 'Form S-3 Registration Statement', 'awards2018 Stock', 'Contractual', 'recall.\\n  &', 'Tranche', '\\n  &#x2022;mandate', 'Comparison', 'Series A Preferred Stock to Amgen', 'products;\\n  &#x2022;actual', 'percentages)\\n    &', 'FDA.\\n  &#160;\\n', 'the Loan Agreement', 'revenue;\\n  &#x2022;diversion', 'the International Data Transfer Agreement and International Data', 'Hercules Capital, Inc.', 'Inherent Limitations on Effectiveness', 'ATM', 'including:\\n  &#x2022;the', 'Dear Healthcare Provider', 'x2022;refuse', 'and\\n  &#x2022;general', 'Protecting Our Intellectual Property \\n', 'Incentive Plan\\n        &', 'us;\\n  &#x2022;suspend', 'products;\\n  &#x2022;address', 'the Registrant&#x2019;s Current Report', 'patents;\\n  &#x2022;issued', 'partners.\\n  &', 'Accounting Standards Codification', '\\n        &', 'SEC', 'agreements.\\n', 'the &#x201c;Company&#x201d;)', 'noncompliance;\\n  &#', 'the Federal Trade Commission Act', 'price.\\n  &', 'candidates;\\n  &#x2022;competitors', 'the FDA&#x2019;s Quality System Regulation', 'ContentsAkero Therapeutics, Inc.Notes', 'and\\n  &#x2022;lack', '\\n    &', 'property.\\n'}"
AKTX,
AKYA,"{'ASC', 'FASB', 'LLC', 'Capital ResourcesAs', 'PKI', 'the License Agreement', 'Innovatus', 'LiquiditySince', 'ContentsResults', 'the Equity Distribution Agreement', 'Rule&#160;12b-2', 'ended &#8203;Nine months ended &#8203;&#8203;September&#160;30,&#160;&#8203;September&#160;30,&#160;&#8203;&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022Net loss&#8203;$', 'Contracts with Customers', 'ATM', 'ContentsAkoya', 'ended &#8203;Nine months ended &#8203;&#8203;September&#160;30,&#160;&#8203;September&#160;30,&#160;&#8203;&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022North', 'December&#160;31', 'the customer).Service and Other RevenueProduct', 'the Interactive Data File', 'FDA', 'Morgan Stanley &', 'QPS', 'Principal Executive Officer Pursuant', 'Loan', 'Disaggregation of RevenueThe Company', 'profit&#8203;$', 'Acrivon Therapeutics, Inc.', 'ContentsThe', '5,107&#160;&#8203', 'Registrant', 'Piper Sandler &amp', 'the &#8220;Optional Shares&#8221', 'the Quarterly Report on Form&#160;10-Q.', 'Company', '12,325Total', 'CMO', 'the Securities Exchange Act', 'ended &#8203;&#8203;&#8203;&#8203;&#8203;&#160;&#8203;&#8203;September&#160;30,&#160;&#8203;Change&#160;($', 'the Sarbanes-Oxley Act', 'the Midcap Trust Term Loan', 'ContentsThe Acrivon Agreement', 'Consolidated Statements&#160;of Operations', 'Page Interactive Data File', 'Company&#160;under', 'Principal Financial and Accounting Officer Pursuant', 'CPO', 'Innovatus Life Sciences Lending Fund I, LP (&#8220;Innovatus&#8221'}"
ALDX,"{'ASC', 'Reliance', 'Security Agreement', 'the Option Agreement', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'EU', '\\n  &#x2022;result', 'ALDEYRA THERAPEUTICS', 'the Internal Revenue Code', 'technologies;\\n  &#x2022;maintain', 'Consolidated Appropriations Act', 'Indicate', '26\\n', 'the Department of Labor', 'ADX-629', 'CPRA', 'Treasury', '2021 Jefferies Sales Agreement', 'Option', 'the Securities Exchange Act', 'NOL', 'AbbVie', 'and\\n  &#x2022;expand', 'us.\\n  &', '\\n  &#x2022;prevent', 'Massachusetts Eye', '\\n  &#x2022;expenses', 'the Wall Street Journal', 'HHS', 'Trade Control Laws', 'the Fourth Loan Tranche', 'Regulation (EC', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'x2014;\\n        &', ': &', 'reproxalap;\\n  &#', 'FDA', 'Loan', 'Risks Related', 'HIPAA', 'Company', '\\n  &#x2022;perceived', 'the Prime Rate', 'USPTO', 'TAXES', 'Manufacturers', 'Results of Operations', 'the California Privacy Rights Act', 'the Health Insurance Portability', 'NIP', '\\n  &#160;\\n', 'the California Consumer Privacy Act', 'herein.\\n  &', 'the Delaware General Corporation Law', '\\n  &#x2022;cause', 'the Selected Schedule Evaluation Period', '\\n  &#x2022;responding', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Hercules Credit Facility', '\\n  &#x2022;the USPTO', '\\n  &#', 'the Supplemental End of Term Charge', 'CMC', 'European Parliament', 'the Northern Ireland Legislative Assembly', 'Helio Vision, Inc.', 'products.\\n  &', 'The Nasdaq Capital Market', 'candidates;\\n  &#x2022;pursue', '\\n  &#x2022;require', 'NDA', 'FASB ASC Topic', 'Fourth Loan Tranche', 'Tranche', '47\\n', 'the 2021 Jefferies Sales Agreement', 'companies&#x2019', 'reputation.\\n  &', '\\n  &', 'the Court of Chancery of the State of Delaware', 'Finance', 'European Council', 'Nasdaq&#x2019;s', 'the Option Agreement Effective Date', 'the UK Parliament', 'the Registrant&#x2019;s Current Report', 'Lender&#x2019;s', 'Employee Matters', '\\n        &', 'SEC', 'Trade Control', 'the Food and Drug Administration', 'Helio Vision', 'AbbVie Inc.', '42\\n  \\n  &#', 'the Northern Ireland Protocol', 'Nasdaq', 'Corporate Integrity Agreements', '\\n    &', 'the Option Extension Fee'}"
ALEC,"{'ASC', '\\n  &#x2022;injury', 'AL002 LTE', 'EC', 'FTD', '\\n  &#x2022;variations', 'The Sarbanes-Oxley Act', 'technologies;\\n  &#x2022;collaborators', 'EMA', '\\n  &#x2022;volatility', '\\n  &#x2022;developments', 'Sarbanes-Oxley Act Section', 'the GSK Agreement', '\\n  &#x2022;costs', 'Trademark Office', 'use.\\n  Risks Related', '\\n  &#x2022;compliance', 'Court', 'x2022;a', 'GSK Agreements', '\\n  &#x2022;differing', '\\n    Research', 'FTD-GRN', 'the U.S. Congress of the', 'GlaxoSmithKline plc', 'Condensed Consolidated Statements of Cash Flows \\n', 'AbbVie', 'data)\\n  &#160;\\n', 'COVID-19', '\\n  &#x2022;workforce', 'the Co-Development and Option Agreement', 'marketable&#160;&#160;&#160;securities\\n    &', '\\n  &#x2022;expenses', 'Condensed Consolidated Statement', 'compensation\\n    &', 'the Principal Financial and Accounting Officer', 'the Fast Track designation.\\n  Fast Track', '\\n  &#x2022;product', '\\n  &#x2022;sufficient', '\\n  &#x2022;publicity', '\\n  &#x2022;substantial', '\\n  &#x2022;assimilation', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'Congress', 'the Securities and Exchange Commission', 'IND application.\\n', 'and\\n  ii\\n', 'Condensed Consolidated Balance Sheets\\n', '\\n  &#x2022;general', 'Compensation Stock', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'statements.\\n  &', '\\n  &#x2022;clinical', '\\n  &#x2022;difficulties', 'Research and Development Expenses \\n  Research', 'and\\n  &#', 'Consumer Protection Act', '30\\n', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', '\\n  &#x2022;others', '\\n  &#x2022;regulatory', 'plan\\n    &', '\\n  &#x2022;occurrence', 'activities\\n    &', 'AL002', 'Company', '\\n  &#x2022;facilities', '\\n  &#x2022;Analogous', 'USPTO', 'AbbVie Biotechnology, Ltd.', '\\n  &#x2022;laboratory', '\\n  &#x2022;impose', 'Federal Circuit', 'UK Bribery Act', 'Department of Justice', 'CTA', '\\n  &#x2022;seize', 'Institutional Review Board', 'the European Commission', '\\n  &#x2022;addition', 'FCPA', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'Stockholders&#x2019', '\\n  &#x2022;assumption', '\\n  &#x2022;sales', '\\n  &#x2022;exhaustion', '\\n  &#x2022;commencement', 'Item 408 of Regulation S-K).\\n  &', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', '\\n  &#x2022;retention', '\\n  &#x2022;diversion', '\\n  &#x2022;require', 'Condensed Consolidated Statements of Operations and Comprehensive Income', '\\n  &#x2022;trade', 'use.\\n  Obtaining', '\\n  &#x2022;negative', 'Condensed Consolidated Financial Statements\\n', '\\n  &#x2022;existing', 'obligation.7\\n       &', '\\n  &#x2022;inability', '\\n  &#x2022;announcement', 'the Sarbanes-Oxley Act', 'IPO', 'Comparison', '\\n  &#x2022;our', '\\n  &#x2022;key', 'ARIA', 'Hamas', 'Form S-3', '\\n  &#x2022;convenience', 'Restricted Cash The Company', '\\n    Balance &#', '\\n  &', '\\n  &#x2022;delays', '\\n  &#x2022;business', 'x2022;refuse', 'the State of Delaware', '\\n  &#x2022;risks', '\\n  &#x2022;restrictions', 'AbbVie).\\n  &#x2022;We', '\\n  &#x2022;suspend', '\\n  &#x2022;identifying', 'GSK Agreement', '\\n  &#x2022;successful', '\\n  &#x2022;withdrawal', 'SEC', '\\n  &#x2022;potential', 'Collaboration and License Agreement', 'Liquidity and Capital Resources \\n', 'NASDAQ', 'operating&#160;&#160;&#160;activities:\\n    &', 'Glaxo Wellcome UK Limited', 'GSK', '\\n  &#x2022;failure', 'AL101 AD', 'x2022;as', 'the European Union', '\\n  &#x2022;actual', 'Fair Value of Financial Instruments', '\\n    &', 'the Principal Executive Officer', 'No &#9744;\\n  Indicate', 'property.\\n', 'collaborator&#x2019;s', '\\n  &#x2022;expiration'}"
ALGN,
ALGS,"{'ASC', 'LLC', 'MaximumMemberalgs', 'Inventiva Pharma SA', 'MerckLicenseAndResearchCollaborationMember2022-01-012022-01-310001799448us-gaap', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001799448algs', 'Galmed Pharmaceuticals Ltd.', 'Amoytop Biotech Co., Ltd', 'Jefferies LLC', '\\n  &#x2022;costs', 'the KU Leuven Agreement', 'EU', '\\n  &#x2022;completing', 'EquipmentMember2023', '\\n  &#x2022;analogous', 'x2022;a', 'ATM Offering Programs', 'Pfizer Inc.', 'Indicate', 'UNITED STATES', 'Sarbanes-Oxley', 'Viking Therapeutics', 'EUA', 'HBeAg', '\\n    Research', 'Form S-1', 'FronThera US Pharmaceuticals', 'ACA', 'the Children&#x2019;s Health Insurance Program', 'the Securities Exchange Act', '\\n    &#160;&#160;&#160;Restricted cash\\n    &', '\\n    &#160;&#160;&#160;Acquisition', 'Contracts with Customers (ASC', 'impacted.\\n  &#x2022;Our', '\\n  &#x2022;establishing', '\\n  &#x2022;expenditures', 'COVID-19', 'this Expanded Arrangement, Merck', 'THR&#x2011;&#xdf', '\\n  &#x2022;obtaining', 'Eli Lilly and Company', 'Gilead, Intercept Pharmaceuticals, Inc.', 'Takeda Pharmaceutical Company Limited', 'stock.\\n  Risks', 'FASB', '\\n  &#x2022;rights', 'the Centre for Drug Design and Discovery', '\\n  &#x2022;adverse', 'Anti-Kickback Statute', 'the Centre for Drug Design', '\\n    Preferred Stock', '\\n  &#x2022;product', '\\n  &#x2022;substantial', 'ALIGOS THERAPEUTICS,', '4,816\\n    &', 'NGM Biopharmaceuticals, Inc.', '\\n  &#x2022;initiation', '\\n  &#x2022;issued', '\\n  &#x2022;defending', '\\n  &#x2022;refusal', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', '\\n  &#x2022;any', 'GDPR', '\\n  &#x2022;expanding', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'LuxnaBiotechCoLtdMember2023-01-012023-09-3000017994482022-01-012022-12-3100017994482022-09-300001799448algs', 'x201c;seek,&#x201d', '\\n  &#x2022;maintaining', '30\\n', '\\n  &#x2022;others', '\\n  &#x2022;loss', 'HIPAA', '\\n  &#x2022;negotiating', 'REMS', '\\n  &#x2022;fines', 'Incyte Corporation', 'Company', 'Terns Pharmaceuticals, Inc.', 'MerckMemberalgs', 'expense)\\n    &', 'USPTO', 'Adopted Pursuant to Section 302', 'CHB', '\\n  &#x2022;injunctions', 'FCA', 'KU Leuven&#x2019;s Rega Institute for Medical Research', '\\n  &#x2022;whether', 'Genfit SA', 'Development Agreement and Research Collaboration Agreement', '\\n  &#x2022;achieving', '\\n    &#', '7\\n     &#160;The Company', 'GLP', 'the Delaware General Corporation Law', 'LuxnaBiotechCoLtdMember2023-07-012023-09-300001799448us-gaap', '89bio, Inc.', 'Novo Nordisk A/S', 'CMS', 'Madrigal Pharmaceuticals', 'AbbVie, Inc.', 'collaborations\\n    &', '\\n    &#160;&#160;&#160;Vesting', 'Merck', '\\n  &#x2022;future', 'Phase 2', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', '\\n  &#x2022;adoption', 'Stockholders&#x2019', 'Alexion Pharmaceuticals Inc.', 'HBV', 'the Department of Health and Human Services', '\\n  &#x2022;coverage', 'x2022;we', 'VehiclesMember2023', 'ALG-097558', 'Roche', 'Pfizer, Inc.', '\\n  &#x2022;exhaustion', '\\n  &#x2022;launching', '\\n  &#', 'ATM Offering Program', '\\n  &#x2022;managing', 'the Nasdaq Stock Market LLC', '\\n  &#x2022;collaborators', 'NonVotingCommonStocksMember2023', 'MediciNova, Inc.', 'Akero Therapeutics, Inc.', 'FixedMaturitiesMember2022-07-012022-09-300001799448algs', '\\n  &#x2022;decreased', 'Sanofi S.A./Regeneron Pharmaceuticals', 'NDA', 'a Medication Guide', 'Atea Pharmaceuticals, Inc.', 'CONDENSED CONSOLIDATED BALANCE SHEETS \\n', 'Novartis Pharmaceuticals Corporation', '\\n  &#x2022;technological', 'x201c;anticipate,&#x201d; &#', 'the Sarbanes-Oxley Act', '\\n  &#x2022;inability', 'and\\n  &#x2022;delays', 'the indemnified party', 'IPO', 'prospects.\\n  &', 'Bristol-Myers Squibb Company', 'the Center for Innovation and Stimulation of Drug Discovery', 'Galectin Therapeutics Inc.', '\\n  &#x2022;our', 'respectively.\\n    &', 'HemoShear Therapeutics', 'the Rega Institute for Medical Research', 'NASH', 'Good Laboratory Practice', 'Form S-3', 'Emory University', 'EmoryUniversityMember2018-06-300001799448us-gaap', '\\n  &#x2022;convenience', 'Enanta Pharmaceuticals, Inc.', '\\n  &#x2022;We', '\\n  &#x2022;reliance', '\\n  &#x2022;seeking', 'LeaseholdImprovementsMember2022-12-310001799448us-gaap', 'iii\\n', '\\n  &', 'Unaudited Condensed Consolidated Financial Statements\\n    ', '\\n  &#x2022;delays', 'The Anti-Kickback Statute', 'Luxna Biotech Co., Ltd.', 'Nasdaq&#x2019;s', 'the ADC Therapeutics', 'the Emory License Agreement', 'Complaint', 'Pliant Therapeutics, Inc.', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', '\\n  &#x2022;efficacy', 'Sanofi S.A.', 'FairValueInputsLevel1Member2022-12-310001799448us-gaap', 'the OTC Markets', '\\n  &#x2022;If', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Centre for Drug Design', 'Aligos Therapeutics, Inc.', '\\n    Interest', '\\n        &', 'SEC', 'GCP', 'USTreasurySecuritiesMember2022-12-310001799448us-gaap', 'IU/mL', 'USTreasurySecuritiesMember2022-12-310001799448algs', 'FixedMaturitiesMember2022-01-012022-09-3000017994482022-12-310001799448algs', 'Novartis', 'the Federal Trade Commission Act', 'Cirius Therapeutics, Inc.', 'Nasdaq', 'the European Union', '\\n    &', 'AstraZeneca PLC', 'MerckLicenseAndResearchCollaborationMember2022-01-310001799448us-gaap', 'ETV'}"
ALHC,"{'the Company&#x2019;s Registration Statement on Form S-1', 'The Oxford Loan Agreement', 'LLC', 'the Loan Agreement', 'CMS &', 'CMS', 'The Code of Federal Regulations', 'partners.\\n  &#x2022;Drive Growth', 'Oxford Finance', 'The National Association of Insurance Commissioners', '\\n  &', 'IPA', 'Exhibits.\\n  &#160;\\n', 'Medicare', 'Community Health', 'the Compensation Committee', 'Unregistered Sales of Equity', 'the Oxford Loan Agreement', 'Health Plan', '\\n  &#', 'revenue)\\n    &', 'SEC File No', 'Lenders', '\\n    ', 'information.\\n  &', 'the &#x201c;Exchange', 'Medicare Advantage', 'Company', 'the Securities Exchange Act', 'ACO', 'the Sarbanes-Oxley Act', '\\n    Interest expense\\n    &', 'HMOs', 'Equity Securities', 'Adopted Pursuant to Section 302', 'Significant Accounting', 'Healthcare, Inc.', 'Adjusted Gross Profit', 'MBR', 'Alignment Healthcare USA', '\\n    &', 'the &#x201c;Oxford Loan'}"
ALIM,
ALKS,"{'the &#x201c;Results', 'Tribunal', 'Acorda Therapeutics, Inc. (&', 'No &#9744;\\n  &#', 'MA Inc.', 'INVEGA&#174', 'EstimatesThe', 'Janssen Pharmaceutica N.V.', 'Alkermes Pharma Ireland Limited', 'Janssen&#x2019;s', 'Alkermes, Inc.', 'Incentive Plan', 'Contracts with Customers', 'Teva', 'this Quarterly Report on Form 10-Q', 'products;\\n  &#x2022;our', 'x2014;\\n        &', 'NanoCrystal', 'environment.\\n  &#160;\\n', 'Bio, Inc.', 'The Gainesville Transaction', 'Johnson &', 'FDA', 'the Alkermes plc 2018 Stock Option', 'the &#x201c;Settlement Agreement&#x201d', 'LinkeRx and NanoCrystal', '\\n  &#', 'AMPYRA&#174;&#x2014;Acorda Therapeutics, Inc.', 'the Gainesville Transaction', 'Healthcare', 'and\\n  &#', 'patents;\\n  &#x2022;our', 'CABENUVA', 'Indicate', 'expectations;\\n  &#x2022;our', 'HAFYERA', 'products.\\n  &', 'No.3) Limited', '\\n        &', 'ALKERMES PLC', 'non-U.S. currency exchange', 'Meloxicam', 'Company', 'INVEGA HAFYERA&#174', 'the Financial Accounting Standards Board', 'Tribunal&#x2019;s', 'KEYTRUDA&#174;&#x2014;Merck Sharp &amp', 'the &#x201c;Notes', 'the NY Southern District Court', 'INVEGA TRINZA&#174', 'Acorda', 'the Final Award', 'COVID-19', 'Dohme Corp.', 'RISPERDAL CONSTA&#174;&#x2014;Johnson &amp', 'INVEGA HAFYERA/BYANNLI', 'Investing Activities \\n  &#', 'Equity Securities', 'taxes;\\n  &#x2022;our', 'New Accounting PronouncementsFrom', 'Condensed Consolidated Financial', 'XEPLION&#174', 'the &#x201c;Collaborative Arrangements&#x2014;Janssen&#x201d', 'INVEGA', '\\n  &#x2022;our'}"
ALLK,"{'LLC', 'Cowen and Company', 'SanCarlosLeaseAgreementMember2022', 'RestrictedStockUnitsRSUMember2023-09-3000015648242023-07-012023-09-300001564824us-gaap', 'Form S-3', 'InvestmentsMember2023', 'Exclusive License Agreement', '\\n    Interest income\\n    &', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06', 'LicenseAgreementTermsMember2023-07-012023-09-300001564824us-gaap', '\\n', 'SanCarlosLeaseAgreementMember2023', 'the &#x201c;Termination', 'FairValueMeasurementsRecurringMember2022-12-3100015648242023-09-300001564824allk', 'Supplemental DisclosuresProperty', 'ContingenciesIn-Licensing Agreements', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001564824allk', 'FairValueMeasurementsRecurringMember2022-12-3100015648242023-01-012023-03-310001564824us-gaap', 'The Johns Hopkins University\\n', '\\n  Research and Development Expenses \\n  Research', 'License Agreement with', 'Restricted CashThe Company', 'LicenseAgreementTermsMember2023-01-012023-09-300001564824allk', 'TwoThousandEighteenEmployeeStockPurchasePlanMember2023-07-012023-09-3000015648242022-07-012022-09-3000015648242023-01-012023-09-300001564824allk:', 'improvements;\\n  &#x2022;costs', 'Stockholders&#x2019', 'MaximumMember2022-12-310001564824us-gaap', 'this Quarterly Report on Form 10-Q', 'BioWa Inc.', 'The Termination Agreement', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'THE SECURITIES EXCHANGE ACT OF', 'Lonza Sales AG', 'Lonza AG', '\\n  &#', 'EquipmentMember2023', 'commenced.\\n  &', '\\n        Laboratory equipment\\n', 'depreciation\\n        &', '26\\n', 'the &#x201c;Exchange', 'administrative.\\n  Research and Development Expenses\\n  Research', 'level.\\n  &', '\\n    Research', 'equipment.\\n  Cash Provided by Financing Activities\\n  Net', 'JHU', 'Lonza Sales', '\\n        &', 'Balance Sheet Components', 'Restricted', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001564824us-gaap', 'Company', 'SanCarlosLeaseAgreementMember2023-09-300001564824allk', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-3000015648242022-12-310001564824us-gaap', 'Equipment, Net Property', 'the Securities Exchange Act', 'TwoThousandEighteenEmployeeStockPurchasePlanMember2023-01-012023-09-300001564824allk:', 'Lonza Sales Ltd', 'FairValueMeasurementsRecurringMember2023', 'and\\n  &#x2022;allocated', 'the Sarbanes-Oxley Act', 'Adopted Pursuant to Section 302', 'The Johns Hopkins University', 'ExclusiveLicenseAgreementWithTheJohnsHopkinsUniversityMember2023', 'the ATM Offering', 'LeasesOperating Leases', '2,275\\n          &', 'Charter)\\n  &#', 'the U.S. Securities and Exchange Commission', '\\n    &', '\\n    &#', 'BioWa'}"
ALLO,"{'the Allogene Overland Biopharm', 'Cellectis S.A.', 'CY) Inc.', 'the License Agreement and', 'CellectisAs', 'the JV Territory', 'Party TransactionsCollaboration', 'Bellco', 'Anti-Spam Legislation (&#8220;CASL&#8221', 'EstimatesOur', 'the Notch Agreement, Allogene', 'Share Purchase Agreement with Allogene Overland', 'Development ExpensesResearch', 'ContentsExhibitnumberDescription of document3.1Amended and', 'the License Agreement to Allogene Overland Biopharm', 'the Company a Research Collaboration and License Agreement', 'Letter of Agreement', 'Overland Pharmaceuticals', 'COVID-19', 'ContentsFor', 'the America Invents Act', 'Antion of $3.5 million', 'Notch of $', 'FASB', 'Company\\', 'Pfizer', 'Servier of', 'the Notch Agreement, Notch', 'Antion Collaboration and License Agreement', 'the Original Cellectis Agreement.&#160;The Original Cellectis Agreement', 'the Pfizer Agreement', 'Research Collaboration and License Agreement', 'Medicare', 'ALPHA2', 'a Cellectis Target', 'Pipeline and Development Strategy', 'FDA', 'the License Agreement with Allogene Overland', 'NetProperty', 'the Cellectis Target', 'RSU', 'the Notch Agreement', 'the European Union&#8217;s General Data Protection Regulation', 'ContentsThe', 'Risks Related', 'CAR+', 'the Cellectis Agreement', 'Company', 'BCMA', 'ContentsOur Research and Development and License AgreementsAsset Contribution Agreement', 'Cowen', 'ContentsIn December 2020', 'NHL', 'Servier', 'Asset Contribution Agreement', 'The Notch Agreement', 'ESG', 'NetInterest', 'Critical Accounting Policies', 'FC', 'Claudin', 'EXPAND', 'ALLO-501A', 'License Agreement', 'the Personal Information Protection and Electronic Documents Act', 'CAR', 'Notch of $10.0 million', 'IRB', 'SAP', 'CMC', 'Notch\\', 'HK) Limited', 'the Servier Agreement', 'Registrant', 'TALEN', 'Contentsmonths', 'Exclusive Collaboration and License Agreement', 'CMO', 'the Ex-US Option', 'the Letter Agreement', 'IPO', 'Limited', 'The Cellectis Agreement', 'Earl Douglas.10.2Employment Letter of Agreement', 'Equipment', 'Cowen and Company', 'Hamas', 'Notch Therapeutics Inc.', 'Notch', 'the License Agreement', 'autoimmune hepatitis &#8211', 'this Quarterly Report', 'Antion', '2022.The Company', 'ATM', 'FDA&#8217;s', 'PRC) Co.', 'CALM', 'United', 'Adopted Accounting PronouncementsThere', 'Joint Venture', 'SEC', 'GCP', 'Collaboration and License Agreement', 'administrative54,449&#160;58,303&#160;(3,854)(7)%Total', 'BLA', 'Territory', 'The Antion Collaboration and License Agreement', '2018).4.3Investors Rights Agreement', 'TRAVERSE'}"
ALLR,"{'ASC', 'API', 'Common Stock and Series A Preferred', 'LiPlasome License Agreement', 'a Triggering Event under Section', 'RRA', 'The Nasdaq Capital', 'State', 'the 3i June Promissory Note', 'the Conversion Date', 'Financial Instruments', 'the March', 'Out-License Agreement', 'Series A Preferred Stock', 'Nasdaq Listing Rule', 'the Conversion Price', 'Allarity Therapeutics Europe ApS', 'the Series A Preferred Stock', '\\n    Research', '1)&#160;is', 'Form S-1', 'the Inducement Warrants', 'the Certificate of Designations of Series', 'A Preferred Stock', 'the Securities Exchange Act', 'the\\nlicense', 'the Allowable Grace Period', 'the Public Information Failure', 'Holder', 'March&#160;28', 'defined\\nin the Warrant Agreements', 'Warrants', 'FASB', 'the Securities Purchase Agreement', 'Name:\\n', 'Series C Preferred Stock', 'the Resale Registration Statement', 'cured.\\n\\n&#160;\\n\\nIn', 'the Amended COD)', 'Internal Control', 'the term\\nSeries A Preferred Stock Conversion Price', 'our Series A Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;)\\nand', 'the Conversion Amount', 'the Exchange Agreement', 'The Resale Registration Statement', 'Financial Condition', 'FDA', 'Original', 'Existing Warrants', 'cash.\\n\\n&#160;\\n\\nIn', 'applicable\\nor', 'the Original Agreement', 'Common Stock', 'notes.\\n\\n&#160;\\n\\nRecently Issued Accounting Pronouncements\\n\\n&#160;\\n\\nSee', 'Company', '\\n  &#160;\\n\\n\\n\\n\\n\\n', 'the New Warrant Shares', 'Section', 'Series C Preferred', 'Black-Scholes', 'the September Investors Company', 'Triggering Event under Section', 'ASU', 'Financial Reporting', 'Series A Preferred Stock beneficially\\nowns', 'Allarity Therapeutics, Inc.', 'the Certificate of Designations of Series A Preferred Stock', 'Series A\\nPreferred Stock', 'Nasdaq Listing Qualifications', 'Modification and Exchange Agreement', 'Nasdaq Listing Rule 5815(d)(4)(B', 'ASC 570', 'License Agreement', 'the Series A Convertible Preferred Stock', 'agreements:\\n\\n&#160;\\n\\n  &#160', 'Waiver', 'the Forbearance Agreement', 'the Cancellation of Debt Agreement', 'the April Offering Closing', 'the Registration Delay Payments the Company', 'Interim Chief\\nFinancial Officer', 'Allarity Therapeutics ApS', 'a Securities Purchase Agreement (&', 'The Nasdaq Capital Market', 'Allarity Therapeutics Europe', 'NDA', 'The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) staff\\nhas', 'The June Share Consolidation', 'June&#160;29', 'Inducement Warrants or Inducement Warrant', 'the Exchange Shares', 'Letter Agreement between\\nChosa Oncology Ltd.', '3i.\\n\\n&#160;\\n\\nThe Company', 'Secured Note Purchase', 'Phase 2 Clinical Trial', 'the Amended COD', 'the Series A Certificate of Designations', 'the Registration\\nRights Agreement (&#', 'April Warrants', 'filed\\nour Annual Report on Form 10-K', 'the Series C Preferred\\nStock', 'Company&#8217;s\\nassets', 'the April Common Warrants', 'COD', 'Smerud Medical Research', 'Black Scholes', 'Board', 'SPA', 'the Series C Preferred Stock', 'made\\nto', 'the Inducement Letter', 'Company\\nand', 'the Board of Directors', 'the June Share Consolidation', 'December&#160;31', 'a Triggering Event under Section 5(a)(ii', 'the Triggering Event', 'the April Offering', 'defined\\nin the Cancellation of Debt Agreement', 'the Series\\nA Convertible Preferred Stock', 'the Certificate of Designations', 'SEC', 'and\\n  \\n    &', 'Factors that\\nthe Company', 'the September\\n2023 Inducement Letter', 'Forbearance Agreement', 'the &#8220;Oncoheroes', 'Novartis', 'the FASB&#8217;s Accounting Standards Codification', 'Total&#160;\\n', 'the License Parties relating\\nto the Compound', 'the 3i Warrants', 'July Warrants', 'Nasdaq', '\\n    &'}"
ALNY,
ALPN,
ALRN,
ALT,"{'FASB', 'LeasesThe', 'LLC', 'Evercore Group L.L.C.', 'September&#160;30,&#160;2022', 'Spitfire', 'Critical Accounting', 'ContentsFunded Warrant', 'Chapter&#160;63 of Title 18', 'the Interactive Data File', 'B. Riley Securities, Inc.', 'February&#160;25', 'Principal Executive Officer Pursuant', 'Pre-Funded Warrants', 'ContentsAt-the-Market OfferingsOn', 'Piper Sandler&#160;&amp', 'Restated Bylaws of Altimmune, Inc.', 'ContentsThe', 'JMP Securities', 'Common StockThe Amended and Restated Certificate of Incorporation', 'Piper Sandler &amp', 'SEC', 'Company', 'XBRL Instance Document', 'Restated Certificate of Incorporation', 'the Securities Exchange Act', 'Item&#160;10 of Regulation S-K', 'Results of Operations', 'Page Interactive Data File', 'Spitfire Pharma, Inc. (&', 'deemed &#8220;filed&#8221', 'ASU No', 'the Registration Statement'}"
ALVO,
ALVR,
ALXO,"{'\\n  &#x25aa;our', 'the FDA&#x2019;s Oncology Center of Excellence', 'Exhibit 32.1', 'Contractual Obligations', 'candidates;\\n  &#x2022;the', 'EMA', '\\n  &#x25aa;restrictions', 'x25aa;our', 'Principal Executive Officer', '\\n  &#x25aa;drug', 'procedures.\\n  Changes', 'decline.\\n  Risks Related', 'N=23', 'EEA', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'Tallac', 'programs.\\n', 'federal and/or', 'AGICC', '\\n  &#x25aa;refusal', '\\n  &#x25aa;imposition', 'ALX Oncology Limited', 'the Tallac Services Agreement', 'Credit Suisse Securities', 'Form S-1', 'SOX', 'ACA', 'Eli Lilly', 'months)\\n        &', 'Jazz Pharmaceuticals plc', 'Leap Healthcare Collaborative', 'Quantum Leap Healthcare Collaborative', 'the Securities Exchange Act', 'First Citizens Bank', 'COVID-19', '\\n  &#x25aa;changes', 'Shelf Registration Statement', 'the FDA&#x2019;s Office of Orphan Products Development', 'SVB-First Citizens', 'Sanofi', 'KBI Biopharma, Inc.', 'Tallac Therapeutics, Inc.', 'NetThe', 'the California Department of Financial Protection and Innovation', 'the General Services Administration', 'candidates;\\n  &#x2022;obtaining', 'EstimatesThe', 'Tallac Therapeutics', 'the U.S. Congress', 'Internal Control', 'ALX Oncology Inc.', 'Medicaid', 'the Securities and Exchange Commission', 'Tallac&#x2019;s', 'Medicare', 'Congress', 'Obtaining', 'x2014;\\n        &', '27\\n', 'Principal Accounting Officer', 'FDA', 'PreparationThe', 'national data protection authority', 'Loan', '\\n        Laboratory equipment\\n', '\\n  &#x25aa;injunctions', 'and\\n  &#', '\\n  &#x25aa;we', 'candidates;\\n  &#x2022;our', 'depreciation\\n        &', '\\n  Effective', 'the Federal Deposit Insurance Corporation', 'Tallac Services Agreement', 'HIPAA', 'REMS', 'Silicon Valley Bank', 'Company', 'management&#x2019;s attention', 'USPTO', 'SVB', 'ALTA-002', 'Cantor Fitzgerald &amp', 'SVBB', 'the European Commission', 'CRO', 'ODD', 'ConsolidationAll', 'TRICARE', 'AIA', 'candidates;\\n  &#', 'Principal Financial Officer', 'Oxford Finance', 'Loan Agreement', 'chemotherapy.\\n', 'the UK Extension', 'Merck', 'CCPA', 'FCPA', 'the U.S. Internal Revenue Code', 'the Federal Supply Schedule', '\\n  &#', 'the Nasdaq Stock Market LLC', 'Lenders', 'and\\n  &#x2022;maintaining', 'Orphan Drug Designation', 'Oxford Finance Credit Fund II LP', 'gastric/GEJ cancer.\\n', 'the Academic Gastrointestinal Cancer Consortium', 'FDIC', 'See &#', 'x201c;anticipate,&#x201d; &#', 'the Lender of other rights', 'the Sarbanes-Oxley Act', 'indicated.\\n  &', 'reporting.\\n', '\\n  &#x25aa;the', 'Our Financial Position', 'the Loan Agreement', 'Alexo International Holdings Limited', 'MSA', 'x25aa;Jazz Pharmaceuticals plc', 'candidates;\\n  &#x25aa;the', '\\n  &', 'Finance', 'European Union', 'Co.', 'stock.\\n  Risk Factors Summary\\n  ', 'the State of Delaware', 'and\\n  &#x25aa;our', '\\n  &#x25aa;Analogous', 'ALX Oncology Holdings Inc.', 'x25aa;ASPEN-06 - Gastric', 'Tallac Service AgreementIn', 'candidates;\\n  &#x2022;protecting', '\\n        &', 'SEC', 'the Shelf Registration Statement', 'SOFR', 'Credit Suisse', '\\n  &#x25aa;withdrawal', '\\n  &#x25aa;developments', 'Investigator-Sponsored Trials', 'the Biologics Price Competition and Innovation Act', '\\n  &#x25aa;identifying', 'the European Union', 'NO &', '\\n  &#x25aa;delays', '\\n    &', 'Nasdaq', 'x25aa;voluntary', 'The Organization for Economic Cooperation and Development'}"
ALZN,
AMAM,
AMED,
AMEH,
AMGN,
AMLX,"{'\\n  &#x2022;injury', '\\n  &#x2022;effectively', 'operations.\\n  &#160;\\n', 'Incentive Plan', 'health authority.\\n  &#', '\\n  &#x2022;exclusion', 'EMA', '\\n  &#x2022;satisfaction', 'Standard Contractual Clauses', 'EEA', '\\n  &#x2022;termination', '\\n  &#x2022;costs', 'financial condition.\\n  &#', '\\n  &#x2022;making', 'EU', 'financial condition.\\n  &', 'the Internal Revenue Code', 'penalties.\\n  &', 'x2022;a', 'Sunnybrook Research Institute', 'accurate.\\n  &', 'population.\\n  &#x2022;We', 'the ALS Association', 'the Securities Exchange Act', 'ALS Association', '\\n  &#x2022;recall', 'CNS', '\\n  &#x2022;establishing', 'COVID-19', 'Adopted Accounting', '\\n  &#x2022;obtaining', 'candidates.\\n  &#160;\\n', '\\n  &#x2022;expenses', '\\n  &#x2022;provide', 'ALS', 'FASB', 'indications.\\n  &', 'Anti-Kickback Statute', '\\n  &#x2022;significant', '\\n  &#x2022;product', 'arrangement.\\n  &#160;\\n', '\\n  &#x2022;substantial', 'the Washington University School of Medicine', '\\n  &#x2022;issued', 'collaborators.\\n  &', 'manufacturers&#x2019', 'goods\\n        &', '\\n  &#x2022;refusal', 'Medicaid', 'Medicare', 'x2014;\\n        &', 'ALS Finding', 'GTN', 'GDPR', 'FDA', 'Health Canada', '\\n  &#x2022;collaborations', 'FAIR VALUE', 'activities;\\n  &#x2022;expenses', 'the Patented Medicine Prices Review Board', '\\n  &#x2022;ownership', 'General Risk Factors \\n  &#', '\\n  &#x2022;disagreements', '\\n  &#x2022;maintaining', '\\n  &#x2022;warning', '\\n  &#x2022;others', '\\n  &#x2022;loss', '\\n  &#x2022;requirements', '\\n        Treasury', '\\n  &#x2022;fines', '\\n  &#x2022;entry', 'Company', '\\n  &#x2022;divide', 'UK&#x2019;s', 'CHMP', '\\n        Agency', '\\n  &#x2022;injunctions', 'AD', '\\n  &#x2022;limitations', 'FCA', 'SVB', '\\n  &#x2022;ensuring', '50\\n', 'operations.\\n  &#x2022;AMX0035', 'the Delaware General Corporation Law', 'the European Commission', 'Alzheimer&#x2019;s Drug Discovery Foundation', 'WS', 'CMS.\\n  &', 'outcomes.\\n  &', 'CMS', 'OLE', '2022;\\n  &#x2022;our', 'measures.\\n  &', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', 'the Alzheimer&#x2019;s Association', 'the U.S. Department of Health and Human Services', 'The UK Government', '\\n  &#x2022;the USPTO', '\\n  &#x2022;suspension', '\\n  &#', '\\n  &#x2022;collaborators', '\\n  &#x2022;diversion', 'initiatives.\\n  &#', '\\n  &#x2022;decreased', '\\n  &#x2022;require', 'NDA', 'Digital Information Bill', 'a Cure Foundation', 'prospects.\\n  &', 'ALBRIOZA', 'commercialized.\\n  &#', 'companies&#x2019', 'ASU No', '\\n  &#x2022;enforcing', '\\n  &#x2022;our', 'HELIOS', 'Cure Alzheimer&#x2019;s Fund', 'treasury', '2022.The Company', 'commercialization.\\n  &#', '\\n  &', 'the Court of Chancery of the State of Delaware', 'Contingencies Lease CommitmentsThe Company', 'MAA', 'PB', 'operations.\\n  &', '\\n  &#x2022;restrictions', 'Medicaid Services', 'the Federal Policy for the Protection of Human Subjects', 'Healthcare', '340B', 'the Internal Revenue Service', 'harmed.\\n  &#160;\\n', '\\n  &#x2022;withdrawal', '\\n  &#x2022;successful', 'Alzheimer&#x2019;s Association and Cure Alzheimer&#x2019;s Fund', 'the U.S. Treasury Department', '80\\n', 'SEC', 'prohibitive.\\n  &', '\\n  &#x2022;potential', 'the FDA&#x2019;s Advisory Committee', '\\n  &#x2022;do', 'the Centers for Medicare &', 'AMX0035;\\n  &#x2022;the FDA&#x2019;s', '\\n  &#x2022;manufacturing', 'PHOENIX', '\\n  &#x2022;permit', 'Nasdaq', 'recalculation.\\n  &', '\\n    &', 'Biogen', '\\n  &#x2022;receipt'}"
AMPH,"{'API', 'the Wells Fargo Term Loan', 'LLC', 'see &#8220;Part', 'BASQIMI&#174', 'Chargebacks', 'the Transition Services Agreement', 'TO CONDENSED CONSOLIDATED FINANCIAL', 'National Association - Due', 'Principal Executive Officer', 'TSA', 'the Patient Protection', 'Jefferies LLC', 'Amphastar Pharmaceuticals, Inc.', 'Lilly', 'method.&#8203;As', 'the Securities Exchange Act', 'Cardinal Health, Inc.', 'AmerisourceBergen Corporation', 'USE OF PROCEEDS', '7,770)&#8203;Total', 'AFP', 'USD', 'Capital One', '10,175&#8203;Total', 'Medicaid', 'IMS', 'the Securities and Exchange Commission', 'Medicare', 'Congress', 'Revolving Credit Facility', 'FDA', 'National Association', 'RSU', 'Nanjing Hanxin Biomedical Testing Service Co., Ltd.', 'Loan', 'Regulation S-K Item', 'Company', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)&#8203;&#8203;of', 'U.S. Bank Trust Company', 'Eli Lilly &', 'Credit Agreement', 'Wells Fargo', 'Contentsdrug', 'J.P. Morgan Securities', 'Nanjing Letop Biotechnology Co., Ltd.', 'Board of Directors', 'EQUITY SECURITIES', 'the Credit Agreement', 'McKesson Corporation', 'maturity.&#8203;The Credit Agreement', 'Months Ended &#', 'NDA', 'Letop', 'Section&#160;13&#160;or&#160;15(d', 'BofA Securities Inc.', 'Long Lived Assets', 'the Sarbanes-Oxley Act', 'Wells Fargo Securities', 'the FDA&#8217;s Center for Device and Radiological Health', 'the Purchase Agreement', 'Months Ended &', 'treasury', 'the Wells Fargo Term Loan.&#8203;In', 'Administrative', 'Wells Fargo Bank', 'the Health Care and Education Affordability Reconciliation Act', 'Wells Fargo Term Loan', 'Identifiable Definite-Lived Intangible Assets&#8203;The Company', 'AmerisourceBergen', 'the Independent Payment Advisory Board', 'Research Agreement', 'Capital Resources&#8203;Cash Requirements', 'SEC', 'ANP', '7,761)&#8203;&#8203', 'Interactive Data File', 'Recombinant Human Insulin Research Cell Banks', 'Rule 405 of Regulation S-T'}"
AMRN,
AMTI,
ANAB,
ANEB,"{'API', 'Offer Letter', 'CRO', 'develop.\\n', 'the License Agreement', 'level.\\n\\n&#160;\\n\\nChanges\\nin Internal Control', 'HHS', 'The License Agreement', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Security Agreement', 'yields.\\n', 'officials.\\n\\n&#160;\\n\\n    &', 'candidates.\\n\\n&#160;\\n\\nWe', 'Security', 'Medicare', 'JFL Capital Management\\nLLC (&#8220;JFL&#8221', 'undesirable\\nor', 'Anebulo Pharmaceuticals, Inc.', 'FDA', 'destroy\\nor', 'future\\ncollaborations', 'Loan', 'whether\\nto', 'clinical\\ninvestigators', 'United\\nStates', 'vulnerabilities.\\n\\n&#160;\\n\\nApplicable\\ndata', 'CPRA', 'will\\nbe', 'REMS', 'period.\\n\\n&#160;\\n\\nNote\\n2', 'NDA', 'suffer.\\n', 'Sterling Pharma Solutions', 'ACI', 'SEC', 'LSA', 'and\\n  \\n    &', 'Company', 'CMO', 'Business, Financial Condition', 'materially\\nharmed.\\n\\n&#160;\\n\\n\\n\\n    &', 'Centre for Human Drug Research', 'the European Economic Area', 'JFL\\nCapital Management LLC (&#8220;JFL&#8221', 'the Securities Exchange Act', 'SRL', 'Vernalis Development Limited', 'the Sarbanes-Oxley Act', 'Adopted Pursuant to Section 302', 'resources.\\n\\n&#160;\\n\\nFuture\\nsales', 'IPO', 'collaborators;\\n', 'JFL Capital Management', 'candidates.\\n  \\n    &', 'Capital', 'Nasdaq', '\\n    &', 'Manufacturing Contract', 'the License Agreement.\\n\\n&#160;\\n\\nDisputes\\nmay', 'Capital Resources', 'LP (&', 'milestones.\\n\\n\\n\\n&#160;\\n\\nLoan'}"
ANGO,
ANIK,"{'\\n       &#xa0;\\n       &#xa0;\\n', '0.10\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     0.32\\n     &#xa0;\\n     &#xa0;\\n     &#', 'LLC', 'Credit Agreement', 'the Parcus Medical', '\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#', 'risks.\\n  &#', 'No &#x2610;\\n&#xa0;\\nIndicate', 'Arthrosurface, Inc', '0.14\\n     &#xa0;\\n     &#xa0;\\n     &#', 'respectively:\\n  &#', '0.27\\n     &#', 'Diluted', 'EPS', '0.20\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Weighted Average Fair Value &#', 'HA', 'the Current Report on Form 8-K', '36,256\\n       &#xa0;\\n       &#xa0;\\n', 'Bank of America N.A.', 'FDA', '\\n   &#', 'Integrity Implant System', '\\n  &#xa0;\\n  &#', '\\n  &#', 'GAAP Diluted', 'Condensed Consolidated Statement of Operations and Comprehensive Income', '2022 &', '\\n       &#xa0;\\n       &#', 'the Parcus Medical Merger Agreement', 'Products\\n  &#', 'Hyaff', 'OA Pain Management', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', '448\\n       &#', '\\n       &#xa0;\\n       &#xa0;\\n       ', 'future operations.\\n  &#xa0;\\n  &#', 'costs.&#xa0;\\n  &#', '1,566\\n       &#', 'Performance Stock Units\\n   &#', 'Condensed Consolidated Statements', '\\n     &#', 'procedures.\\n  &#', 'Condensed Consolidated Balance Sheets', 'Parcus Medical', 'Company', 'Non-Orthopedic', 'years.\\n   &', 'companies.\\n  &#xa0;\\n  &#', 'Condensed Consolidated Statements of Cash Flows', '0.11\\n     &#xa0;\\n     &#xa0;\\n     &#', 'respectively.\\n  &#', 'the Securities Exchange Act', '34,682\\n       &#xa0;\\n       &#xa0;\\n', 'Bank of America', '\\n       &#', 'Arthrosurface', '0.27\\n     &#xa0;\\n     &#xa0;\\n     &#', 'OA Pain', 'xa0;\\n       &#', 'Tax, Depreciation', 'Adjusted Gross Profit', 'costs.\\n  &#', '353\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n', '\\n    &#', 'Condensed Consolidated Financial Statements'}"
ANIP,
ANIX,
ANL,
ANNX,"{'\\n  &#x2022;expansion', 'EMA', '\\n  &#x2022;an', 'EEA', 'this Quarterly Report on Form 10-Q', '\\n  &#x2022;having', 'Condensed Consolidated Statements of Comprehensive Loss \\n', 'EU', 'GBS', '\\n  &#x2022;analogous', 'x2022;a', 'management;\\n  &#x2022;new', 'Principal Executive', 'ACA', 'the Children&#x2019;s Health Insurance Program', 'the Securities Exchange Act', 'the European Economic Area', 'guidance;\\n  &#x2022;any', '\\n  &#x2022;expenditures', '\\n  &#x2022;preclinical', '\\n  &#x2022;obtaining', 'candidates;\\n  &#x2022;acquisitions', 'and\\n  &', 'Condensed Consolidated Financial Statements(Unaudited)&#160;The', 'reference.\\n  &', 'the Brisbane Lease', 'x201c;Risk', 'Internal Control', 'manufacturers&#x2019', '\\n  &#x2022;a', 'Medicaid', 'Medicare', '\\n  &#x2022;extension', 'GDPR', 'FDA', '\\n  &#x2022;collaborations', 'the Data Safety Monitoring Board', 'Cowen and Company LLC', '\\n  &#x2022;clinical', 'and\\n  &#', '\\n  &#x2022;continue', 'the Medicaid Drug Rebate Program', 'HIPAA', 'capital commitments;\\n  &#x2022;developments', '\\n  &#x2022;new', 'Patient-Centered Outcomes Research Institute', 'Company', 'USPTO', '\\n  &#x2022;laboratory', '\\n  &#x2022;addressing', '\\n  &#x2022;impose', 'commercialization;\\n  &#x2022;quarterly', 'the Health Insurance Portability', '\\n  &#x2022;seize', 'Cowen', 'GLP', 'the Delaware General Corporation Law', 'Capital Requirements \\n', 'CMS', 'candidates;\\n  &#', '\\n  &#x2022;recruiting', '\\n  &#x2022;establishment', '32\\n', 'UK Data Protection Act 2018', 'CCPA', '\\n  &#x2022;future', 'analysts;\\n  &#x2022;announcements', '\\n  &#x2022;the', 'Orphan Drug', '\\n  &#x2022;coverage', '\\n  &#x2022;timing', '\\n  &#', 'law;\\n  &#', '\\n  &#x2022;imposition', '\\n  &#x2022;collaborators', 'Registrant', 'NDA', 'candidates.\\n  &#x2022;Our', '\\n  &#x2022;reaching', 'reporting.\\n', 'Adopted Accounting PronouncementsThe Company', 'companies&#x2019', 'products.\\n  &#x2022;Our', '\\n  &#x2022;obtaining IRB', 'GA', 'litigation;\\n  &#x2022;changes', 'Medicaid Innovation', 'candidates;\\n  &#x2022;market', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '\\n  &#x2022;delays', '44\\n', 'the State of Delaware', '\\n  &#x2022;identify', 'x2022;refuse', '\\n  &#x2022;the U.S. Foreign Corrupt Practices Act', '\\n  &#x2022;disputes', 'Medicaid Services', '\\n  &#x2022;suspend', 'the European Union General Data Protection Regulation', 'businesses;\\n  &#x2022;manufacturing', '\\n  &#x2022;the FDA', 'candidates;\\n  &#x2022;public', '\\n  &#x2022;identifying', 'the Court of Chancery', '\\n        &', 'SEC', 'GCP', 'the Centers for Medicare &', 'the Health Information Technology for Economic and Clinical Health Act', '\\n    &', '\\n  &#x2022;manage', '\\n  &#x2022;professional'}"
ANTX,"{'LLC', 'Global Health Agreement with Adjuvant', 'AccountingStandardsUpdate201613Member2023-09-300001880438us-gaap', 'candidates;\\n  &#x2022;the', 'Contractual Obligations', 'The Sarbanes-Oxley Act', 'x25aa;our', 'Board;\\n  &#x2022;require', 'Nasdaq Stock Market LLC', 'IndemnificationsThe Company', 'NonStatutoryStockOptionsMember2023', 'OverAllotmentOptionMember2022-04-012022-06-300001880438us-gaap', 'EU', 'Public Offering of Common Stock\\n  ', 'Alley', 'our Board;\\n  &#x2022;limit', 'the U.S. Foreign Corrupt Practices Act', 'AccountingStandardsUpdate202110Member2022-07', 'Form S-1', 'ICH', 'respectively.&#160;&#160;12&#160;&#160;\\n     &#160;Cloud', 'stock.\\n  Provisions', 'yields;\\n  &#', 'COVID-19', 'the ATM Offering', 'Adopted Accounting', 'candidates.\\n  Coverage', 'the Registration of Pharmaceuticals for Human Use', 'regulations.\\n  &', 'FASB', 'Adjuvant&#x2019;s', 'x25aa;Our', 'Pfizer', 'Anti-Kickback Statute', 'nebulizer);\\n  &#x2022;the', 'the California Department of Financial Protection and Innovation', 'HHS', 'EstimatesThe', 'care regimen;\\n  &#x2022;the', 'relief.\\n  &#160;\\n  &#160;\\n  ', 'UniversityOfGeorgiaResearchFoundationMember2023-01-012023-09-300001880438us-gaap', 'Chagas', 'x201c;Risk', 'manufacturers&#x2019', 'claims.\\n  &', 'UniversityGeorgiaResearchFoundationMember2022-09-012022-09-300001880438antx', 'Medicaid', 'Medicare', 'and\\n  &#x2022;require', 'TwoThousandTwentyTwoEmployeeStockPurchasePlanMember2023-07-012023-09-300001880438antx', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'costs;\\n  &#x2022;our', 'condition.\\n  &', 'ArrangementsThe Company', 'and\\n  &#', 'the Federal Deposit Insurance Corporation', 'the Medicaid Drug Rebate Program', 'impaired.\\n  &#', 'the FDA&#x2019;s Accelerated Approval Program', 'activities\\n    &', '\\n  Commission File Number', 'Company', 'personnel.\\n  &#x25aa;We', 'payroll taxes;\\n  &#x2022;foreign', 'USPTO', 'Significant Accounting', 'Results of Operations', 'EU&#x2019;s', 'and\\n  &#x2022;business', 'Charter)\\n  &#', 'territories;\\n  &#', '\\n    &#', 'the Delaware General Corporation Law', 'MaximumMember2022-09-012022-09-300001880438us-gaap', 'USD\\n  &', 'Evercore Group L.L.C.', 'the European Commission', 'the University of Georgia Research Foundation', 'Critical Accounting Policies', 'NewlyHiredEmployeesMember2023', 'OverAllotmentOptionMember2022-04-012022-06-300001880438srt', 'UGARF', 'AccountingStandardsUpdate201815Member2022-07-010001880438us-gaap', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'relationships;\\n  &', 'NationalInstituteOfAllergyAndInfectiousDiseasesMember2022-09-012022-09-300001880438antx', 'control;\\n  &#x2022;entrenching', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'Global Health AgreementIn', 'sector.\\n  &#', 'StockOptionsIssuedAndOutstandingMember2022-12-31xbrli', 'License', '\\n  &#', 'Recent Accounting Pronouncements\\n', 'approved.\\n  &#x25aa;We', 'personnel;\\n  &#x2022;our', 'sanctions.\\n  &', 'Shares', 'the Annual Report on Form 10-K', 'the Global Health Agreement, Adjuvant', 'the Underwritten Offering', 'MAC', 'consent;\\n  &#x2022;limit', 'the Global Health Agreement', 'acquire;\\n  &#x2022;the', 'bylaws.\\n  &', 'FairValueMeasurementsRecurringMember2023', 'Leerink Partners', 'IPO', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001880438antx', 'Brii Biosciences Limited', 'REMS;\\n  &#x2022;whether', 'CFO', '16\\n  &', 'prospects.\\n  &', '\\n  &#x25aa;the', 'EquityCommon', 'ASU No', '77\\n  &', 'Cowen and Company', 'Our Financial Position', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-3000018804382023-04-012023-06-300001880438antx', 'Anacor Pharmaceuticals, Inc. (&#x201c;Anacor&#x201d', 'Board', 'Melinda Gates Foundation', 'Our Business, Industry', 'the United States;\\n  &#x2022;production', 'markets;\\n  &#x2022;compliance', 'the Board of Directors', 'ATM', 'including:\\n  &#x2022;the', 'operations.\\n  Risk Factors Summary\\n  ', 'TwoThousandTwentyTwoEmployeeStockPurchasePlanMember2022', 'the World Bank', 'AN2 Therapeutics', 'TwoThousandTwentyTwoEmployeeStockPurchasePlanMember2023-01-012023-09', 'and\\n  &#x25aa;our', 'terrorism.\\n  &', 'Medicaid Services', 'NTM', 'agreement).Adjuvant&#x2019;s', 'Anacor&#x2019;s', 'Healthcare', 'Interim &#x201c;topline&#x201d', 'UniversityOfGeorgiaResearchFoundationMember2022-09-012022-09-300001880438us-gaap', 'NIAID', 'institutions.\\n  &', 'Issuer Purchases of Equity', 'Anacor', 'the Anacor License', 'The European Commission', 'Adjuvant Global Health Technology Fund', 'the Centers for Medicare &', 'The Global Health Agreement', 'the International Council for Harmonisation of Technical Requirements', 'Equity Securities', 'the Board;\\n  &#', 'candidates.\\n  &#x25aa;The', 'foreign countries;\\n  &#x2022;the', 'GSK', 'presented.&#160;&#160;20&#160;&#160;\\n     &', 'the European Union', '\\n    &', 'costs.\\n  Risks Related', 'Internal Control Over Financial Reporting\\n'}"
AONC,
APDN,
APGE,"{'LLC', '2022.Legal ProceedingsThe Company', 'OX40L Research Program', 'The Sarbanes-Oxley Act', 'Incentive Plan', 'Apogee Therapeutics, Inc.', 'License Agreements', 'Research Programs', 'the Option Agreement', 'Pritchett HendersonChief Financial Officer(principal', 'ExhibitsThe', 'the Leahy-Smith America Invents Act', 'Apogee Therapeutics', 'EU', 'the Public Company Accounting Oversight Board', 'Prospectus', 'inception)&#8203;$ &#8212;&#8203;$ &', 'ContentsConcentrations of Credit Risk', 'UPC', 'Form S-1', 'Option', 'ContentsWe', 'AgreementsThe Company', 'the License Agreements', 'the Securities Exchange Act', 'OPM', 'the Tranche Options', 'Paragon Therapeutics, Inc. (&', 'a Series A Unit', 'Restated Certificate of Incorporation of the Registrant', 'Apogee', 'FDA', 'WuXi Biologics', 'the &#8220;Cell Line License', 'the IL-13 Research Program', 'Indemnification Agreement', 'Unit Holders', 'ContentsThe', 'Risks Related', 'ExpensesAccrued', 'Research Program', 'Company', 'M.D', 'PartiesUnder', 'Apogee Therapeutics, Inc. &', 'Paragon', 'License Agreement', 'this Quarterly Report on Form&#160;10-Q', 'funds&#8203;$ 103,776&#8203;$ &#8212;&#8203;$ &', 'The Patient Protection', 'the IL-13 License Agreement', 'License', 'The WuXi Biologics MSA', 'Registrant', 'Exchange', 'DevelopmentResearch', 'Biologics Master Services Agreement&#8201;&#8212;&#8201;WuXi Biologics', '57Total &', 'the Series A Preferred Unit', 'ContentsOur', 'expense&#8203;$417&#8203;$ 755&#8203;$ &#8212;&#8203;General', 'the ESPP.Equity-Based Compensation ExpenseThe', 'the Sarbanes-Oxley Act', 'Value MeasurementsThe Company', 'the indemnified party', 'IPO', 'European Unified Patent Court', '116,957&#8203;$ &', 'deemed &#8220;filed&#8221', 'ContentsUnless', 'treasury', 'Board', 'Preferred Unit', 'Tranche Options', 'the State of Delaware', 'PropertyOur', 'the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221', 'Healthcare', 'InflationInflation', 'MONTHS &', 'ExpensesOur', 'SEC', 'the General Corporation Law', 'Paragon Therapeutics, Inc.', '515Total&#8203;$', 'Equity Securities', 'the Biologics Price Competition and Innovation Act', 'the European Union', 'WuXi Biologics MSA.Cell Line License Agreement&#8201;&#8212;&#8201;WuXi Biologics', 'the Registration Statement'}"
APLM,
APLS,"{'ASC', 'SYFOVRE;\\n  &#x2022;our', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', 'SwedishOrphanBiovitrumABPublMember2020-10-272020-10-270001492422apls', 'EC', 'candidates;\\n  &#x2022;the', 'EMA', 'MaximumMemberapls', 'this Quarterly Report on Form 10-Q', 'ProductMember2023', 'MaximumMember2023-01-012023-09-300001492422apls', 'Unaudited Condensed Consolidated Financial Statements', 'ExchangeAgreementsMember2022-07-012022-07-310001492422us-gaap', 'AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2022-12-310001492422apls', 'UNITED STATES', 'Beam Therapeutics, Inc.', 'transactions.\\n  &', 'the Financial Accounting Standards Board', 'FairValueMeasurementsNonrecurringMember2023-09-300001492422us-gaap', 'FairValueMeasurementsNonrecurringMember2023-09-300001492422apls', 'C3', 'ALS', 'AllowanceForChargebacksDiscountsAndFeesMember2023-03-3100014924222022-04-012022-06-300001492422apls', '\\n        &#160;Less', 'SwedishOrphanBiovitrumABPublMember2020-10-272020-10-270001492422us-gaap', 'SwedishOrphanBiovitrumABPublMember2020-10-310001492422apls', 'SwedishOrphanBiovitrumABPublMember2020-11-302020-11', 'ProductRevenueAllowanceAndReservesMember2023-04-012023-06-300001492422us-gaap', 'the Securities and Exchange Commission', 'Medicare', 'Pennsylvania License Agreement&#160;The Company', 'x2014;\\n        &', 'AllowanceForChargebacksDiscountsAndFeesMember2023-04-012023-06-300001492422apls', 'ProductRevenueAllowanceAndReservesMember2023-01-012023-03-310001492422us-gaap', 'FDA', 'HSCT-TMA', 'SobiAgreementAndAnotherLicensingTransactionMember2023-09-3000014924222021-12-310001492422us-gaap', 'and\\n  &#', 'MaximumMember2023-09-300001492422apls', 'Sales\\n  &#', 'SYFOVRE', 'the Federal Deposit Insurance Corporation', 'SFJ', 'C3;\\n  &#x2022;our', 'activities\\n    &', 'Company', 'APELLIS PHARMACEUTICALS', 'Significant Accounting', 'tax).\\n  &#160;\\n', 'AllowanceForChargebacksDiscountsAndFeesMember2023-01-012023-03-310001492422apls', 'Beam', 'USD\\n  &', 'the European Commission', 'CAD', 'VehiclesMember2023', 'strategy;\\n  &#x2022;our', 'SYFOVRE.&#160;In', '\\n  &#', 'words.\\n', '\\n    &', 'ProductMember2022', 'Swedish Orphan Biovitrum AB', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001492422apls', 'SYFOVRE.&#160;As', 'FASB ASC Topic', 'INC', 'Inc.;\\n  &#x2022;the', 'DevelopmentLiabilityMember2022-12-310001492422apls', 'FairValueMeasurementsNonrecurringMember2023-01-012023-09-3000014924222022-09-300001492422apls', 'ex-U.S.', 'into.\\n  &', 'SFJ Pharmaceuticals Group', 'TwoThousandTenLicenseAgreementMember2023-01-012023-09-300001492422apls', 'Regulation S-K):\\n  &', 'The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &', 'GA', 'GALE', '\\n  &#9744;\\tTRANSITION', 'discount\\n        &#160;\\n        &#160;\\n', 'AllowanceForChargebacksDiscountsAndFeesMember2023-07-012023-09-300001492422apls', 'the State of Delaware', 'MAA', 'The Company and Beam', 'AllowanceForChargebacksDiscountsAndFeesMember2023-06-300001492422apls', 'AccountingStandardsUpdate202006Member2023-09-300001492422apls', 'the European Medicines Agency', 'C3G.', 'Significant Accounting Policies', '\\n        &', 'Sobi.\\n  &#160;\\n', 'PNH', 'SalesReturnsAndAllowancesMember2023-04-012023-06-300001492422us-gaap', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001492422apls', 'SyfovreMember2023'}"
APLT,
APM,
APRE,"{'API', 'candidates;&#9679;a', 'inventors;&#9679;we', 'LLC', 'EMA', 'ContentsAprea Therapeutics, Inc.', 'General Data Protection Regulation', 'the Federal Reserve', 'EU', 'assets&#8203;$ &#8212;&#8203;$ &', 'Series A Preferred Stock', 'ContentsEven', 'Form S-1', 'ContentsWe', 'the 2020 Shelf Registration Statement', 'the Financial Accounting Standards Board', 'RMP', 'institute a &#8220;poison', 'the Merger Agreement', 'Aprea AB', 'the U.S. Congress', 'the Department of Justice', 'Medicaid', 'Medicare', 'Congress', 'FDA', 'Prospectus Supplement', 'the Hatch-Waxman Act', 'DDR', 'HIPAA', 'the National Cancer Institute', 'initiatives.&#8203;As', 'the United States;&#9679;the', 'REMS', 'RBC Capital Markets', 'ContentsAlthough', 'Company', 'the Department of the Treasury', 'USPTO', 'the EU Risk Management Plan', 'Condensed Consolidated Financial', 'SVB', 'cost&#8203;$ &#', 'Signature Bank', 'the Delaware General Corporation Law', 'J.P. Morgan Securities', 'UK Data Protection Act 2018', 'ContentsAn', 'the Nasdaq Stock Market', 'IRB', 'liabilities&#8203;$ &#', 'Morgan Stanley &', 'ContentsContingent Value Rights AgreementIn', '61,248&#8203;$ &', 'NDA', 'Series A Non-Voting Convertible Preferred Stock', 'DOJ', 'FDIC', 'the Sarbanes-Oxley Act', 'IPO', 'Black Scholes', 'ATM', 'FDA&#8217;s', 'U.S. GAAP.&#8203;As', 'the National Cancer Institute of the National Institutes of Health (&#8220;NIH&#8221', 'IPR&amp;D', 'the State of Delaware', 'MAA', 'the Drug Price Competition and Patent Term Restoration Act', 'The Foreign Corrupt Practices Act', '64,056&#8203;$ &#', 'cGMPs.&#8203;Accordingly', 'SEC', 'the Shelf Registration Statement', 'the United States', 'ContentsOff', 'ContentsFailure', '*&', 'the Listing Rules of the Nasdaq Stock Market and/or', 'The Securities and Exchange Commission', 'Nasdaq'}"
APTO,"{'years)\\n        &', 'management&#x2019;s', 'treasury', 'CBCA', 'XBRL', 'Board', 'MDS', '\\n', 'AML', 'SLL', 'the Commitment Shares', 'the Canada Deposit Insurance Corporation', 'LIQUIDITY', 'LLC (&#34;Keystone&#34', 'the New Incentive Plan', 'the Total Commitment', 'ATM Facility', 'the Employee Stock Purchase Plan (&#34;ESPP&#34', 'ATM', 'Reverse Stock', 'TUS', 'the Securities and Exchange Commission', 'Canaccord Genuity LLC (&', 'the Aptose Biosciences Inc.', 'SYK', 'this Quarterly Report on Form 10-Q', 'Co. (&', 'ESPP', 'Corporation', 'the Interactive Data File', 'CLL', 'Keystone', '\\n  &#', 'HanmiOn August 10, 2023', 'Keystone Capital Partners', 'Jones Trading Institutional Services', 'PROGRAM', 'APTIVATE', '50%-16', 'the Employee Stock Purchase Plan', 'the Federal Deposit Insurance Corporation', 'the &#x201c;Exchange', 'the United States Exchange Act', 'Inline Extensible Business Reporting Language (Inline XBRL', 'myeloid kinase', 'Piper Sandler &amp', '\\n        &', 'SEC', 'Adopted Pursuant to Section 906', 'the &#x201c;Initial Commitment', 'Company', 'the Hanmi Subscription Agreement', 'the Share Option Plan', 'Hanmi', 'the &#x201c;Total', 'Nasdaq', 'Phase 1a', 'Chief Executive', 'No &#9744;\\n  Indicate'}"
APVO,"{'ASC', 'costs.\\n  Other Income (Expense', '20\\n', 'Aptevo BioTherapeutics', 'the Equity Distribution Agreement', 'Aptevo BioTherapeutics\\n    &', 'Purchase Agreement and Registration Rights Agreement', 'Liabilities &#', 'Leases&#160;Office Space Lease - OperatingWe', 'this Quarterly Report on Form 10-Q', 'EU', 'IXINITY;\\n  &#x2022;whether', 'Alligator Bioscience AB', 'Lincoln Park', 'Debt &', 'Nasdaq Listing Rule 5550(a)(2', 'this Quarterly Report on Form 10-Q.\\n  ', 'Saol', 'Treasury', 'Lincoln Park Financial', 'the Equity Distribution Agreement with', 'the Registration Statement on Form S-3', 'HCR&#x2019;s', 'General Instruction I.B.6', 'The Equity Distribution Agreement', 'Pfizer', 'Contingencies', 'volatile.\\n  &#x2022;Our', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'Extinguishment of Liabilities', 'a Series A Junior Participating Preferred Share', 'x2014;\\n        &', '27\\n', 'GDPR', 'Purchase Agreement with XOMA', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Purchase Agreement (&', 'LLC (&#34;Lincoln', 'GMP', 'and\\n  &#x2022;overhead', 'Collaboration AgreementsAlligator Bioscience', '\\n  &#x2022;Our', 'and\\n  &#', '30\\n', 'Saol International Limited', 'the &#x201c;Inducement', 'Risks Related', 'Company', 'Stockholders', 'Lincoln', 'Results of Operations', 'ADAPTIR', 'Charter)\\n  &#', 'Commercial Platform License Agreement', '\\n    &#', 'the California Consumer Privacy Act', 'Medexus Pharmaceuticals, Inc. (&#34;Medexus&#34;)', 'Aptevo Research and Development', 'Purchase Agreement', 'harmed.\\n  &#x2022;Actions', 'Credit Agreement', 'the European Commission', 'ADAPTIR-FLEX platforms.\\n  &#x2022;If', 'the Nasdaq Capital Market', 'CMS', 'RUXIENCE', 'Contracts with Customers', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', '\\n  &#x2022;capital', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'the Royalty Purchase Agreement', 'data.\\n  &#x2022;Serious', 'Piper Sandler &', 'MidCap', '\\n  &#', 'LLC Purchase Agreement', 'OMT\\', 'the Credit Agreement', 'Liability Related', 'Lincoln Park Capital Fund', 'constraints.\\n  &#x2022;We', '\\n  &#x2022;our', 'HealthCare Royalty Management', 'Form S-3', 'Co (&#34;Piper Sandler&#34;)', 'Board', 'Medexus', '\\n  &#x2022;We', 'and,\\n  &#x2022;our', 'XOMA', 'OMT', 'Nasdaq&#x2019;s', 'LLC (&#34;HCR&#34;)', 'HCR', 'Royalty Purchase Agreement', 'approved.\\n  &#x2022;Our', 'candidates.\\n  &#x2022;We', 'Co (&#34;Piper Sandler&#34', 'Kamada\\n    &', 'Amendment to Royalty Purchase Agreement', 'the Court of Chancery', '\\n        &', 'SEC', 'future indebtedness;\\n  &#', 'agreements.\\n', 'Collaboration and License Agreement', 'Milestone Payments', 'the &#x201c;Purchase', 'TNFR', 'Nasdaq', 'Kamada Ltd.', '\\n    &', 'Internal Control Over Financial Reporting\\n'}"
APYX,"{'Perceptive', 'Tara SembTara SembChief Financial Officer', 'Credit Agreement', 'Apyx Medical CorporationDate', 'IICharles D. Goodwin IIPresident', 'Credit, Security and Guaranty Agreement', 'the Board of Directors', 'CollateralThe', 'Director(Principal Executive', 'the Financial Accounting Standards Board&#8217;s Accounting Standards Codification', 'CovenantsThe MidCap Credit Agreement', 'the Perceptive Credit Agreement', 'the Securities and Exchange Commission', 'ContentsAPYX MEDICAL CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued(Unaudited)LoansThe', 'FL', 'LoansThe', 'DefaultThe MidCap Credit Agreement', 'the U.S. Food and Drug Administration', 'FDA', 'Helium Plasma Technology', 'MidCap', 'the MidCap Credit', 'the Nasdaq Stock Market', 'Internal Control Over Financial ReportingIn', 'MidCap Financial Trust', 'JOINT', 'Clearwater', 'MidCap Funding IV Trust', 'ContentsAPYX MEDICAL CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued(Unaudited)NOTE', 'the Credit Agreement', 'ContentsAPYX MEDICAL CORPORATIONNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued(Unaudited)Events', '160;&#160;&#160;&#160;LEASESOperating LeasesThe Company', 'Apyx China Holding Corp.', 'No &#9744;Indicate', 'MidCap Credit', 'Company', 'the Securities Exchange Act', 'The MidCap Credit Agreement', 'the Safety Communication', 'Perceptive Credit Agreement', 'the Perceptive Credit', 'DefaultThe Perceptive Credit Agreement', 'IRS', 'the MidCap Credit Agreement', 'a Safety Communication', 'the Company&#8217;s Board of Directors', 'FacilityThe Company', 'ContentsAPYX MEDICAL CORPORATIONSIGNATURESPursuant', ': &#9746', 'Advanced Energy', 'CovenantsThe Perceptive Credit Agreement', 'Property'}"
AQST,"{'ASC', 'Manufacture', 'LLC', 'This Accounting Standards Update', 'Sunovion', 'the Sale of Future RevenueOn', 'Internal Control Over Financial ReportingThere', 'Financial Instruments &#8211', 'RequirementsThe', 'the Separation Agreement', 'the Exercising Holder', 'this Quarterly Report on Form 10-Q', 'include:&#8226;Suboxone&#174', 'EU', 'the Lincoln Park Purchase Agreement', 'Consolidated Statements of Operations and Comprehensive Income', 'Principal Executive Officer Pursuant', 'Court', 'Research Fees &#8211', 'EpiPen', 'Assertio 36Table of', 'Atnahs Pharma UK Limited The Company', 'the Amended Equity Distribution Agreement', 'Cynapsus Therapeutics, Inc.', 'Exservan', 'Fair Value MeasurementsCertain', 'the Securities Exchange Act', 'Item 408 of', 'Contentstandards', 'Otter Pharmaceuticals', 'CNS', 'Assertio Holdings', 'Aquestive', 'ContentThe Company', 'Research FeesWe', 'Capital Resources', 'ALS', 'the Sunovion License Agreement', 'the Indivior Commercial Exploitation Agreement', 'FASB', 'Assertio for Sympazan', 'the Securities Purchase Agreement', 'Item 4.&#160;&#160;&#160;&#160;Mine Safety DisclosuresNot', 'Contingencies', 'the Securities and Exchange Commission', 'the American Institute of Certified Public', 'Regulation S-K).Item', 'FDA', 'Legal Proceedings', 'IM', 'Principal Executive Officer Pursuant to Rules', 'Haisco', 'the Securities Purchase Agreements', 'Active Pharmaceutical Ingredients (&#', 'Principal Financial Officer Pursuant to Rules', 'Suboxone', 'Common Stock', 'Company', 'Zevra Therapeutics, Inc.', 'Adopted Pursuant to Section 302', '258pg/mL and', 'Sunovion Pharmaceuticals Inc.', 'the ""Monetization Agreement', 'Marathon Asset Management (&', 'the Pharmanovia Agreement', 'AssetsThe', 'ALS Treatment', 'Purchase Agreement', 'KYNMOBI', 'ASU', 'Lincoln Park Purchase Agreement', 'the Existing Warrants', 'the Assertio License Agreement', 'the Monetization Agreement', 'Atnahs Pharma UK Limited', 'Accounting and Valuation Guide', 'China.&#8226;KYNMOBI&#174;&#8211', 'Alvogen', 'KemPharm', 'Monetization Agreement', 'Amended Complaint', 'Warrants Issued Under Securities Purchase AgreementsIn', 'ContentHoldings, Inc. (&#8220;Assertio&#8221;)', 'the Additional Warrants', 'the Indivior License Agreement', 'the &#8220;Indivior License', 'the &#8220;Territory&#8221', 'Contentseparate', 'Registrant', 'Lincoln Park Capital Fund', 'Entity&#8217;s Own Equity', 'Accounting and Valuation Guide, Valuation of Privately-Held Company Equity Securities Issued as Compensation', 'NDA', 'Condensed Consolidated Statements of Operations and Comprehensive Income', 'the American Institute of Certified Public Accountants Accounting', 'BioDelivery Sciences International, Inc.', 'Cardinal Health', 'the Sarbanes-Oxley Act of 2002', 'LiquidityWe', 'the Uniform Standards of Professional Appraisal Practice', 'Common Stock and Common Stock Warrants', 'Form S-3', 'ChinaThe Company', 'Contracts', 'Mitsubishi Tanabe Pharma Holdings America, Inc.', 'License, Development and Supply Agreement', 'the Fourth Supplemental Indenture', 'ATM', 'the American Society of Appraisers', 'Marathon Asset Management', 'Agreement', 'Piper Jaffray &amp', 'Good Manufacturing Practice', '268pg/mL', 'MAM Pangolin Royalty', 'the Shenzhen Stock Exchange', 'Loans Payable', 'Reckitt Benckiser Pharmaceuticals, Inc.', 'Issuer Purchases of Equity', 'the Assertio Agreement', 'Additional Notes', 'ExpensesOur', 'Accounting for Convertible Instruments', 'ContentLicensing Agreement', 'Administrative ExpensesSelling', 'Collaboration and License Agreement', 'Credit Losses', 'License and Supply Agreement', 'the Initial Warrants', 'Equity Securities', 'Fair Value Measurement', 'Indivior', '6.&#160;&#160;&#160;&#160;Financial Instruments &#8211', 'Zevra Therapeutics Inc.', 'the European Union', 'Contentrebates', 'KemPharm, Inc.'}"
ARAV,"{'ASC', 'Recent Accounting Pronouncements  &#', 'LLC', 'Common Stock &#', 'xa0;&#xa0;9,562&#xa0;&#xa0;&#xa0;57,970&#xa0;\\n Restricted', '\\n      &#', 'Stanford', 'the Equity Distribution Agreement', 'Three Months Ended &#', '2023 &#', '28,692\\n      &#', '\\n   &#xa0;&#xa0;\\n', 'this Quarterly Report on Form 10-Q', 'xa0;&#xa0;2,408&#xa0;&#xa0;&#xa0;2,445&#xa0;\\n Property', 'Marsh Facility', 'Shares &#xa0;&#xa0', '\\n   &#', '738\\n      &#', 'change&#xa0;in', 'Amount &#xa0;&#xa0', '5,520\\n      &#', 'Increase/ \\n     &#', 'Nine Months Ended &#xa0;\\n&#xa0;&#xa0', 'the Financial Accounting Standards Board', '\\n   &#xa0;&#xa0', 'Certificate of Incorporation', 'flows.\\n  &#', 'transaction.\\n  &#', 'Paid-In &', 'Deficit &#', 'The Board of Trustees', 'Consideration &#', 'xa0;&#xa0;1,265&#xa0;&#xa0;&#xa0;26,881&#xa0;\\n Total liabilities &', 'equity &#xa0;$13,049&#xa0;&#xa0;$62,153&#xa0;\\n\\n', 'Fair', 'Registered Direct Offerings\\n   &', 'FASB', 'Contracts with Customers &#', 'net &', 'liabilities &', 'Eshelman Ventures', 'its&#xa0;PROC&#xa0;study.&#xa0;\\n   &#', 'xa0;&#xa0;413&#xa0;&#xa0;&#xa0;383&#xa0;&#xa0;&#xa0;1,261&#xa0;&#xa0;&#xa0;1,308&#xa0;\\n Total &', 'Deficit &#xa0;&#xa0', 'the&#xa0;1020 Marsh Facility', 'the Black Scholes Value', '147\\n      &#', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'the 3D Medicines Agreement', '\\n &#', 'Multiple Performance Obligations &#', 'a customer.&#xa0;The Company', 'SEC File No', 'compensation &#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;292&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;292&#xa0;\\n Net income &#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;21,226&#xa0;&#xa0;&#xa0;21,226&#xa0;\\n Balances', 'xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;620&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;620&#xa0;\\n Net', 'Company', 'The Certificate of Incorporation', 'Scope Exceptions', 'endpoint.\\n  &#', 'the 3D Medicine Agreements', 'Aravive, Inc. (&', '\\n    &#', 'liabilities &#xa0;&#xa0;2,233&#xa0;&#xa0;&#xa0;6,738&#xa0;\\n', 'statements.\\n  &#', 'Related Party Transaction\\n   &', 'General and Administrative Expense\\n  &#', 'this Quarterly Report on Form 10-Q.', 'Nasdaq Listing Rules', 'xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;639&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;639&#xa0;\\n Net loss &', 'Additional &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; Total &#xa0;\\n&#xa0;&#xa0', 'the heading &#x201c;Special', 'Exercise Price &#xa0', '2022 &#', 'Additional Information\\n  &#', '\\n  &#', 'CMC', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Stanford University', 'xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;725&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;725&#xa0;\\n Net', 'Executive', 'Accumulated &#xa0;&#xa0', 'CONDENSED CONSOLIDATED BALANCE SHEETS \\n', 'xa0;&#xa0;13,694,095&#xa0;&#xa0;&#xa0;1&#xa0;&#xa0;&#xa0;(1)&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;\\n Stock', 'Procedures\\n  &#', 'rate.\\n   &#', 'Liquidity and Capital Resources \\n  &#', '2023 &#xa0;&#xa0;59,844,850&#xa0;&#xa0;$6&#xa0;&#xa0;$627,466&#xa0;&#xa0;$(666,083)&#xa0;$(38,611)\\n Issuance', 'Comparison', 'Form \\n     &#', '3D Medicines', 'Capital &#xa0;&#xa0', 'the Company&#x2019;s Board of Directors', 'Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;)', 'Contingencies \\n   &#', 'Form S-3', 'Indemnification \\n   &#', 'Research and Development Expense \\n  &#', 'Contracts', 'AXLerate', 'price&#xa0;as', 'Nasdaq&#x2019;s', 'ARAVIVE, INC.', 'the State of Delaware', 'Litigation \\n   &#', 'Co.', '2022 &', 'Increase/ \\n     &#xa0;\\n     &#', 'Distinguishing Liabilities', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', 'Equity &#xa0;\\n Balances', 'xa0;\\n Operating Expenses &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Research', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', '\\n     &#', 'SEC', '9,651\\n      &#', '9,651\\n     &#xa0;\\n     &#xa0;\\n     &#', 'the &#x201c;Company&#x201d;)', 'made.\\n  &#', 'Consideration', 'Nasdaq', 'capital &#', ""Stockholders\\' &#xa0;\\n&#xa0;&#xa0""}"
ARAY,
ARCT,"{'ASC', 'Arcturus Therapeutics, Inc.', 'LLC', 'Wells Fargo Loan', 'The Vinbiocare Support Agreement', 'Arcturus-Owned mRNA Therapeutic Candidates:\\n  &', 'Accounting for Government Grants and Disclosure of Government Assistance', 'the North American Cystic Fibrosis Conference', 'Exhibit 10.38', 'Ultragenyx Pharmaceutical Inc.', 'ARCT-154;\\n  &#x2022;the', 'Item 408 of Regulation S-K', 'CF Ferret', 'the Israeli Ministry of Health', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001768224us-gaap', 'the Economic Development Board of the Republic of Singapore', 'Cystic Fibrosis Foundation', 'Meiji Holdings Co., Ltd.', 'BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-01-012023-09-3000017682242023-07-012023-09-300001768224arct', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'EU', 'EquipmentMember2023', 'ARCALIS', 'Exhibit 99.2', 'Wells Fargo Credit Agreement', 'Arcturus&#x2019', 'UGX', 'Seqirus, Inc. (&#x201c;CSL', 'the Cystic Fibrosis', 'Wells Fargo Credit Agreement \\n', 'Supply', 'CSL Limited', 'revenue.\\n  &#', 'COVID-19', 'Meiji Seika Pharma Co., Ltd.', 'Western Alliance Bank', 'Supply Agreements', 'the CFF Agreement', 'Arcturus Therapeutics Ltd.', 'the Vinbiocare License and Supply Agreements', 'Current Report on Form 8-K', 'Vallon Pharmaceuticals, Inc. (&', 'Internal Control', 'CureVac AG', 'National Association (&#', 'CFF', 'CureVac', 'Principal Accounting Officer', 'the Department of Defense;\\n  &#x2022;our', 'Western Alliance', 'Development Program Letter Agreement', 'Vallon', 'THE SECURITIES EXCHANGE ACT OF', 'National Association', 'GRI Bio', 'CollaborationRevenueMember2022', 'Clinical Research Organizations', 'Loan', 'and\\n  &#', 'Vinbiocare Biotechnology Joint Stock Company (&', 'commercialization;\\n  &#x2022;our', 'candidates;\\n  &#x2022;our', 'GRI Bio, Inc. (&', 'Variable Interest', 'Development and Option Agreement', '30\\n', 'concern.\\n  Item 2', 'BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2022-08-012022-08-310001768224arct:VinbiocareAgreementMember2023-02-280001768224arct', 'Company', 'Vingroup Joint Stock Company', 'CSL', 'Flu Collaboration Program Updates\\n', 'the Registration Statement on Form S-8', 'the Registration Statement on Form S-4', 'FebruaryTwoThousandAndTwentyLeaseAgreementMember2023-01-012023-09-300001768224country', 'CF', 'Quarterly Report on Form 10-Q', 'Vinbiocare', 'Marina Biotech', 'Charter)\\n  &#', '\\n    &#', 'Arcturus', 'Wells Fargo', 'medicines.\\n  &', 'the Vinbiocare Support Agreement', 'Seqirus Inc. (&#x201c;CSL', 'the Western Alliance Agreement', 'SG2022-01-012022-12-310001768224srt', 'the Economic Development of Singapore', '\\n  &#x2022;future', 'SG2022-01-012022-09-300001768224arct', 'ARE-SD Region', '\\n  &#x2022;the', 'ARCT-032;\\n  &#x2022;our', 'the U.S. Department of Health and Human Services', '\\n  &#x2022;interactions', 'the Office of the Assistant', 'the Cystic Fibrosis Foundation Agreement', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', '\\n  &#', 'the Study Support Agreement', 'the Company&#x2019;s Report of Foreign Private Issuer on Form 6-K', 'NDA', 'PhaseIClinicalStudyMember2023', 'Response', 'Contingencies Cystic Fibrosis Foundation', 'RevenueThe Company', 'organization)\\n    &#160;\\n', 'DebtWells Fargo Credit AgreementOn', 'the Company&#x2019;s Registration Statement on', 'Wells Fargo Securities', 'the &#x201c;Vinbiocare License &', 'Joint Ventures', 'ARCTURUS THERAPEUTICS HOLDINGS INC.\\n', 'Vinbiocare (the &#', 'the Amount of Award', '\\n  &#x2022;our', 'the Biomedical Advanced Research and Development Authority', 'the &#x201c;Development and Option Agreement&#x201d', 'BiomedicalAdvancedResearchAndDevelopmentAuthorityMember2023-07-012023-09-300001768224arct', '\\n        &#', 'development &amp', 'the &#x201c;Western Alliance', '\\n        &#160;General', 'iii\\n', 'world&#x2019;s', 'CFTR', 'COVID', 'Pre-Launch InventoryPrior', 'SARS-CoV-2', 'Wells Fargo Bank', 'Vinbiocare&#x2019;s', 'Seqirus Inc. \\n', 'efforts;\\n  &#x2022;the', 'Arcturus Therapeutics Holdings Inc.', 'Related Party', 'the Cystic Fibrosis Foundation', 'Equity Method Investments', '\\n        &', 'SEC', 'Collaboration and License Agreement', 'product.\\n  &', 'LeaseholdImprovementsMember2022-12-310001768224us-gaap', 'PhaseIClinicalStudyMember2023-08-012023-08-310001768224arct', 'ASC 606.The Company', 'License &', 'the Singapore Loan', 'Seqirus&#x201d;);\\n  &#x2022;the', '\\n    &', 'Arcturus Therapeutics Inc.'}"
ARDX,
ARGX,
ARQT,"{'ASC', 'Janus', 'the Delaware General Corporation Law', 'Company\\', 'the Loan Agreement', 'ARQ-255', 'The License Agreement', 'Loan Agreement', 'Qualitative Disclosures', 'SLR Investment Corp.', 'ATM', 'Iolyx', 'U.S. Food and Drug Administration', 'the Committee of Sponsoring Organizations of the Treadway Commission', 'Jiangsu Hengrui Medicine Co., Ltd.', 'ActivityThe', 'the Huadong Licensed Products', 'License Agreement', 'the Hengrui License Agreement', 'The Loan Agreement', 'SLR', 'License Agreements &', 'LiquidityOur', 'the Maturity Date', 'RequirementsSources', 'FDA', 'Condensed Consolidated Financial Statements(unaudited)Agreement', 'Ducentis Biotherapeutics LTD', 'Biotherapeutics LTD AcquisitionOn', 'RSU', 'Prepaid Nonclinical and', 'Hengrui Exclusive Option', 'No &#9744;Indicate', 'the AstraZeneca License Agreement', 'the Iolyx Agreement', 'ContentsThe', '2023.Recent Accounting', 'U.S. Treasury', 'Adopted Accounting PronouncementsThere', 'Iolyx\\', 'Treasury', 'AstraZeneca', 'Arcutis Canada', 'Condensed Consolidated Financial Statements(unaudited)If', 'SEC', 'Company', 'AgreementsThe Company', 'the Securities Exchange Act', 'Condensed Consolidated Financial Statements6Item', 'I.', 'Hengrui', '*&', 'the Huadong Agreement', 'the Default Rate', 'IPO', 'Arcutis Biopharmaceuticals, Inc.', 'Consolidated Balance', 'AstraZeneca AB', 'Condensed Consolidated Financial', 'the European Union', 'the Hengrui Option', 'Huadong Agreement', 'ContentsLiquidity, Capital Resources', 'ContentsIn'}"
ARTL,
ARVN,
ARWR,
ASLN,
ASMB,
ASND,
ASRT,"{'L.P.', 'the Merger Agreement', 'API', 'SOLUMATRIX', 'Spectrum Pharmaceutical, Inc. (&', 'assets281&#160;&#8212;&#160;Total', 'Cosette Pharmaceuticals, Inc.', 'Cosette', 'Antares', 'Rite Aid Corporation', 'spondylitisINDOCIN&#174', 'this Quarterly Report', 'the Cosette Supply Agreement', 'Retailer Plaintiffs', 'INDOCIN', 'the Amended Registration Statement on Form S-4', 'JHS', 'District Court', 'Navigators Specialty Insurance Company (&#8220;Navigators&#8221', 'ATM', 'a Collaborative License', 'CR Group L.P.', 'Royalty Rights ObligationIn', 'LIABILITIES &#', 'the &#8220;Cosette Supply', 'the Initial Purchasers', 'bursitis and/or', 'Lake Forest', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'NET &', 'INDOCIN Suppositories', 'LiabilityThe Company', 'FDA', 'the Overallotment Option', 'NES Therapeutic, Inc. (&', 'CVR', 'netProduct', 'SubpoenasAs', 'NSAID', 'ROLVEDON', 'Condensed Consolidated Statements of Comprehensive Loss', 'the U.S. District Court', 'the Annual Report on Form 10-K', 'ValueProducts', 'NES', '2022Prepaid', 'the Kroger Co.', 'Insurance Litigation', 'Condensed Consolidated Balance Sheets', 'G&amp;W Laboratories, Inc.', 'Company', 'the New York Department of Financial Services', 'CVS Pharmacy, Inc.', 'U.S. Bank Trust Company', 'Zyla Life Sciences (&#8220;Zyla&#8221', 'the U.S. Senate Committee on Homeland Security', 'Hy-Vee, Inc.', 'BLA', 'the &#8220;Risks Relating to the Combined Company&#8221', 'Cosette Pharmaceuticals Supply', 'the &#8220;Risk Factors&#8221', 'Assertio Holdings', 'the Note Agreement', 'INDOCIN Suppositories to Zyla', 'Confidential Settlement Agreement and Mutual Release', 'Secured Notes', 'the Jubilant HollisterStier Agreement', 'the U.S. Securities and Exchange Commission', 'SPRIX', 'Governmental Affairs', 'OXAYDO', 'the Albertsons Companies, Inc.', 'REVENUE &'}"
ATAI,
ATEC,"{'ASC', 'FASB', 'LLC', 'years)\\n        &', 'LitigationThe Company', 'purchasers&#x2019', 'Internal Control', 'Squadron Medical Finance Solutions', 'Revolving Credit Facility', 'x2014;\\n        &', 'ESPP', 'this Quarterly Report on Form 10-Q', 'The Revolving Credit Facility', 'Braidwell Term Loan&#x2019;s', 'the SEC&#x2019;s Disclosure Update', 'RoyaltiesThe Company', '\\n  &#', 'EOS', 'the Braidwell Term Loan', 'Indicate', 'The Capped Call Transactions', 'No Squadron Medical Warrants', 'DDTL', 'the Revolving Credit Facility', 'NuVasive', '\\n        &', 'SEC', 'Delaware Chancery Court', 'Response', 'Company', 'Navigation', 'the Securities Exchange Act', 'WarrantsThe Company', 'Disclosure Improvements - Codification Amendments', 'COVID-19', 'the Delaware Court', '\\n    &', 'the Capped Call Transactions'}"
ATHA,"{'ASC', 'regulators;\\n  &#x2022;costs', 'The Sarbanes-Oxley Act', 'EMA', 'WSU', 'ATH-1017)\\n    &', 'and\\n  &#x2022;provide', 'consent;\\n  &#x2022;provide', 'the Internal Revenue Code', 'Athira&#x2019;s', '\\n    Research', '\\n    Direct costs:\\n    &', 'Form S-1', 'products&#x37e;\\n  &#', 'ACA', 'the Securities Exchange Act', '\\n  Research', 'choose);\\n  &#x2022;provide', 'CNS', 'SPO', 'Washington State University (&#x201c;WSU&#x201d', 'Business&#x2014;Our Collaboration', 'and&#x2022;$600,000 &#', 'and\\n  &', '\\n  &#x2022;additional', 'HHS', 'the National Institutes of Health', 'the National Institutes of Health (&#34;NIH&#34;)', 'approved&#x37e;\\n  &#x2022;the', 'and\\n  &#x2022;collaborators', 'Business&#x2014;Competition&#x201d', 'inflation.\\n  Grant Income\\n  Grant', 'the Department of Justice', 'Medicaid', 'the Securities and Exchange Commission', 'Diluted', 'Medicare', 'Congress', 'Obtaining', 'stockholders&#x2019', 'the U.S. Centers for Medicare &', '27\\n', '\\n  Research and Development Expenses\\n', 'candidates;\\n  &#x2022;a', 'GDPR', 'FDA', 'NIH', '\\n  &#x2022;Intellectual', 'and\\n  &#', 'distribution;\\n  &#x2022;collaborators', 'candidates;\\n  &#x2022;initiate', '\\n  &#x2022;changes', 'efforts&#x37e;\\n  &#x2022;unfavorable', '\\n  &#x2022;continue', 'the Medicaid Drug Rebate Program', 'AssumptionsThe', 'REMS', 'Company', 'ATH', 'and\\n  &#x2022;the', 'USPTO', 'liability;\\n  &#x2022;disputes', 'profits.\\n', 'Results of Operations', 'FCA', 'administration&#x37e;\\n  &#x2022;the', 'AgreementsWashington State University', 'GLP', 'the Delaware General Corporation Law', 'ESG', 'CMS', 'relationships;\\n  &#x2022;risks', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'revenue;\\n  &#x2022;exhaustion', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'financial condition.\\n  &#x2022;Clinical', 'the U.S. Department of Health and Human Services', 'directors;\\n  &#x2022;provide', '\\n  &#', 'the Organization for Economic Cooperation and Development', 'the National Institute on Health', 'NDA', '\\n  &#x2022;additions', 'patentable;\\n  &#x2022;the', 'Medicaid Drug Rebate Program', 'IRA', 'LIFT-AD', 'Sections 11', 'WSU&#x2019;s', '10\\n       &', 'candidates;\\n  &#x2022;expand', 'candidates;\\n  &#x2022;acquire', 'the Consolidated Appropriations Act', 'Economy,&#x201d', 'IPO', 'the Sarbanes-Oxley Act', 'BBB', 'Comparison', 'the National Institutes of Health.\\n  ', 'including:\\n  &#x2022;the', 'European Union', 'SegmentsThe Company', 'Medicaid Services', '\\n  &#x2022;restrictions', 'capabilities.\\n', 'efforts;\\n  &#x2022;incur', 'patents;\\n  &#x2022;issued', 'the European Medicines Agency', '\\n  &#x2022;withdrawal', 'employees.\\n  Patent', '\\n    ', 'the U.S. District Court', '\\n        &', 'SEC', 'GCP', 'the National Institute on Aging of', 'authorities&#x37e;\\n  &#', '\\n    &', 'No &#9744;\\n  Indicate', 'property.\\n', '9,908\\n    &'}"
ATHE,
ATNF,
ATOS,
ATRA,"{'ASC', 'HCT', 'EC', 'Reliance', 'Regulation', 'WarrantMemberatra', 'EMA', 'EEA', 'the Council of the Queensland Institute of Medical Research (QIMR Berghofer', '5,726\\n     &', 'EU', 'JSC', 'HSCT', 'Charles River Laboratories Inc.', 'Bayer AG', 'FUJIFILM Diosynth Biotechnologies California, Inc.', 'FUJIFILM Holdings America Corporation', 'Indicate', 'BPCIA', 'CPRA', '76\\n   &', 'Treasury', 'the Pierre Fabre Commercialization Agreement', 'Quality Agreement', 'x2014;\\n     &', 'the Financial Accounting Standards Board', 'the Bayer Tech Transfer Agreement', '69\\n   &', 'pay&#x201d', 'Certificate of Incorporation', 'COVID-19', 'Swiss-U.S. Privacy Shield', 'the Additional Territory', 'Ebvallo', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001604464us', 'the UK Information Commissioner&#x2019;s Office', 'MaximumMemberatra', 'MaximumMember2023-01-012023-09-300001604464us-gaap', 'Pierre Fabre&#x2019;s', 'FASB', 'the Condensed Consolidated Statements of Operations and Comprehensive Income', 'the Bayer License Agreement', 'HHV06', 'x2022;if', 'Charles River Laboratories', 'the National Institutes of Health', 'Viracta Therapeutics, Inc.', 'L.P. (HCRx', 'ATOM Facility', 'the Adequacy Decision &#', 'x201c;Risk', 'Medicaid', 'Medicare', 'Diluted', 'the Technology Transfer Agreement', 'the HCRx Agreement', 'RestrictedStockUnitsRSUMember2023-09-300001604464us-gaap', 'SPMS', 'the European Patent Office', 'FDA', 'Initial Territory', 'HcrxAgreementMember2023-01-012023-09-300001604464us-gaap', 'the heading &#x201c;1A.', 'US BLA', 'Recent Accounting PronouncementsWe', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001604464us', 'Risks Related', 'HIPAA', 'FTC', 'the Termination, Amendment and Program Transfer Agreement (Bayer Termination Agreement', 'USPTO', 'UK&#x2019;s', 'HealthCare Royalty Partners', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n    \\n', 'the Initial Territory', 'ICO', 'the Secretaries of Health and Human Services', '9746;\\n     QUARTERLY REPORT PURSUANT', '\\n     &', 'Cowen', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001604464us', 'COVID-19 Business UpdateWe', 'Condensed Consolidated Financial Statements', 'L.P.', 'the Delaware General Corporation Law', 'ASU', 'CRO', 'the European Commission', 'the Fujifilm Transaction', 'a Technology Transfer Agreement with', 'UnderwrittenPublicOfferingMember2023', 'LeaseholdImprovementsMember2022-12-310001604464atra', 'CommitmentsWe', 'CMS', 'this Quarterly Report on Form 10-Q.', 'EBV', 'ATM Facility', 'Liquidity and Capital Resources Sources of LiquiditySince', 'Labor', 'the 2023 Registration Statement', 'AtTheMarketOfferingMember2022-01-012022-03-310001604464atra', 'CRL Manufacturing AgreementIn', 'Bayer', 'TwoThousandFourteenEquityIncentivePlanAndInducementPlanMember2023-01-012023-09-300001604464us-gaap', 'Cognate BioServices, Inc.', 'The Biologics Price Competition and Innovation Act', 'RevenuesWe', '2022\\n         &', 'Research and Development Expenses', 'IRB', 'the U.S. Department of Commerce', 'CMC', 'Data Bridge &', 'PartnershipOn', 'FDB', 'THE SECURITIES EXCHANGE ACT OF 1934\\n', 'Memorial Sloan Kettering Cancer Center', '27\\n   &', ': &#x2022;continuing', 'the Bayer Agreements', 'FairValueMeasurementsRecurringMember2023', 'the Consolidated Appropriations Act', 'the US BLA', 'Operating Capital Requirements', 'PPMS', 'ALLELE', 'HLA', 'Cowen and Company', 'Form S-3', 'Ebvallo for EBV+', 'the ATOM Facility', 'ViraCyte', 'Commercial Manufacturing Services Agreement', 'Bayer (Bayer License Agreement', 'California Privacy Protection Agency', 'Bayer License Agreement', 'Accelerated Approval Program', 'Pierre Fabre Commercialization Agreement', 'MAA', 'MinimumMemberatra', 'HCR Molag Fund L.P.', '73,929\\n         &', 'JCV', 'European Commission', 'CMV', 'HCR Molag Fund', '\\n     &#', 'us &#', 'SEC', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001604464us-gaap', 'CRL', 'BLA', 'Territory', 'the Marketing Authorization Application', 'Condensed Consolidated Statements of Cash Flows', 'Commercialization Agreement', 'ATA188', 'MSK', 'BIOTHERAPEUTICS', 'the Research, Development and License Agreement', 'BKV', 'CommercializationRevenueMember2023'}"
ATRC,"{'Consolidated Statements of Operations', 'OverviewWe', 'No &#9744', 'the Loan Agreement', 'the License Agreement', 'Reliance', 'Consolidated Statements', 'LAA', 'RevenuesAmount', 'Loan Agreement', 'the heading &#8220;Legal&#8221', 'Note 1', 'InformationDuring', 'the Condensed Consolidated Balance Sheets', 'ROU', 'The Loan Agreement', 'Control systems', 'thereafter1,169&#160;4,824&#160;Total', 'Consolidated Statements of Cash Flows', 'Clinic', 'the Condensed Consolidated Financial Statements', 'AAA', 'noncurrent$60,0008.LEASESThe Company', 'Loan', 'SentreHEART', 'Condensed Consolidated Financial Statements7Item', 'Indicate', 'PMA', 'CCF Intellectual Property', 'the Cleveland Clinic Foundation', 'Demand for Arbitration', 'Company', 'The Assignment Agreement', 'CONTINGENCIESLicense Agreement', 'this Quarterly Report on Form 10-Q.Recent', 'Consolidated Balance Sheets', 'LeasesOperating', 'Answering Statement', 'Results of Operations', 'ContentsATRICURE', 'IDx Medical, Ltd.', 'the American Arbitration Association', 'Counterclaims'}"
ATRI,
ATXI,
ATXS,"{'ContentsSummary', 'OverviewWe', 'Physician Payments Sunshine Act', 'The Sarbanes-Oxley Act', 'EMA', 'trial;&#9679;we', 'Ichnos Sciences Inc.', 'September&#160;30,&#160;2023&#8203;&#8203;Quoted&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203', 'the Federal Food, Drug', 'EEA', 'ExhibitsThe', 'Development ExpensesResearch', 'Grant Thornton LLP', 'Series&#160;X Preferred Stock', 'EU', 'Pre-Funded Warrant', 'BPCIA', 'Ichnos as &#', 'the Jefferies ATM Program', 'CPRA', '16,508&#8203;$ &#', 'SOX', 'ALPHA', 'ContentsWe', 'the Financial Accounting Standards Board', 'ContentsOther Income', 'NetOther', 'The California Privacy Rights Act', 'the Licensed Intellectual Property', 'Critical Accounting EstimatesThis', 'ContentsIn', 'Ichnos as &#8220;ISB 830&#8221', 'FASB', 'OX40R', 'HHS', '69,000&#8203;&#8203; &#8212;&#8203;&#8203', 'Medicaid', 'Medicare', 'Congress', 'a Committee for Medicinal Products for Human Use', 'FDA', 'Ichnos Sciences SA', 'Jefferies LLC (&#8220;Jefferies&#8221', 'Risks Related to Regulatory Approval', '69,000&#8203;$ &', 'the Certificate of Designation', 'the Federal Deposit Insurance Corporation', 'Risks Related', 'ExpensesAccrued', 'HIPAA', 'REMS', 'KALBITOR', 'FDARA', 'Company', 'USPTO', 'agreements&#8203;$ 69,000&#8203;$ &', 'CRO', 'the European Commission', 'ContentsNoncompliance', 'CMS', 'OperationsComparison', '69,000&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Gross&#160;Unrealized&#8203;Gross&#160;Unrealized&#8203;&#8203;&#8203;&#8203;&#160;&#160;&#160;&#160;Amortized&#160;Cost&#160;&#160;&#160;&#160;Gains&#160;&#160;&#160;&#160;Losses&#160;&#160;&#160;&#160;Fair&#160;ValueDecember&#160;31,&#160;2022&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Corporate', 'Restated 2015 Stock Incentive Plan', 'the European Academy of Allergy and Clinical Immunology Annual Meeting', 'funds&#8203;$ 3,876&#8203;$ &#8212;&#8203;$ &#8212;&#8203;$ 3,876Short', 'License Agreement', 'this Quarterly Report on Form&#160;10-Q', 'Ichnos', 'The Biologics Price Competition and Innovation Act', 'the Company as &#8220;STAR-0310', 'RequirementsOur', 'License', 'IRB', 'Amgen', 'the Children&#8217;s Health Insurance Program', 'NDA', 'BylawsProvisions', 'Restated Certificate of Incorporation', 'IRA', 'the Sarbanes-Oxley Act', 'Preferred Stock', 'HAE', 'the License Agreement', 'Financial Instruments-Credit Losses', 'CJEU', 'the Court of Chancery of the State of Delaware', 'European Union', 'the State of Delaware', 'Omnibus', 'Distinguishing Liabilities', '69,000&#8203;$ &#8212;&#8203;$ &', 'the Internal Revenue Service', 'Accounting Standards Codification', 'Employee Matters', 'Series X Preferred Stock', 'the Material Risks', 'the Court of Chancery', 'the U.S. Treasury Department', 'SEC', 'development&#160;$', 'BLA', 'the General Corporation Law', 'Contentsand', 'bonds&#8203;&#8203', '1,944&#8203;$ &', 'the European Union', 'October&#160;4', 'compensation&#8203;&#8203'}"
AUGX,"{'Health Enterprises', 'LLC', 'the SVB Loan', 'Form S-3', 'Issued Accounting', 'the Loan Agreement', 'Notebuilder Platform\\nwhich', 'Credit Risk', 'Augmedix Operating Corporation', 'cost&#160;\\n    &', 'MDS', 'Eastward Capital\\nPartners (&#8220;Eastward&#8221', 'State', 'costs\\n\\n&#160;\\n\\nThe Company', 'portion&#160;\\n    &#160;(1,434)\\n', 'the SVB Loan Agreement', 'regulations.\\n  \\n&#160;\\n\\nWe', 'Augmedix, Inc.', 'this Quarterly Report on Form 10-Q', 'marketing&#160;\\n    &', 'Employee Benefit Plan\\n\\n&#160;\\n\\nThe Company', 'Augmedix Bangladesh Limited', 'the Current Report on Form 8-K', 'the State of Delaware', 'the Current\\n    Report on Form 8-K', 'Turo Inc.', 'the Eastward Loan Agreement', 'Pacific Central Coast Health Centers', 'Regulation S-K.\\n\\n&#160;&#160;\\n\\n\\n\\n\\n\\n\\n\\n    37\\n    &', 'cost&#160;\\n    $', 'the Equity Line of Credit with Redmile Group', 'Loan', 'Suite 1300', '\\n    &', 'Dignity Health', 'by:&#160;\\n    &', 'Augmedix Operating Corp.', 'Related Party', 'Health', 'Silicon Valley Bank', 'cash&#160;\\n    &', 'Private Limited', 'SEC', 'Malo Holdings Corporation', 'Security Agreement\\n\\n&#160;\\n\\nOn\\nMarch', 'Company', 'Health Medical Foundation', '111 Sutter Street', 'the Critical Accounting Policies', 'Company\\nachieves', 'the &#8220;Effective', 'the Sarbanes-Oxley Act', 'Bangladesh', 'Tranche', 'Turo, Inc.', 'August Acquisition Corp', '\\n\\n\\n&#160;\\n\\nThe\\nSVB Loan Agreement', 'SVB', 'Health Enterprises adding physicians.\\nDollar', 'expect.\\n\\n&#160;\\n\\nOverview\\n\\n&#160;\\n\\nAugmedix, Inc.', 'customer\\nbase', 'ASC 842.\\n\\n&#160;\\n\\nThe Company'}"
AUPH,"{'USTreasuryBillSecuritiesMember2023', 'MaximumMember2023', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001600620us-gaap', 'Company\\', 'MillerJoseph MillerChief Financial Officer(Principal Financial and Accounting Officer)32\\n\\n\\n', 'the European Commission', 'LicenseAgreementTermsMember2023-07-012023-09-300001600620auph', 'CRO', 'USTreasuryBondSecuritiesMember2023', 'EC', 'RockvilleMarylandMember2023-09-300001600620auph', 'PatentsMember2023', 'OperationsThree', '30,20232022(in', 'Director(Principal Executive', 'thereafter:(in thousands)Finance Lease PaymentsOperating Lease PaymentsRemainder', 'USTreasuryBondSecuritiesMember2022-12-310001600620us-gaap', 'U.S. Food and Drug Administration', 'NetNet', 'AmendedAndRestatedEquityIncentivePlanMember2021-06-012021-06-300001600620us-gaap', 'Canada(State', 'CNI', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'NetTotal', 'ProductMember2023', 'OfficerMemberauph', 'EU', 'Riptide', 'FDA', 'PHARMACEUTICALS', 'USTreasuryBillSecuritiesMember2022-12-310001600620us-gaap', 'Trademark Office', 'AvenueEdmonton', 'Otsuka Pharmaceutical Co., Ltd.', 'Otsuka', 'USAgencySecurityMember2022', 'payments$85,521&#160;$7,693&#160;BeinheimThe Company', 'MMF', 'net77%48%90%74%License', 'FairValueInputsLevel1Member2022-12-310001600620us-gaap', 'LeaseholdImprovementsMember2022-12-310001600620us-gaap', 'ProductMember2022', 'ILJINMemberauph', 'Riptide Bioscience, Inc. (Riptide', 'SEC', 'InventoriesMember2023', 'Company', 'Otsuka Pharmaceuticals Co. Ltd.', 'the Securities Exchange Act', 'the heading &#8220;Risk Factors&#8221', 'LicenseAgreementTermsMember2023-01-012023-09-300001600620auph', 'PerformanceShareSandRestrictedStockUnitsRSUsMember2022-12-310001600620srt', 'USPTO', 'GreenleafPeter GreenleafChief Executive Officer', 'Riptide LicenseOn', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001600620us-gaap', 'the European Union', 'the U.S. Securities and Exchange Commission'}"
AURA,"{'\\n  &#x25aa;our', '\\n  &#x25aa;misappropriation', 'Good Manufacturing Practices', '\\n  &#x25aa;results', '20\\n', 'UroGen Pharma Ltd.', 'discount\\n    &', 'the SCS Microinjector', 'x25aa;our', 'Exhibits.\\n  &#160;\\n', 'EEA', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'Phase 4', 'the Transition Agreement', '26\\n', 'Inserm-Transfert', '\\n    Research', 'Clearside License', 'the Securities Exchange Act', 'Life Technologies', 'Research', 'x201c;smaller', 'Certificate of Incorporation', '\\n  &#x25aa;sales', 'Principal Financial Officer Pursuant', '\\n  &#x25aa;changes', '\\n  &#x25aa;failure', 'FASB', 'the FDA&#x2019;s Division of Oncology', 'Anti-Kickback Statute', 'this Quarterly Report on Form 10-Q entitled &#x201c;Risk', '\\n  &#x25aa;fluctuations', 'the Life Technologies', 'Transition Services', 'the NIH Exclusive License Agreement', 'Internal Control', 'Medicaid', 'Medicare', '\\n  &#x25aa;trading', 'the Delaware General Corporate Law', 'GDPR', 'detected.\\n', 'FDA', 'NIH', 'Specifically', 'and\\n  &#', 'NMIBC', 'EGC', '30\\n', 'ImmunityBio', 'REMS', 'Company', 'expense)\\n    &', 'USPTO', 'Adopted Pursuant to Section 302', '\\n  &#160;\\n', 'healthcare and/or impose price', 'LI-COR Non-Exclusive License and Supply Agreement', '50\\n', 'FerGene, Inc.', 'CRO', '\\n  ', 'the European Commission', 'the U.S. Patent and Trademark Office', 'LI-COR', '\\n  &#x25aa;any', '\\n  &#', '\\n  &#x25aa;speculation', '\\n  &#x25aa;assimilation', 'The Transition Agreement', 'Life Technologies Corporation', 'CG Oncology, Inc.', '6,636\\n    &', 'the Sarbanes-Oxley Act', 'Research and Development Expenses \\n', 'reporting.\\n', 'Comparison', '\\n  &#x25aa;the', 'ASU No', '\\n  &#x25aa;production', 'Form S-3', 'Board', 'SPA', 'melanoma.\\n  &', 'this Quarterly Report', '\\n  &#x25aa;lack', 'ATM', '\\n  &', '\\n  Regulation', '\\n  &#x25aa;termination', 'Non-Exclusive License Agreement', 'Non-Exclusive Agreement', 'CRADA', 'ESPP', '\\n  &#x25aa;actual', 'Sesen Bio, Inc.', 'the Registrant&#x2019;s Registration Statement on Form S-1', '\\n  &#x25aa;announcement', 'National Institute of Health', 'the Internal Revenue Service', 'the 2022 Shelf', 'the U.S. Treasury Department', 'SEC', 'BLA', 'calamities;\\n  &#x25aa;acts', 'the Company&#x2019;s Annual Report on Form 10-K.', '\\n  &#x25aa;variations', '\\n  &#x25aa;additions', 'Collaboration Research and Development Agreement', 'IRS', '\\n  &#x25aa;developments', '\\n    &'}"
AUTL,"{'ASC', 'Miltenyi Biotech B.V. &', 'VAT', 'Forge Life Sciences Nominee I Limited', 'Phase 1 CARPALL Study &#9702;The', 'Syncona Portfolio Limited', 'Principal Executive Officer', 'the Unaudited Condensed Consolidated Financial Statements11Item 2', 'Adaptive\\', 'the Cabaletta Agreement', 'this Quarterly Report on Form 10-Q', 'Blackstone Development Payments', 'Foreign Currency Exchange Risk&#160;&#160;&#160;&#160;We', 'Cell Therapy Catapult Limited', 'the Public Company Accounting Oversight Board', 'pursue&#160;in-licenses&#160;or', 'the United Kingdom &#8220;patent box&#8221', 'the Sarbanes-Oxley Act of', 'Adaptive', 'Miltenyi\\', 'Option', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Acute Lymphoblastic Leukemia', 'Principal Financial Officer Pursuant', 'FASB', 'UCL Business Ltd', 'Annual Report', 'B.V. &', '333-224720))10.1*&#8224;Lease Agreement', 'Association of Autolus Therapeutics plc', 'MediaWorks', 'Internal Control', 'the Securities and Exchange Commission', 'ContingenciesLicense AgreementsThe Company', 'UCLB', 'EBMT', 'Principal Executive Officer Pursuant to Rules', 'Condensed Consolidated Statements', 'Company', 'BCMA', 'Adopted Pursuant to Section 302', 'Forge Life Sciences Nominee', 'Significant Accounting', 'Phase 1 MCARTY Study &', 'Financial Information6Unaudited', '10%.Value Added Tax', 'The Nucleus Marshgate', 'the Reef Group', 'Whitewood Media Village GP Limited', '15d &#8211', 'Supply Agreement', 'Blackstone', 'the Blackstone Agreements', 'The Blackstone Collaboration Liability', 'Forge Life Sciences Nominee for The Nucleus', 'Whitewood Media Village Nominee Limited', 'Cabaletta Bio Inc.', 'University College London', 'ModernaTX, Inc. (&', 'the Sarbanes-Oxley Act', 'RDEC', 'the Securities and Exchange Act', 'the European Society for Blood and Marrow Transplantation', 'the Moderna Agreement', ""Company\\'s"", 'Condensed Consolidated Statements of Operations and Comprehensive Loss', 'Adaptive Biotechnologies Corporation', 'Note&#160;2, &', 'UCL', 'Multiple Myeloma &#8211', 'Administrative ExpensesGeneral', 'Note 2', 'LeasesThe Company', 'SEC', 'Financial ReportingNo', 'Condensed Consolidated Statements of Cash Flows', 'Noile-Immune Biotech Inc.', 'Qatar Investment Authority'}"
AVAH,"{'ITGC', 'FASB', 'LLC', 'ASU', 'Epic/Freedom', 'AVEANNA HEALTHCARE HOLDINGS INC.', 'the Delaware Superior Court', 'HHS', 'MS revenue.\\n  &#160;\\n', 'episode.\\n  &#', 'Reference Rate Reform', 'Integration Management Office', 'ended\\n    &', 'purposes.\\n', 'the Antitrust Division', 'Inherent Limitations on Effectiveness', 'THE CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)&#160;848', 'the Pediatric Home Health Seller', 'Scope', 'and\\n  &#x2022;an $11.7 million', 'DSO', 'revenue;\\n  &#x2022;a $5.4 million', 'Internal Control', 'Medicaid', 'ended\\n        &', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Tricare', 'Medicare', 'herewith:\\n  &#160;\\n', 'Defendants&#x2019', '95,438\\n    &', 'United States', 'IPO Options and Management Restricted Units&#160;The Company', 'the &#x201c;Pediatric Home Health', 'National Association', 'Hospice', 'HHH', '24\\n  &#160;\\n', '\\n  &#', 'SUBSIDIARIES \\n  NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS\\n  (Unaudited)\\n  &#160;\\n  5', 'the &#x201c;Securitization', 'PDS revenue;\\n  &', 'revenue;\\n  &#x2022;a $11.7 million', 'the Internal Revenue Service', 'PNC Capital Markets', 'PPE', 'Depreciation', 'Private Duty Services', 'Treasury', '\\n        &', 'PDS', 'Item 408 of Regulation S-K.\\n', 'SOFR', 'collectively &#x201c;patient', 'Webster Capital Corporation', 'Aveanna Healthcare LLC', 'Aveanna Healthcare', 'Company', 'Financial Reporting\\n  Except', 'the Securities Exchange Act', 'AUSA', 'the &#x201c;Escrow Funds&#x201d', 'Medical Solutions', 'IRS', 'periods.\\n  &', 'the Sarbanes-Oxley Act', 'PNC Bank', 'Adopted Pursuant to Section 302', 'Home Health &', 'the Receivables Financing Agreement', '\\n    &', 'and\\n  &', 'the Securitization Facility', 'Defendants'}"
AVDL,
AVGR,"{'Rules&#xa0;13a-15(e)&#xa0;and 15d-15(e)&#xa0;under the Exchange Act', 'the Company&#x2019;s Board of Directors', 'CRG Partners III L.P.', 'the Preferred Investment Options', 'collectively &#x201c;CRG&#x201d', 'registered:\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tCommon Stock', 'management&#x2019;s', 'LLC', 'Form S-3', 'the Loan Agreement', 'the California Department of Financial Protection and Innovation', 'FASB', 'the Securities Purchase Agreement', 'The Placement Agent Warrants', 'The Nasdaq Stock Market', 'the Placement Agent Warrants', 'this Quarterly Report', 'The Market Offering Agreement', 'Financial Statements', 'Loan Agreement', 'The Market Offering', 'Contracts', 'INSIGHT', 'the future.\\n\\n&#xa0;\\n\\nReverse Stock Split\\n\\n&#xa0;\\n\\nOn', 'PIK', 'Material Adverse Changes', 'a Term Loan Agreement', 'the Common Warrants', 'Derivatives', 'B Preferred Investment Options', 'equivalents\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t459,019\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t369,425\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t483,947\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t166,018\\n\\t\\t\\t&#xa0;\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tCommon', 'Preferred Investment Options', 'Geographical Information\\n\\n&#xa0;\\n\\nThe Company', 'FDA', 'Purchase Agreement', 'business.\\n\\n\\n&#xa0;\\n\\n&#xa0;\\n\\n\\n7', 'Amendments', 'Loan', 'Nasdaq Capital Market\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nIndicate', 'A Preferred Investment Options', 'the Company&#x2019;s Annual Report', 'the Federal Deposit Insurance Corporation', 'the CRG Loan', 'the &#x201c;Material Adverse', 'H.C. Wainwright &amp', 'Disclosure Controls and Procedures\\n\\n&#xa0;\\n\\nWe', 'Nasdaq Listing Rule 5550(a)(2', 'No &#x2610;\\n\\n&#xa0;\\n\\nIndicate', 'Silicon Valley Bank', 'Conversion and Other Options', 'SEC', 'Accounting for Convertible Instruments', 'the Waiver Agreement', 'Entity&#x2019;s Own Equity', 'the Listing Qualifications Department', 'x201c;Loan', 'the Company&#x2019;s Amended', 'Company', 'the Securities Exchange Act', 'Securities Purchase Agreement', 'First Citizens Bank', 'no &#x201c;Material Adverse', 'COVID-19', 'the Event of Default', 'CRG', 'the Series&#xa0;E Purchase Agreement', 'the Stated Maturity Date', 'the Retention Bonus Payments', 'ASU No'}"
AVIR,"{'INC.', 'The Roche License Agreement', '\\n  &#x2022;more', '\\n', '\\n  &#x2022;incur', 'costs.\\n  Interest Income and Other, Net \\n', '\\n  &#x2022;expansion', 'Gilead Sciences', '\\n  &#x2022;publication', 'the UK Medicines', '\\n  &#x2022;an', 'the disease.\\n  &#x2022;If', '\\n  &#x2022;developments', 'the Center for Medicare', 'the Company&#x2019;s Annual Report on Form 10-K', 'EU', 'MSD International GmbH', 'Court', 'the Trade-Related Aspects of Intellectual Property', 'Pfizer Inc.', 'Merck License Agreement\\n', '\\n  &#x2022;foreign', '26\\n', 'Interim Financial Information', 'EUA', 'Related Party TransactionsThe Company', 'ACA', 'Jefferies LLC (&#x201c;Jefferies&#x201d;)', 'Interest Rate Sensitivity', 'Franklin Street', 'Misconduct', 'COVID-19', '\\n  &#x2022;a Patient-Centered Outcomes Research Institute', 'HHS', 'The US Supreme Court', 'x201c;Merck License', 'candidates;\\n  &#x2022;collaborators', '\\n  &#x2022;significant', 'Genentech, Inc.', '\\n  Third party', 'x201c;Risk', 'Contingent Consulting FeeThe Company', '\\n  &#x2022;a', 'the Inflation Reduction Act', '\\n  &#x2022;extension', 'the Securities and Exchange Commission', 'Medicare', 'Medicaid', '\\n  &#x2022;developing', '\\n  &#x2022;hire', 'GDPR', '\\n  &#x2022;general', 'C. Liquidity', 'use.\\n  ', 'FDA', '\\n  &#x2022;collaborations', 'x2018;361', 'and\\n  &#', 'WHO', '\\n  &#x2022;changes', '\\n  &#x2022;continue', '\\n  &#x2022;collaboration', '77\\n', 'the Medicaid Drug Rebate Program', '\\n  &#x2022;regulatory', 'COV19', 'HIPAA', 'REMS', 'plan\\n    &', 'Merck &', 'FTC', 'Company', 'USPTO', 'UK&#x2019;s', '\\n  &#x2022;impose', 'the Leahy-Smith Act', 'customs', '\\n  &#x2022;seize', '\\n  &#x2022;whether', '\\n  &#x2022;obtaining NDA', 'the California Consumer Privacy Act', '\\n  ', 'ESG', 'CMS', 'HCV;\\n  &#x2022;the', '\\n  &#x2022;establishment', 'Merck', '\\n  &#x2022;acquire', 'Roche.6\\n     &', '\\n  &#x2022;the', 'the Department of Health and Human Services', 'the US Public Health Service Act', 'Roche', 'the Financial Accounting Standard Board', 'the US Foreign Corrupt Practices Act', '\\n  &#x2022;launching', '\\n  &#', '\\n  &#x2022;formulating', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', '\\n  &#x2022;different', '\\n  &#x2022;revenue', '\\n  &#x2022;make', 'NDA', 'and\\n  &#x2022;maintaining', 'Regulatory Agency', 'Co, Inc. (&', '\\n  &#x2022;cultural', 'TCA', 'decline.\\n  Provisions', 'the indemnified party', 'Gilead', 'HCV', 'companies&#x2019', '\\n  &#x2022;our', '\\n  &#x2022;key', '\\n  &#x2022;announcements', 'Form S-3', '\\n  &#x2022;convenience', '\\n  &#x2022;We', 'Medicaid Innovation', '\\n  &', '44\\n', 'the Roche License Agreement', 'personnel.\\n  &#x2022;We', 'the State of Delaware', 'the Merck License Agreement', 'the Federal Food, Drug and Cosmetic Act', 'x2022;refuse', '\\n  &#x2022;unanticipated', 'SARS-CoV-2', '\\n  &#x2022;disputes', '\\n  &#x2022;increases', '\\n  &#x2022;foreign exchange', '\\n  &#x2022;suspend', '\\n  &#x2022;efficacy', 'Healthcare', 'the European Medicines Agency', '\\n        &', 'SEC', 'LeasesThe Company', '\\n  &#x2022;potential', 'performance;\\n  &#x2022;the', 'the Budget Control Act', '\\n  &#x2022;manufacturing', '\\n  &#x2022;undertaking', '\\n  &#x2022;development of third', 'the Health Information Technology for Economic and Clinical Health Act', '\\n  &#x2022;failure', '\\n  &#x2022;reduced', '\\n  &#x2022;actual', 'Nasdaq', 'collaborators;\\n  &#x2022;maintain', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
AVRO,"{'THE SECURITIES EXCHANGE ACT OF 1934 \\n', 'Mayo Collaborative Services', 'the University of Manchester', '\\n', 'PropertyPlantAndEquipmentMember2022', 'LundUniversityRightsHoldersAgreementMember2022-07-012022-09-300001681087avro', 'EMA', 'RestrictedStockUnitsRSUMember2023-01-012023-09-3000016810872022-06-300001681087us-gaap', 'Novartis Pharma AG', 'investigation;\\n  &#x2022;availability', 'Pompe', 'EEA', '9746;\\n    &', 'Asset Purchase Agreement', 'Term Loan Agreement', 'AVR-RD-04', 'Phase 4', 'journals;\\n  &#', 'GenStem', 'Indicate', 'UNITED STATES', '26\\n', 'LoanAndSecurityAgreementMember2023-01-012023-09-300001681087avro', 'delayed.\\n  &#160;\\n  Changes', 'UHN', 'stockholder litigation;\\n  &#x2022;changes', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'LeaseholdImprovementsMember2022-12-310001681087us-gaap', '9744;\\n    &', 'UHN 1,161,665', 'COVID-19', 'and\\n  &#x2022;ability', 'or\\n  &#x2022;changes', 'candidates;\\n  &#x2022;seeking', 'Credit Losses,&#x201d', 'Series B Preferred Stock', 'candidates;\\n  &#x2022;failure', 'candidates;\\n  &#x2022;an', 'and\\n  &', 'First-Citizens Bank &amp', 'and\\n  &#x2022;favorable', 'Lund University', 'FASB', 'HHS', 'BioMarin Pharmaceutical Inc.', 'the Asset Sale', 'Restated Certificate of Incorporation of the Registrant', 'Related Party Transactions UHN', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the &#x201c;Maturity Date&#x201d', 'The University of Manchester', 'x2014;\\n        &', 'GDPR', 'FDA', 'NIH', 'strategic alternatives;\\n  &#x2022;adverse', 'BioMarinPharmaceuticalIncMember2023-07-012023-09-300001681087avro', 'AVR-RD-05', 'delayed.\\n  &#160;\\n', 'GeneralAndAdministrativeExpenseMember2022-07-012022-09-3000016810872022-01-012022-09-300001681087us-gaap', '\\n  Other (Expense) Income, Net \\n  Other (expense', 'consent;\\n  &#', 'Note 3 &#x201c;License', 'Loan', 'and\\n  &#', 'Prometheus Laboratories', 'EGC', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001681087srt', 'equipment.\\n  Financing Activities \\n  ', 'REMS', 'Silicon Valley Bank', 'the Delaware Forum Provision', 'and\\n  &#x2022;disruptions', 'Company', 'management&#x2019;s attention', 'requirements;\\n  &#x2022;economic', 'USPTO', 'UHNagreementMember2016', 'Significant Accounting', 'IBC', 'profits.\\n', 'the Leahy-Smith Act', '\\n  &#160;\\n', 'Lund University Rights HoldersOn', 'and\\n  &#x2022;business', 'SVB', 'the Term Loan Facility', '\\n    &#', 'TwoThousandTwentyInducementPlanMember2022', 'GLP', 'the Delaware General Corporation Law', 'the public;\\n  &#x2022;failure', 'ASU', 'the European Commission', 'CMS', 'candidates;\\n  &#', 'AVR-RD-03', 'Prepaid', 'ILAP', 'ATM Facility', 'CAD', 'new collaborations;\\n  &#x2022;failure', 'UoM', 'TCI', 'This Quarterly Report on Form 10', 'the U.S. Department of Health and Human Services', 'the Asset Purchase Agreement', '\\n        Laboratory', 'directors;\\n  &#x2022;provide', 'FAB', 'the Supreme Court', 'Financial Instruments &#', 'IRB', '\\n  &#', 'Separation Services Agreement', 'Board of Directors', 'the Fabry License Agreement', 'PropertyPlantAndEquipmentMember2022-01-012022-09-300001681087us-gaap', 'the Interleukin 12 License Agreement', 'products.\\n  &', 'sanctions.\\n  &', 'include:\\n  &#x2022;delays', '\\n  &#x2022;require', 'patentable;\\n  &#x2022;the', 'regimens;\\n  &#x2022;availability', 'the Term Loan Agreement', 'Centers for Medicare &', 'president;\\n  &#x2022;prohibit', 'prices;\\n  &#', 'Novartis Pharmaceuticals Corporation', 'directors;\\n  &#', 'the:\\n  &#x2022;size', 'FairValueMeasurementsRecurringMember2023', 'the United States National Institutes of Health', 'the Sarbanes-Oxley Act', 'organization)\\n    &#160;\\n', 'IPO', 'prospects.\\n  &', 'the indemnified party', 'litigation;\\n  &#x2022;the', 'Earthquakes', 'Form S-3', 'the Loan Agreement', 'LundUniversityRightsHoldersAgreementMember2022-01-012022-09-300001681087avro', 'BioMarinPharmaceuticalIncMember2023-01-012023-09-300001681087us-gaap', 'the trial;\\n  &#x2022;patient', 'performance.\\n  &', 'markets;\\n  &#x2022;compliance', 'iii\\n', '\\n  &', 'the Court of Chancery of the State of Delaware', 'Nasdaq&#x2019;s', 'University Health Network', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001681087avro', 'AVROBIO, INC', 'Medicaid Services', 'Trust', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001681087avro', 'LoanAndSecurityAgreementMember2021-11-022021-11-020001681087us-gaap', 'patents;\\n  &#x2022;our', 'patents;\\n  &#x2022;issued', 'the Internal Revenue Service', 'Note 2', 'candidates;\\n  &#x2022;establishing', 'x201c;Financial Instruments &#', 'the European Medicines Agency', 'programs.\\n  &#160;\\n', 'the U.S. Treasury Department', 'commitments.\\n  &#x2022;We', 'Papillon Therapeutics, Inc. (&', '\\n        &', 'SEC', 'AVR-RD-01', 'agreements.\\n', 'GCP', 'x201c;Loan', 'candidates.\\n  &', 'BLA', 'stock.\\n  &', '\\n  Emerging Growth Company Status \\n', 'LundUniversityRightsHoldersAgreementMember2023-01-012023-09-300001681087avro', 'Novartis', 'the Federal Trade Commission Act', 'CFRA', 'Credit Losses', 'BioMarin', 'fires.\\n  &', 'the future;\\n  &#', 'MPSII', 'products;\\n  &#x2022;restrictions', 'Nasdaq', '\\n    &', 'property.\\n', 'Note 3 &#x201c;License Agreements.&#x201d', 'Government Regulation &'}"
AVTE,"{'BofA Securities, Inc.', 'funds&#8203;$', 'the European Commission', 'September&#160;30,&#160;2022', 'Form S-3', 'Anti-Kickback Statute', 'the Safety Monitoring Committee', 'the Foster City Lease', 'AIA', 'ContentsRisks Related to Government RegulationWe', 'Physician Payments Sunshine Act', 'EMA', 'Internal Control', 'Medicaid', 'Medicare', 'ATM Program', 'Financial ReportingManagement', 'the International Trade Commission', 'EEA', 'GDPR', 'ATM Equity OfferingSM', '79,982&#8203;$ &', 'FDA', 'United Therapeutics Corporation', 'Phase 4', 'IRB', 'GMP', 'volatility&#160;90.8 - 91.5%&#160;&#160;73.6 - 73.8%&#160;73.9 - 91.5%&#160;&#160;73.6 - 76.5%&#8203;Risk-free interest rate&#160;4.1 - 4.4%&#160;&#160;2.7 - 4.1%&#160;3.5 - 4.4%&#160;&#160;1.6 - 4.1%&#8203;Expected', 'DPI', 'the &#8220;evergreen&#8221', 'No &#9744;Indicate', 'CPRA', 'PIPL', 'REMS', 'NDA', 'Treasury', 'ContentsMoreover', 'SEC', 'ContentsWe', 'GCP', 'The Lease Term', 'Company', 'the European Economic Area', 'markets;&#9679;we', 'USPTO', 'bonds&#8203;&#8203', 'the Sarbanes-Oxley Act', 'COVID-19', 'PAH', 'United Therapeutics', 'IPO', 'the California Privacy Rights Act', 'GSK', 'the European Union', 'Nasdaq', 'September&#160;1'}"
AVTX,"{'ContentsCash', 'BioScience, Inc. (&#8220;Aytu&#8221', 'LLC', 'Avalo Therapeutics, Inc.', 'KKC', 'Principal Executive Officer', '2023).10.4Payoff Letter', 'Horizon', 'LP (&#8220;Powerscourt&#8221', 'Astellas Pharma, Inc. (&#8220;Astellas&#8221;)', 'The ES Transaction', 'ES Therapeutics', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'ContentsNo', 'the Make-Whole Payments', 'ContentsAvalo', 'Procedures.&#160;Evaluation of Disclosure Controls', 'Avalo', 'Warrants', 'FASB', 'Apollo AP43 Limited', 'Venrock Healthcare Capital Partners (&#8220;Venrock&#8221;)', 'thousands):&#160;As', 'TRIS', 'Capital NeedsThe Company', 'Nantahala Capital Management', 'AUG Therapeutics', '2023).3.1Fourth Amended', 'Astellas License AgreementThe Company', 'ContentsThe', 'LeoGroup Private Investment Access', 'Horizon Credit II', '2023).10.1Second Forbearance Agreement', 'Apollo', 'the &#8220;AVTX-007 Milestones', 'Merck &', 'Company', 'The KKC License Agreement', 'Horizon Technology Finance Corporation', 'Oppenheimer &amp', 'the TRIS Obligations', 'L.P.', 'Burnham Prebys License', 'Capital Structure &', 'Principal Financial Officer', 'Powerscourt Investments XXV Trust', 'Co. Inc.', 'Unaudited Financial Statements.104Cover Page Interactive Data File', 'Teva', 'this Quarterly Report on Form&#160;10-Q', 'Horizon Funding Trust', 'Sanford Burnham Prebys Medical Discovery Institute', 'Condensed Consolidated Statements of Operations (Unaudited', 'Rule&#160;13a-15(b)&#160;and Rule&#160;15d-15(b)&#160;of', 'Kyowa Kirin Co., Ltd.', 'Lenders', 'Oppenheimer', 'Condensed Consolidated Statements of Changes', 'NDA', 'Condensed Consolidated Balance Sheets', 'AVTX-006 Royalty Agreement', 'ContentsIncome Tax Expense The Company', 'the Sarbanes-Oxley Act', 'Powerscourt Investments XXV', 'the &#8220;Karbinal', 'ASU No', 'section under &#8220;Management&#8217;s Discussion and Analysis of Financial Condition', 'Investors', 'Our Financial Position', 'non-current$&#8212;&#160;$13,486&#160;1 Balance', 'the Loan Agreement', 'Board', 'Exclusive Patent License Agreement', 'OSI Pharmaceuticals', 'the Royalty Agreement', 'the Accounting Standards Codification', 'Co., Inc.', 'Sanford Burnham Prebys License Agreement', 'the Sanford Burnham Prebys License Agreement', 'SEC', 'Fair Value Measurements and Disclosures (&', 'TRIS Pharma Inc.', 'Janssen Pharmaceutics, Inc.', 'Rule 405 of Regulation S-T', 'Nasdaq', 'Asset Management'}"
AVXL,
AWH,
AXDX,"{'ASC', 'The Forbearance Agreement', 'RELATED-PARTY', 'the U.S. Government', 'Principal Financial Officer', 'Remaining Performance Obligations', 'the Conversion Option', 'the Secured Note', 'Restructuring Transactions', 'the Schuler Trust', 'Private Placement', 'PIK', 'Dickinson and Company (&', 'Instruments Classified as Property and EquipmentProperty', 'AST', 'EQUIPMENTProperty', 'Amendment to Certificate of Incorporation of RegistrantIncorporated', 'Principal Executive Officer', 'RecognitionThe Company', 'the U.S. Centers for Disease Control and Prevention', '10-Q.The Company', 'Obligations', 'Yes &#9744', 'September&#160;30, 2023 (in', 'Organization and Nature of Business;', 'XBRL Taxonomy Extension Definition Linkbase DocumentFiled', 'The Conversion Option', 'the Forbearance Agreement', 'the Maturity Date', 'the &#8220;Collateral Agent&#8221;)', 'ChangeNet', 'Definitive Information Statement', 'FDA', 'the Interactive Data File', 'National Association', 'price.&#8226;At', 'The Schuler Purchase Obligation', 'disclosures.17LeasesThe Company', 'March&#160;24', 'Restated Bylaws of RegistrantIncorporated', 'Series A Preferred Stock', 'WarrantThe Warrant', 'EQUITYAugust 2022', '/ &#8220;razor-blade&#8221', 'Research and Development', 'Note&#8221', 'the &#8220;August 2022 Exchange', 'Support Agreement', 'the Restructuring Transactions', 'FlowsThe', 'the &#8220;Secured', 'the Certificate of Incorporation of RegistrantIncorporated', 'Accelerate', 'BD', 'the Ad Hoc Noteholder Group', 'Company', 'the Securities Exchange Act', 'U.S. Bank Trust Company', 'the Amended and Restated Bylaws of RegistrantIncorporated', 'CE IVDR registration', 'Trustee', 'FDIC', 'the Accelerate Arc Products', 'the Restructuring Support Agreement.28The', 'September&#160;30, 2023', 'the March 2022 Exchange Agreement', 'the Sarbanes-Oxley Act', 'OverviewAccelerate', 'Accelerate Arc Products', 'BC Kit', 'the Schuler Purchase Obligation', 'Fair Value of Financial Instruments', 'the Company.41March 2022 Exchange Transaction During', 'the Jack W. Schuler Living Trust', 'Results of Operations - Capital Resources', 'the Restructuring Support Agreement'}"
AXGN,
AXNX,"{'Legal MattersThe Company', 'in)&#160;&#160;Operating', 'March&#160;1', 'the License Agreement', 'ContentsCompany', 'Critical Accounting Policies', 'this Quarterly Report', 'Contractual Obligations', 'SystemsOur', 'In-Process Research &', 'Micro Systems Engineering', 'this Quarterly Report on Form 10-Q', 'ROU', 'Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures', 'Legal Matters', 'FDA', 'Intangible AssetsPatent', 'Employee Benefit PlanThe Company', 'the Medtronic Litigation', 'JAMS', 'DevelopmentAcquired', 'Research and Development Expenses Research', 'The Medtronic Litigation', 'PMA', 'SEC', 'Europ&#233;enne', 'Bulkamid', 'Company', 'F15', 'ContentsNet', 'SNM', 'This Quarterly Report on Form 10-Q', 'Axonics, Inc.', 'ContentsTotal'}"
AXSM,"{'ASC', ""Variable ConsiderationThe Company\\'s"", 'investigation;\\n  &#', '\\n  &#x2022;Revise', 'LLC', '\\n  &#x2022;develop', 'completion;\\n  &#x2022;the', 'the Tranche 4 Advance', 'candidates;\\n  &#x2022;hire', '\\n  &#x2022;expand', 'Regulation S-K).\\n  95\\n', 'Security Agreement', 'Contracts with Customers (&#', 'Security Agreement &#', 'Duke', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'the Patient Protection', 'grant cross', 'physicians;\\n  &#x2022;effectiveness', 'Lilly', 'NY', 'EU', 'requirements;\\n  &#x2022;collaborators', 'Court of Chancery', 'Antecip Bioventures II', 'AXS-05', 'Pfizer Inc.', 'Indicate', 'Axsome', 'commercialization.\\n  Specifically', 'limited.\\n  &#x2022;We', 'commercialization.\\n  Undesirable', 'and\\n  &#x2022;product', 'the Maturity Extension Conditions', 'organization;\\n  &#x2022;ensure', 'ACA', 'x201c;Pharmanovia License', 'Financial Information', 'the Securities Exchange Act', 'COVID-19 pandemic;\\n  &#', 'MDD', 'candidates;\\n  &#x2022;significant', 'CNS', 'Shelf Registration Statement', 'Eli Lilly and Company', 'and\\n  &#x2022;the FDA', 'Significant Accounting PoliciesSignificant Risks', 'Tranche 1D Advance', 'x2022;a court', 'the Orange Book', 'Pfizer', 'all Term Loan Advances', 'x2022;if', 'and\\n  &#x2022;collaborators', 'One Word Trade Center', 'Financial Statements', 'costs;\\n  &#x2022;exposure', '\\n  &#x2022;Require', 'prospects.\\n  &#x2022;We', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the trial;\\n  &#x2022;patients&#x2019', 'Obtaining', 'SVB Securities', 'the &#x201c;Direct', 'candidates;\\n  &#x2022;a', 'GDPR', 'including:\\n  &#x2022;infringement', 'FDA', 'candidates.\\n  &#', 'EquivalentsThe Company', 'the Licensed Products', 'Loan', 'the Hatch-Waxman Act', 'and\\n  &#', 'Rule 10b5-1', 'the Defense Health Agency', 'know&#x2011;how', 'the Medicaid Drug Rebate Program', 'Duke University', 'Company', 'and\\n  &#x2022;redesigning', 'USPTO', 'ContentsThe Company', 'Antecip Bioventures\\n  ', 'quantities;\\n  &#x2022;our', 'Abbreviated New Drug', 'the Term Loan Advances', 'SVB', 'Auvelity', 'the 2020 Term Loan', 'ADHD);\\n  &#x2022;continue', 'NMDA', 'Advance Magazine Publishers', 'the Delaware General Corporation Law', 'ESG', 'Exclusive License Agreement', 'TRICARE', 'the Term Loan Advance', 'revenues.\\n  &#', 'Loan Agreement', 'Atnahs Pharma UK Limited', 'product;\\n  &#x2022;disagreements', 'the Asset Purchase Agreement', 'fibromyalgia;\\n  &#x2022;continue', 'CSA', 'and\\n  &#x2022;continue', 'License', '\\n  &#', 'the Malta Subsidiary', 'FDA Orphan Drug Designation', 'CNS disorders;\\n  &#', 'Lenders', 'commercialized.\\n  &#x2022;If', 'the Pharmanovia License Agreement', 'including:\\n  &#x2022;our', 'Hercules Capital, Inc', 'Security AgreementHercules Capital', 'NDA', 'we:\\n  &#', 'AD agitation.\\n  &#x2022;We', 'World Trade Center Lease\\n', 'Axsome Malta', 'the 2022 Shelf Registration Statement', 'Leerink Partners', 'the Sarbanes-Oxley Act', 'Herriot Tabuteau', 'Regulation S-K', 'AXS&#x2011;05', 'First Amendment to Loan', 'the Purchase Agreement', '\\n  &#x2022;our', 'requirements.\\n  &#x2022;If', 'narcolepsy;\\n  &#x2022;continue', 'the Loan Agreement', 'the License Agreement', 'Board', 'One World Trade Center', 'Hercules Capital, Inc.', 'Inventory&#160;The Company', 'the Court of Chancery of the State of Delaware', 'revenues.\\n  &#x2022;If', 'candidates;\\n  &#x2022;conduct', '44\\n', 'PfizerIn', 'DEA', 'Tranche 5 Advance', 'and\\n  &#x2022;inability', 'consents;\\n  &#x2022;risk', 'efforts.\\n  &#x2022;Our', 'we:\\n  &#x2022;continue', 'the &#x201c;March 2022', 'Significant Accounting Policies', '42\\n  \\n  Table of Contents\\n  &#x2022;Subject', 'SEC', 'the U.S. Drug Enforcement Administration', 'GCP', 'agreements.\\n', 'x201c;Loan', 'Territory', 'License AgreementsLicense Agreement', 'the European Union', 'Nasdaq'}"
AYTU,
AZN,
AZTA,
BACK,"{'LLC', 'Company Shares', 'the Rebuttal of Notice', 'IMAC Management of Illinois', '\\n', 'State', 'LLC (&#8220;IMAC Florida&#8221;)', 'the Company (&#', 'Health', 'the Securities Exchange Act', 'IMAC', 'Internal Control&#8212;Integrated Framework', 'THER', 'Convertible Preferred Stock and Warrants', 'the Securities\\nand Exchange Commission', 'the Theralink Common Stock, &#8220;Theralink', 'the Committee of Sponsoring', 'Warrants', 'the Merger Agreement', 'Kepro', 'including\\nour', 'Holdings', 'the Certificate of Incorporation of IMAC Holdings, Inc.', 'Murray', 'and\\n&#8220;IMAC', 'Company&#8217;s\\ncommon', 'Theralink&#8217;s\\nboard', 'the Back Space', 'Company\\nShares', 'DEFICIT)&#160;\\n    &', 'Note 13&#160;\\n    &', 'LLC (&#8220;IMAC Illinois&#8221;)', 'Company', 'Designation of Preferences, Rights and Limitations of Series A-1 Convertible Preferred Stock of IMAC Holdings, Inc.', 'Management of Florida', 'LLC (&#8220;IMAC St. Louis&#8221;)', 'Unit Purchase Option', 'Theralink Technologies, Inc.', 'net&#160;\\n    &', 'Louisiana Orthopedic', 'LLC (&#8220;Advantage Therapy&#8221;),\\nIMAC', 'capitalized\\nat', 'IMAC Merger Sub, Inc.', 'Progressive Health and Rehabilitation, Ltd.', 'IMAC Management', 'IMAC Management Services', 'controls\\nand', 'A-1 Convertible Preferred Stock', 'Louisiana Orthopaedic &', 'the Board of Directors&#8217', 'the Corporate Conversion', 'Purchasers', 'Series A-2 Convertible Preferred Stock', 'respectively.&#160;\\n    &#160;4,300,000&#160;&#160;\\n    &', '\\n&#160;\\n\\nResults\\nof Operations', 'IMAC Florida', 'Exhibit 3.2', 'Merger', 'IMAC Regeneration Management of Nashville,\\nLLC', 'Theralink\\nCommon Stock', 'the Treadway Commission', 'IMAC Regeneration\\nManagement', 'LLC (&#8220;IMAC Texas&#8221;) IMAC Regeneration Management of Nashville', 'Disc Institute, Ltd.', 'the Securities and Exchange Act', 'Form S-3', 'IMAC Holdings, Inc.', 'EQUITY', 'Curis Express', 'portion&#160;\\n    &', 'compliance\\nwith the Minimum Equity Rule', 'LLC (&#8220;IMAC Nashville&#8221', 'BackSpace', 'SEC', 'LLC to\\nCuris Express', 'GAAP', 'request.\\n\\n&#160;\\n\\nNote\\n14 &#8211', 'Nasdaq', 'IMAC Regeneration Center of Nashville', '\\n    &', 'LLC (&#8220;IMAC', 'realized.\\n\\n&#160;\\n\\nNewly\\nAdopted Accounting'}"
BBIO,"{'ASC', 'Exhibit 4.1)\\n    &', 'years)\\n        &', 'thousands)\\n  &', 'LLC', 'Bristol-Myers Squibb Company (&#', '\\n    Interest income\\n    &', 'Included in &#x201c;Prepaid', 'Unaudited)\\n  &#160;\\n  14.Public', 'the &#x201c;Collateral Agent&#x201d;)', 'Eidos Therapeutics, Inc. (', 'QED', 'procedures.\\n  Changes', '\\n  &#x2022;acknowledged', 'the Federal Reserve', 'Credit Risk and Other Risks', 'this Quarterly Report on Form 10-Q', 'PRV', 'KKR Genetic Disorder L.P.', 'the Helsinn Parties', 'the &#', 'Resilience Development and Manufacturing Service', 'the Resilience Agreements', 'periods:\\n  &#160;\\n', 'Eidos Therapeutics, Inc.', 'the Exclusive (Equity) Agreement', 'Amended Loan Agreement;\\n  &#x2022;permitted', 'things:\\n  &#x2022;permitted', 'the &#x201c;Amended Loan', 'LianBio', 'Included in &', 'the Leland Stanford Junior University', 'the Securities Exchange Act', 'Resilience', 'Condensed Consolidated Statements of Cash Flows \\n', 'Offerings,', 'FMI', 'COVID-19', 'KKR Capital Markets LLC (&#x201c;KCM&#x201d;)', 'QED Therapeutics, Inc', 'x201c;BridgeBio&#x201d', 'Voting Interest Entity', 'the Acoramidis Milestone', 'Note 13)\\n        &', 'Other Research and Development Agreements Stanford License Agreement', 'the Capped Call Transactions', 'compensation\\n    &', 'Description of Business BridgeBio Pharma, Inc. (&#', 'Unaudited)\\n  &#160;\\n  8.Commitments', 'Helsinn', 'Resilience US, Inc. (&', 'SVB Securities LLC', 'Initial Leidos License', 'Material Changes to Nomination Procedures\\n  None.\\n', 'Private Placement', 'PIK', 'the Capped Call Counterparties', 'U.S. Food and Drug Administration', 'Internal Control', 'Capped Call', 'x2014;\\n        &', ': &', 'Globe Merger Sub I, Inc.', 'FDA', 'statements.\\n  &', 'Novartis International Pharmaceutical, Inc.', 'The Leidos Agreements', 'reporting.\\n  &', 'Loan', 'Alexion Pharmaceuticals, Inc.', 'and\\n  &#', 'the LianBio Exclusivity Agreement', 'the Private Placement', 'TRUSELTIQTM', 'x201c;Common', 'Condensed Consolidated Statements', 'activities\\n    &', 'Guarantors', '\\n    &#160;&#160;4.1\\n    &', 'BridgeBio Pharma, Inc.', 'the Department of the Treasury', 'MTA', 'Share Repurchase Program', 'Milestone AwardsApart', 'U.S. Bank National Association', 'a Project Agreement', 'QED-LianBio License Agreement', 'QED-Helsinn License and Collaboration Agreement', '6,826\\n        &', 'the Amended Loan Agreement', 'SecuritiesThe', 'the Term Loan Advances', 'VOE', 'SVB', 'Navire Pharma, Inc. (&#x201c;Navire&#x201d;)', 'KKR Capital Markets LLC', 'Signature Bank', 'Condensed Consolidated Financial Statements', 'Follow', '\\n    &#', 'Evercore Group L.L.C.', 'Eidos', 'BMS', 'Globe Merger Sub II, Inc.', 'Contingencies Milestone Compensation Arrangements', 'License Agreement', 'The Loan Agreement', 'KCM', 'the Securities Exchange Commission', 'Leidos', 'UncertaintiesFinancial', 'fee\\n        &', 'KRAS G12C', '\\n  &#x2022;amended', '\\n  &#', 'the Origin-Sentynl APA', 'Aspa', 'Morgan Stanley &', 'and\\n  &#x2022;modified', 'Board of Directors', '\\n    &#160;&#160;4.6\\n    &', 'Taxes', 'Lenders', 'Alexion Pharma International Operations Unlimited Company', 'Stanford University', 'Registrant', 'Diagnostics Agreement with Foundation Medicine', 'respectively.\\n  &', '15.Stock-Based Compensation', 'NDA', 'exchange &', '\\n    &#160;&#160;4.5\\n    &', 'the &#x201c;Transfers', 'the &#x201c;Administrative', 'the Leidos Agreements', 'fixed.\\n  &', 'FDIC', 'BridgeBio Pharma', 'the Navire-LianBio License Agreement', 'Tranche', 'BridgeBio&#x2019;s Current Report', '47\\n', '\\n    &#160;&#160;4.4\\n    &', 'Navire', 'Exhibit 4.1).\\n    &', 'Leidos Biomedical Research, Inc.', 'the Exchange Program', 'BridgeBio&#x2019;s', 'Condensed Consolidated Financial Statements \\n', 'Unaudited)\\n  &#160;\\n  13.LeasesWe', 'treasury', 'the Loan Agreement', 'Form S-3', 'Goldman Sachs &', 'Restricted Cash:\\n    &', 'Foundation Medicine, Inc.', 'the Eidos-Alexion License Agreement', 'Contracts', 'ATM', '\\n  &', 'VIE', 'Equity Investments', 'value.\\n  Revenue\\n  The', 'the U.S. Food and Drug Administration', 'IPR&amp;D', 'Indenture', 'BBP', 'the &#x201c;Maturity', 'Leidos Biomedical Research License and Cooperative Research and Development AgreementsIn', 'the Board of Trustees', 'TheRas, Inc. (&', 'Nonfinancial AssetsSale of Priority Review', 'The Capped Call Transactions', 'x201c;Private', 'Alexion', '\\n        &', 'SEC', 'Restricted', 'BridgeBio', 'Exchange Program', 'the &#x201c;Company&#x201d;)', 'Novartis', 'the Term Loan Amortization Date', 'the Origin-Alexion APA', 'Adrenas Therapeutics Inc.', 'Aspa Therapeutics, Inc. (&#x201c;Aspa&#x201d', 'Additional Leidos Licenses', '\\n    &#160;&#160;Total', 'Development and Manufacturing Services Agreement', 'PellePharm\\n    &', '\\n  &#x2022;reduced', '\\n    &'}"
BBLG,
BCAB,"{'ASC', 'years)\\n        &', 'Bristol-Myers Squibb Company (&#', 'candidates.\\n  &#x2022;If', '\\n    Interest income\\n    &', 'State', 'all;\\n  &#x2022;delays', 'The Sarbanes-Oxley Act', 'EMA', 'Rules 13a-15(b', 'the Securities Act.\\n  We', 'CAB Programs\\n    &', 'this Quarterly Report on Form 10-Q', 'the Condensed Balance Sheets', 'Jefferies LLC', 'PCT', 'and\\n  &#x2022;analogous', 'others:\\n  &#x2022;identifying', 'NSCLC', '\\n    Research', 'ACA', 'benefits;\\n  &#x2022;difficulties', 'the Securities Exchange Act', '\\n  Research', 'Jefferies', 'and\\n  &#x2022;improving', 'The BeiGene Collaboration', 'COVID-19', 'CAB', 'patents.\\n  &#x2022;The', 'the product;\\n  &#x2022;withdrawal', 'ROR2', 'x2022;high', 'HHS', 'Cover Page Interactive Data File', 'the FDA;\\n  &#x2022;delays', 'EstimatesThe', 'Adopted Pursuant to Section 906', 'market.\\n  &#x2022;Intellectual', 'manufacturers&#x2019', 'others:\\n  &#x2022;delays', 'Medicaid', 'the Securities and Exchange Commission', 'AXL', 'Medicare', 'x2014;\\n        &', 'FDA', 'AXL-ADC)\\n    &', 'Jefferies LLC (&#x201c;Jefferies&#x201d', 'QHP', 'and\\n  &#', 'others;\\n  &#x2022;collaborators', 'CAB BiSpecific', 'HIPAA', 'Silicon Valley Bank', 'Going ConcernThe Company', 'data;\\n  &#x2022;delays', 'PresentationThe', 'candidates;\\n  &#x2022;regulatory', 'Company', 'expense)\\n    &', 'payroll taxes;\\n  &#x2022;foreign', 'USPTO', 'rights.\\n  &#', 'liability;\\n  &#x2022;disputes', 'candidates;\\n  &#x2022;delays', 'facilities;\\n  &#x2022;success', 'the Condensed Statements of Operations', 'and\\n  &#x2022;business', 'prospects.\\n  &#x2022;Our', 'liability;\\n  &#x2022;collaborators', 'the BeiGene Collaboration', 'CMS', 'BMS', 'ROR2-ADC)\\n    &', 'candidates.\\n  &#x2022;The', 'patentable.\\n  &#', 'FCPA', 'Stockholders&#x2019', 'the U.S. Department of Health and Human Services', 'the Department of Health and Human Services', 'the Oncology Center of Excellence', 'IRB', '\\n  &#', '\\n  Research and Development Expense\\n', 'candidates;\\n  &#x2022;collaborations', 'infringed.\\n  &#', 'BeiGene', 'BioAtla', 'Related Party TransactionsHimalaya Therapeutics SEZCClinical Trial Services', '47\\n', 'Condensed Financial Statements', 'and\\n  &#x2022;injunctions', 'BA3011', 'Hamas', 'ROR2 TmPS', 'the United States;\\n  &#x2022;production', 'Management&#x2019;s', '\\n  &', 'the Court of Chancery of the State of Delaware', 'approvals;\\n  &#x2022;product', 'candidates.\\n  &#x2022;Others', 'ESPP', 'BeiGene Collaboration', 'the State of Delaware', 'the Interactive Data File', 'Medicaid Services', 'Healthcare', 'stock.\\n  Risk Factors\\n  Risks', '\\n        &', 'SEC', 'Restricted', 'LeasesThe Company', 'agreements.\\n', 'BLA', 'the General Corporation Law', 'Data Safety Monitoring Board', 'the BMS Agreement', 'each site;\\n  &#x2022;challenges', 'the Centers for Medicare &', 'Himalaya Therapeutics Limited Company', '\\n    External expenses:\\n', 'candidates.\\n  Competition', 'and\\n  &#x2022;changes', 'Children&#x2019;s Health Insurance Programs', '17\\n', '\\n    &', 'parties.\\n  &#x2022;We', 'others:\\n  &#x2022;differing'}"
BCDA,"{'this Quarterly Report', 'BioCardia', 'the California Institute of Regenerative Medicine (CIRM', '\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tRelated Party', 'the Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study', 'Internal Control', 'New York Heart Association Class II', 'Medicare', 'Success', 'the Litigation Funding Settlement', 'this Quarterly Report on Form 10-Q', 'Chronic Myocardial Ischemia', 'TRIDENT', 'Development Expenses \\n\\n&#xa0;\\n\\nOur', 'COVID', 'FDA', 'Cantor', 'BSLF', 'IRB', 'Investigational New Drug', 'CellProthera', 'the Transendocardial Autologous Cells', 'SEC', 'TAC-HFT', 'ATM Offering', 'Japan&#x2019;s Pharmaceutical and Medical Device Agency', 'Litigation Funding Agreement (Funding Agreement', 'L.L.C.', 'Ischemic Heart Failure Trial', 'COVID-19', 'Operations \\n\\n&#xa0;\\n\\nComparison of Three', 'the ATM Offering', 'the Transendocardial Stem Cell Injection Delivery Effects on Neomyogenesis Study', 'Nasdaq'}"
BCEL,"{'ASC', 'the Delaware General Corporation Law', 'LLC', 'Cowen and Company', 'Consulting Agreement', 'CollaborationsHistorically', 'Form S-3', 'Baker Brothers', 'ContentsAdditionally', 'the Grant Agreement', 'the Vaccine Alliance', 'Principal Financial Officer', 'ASU 2018-18', 'No  &#9723;Indicate', 'the Lease Modification Agreement.7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accrued ExpensesAccrued', 'Financial Statements', '2022.The Company', 'Contents8.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LeasesThe Company', '500&#8203;&#8203; &#8212;Professional', 'benefits&#8203;$', 'this Quarterly Report on Form 10-Q.', 'Lease', 'CJEU', 'the Court of Chancery of the State of Delaware', 'Principal Executive Officer', 'Medicare', 'Medicaid', 'GDPR', 'Zymeworks Inc (&', 'Xencor, Inc.', '835 Industrial Road,', 'Agreement for Modification of Lease', 'The Lease Modification Agreement', 'License', 'Gates', 'ADC', 'Stanford', 'insurance&#8203;&#8203', 'Strategic Review', 'Stanford University', 'Nine Months Ended &#', 'the Lease Modification Agreement', 'APN-497444', 'HIPAA', 'Melinda Gates Medical Research Institute', 'Significant Accounting Policies', 'PlanThe Company', 'the Xencor Agreement', 'SEC', '9,681&#8203;&#8203;- 18', 'the Health Information Technology for Economic and Clinical - 45', 'the Minimum Bid Requirement', 'Collaboration and License Agreement', 'Company', 'ContentsOur', 'the U.S. Patent and Trademark Office', 'ARE-San Francisco', 'Nasdaq Listing Qualifications Panel', 'the Federal Trade Commission Act', 'USPTO', 'ContentsThe Company', 'FactorsOur', 'the Health Insurance Portability', '563Total', 'In-Licensing Arrangements &', 'Nasdaq', 'the August 2023 Reorganization', 'Cowen', 'Rate Risk &', 'the European Union', 'the Bill &', 'Qualitative Disclosures About Market'}"
BCLI,
BCRX,
BCTX,
BCYC,
BDRX,
BDSX,
BDTX,
BEAM,
BEAT,"{'Maverick Capital Partners', 'OverviewWe', 'LLC', 'ProceduresWe', 'Form S-3', 'SPA', 'Triple Ring Technologies, Inc (&#8220;TRT&#8221', 'the Securities and Exchange Commission', 'Incorporation', 'ExhibitsThe', 'this Quarterly Report on Form 10-Q', 'Articles of Incorporation', 'the State of Delaware', 'Electrocardiogram (&#8220;ECG&#8221', 'Alliance Global Partners', 'Professional Services AgreementIn', 'LLC (&#8220;Investor&#8221;)', 'No &#9744;Indicate', 'the Federal Deposit Insurance Corporation', 'Form S-1', 'SEC', 'NPA', 'Company', 'the Sarbanes-Oxley Act', 'Results of Operations', '7 &#8211', 'the Registration Statement'}"
BFRG,
BFRI,"{'this Line of Credit', 'Maruho', 'LLC', 'BSM', 'the International Chamber of Commerce', 'Dividend yield&#160;\\n    &', 'the Loan Agreement', 'Restricted Stock', 'Contingencies', 'Loan Agreement', 'Aggregate Intrinsic Value', 'the Reverse Stock Split', '2016 Services Agreement', 'Accrued Expenses and Other Current', 'year.\\n\\n&#160;\\n\\nChange\\nin Fair Value of Contingent', 'Transfer Agreement', 'Xepi&#174', 'Agreement.\\n\\n&#160;\\n\\nThe\\nCompany', 'cash\\nand', 'the &#8220;Share Purchase', 'The Loan Agreement', '\\n    Interest income &', 'Fair Value Warrant', 'Cutanea\\nproducts', 'net&#160;\\n', 'IP', 'Biofrontera Inc.', 'Optical Tools LLC (&#8220;Optical', 'includes\\nan Unused Line Fee Rate', 'Roth Capital Partner', 'RSU', 'consideration&#160;\\n    &', '\\n\\n\\n\\n&#160;\\n\\n5.\\nRevenue\\n\\n&#160;\\n\\nWe\\ngenerate', 'Loan', 'payments&#160;\\n    &', '\\n&#160;\\n\\nAdjusted\\nEBITDA\\n\\n&#160;\\n\\nAdjusted\\nEBITDA', 'the Biofrontera Group', 'reserves&#160;\\n    &', 'Optical Tools', 'the Common Stock', 'Units (&#8220;RSUs&#8221', 'the Company&#8217;s\\nCommon Stock', 'The Allocation Agreement', 'cash&#160;\\n    &', 'Restricted', 'the U.S. District Court', '\\n    Interest', 'Common Stock', 'and\\n  \\n    &', 'Bioscience', 'Company', 'MidCap Business Credit LLC', 'MidCap Business Credit', 'U.S. GAAP.\\n\\n&#160;\\n\\nChange\\nin', 'Biofrontera AG', 'Cutanea Life Sciences, Inc. (&#8220;Cutanea&#8221', 'FASB ASC Topic', 'Share Purchase Agreement', 'Maruho Co, Ltd.', 'Licensors', 'Fair Value of Warrant', 'SEC', 'Credit Limit', 'Bio-FRI GmbH', 'Biofrontera Pharma GmbH', 'the Share Purchase Agreement', 'Stock Options', 'the underlying\\nvalue of the Common Stock', 'net&#160;\\n    &', 'the Amended Settlement Allocation Agreement', '\\n    &', 'the Settlement Allocation Agreement (&', '\\n    &#', 'Biofrontera Bioscience', 'DUSA'}"
BGNE,"{'ASC', 'The HGR Regulation', 'PRC &', 'ShareOptionAndIncentivePlan2016Member2023-01-012023-09-300001651308bgne:', 'China Broad Market Development Agreement', 'the Foreign Investment Security Review Measures', 'Co-Development Funding CommitmentUnder the Amgen', 'BLINCYTO&#174', 'China Merchants Bank', 'KYPROLIS&#174', 'EMA', 'HGR', 'CostOfSalesMember2022', 'Contentsbinding', 'ShareOptionAndIncentivePlan2016Member2023-09-300001651308us', 'OtherIncomeMember2023-07-012023-09-300001651308us-gaap', 'Novartis Pharma AG', 'Celgene Logistics S&#224;rl', 'NMPA', 'Biologics License Application', 'CollaborationOtherMember2022', 'ProductMember2023', 'RevlimidMember2023-01-012023-09-300001651308us-gaap', 'EU', 'ContentsUse', 'Republic of China', 'the Public Company Accounting Oversight Board', 'Bristol-Myers Squibb Company (&#8220;BMS&#8221', 'the Novartis Territory', 'ContentsGross MarginGross', 'LeapTherapeuticIncMember2023-01-012023-09-300001651308bgne', 'XgevaMember2022', 'PIPL', 'Euro', 'InventoriesMember2023', 'LeapTherapeuticIncMember2022-01-012022-09-300001651308us', 'the Securities Exchange Act', 'CN2023-01-012023-09-300001651308country', 'the Amended and Restated Quality Agreement', 'The Stock Exchange', 'Item&#160;2 &#8211', 'Measures of Cross-Border Data Transfer Security Assessment', 'COVID-19', 'ContentsLine of CreditOn July 28, 2023', 'BMS-Celgene License', 'AmgenIncMember2022', 'ObligationsThe', 'Development CommitmentThe Company', 'PamiparibMember2023-01-012023-09-300001651308us-gaap', 'Clinical Development and Commercialization of Our Medicines and Drug Candidates &', 'Company\\', 'The Settlement Agreement', 'assets1,287&#160;187&#160;1,100&#160;588.2&#160;%1,662&#160;563&#160;1,099&#160;195.2&#160;%Total', 'Hong Kong Special Administration Region', 'ADSs, and/or RMB Shares', 'LLC (&#8220;Catalent&#8221', 'Hong Kong Limited', 'XgevaMember2023', 'the National Intellectual Property Administration', 'HGRAC', 'ContentsCenters', 'BeiGene Suzhou Co.', 'the Share Subscription Agreement', 'Internal Control', 'the HGR Regulation', 'Capital ResourcesThe', 'Medicaid', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'Medicare', 'ContentsIn December', 'SAFE', 'the State Council', 'the Federal Trade Commission', 'US2023-01-012023-09-300001651308country', 'Zone Technology Holding Group Co., Ltd.', 'Geographic InformationThe Company', 'the Cyberspace Administration of China', 'BrukinsaMember2023', 'FDA', 'US2022-01-012022-09-300001651308country', 'NetProperty', 'the State Administration for Market Regulation', 'HGR Regulation', 'GMP', 'the Revised Confidentiality and Archives Administration Provisions', 'ADS', 'US2023-01-012023-09-300001651308us-gaap', 'ContentsThe', 'Risks Related', 'the Holding Foreign Companies Accountable Act', 'ChinaConstructionBankMember2022-12-310001651308bgne:', 'Lease CommitmentsWe', 'Rule&#160;13a&#8209;15(d)&#160;and', 'LeapTherapeuticIncMember2022-07-012022-09-300001651308bgne', 'LeapTherapeuticIncMember2023-09-300001651308bgne', 'AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300001651308country', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001651308us-gaap', 'Luye Pharma Group', 'LSA', 'Company', 'CSRC', 'Co-Founder', 'OtherIncomeMember2023-01-012023-09-300001651308us', 'BeiGene, Ltd.', 'ShareOptionAndIncentivePlan2016Member2022-03-312022-03-310001651308bgne:InducementEquityPlan2018Member2018-06-300001651308bgne', 'ContentsThe Company', 'or&#8226;a', 'EuropeMember2022', 'profit-', 'TEVIMBRA', 'FCA', 'US2022-01-012022-09-300001651308us-gaap', 'ESCC', 'Intangible AssetsIntangible', 'the Amgen - BeiGene Collaboration', 'GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001651308us-gaap', 'KYPROLIS', 'the European Commission', 'China CITIC Bank', 'ProductMembercountry', 'Contentsdrug', 'CMS', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001651308us', 'BMS', 'BEPS', 'BMS-Celgene', 'NovartisMember2023', 'SAMR', 'Arbitration', 'GET Technology Development Co., Ltd.', 'LeapTherapeuticIncMember2023-07-012023-09-300001651308bgne', 'Catalent Pharma Solutions', 'Leap Therapeutics, Inc. (&', 'the Committee for Medicinal Products for Human Use', 'SSA', 'Financial ReportingThere', 'Upfront', 'Amgen', 'China Minsheng Bank', 'the OECD/G20 Inclusive Framework', 'ProductMember2022', 'China Merchants Bank Co., Ltd.', 'Macau SAR', 'ADSs, RMB Shares', 'Office of Foreign Asset Control', 'BLINCYTO', 'ContentsOur', 'the Security Review Rules', 'FairValueMeasurementsRecurringMember2023', 'CollaborativeArrangementMember2022', 'BeiGene', 'the Anti-Monopoly Law', 'LeaseholdImprovementsMember2022-12-310001651308us-gaap', 'ExpenseInterest', 'ShareOptionAndIncentivePlan2016Member2023-01-012023-09-300001651308us', 'Cybersecurity Review Measures', 'American Depositary Share (&', 'metabolic data', 'CollaborationMember2023-01-012023-09-300001651308srt', 'SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001651308bgne', 'PamiparibMember2023-07-012023-09-300001651308us-gaap', 'US2023-07-012023-09-300001651308us-gaap', 'ShareOptionAndIncentivePlan2016Member2023-09-300001651308bgne', 'ManufacturingEquipmentMember2023-09-300001651308bgne', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001651308us', 'Form S-3', 'ALL.Amgen', 'SettlementOn', 'the STAR Market', 'QA', 'this Quarterly Report', 'ADSs and/or RMB Shares', 'LeapTherapeuticIncMember2023-09-300001651308us-gaap', 'CollaborationMember2023-07-012023-09-300001651308bgne:CollaborationMember2022', 'The Implementing Rules for the HGR Regulation', 'GET (&#8220;Shareholder', 'EuropeMember2023', 'US2022', 'Amgen Inc.', 'the U.S. Food and Drug Administration', 'Clinical Development and Commercialization of Our Medicines and Drug', 'Medicaid Services', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001651308us', '340B', 'ContentsUnexpected', 'TIGIT', 'Boehringer Ingelheim Biopharmaceuticals', 'USTreasurySecuritiesMember2022-12-310001651308bgne', 'the European Medicines Agency', 'the Ministry of Science and Technology', 'Novartis 70Table', 'ABRAXANE', 'InflationInflation', 'OperationsThe', 'BeiGene Biologics Co., Ltd.', 'SEC', 'a Settlement and Termination Agreement', 'LeapTherapeuticIncMember2022-12-310001651308bgne', 'Novartis', 'BTK', 'LicenseMember2023-09-300001651308bgne:', 'CFIUS', 'the Foreign Corrupt Practices Act', 'NovartisMemberbgne', 'ContentsNet', 'Interactive Data File', 'RightToAccessIntellectualPropertyRevenueMember2023', 'Rule 405 of Regulation S-T', 'the European Union', 'Nasdaq', 'CollaborationMember2023-01-012023-09-300001651308bgne:CollaborationMember2022-01-012022-09-3000016513082023-07-012023-09-3000016513082022-07-012022-09-3000016513082022-01-012022-09-3000016513082021-12-3100016513082022-09-300001651308us-gaap', 'Item 1A &#8212'}"
BGXX,"{'Sellers', 'FASB', 'Financial Reporting', 'the Black-Scholes', 'Exhibit 32.1', 'this Quarterly Report', 'Basis of Presentation', 'recognition\\nand', 'Related Information&#8221', 'the Lender', 'Original June Report', 'DEA', 'Equipment\\n\\n\\n\\n\\n&#160;\\n\\nProperty,\\nplant', 'the\\n    Securities and Exchange Commission', 'the Condensed Consolidated Financial Statements', 'Company&#8217;s\\noperations', 'the Sellers.\\n\\n&#160;\\n\\nVoting\\nAgreement\\n\\n&#160;\\n\\nThe\\nVoting Agreement', 'the Company (Note 11).\\n\\n&#160;\\n\\nIncluded\\nin', 'Transferred Shares', 'Alterola', 'the &#8220;Repayment', 'Registrant', 'Alterola or\\nthe', 'this Quarterly Report on Form 10-Q.\\n\\n&#160;\\n\\nThese\\nfactors', 'Entity&#8217;s Own Equity', 'Form S-1', 'SEC', 'in\\nthe &#8220;Risk Factors&#8221', 'cannabis\\ncommercially', 'Memorandum of Agreement', 'DEA Document', 'Company', 'the investee.\\nThe Company', 'the Securities Exchange Act', 'Grants Greenhouse Growers, Inc.', 'Adopted Accounting', 'Company,\\nto', 'RB0649383', '\\n    &', 'Compensation- Stock Compensation', 'the Bright Green Group of Companies'}"
BIAF,"{'ASC', 'bioAffinity Technologies, Inc.', 'LLC', 'FASB', 'ASU', 'the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221', 'Form\\nS-1', 'Common Stock&#160;\\n    $&#', 'Dividend yield&#160;\\n    &', 'Social Media', 'the Registrant&#8217;s Current Report on Form 8-K', 'CMS', 'the Medical Director\\nand Laboratory', 'this Quarterly Report', 'Village Oaks Pathology Services', '\\n    Trade', 'The Joyce Living Trust', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Precision Pathology Services', 'State', 'Equipment Usage Attachment', 'Contracts with Customers', 'Employment Agreement', 'the Asset Purchase Agreement', 'Professional Services Agreement', '2q2022 &#8211', 'Asset Purchase Agreement', 'National Sales Director', '8212;&#160;\\n    &', 'The University of Texas', 'Defense study&#160;\\n    &', 'Medicaid Services', 'HCPs', 'if:\\n\\n&#160;\\n\\n\\n', 'ir.bioaffinitytech.com', 'Registrant', 'PPLS', 'the College of American Pathologists (&#8220;CAP&#8221', 'the College of American Pathologists (&#8220;CAP&#8221;)\\nand', 'SEC', 'Pathology Laboratory Services', 'Precision Pathology Laboratory Services', 'LDT', 'No &#9746;\\n\\n&#160;\\n\\nThe\\nnumber', 'Company', 'the Financial Accounting Standards Board', 'CAP', 'the Medical Director', 'Therapeutics', '9,502,243.\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\n\\n\\n    &', 'periods.\\n\\n&#160;\\n\\nRecent\\nAccounting Pronouncements\\n\\n&#160;\\n\\nThe\\nCompany', 'Austin/San Antonio', 'the Joyce Employment Agreement', 'the Certificate of Incorporation of Registrant', 'the Joyce Trust', '\\n    &', 'Laboratories Services'}"
BIIB,
BIMI,"{'ASC', '\\n    Exchange', 'Guanzan', 'Installment Floor Amount&#8221;).\\n\\n&#160;\\n\\nIn 2022', 'Healthy Technology Co.', 'OPERATIONS&#160;\\n    &', 'Chongqing Zhuoda Pharmaceutical Co., Ltd.', 'THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n&#160;\\n\\n1.\\nORGANIZATION AND BUSINESS BACKGROUND\\n\\n&#160;\\n\\nBIMI\\nInternational Medical, Inc.', 'Boyi Technology Co.,', 'the Interim CFO', 'GYN Hospital Co., Ltd.', 'the Conversion Price', 'the Consolidated Statement of Equity', 'the Company adopted Accounting Standards Update', 'customers\\nin', 'Company&#8217;s\\noperating', 'the &#8220;Conversion', 'Guanzan Technology Co., Ltd.', 'COVID-19', 'compensation.\\n\\n&#160;\\n\\nOn', 'the Floor Amount Issuance.\\n\\n&#160;\\n\\nDuring', '\\n&#160;\\n\\nThe Company', 'the Floor Amount Issuance.\\n\\n&#160;\\n\\nIn 2022', 'the Reverse Splits', 'Yuxi Minkang Hospital Co.', '\\n    Office equipment\\n    &', 'the Floor Amount Issuance.\\n\\n&#160;\\n\\nOn', '\\n    Office equipment&#160;\\n    ', 'Xinrongxin,\\nwhich', 'the Additional Notes.&#160;\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n    36\\n', 'Beneficial', 'Common Stock', 'QIANGSHENG', 'Company', 'FLOW INFORMATION:&#160;\\n    &', 'Institutional', 'a Stock Combination Event,\\nthe Event Market Price', 'net&#160;\\n    &', 'Institutional Investor', 'Xinrongxin Industrial Development Co., Ltd.', '\\n    &#', 'ASU', 'the Floor Amount Issuance', 'Phenix Bio Inc.', 'EXPENSE)&#160;\\n    &', 'the Event Market Price Adjustment', 'Ltd.(&#8220;Shude&#8221;)\\n    &', 'following\\nsuch Stock Combination Event Date', 'Ltd\\n    &', 'the NF Group\\nand', 'influence.\\n\\n&#160;\\n\\n  &#9679', 'the NF Group', 'mainly\\ndue', 'liabilities&#160;\\n    &', 'the Event Market\\nPrice Adjustment', 'Institutional Investors', '2023&#160;\\n    &', 'Fudan Bank', 'Customers (&#', 'and\\n  \\n&#160;\\n\\n\\n  \\n    &', 'the Common Stock', 'receivables\\nis', 'reporting;\\n(3', 'PER SHARE&#160;\\n    &', 'COO', 'Total&#160;\\n    &', 'Qiangsheng Hospital Co.', 'the United\\nStates Dollar (&#8220;US$&#8221', 'the Company&#8217;s Board of Directors', 'interests\\nin Phenix Bio Inc.', 'original\\nseller', 'CFO', 'life&#160;\\n    &', 'Eurasia Hospital Co.', 'EURASIA', 'Chaohu Zhongshan Minimally Invasive Hospital', 'the Institutional Investors,\\ntogether', 'expensed.\\n\\n&#160;\\n\\n  &#9679', 'LOSS)&#160;\\n    &', 'Chongqing Kingmoon &', 'Conversion Price&#8221', 'Wuzhou Qiangsheng Hospital', 'GUANZAN', 'the Institutional Investors', 'the Company the Company', 'the Event Market Price', 'parties&#160;(1)&#160;\\n    &', 'the Company&#8217;s\\nCommon Stock', 'SEC', 'Ltd.\\n    &', 'NASDAQ', 'of\\nCommon Stock', 'Leases', 'collectability\\nof', 'Pukung Limited (&#8220;Pukung&#8221;)', 'assets&#160;\\n    &', '\\n    &', 'the VWAP Price'}"
BIOL,"{'compensation\\n    &', 'disposals\\n    &', '489\\n        &', 'Credit Agreement', 'Hamas', 'SWK Funding LLC (&#x201c;SWK&#x201d;)', '7\\n    &', 'BIOLASE', '\\n    Provision', '4,889\\n    &', 'SWK Loan\\n        &', '\\n  &', 'Concentration of Credit Risk', 'Unaudited)\\n  &#160;\\n  4\\n  ', 'x2014;\\n        &', 'Lake Forest', 'x201c;BIOLASE&#x201d', 'loan\\n    &', 'FDA', 'the SWK Loan', 'Unaudited)\\n  &#160;\\n', 'Convertible Preferred Stock', '\\n  &#', 'the Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;)', 'AllocationThe', 'the Series H Convertible Preferred Stock', 'the Credit Agreement', 'the &#x201c;Credit', 'Indicate', 'Waterlase', '\\n    ', 'the &#x201c;Exchange', 'Nasdaq Listing Rule 5550(a)(2', 'discount\\n        &#160;\\n        &#160;\\n        2,800\\n        &', 'discount\\n        &#160;\\n        ', 'NOTE 12&#x2014;CONCENTRATIONS Revenue', 'Significant Accounting Policies', 'Euro', '\\n        &', 'the Listing Qualifications Department', 'activities\\n    &', 'United States\\n    &', 'Company', 'the Securities Exchange Act', 'INC', 'London Interbank Bank', 'the Series H Warrants', '\\n  Management', 'Net Loss', 'the Series J Warrants', 'Stock\\n    &', 'the Series J Convertible Preferred Stock', '\\n    &'}"
BIOR,
BIVI,
BJDX,"{'Amended (the &#8220;Exchange', 'ASU', 'the Nasdaq Capital Market', 'Address of Principal Executive Offices', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'State', 'the New Toray Supply Agreement', 'Internal Control', 'The New Toray Supply Agreement\\nhas', 'Symphony', 'Toray Industries, Inc.', 'Cartridges', 'rules\\nand', 'Financial Reporting\\n\\n&#160;\\n\\n\\n\\nWe\\nconducted', 'Purchasers', 'U.S. Securities and Exchange Commission', 'MA  &#160', 'the Company&#8217;s\\nAnnual Report on Form 10-K.', 'FDA', 'Toray Industries,\\n    Inc.', 'The Nasdaq Stock Market\\nLLC', 'Bluejay Diagnostics, Inc.', 'Exhibit 3.1', 'License', '2021.\\n\\n&#160;\\n\\nUnder\\nthe New Toray License Agreement', 'Suite', 'Sanyoseiko', 'the Nasdaq Listing Qualifications Staff', 'NanoHybrids, Inc. (&#8220;NanoHybrids&#8221', 'item.\\n\\n&#160;\\n\\nItem\\n4', 'Contracts with Customers (Topic', 'the New Toray License Agreement', 'the risks\\nin &#8220;Risks Related to Our', 'Form S-1', 'Former Address and Former Fiscal Year', 'Condensed Consolidated Balance Sheets', 'Company', 'the Securities Exchange Act', 'The New Toray\\nLicense Agreement', 'Restated Certificate of Incorporation', 'Securities Purchase Agreement', 'a Master Supply Agreement', 'SanyoSeiko', 'Company&#8217;s\\nresearch', 'License and Supply Agreement', 'NanoHybrids', '\\n    &', 'Restated License Agreement'}"
BLFS,
BLRX,
BLUE,"{'Consolidated Statements of Operations', 'ContentsSummary', 'the Delaware General Corporation Law', 'SRT', 'LLC', 'ESG', 'HHS', 'commitmentsThe Company', 'MDS', 'ContentsAdditionally', 'CMS', 'Lonza Houston, Inc.', 'Melinda Gates Foundation', 'Consolidated Statements', 'Reliance', 'FDA&#8217;s', 'the Court of Chancery of the State of Delaware', 'SCD', 'the Underwriting Agreement', 'Third Rock Ventures', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'ContentsFurthermore', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'GDPR', 'Rare Pediatric Disease Priority Review Vouchers', 'Consolidated Statements of Cash Flows', 'PRV', 'FDA', 'IRB', 'GMP', 'QTC', 'Court', 'SKYSONA', '2seventy\\', 'OperationsThe', 'market&#8221', 'Group C', 'LeasesThe Company', 'SEC', 'the Material and Other Risks Associated', 'myeloid', 'ZYNTEGLO', 'FTC', 'Company', 'BLA', 'Vertex Pharmaceuticals', 'ContentsOur', 'the Securities Exchange Act', 'the unaudited financial information', 'the Federal Trade Commission Act', 'Jefferies', 'IRS', 'the U.S. PTO', 'Consolidated Balance Sheets', 'COVID-19', 'the indemnified party', 'Arbitrator', 'the European Union', 'Medicare Administrative Contractors (&#8220;MACs&#8221', 'Condensed Consolidated Financial Statements'}"
BMEA,"{'\\n  &#x2022;injury', 'LLC', '4,169\\n        &', 'Men1', 'AML', '\\n', 'Financial Statements&#x2014;Recent', 'Financial Instruments', 'the Federal Reserve', 'this Quarterly Report on Form 10-Q', '\\n  &#x2022;making', '\\n  &#x2022;costs', 'Stock-Based Compensation ExpenseTotal', 'x2022;a', 'Sensitive Information', 'FUSIONTM System', '\\n  &#x2022;completion', 'Form S-1', 'Point Sur Investors Fund I', '\\n  &#x2022;establishing', 'IndemnificationThe Company', 'COVID-19', '\\n  &#x2022;whether BMF-219', '\\n  &#x2022;obtaining', 'Ramses Erdtmann', '\\n  &#x2022;expenses', 'FASB', '\\n  &#x2022;product', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', '\\n  &#x2022;initiation', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'FDA', '\\n  &#x2022;collaborations', 'NetProperty', 'statements.\\n  &', '\\n        Laboratory equipment\\n', '3,847\\n        &', '\\n  &#x2022;Our', '\\n  &#x2022;maintaining', '\\n  &#x2022;relative', 'depreciation\\n        &', '\\n  &#x2022;others', '\\n  &#x2022;loss', 'HIPAA', 'REMS', 'Company', 'the Department of the Treasury', 'USPTO', 'General Risk Factors \\n', '\\n  &#x2022;laboratory', '\\n  &#x2022;limitations', 'Biomea Fusion, Inc.', '\\n  &#x2022;whether', 'SVB', 'Signature Bank', '\\n  &#x2022;physicians', 'the Delaware General Corporation Law', 'ASU', 'The Shelf Registration Statement', 'Restricted Cash&#160;The Company', '\\n  &#x2022;the', 'x2022;we', '\\n  &#x2022;exhaustion', 'Financial Instruments &#', '\\n  &#', '\\n  &#x2022;collaborators', 'KRAS', '\\n  &#x2022;retention', 'estimates.6\\n     &#160;&#160;&#160;Segments&#160;The Company', '\\n  &#x2022;decreased', 'NDA', 'NPM1', 'CMO', 'Capital StructureCommon Stock', 'FDIC', 'the Sarbanes-Oxley Act', 'the indemnified party', 'noted.\\n  &', 'IPO', 'This Quarterly Report on Form 10-Q', 'companies&#x2019', '\\n  &#x2022;our', '\\n  &#x2022;pricing', 'Form S-3', 'iii\\n', '\\n  &', 'HITECH', 'the Court of Chancery of the State of Delaware', 'combination.\\n  &', '\\n          Laboratory', 'Biomea', '4th Floor', 'the State of Delaware', '\\n  &#x2022;risks', 'Sarbanes-Oxley Act', 'BMF-219\\n  &#160;\\n', '\\n  &#x2022;withdrawal', '\\n  &#x2022;successful', 'the Court of Chancery', '5,575\\n        &', '\\n        &', 'SEC', 'the Shelf Registration Statement', 'Cormorant Asset Management', 'stock.\\n  &', '42\\n  \\n  &#', 'Credit Losses', 'payors;\\n  &#x2022;effectively', 'Equity Securities', 'MLL', '\\n  &#x2022;receipt', 'property.\\n'}"
BMRA,
BMRN,
BNGO,"{'ASC', 'LLC', 'the Underwriting Agreement).4.4', 'Quality Systems Regulations', 'Principal Executive Officer', 'Trust Company LLC', 'this Quarterly Report on Form 10-Q', 'RUO', 'Warrant Agent Agreement', 'the Company&#8217;s Series A Preferred Stock', 'Nasdaq Listing Rule', 'CPRA', 'Regulation S-K.', 'market&#8221', 'Future Capital RequirementsWe', 'ContentsWe', 'the Securities Exchange Act', 'The American Medical Association', 'Private Placement Notes', 'Warrants', 'Company, Incorporated', 'Princeton University', 'Internal Control', 'Medicaid', 'the Securities and Exchange Commission', 'Diluted', 'Medicare', 'OGM', ': &', 'FDA', 'the Chair of the Company&#8217;s board of directors', 'RSU', 'the Registered Warrants', 'HIPAA', 'Goodwill', 'ContentsSelling', 'LDT', 'Company', 'USPTO', 'BioDiscovery', 'Purigen', 'the California Privacy Rights Act', 'Cowen', 'AKS', 'the California Consumer Privacy Act', 'the Delaware General Corporation Law', 'Sensitive Data', 'Princeton', 'the FDA&#8217;s Quality System Regulation', 'CMS', 'Principal Financial Officer', 'this Quarterly Report on Form 10-Q.', 'CPT', ': &#', 'VIA', 'The Nasdaq Capital Market', 'Exchange', 'the Annual Report on Form 10-K', 'IVD', 'ContentsOur', 'Restated Certificate of Incorporation', 'Cowen and Company', 'the Clinical Laboratory Improvement Amendment', 'the Court of Chancery of the State of Delaware', 'this Quarterly Report on Form 10-Q.Changes', 'Midcap Financial Trust.4.3', 'USE OF PROCEEDSIssuer', 'The Nasdaq Capital Market (&#8220;Nasdaq&#8221', 'LDTs', 'PMA', 'Bionano Laboratories', 'OIG', 'Warrant Certificate', 'Series A Preferred', 'Stifel, Nicolaus &amp', 'SEC', 'Administrative ExpensesSelling', 'DCF', 'Soheil', 'AMA', '*&', 'BTIG', 'Ionic Purification', 'Acquisitions', 'Nasdaq'}"
BNOX,
BNR,
BNTC,"{'Consolidated Statements of Operations', 'Concentrations of Risk  Financial', 'ASC', 'FASB', 'LLC', 'Royal Holloway University of London', 'ASU', 'the Securities and Exchange Act', 'Benitec Biopharma Inc.', 'OPMD', 'the Quality System Regulation', 'Critical Accounting Policies', '\\n &', 'the Black-Scholes Option Pricing Model', 'Biopharma Proprietary Limited', 'EMA', 'the Scheme Implementation Agreement', 'FDA&#8217;s', 'Benitec Limited', 'the Genetic Modification Clinical Research Information System', '\\n&#160;&#160;\\n&#160;\\n(56\\n)&#160;\\n&#160;\\n&#160;\\n(507\\n)&#160', 'April&#160;15', 'this Quarterly Report on Form 10-Q', '\\n&#160;&#160;\\n&#160;\\n(80\\n)&#160;\\n&#160;\\n&#160;\\n(513\\n)&#160', 'the symbol &#', 'the State of Western Australia', 'FDA', 'NIH', 'Significant Accounting Estimates', 'the NH Study', 'the Institut de Myologie', 'IRB', 'PABPN1', 'Corporate Information', 'Regulation S-K.  Item&#160;6', 'August&#160;11', 'BIOPHARMA INC.', 'AAV', 'IP Holdings', 'VFSS', 'the Royal Holloway University of London', 'REMS', 'Royalties', 'the Nasdaq Capital Market (&#8220;Nasdaq&#8221', 'SEC', 'Citizens JMP Securities', 'GCP', 'the NIH Office of Science Policy', 'IVD', '\\n\\n&#160;\\n&#160;&#160;\\n &#160', 'Company', 'HP', 'BLA', 'FDA Post-Approval Requirements', 'DQSA', 'Research', 'CECL', '\\n&#160', 'Benitec', 'COVID-19', '\\n&#160;\\n&#160;\\n &#160', '\\n&#160;&#160;\\n$\\n(2.76\\n)&#160;\\n&#160;\\n$\\n(7.98\\n)&#160', 'OSP', 'Scheme', 'Otolaryngology', 'Benitec Biopharma Limited', 'Holder', 'the European Union', 'Unrealized', 'Consolidated Financial Statements', 'Restated Certificate of Incorporation of Benitec Biopharma Inc.', 'Weighted', 'NH', 'Report'}"
BNTX,
BOLT,"{'ASC', 'collaboration.\\n  Oncology Research and Development Collaboration with Genmab A/S \\n', 'LLC', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', 'Bristol-Myers Squibb Company (&#', 'Stanford', 'Bolt Biotherapeutics, Inc.', 'Innovent&#x2019;s', 'the Toray Agreement', 'this Quarterly Report on Form 10-Q', 'loss.&#160;The Company', 'patents.\\n  Effective', 'EquipmentMember2023', 'Roche&#x2019;s', 'GenmabAgreementMember2023-01-012023-09-300001641281us-gaap', 'Indicate', '26\\n', '\\n    Research', 'USTreasurySecuritiesMember2022-12-3100016412812022-07-012022-09-300001641281us-gaap', 'Form S-1', 'Stanford&#x2019;s', 'Oncology Clinical Trial Collaboration and Supply Agreement', 'the Leland Stanford Junior University', 'x201c;Toray', 'The Board of Trustees', 'EirGenix Agreement', 'EirGenix', 'Exhibits', 'the Stanford Agreement', '4,230\\n        &', 'Internal Control', 'License and Equity Agreement License and Equity Agreement', 'LeaseholdImprovementsMember2022-12-310001641281us-gaap', 'FDA', 'Legal Proceedings', 'GenmabAgreementMember2023-07-012023-09-300001641281us-gaap', 'BOLT', 'Financial Reporting \\n', 'Bristol-Myers', '\\n        Laboratory equipment\\n', 'equipment.\\n  Financing Activities \\n  ', '\\n  &#x2022;regulatory', 'activities\\n    &', 'TD Cowen', 'Company', 'MaximumMemberbolt', 'Balance Sheet Components Property and Equipment', 'Cowen', '\\n    &#', 'Toray Industries, Inc. (&', 'Innovent', 'GenmabAgreementMember2023-09-300001641281bolt', 'BMS', 'TwoThousandTwentyOneEquityIncentivePlanMember2023', 'the Roche Agreement', 'CommonStockOutstandingSubjectToRepurchaseRelatedToUnvestedEarlyExercisedStockOptionsAndRestrictedStockAwardsMember2023-01-012023-09-300001641281us-gaap', 'Credit Risk Financial', 'the &#x201c;Chesapeake Master', 'Stock-Based Compensation Expense The', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'Roche', 'BDC-1001 Orphan Drug Designation', '\\n  &#', 'BMS&#x2019;s', 'Stanford University', 'Registrant', 'ISAC', 'The Innovent Agreement', 'License and Collaboration Agreement', 'FairValueMeasurementsRecurringMember2023', 'MaximumMember2022-03-302022-03-300001641281srt', 'partners.\\n  Research and Development Expenses \\n  Research', 'Clinical Supply Agreement', 'IPO', '\\n  Oncology Clinical Trial Collaboration and Supply Agreement', 'Bristol-Myers Squibb Company', 'Comparison', '\\n  &#x2022;our', 'Property', '\\n        Office equipment\\n        &', 'Cowen and Company', 'Form S-3', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001641281us-gaap', 'the Genmab Agreement', '\\n  &', 'ATM', 'ESPP', 'the U.S. Food and Drug Administration', 'The Stanford Agreement', 'MaximumMember2023-01-012023-09-300001641281us-gaap', 'Bristol-Myers Squibb', 'Related Party', 'the Chesapeake Master Lease', '\\n        &', 'SEC', 'myeloid', 'Toray Industries', 'the BMS Agreement', 'BIOTHERAPEUTICS', 'GenmabAgreementMember2023-01-012023-09-300001641281srt', '\\n    &', 'TwoThousandTwentyOneEquityIncentivePlanMember2021-01', 'the Registration Statement'}"
BPMC,
BPTH,
BPTS,
BRKR,
BRNS,"{'FASB', 'The Harwell Science and Innovation Campus', 'MinimumMembervacc', 'Biotherapeutics North America', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)&#8203;15.Related Party TransactionsDuring', 'LicenseMember2023-01-012023-09-300001828185us-gaap', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(UNAUDITED)&#8203;Recently', 'Unregistered Sales of Equity Securities', 'American Depositary Shares', 'ContentsBased', 'EstimatesThe', '2022.LeasesThe Company', 'this Quarterly Report', 'the University of Oxford', 'WalesNot', 'the OUI License Agreement Amendment', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'the Securities and Exchange Commission', 'Jefferies LLC', 'LeaseholdImprovementsMember2022-01-012022-09-300001828185us-gaap', 'NoncontrollingInterestMember2023-04-012023-06-300001828185us-gaap', 'OUI', 'Barinthus Biotherapeutics plc', 'ContentsUse', 'Research and Development IncentivesFor', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001828185us-gaap', 'Shelf', 'ContentsRemediation EffortsDuring', 'LicenseMember2023-07-012023-09-300001828185us-gaap', 'Form S-1', 'Vaccitech USA, Inc.', 'AstraZeneca', 'ERP', 'EURutr', 'Initial Public', 'Unregistered Equity SecuritiesNone.34\\nTable', 'Company', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-3000018281852022-01-012022-09-300001828185us-gaap', 'Note 14 &#8220;Commitment', 'BIOTHERAPEUTICS', 'IPO', 'Significant Accounting PoliciesThe', 'This Quarterly Report'}"
BRTX,"{'FASB', 'LLC', 'ASU', '\\n\\n&#160;\\n\\nNote\\n7 &#8211', 'The Series A', 'CRO', 'this Quarterly Report', 'results.\\n\\n&#160;\\n\\nReaders\\nare', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'JonesTrading Institutional Services', 'BioRestorative Therapies', 'the Company&#8217;s\\ncomputation of diluted net', 'FDA', 'Professional Research Consulting, Inc.', 'BioRestorative Therapies, Inc.', 'NON-CANCELABLE LEASES', 'payments&#160;\\n    &', 'Financial Instruments - Credit Losses', 'BRTX', 'principal\\nfinancial', 'the Food and Drug Administration', 'Company', 'Dragonfly', 'Capital on Demand Sales Agreement', 'the Securities Exchange', 'SCTC', 'Total&#160;\\n    &', '\\n    &'}"
BSGM,"{'ASC', 'LLC', 'Dividend yield&#160;\\n    &', 'Mayo\\nFoundation for Medical Education', 'BioSig Technologies', 'Procedures\\n    &', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'NVIDIA Inception', 'Know-How License Agreement &#8211', 'the\\nEP Software Agreement', 'BioSig of $', '2023\\n\\n(unaudited)\\n\\n&#160;\\n\\nBioSig\\nAI Sciences', 'no consideration.\\n\\n&#160;\\n\\nNOTE\\n14 &#8211', 'PURE', 'Platform&#8217;s', 'the Listing Qualifications Department', 'the Securities Exchange Act', 'COVID-19', 'the Securities Act.\\n\\n&#160;\\n\\nITEM\\n3', 'the University of Pennsylvania', 'Consulting Agreement\\n\\n&#160;\\n\\nOn\\nJune', 'Expected life&#160;\\n    &', 'FASB', 'those\\narrangements.\\n\\n&#160;\\n\\nWe\\nrecord', '\\n\\n&#160;\\n\\nNOTE\\n7 &#8211', 'ViralClear', 'Financial Genetics', 'THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\nSEPTEMBER\\n30', 'Clinic', 'FDA', 'at\\nMayo Clinic', 'Company&#8217;s\\ncommon', 'Reified Labs LLC (&', 'The Tools Agreement', 'Financial Condition', 'the Journal of Cardiovascular Electrophysiology', 'Long-Term Incentive Plan', 'Reified', 'Ascendiant Capital Markets', 'Inc.\\n\\n&#160;\\n\\nViralClear\\nPharmaceuticals, Inc. (&', 'Classic Solutions Corp', 'AI', 'ViralClear&#8217;s Board of Directors', 'and\\ntandem', 'Company', 'NeuroClear', 'volatility&#160;\\n    &#', 'the Series C Preferred', 'the Ascendiant Sales Agreement', 'arrhythmias\\nin', 'Research (&#8220;Mayo&#8221', 'ASU', 'the Nasdaq Capital Market', 'agreement.\\n\\n&#160;\\n\\nRecent\\nAccounting Pronouncements\\n\\n&#160;\\n\\nIn\\nJune 2016', 'J. Safier Enterprises LLC', 'the EP Software Agreement', 'PIPES', 'EP Software', 'Mayo Clinic', 'the following:\\n\\n&#160;\\n\\nSCHEDULE OF ACCOUNTS PAYABLE', 'Alchemist Assets Inc.', 'The Nasdaq Capital Market\\npursuant', 'the Nasdaq Stock Market', 'Mayo', 'EQUITY SECURITIES', 'PROCEDURES\\n\\n&#160;\\n\\nEvaluation\\nof Disclosure Controls', 'Ascendiant', 'Capital Resources and Going Concern', 'BioSig Technologies, Inc.', 'Total&#160;\\n    &', 'NON-CONTROLLING', 'timely\\nand', 'Nasdaq Listing Rule&#160;5550(a)(2', 'Financial Instruments-Credit Losses', 'us.\\n\\n\\n\\n&#160;\\n\\n\\n\\n', 'portion&#160;\\n    &', 'Artificial Intelligence', 'Cleveland Clinic', 'Outstanding&#160;&#160;\\n', 'BioSig', 'the State of Delaware', 'ASC 480,\\nDistinguishing Liabilities from Equity (ASC 480', 'the Cantor Sales Agreement', 'Know-How License', 'Cantor', 'The EP Software Agreement', 'the Patent Rights', 'travel&#160;\\n    &', 'the BioSig AI', 'Texas Cardiac Arrhythmia Institute', 'Accounting Standards Codification', 'U.S. Treasury', 'Restated Patent', 'SEC', '2025&#160;\\n    &', 'MBS GLOEQ Corp.', 'BioSig AI', 'FINANCIAL INFORMATION\\n    &', 'Options&#160;\\n', 'the Tools Agreement', 'RESTRICTED', 'Nasdaq', '\\n    &'}"
BTAI,
BTCY,
BTMD,"{'ASC', 'LLC', 'the &#x201c;AnazaoHealth Pharmacy Services', 'ERISA', 'the Business Combination Agreement', 'the Holdings Units', 'and\\n  &#x2022;logistics', 'the Lenders (&#x201c;Administrative', 'capacity;\\n  &#x2022;issues', 'term.\\n', 'The Bank of America Credit Agreement', 'TRA', 'BioTE Medical for a period of', 'Basis Points', 'Biote IP', 'practitioners;\\n  &#x2022;medical', 'Loan Document', 'Form S-1', 'the &#x201c;Bank of America Credit', 'the New Independent Contractor Agreement', 'COVID-19', '&#x201c;us', 'Donovitz', 'equity.9\\n     &#160;Defined Contribution Retirement', 'BASIS OF PRESENTATIONDescription of Business&#x2014;biote Corp.', 'the Bank of America Term Loan', 'Warrants', 'compensation\\n    &', 'schedules;\\n  &#x2022;the', 'investment.\\n  Gain', 'FASB', 'AnazaoHealth', 'Anti-Kickback Statute', 'Loan Party', 'Holdings', 'holidays;\\n  &#', '3,816\\n          &', 'Medicaid', 'Medicare', 'x2014;\\n        &', '4,142\\n        &', 'IP', 'the &#x201c;Outsourcing Facility Services', 'BioTE Holdings', 'the &#x201c;Biote Method&#x201d', 'all;\\n  &#x2022;breach', 'FDA', 'clinics&#x201d;);\\n  &#x2022;number', 'Truist Bank', 'and\\n  &#x2022;global', 'statements.\\n  &', 'Unaudited)\\n  &#160;\\n', 'the Insider Letter', 'the District Court', 'females;\\n  &#x2022;our', 'NASEM', 'the Market Value', 'HIPAA', 'the Bank of America Credit Agreement', 'x201c;Private Placement', 'activities\\n    &', '\\n    Business Combination', 'the Private Placement Warrants', 'Company', 'the BioTE Medical', 'Bank of America', 'USPTO', 'Business Combinations', 'federal healthcare programs;\\n  &#x2022;similar', '4,165\\n    &', '\\n    Business Combination: Reverse', 'the Affected Periods', 'Haymaker Acquisition Corp. III&#x2019;s Current Report', 'Credit Agreement', 'ASU', 'Outsourcing Facility Services Agreement', 'Private Placement Warrants Purchase Agreement', 'Retained Holdings Units', 'NETCapitalized', 'AnazaoHealth Corporation', 'Item 10 of Regulation S-K', 'manufacturing;\\n  &#x2022;costs', 'Registration Rights Agreement', '\\n    Business Combination: Noncontrolling', 'Haymaker Acquisition Corp. III', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the &#x201c;Company,&#x201d', 'Truist Securities, Inc.', 'N.A', 'Monte-Carlo', 'the BioTE Companies', 'lender&#x2019;s', 'Trust Company', '\\n  &#', 'Lani D. Consulting', 'the Credit Agreement', 'the &#x201c;Credit', 'the &#x201c;Asteria Health Pharmacy Services', 'redemption:&#x2022;in', 'Founder Advisor', 'Conversion and Other Options', 'Entity&#x2019;s Own Equity', 'Executive', 'IRA', 'The Company&#x2019;s Public Warrants', 'the Delaware Court of Chancery', 'Public Warrants', 'x201c;anticipate,&#x201d; &#x201c;believe,&#x201d', 'the &#x201c;Consent', 'the &#x201c;New Independent Contractor', 'Credit AgreementsOn', 'the &#x201c;False Claims Act&#x201d', 'Board', 'Investments, Inc.', 'this Quarterly Report', 'EQUITY', 'the Warrants (the &#x201c;Consent', 'LLC (&#x201c;BioTE', 'Contracts', '\\n  &', 'the Sponsor Earnout Shares', 'thousands)\\n          &#160;\\n', 'Derivatives', 'ESPP', 'the State of Delaware', 'BioTE Medical', 'Pharmacy Services Agreement', 'LIABILITY', '3,112\\n          &', 'the Revolving Loans', 'Haymaker', '503\\n          &', 'BioTE Medical&#x2019;s', 'Continental Stock Transfer &amp', 'BioTe IP', 'Adopted Accounting Pronouncements\\n', 'the Biote Method', 'share;\\n  &#', 'and\\n  &#x2022;HIPAA', '\\n        &', 'SEC', 'Accounting for Convertible Instruments', 'Lani Hammonds Donovitz', 'footprint.\\n  &', 'The Biote Method', 'the Business Combination', 'Business Development', 'Nasdaq', '\\n    &', 'property.\\n', 'x201c;seek,&#x201d'}"
BTTX,
BVS,"{'Call Option', 'Tax Receivable AgreementThe Company', 'Bioness Acquisition', 'Bioventus LLC&#8217;s', 'Credit Agreement', 'First Paper Milestone', 'Bioventus Inc.', 'International', 'BV LLC (&', 'MTF', 'Commercial Supply Agreement', 'the Wound Business', 'ContentsNoncontrolling', 'Therapies24,855&#160;38,096&#160;89,187&#160;102,475&#160;Surgical', 'the Securities and Exchange Commission', 'Credit and Guaranty Agreement', 'the Development Agreement', 'the Option Agreement', 'TheraSkin', 'Regulation S-K).Item', 'Original BV LLC Owners (&#8220;Former', 'OA', 'AgreementThe BV LLC Agreement', 'Risk Factors', 'the Company&#8217;s Board of Directors (&#8220;BOD&#8221;)', 'Disposal Group', 'and(c)Monitoring &#8211', 'BV LLC (&#8220;BV', 'Agili-C', 'Bioventus', 'Court', 'the Bloomberg Valuation', 'Trust', 'Elron', 'the Board of Directors (&#8220;BOD&#8221;)', 'ContentsKey', 'ContentsThe', 'the Original BV LLC Owners', 'the Disposal Group', 'MOTYS', 'GoodwillGoodwill', 'the Settlement Agreement', 'Integration Assessment (&#8220;Project Action&#8221', 'the &#8220;Settlement', 'debt(19,584)(33,056)Unamortized', 'ContentsWe', 'Hod Hasharon', 'Company', 'the Bioness Merger Agreement', 'pronouncementsThe Company', 'Committee of Sponsoring Organizations of the Treadway Commission', 'Trustee', 'BV', 'Item 408 of', 'ContentsThe Company', 'COVID-19', 'CartiHeal', 'IPO', 'b)The Company', 'Elron Ventures Ltd.', 'BV LLC (&#8220;Original BV LLC Owners&#8221', 'LLC Interests', 'Misonix and Bioness', 'Conducts', 'Project Action', 'Bioness', 'the Musculoskeletal Transplant Foundation', 'the Amended 2019 Credit Agreement', 'Accounting Transformation &', 'ContentsNon-GAAP Financial Measures - Adjusted', 'the Delaware State Court of Chancery'}"
BWAY,
BWV,
BYSI,
CABA,"{'EC&#x2019;s', '\\n  &#x2022;injury', 'LLC', 'Registrant&#x2019;s', '\\n', 'Oxford', 'Lancet Rheumatology', 'Exhibits.\\n  &#160;\\n', 'the Center for Advanced Retinal and Ocular Therapeutics', 'Artisan Collaboration and License Agreement', 'ATM Program', 'the Autolus Agreement', 'the EU Commission', 'EEA', '\\n  &#x2022;having', '\\n  &#x2022;costs', 'the United States Food and Drug Administration', 'the Public Company Accounting Oversight Board', 'the Internal Revenue Code', 'x2022;a', 'Oxford&#x2019;s', 'Oxford Biomedica', 'UPC', 'CPRA', 'the Company&#x2019;s Third Amended and Restated Certificate of Incorporation', 'the 2020 Shelf Registration Statement', 'arise.\\n  &#', '\\n  &#x2022;adding', 'Shelf Registration Statement', '\\n  &#x2022;obtaining', 'the University of Pennsylvania', 'MusCAARTesTM', 'TPP', 'WuXi', 'HHS', '\\n  &#x2022;product', 'Licence and Supply', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', '\\n  &#x2022;refusal', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'the 2023 Shelf Registration Statement', 'the Delaware General Corporate Law', 'agreement.\\n  &#', 'GDPR', 'FDA', 'Autolus&#160;In', '\\n  &#x2022;clinical', '\\n  &#x2022;difficulties', 'the U.S. Food and Drug Association&#x2019;s', '\\n  &#x2022;changes', '\\n  &#x2022;others', '\\n  &#x2022;loss', 'Risks Related', 'February 2028.&#160;Research Service Agreement', 'REMS', '\\n  &#x2022;occurrence', '\\n  &#x2022;fines', 'LSA', 'Company', 'Artisan', 'USPTO', '\\n  &#x2022;addressing', '\\n  &#x2022;injunctions', '\\n  &#x2022;limitations', 'notice.\\n  &', 'Cowen', '\\n  &#x2022;whether', 'all.\\n  &', 'SLE', 'SVB', '\\n  Subjects', 'the Children&#x2019;s Hospital of Philadelphia', 'CRO', 'personnel.\\n  &', 'CMS', '\\n  &#x2022;recruiting', 'Uncertainties &#160;The Company', 'Autolus Holdings', '\\n  &#x2022;the', 'License Agreement', 'the U.S. Department of Health and Human Services', 'the WuXi Agreement for WuXi', '\\n  &#x2022;disruption', '\\n  &#x2022;exhaustion', 'omitted.9\\n       &#', 'Children&#x2019;s Hospital', 'The CARTA Services Agreement', 'IASO', 'IRB', '\\n  &#', '\\n  &#x2022;imposition', 'Investigational New Drug', '\\n  &#x2022;patients', '\\n  &#x2022;possible', 'successful.\\n  &', '\\n  &#x2022;retention', '\\n  &#x2022;diversion', '\\n  &#x2022;decreased', 'Risks Related to Ownership of Our Common Stock \\n', 'Artisan Bio, Inc.', 'CMO', 'Restated Certificate of Incorporation', '\\n  &#x2022;reaching', 'the CAART Services Agreement', 'NMJ', 'the Sarbanes-Oxley Act', '\\n  &#x2022;inability', 'IPO', 'prospects.\\n  &', 'This Quarterly Report on Form 10-Q', 'Restated License Agreement', '\\n  &#x2022;our', '\\n  &#x2022;obtaining IRB', 'Cowen and Company', 'Form S-3', 'WuXi Manufacturing Agreement\\n  &', 'the License Agreement', 'CARTA', '\\n  &#x2022;We', 'the International Data Transfer Agreement and International Data', 'Our Business, Technology and Industry \\n  &', '\\n  &', 'structure.\\n  &#x2022;We', '\\n  &#x2022;delays', 'Virginia&#x2019;s', '44\\n', 'CAAR', '\\n  &#x2022;transfer', '\\n  &#x2022;unanticipated', 'WuXi Advanced Therapies, Inc.', '\\n  &#x2022;increases', '\\n  &#x2022;restrictions', 'Medicaid Services', 'Master Translational Research Service Agreements', '\\n  &#x2022;withdrawal', 'the American Society for Gene and Cell', 'the CARTA Services Agreement', '\\n        &', 'LeasesThe Company', 'SEC', 'GCP', 'candidates.\\n  &', 'BLA', 'CABA-201', 'the WuXi Agreement', '\\n  &#x2022;manufacturing', 'the Centers for Medicare', 'this Quarterly Report on Form 10-Q.\\n  &#160;\\n', '\\n  &#x2022;failure', 'Development and Manufacturing Services Agreement', 'Autolus\\', 'the European Union'}"
CADL,"{'ASC', 'Net Fixed', 'LLC', 'Fair Value of Financial Assets', 'the NC Ohio Warrants', '\\n    Interest income\\n    &', '\\n', 'candidates;\\n  &#x2022;the', 'EMA', 'LeaseOn', 'Ellka Holdings', 'Standard Contractual Clauses', 'the Option Agreement', 'MGB', 'the Federal Reserve', 'EEA', 'Advantagene, Inc.', 'collaborators;\\n  &#x2022;the', 'the Licensed IP Rights', 'efficiencies.\\n  &#', 'BPCIA', 'UPC', 'countries;\\n  &#x2022;developments', 'revenues.\\n  &#x2022;The', 'CPRA', '\\n    Research', 'equipment.\\n', 'CAN-3110;\\n  &#', 'and\\n  &#x2022;product', 'Form S-1', 'ACA', 'patents;\\n  &#', 'the Periphagen Agreements', 'Advanced Analytics', 'candidates;\\n  &#x2022;significant', 'all;\\n  &#x2022;collaborators', 'Candel\\', 'the American Arbitration Association', 'the University of Pennsylvania', 'Property and Equipment Property', 'Company\\', 'The Wall Street Journal', 'and\\n  &#x2022;collaborators', 'candidates;\\n  &#x2022;collaborators', 'Stock-Based Compensation', 'x201c;Risk', 'manufacturers&#x2019', 'Medicare', 'Exhibits.\\n  &#160;\\n  &#160;\\n', 'x2014;\\n        &', 'GDPR', 'candidates;\\n  &#x2022;a', 'agreements;\\n  &#x2022;costs', 'FDA', 'the collaborations;\\n  &#x2022;collaborators', '\\n    Loan Agreement', 'Loan', '\\n        Laboratory equipment\\n', 'and\\n  &#', 'Candel Therapeutics Securities Corporation', 'products;\\n  &#x2022;developments', 'candidates;\\n  &#x2022;our', 'depreciation\\n        &', 'functions;\\n  &#x2022;expenses', 'HIPAA', 'Silicon Valley Bank', 'capital commitments;\\n  &#x2022;regulatory', 'the International Data Transfer Agreement', 'process.\\n', 'Company', 'the Department of the Treasury', 'analysts;\\n  &#x2022;variations', 'HGG', '\\n    Interest expense\\n    &', 'outstanding.\\n  &#160;\\n', 'development;\\n  &#x2022;unwillingness', 'Ellka', 'all;\\n  &#', 'SVB', 'the Periphagen Note', 'Signature Bank', 'ASU', 'SEC&#x2019;s &#', 'Loan Agreement', 'Periphagen, Inc.', 'The Nasdaq Global Market (&#x201c;Nasdaq&#x201d;)', 'technologies;\\n  &#', 'candidates;\\n  &#x2022;impairment', 'Contractual Obligations and Commitments \\n', '\\n  &#x2022;the', 'The Loan Agreement', 'SITC', 'the NC Incorporated Ohio Trust', 'HSV', 'License', '\\n  &#', 'the Massachusetts Life Sciences Center', 'licenses;\\n  &#x2022;disagreements', 'and\\n  &#x2022;disputes', 'the Health Care and Education Reconciliation Act', 'Shelf', 'Ventagen', 'Candel Therapeutics, Inc.', 'FDIC', 'Periphagen', 'the Initial Public Offering of Common Stock\\n  ', 'IPO', 'operations.\\n  Determination of Fair Value', 'Comparison', 'This Quarterly Report', '\\n          Laboratory equipment\\n          &#', 'property.\\n', 'limited.\\n  &#x2022;If', 'UPenn', 'ICI', '\\n  &#x2022;announcements', 'Form S-3', 'the Loan Agreement', 'SPA', 'technologies;\\n  &#x2022;additions', 'including:\\n  &#x2022;the', 'the SVB Loan Agreement', 'the Periphagen License Agreement', 'Nasdaq&#x2019;s', 'CCC', 'decline.\\n  &', 'the MGB Clinical Trial Agreement', 'the Registrant&#x2019;s Current Report', '\\n  &#x2022;If', '\\n    ', 'the MGB License', '\\n        &', 'SEC', 'agreements.\\n', 'the Exclusive License Agreement', 'inhibitors;\\n  &#x2022;actual', 'Territory', 'Equity Securities', 'development programs;\\n  &#x2022;the', 'Unregistered Equity', 'the Registrant&#x2019;s Registration Statement', 'Licensed IP Rights', 'the Biologics Price Competition and Innovation Act', 'the European Union', 'Nasdaq', '\\n    &', 'candidates.\\n  Difficulty', 'Unaudited Interim Financial Information'}"
CALC,"{'AP', 'API', 'LLC', 'AIPT', 'SOC;\\n  &#x2022;cultural', '\\n', 'candidates;\\n  &#x2022;the', 'EMA', 'Exhibits.\\n  &#160;\\n', 'Financial Instruments', 'Fred Middleton.\\n    &', 'Condensed Consolidated Statements of Operations and Comprehensive', 'this Quarterly Report on Form 10-Q', 'Series D Convertible Preferred Stock of CalciMedica', 'CalciMedica', 'SIRS', 'operations.\\n  &#x2022;Our', 'EU', 'The Preferred Warrants', '\\n  &#x2022;publications', 'Financial Instruments&#x2014;Credit Losses', 'CalciMedica Subsidiary, Inc.', '\\n    Research', 'H.C. Wainwright &amp', 'x201c;Reverse Stock', 'the Securities Exchange Act', 'California&#x2019;s', '\\n  Research', 'COVID-19', 'and\\n  &', 'the Merger Agreement', 'FASB', '\\n  &#x2022;additional', '\\n  &#x2022;discover', 'operations.\\n  &#x2022;We', 'the US Physician Payments Sunshine Act', 'candidate;\\n  &#x2022;our', 'prospects.\\n  &#x2022;We', 'Internal Control', 'manufacturers&#x2019', 'equipment.\\n  Net Cash Provided by Financing Activities\\n  Cash', 'Medicaid', 'Medicare', 'prices;\\n  &#x2022;convenience', 'Congress', 'GDPR', 'candidates;\\n  &#x2022;a', 'C-1', 'FDA', 'Auxora;\\n  &#x2022;the', 'H.C Wainwright &amp', 'candidates;\\n  &#x2022;identification', 'CalciMedica, Inc.', 'Lease AgreementsThe Company', 'and\\n  &#', 'candidates;\\n  &#x2022;our', 'collaborations;\\n  &#x2022;collaborators', 'Trademark Office (&#x201c;USPTO&#x201d', 'Auxora', 'REMS', 'Condensed Consolidated Statements', 'activities\\n    &', 'quantity.\\n  &#', 'Company', 'the Merger\\n    &#160;\\n    $\\n    ', 'and\\n  &#x2022;the', 'expense)\\n    &', 'USPTO', 'General Risk Factors \\n', 'the ATM Facility', 'Adopted Pursuant to Section 302', '\\n    Chemistry', 'liability;\\n  &#x2022;disputes', 'and\\n  &#x2022;diminished', 'Reverse Merger Transaction', 'Black-Scholes', 'FCA', 'Auxora;\\n  &#', 'the California Consumer Privacy Act', 'the Delaware General Corporation Law', 'ASU', 'CRO', 'the European Commission', 'regulations;\\n  &#x2022;potential', 'The Shelf Registration Statement', '\\n    Consultants', 'CalciMedica, Inc. (&#x201c;Private', '\\n    Preclinical', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'CMO&#x2019;s', 'performance;\\n  &#x2022;our', 'x2022;a collaborator&#x2019;s', 'SOC', 'and\\n  &#x2022;continue', 'candidates;\\n  &#x2022;manage', '\\n  &#', 'estimates.\\n  ', '\\n  &#x2022;collaborators', 'Graybug (&#x201c;Merger', 'Eric Roberts.\\n    &', 'profitably.\\n  &#x2022;We', 'Graybug Vision, Inc.', 'Orphan Drug Designation', 'the Sarbanes-Oxley Act', '\\n  &#x2022;some', 'Comparison', 'SG Dan Equity Holdings', 'the Hybrid Method (&', 'Form S-3', 'plan.\\n  &#x2022;If', 'Black Scholes', 'disadvantage.\\n', 'Graybug&#x2019;s', 'ATM', 'presented.\\n  &', '\\n  &', 'the Market Offering Agreement', 'any;\\n  &#x2022;the', 'the &#x201c;Shelf Registration', 'the U.S. Food and Drug Administration', '\\n  &#x2022;identify', '\\n  Research and Development Expenses\\n  Research', 'Graybug Vision, Inc. (&', '\\n  &#x2022;efficacy', '\\n  &#160;(1', 'relationships;\\n', '\\n    Maturity of investments\\n    &', 'Adopted Accounting Pronouncements\\n', 'Related Party', 'SEC', 'the Shelf Registration Statement', 'Orphan Drug Designation for Auxora', 'GCP', 'United Kingdom Trade and Cooperation Agreement', 'ALL', 'The ATM Facility', 'the Federal Trade Commission Act', 'the Budget Control Act', 'internal controls;\\n  &#x2022;existing regulations', 'Nasdaq', 'the European Union', '\\n    &', '\\n  &#x2022;manage'}"
CALT,
CAPR,
CARA,"{'ASC', 'API', 'LLC', 'Liechtenstein', 'Fresenius', 'HCRX Investments Holdco', 'difelikefalin', 'Fresenius Medical Care North America', 'Difelikefalin', 'a Product Agreement', 'the Vifor Stock Purchase Agreement', 'the New England Journal of Medicine', 'the Private Securities Litigation Reform Act', 'the Covered License Agreements', 'Jefferies LLC', 'EU', 'the CSL Vifor', 'Fresenius Medical Center', 'Kun Dang Pharmaceutical Corporation', 'the Vifor International Supply Agreement', 'Financial Accounting Standards Board Accounting Standards Codification', 'November&#160;13', 'HCR the Royalties', 'ContentsCARA', 'HCR Agreement', 'CSL Limited', 'the Vifor Supply Agreement', 'the Securities Exchange Act', '66&#8203;$ &#', 'NetOther', 'The Vifor Fresenius Medical Care Renal Pharma Ltd. Supply Agreement', '2023)&#160;&#160;&#160;&#160;$', 'Fresenius Medical Care Renal Pharma Ltd.&#8203;$ &', 'Maruishi Pharmaceutical Co.&#160;Ltd', 'Jefferies', 'COVID-19', 'Shelf Registration Statement', '66&#8203;$ &', 'ContentsIn', 'Cara Royalty Sub', 'Stock Awards', 'ESRD', 'net &', 'LiquiditySince', 'Contingencies', 'KALMTM-1', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'Phase 3 trials &', 'Yes &#9744', 'NRS', 'the First Milestone Payment', 'FDA', 'The Vifor International Supply Agreement', 'The API Commercial Supply Agreement', 'Stock-Based Compensation).&#8203', 'CKD', 'Vifor Agreement', '6,779&#8203;$ &#8212;&#8203;Weighted', 'Royalties', 'Winhealth Pharma', 'Company', 'Chong Kun Dang Pharmaceutical Corporation', 'Results of Operations', 'the Maruishi Agreement', 'AD', 'Cara Therapeutics, Inc.', '2022Revenue&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Three Months Ended &', 'Royalty Sub', 'L.P.', 'Vifor Fresenius Medical Care Renal Pharma Ltd.', 'the European Commission', 'CMS', 'OperationsComparison', 'The Shelf Registration Statement', 'New Drug Application', 'Fresenius Medical Care', 'CSL Vifor', 'ResultsThe', 'Recent Developments &#8211', 'the Enteris License Agreement', '6,779&#8203;$ &', 'the Contribution and Servicing Agreement', 'this Quarterly Report on Form&#160;10-Q', 'Patheon UK Limited', 'the Sales Agreement', 'the CKDP Agreement', 'NRS of &#8805', 'CandidatesOur', 'the Covered License Agreement to Royalty Sub', 'ContingenciesLicense Agreement', 'RFI', 'Notice and Comment Rulemaking', 'SLJ Atlantic Stamford', 'FMCNA', 'NDA', 'NP', '415&#8203;$ &#', 'baseline &#8805;3', 'CKDP', 'IPO', 'KORSUVA', 'the New Lease', 'Results of Operations &', 'CHRISTOPHER', 'Healthcare Royalty Partners IV', 'Condensed Financial Statements', 'Months Ended &', 'Hamas', 'PPL', 'MSA', '2022.The Company', 'ContentsItem&#160;2.Management&#8217;s Discussion and Analysis of Financial Condition', 'Vifor International Supply Agreement', 'Kapruvia', 'the API Commercial Supply Agreement', 'milestone fees&#8203;$ 910&#8203;$ &#', 'HCR', 'License AgreementsPolypeptide Laboratories S.A.', 'CSL 53\\nTable of ContentsVifor&#8217;s', 'Vifor International', 'Maruishi Pharmaceutical Co.', 'Related Party Transactions', 'Polypeptide Laboratories S.A.', 'Recognition', 'The Vifor Supply Agreement', 'SEC', 'the Shelf Registration Statement', 'Vifor Pharma Group', 'data)(unaudited)The Company', 'Territory', 'ContentsNet', 'the European Union'}"
CARM,"{'yield&#8212;&#160;&#8212;&#160;Stock-Based Compensation ExpenseThe Company', 'MHRA', 'Legacy Carisma', 'Development ExpensesWe', 'Contentsmaterial', 'Contractual Obligations', 'EMA', 'Plumley Complaint', 'MMA', 'the Federal Food, Drug', 'this Quarterly Report on Form 10-Q', 'the Patient Protection', 'Sesen Bio', 'JSC', 'YearsContractual', 'CPRA', 'the European Medical Agency', 'Moderna TX Inc.', 'FlowsThe', 'the Office of Therapeutic Products', 'ContentsWe', 'ACA', 'COVID-19', 'The Merger Agreement', 'the University of Pennsylvania', 'the Merger Agreement', 'Months EndedSeptember 30,20232022Collaboration', 'Trade Control Laws', 'Contentscommittee', 'Medicaid', 'Medicare', 'Congress', 'the Securities and Exchange Commission', 'OTP', 'LNP', 'FDA', 'Risks Related to Regulatory Approval', 'the Hatch-Waxman Act', 'Risks Related', 'HIPAA', 'the FDA.The FDA', 'the European Union Data Protection Directive', 'FDARA', 'FTC', 'Company', 'The Novartis Agreement', 'USPTO', 'the California Privacy Rights Act', 'Moderna License Agreement', 'the Combined Company', 'Certificate of Incorporation of Carisma Therapeutics Inc.', 'the European Commission', 'OTAT', 'Carisma', 'OperationsComparison', 'Operations, Inc.', 'CommitmentsThe', 'Moderna Collaboration', 'CAR', 'CARISMA Therapeutics Inc.', 'the Sale Agreement', 'the Moderna License Agreement', 'ContentsOur', 'IRA', 'Novartis Pharmaceuticals Corporation', '10)&#160;&#160;&#160;&#160;Related-Party TransactionsThe Company', 'New York University Langone Health', 'Regulation S-K', 'Merger', 'ExpenseInterest', 'development$418&#160;$45&#160;$452&#160;$122&#160;General and administrative430&#160;43&#160;991&#160;113&#160;$848&#160;$88&#160;$1,443&#160;$235&#160;The Company', 'U.S. Supreme Court', 'Seahawk Merger Sub, Inc.', 'the Penn License Agreement', 'Form S-3', 'The Moderna License Agreement', 'University of Pennsylvania LicenseIn', 'mRNA/LNP', 'the Registration Statement', 'New York University', 'European Union', 'Sesen Bio, Inc.', 'the Company (&#8220;Merger', 'the Health Care and Education Affordability Reconciliation Act', 'Healthcare', 'the Drug Price Competition and Patent Term Restoration Act', 'Novartis Agreement', '2023.Recent Accounting', 'Carisma Therapeutics Inc.', 'the Collaboration and License Agreement', 'the Medicare Prescription Drug', 'SEC', 'Collaboration and License Agreement', 'the European Union', 'Vpx', 'expenses1,958&#160;647&#160;Total'}"
CASI,
CBAY,"{'the Securities and Exchange', 'Principal Executive Officer', 'Financial Instruments', 'Chemistry', 'the research and/or development', 'Contents\\n\\n\\n\\n\\n\\n\\n&#160;\\n&#8226;\\n&#160;\\n', 'sufficient&#160;to', 'PBC', 'the Securities Exchange Act', 'Research', 'COVID-19', 'FINANCIAL INFORMATION  &', 'Rule&#160;13a-15(e', 'FASB', '\\n &', 'The License Agreement', 'Accrued', 'RESPONSE', 'Medicaid', 'Medicare', 'January&#160;23', '\\n&#160;&#160;\\nS-8\\n&#160;&#160;\\n&#160;\\n333-273887\\n&#160;\\n&#160;&#160;\\n&#160;\\n99.1\\n&#160;\\n&#160;&#160;\\n&#160;\\n8/10/2023\\n&#160;\\n\\n\\n\\n\\n\\n\\n\\n\\n &#160;&#160;31.1+\\n&#160;&#160;\\nCertification', 'Adjustments', 'Capital Requirements', 'FDA', 'Development Financing Agreement The Company', 'the Licensed Products', 'activities\\n&#160;&#160;\\n&#160;\\n343,043\\n&#160;\\n&#160;&#160;\\n&#160;\\n24,550\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'the Initial Term', 'Milestone', '\\n\\n&#160;\\n&#160;&#160;\\n &#160', 'Company', 'Results of Operations', 'Kaken', 'Unrealized', 'PPAR&#100', 'Concentration of Risk  Cash', 'the Development Financing Agreement', 'ASU', 'Transtech Corporation', 'Collaboration and License Agreement On', 'Financial Instruments&#8212;Credit Losses', 'development costs\\n&#160;&#160;\\n&#160;\\n9,652\\n&#160;\\n&#160;&#160;\\n&#160;\\n6,229\\n&#160;\\n&#160;&#160;\\n&#160;\\n3,423\\n&#160;\\n&#160;\\n&#160;\\n27,789\\n&#160;\\n&#160;&#160;\\n&#160;\\n19,173\\n&#160;\\n&#160;&#160;\\n&#160;\\n8,616\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'The Financing Agreement', 'this Quarterly Report on Form&#160;10-Q', 'the Financing Agreement', 'PBC &#', 'the Participant&#8217;s Continuous Service', 'IRB', 'Contents\\n\\n\\n\\n Research', '\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;\\n&#160;\\n30\\n&#160', 'CMC', 'x)&#160;Material Breach', '\\n&#160;&#160;\\n&#160;\\n253,430\\n&#160;\\n&#160;\\n&#160;\\n(95,115\\n)&#160', 'development\\n&#160;&#160;\\n$\\n19,962\\n&#160;\\n&#160;&#160;\\n$\\n15,459\\n&#160;\\n&#160;&#160;\\n$\\n4,503\\n&#160;\\n&#160;\\n$\\n58,050\\n&#160;\\n&#160;&#160;\\n$\\n51,765\\n&#160;\\n&#160;&#160;\\n$\\n6,285\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'net:\\n&#160;&#160;\\n\\n\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\n\\n\\n\\n Interest income\\n&#160;&#160;\\n&#160;\\n3,170\\n&#160;\\n&#160;\\n&#160;\\n677\\n&#160;\\n&#160;\\n&#160;\\n2,493\\n&#160;\\n&#160;\\n&#160;\\n7,810\\n&#160;\\n&#160;\\n&#160;\\n1,096\\n&#160;\\n&#160;\\n&#160;\\n6,714\\n&#160;\\n\\n Interest', 'NDA', 'Condensed Consolidated Balance Sheets', '\\n&#160', 'This Quarterly Report', 'Property', 'Form S-3', 'Stock-Based Compensation Expense  Stock', 'the License Agreement', 'Board', 'studies\\n&#160;&#160;\\n&#160;\\n234\\n&#160;\\n&#160;&#160;\\n&#160;\\n48\\n&#160;\\n&#160;&#160;\\n&#160;\\n186\\n&#160;\\n&#160;\\n&#160;\\n1,180\\n&#160;\\n&#160;&#160;\\n&#160;\\n434\\n&#160;\\n&#160;&#160;\\n&#160;\\n746\\n&#160;\\n\\n\\n&#160;&#160;\\n &#160;\\n &#160;\\n&#160;\\n&#160;&#160;\\n &', 'Development Financing Agreement  On July&#160;30', 'Condensed Consolidated Statements of Operations and Comprehensive Loss', 'net\\n&#160;&#160;\\n&#160;\\n(1,675\\n)&#160;\\n&#160;\\n&#160;\\n(3,142\\n)&#160;\\n&#160;\\n&#160;\\n1,467\\n&#160;\\n&#160;\\n&#160;\\n(4,287\\n)&#160;\\n&#160;\\n&#160;\\n(9,734\\n)&#160;\\n&#160;\\n&#160;\\n5,447\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'the Board of Directors', 'ATM', '\\n&#160;&#160;\\n\\n\\n\\n&#160;\\n\\n\\n \\n\\n Net', 'CymaBay Therapeutics, Inc.', 'Janssen NV', 'Significant Accounting Policies', 'SEC', 'Kaken Pharmaceuticals Co., Ltd', 'expenses\\n&#160;&#160;\\n&#160;\\n32,207\\n&#160;\\n&#160;\\n&#160;\\n21,363\\n&#160;\\n&#160;\\n&#160;\\n10,844\\n&#160;\\n&#160;\\n&#160;\\n90,197\\n&#160;\\n&#160;\\n&#160;\\n69,634\\n&#160;\\n&#160;\\n&#160;\\n20,563\\n&#160;\\n\\n\\n&#160;&#160;\\n &#', 'Regulatory Approval', 'Collaboration and License Agreement', 'Reference\\n&#160;\\n\\n Exhibit No.\\n&#160;&#160;\\n Description', 'equivalents\\n&#160;&#160;\\n$\\n253,430\\n&#160;\\n&#160;&#160;\\n$\\n(95,115\\n)&#160;\\n\\n\\n&#160;&#160;\\n &', 'Condensed Consolidated Statements of Cash Flows', 'costs\\n&#160;&#160;\\n&#160;\\n10,310\\n&#160;\\n&#160;&#160;\\n&#160;\\n9,230\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,080\\n&#160;\\n&#160;\\n&#160;\\n30,261\\n&#160;\\n&#160;&#160;\\n&#160;\\n32,592\\n&#160;\\n&#160;&#160;\\n&#160;\\n(2,331\\n)&#160;\\n\\n Internal', '\\n&#160;\\n&#160;\\n &#160', 'Weighted'}"
CBUS,"{'the Merger Agreement', 'the Amended Cellectis License', 'the Reverse Stock Splits', 'LLC', 'FASB', 'Up-C Units', 'Common Warrants', 'Contentsvested', 'the Fundamental Transaction', 'Non-Profit FoundationDuring 2022', 'the Fundamental Change Put', 'ARO', 'Class B Common Stock', 'Restated Bylaws of Cibus, Inc.', 'InformationDuring', 'the Common Warrants', 'the Merger Transactions', 'the Annual Report', 'this Quarterly Report on Form 10-Q', 'Cibus Global Members', 'Jefferies LLC', 'the Royalty Holders', 'Trait Machine', 'software3 - 53,264&#160;912&#160;Assets', 'AssetsIntangible', 'the Common Units', 'the Calyxt Field', 'the Trait Machine', 'Warrant Exchange Agreement', 'A Common Stock', 'Legacy Calyxt', 'the Amended Certificate of Incorporation', 'Legacy Common Stock', 'Cash EquivalentsThe Company', 'The Amended Certificate of Incorporation', 'Indicate', 'the Warrant Exchange Agreement', 'Nucelis', 'Cibus Global', 'Trait Machine/RTDS', 'Indefinite-Lived Intangible AssetsAs of September&#160;30', 'Series A Preferred Units', 'SEC', 'Restricted', 'Cibus', 'The Cibus Non-Profit Foundation', 'Impairment Testing of', 'NetIn', 'Company', 'NASDAQ Stock Market LLCIndicate', 'the Securities Exchange Act', 'Regulation FD', 'Class A Common Stock', 'ContentsNon', 'the Cibus Charitable Foundation, Inc.', 'Royalty Liability Interest', 'the ATM Facility', 'the Cibus Non-Profit Foundation', 'GMO', 'RELATED-PARTY TRANSACTIONS Prior', 'Calyxt, Inc.', 'the Royalty Liability', 'Regulation S-K).-'}"
CCCC,
CCLD,"{'ASC', 'FASB', 'ASU', 'this Quarterly Report', 'UAE', 'that\\nmay', 'care\\nand', 'this Quarterly Report on Form 10', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Contracts', 'Company.\\n\\n&#160;\\n\\n8', 'margin&#160;\\n    &#160;1.8%&#160;\\n    &', 'this Quarterly Report on Form 10-Q', 'net&#160;\\n', 'the Compensation Committee', '\\n    Group', 'income&#160;\\n', 'The Medical Practice Management', 'the Compensation Committee of the Board of Directors', 'Consolidated Financial', 'RSU', 'Internal Control Over Financial', 'the &#8220;Pakistan', 'CONTINGENCIES\\n\\n\\n\\n&#160;\\n\\nLegal\\nProceedings', 'operations.\\n\\n&#160;\\n\\nIncome\\nTax Provision', 'MTBC Acquisition Corp.', 'services&#160;\\n    &', 'MAC', 'services\\nto assist medical', 'Executive', 'Company', 'and\\n  \\n    &', 'RCM', 'respectively.\\n\\n&#160;\\n\\nAmortization\\nExpense', 'FDIC', 'Randolph Pain Relief and Wellness Center', 'Medical Practice Management\\nsegment.\\n\\n&#160;\\n\\nOperating\\nExpenses\\n\\n&#160;\\n\\nDirect\\nOperating Costs', 'SVB', 'Series B Preferred Stock', 'Control Arrangements &', '\\n    &', 'obligation.\\n\\n&#160;\\n\\nMedical\\npractice', 'number\\nof', 'income&#160;\\n    &'}"
CCLDO,"{'ASC', 'FASB', 'ASU', 'this Quarterly Report', 'UAE', 'that\\nmay', 'care\\nand', 'this Quarterly Report on Form 10', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Contracts', 'Company.\\n\\n&#160;\\n\\n8', 'margin&#160;\\n    &#160;1.8%&#160;\\n    &', 'this Quarterly Report on Form 10-Q', 'net&#160;\\n', 'the Compensation Committee', '\\n    Group', 'income&#160;\\n', 'The Medical Practice Management', 'the Compensation Committee of the Board of Directors', 'Consolidated Financial', 'RSU', 'Internal Control Over Financial', 'the &#8220;Pakistan', 'CONTINGENCIES\\n\\n\\n\\n&#160;\\n\\nLegal\\nProceedings', 'operations.\\n\\n&#160;\\n\\nIncome\\nTax Provision', 'MTBC Acquisition Corp.', 'services&#160;\\n    &', 'MAC', 'services\\nto assist medical', 'Executive', 'Company', 'and\\n  \\n    &', 'RCM', 'respectively.\\n\\n&#160;\\n\\nAmortization\\nExpense', 'FDIC', 'Randolph Pain Relief and Wellness Center', 'Medical Practice Management\\nsegment.\\n\\n&#160;\\n\\nOperating\\nExpenses\\n\\n&#160;\\n\\nDirect\\nOperating Costs', 'SVB', 'Series B Preferred Stock', 'Control Arrangements &', '\\n    &', 'obligation.\\n\\n&#160;\\n\\nMedical\\npractice', 'number\\nof', 'income&#160;\\n    &'}"
CCLDP,"{'ASC', 'FASB', 'ASU', 'this Quarterly Report', 'UAE', 'that\\nmay', 'care\\nand', 'this Quarterly Report on Form 10', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Contracts', 'Company.\\n\\n&#160;\\n\\n8', 'margin&#160;\\n    &#160;1.8%&#160;\\n    &', 'this Quarterly Report on Form 10-Q', 'net&#160;\\n', 'the Compensation Committee', '\\n    Group', 'income&#160;\\n', 'The Medical Practice Management', 'the Compensation Committee of the Board of Directors', 'Consolidated Financial', 'RSU', 'Internal Control Over Financial', 'the &#8220;Pakistan', 'CONTINGENCIES\\n\\n\\n\\n&#160;\\n\\nLegal\\nProceedings', 'operations.\\n\\n&#160;\\n\\nIncome\\nTax Provision', 'MTBC Acquisition Corp.', 'services&#160;\\n    &', 'MAC', 'services\\nto assist medical', 'Executive', 'Company', 'and\\n  \\n    &', 'RCM', 'respectively.\\n\\n&#160;\\n\\nAmortization\\nExpense', 'FDIC', 'Randolph Pain Relief and Wellness Center', 'Medical Practice Management\\nsegment.\\n\\n&#160;\\n\\nOperating\\nExpenses\\n\\n&#160;\\n\\nDirect\\nOperating Costs', 'SVB', 'Series B Preferred Stock', 'Control Arrangements &', '\\n    &', 'obligation.\\n\\n&#160;\\n\\nMedical\\npractice', 'number\\nof', 'income&#160;\\n    &'}"
CCRN,
CDIO,"{'Placement', 'LLC', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Loss', 'remaining\\nin the Trust', 'Exhibit 32.1', 'the previously\\nannounced Business Combination', 'LLC (&#8220;Benchmark&#8221', 'the Business Combination Agreement', 'activities:&#160;\\n    &', 'Letter and Potential Mootness Fee', 'this Quarterly Report on Form 10-Q', 'Company&#8217;s\\ncounsel', 'the Placement Agent Agreement', 'Cardio', 'Clinical Laboratory Improvement Amendments', '\\n    Office', 'Yorkville\\na Convertible Debenture', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Change', 'the Second Closing', 'Board of Directors\\nimmediately', 'Exhibit 4.3)\\n    &', 'Company&#8217;s\\ndirectors', 'cash&#160;\\n    &', 'the Merger Agreement.\\n\\n&#160;\\n\\nThe Legacy Cardio\\nStockholders', 'the Securities Exchange Act', 'calculation&#160;\\n    &', 'Mana to Legacy Cardio', 'warrants&#160;\\n    &', 'Mana Capital Acquisition Corp.', 'to\\nthe Business Combination Agreement', '\\n    &#160;&#160;&#160;&#160;General', 'the Merger Agreement&#160;(the &#8220;Exchange', 'cash&#160;\\n    &#', 'the Securities Purchase Agreement', 'the SEC.\\n\\nThe Business Combination', 'respectively&#160;\\n    &', 'the Cardio Diagnostics Holdings', 'UNAUDITED)&#160;\\n    \\n\\n&#160;\\n\\nRecent Accounting Pronouncements\\n\\n&#160;\\n\\nWe', 'the Securities and Exchange Commission', '\\n    &#160;&#160;&#160;&#160;Convertible', 'Boustead Securities', 'FDA', 'Cardio Diagnostics', 'Integrated Genetic-Epigenetic\\nEngine&#8482', 'debt&#160;\\n    &', 'the University of Iowa', 'the shareholders\\n    &', 'liabilities:&#160;\\n    &', 'AI', 'LLC (&#8220;Boustead', 'Equity Incentive Plan\\n(the &', 'Common Stock', 'Cardio Diagnostics, Inc.', 'the First Convertible Debenture', 'Company', 'the S-4 Registration Statement', 'DIAGNNOSTICS HOLDINGS', 'Significant Accounting', '\\n    &#160;&#160;&#160;&#160;Payments', '1 - Organization and Basis of Presentation\\n\\n&#160;\\n\\nThe', 'vest.&#160;The Company', 'net&#160;\\n    &', 'LLC (&#34;Boustead', '\\n    &#', 'income&#160;\\n    &', 'The Nasdaq Capital Market\\n(&#34;Nasdaq&#8221;)', 'Purchase Agreement', 'the Preparation of Financial Statements\\n\\n&#160;\\n\\nThe', 'Cardio\\nDiagnostics Holdings, Inc.', 'Awards Classified as Equity', '\\n    &#160;&#160;&#160;&#160;Purchases', '\\n\\n&#160;\\n\\nBoustead Securities', 'Regulation S-K.\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n', 'Advisory Services Agreement\\n(the &#8220;Placement', 'controls\\nand', 'cash\\nand', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;Debt', 'for:&#160;\\n    &', 'Mana Merger Sub, Inc. (&', 'Trust Company', 'The Benchmark Company', 'Board of Directors', 'the Business Combination\\nAgreement', '2023&#160;\\n    &', 'Registrant', 'The Nasdaq Capital Market', 'Company&#8217;s\\nacquired', 'this Quarterly Report on Form 10-Q.&#160;\\n\\n&#160;\\n\\n\\n  \\n    &', 'the Sarbanes-Oxley Act', 'the Letter Agreement', 'Mana', 'the &#8220;Business Combination', 'capital&#160;\\n    &', 'Yorkville', 'Advisory Services Agreement', 'respectively&#160;\\n    &#160;131&#160;&#160;\\n    &#160;95&#160;\\n', 'Cardio Diagnostics Holdings', 'YA Securities Purchase Agreement', '\\n    &#160;&#160;&#160;&#160;Acquisition', 'equipment&#160;\\n    &', 'Mana Capital', '\\n    &#160;&#160;&#160;&#160;Property', 'LDTs', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;Adjustment', 'SPAC', 'share:&#160;\\n    &', 'Continental Stock Transfer &amp', 'fee&#160;\\n    &', 'receivable&#160;\\n    &', 'Intangible Assets\\n\\n&#160;\\n\\nThe', 'SEC', 'and\\n  \\n    &', '\\n    &#160;&#160;&#160;&#160;Repayment', 'Mana Merger Sub, Inc.', 'the Company&#8217;s Common Stock (&#8220;Conversion', 'the Business Combination', 'the &#8220;S-4 Registration', '\\n    &#160;&#160;&#160;&#160;&#160;&#160;Notes', 'Artificial Intelligence (&#8220;AI&#8221;)-driven', 'contention appears\\nto', 'ASC Topic', '\\n    &', 'Cardio Diagnostics,\\nInc', 'the Registration Statement'}"
CDMO,"{'ASU', 'leases&#160;\\n    &#160;&#160;&#160;&#160;\\n    &', 'cost&#160;\\n    &', 'leases&#160;\\n    &', 'this Quarterly Report', 'portion&#160;\\n    &', 'Value Measurements \\n\\n&#160;\\n\\nFair', 'the Securities and Exchange Commission', 'incurred.\\n\\n&#160;\\n\\nWe', 'portion&#160;\\n    &#', 'Indenture', '\\n    Laboratory', 'Credit', 'cost&#160;\\n    $', 'covenant.\\n\\n&#160;\\n\\nThe Credit Agreement', '2023&#160;\\n    &', 'Registrant', 'pledged\\nas', 'will\\nbe', '\\n\\n\\n&#160;\\nPerformance Stock Units\\n\\n&#160;\\n\\nThe Compensation Committee of\\nthe Board of Directors', 'circumstances.\\n\\n&#160;\\n\\nWe', 'Principal Executive', 'herewith.\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'the tax\\nimpact of stock', 'the Securities Exchange Act', 'RSU activity&#160;\\n    &', 'Principal Accounting Officer)\\n\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n', '2028&#160;&#160;\\n    &', 'Capital', 'net&#160;\\n    &', 'in\\nthousands):\\n\\n\\n', '\\n    &'}"
CDNA,"{'LLC', 'XynManagement, Inc.', 'Intangible', 'February&#160;27', 'Stanford', 'HLA Data', 'CE mark', 'this Quarterly Report on Form 10-Q', 'the Journal of Molecular Diagnostics', 'the Federal Circuit', 'CLFS', 'EU', 'Court', 'Miromatrix Medical, Inc. (&', 'Network', 'NGS', 'Illumina, Inc.', 'LCD', 'SOX', 'ContentsWe', 'AlloCell', 'the Leland Stanford Junior University', 'The Nasdaq Stock Market LLC', 'the Securities Exchange Act', 'Billing Articles', 'mTilda', 'AlloMap Heart', 'BFS Molecular', 'CID', 'iBox', 'the Revised Billing Article', 'Palmetto', 'payments35,210&#160;Less', 'Judicial Arbitration and Mediation Services, Inc.', 'Anti-Kickback Statute', 'ALARM', 'the United States Supreme Court', 'the Superior Court', 'Fremantle', 'ContentsIn December 2021', 'the Repurchase Program', 'the Securities and Exchange Commission', 'Medicare', 'Tx Access', 'QTYPE', 'ObligationsFor', 'Medicaid', 'Johns Hopkins University', 'FDA', 'ContentsThe', 'Risks Related', 'the MolDX Program of Palmetto', 'HIPAA', 'the United States Court of Appeals', 'Silicon Valley Bank', 'Company', 'TTP', 'the Edelman Derivative Action', 'MAAA', 'KidneyCare', 'September&#160;30, 2023', 'the Illumina Agreement', 'Cerner and Epic', 'ContentsThere', 'Review', 'CMS', 'this Quarterly Report on Form 10-Q.', 'SecuritiesAll', '40Table of Contentstransplant', 'Digital Solutions RevenueOur', 'Stanford License', 'TransChart', 'TPE', 'September&#160;30,', 'Revised Billing Article', 'Carrying AmountAccumulated AmortizationForeign Currency', 'the Billing Articles', 'Board of Directors', 'the Transplant Pharmacy', 'SHORE', 'De Novo', 'the U.S. Supreme Court', 'MediGO, Inc.', 'The Illumina Agreement', 'the ""University Agreement', 'leases$1,172&#160;$822&#160;$3,871&#160;$2,746&#160;Royalty CommitmentsThe Board of Trustees', 'XynManagement', 'Cibiltech', 'Stock Repurchase Program', 'DOJ', 'the Company&#8217;s Board of Directors', 'Recent Accounting', 'Ottr, Inc.', 'HLA Data Systems', 'the Healthcare Regulatory EnvironmentIn', 'HLA', 'assets$75,014&#160;$(27,175)$(4,788)$43,051&#160;Acquisition of Intangible AssetsIn', 'Finance', 'ROU', 'Natera', '5310.The Company', 'LDTs', 'Sarbanes-Oxley Act', 'Medicaid Services', 'Laboratory Information Management System', 'OKRA', 'The Centers for Medicare &', 'Digital', 'SEC', 'Restricted', 'Digital SolutionsSales', 'PAMA', 'the Stevenson Derivative Action', 'the Health Information Technology for Economic and Clinical Health Act', 'AlloMap', 'Digital SolutionsIn 2019', 'the Assessing Chimerism and Relapse of Bone', 'the Registration Statement'}"
CDT,
CDTX,"{'ASC', 'the Development Candidate', 'LLC', 'Melinta Territory', 'Co', 'FINANCIAL OPERATIONS OVERVIEWRevenuesTo', 'obligation.&#160;The Company', 'EU', 'Lender', 'CPRA', 'the Anti-Kickback Statute and Foreign Corrupt Practices', 'the Financial Accounting Standards Board', 'Anti-Spam Legislation', 'the Securities Exchange Act', 'Need for Additional CapitalWe', 'COVID-19', 'FASB', 'ProceduresWe', 'HHS', 'the Research Plan', 'Internal Control', 'EQUITYControlled Equity', 'Medicaid', 'REZZAYO', 'Medicare', 'EPS', 'the Securities and Exchange Commission', 'Congress', 'the Global Development Plan', 'actions.64In', 'FDA', 'a CustomerThe Company', 'Cash EquivalentsThe Company', 'the Melinta Territory', 'Risks Related', 'AI', 'Company', 'FASB ASC 260', 'REZZAYOTM', 'loss).24Research and Development Services', 'USPTO', 'Mundipharma Medical Company', 'FAR', 'Interim Financial DataThe', 'GLP', 'Cantor Fitzgerald &amp', 'PROCEDURESDisclosure Controls', 'CRO', 'CMS', 'the ReSTORE Trial', 'Pacific Western Bank', 'Contracts with Customers', 'NTAP', 'RecognitionThe Company', 'the Personal Information Protection and Electronic Documents Act', 'the Janssen Collaboration Agreement', 'the Sales Agreement', 'CMC', 'the Melinta License Agreement', 'The Nasdaq Capital Market', 'NDA', 'U.S. Government Contracts', 'Per ShareThe Company', 'the U.S.Melinta License AgreementOn', 'Financial ReportingAn', 'U.S.Furthermore', 'Development Services', 'Our Financial Position', 'the Loan Agreement', 'EIP', 'ITEM&#160;3', 'the Accounting Standards Codification', 'ESPP', 'Cantor', 'Medicaid Services', 'the Term A Loan', 'the Commercial Supply Agreements', 'Healthcare', 'Federal Acquisition Regulations', 'DFC', 'the Mundipharma Collaboration Agreement', 'Employee Matters', 'The Melinta License Agreement', 'SEC', 'Collaboration and License Agreement', 'WuXi XDC', 'QIDP', 'the Centers for Medicare &', 'the European Union', 'Nasdaq', 'the Series X Convertible Preferred Stock', 'Series X Convertible Preferred Stock'}"
CDXC,"{'Joint Venture Agreement', 'Elysium', '2023Consumer Products', 'Western Alliance Bank', 'the California Action', 'sales15,694&#160;2,302&#160;2,277&#160;&#8212;&#160;20,273&#160;Gross', 'Credit Agreement', 'the License Agreement', 'Taikuk', 'the Unaudited Condensed Consolidated Financial StatementsOn', 'the Unaudited Condensed Consolidated Financial StatementsElysium&#8217;s', ': &#8226;the', 'Once Blue Hat Registration', 'the Department of Commerce', 'the Department of Transportation', 'the Trademark License and Royalty Agreement', 'the &#8220;Shareholders', 'Dartmouth College', 'the Private Securities Litigation Reform Act', 'InformationDuring', 'Elysium Health', 'Supply Agreement', 'EEA', 'the U.S. House of Representatives', 'the Supply Agreement', 'the Federal Circuit', 'COVID', 'the SDNY Court', 'GDPR', 'Elysium Health, Inc.', 'the &#', 'Unaudited Condensed Consolidated Financial Statements', 'FDA', 'SubsidiariesNotes', 'U.S. Data Bridge', 'the Unaudited Condensed Consolidated Financial StatementsNote', 'Court', 'MarketingSales', 'U.K. &#8211', 'the Department of Agriculture', 'Risks Related to Regulatory', 'Elysium (License Agreement', 'Federal Rule of Civil', 'the Unaudited Condensed Consolidated Financial StatementsThree', 'the Taikuk Fee and Subscription Price', 'Regulation S-K Item', 'the U.S. District Court', 'ChromaDex Corporation', 'FTC', 'ContentsWe', 'Company', 'ContentsOur', 'the Securities Exchange Act', 'Taikuk Group Ltd', 'ContentsChromaDex Corporation', 'the California Uniform Trade Secrets Act', 'ERTC', 'RevenueThe Company', 'the Joint Venture', 'the Federal Defend Trade Secrets Act', 'Territory', 'ChromaDex Asia Pacific Ventures Limited', 'NOL', 'ChromaDex', 'the Shareholders Agreement', 'The Shareholders Agreement', 'Unaudited Condensed Consolidated Statements of Operations', 'Results of Operations', 'The Grace Manufacturing Agreement', 'the U.S. Court of Appeals', 'NR', 'Asia Pacific Scientific', 'ContentsOperating Expenses-Sales', 'IPR', 'services(92)(50)(84)(94)49&#160;(292)Total', 'California Action'}"
CDXS,
CELC,"{'cancer\\n(mCRPC', 'FASB', 'Series A Convertible Preferred\\nStock', 'Series A Preferred Stock and warrants\\nexercisable', 'ASU', 'Pfizer', 'the Securities Purchase Agreement', 'LLC', 'the Loan Agreement', 'the Quarterly Report on Form\\n    ', 'Purchase Common Stock', 'Cover Page Interactive Data File', 'this Quarterly Report', 'Loan Agreement', 'Company\\nalso', 'PIK3CA WT', 'Expanded Access', 'Report', 'Celcuity', 'a Loan Agreement', 'the Condensed Balance Sheets', 'Cedar Point Capital', 'partnership\\nagreements', '2017).\\n', 'Lender', 'Pfizer, Inc.', 'forms.\\n\\n&#160;\\n\\nChanges\\nin Internal Control Over Financial', 'Loan', 'Bayer AG', 'Condensed Financial', 'Innovatus Life Sciences Lending Fund I', 'CELC-G-201', 'the Jefferies agreement.\\n\\n&#160;\\n\\nInnovatus\\nLoan Agreement', 'the Innovatus Loan Agreement', 'Limitations of Series A Convertible Preferred Stock', 'Celcuity LLC', '\\n    Research', 'the Common Stock', 'the Private Placement', 'MTD', 'SEC', 'Common Stock', 'Company', 'the Financial Accounting Standards Board', 'CELsignia', 'the Registrable Securities', 'the Securities Exchange Act', 'the Certifications of Designations of Preferences, Rights', 'Exhibit 3.2', 'Operations', 'Loan Amount', 'Series A Convertible Preferred', 'the Sarbanes-Oxley Act', 'NO &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'operations.\\n\\n&#160;\\n\\nRecently\\nAdopted Accounting Pronouncements\\n\\n&#160;\\n\\nIn\\nJune 2016', 'the Condensed Statements of Changes', 'CELsignia\\nplatform', 'net&#160;\\n    &', '\\n    &', 'YES &#9746', 'Equity', 'Celcuity Inc.', 'Craig-Hallum Capital Group'}"
CELU,
CELZ,
CERE,"{'\\n  &#x2022;injury', 'Good Manufacturing Practices', '\\n', 'StockPursuant', 'EMA', 'EEA/UK', 'EEA', '\\n  &#x2022;termination', 'Jefferies LLC', '\\n  &#x2022;costs', 'stock.\\n  Effective', 'EU', 'Phase 4', 'the Bain Funding Agreement', 'Financing Liabilities', 'Pfizer License Agreement\\n', 'Related Parties', '\\n    Research', 'patents;\\n  &#', 'the Securities Exchange Act', 'MDD', 'COVID-19', 'NovaQuest', 'Bain', 'deceptive intent;\\n  &#', 'the Funding Agreements', '\\n  &#x2022;expenses', 'and\\n  &', 'and\\n  &#x2022;collaborations', 'FASB', 'Pfizer', 'the Bain Funding Commitment', 'Anti-Kickback Statute', '\\n  &#x2022;significant', '\\n  &#x2022;product', '\\n  &#x2022;substantial', 'Research Collaboration and License Agreement', 'manufacturers&#x2019', 'L.P. (NovaQuest', 'Medicaid', 'Medicare', 'the Amended and Restated Registration and Shareholder Rights Agreement', '\\n  &#x2022;refusal', '\\n  &#x2022;CVL-354', 'x2014;\\n        &', 'KORA', 'candidates;\\n  &#x2022;a', 'GDPR', 'the Funding Investors', 'provisions:\\n  &#x2022;permitting', 'FDA', 'Legal Proceedings', 'national data protection authority', 'the United States;\\n  &#x2022;the', 'and\\n  &#', 'NIDA', 'the Total Funding Commitment', '\\n  &#x2022;loss', 'REMS', '\\n  &#x2022;fines', 'BC Pinnacle Holdings', '\\n    Interest expense\\n    &', 'Compensation Expense', '\\n  &#x2022;injunctions', 'External Party', 'the Pfizer License Agreement', 'CMS', 'use;\\n  &#', 'litigation;\\n  &#x2022;collaborators', 'acceptance.\\n  Efforts', 'and\\n  &#x2022;our', '\\n  &#x2022;the', 'Stockholders&#x2019', 'the U.S. Internal Revenue Code', 'ARYA Sciences Holdings II', 'products;\\n  &#x2022;disagreements', '\\n  &#', 'Board of Directors', '\\n  &#x2022;diversion', 'Pfizer License Agreement', 'plan\\n        &', 'Trustee', 'risk.\\n', 'ATM ProgramIn', 'the Sarbanes-Oxley Act', 'the indemnified party', 'prospects.\\n  &', 'This Quarterly Report', 'the National Institute on Drug Abuse', 'Funding Investors', '\\n  &#x2022;our', 'NovaQuest Co-Investment Fund XVI', 'the NovaQuest Funding Agreement', 'L-dopa&#x2019;s', 'the Securities Act.\\n  The', 'this Quarterly Report', 'the International Data Transfer Agreement and International Data', 'Bain Investor', 'Good Clinical Practices', 'including:\\n  &#x2022;the', 'Contractual Obligations and Other Commitments \\n', '44\\n', 'Perceptive Life Sciences Master Fund Ltd', 'Bain Capital Private Equity, LP and Bain Capital Life Sciences', '\\n  Research and Development \\n', 'the corporation.\\n  Pursuant', 'Indenture', '\\n  &#x2022;restrictions', 'Healthcare', 'the Internal Revenue Service', '\\n  &#x2022;withdrawal', 'Significant Accounting Policies', 'candidates.\\n  Collaboration', 'expensive;\\n  &#x2022;collaborators', 'the U.S. Treasury Department', 'SEC', 'the General Corporation Law', 'the Business Combination', 'The Pfizer License Agreement', 'acquirer;\\n  &#x2022;that', '\\n  &#x2022;materials', 'Nasdaq', 'the European Union', '\\n    &'}"
CERS,
CERT,"{'ASC', 'CompetitionThe', 'LLC', 'Credit Agreement', 'The Credit Agreement', 'Board', 'Contents Based', 'Legal proceedingsThe Company', 'this Quarterly Report', 'Vyasa Analytics', 'EnvironmentThe', 'Contractual Obligations', 'Except Per Share and Share Data)Basic', 'EMA', 'Contentscarryforwards', 'EQT', 'the Securities and Exchange Commission', 'the IPO.The Company', 'shareholders$(48,965)$3,936&#160;$(42,901)$5,557&#160;Basic', 'September&#160;30,', 'DIDB', 'the Secured Overnight Funding Rate (&#8220;SOFR&#8221', 'Formedix Limited', 'Software Service', 'the Arsenal Transaction', 'FDA', 'ActivitiesOur', 'Arsenal', 'August&#160;11', 'University of Washington', 'EventOn', 'the Drug Interaction Database', 'ContentsThe', 'Accounting Standards Update', 'FlowsThe', 'the University of Washington', 'ProceduresUnder', 'SEC', 'SOFR', 'ShareBasic', 'Company', 'the Financial Accounting Standards Board', 'ContentsMaintenance', 'The University of Washington', 'NOL', 'Amended and Restated Employment Agreement', 'COVID-19', 'Arsenal Capital Partners (&#8220;Arsenal&#8221;)', 'IPO', 'ContentsNet Income', 'Credit Spread Adjustment', 'ASC Topic'}"
CGC,"{'ASC', 'LLC', 'the Final Closing', 'the Wana Amending Agreement', 'Consolidated Statements of Cash', 'Transaction&#34', 'the &#x201c;Wana', 'Contractual Obligations', 'the Supreme Arrangement', 'the Reorganization Canopy USA', 'the &#x201c;TerrAscend', 'Canopy Growth \\n', 'indicated)\\n    2023\\n    &', 'compensation1\\n    &', 'Exhibits.\\n  &#160;\\n', 'the &#x201c;Reorganization Amendments&#x201d;).\\n', 'the Annual Report', 'Canopy USA Common', 'Supreme Shares', 'Canopy Growth', 'Private Placement &#', 'the Wana Repurchase Right', 'Acreage (&#', 'The TerrAscend Exchangeable Shares', 'Non-Voting Shares', 'the &#x201c;Convertible Debenture', 'the parties.\\n  &', 'the Canopy USA Common Shares', 'Unit Offering\\n  &#', 'the &#x201c;Option Premium&#x201d', 'Canopy Medical', 'the Acreage Floating Option', 'the Securities Exchange Act', 'The Omnibus Equity Incentive Plan', 'the &#x201c;Original Acreage', 'the Supreme Debentures', 'Exchangeable Shares', 'Reorganization - Creation of Canopy', 'Debentures', 'AgreementsOn', 'High Street Capital Partners', 'and\\n  &', 'the Credit Facility', 'compensation\\n    &', 'Fixed Shares', 'The Protection Agreement', 'the &#x201c;Supreme', 'the Company&#x2019;s Quarterly Report on Form 10-Q', 'management&#x2019;s', 'amortization1\\n    &', 'The Cima Group', 'Indiva', 'the Exchange Transaction', 'Acreage Holdings, Inc.', 'Huneeus 2017 Irrevocable Trust', 'Constellation Brands', 'Canopy USA Common Share', 'HSCP&#x2019;s', '\\n    &#160;Selling', 'the Ontario Superior Court of Justice', 'National Association', 'statements.\\n  &', 'the Interim Financial', 'Credit Facility', 'Greenstar Canada Investment Limited Partnership', 'BioSteel Sports Nutrition Inc.', 'Canopy', 'CBD isolate.\\n  &', 'the Option Premium', 'Mountain High Products', 'Regulation S-K. \\n', 'the &#x201c;Amended', 'Company', 'Tweed Inc.', 'the Convertible Debenture Agreement', 'the Floating Share Arrangement Agreement', '\\n  Management', 'the Interim Financial Statements', '\\n  &#x2022;Storz &', '\\n  &#160;\\n', 'Lemurian, Inc. (&', '70\\n', 'Institutional Investor', 'the &#x201c;Original Acreage Arrangement', 'Acreage (the &#', '\\n    &#', 'translations.\\n  &', 'the Canopy Growth Corporation', 'the CBI Note', 'Developments&#34', 'the &#x201c;Wana Amending Agreement&#x201d', 'The Floating Share Arrangement', 'ASU', 'Credit Agreement', 'x201c;Canopy USA', 'the Acreage Amended Arrangement', 'The Canopy USA Common Shares', 'Indiva Limited', 'bps\\n    &', 'equipment.\\n    &', '\\n    &#160;Depreciation', 'the Institutional Investor', 'Wilmington Trust', 'the Indiva Investment', 'the Canopy USA Board', 'correct.\\n  &', 'the Supreme Court', 'the April 2023 Exchange Agreement', 'the Original Acreage Arrangement Agreement', 'respectively).\\n  6', 'CBG Holdings', '\\n  &#', 'The Over-Allotment Option', 'the Subscription Agreements', 'the Floating Share Arrangement', 'the Credit Agreement', 'x201c;April 2023 Exchange', 'Indiva Inc.', 'the &#x201c;Credit', '\\n    &', 'Odyssey Trust Company', 'the Acreage Amending Agreement', 'the &#x201c;Acreage Amended', 'the Tranche A Warrants', 'Hershey Canada Inc.', 'Non-U.S. Employees', '\\n    &#160;General', '\\n    &#160;Total', 'tax\\n        &', 'BioSteel', 'Trust&#x2019;s', 'the Existing Acreage Arrangement Agreement', 'CBI', 'CPG', 'the Wana Options', 'Key Decisions', 'Trustee', 'x201c;Canopy USA Common', 'the Fixed Shares', 'the &#x201c;Floating Share', 'Canopy USA', 'Spectrum Therapeutics', 'the Sarbanes-Oxley Act', 'Canopy USA Common Shares', ""Canopy USA\\'s"", 'the CBI Transaction', 'Exchangeable Share', 'businesses.\\n  &', 'Acreage, Canopy Growth', 'below.\\n  &', 'Supreme Cannabis', 'TerrAscend', 'Canadian dollars)\\n    &', 'Board', 'the Reorganization and Reorganization Amendments', 'the &#x201c;Amended Credit', 'this Quarterly Report', 'the &#x201c;Reorganization', 'Acreage Agreements\\n  &', 'Acreage&#x2019;s', '\\n  &', 'the &#x201c;Exchangeable', 'the Triggering Event', '\\n    &#160;(Gain)/loss', 'the Canopy USA Common', 'x201c;Wana Repurchase', '2022 &', 'Canopy Notes', 'Credit Facility\\n  &', 'CBG', 'the Company&#x2019;s Annual Report', 'Acreage', 'the Second Amended and Restated Investor Rights \\n', 'Canopy USA Class B Shares', 'the Second Amended and Restated Investor Rights Agreement', 'the U.S. District Court', 'Share', '\\n        &', 'SEC', 'the Convertible Debentures', 'Noteholders', 'prices.\\n  &', 'the Indiva License Agreement', 'Canopy Growth Corporation', 'Storz &', 'TSX', 'the TerrAscend Exchangeable Shares', 'the Reorganization Amendments', 'the Non-Voting Shares', 'BioSteel Canada\\n        &', 'the Jetty Options'}"
CGEM,"{'Cullinan Pearl\\n    &', 'THE CONSOLIDATED FINANCIAL STATEMENTS\\n  ', 'LLC', 'years)\\n        &', 'Universit&#xe4;tsmedizin Gesellschaft', 'Cowen and Company', 'Cullinan Pearl Corp.', 'Icahn School of Medicine', '\\n', 'LiquidityThe Company', 'Rule 424(b)(4', 'Business and Basis of Presentation Organization Cullinan Oncology, Inc.', 'Deutsches Krebsforschungszentrum', 'MIT', 'improvements (&#x201c;Suite', 'Cullinan\\', 'the Securities and Exchange Commission', 'the Registrant&#x2019;s Annual Report', 'this Quarterly Report on Form 10-Q', 'x2014;\\n        &', 'EGFRex20 NSCLC', 'the &#x201c;Use', 'Exhibit 3.1', 'T&#xfc;bingen', 'the &#34;Company&#34;)', 'CMC', 'L.P., Biotechnology Value Fund II', 'Research and Development Expenses \\n  Research', '2023.Co-Development Agreement', 'CLN-617', '\\n    &', '\\n    ', 'Faculty of Medicine', '\\n    Research', 'Issuer Purchases of Equity', 'the Certificate of Amendment', '\\n        &', 'Cullinan AmberCullinan Amber Corp.', 'SEC', 'Company', 'Stockholders', 'CULLINAN ONCOLOGY', '\\n  Research and Development Expenses \\n', 'Biotechnology Value Fund', 'Exhibit 3.2', 'the Massachusetts Institute of Technology', 'Eberhard Karls University of T&#xfc;bingen', 'Equity Securities', 'IPO', 'Comparison', 'Taiho Pharmaceutical Co., Ltd (&#34;Taiho&#34', 'NO &', 'the Harbour License Agreement', 'L.P., Biotechnology Value Trading Fund OS LP', 'YES &#9746', 'Cullinan\\n    &'}"
CGEN,
CGTX,
CHEK,
CHRS,"{'LLC', 'CMOs', 'Reliance', 'EC', 'the Public Offering', 'Novartis Institutes', 'RRA', 'Amgen Manufacturing Inc.', 'EMA', 'CHS-114', 'Commercialization Option', 'Health and Human Services', 'Principal Executive Officer', 'Contentsbreach', 'EEA', 'this Quarterly Report on Form 10-Q', 'the Bioeq License Agreement', 'Debt ExtinguishmentLoss', 'the Novartis Agreement', 'EventsCommon Stock', 'national and/or local clinical guidelines', 'Internal Control Over Financial Reporting', 'IND', 'BPCIA', 'Euro', 'ContentsWe', 'all.&#160;A', 'purposes.&#8203;Our', 'Principal Executive Officer Required under Securities Exchange Act Rule&#160;13a-14(a)&#160;and 15d-14(a).&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;X&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;31.2&#8203;Certification', 'AbbVie', 'COVID-19', 'the ATM Offering', 'The Bioeq Manufacturing Agreement', 'November&#160;4', 'nonemployees:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203', 'HHS', 'the Superior Court', 'Critical Accounting', 'the Underwriting Agreement', 'Medicaid', 'the Securities and Exchange Commission', 'Coherus', 'Intangible Assets', 'CompensationThe', 'Diluted', 'Medicare', 'Novartis International AG', 'the U.S. Dollar', ': &', 'FDA', 'DeficitPublic Offering On May&#160;16', 'Healthcare Royalty Partners', 'the District Court', 'ContentsThe', 'Risks Related', 'Tranche C Loan', 'the Medicaid Drug Rebate Program', 'Goodwill', 'TD Cowen', 'Company', 'UDENYCA', 'CHS-1000', 'the Term Sheet', 'ContingenciesPurchase CommitmentsThe Company', 'USPTO', 'BeiGene, Ltd.', 'ContentsThe Company', 'U.S. Bank National Association', 'Bioeq', 'the Competent Authorities', 'Citigroup Global Markets Inc.', 'expense&#8203;$', 'Condensed Consolidated Financial Statements', 'GLP', 'the Delaware General Corporation Law', 'inventory&#8203;$ 373&#8203;$ 290&#8203;$', 'EEA Competent Authority', 'YUSIMRY', 'CMS', 'ConsolidationThe', 'NetGoodwill', 'Months Ended', 'presented:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Nine Months Ended &', 'Principal Financial Officer', 'Loan Agreement', 'J.P. Morgan Securities', 'AbbVie Biotechnology Ltd', 'The Loan Agreement', 'this Quarterly Report on Form&#160;10-Q', 'the Supreme Court', 'Underwriters', 'IRB', 'Regulation S-K.&#8203;ITEM&#160', 'Lenders', 'Shanghai Junshi Biosciences Co., Ltd.', 'the Bioeq Licensed Products', 'Amgen', 'Factors&#8212', 'the Surface Acquisition.49\\nTable of', 'NDA', 'the Stock Service Fee Payment', 'Exclusive License and Commercialization Agreement', 'CMO', 'Tranche B Loan', 'Genentech', ') &', 'ExpenseInterest', 'Directive 2001/83/EC', 'assets&#8203;&#8203;&#8203;$ 39,769&#8203;Surface', 'IPR', 'the Option Shares', 'Bioeq AG', 'the Surface Acquisition', 'Months Ended &', 'Cowen and Company', 'Hamas', 'the Loan Agreement', 'Optional Stock Purchase Agreement', 'ContentsExcluding', 'ATM', 'FDA&#8217;s', 'the Stock Purchase Agreement', '82&#8203;$ &#', 'Amgen Inc.', 'ESPP', 'IPR&amp;D', 'thousands)Statement of Operations Classification&#160;&#160;&#160;&#160;September&#160;30,&#160;2023&#160;&#160;&#160;&#160;September&#160;30,&#160;2023Currency', 'MAA', 'Successor Trustee', 'PAS', 'SEC', 'ATM Offering', 'the Bioeq Manufacturing Agreement', 'GCP', 'BLA', 'AbbVie Inc.', 'GSK', 'Earthquakes', 'the Registration Statement'}"
CING,"{'CTx-2103', '\\n    Active', 'LLC', 'Indegene', 'Cingulate', 'the ATM Agreement', 'Werth Family Investment Associates', 'the CTx-1301 New Drug Application', 'New Drug Application', 'The Market Offering Agreement', 'difference\\nbetween', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'incurring\\nadditional', 'Estimated&#160;&#160;\\n    &', 'the Securities and Exchange Commission', 'Congress', 'the Note Conversion Agreement', 'FDA', 'Lincoln Park', 'CTx-1302', 'the Internal Revenue Code', 'CTx-1302\\n(dextroamphetamine', 'PTR', 'BDD Pharma Limited', 'pursuant\\nto', '\\n    ', 'the LP Purchase', 'Cingulate Therapeutics', 'H.C. Wainwright &amp', 'WFIA', 'the Board of Directors.\\n\\n&#160;\\n\\n(9)\\nSale of Securities\\n\\n&#160;\\n\\nPrivate\\nPlacement\\n\\n&#160;\\n\\nOn\\nAugust 11, 2023', 'Lincoln Park Capital Fund', 'NDA', 'SEC', 'Material\\nAgreements&#8221', 'BDD Pharma Limited.\\n\\n&#160;\\n\\nSecurities\\nIssuances', 'Company', 'ultimate\\nresolution', 'Cingulate Therapeutics LLC', 'Lincoln', 'the Securities Exchange Act', 'Indegene, Inc.', 'Cingulate Inc.', 'the Sarbanes-Oxley Act', 'Lincoln Park Agreement', 'Business &#8211', 'Adopted Pursuant to Section 302', 'HCW', 'the Lincoln Park Agreement', 'Capital', 'net&#160;\\n    &', 'Nasdaq', 'the LP Purchase Agreement', '\\n    &', 'Societal', 'issued\\nin', 'Property'}"
CJJD,
CKPT,"{'ASC', 'Extensible Business Reporting Language', 'LLC', '700,000&#160;$ &', 'State', 'Risks Pertaining to Intellectual Property', 'TGTX', 'grant cross', 'the Condensed Consolidated Financial Statements', 'the Public Company Accounting Oversight Board', 'Registered Direct Offering', 'this Executive Order', 'Fortress for the Annual Equity Fee', 'the Department of Labor', '30,461&#8203;&#8203', 'ContentsCheckpoint', 'the Condensed Statements', 'BioAdvisors', 'Treasury', 'Fair Value MeasurementThe Company', 'ContentsWe', 'ACA', 'Management Services Agreement', '700,000&#160;$ &#8212;&#8203', 'License AgreementsThe Company', 'COVID-19', 'ContentsFor', 'Caribe BioAdvisors', 'Capital Resources', 'Anti-Kickback Statute', '9,011&#8203;&#160', 'Contingencies', 'NeuPharma', 'BET', 'Checkpoint', 'Medicaid', 'Medicare', 'United States', 'FDA', 'operations &', 'Condensed Financial Statements(Unaudited)Note&#160;1&#160;- Organization and Description of Business OperationsCheckpoint Therapeutics, Inc.', 'party&#8203;&#8203', 'Proportionate', 'Risks Related', 'the Medicaid Drug Rebate Program', 'HIPAA', 'Going ConcernThe Company', 'ContentsItem&#160;2.&#160;Financial Information', '700,000&#160;&#160;$ &#8212;&#8203', 'Patient-Centered Outcomes Research Institute', 'Company', 'LLC (&#8220;Caribe&#8221;)', 'USPTO', 'the Condensed Statements of Operations', 'the &#8220;Founders', 'the Management Services Agreement', 'Loss &#8203;$', '2&#8203;$ &', 'the Condensed Consolidated Statements of Cash Flows', 'CMS', 'OperationsComparison', 'the Condensed Consolidated Balance Sheets', 'ActivitiesNet', 'the Department of Health and Human Services', '1,977&#8203;&#8203', 'Intellectual Property', '9,179)&#8203;&#8203; &#8212;Changes', 'TGTX.Research and Development ExpensesResearch', 'Upfront', 'National Securities Corporation', 'the Prescription Drug User Fee Act', 'Condensed Statements of Operations', 'Caribe', 'Center for Medicare', '2&#8203;$ &#', 'The Founders Agreement', 'These &#', '4.78)&#8203;&#8203;&#160;&#8203;&#8203;&#160;&#8203;&#8203;&#8203;&#8203;&#8203;&#160;&#8203;Basic', 'Form S-3', 'Board', 'stock.&#8221', 'the Board of Directors', 'ContentsCheckpoint Therapeutics, Inc.Notes', 'party &', 'the State of Delaware', 'the Federal Food, Drug and Cosmetic Act', 'Restricted Stock UnitsThe', 'Fortress', 'taxes&#8203; &', 'Condensed Financial', 'Accounting Standards Codification', 'Research and Development', '10,712&#8203;&#8203', 'Hawkins BioVentures', 'the Condensed Consolidated Statements of Operations', 'ContentsResearch', 'Jubilant Biosys Limited', '*&', 'the Founders Agreement', 'CI', 'administrative &#8203;&#160', 'Page Interactive Data File', 'Medicaid Innovation (&#8220;CMMI&#8221', 'the European Union', 'the Condensed Consolidated Statement'}"
CLDX,"{'Consolidated Statements of Operations', 'the Merger Agreement', 'FASB', 'Cantor Fitzgerald &amp', '26%Total', 'equivalents&#8203;$ 16,813&#8203;&#8203', 'Venereology', 'EAACI', 'the Dermatology Life Quality Index', 'OTHER', 'Unaudited Financial', 'Congress', 'ContentsFurthermore', 'ColdU', 'this Quarterly Report on Form 10-Q', 'IPR&amp;D', 'Consolidated Statements of Cash Flows', 'KIT', 'Cantor', 'CSU', 'DermNet', 'DLQI', 'Kolltan Pharmaceuticals, Inc. (&', 'EADV', 'agreements&#8203;$ 2 &#8203;$ &#', 'the European Academy of Dermatology &', 'EoE', 'the Litigation', 'Rockefeller', 'the Settlement Agreement', 'the Successful Completion', 'Company', 'the New Jersey Economic Development Authority', 'the Term Sheet', 'ContentsThe Company', 'Unaudited Condensed Consolidated Financial Statements6Item', '60Total &#', 'ContentsNet', 'the European Academy of Allergy and Clinical Immunology', 'Co. (&#8220;Cantor&#8221', 'CDX-0159)&#8203;Barzolvolimab'}"
CLGN,
CLLS,
CLNN,"{'\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       ', '420\\n      &#', '\\n      &#', 'Leases\\n   &', '9,975\\n       &#xa0;\\n       &#xa0;\\n', 'EMA', '2023 &#', 'the Clene Nanomedicine', 'values.\\n   &', '3,237\\n      &#', 'Amyotrophic Lateral Sclerosis', 'liabilities &#xa0;&#xa0;3,194&#xa0;&#xa0;&#xa0;3,863&#xa0;\\n', '5,007\\n       &#', 'Lincoln Park', 'the ATM Prospectus Supplement', '\\n   &#', 'EQUITY &#', '\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       ', 'panel.\\n  &#', 'xa0;&#xa0;553&#xa0;&#xa0;&#xa0;488&#xa0;\\n Finance', 'and&#xa0;interest', 'concern.\\n   &#', '402\\n      &#', 'Segment Information\\n   &#', 'weaknesses.\\n  &#', 'the &#x201c;2019 Cecil Loan&#x201d', 'the Securities Exchange Act', 'net.\\n   &', '\\n   &#xa0;&#xa0', 'the offering.\\n  &#', '931\\n      &#', 'Parkinson&#x2019;s Disease (&#x201c;PD&#x201d;).&#xa0;Our', '9,770\\n       &#', 'necessary.\\n  &#', 'No &#', 'reporting.\\n  &#', 'ALS', 'Multiple Sclerosis (&#x201c;MS&#x201d;)', 'net &', 'the National Institute of Neurological Disorders and Stroke', '9,650\\n      &#', 'Internal Control', 'DHCD', 'Lincoln Park&#x2019;s', '9,483\\n       &', 'FDA', '\\n       &#xa0;\\n       &#', 'Canaccord&#xa0;and Oppenheimer &amp', '819\\n      &#', 'Maryland Loans\\n   &#', 'loss&#xa0;in', '\\n       &#xa0;\\n       &#xa0;\\n       ', 'CONDENSED CONSOLIDATED', 'Condensed Consolidated Statements', 'sources:\\n  &#', 'Common Stock', 'Company', 'Lincoln', 'Initial Stockholders', 'Canaccord Genuity', 'xa0;\\n       &#', '5,000\\n      &#', '44\\n      &#', '333\\n      &#', '\\n    &#', 'the New Avenue Warrant', 'CLENE', 'Condensed Consolidated Financial Statements', 'statements.\\n  &#', 'Condensed Consolidated Statements of Operations', '9,979\\n      &#', 'xa0;&#xa0;58&#xa0;&#xa0;&#xa0;58&#xa0;\\n', '\\n       &#xa0;\\n        Interest Rate \\n       &#xa0;\\n       &#', 'the National Institute of Health', 'penalties.\\n   &', 'Co. Inc.', 'Condensed Consolidated Statements of Cash Flows \\n       ', 'Unaudited)\\n  &#', 'LIABILITIES &#', 'the Current Report on Form 8-K', 'STOCKHOLDERS&#x2019', 'Restated Certificate of Incorporation of Clene Inc.', '\\n  &#', 'liabilities &#', 'ASSETS &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Current', '3,666\\n      &#', 'the Department of Housing and Community Development (&#x201c;DHCD&#x201d', 'the &#x201c;Purchase Agreement Prospectus', 'Columbia University and Synapticure', 'the Tranche A Warrants', 'the &#x201c;Exchange', 'NDA', '\\n\\n   &', '5,000\\n       &#xa0;\\n       &#xa0;\\n', 'Condensed Consolidated Balance Sheets', 'Pursuant', 'respectively.\\n  &#', 'EQUITY &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Current liabilities: &', 'REPAIR-MS', 'Procedures\\n  &#', '875\\n      &#', '5,000\\n       &#', 'Advance Cecil Inc.', 'capital &', '\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#', 'the FDA.\\n  &#xa0;\\n  Research', 'Financial Reporting\\n  &#', 'Tranche A Warrants', 'EQUITY &#xa0;&#xa0;21,406&#xa0;&#xa0;&#xa0;3,237&#xa0;\\n TOTAL LIABILITIES', 'the Purchase Agreement', 'costs.\\n   &#', 'the &#x201c;2019 MD Loan&#x201d', 'electro-crystal-chemistry', '\\n       Financial Statements', 'Form S-3', 'the &#x201c;2021 Avenue', '\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#', '97,026,964\\n      &#', 'EQUITY', 'the National Multiple Sclerosis Society (&#x201c;NMSS&#x201d', 'ATM', 'effect.\\n  &#', 'respectively.\\n   &#', 'MS', 'Initial Stockholders Contingent Earn-outs', '\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#', '2022 &', 'the Pooled Resource Open-Access ALS Clinical Trials (&#x201c;PRO', 'xa0;&#xa0;4,287&#xa0;&#xa0;&#xa0;4,602&#xa0;\\n Property', 'Related Party', 'xa0;&#xa0;5,080&#xa0;&#xa0;&#xa0;5,557&#xa0;\\n Finance', 'SEC', 'Restricted', 'factors.\\n  &#', 'agreements.\\n', '\\n     &#', '\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#', 'the &#x201c;Purchase', '\\n       &#', 'Phase 3', 'commenced&#xa0;in', 'Tranche B Warrants', 'Nasdaq', 'concern.\\n  &#', 'Segment Information\\n   &', '6,675\\n       &#xa0;\\n       &#'}"
CLOV,
CLPT,"{'Capital ResourcesWe', 'the Securities Purchase Agreement and Senior Secured Convertible Notes', 'Neuro, Inc.Notes', 'SPA', 'Condensed Consolidated Financial Statements(Unaudited)&#8226;Functional', 'RSUs$8,187&#160;1.94Stock Option ActivityStock', '2023Unrecognized ExpenseRemaining Weighted-Average Recognition Period', 'this Quarterly Report', 'Condensed Consolidated Financial Statements(Unaudited)In 2020', 'Condensed Consolidated Financial Statements(Unaudited)On', 'London Interbank Offered Rate', 'Condensed Consolidated Financial Statements(Unaudited)(1)Intrinsic', 'a Securities Purchase Agreement', 'December&#160;31', 'Petrichor Opportunities Fund I LP', 'Condensed Consolidated Financial Statements(Unaudited)September&#160;30', 'Intangible AssetsThe Company', 'the Condensed Consolidated Financial Statements', 'PTC Therapeutics, Inc.', 'RSA', 'RSU', 'Restated Certificate of Incorporation of MRI Interventions, Inc.', 'Condensed Consolidated Financial Statements(Unaudited)Nine Months Ended September', 'Note Payable MaturityScheduled', 'ExpensesOur', 'SEC', 'Financial Officer(Principal Financial Officer', 'SOFR', 'Company', 'expense$4,536&#160;$2,954&#160;Share', 'ClearPoint Neuro, Inc.', 'ClearPoint', 'the Securities Exchange Act', 'ActivityRestricted', 'Contractual Life', 'Principal Accounting Officer)32\\n\\n\\n'}"
CLRB,"{'Form S-3', 'HNC', 'PDC', 'the Equity Distribution Agreement', 'Fast Track Designation', 'Co. Inc.', 'U.S. Food and Drug Administration', 'ATM', 'MM', 'the Sales Agreement', 'OperationsResearch', 'FDA', 'Series E-1', 'TBD &gt;60 mCi/m2', 'Tranche A Preferred', 'UWCCC', 'the Division of Oncology', 'Accounting Standards Codification', 'the Series C Convertible Preferred', 'E-1', 'SEC', 'Orano Med', 'Elimination of the Series A Convertible Preferred Stock', 'Company', 'the Series B Convertible Preferred Stock', 'the Original Per Share Price', 'COVID-19', 'Tranche', 'EBRT', 'IntoCell Inc.', 'Oppenheimer &amp', 'the Amended HQ Lease'}"
CLSD,"{'LLC', 'EC', '\\n', 'Aura Biosciences', 'Arctic Vision', 'the ASEAN Countries', 'Co. (&#34;Cantor&#34', 'the &#x201c;License', 'NSAIDs', 'Option', 'the Securities Exchange Act', 'Notified Body,', 'ATM Agreement with', 'BioCryst&#x2019;s', 'REGENXBIO Inc.', 'SCS Microinjector', 'European Community', 'the Arctic Vision License Agreement', 'and\\n  &#x2022;launching', 'Aura Biosciences, Inc.', 'ContingenciesLease', 'The License Agreement', 'the Second Milestone Event', 'ATM Agreement', 'the Sublicensee Action', 'Aura License Agreement', 'Principal Financial', 'FDA', 'statements.\\n  &', 'Royalties', 'Milestone Event&#34', 'Company', 'the Aura License Agreement', 'XIPERE', 'the Arctic License Agreement', 'Royalty Sub', 'the Arctic Territory', 'Bausch + Lomb (&#x201c;Bausch&#x201d;)', 'Cantor Fitzgerald &amp', 'dividends.\\n', 'REGENXBIO License Agreement', 'the &#x201c;Initial', 'BioCryst Pharmaceuticals, Inc. (&#x201c;BioCryst&#x201d;)', 'BioCryst', 'License Agreement', 'BioCryst Pharmaceuticals, Inc.', '\\n  &#', 'Bausch License Agreement', 'Registrant', 'The Nasdaq Capital Market', 'the Bausch License Agreement', 'x201c;Aura License', 'Bausch Health', 'REGENXBIO, Inc.', 'the &#x201c;Closing Date&#x201d;)', 'HealthCare Royalty Management', 'Cowen and Company', 'Emory University', 'the License Agreement', 'the &#x201c;Arctic', '4,637\\n    &', 'ATM', 'the REGENXBIO Option', 'HCR', 'Cantor', 'Clearside Royalty', 'BioCryst Pharmaceuticals', 'Bausch', 'Intertek Medical Notified Body', 'the &#x201c;Arctic License', '\\n        &', 'SEC', 'Royalties from Royalty Sub', 'The Georgia Tech Research Corporation', 'the Initial Cap', 'SCS', '\\n    &'}"
CLVR,
CMAX,"{'ASC', 'L.P. (&#', 'LLC', '\\n  &#x2022;As', '\\n    Interest income\\n    &', 'CareMax\\', 'experience.\\n  &#x2022;As', 'the Business Combination Agreement', 'Sparta Holding Co.', 'Contractual Obligations', 'Delaware &#160;(15)\\n     CAREMAX, inc', 'Security Agreement', 'the Public Warrants', 'the Steward Closing Date', 'CareMax Medical Group', 'SACN Holdco', 'IMC Parent', 'the Federal Reserve Bank', 'Steward Integrated Care Network, Inc.', 'the Company (&#x201c;Merger Sub I&#x201d;)', 'reporting.\\n  &#x2022;As', 'Financial Information', 'the Securities Exchange Act', 'Class A Common Stock', 'L.L.C.', 'the Steward Closing', '\\n    Medicare Government', 'Platform Contribution', 'remediated.\\n  &#160;\\n', 'the Merger Agreement', 'The Credit Agreement', 'the Secured Overnight Financing Rate', 'Medicaid Risk-Based Revenue Medicare', 'SNCN Holdco Inc.', 'the Earnout Share Consideration', 'the &#34;Targets&#34;)', 'facilities.\\n  &', 'Security', 'Medicaid', 'Medicare', 'Intangible Assets', 'CareOptimize', 'The Business Combination', 'x2014;\\n        &', 'the &#x201c;Initial Term', 'Steward Health Care System', 'THE SECURITIES EXCHANGE ACT OF', 'RELATED PARTY DEBT&#160;Credit Agreement &#', 'the ACO.\\n  &', 'Loan', 'the Company (&#x201c;Merger Sub', 'L.P. (&', 'MCREM', 'CareMax, Inc.', 'Goodwill', 'Medicaid Risk-Based Revenue', 'Advisor', 'the Private Placement Warrants', 'Company', 'the &#x201c;Advisory', 'enhanced.\\n  &', 'Security Agreement - Related Party Debt &', 'n/k/a as', 'Steward Accountable Care Network', 'Related CM Advisor', 'the Advisory Agreement', 'Charter)\\n  &#', '\\n    &#', 'Report', 'Credit Agreement', 'CMS', 'Elevance Health', 'EVENTS &', 'the &#x201c;Initial', 'IPA', 'Financial Reporting and Technical Accounting', 'FAIR VALUE MEASUREMENTS&#160;Financial Instruments', 'Procedures\\n  &', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'the &#x201c;Delayed', 'regularly reviews financial', '\\n  &#', 'the Credit Agreement', 'Lenders', 'the &#x201c;Credit', 'program.\\n  &#160;\\n', 'Medicare Advantage', 'the Company (&#x201c;Merger', 'Pursuant', 'the &#x201c;Business', 'the &#x201c;Series A', 'MSR', 'Sparta Sub Inc.', 'the Sarbanes-Oxley Act', 'factors.\\n  &', 'IPO', 'Public Warrants', 'the &#x201c;Merger', 'the &#x201c;Steward', 'AccumulatedAmortization\\n        &', 'IMC Holdings', 'the Subscription Agreement', 'Steward Accountable Care Network, Inc.', 'CAJ', 'Board', 'MSO', 'Steward National Care Network, Inc.', 'the Steward Acquisition', 'CareMax', 'Contracts with Customers (&', 'Deerfield Partners', 'CAREMAX, inc', 'n/k/a Steward National Care Network', 'Transition Services Agreement', 'COVID', 'Initial Term Loans', 'SNCN Holdco', 'the Company (&#x201c;Merger Sub II&#x201d;)', 'Legal Counsel', 'CAJ Lending LLC (&#', 'the Existing Credit Agreement', 'Significant Accounting Policies', 'SICN Holdco Inc.', '\\n        &', 'SEC', 'Deerfield Partners L.P.', 'the Business Combination', 'the Medicare Shared Savings Receivables', 'respectively).&#160;As', 'IMC Medical Group Holdings', 'liabilities.\\n  &#x2022;During', 'the  Securities and Exchange Act', '\\n    &', 'The Related Companies,'}"
CMMB,
CMND,
CMPS,
CMPX,
CMRX,
CNSP,"{'the FASB\\nissued Accounting Standards Update', 'CRO', 'PLN', 'response\\nto', 'Houston Pharmaceuticals, Inc. (&', 'LLC (&#8220;ALI&#8221;)', 'Berubicin', 'License Agreement', 'Reata', 'the HPI License', 'UTMDACC', 'Animal Life Sciences', 'a Technology Rights\\nand Development Agreement', 'the State of Texas', 'Company&#8217;s\\ncommon', 'Reata Pharmaceuticals, Inc. (&', 'HPI', 'Pomeranian Medical University', 'Reata Pharmaceuticals, Inc. (&#', '\\n    &', 'the U.S. Food and Drug\\nAdministration (&#8220;FDA&#8221', 'agreement\\nwith', 'Agreement,\\nor', 'and\\n$41,075', 'PUM', 'the Inducement Warrants', 'SEC', 'commercialize\\nlicensed', 'ALI', 'The Board of Regents of The University of Texas System', 'Company', 'the WP1244 Agreement.\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'Data Safety Monitoring Board', 'Sponsored Research Agreement', 'WPD', 'Glioblastoma Multiforme', 'Company\\npaid', 'CNS', 'the Reata Agreement', 'IPO', 'The University of Texas M. D. Anderson Cancer Center (&', 'Glioblastoma', 'Holder', '\\n    &#160;Schedule', 'WPD\\nPharmaceuticals, Inc. (&#8220;WPD&#8221'}"
CNTA,"{'ASC', 'API', 'LLC', 'Generic Risk FactorsBusiness', 'the Note Purchase Agreement', 'Reliance', 'AML', 'ALERT Study', 'EMA', 'the EU Commission', 'DTA', 'EEA', 'Development ExpensesResearch', 'ADS holders&#8217', 'EU', 'the Public Company Accounting Oversight Board', 'ADPKD', 'the Boston Lease', 'Restricted Stock Awards', 'the Unaudited Interim Consolidated Financial StatementsCash', 'NSCLC', 'CPRA', 'American Depository Shares', 'Concentrations of Credit RiskFinancial', 'the State of New York', 'the Securities Exchange Act', 'Data Protection Requirements', 'NCT05789524', 'TranslationOur', 'Deposit Agreement', 'portion$9,020&#160;Licensing', 'Adopted Pursuant to Section 906', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'the Data Protection Requirements', 'Unaudited Consolidated Financial Statements', 'NCT05789537).While', 'Orexia Therapeutics Limited', 'stringent Data Protection Requirements', 'FDA', 'Centessa Pharmaceuticals plc', 'the EMA&#8217;s Committee for Orphan Medicinal Products', 'Processing', 'ADS', 'Oberland Capital Management', 'Cash EquivalentsThe Company', 'Risks Related', 'ALT', 'September&#160;30', 'REMS', 'AATD', 'Company', 'USPTO', 'the Unaudited Interim Consolidated Financial Statementswell', 'the Note Purchase Agreement with Oberland Capital', 'Institutional Review Board', 'Oberland Capital', 'the Unaudited Interim Consolidated Financial Statementsprobability', 'the European Commission', 'Regulation S-X and Regulation S-K', 'the ALERT Study', 'Success', 'Purchasers', 'MAD', 'Good Clinical Practice', 'PRESent-2', 'Investigational New Drug', 'Leases (&', 'Contractual Obligations and Other Commitments', 'Collaborative ArrangementsThe Company', 'Cocoon SA', 'Sections 11', 'Leerink Partners', 'the Sarbanes-Oxley Act', 'Non-Human Primate', 'ContentsCentessa Pharmaceuticals plc', 'HM Revenue&#160;&amp', 'Form S-3', 'Board', 'Restricted Share Awards', '9 (&', 'the Oberland Capital Notes', 'California Privacy Protection Agency', 'the Unaudited Interim Consolidated Financial StatementsThe', 'the Standard Contractual Clauses', 'the Oberland Capital Financing Agreement', 'HB', 'a&#160;non-U.S.&#160;corporation', 'Percent Shareholders', 'the &#8220;simplified', 'the Internal Revenue Service', 'United', 'OperationsThe', 'Initial Public', 'ERP', 'SEC', 'GCP', 'Milestone Payments', 'Customs (&#8220;HMRC&#8221', 'Qualitative Disclosure About Market', 'the Company&#8217;s Compensation Committee', 'ADSs constitute &#8220;marketable&#8221', 'the European Union', 'Related Party TransactionsMaster Services'}"
CNTB,
CNTG,
CNTX,
COCH,"{'ASC', 'LLC', 'redemptions&#160;\\n    &', 'the Closing.\\n\\n\\n&#160;\\n\\n  &#160', 'the Business Combination Agreement', 'Envoy', 'the Envoy Bridge Note', 'GAT Funding', 'the Proxy Statement/Prospectus', 'Meteora Select Trading Opportunities Master', 'and\\n\\n\\n&#160;\\n\\n\\n&#9679;facility-related\\nexpenses', 'the Company&#8217;s Series A Preferred Stock', 'Series A Preferred Stock', 'the Series A Preferred Stock', 'Envoy Medical GmbH\\n(Ansbach', 'the Envoy\\nBridge Note', '\\n    Research', '\\n    Exchange of Anzu Class B Common Stock for Series A Preferred Stock&#160;\\n    &', 'cash&#160;\\n    &', 'Anzu Special Acquisition Corp\\nI', 'Meteora parties&#160;\\n    &', 'financing\\nat', 'Meteora Strategic Capital', 'FASB', 'the Business Combination was cancelled\\nin', 'Series A Preferred\\nStock', 'Letter Agreement', '\\n    Exchange of Envoy Common Stock', 'LLC (&#8220;MSC&#8221;\\nand', 'Note 2 &#', 'respectively&#160;\\n    &', 'follows:&#160;\\n\\n&#160;\\n\\n\\n\\n\\n&#9679;Identify\\n                                            ', 'the Society of\\nActuaries.\\n\\n&#160;\\n\\nRecently Issued/Adopted Accounting Pronouncements\\n\\n&#160;\\n\\nA\\ndiscussion', 'FDA', 'Envoy Medical, Inc.', 'the Forward Purchase Agreement', 'Forward Purchase Agreement', 'the contract&#160;\\n\\n&#160;\\n\\n\\n&#9679;Determine\\n                                            ', 'U.S. GAAP.\\n\\n&#160;\\n\\nThe Company', 'the Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'the Sponsor Support Agreement', 'the SEC.\\n\\n&#160;\\n\\nRelated Party', 'conclusion\\nby', 'liabilities:&#160;\\n    &', 'respectively.\\n\\n&#160;\\n\\nOn', 'Anzu Special Acquisition Corp I', 'MCP', '\\n    Exchange of Anzu Class A Common Stock', 'liability&#160;\\n    &', 'Company', 'American Stock Transfer &amp', '\\n\\n\\n&#160;\\n\\n\\n*1,000,000', 'net&#160;\\n    &', 'Report', 'Envoy Medical Corporation', 'Purchase Agreement', 'deficit):&#160;\\n    &', 'Envoy Common Stock', 'Envoy Medical, Inc. Indemnification Agreement', 'Meteora Capital Partners,\\nLP', 'Contracts with Customers', 'portion&#160;\\n    &#160;2,025&#160;&#160;\\n    &#160;2,143&#160;\\n', 'CONSOLIDATED BALANCE SHEETS \\n\\n(UNAUDITED)\\n\\n(In thousands', 'basic&#160;\\n    &', '\\n\\n\\n&#160;\\n\\nThe Company', 'Trust Company', 'forward\\npurchase', 'Initial Spearman', 'Meteora Special Opportunity Fund I, LP (&', 'Note 1 &#8211', 'Company&#8217;s\\ncontracts', '2023&#160;\\n    &', 'prepaid\\nthe Envoy Bridge Note', 'the Sponsor Support\\nAgreement', 'Risk\\n\\n&#160;\\n\\nWe', 'Pursuant', 'the Closing (&#8220;Envoy Preferred', '\\n    Increase', 'the Sarbanes-Oxley Act', 'the PIPE Transaction', 'the &#8220;Business Combination', 'the Subscription Agreement', 'portion&#160;\\n    &', 'of\\n$1.00', 'Envoy Merger Sub, Inc.', 'Envoy Warrants&#160;\\n    &', 'SPAC', '\\n    Exchange of Envoy Preferred Stock for New Envoy Class', 'the &#8220;Forward\\nPurchase', 'Series\\nA Preferred Stock', 'the Business and Basis of Presentation\\n\\n&#160;\\n\\nEnvoy Medical, Inc. (&#8220;Envoy\\nMedical&#8221', 'MSTO', 'Note 4).\\n\\n&#160;\\n\\nDerivative Financial Instruments\\n\\n&#160;\\n\\nThe\\nCompany', 'Series A Preferred', 'SEC', 'Restricted', 'New Envoy\\nClass A Common', 'Envoy\\nentered', 'United States dollars', 'Anzu Special Acquisition Corp', 'the Business Combination', 'Anzu (&#8220;Merger', 'New Envoy\\nClass A Common Stock', 'Total&#160;\\n', 'the Initial Spearman Plaintiffs', 'net&#160;\\n    &#160;109&#160;&#160;\\n    &', 'assets&#160;\\n    &', '\\n    &', '\\n    Forward'}"
COCP,"{'ASC', 'Reference\\n    &', 'Dohme Corp.&#8221', 'Cocrystal', 'Principal Financial Officer', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Foundation', 'Merck', 'intent\\nto', 'Purchasers', 'thousands):\\n\\n&#160;\\n\\nSchedule\\nof Maturities of Operating Lease', 'Collaborations-Merck Sharp &', 'Principal Executive Office)\\n', '2023.\\n\\n&#160;\\n\\nLiberty\\nInsurance Underwriters Inc.', 'Note 9 &#8211', 'Co-Chief Executive', 'payments&#160;\\n    &', 'PROCEDURES\\n\\n&#160;\\n\\nEvaluation\\nof Disclosure Controls', 'The Nasdaq Capital Market', 'Accounts Payable', 'H.C. Wainwright &amp;\\nCo.', 'Principal Executive', 'SEC', 'LLC (&#8220;Wainwright&#8221;)', 'Company', 'the Securities Exchange Act', 'FASB ASC Topic', '\\n    &', 'position.\\n\\n&#160;\\n\\nLiberty\\nInsurance Underwriters Inc.'}"
CODX,"{'Hukui', 'the Shelf Registration', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'satisfied.\\n\\n&#160;\\n\\nResearch\\nand Development\\n\\n&#160;\\n\\nResearch\\nand', 'the &#8220;Shelf Registration', 'Obligations\\n\\n&#160;\\n\\nThe Company', 'Piper Sandler &', 'respectively.\\n\\n&#160;\\n\\n\\n\\n    &', 'Court', 'Registrant', 'Hukui Tech, Inc.', 'Piper Sandler &amp', 'SEC', 'the Shelf Registration Statement', 'Company', 'the Financial Accounting Standards Board', 'the European Community', 'organization)\\n    &#160;\\n', 'Defendants Hukui Technology, Inc.', 'legal\\nproceedings', '\\n    &', 'met.\\n\\n&#160;\\n\\nThe\\nCompany'}"
COEP,"{'ASC', 'AG Note', 'LLC', 'Working Capital Loans', 'VyGen-Bio, Inc. (&', 'Deverra', 'redemption.\\n  \\n&#160;\\n\\nIf the Company', 'the University of Pittsburgh.\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'Principal Financial Officer', 'Vy-Gen\\ndrug', 'the Company (&#8220;Lender&#8221;)\\nentered', 'Coeptis Therapeutics', 'mAbs', 'Vy-Gen\\nentered', 'INCOME TAXES\\n\\n&#160;\\nFor', 'exclusive\\nlicense', 'Holder 8 &#8211', 'summarized\\nin', 'Vy-Gen', 'the Public Warrants', 'LLC (&#8220;Vici&#8221;).\\nThrough', 'SynNotch', 'Placement Warrants', 'Vici Health Sciences', 'Holder 12 &#8211', 'the Company&#8217;s\\nPrivate Placement Warrants and Public Warrants', 'The Public Warrants', 'Holder 21 &#8211', 'CAR', 'FDA', 'Alexander Deiters', 'five\\n(5', 'into\\na Shared Services Agreement', 'Shared Services', 'Vycellix, Inc.', 'Therapeutics, Inc.', 'Holder 3 &#8211', 'disclosure.\\n\\n&#160;\\n\\nOur', 'SSA', 'LICENSE', 'Holder 22 &#8211', 'Killer (&#8220;NK&#8221', 'the AG Note', 'Coeptis\\nTherapeutics, Inc.', 'APA', 'United\\nStates', 'milestones.\\n\\n&#160;\\n\\nNOTE 4 &#8211', 'Northland', 'myeloid', 'Coeptis Pharmaceuticals', 'and\\n  \\n    &', 'the Private Placement Warrants', 'Company', 'the Financial Accounting Standards Board', 'Holder 6 &#8211', 'Holder 1 &#8211', 'Holder 7 &#8211', 'the Business Combination', 'FHCRC', 'Operations', 'GEAR', 'Coeptis Therapeutics, Inc.', 'Merger', 'Deverra (&#8220;Borrower&#8221;)', 'right\\nto', 'the University of Pittsburgh', 'Public Warrants', 'the Agreement the Company', 'VyGen-Bio, Inc.', 'future.\\n\\n&#160;\\n\\nWe', 'Imperial', 'No Public Warrants', 'different\\nmonoclonal'}"
COGT,"{'\\n  &#x2022;competition', 'Guggenheim Securities', 'Form S-3', '\\n  &#x2022;payments', '\\n    Interest income\\n    &', 'PEAK', 'the U.S. Patent and Trademark Office', 'Contractual Obligations', '\\n    Property &', '\\n  &', 'CompensationThe', '\\n    Preclinical', '\\n  &#x2022;the', 'x2014;\\n        &', 'the European Patent Office', 'FDA', 'the Cogent Research Team', '4,752\\n        &', '\\n    Laboratory', 'CVR', '\\n  &#', 'x2022;a', '\\n  Interest Income\\n  Interest', 'Indicate', 'Plexxikon', 'the &#x201c;License', 'SUMMIT', '\\n    Research', 'plan\\n    &', 'plan\\n        &', '\\n        &', 'SEC', 'LLC (&#x201c;Guggenheim', 'activities\\n    &', 'Company', 'the Securities Exchange Act', '\\n  &#x2022;facilities', 'compensation)\\n    &', 'INC', '\\n  &#x2022;laboratory', 'Specified Claims', '\\n  &#160;\\n', 'Comparison', 'CO', '\\n    &', '\\n  &#x2022;expenses', '\\n  &#x2022;our'}"
COLL,
COO,"{'\\n  &#x2022;injury', 'years)\\n        &', 'LLC', 'AMD', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n    Interest income\\n    &', '\\n  &#x2022;variations', '\\n  Commission File Number 001-39782', '\\n', 'Medicaid Innovation (&#x201c;CMMI&#x201d;)', '\\n  &#x2022;expansion', 'the University of PennsylvaniaOn April 21, 2023', 'EMA', '\\n  &#x2022;disruptions', 'the Regents of the University of California', '\\n  &#x2022;an', 'Rights Agreement', 'Uneek Mehra\\n', '\\n  &#x2022;termination', 'this Quarterly Report on Form 10-Q', 'the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program', 'the University of California The Company', 'Jefferies LLC', '223,327\\n    &', '\\n  &#x2022;costs', 'B.V. (&#x201c;uniQure&#x201d', 'Molecular Therapeutics, Inc.', 'x2022;a', 'UNITED STATES', 'Effects of Inflation\\n', 'the &#x201c;License', '\\n    Research', 'AGT the Transferred Material', 'UC Agreements', 'ACA', 'Segment Information The Company', 'the Securities Exchange Act', '\\n  &#x2022;expenditures', 'the S-3 Registration Statement', 'COVID-19', 'the License Agreement).Aevitas Therapeutics, Inc.', 'the University of Pennsylvania', 'the Company&#x2019;s 2022 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'the Funding Agreement', 'Registration Statement on Form S-1', 'FASB', '2022\\n         \\n         \\n          &#160;Customer', '\\n  &#x2022;product', 'DirectorPrincipal Executive', '\\n  &#x2022;sufficient', 'the &#x201c;UC Agreements&#x201d', '\\n  &#x2022;publicity', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'CFF', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;general', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'Licensed Products', 'requirements.\\n  &#x2022;Our', 'parties)\\n    &', 'and\\n  &#', 'Registration Statement on Form S-3', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'Center for Medicare &', '\\n  &#x2022;others', 'the Medicaid Drug Rebate Program', 'the Amended uniQure Agreement', 'x201c;CFF', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;loss', '\\n  &#x2022;new', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '99%\\n          &#160;\\n', 'Catalent', 'USPTO', '\\n  &#x2022;impose', '\\n  &#x2022;seize', 'DME', '\\n    &#', 'Report', 'the Delaware General Corporation Law', '\\n  &#x2022;diligence', '\\n  ', 'Capital Requirements \\n', 'the UC Agreements', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD', 'UK Data Protection Act 2018', '\\n  &#x2022;future', 'the Program Advisory Group', '\\n  Interest Rate Sensitivity', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'the Sales Agreement', '497\\n        &', '\\n  &#x2022;coverage', 'Roche', '\\n  &#x2022;exhaustion', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;commencement', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;retention', 'Registrant', 'the UC Regents', '\\n          &', 'technologies.\\n  &#', 'Condensed Statements of Operations', '10\\n       &', '\\n  &#x2022;announcement', 'IPO', 'AWA', '\\n  &#x2022;The', 'companies&#x2019', 'ASU No', 'the Amended uniQure Agreement or the Second uniQure Agreement', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Therapeutic Vector Evolution', 'Form S-3', '\\n  &#x2022;convenience', 'the License Agreement', 'GA', '\\n  &#x2022;We', 'the Funding Agreement Product (&#x201c;Acceptance&#x201d;)', 'the &#x201c;August 2023', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '500\\n    &', 'harmed.\\n  &#x2022;Our', 'European Union', 'Condensed Statements of Comprehensive Loss', '99%\\n          &#', 'the State of Delaware', 'x2022;refuse', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', '\\n  &#x2022;suspend', 'frames.\\n  &', '\\n  &#x2022;the FDA', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Related Party Transactions', 'the Court of Chancery', 'Significant Accounting Policies', 'the &#x201c;Funding Agreement', '\\n        &', 'SEC', 'ATM Offering', 'agreements.\\n', 'Collaboration and License Agreement', 'BLA', 'The CFF Agreement', 'the Centers for Medicare &', 'the University of California and The Trustees of the University of Pennsylvania', '\\n  &#x2022;failure', 'Aevitas Therapeutics, Inc. (&#x201c;Aevitas&#x201d;)', '\\n  &#x2022;reduced', 'the European Union', '\\n  Litigation', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
CORT,
COSM,
COYA,"{'ASC', 'Houston Methodist Research Institute', 'compensation\\n    &', 'FASB', '\\n  &#x2022;develop', 'the Methodist License Agreement', 'ASU', '\\n  &#x2022;add', 'Initial Public Offering\\n  ', 'candidates;\\n  &#x2022;the', '\\n  &', 'SRA', '\\n  &#x2022;initiate', '\\n  &#x2022;acquire', 'Exhibits.\\n  &#160;\\n', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'FASB.&#160;In', 'Houston Methodist Hospital', '\\n    External costs:\\n    &', 'DRL', 'Commercialize,&#x201d', '\\n  &#', 'HMRI', 'personnel;\\n  &#x2022;costs', 'and\\n  &#x2022;incur', '\\n    &', 'Dr. Reddy&#x2019;s Laboratories', '\\n  &#x2022;continue', 'Financial Instruments - Credit Losses', 'capabilities;\\n  &#x2022;the', '\\n    Research', 'the ARS License Agreement', 'the Methodist License', 'Form S-1', 'fees.\\n  &', 'SEC', 'DRL Agreement).\\n  &', 'In-Process Research', 'Company', 'the Securities Exchange Act', 'Sponsored Research Agreement', 'commercialization;\\n  &#x2022;the', 'License and Supply Agreement', 'the Company&#x2019;s Current Report', 'Houston Methodist Research Institute\\n', 'Measurement of Credit Losses on Financial Instruments', 'DRL Agreement', 'Methodist', 'the Methodist License Agreement.&#160;Sponsored Research Agreement', '\\n    Internal costs:\\n    &', 'technologies;\\n  &#x2022;expenses', 'the DRL Agreement', 'The Methodist Hospital', 'Equity Securities', 'Adopted Pursuant to Section 302', 'the Sarbanes-Oxley Act', '17\\n', 'Comparison', '\\n    Internal', 'all.\\n  &', 'Amended and Restated Patent Know How and License Agreement', 'Houston Methodist'}"
CPIX,
CPRX,
CPSI,"{'NTD100.0&#160;million', 'the Company&#8217;s Annual Report on Form 10-K', 'Board', 'the New CTBC Credit Lines', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#8212;(Continued)(Unaudited)Property', 'TO CONDENSED CONSOLIDATED FINANCIAL', 'Contents                                                       SUPER MICRO COMPUTER', 'Compuware', 'EstimatesOur', 'the Securities and Exchange Commission', 'Restricted Stock Units Notice of Grant and Agreement', 'PRSUs', 'the Compensation Committee', 'ReportingThe Company', 'Value DisclosureThe', 'Bade Manufacturing Facility', 'Ablecom', 'CTBC Bank', 'SMCI', 'CTBC Bank2023 CTBC Bank Credit LinesOn', 'AblecomThe Company', 'the Remaining Performance ObligationsRemaining', 'ProceduresUnder', 'Restricted', 'Determining Fair ValueThe', 'Company', 'Performance Stock Option', 'the Securities Exchange Act', 'The New CTBC Credit Lines', 'ProceduresEvaluation of Disclosure Controls', 'Foreign Currency', 'the Company&#8217;s Compensation Committee', 'CFO', 'net$291,669&#160;$290,240&#160;Accrued', 'ContentsCritical Accounting Policies', '10-K (Commission File No', 'Warranties', 'The &#'}"
CRBP,"{'ASC', 'LLC', 'The Amended Loan', 'ComputerHardwareAndSoftwareMember2023', 'Corbus Pharmaceuticals Holdings', 'Contracts with Customers (&#', 'the UCSF License Agreement', '4,450,361\\n        &', 'LendersMember2023', 'ComputerHardwareAndSoftwareMember2022', 'WarrantMember2022-01-012022-09-3000015950972022-12-310001595097us-gaap', 'Litigation Settlement', 'Financial Instruments', 'loss.&#160;The Company', 'InvestmentAgreementMember2023', 'DeferredTaxAssetsMember2023-01-012023-09-300001595097crbp', 'Financial Instruments&#x2014;Credit Losses', 'Indicate', 'the Amended Loan', 'Venn Therapeutics', '2022:&#160;\\n        \\n         \\n', 'and\\n  &#x2022;manufacture', 'WarrantMember2023-07-012023-09-300001595097us-gaap', 'Adopted Accounting', 'Corbus', 'Commission File', 'MaximumMember2023-09-300001595097us-gaap', 'Condensed Consolidated Statement', 'the Certificate of Incorporation', 'FASB', 'Company\\', 'Corbus Pharmaceuticals, Inc.', 'Security', 'x2014;\\n        &', 'expense.&#160;&#160;-11-\\n      Accruals for Research and Development Expenses and Clinical', 'THE SECURITIES EXCHANGE ACT OF', 'the Licensed Products', 'Licensed Products', 'agreements.\\n  &', 'Loan', 'x25cf;\\n', 'charter)\\n  &#160;\\n', 'Panorama Research Inc.', 'WarrantMember2022-07-012022-09-300001595097us-gaap', 'reductions.&#160;The Company', 'TwoThousandFourteenEquityIncentivePlanMember2014-04-012014-04-300001595097us-gaap', 'Company', 'candidates;\\n  &#x2022;continue', '\\n  Management', 'The Series A Preferred Stock', 'CSPC Megalith Biopharmaceutical Co., Ltd (&', 'the CSPC License Agreement.&#160;The Company', 'KTwoHealthVenturesLLCMember2022', 'Financial Instruments&#x2014;Credit', 'FAIR VALUE OF FINANCIAL ASSETS', '\\n    &#', 'Condensed Consolidated Financial Statements', 'ASU', 'Condensed Consolidated Statements of Operations', 'studies.\\n  &', 'and\\n   ', 'Compensation', 'LLC (&#x201c;Milky Way&#x201d;)', 'the &#x201c;UCSF License Agreement&#x201d', 'Credit Risk&#160;The Company', 'License Agreement', 'CSPC Pharmaceutical Group Limited', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'the Jenrin License Agreement', '\\n  &#', 'term.\\n  &', 'concern.\\n  &', 'program.&#160;The Company', 'the Certificate of Designation of the Series A Preferred', '\\n          &', 'we:\\n  &#', 'Condensed Consolidated Balance Sheets', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001595097us-gaap', 'FairValueMeasurementsRecurringMember2023', '4,170,466\\n          &', 'Comparison', 'UCSFLincenseAgreementMember2023-07-012023-09-300001595097us-gaap', 'the Jenrin License Agreement and CSPC License Agreement', 'the Milky Way License Agreement', 'K2WarrantMember2023-09-300001595097us-gaap', 'SeriesAPreferredStockMember2022-12-200001595097us-gaap', 'the &#x201c;Milky', 'MaximumMember2023-01-012023-03-310001595097crbp:TwoThousandFourteenEquityIncentivePlanMember2023-01-010001595097us-gaap', 'LeaseholdImprovementsMember2022-12-310001595097us-gaap', 'WarrantMember2023-01-012023-09-300001595097us-gaap', '\\n  &', 'FairValueMeasurementsRecurringMember2022-12-3100015950972021-05-262021-05-260001595097crbp', 'ROU', 'the Jenrin Agreement', 'UCSFLincenseAgreementMember2023-12-302023-12-300001595097crbp', 'JefferiesLLCMember2023-05-310001595097us-gaap', 'JefferiesLLCMember2023-01-012023-09-300001595097crbp', 'KTwoWarrantMember2020-07-282020-07-280001595097us-gaap', 'The Jenrin Agreement', 'Accounting Standards Codification', 'Research and Development', 'liabilities.&#160;To', 'Issued Accounting Pronouncements&#160;The Company', '\\n        &', '4,423,617\\n          &', 'timely.\\n  &#160;\\n', 'MaximumMember2023-02-122023-02-120001595097crbp', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001595097us-gaap', 'No &#9744;\\n', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001595097crbp', 'the Regents of the University of California (&#x201c;The', 'KTwoWarrantMember2020-07-280001595097srt', 'Financing &', '\\n    &'}"
CRBU,"{'licensees1,564&#160;1,594&#160;(30)Total', 'Exclusive License Agreement for Veterinary Therapeutics', 'Pfizer', 'the Securities Purchase Agreement', 'BCMA Product Candidate', 'Form S-3', 'Restated Certificate of Incorporation of Caribou Biosciences, Inc.', 'September&#160;30, 2023.Emerging Growth Company', 'Pfizer 4,690,431', 'The Shelf Registration Statement', 'Pfizer, Inc. (&#8220;Pfizer&#8221;)', 'AbbVie Manufacturing Management Unlimited Company (&#8220;AbbVie&#8221', 'Contentscondensed', 'the Grant of Program Rights', 'ActivitiesNet', 'the Current Report on Form 8-K', 'Registration StatementOn', 'ContentsTo', 'the Edge Cas9 License Agreement', 'StockCommon', 'Development ExpensesResearch', '8220;B2M&#8221', 'Issued Accounting PronouncementsSee Note', 'net10,654&#160;2,421&#160;8,233&#160;Total', 'FDA', 'RequirementsOur', 'Restated Bylaws of Caribou Biosciences, Inc.', 'Jefferies LLC (&#8220;Jefferies&#8221', 'Principal Executive Officer Pursuant', 'Development AgreementsWe', 'the Information Rights Agreement', 'the Sarbanes-Oxley Act of', 'CRISPR-Cas9', 'ContingenciesResearch', 'Registrant', 'Principal Executive Officer Pursuant to Rules', 'the Collaboration and License Agreement', 'Delaware General Corporation Law', '2023.Stock-Based Compensation ExpenseWe', 'SEC', 'the Shelf Registration Statement', 'SegmentsWe', 'the Pfizer Investment', 'AbbVie', 'Edge', 'Adopted Pursuant to Section 302', 'the Sarbanes-Oxley Act', 'Exclusive License', 'Credit Risk and Other UncertaintiesFinancial', 'Principal Financial Officer Pursuant', 'administrative28,740&#160;29,486&#160;(746)Total', 'the U.S. Securities and Exchange Commission', 'company.&#8221', 'the &#8220;AbbVie'}"
CRDF,"{'ASC', 'Spine', 'LLC', 'Financial Services', 'nerves.\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'Board', 'Cardiff', 'View Properties, Inc.', 'Instruments Issued', 'results.\\n\\n&#160;\\n\\n&#160;\\n\\n\\n17.SEGMENT REPORTING\\n\\n&#160;\\n\\nThe Company', 'Platinum', 'PLLC', 'reporting&#160;\\n    &', 'development.\\n\\n&#160;\\n\\nWe', 'Nevada.\\n\\n&#160;\\n\\nCardiff', 'Critical Accounting', 'Platinum Tax', 'the Securities and Exchange Commission', '2022.\\n\\n&#160;\\n\\n&#160;\\n\\n\\n13.DISCONTINUED OPERATIONS\\n\\n&#160;\\n\\nThe Company', 'the FASB ASC', 'sales&#160;\\n    &#160;2,086,109&#160;&#160;\\n    &', 'compared\\nto', 'Nova', 'Disclosure Controls', 'Tax Defenders', 'Leonite Capital', 'DML HC Series', 'efforts\\nto', 'Financial\\nReporting\\n\\n&#160;\\n\\nWe', 'the Series N Preferred Stock', 'AHI', 'series\\nX', 'debt&#160;\\n    &', 'Healthcare', 'Edge View\\nProperties, Inc.', 'Salmon\\nRiver', 'Note\\n10', 'agreement\\nwith', 'Edge View,\\na', 'SILAC Insurance Company', 'Item 9A &#8220;Controls', 'the Frank Church Wilderness Area', 'sales&#160;\\n    &', 'ninth\\ntranche', '\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'SEC', 'N', 'Company', '\\n\\n&#160;\\n\\n&#160;\\n\\n\\n18.SUBSEQUENT EVENTS\\n\\n&#160;\\n\\nThe Company', 'Consolidated assets&#160;\\n    ', 'Internal Control Over', 'equity\\nline item.\\n\\n&#160;\\n\\nThe Company', 'MDR', '\\n    &', 'ASU No', 'Results of Operations &', 'Edge View'}"
CRDL,
CRGX,"{'years)\\n        &', 'candidates;\\n  &#x2022;the', 'Oxford', 'allogenic', 'the New York Stock Exchange', '\\n  &#x2022;potentially', 'Exhibits.\\n  &#160;\\n', 'this Quarterly Report on Form 10-Q', '\\n    Laboratory', 'of:\\n  &#x2022;direct', 'Lease Agreement', '\\n    Research', 'NCI', '\\n    Direct costs:\\n    &', 'x201c;Reverse Stock', 'Form S-1', 'Research', 'COVID-19', 'Unaudited Condensed Financial Statements&#160;Liquidity', 'FASB', 'reference.\\n  &', 'Rule 424(b)(4', 'Accrued', 'x2014;\\n        &', 'Unaudited Condensed Financial Statements&#160;million', 'manufacturers,\\n  &#x2022;expenses', 'and\\n  &#', 'depreciation\\n        &', 'activities\\n    &', 'Unaudited Condensed Financial', 'Company', 'candidates;\\n  &#x2022;continue', 'Unaudited Condensed Financial Statements&#160;\\n      \\n       \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n       \\n       \\n         \\n        &', 'milestone\\n        &', '\\n  &#x2022;laboratory', '\\n    Interest expense\\n    &', '\\n  &#x2022;addressing', 'including:\\n  &#x2022;costs', 'Unaudited Condensed Financial Statements&#160;Crystal Mackall', 'the Oxford Agreement', 'we:\\n  &#x2022;advance', 'use.\\n  &#x2022;indirect', '32\\n', 'the Lease Agreement', '\\n  &#x2022;the', '\\n    Consulting', 'the U.S. Department of Health and Human Services', 'the Nasdaq Stock Market', '\\n  &#', 'the Series A Agreement', 'Stanford University', 'candidates;\\n  &#x2022;establish', 'including:\\n  &#x2022;personnel', 'acquire;\\n  &#x2022;the', 'the Stanford License Agreement', 'the Series A Preferred Stock Purchase Agreement', 'and\\n  &#x2022;costs', 'IPO', 'NCI License', 'Comparison', 'ClassificationA', 'x201c;anticipate,&#x201d; &#x201c;believe,&#x201d', 'the Company&#x2019;s Board of Directors', '\\n  &#x2022;health authority', 'the Board of Directors', 'candidates;\\n  &#x2022;attract', 'The National Cancer Institute', '7,021\\n        &', 'the Nasdaq Stock Market&#x2019;s National Market', 'IPR&amp;D', 'No  &#9744;\\n  Indicate', 'SPAC', 'SEC', 'agreements.\\n', 'cost\\n        &', 'Equity Securities', '\\n    &'}"
CRIS,
CRMD,"{'ASC', 'CORMEDIX', 'LPAD', 'Cover Page Interactive Data File', 'Regulation S-K.\\n\\n&#160;\\n\\n\\n\\n\\n', 'TauroLock-HEP500', 'Name:\\n', 'NDP', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'European Patent EP', 'the NDP Technology', 'Alcami Corporation', 'ATM', 'the Underwriting Agreement', 'Medicaid', 'product\\nthat', 'this Quarterly Report on Form 10-Q', 'ND Partners LLP&#8217;s', 'the European Patent Office', 'the German Unfair Competition Act', '\\n    \\n\\n&#160;\\n\\nCORMEDIX INC', 'FDA', 'Prospectus Supplement', 'TauroPharm GmbH', 'Court', 'DefenCath', 'Internal Control Over Financial', 'Continued\\n\\n\\n&#160;\\n\\nThe Company', 'PMA', 'U.S. Treasury', 'the Prescription Drug User Fee Act', 'NDA', 'Principal Executive', 'SEC', 'discounts\\nand', 'CRL', 'TauroPharm', 'Centers for Medicare &', 'Company', 'term.\\n\\n&#160;\\n\\nThe Company\\nhas', 'CMO', 'the Securities Exchange Act', 'the Prosl European Patent', 'Tauro-Implant GmbH', 'the Sarbanes-Oxley Act', 'CorMedix', 'property.\\n\\n&#160;\\n\\nWe', '\\n    &'}"
CRNX,"{'Item 408 of Regulation S-K. \\n  &', 'Form S-3', 'the Sanwa Clinical Supply Agreement', 'the Sanwa License', 'Loyal', 'the National Institutes of Health', 'PBO', 'CAH', 'the 2021 Shelf Registration Statement', 'the Australian Taxation Office', 'VIE', '\\n  &', 'GFR', 'ULN', 'Radionetics of', 'Sanwa Kagaku Kenkyusho Co., Ltd.', 'x201c;Financial Instruments - Credit Losses', 'the 2022 Lease', 'Revenue RecognitionThe Company', 'ESPP', 'the Radionetics License', 'NIDDK', 'the Sales Agreement', 'detected.\\n', 'ACTH', 'Radionetics', 'The U.S. Food and Drug Administration', 'FDA', 'PATHFNDR-1', 'NIH', 'Crinetics Australia Pty Ltd', 'RECOGNITIONSanwa Kagaku Kenkyusho Co.', 'RADIONETICSInvestment', 'ADPKD', '\\n  &#', '\\n          &#160;\\n', 'LiquidityFrom', 'IGF-1', 'SEC Rule 13a-15(b', 'Indicate', 'Radionetics Transaction', 'TEAE', 'the &#x201c;Sanwa', 'Accounting Standards Update', 'periods.\\n  Research', '\\n    Research', 'Sanwa License', 'Sanwa Clinical Supply Agreement', 'Registration Statement on', '\\n        &', 'the Loyal License', 'Tax Incentive Program', 'Restricted', 'Sanwa', 'ATM Offering', 'SEC', 'Collaboration and License Agreement', 'Company', 'the Financial Accounting Standards Board', 'the Company&#x2019;s 2018 Incentive Award Plan', 'the &#x201c;Loyal', 'PATHFNDR', 'thousands):&#160;10\\n         &', 'Cellular Longevity Inc.', 'HHM', 'the National Institute of Diabetes and', 'IGF-1 &#', 'Shelf Registration Statement', 'the Company&#x2019;s 2021 Shelf Registration Statement', 'plan\\n          &', 'Longevity, Inc.', 'Comparison', '\\n    &', 'the Radionetics Warrant', 'LAR', 'Loyal (&#34;Loyal&#34'}"
CRON,"{'Cronos GrowCo', 'ContentsSummary', 'Generally Accepted Accounting Principles', 'Financial Instruments &#8211', 'New Israeli Shekel', 'Class A Common Stock of PharmaCann', 'ExhibitsThe', 'the Compensation Committee', 'Cronos Fermentation', 'The Mucci Promissory Note', 'the Peace Naturals Campus', 'Altria Group Inc.', 'the Financial Accounting Standards Board', 'margin(i)16&#160;%15&#160;%N', 'Forward-Looking Statements', 'ContentsFor', 'Group Inc.Notes', 'September&#160;30,20232022Cannabis extracts1,029&#160;4,301&#160;Net revenue$1,029&#160;$4,301&#160;12Cronos Group Inc.Notes', 'Note 2 &#', 'ASU 2022-03', 'netLoans', 'The Israel-Hamas War', 'development1,2462,5414,39210,656General', 'ContentsThe', 'the Cannasoul Collaboration Loan.16Cronos Group Inc.Notes', 'Realignment', 'Loans Receivable', 'The Amended Statement of Claim', 'Company', 'ChangeAs', 'the U.S. Securities and Exchange Commission', 'Qualitative Disclosures About Market', 'Condensed Consolidated Financial Statements', 'ASU', 'conditions &', 'the Ontario Capital Markets Tribunal', 'the Ontario Business Corporations Act', 'expenses214&#160;1,683&#160;2,261&#160;8,750&#160;Interest', 'New Israeli Shekels', 'Board of Directors', 'Cronos Group$(1,644)$(36,991)$(29,173)$(89,850)34Table', 'ASU 2022-02', 'the Settlement Agreement', 'CurrencyTo', 'LivWell', 'Cannasoul Lab Services Ltd.', 'Private Securities Litigation Reform Act', 'Vintage Disclosures', 'the GrowCo Credit Facility', 'LiabilitiesPursuant', 'Cronos', 'Regulation S-K', 'ContentsOperating', 'the PharmaCann Option', 'receivable5,157&#160;8,890&#160;GrowCo Credit', 'ReportedAs Adjusted for Constant CurrencyThree', 'Board', 'SettlementOn', 'Ginkgo', 'this Quarterly Report', 'the Employment Inducement Award Plan', 'Note 7 &#8220;Restructuring&#8221', 'District Court', 'ReportedAs Adjusted', 'the Ontario Securities Act', 'ContentsBy', 'Regulation S-K).Item 6', 'OperationsDiscontinued', 'compensation(4)18&#160;17&#160;121&#160;Depreciation', 'the &#8220;Settlement', 'the U.S. Securities and Exchange Commission).2PART IFINANCIAL INFORMATIONTable of ContentsItem 1', 'Credit Facility$13,293&#160;$74&#160;$(929)$12,438&#160;Mucci Promissory Note91&#160;1&#160;(6)86&#160;Cannasoul Collaboration Loan377&#160;3&#160;(8)372&#160;$13,761&#160;$78&#160;$(943)$12,896&#160;As', 'Item 3 &#', 'Credit Losses', 'A1&#160;pp16&#160;%N/', 'Fair Value Measurement', 'Credit Facility$4,911&#160;$4,427&#160;Add', 'Credit Facility$11,579&#160;$(199)$(283)$11,097&#160;Mucci Promissory Note86&#160;2&#160;(2)86&#160;Cannasoul Collaboration Loan503&#160;4&#160;(14)493&#160;$12,168&#160;$(193)$(299)$11,676&#160;As', 'ContentsExpected', 'ContentsAs ReportedAs Adjusted for Constant'}"
CRSP,"{'ASC', 'MaxCyte, Inc.', 'the ViaCyte JDCA Amendment', '\\n  &#x2022;effectively', 'The ViaCyte JDCA', '20\\n', 'costs.\\n  Collaboration Expense', '\\n', 'Condensed Consolidated Statements of Operations and Comprehensive Loss \\n', 'Vertex JDCA', 'TDT', 'Moffitt Cancer Center', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', '\\n  &#x2022;costs', 'programs.\\n', 'x2022;a', '\\n    Research', 'the Non-Ex License Agreement', 'the Financial Accounting Standards Board', 'CRISPR/Cas9', 'Jefferies', '\\n  &#x2022;establishing', '\\n  &#x2022;obtaining', 'and\\n  &', 'FASB', 'the Vertex Agreements', 'Significant Accounting Policies,&#x201d', '\\n  &#x2022;fees', '\\n  Research and Development Expenses \\n  Research', 'CureVac AG', 'x2014;\\n        &', 'FDA', 'Vertex\\', 'Rule 10b5-1', '2023.New Accounting Pronouncements &', 'Company', 'Significant Accounting PoliciesThe', 'Roswell Park Comprehensive Cancer Center', '\\n  &#x2022;achieving', 'Condensed Consolidated Financial Statements', 'KSQ Therapeutics, Inc. on', 'Condensed Consolidated Statements of Operations', 'JDA', 'Sales Agreement', '\\n  &#', 'Vertex', 'Financial Overview\\n', 'Condensed Consolidated Balance Sheets', 'Orphan Drug Designation', 'CRISPR Therapeutics AG', 'Vertex for Vertex', 'Comparison', 'CHF', '\\n  &#x2022;enforcing', 'DMD', 'the Board of Directors', 'Accounting Analysis', '\\n    Provision', '\\n  &', 'SCD', 'ViaCyte, Inc.', 'Capsida Biotherapeutics, Inc.', 'the Non-Ex License AgreementAs', 'Condensed Consolidated Financial Statements\\n    ', 'ViaCyte', 'the ViaCyte JDCA', '\\n  &#x2022;consultant', '\\n  &#x2022;facility', 'Note 2', '\\n  &#x2022;successful', '\\n        &', 'SEC', 'obligationsThe Company', 'ViaCyte JDCA', '\\n    &', '\\n  &#x2022;receipt', 'property.\\n'}"
CRVO,"{'Impaired', 'The Budget Control Act', 'Vertex&#x2019;s', 'EMA', 'DLB.&#xa0', 'Principal Executive Officer', 'this Note Regarding Forward-Looking Statements', 'Pre-Funded Warrant', 'Food and Drug Administration\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tFDIC\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tFederal Deposit Insurance', 'NIA', 'Bayh-Dole', 'ACA', 'the &#x201c;Sunshine', 'the Children&#x2019;s Health Insurance Program', 'the Securities Exchange Act', 'NOL', 'Statements\\n\\n&#xa0;\\n\\nThis Quarterly Report', 'the Company&#x2019;s Business, Financial Position', 'COVID-19', 'CNS', 'the American Arbitration Association', 'Trademark Office\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tVertex\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tVertex Pharmaceuticals Incorporated\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\n&#xa0;\\n\\n\\n1\\n\\n\\n\\n\\nTable', 'the Certificate of Incorporation', 'the Convertible Notes', 'Failure', 'FASB', 'Anti-Kickback Statute', 'The License Agreement', 'Bribery', 'non-U.S. manufacturers.\\n\\n&#xa0;\\n\\nThe Company', 'Medicaid', 'Medicare', 'Congress', 'FDA', 'administrative\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tGDPR\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tEU General Data Protection Regulation\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tHIPAA\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tthe Health Insurance Portability', 'Generic', 'HIPAA', 'the Company Common Stock', 'REMS', 'Merger.\\n\\n&#xa0;\\n\\nThe', 'Company', 'ANALYSIS OF &#', 'USPTO', 'Nonclinical', 'Rule 15d-14(b).\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t101.INS*\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\tInline XBRL Instance', 'Department of Justice', 'Unaudited Condensed Consolidated Interim Financial Statements\\n\\n\\n\\n\\n&#xa0;\\n\\nDefined Contribution Retirement Plan\\n\\n&#xa0;\\n\\nThe Company', 'CRO', 'the Good Laboratory Practice', 'AIA', 'CMS', 'XBRL Taxonomy Extension Definition', 'AI EIPP Holdings', 'loss\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tp38&#x3b1;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tp38', 'Yes &#x2610', 'FCPA', 'CDR-SB', 'use.\\n\\n&#xa0;\\n\\nThe Company', 'License Agreement', 'Efforts', 'the Department of Health and Human Services', 'Unaudited Condensed Consolidated Interim Financial', 'The Federal Trade Commission', 'the Difffusions Amended Registration Statement on Form S-4', 'IRB', 'License', 'application\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tNIA\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tthe National Institute on Aging of', 'approval.\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nThe Company', 'the U.S. Supreme Court', 'Phase 2a', 'Diffusion Pharmaceuticals Inc.', 'all.\\n\\n&#xa0;\\n\\nThe Company', 'Pursuant', 'CMO', 'IRA', 'the License Agreement with Vertex', 'BFC', 'the Sarbanes-Oxley Act', 'AMP', 'Capital', 'EOAD', 'ASU No', 'Federal', 'Enforcing', 'the License Agreement', 'EIP', 'this Quarterly Report', 'healthcare', 'the Board of Directors', 'Good Clinical Practices', 'the California Labor Code', 'Proceedings', 'Contingencies \\n\\n&#xa0;\\n\\nOperating Leases\\n\\n&#xa0;\\n\\nThe Company', 'the Internal Revenue Service', 'the Registrant&#x2019;s Current Report', 'United', 'the U.S. Treasury Department', 'SEC', 'GCP', 'the United States', 'Data Safety Monitoring Board', 'the National Institutes of Health\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tNOL\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tnet', 'CervoMed Inc.', 'Page Interactive Data File', 'the European Union', 'Nasdaq', 'DLB'}"
CRVS,"{'ASC', 'Corvus Biopharmaceuticals, Ltd.', 'ASU', 'respectively.&#8203;In August 2021', 'the Employee Stock Ownership Plan (&#8220;ESOP&#8221;)', 'Other Current Assets&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Interest receivable&#8203;$', 'rights;&#9679;it', 'CCPA', 'The Scripps Research Institute', 'Investigational New Drug Applications', 'Contentshowever', 'Medicare', 'Contentscollaborative', 'RCC', 'Credit Risk and Other Risks', 'Biologics License Application', 'the Patient Protection', 'Scripps', 'GDPR', 'EU', 'FDA', 'the Kidney Cancer Research Consortium', 'CTR', 'ContentsAny', 'Monash University (Monash', 'Monash of $', 'Corvus Hong Kong Limited', 'Jefferies LLC (&#8220;Jefferies&#8221', 'this Quarterly Report on Form&#160;10-Q.', 'the Nasdaq Global Stock Market (&#8220;Listing', 'the Health Care and Education Reconciliation Act', 'Internal Revenue Service', 'Kyowa Hakko Kirin', 'NSCLC', 'Risks Related', 'Months Ended &#', 'Related Party', 'Form S-1', 'Treasury', 'Balance Sheet Components', 'ContentsWe', 'ACA', 'Company', 'The European Parliament and Council', 'Novartis', 'markets;&#9679;we', 'BTK', 'USPTO', 'Jefferies', 'COVID-19', 'ContentsRisks Related', 'IPO', 'a New Drug Application', 'The Nasdaq Global Market (&#8220;Nasdaq&#8221;)', 'Scripps of $', 'Angel Pharmaceuticals', 'Nasdaq', 'ContentsFor', 'Earthquakes'}"
CSBR,
CSTL,
CTCX,"{'Sellers', 'ASC', '\\n  &#x2022;injury', 'and\\n  &#x2022;exemptions', '\\n', 'the Business Combination Agreement', 'State', 'tibia', 'the Warrant Agreement', 'General Data Protection Regulation', 'the Federal Reserve', '\\n  &#x2022;termination', 'Non-Redemption Agreement', 'the &#', 'Meteora Select Trading Opportunities Master', '\\n  &#x2022;compliance', 'the Public Company Accounting Oversight Board', '\\n  &#x2022;differing', 'the Call/Put Option Pricing Model', '\\n  &#x2022;foreign', 'the Company&#x2019;s Third Amended and Restated Certificate of Incorporation', 'the Securities Exchange Act', 'Regen Med Corporation', '\\n          &#', 'Except', '\\n  &#x2022;production', 'Certificate of Incorporation', 'COVID-19', '5,376,139\\n          &#160;\\n          &#160;\\n', 'Note 9 &#', 'treatment;\\n  &#x2022;the', '\\n  &#x2022;workforce', '\\n  &#x2022;obtaining', 'Notice of Acceleration', 'x201c;Carmell', 'the Reset Price', '\\n  &#x2022;significant', 'Alpha Healthcare Acquisition Corp. III', 'Internal Control Over Financial Reporting\\n  Other', 'Medicaid', 'Medicare', 'Item 408 of Regulation S-K).\\n  Item 6', 'Fair Value\\n          &', 'products;\\n  &#', 'FDA', 'the Forward Purchase Agreement', 'reporting.\\n  &', 'Meteora Special Opportunity Fund I', '\\n  &#x2022;Our', 'x201c;Forward Purchase', '\\n  &#x2022;loss', 'IIIB', 'x201c;Common', 'Carnegie Mellon University', 'MCP', 'Common Stock', 'Company', 'the Department of the Treasury', 'and\\n  &#x2022;the', 'Business Combinations', 'Aztec Merger Sub, Inc.', 'technology.\\n  &#x2022;If', 'the &#x201c;Legacy Carmell', '\\n  &#x2022;unexpected', 'SVB', 'Segment Reporting', 'SBA Loan\\n          &', 'Patent and Trademark Office', 'Signature Bank', 'Fair Value Measurements', '\\n  ', 'products.\\n  &#x2022;We', 'Meteora Capital Partners', 'Critical Accounting Policies', 'statements.\\n  Cautionary Statement Regarding Forward-Looking Statements \\n', '\\n  &#x2022;establishment', 'x201c;Carmell Therapeutics Corporation', 'the Holders (&#x201c;Puritan&#x201d;)', 'Contractual Obligations and Commitments \\n', '\\n  &#x2022;the', 'the AxBio Closing Date', 'the U.S. Department of Health and Human Services', 'IRB', '\\n  &#', 'Axolotl Biologix Acquisition\\n', 'practices.\\n  &#160;\\n', 'the &#x201c;Exchange', '\\n  &#x2022;diversion', 'Healthcare Laws', '\\n  &#x2022;decreased', '\\n  &#x2022;require', 'Fair Value\\n         \\n         \\n          &', '\\n          &', 'Alpha Healthcare Acquisition Corp.', 'Carmell Therapeutics Corporation', '\\n  &#x2022;reaching', 'medications;\\n  &#x2022;the', 'FDIC', '10\\n       &', 'the Sarbanes-Oxley Act', 'Going Concern and Management Plan\\n', 'IPO', '\\n  &#x2022;mandate', 'Carrying\\n          &', 'This Quarterly Report', 'effects.\\n  &', '\\n  &#x2022;our', 'the Notice of Acceleration', 'the License Agreement', 'Board', '\\n  &#x2022;We', 'Axolotl Biologix, Inc. (&', '\\n  &', 'CMU', 'AxBio Acquisition', 'and\\n  &#x2022;identifying', 'the Puritan Convertible Note Warrants', 'Statements of Operations', '\\n  &#x2022;business', 'x2022;refuse', 'Medicaid Services', '\\n  &#x2022;suspend', '\\n  &#x2022;efficacy', 'the AxBio Acquisition', 'Distinguishing Liabilities', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'MSTO', '\\n        &', 'ASC 480', '\\n        \\n         \\n', 'SEC', 'AxBio', 'the United States Patent and Trademark Office', 'the Business Combination', 'Carmell\\', 'the Centers for Medicare &', 'Puritan Partners', 'Carmell', 'the European Union', 'Nasdaq', '\\n    &', '\\n  &#x2022;receipt', 'Government Regulation &'}"
CTKB,"{'Physician Payments Sunshine Act', 'the UK&#8217;s International Data Transfer Agreement / Addendum', 'VAT', 'The Sarbanes-Oxley Act', 'EEA', 'this Quarterly Report on Form 10-Q', 'RUO', 'NO &#9744;Indicate', 'Sensitive Information', 'CPRA', 'Piper Sandler &amp', 'Form S-1', 'market&#8221', 'Anti-Spam Legislation', 'the Securities Exchange Act', ': &#8226;identifying', 'Cytek Biosciences', 'warranty2,782&#160;2,126&#160;Other1,019&#160;1,356&#160;Total', 'Fair', 'Anti-Kickback Statute', 'the National Institutes of Health', 'February&#160;13', 'Contentsparties', 'Medicaid', 'Medicare', 'the Delaware General Corporate Law', ': &', 'FDA', 'NIH', 'Luminex', 'ContentsThe', 'Cytek', 'Contentsmay', 'BD', 'Company', 'USPTO', 'FCA', 'Overview', 'the Delaware General Corporation Law', ': &#8226;inadequate', 'Luminex Corporation (&#8220;Luminex&#8221', 'Impairment of Long-Lived Assets Long', 'Co. (&#8220;Piper&#8221', ': &#8226;decreases', 'CMS', 'Company (&#8220;BD&#8221', 'ImageStream Developed Technology8,900&#160;6Guava', 'the California Privacy Protection Agency', 'Dickinson and Company (&', 'FCPA', 'the Personal Information Protection and Electronic Documents Act', 'Patrik JeanmonodPatrik JeanmonodChief Financial Officer(Principal Financial and Accounting Officer)89\\n\\n\\n', 'the U.S. Department of Health and Human Services Office of Inspector General', 'Registrant', 'the Children&#8217;s Health Insurance Program', 'CLC', 'ContentsAccrued', 'Preferred Stock', 'ContentsOperating', 'IPO', 'Form S-3', 'net48,000&#160;40,477&#160;134,782&#160;115,700&#160;Cost', 'the Board of Directors', 'District Court', 'the Court of Chancery of the State of Delaware', 'the Coherent Agreement', 'PMA', 'Customer deposits$1,645&#160;$1,555&#160;Income', 'OIG', 'this Quarterly Report on Form 10-Q.Sources', 'Coherent NA, Inc. (&#8220;Coherent&#8221', 'SEC', 'netProduct$38,441&#160;$36,389&#160;$2,052&#160;6&#160;%$110,065&#160;$104,963&#160;$5,102&#160;5&#160;%Service9,559&#160;4,088&#160;5,471&#160;134&#160;%24,717&#160;10,737&#160;13,980&#160;130&#160;%Total', 'FCI', 'the European Union', 'Nasdaq', 'YES &#9746', 'the Registration Statement'}"
CTMX,"{'RNA', 'LLC', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', 'candidates.\\n  &#x2022;If', 'price.\\n  Research and Development Expenses\\n', 'LeaseAgreementsMember2023-01-012023-09-3000015019892021-12-310001501989us', 'candidates;\\n  &#x2022;the', 'The Sarbanes-Oxley Act', 'all;\\n  &#x2022;delays', 'AbbVieIrelandUnlimitedCompanyMember2022-01-012022-12-310001501989us', 'the Amgen EGFR Products', 'Collaboration Programs', 'BMS-986249', 'Restricted CashThe Company', 'the Orphan Drug', 'Biologics License Application', 'this Quarterly Report on Form 10-Q', 'the product;\\n  &#', 'collaborators;\\n  &#x2022;the', 'EGFR Products', 'approvals;\\n  &#x2022;the', 'the Transition Agreement', 'Therapeutics, Inc.', 'the Internal Revenue Code', 'Bristol Myers Squibb', 'costs;\\n  &#x2022;delay', 'AbbVieIrelandUnlimitedCompanyMember2023', 'Indicate', 'UNITED STATES', 'Co-Development and Licensing Agreement', 'AbbVie Global Enterprises Ltd.', 'USTreasuryAndGovernmentShorttermDebtSecuritiesMember2023-09-300001501989us', 'the Amgen Agreement', 'designation.\\n', 'submissions&#x37e;\\n  &#', 'AbbVie', 'COVID-19', 'AmgenIncMember2022', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001501989ctmx', 'and\\n  &', 'Recommendation', 'and\\n  &#x2022;collaborations', 'x2022;high', 'Bristol Myers Squibb&#x2019;s', 'Rule 15d-14(a).\\n    &', 'candidates;\\n  &#x2022;limitations', 'the CD71 Agreement', 'the collaboration;\\n  &#', 'WarrantMember2022-01-012022-09-300001501989ctmx', 'x201c;Risk', 'WarrantMember2022-07-012022-09-300001501989ctmx:AmgenIncMemberctmx:CollaborationAndLicenseAgreementMember2017-09-290001501989ctmx', 'Medicaid', 'Medicare', 'x2014;\\n        &', 'factors:\\n  &#x2022;the', 'Regeneron Pharmaceuticals', 'WarrantMember2023-01-012023-09-300001501989us', 'and\\n  &#x2022;refusal', 'FDA', 'the Data Safety Monitoring Board', 'Seagen', 'including:\\n  &#x2022;variations', 'the Regeneron Agreement', '206,447\\n          &', 'The Discovery Agreement', 'EGFR Co-Development', 'us;\\n  &#x2022;the', 'and\\n  &#', 'people;\\n  &#x2022;delays', 'capital commitments;\\n  &#x2022;developments', 'candidates;\\n  &#x2022;regulatory', 'Report &', 'thousands)\\n          &', 'Company', 'respectively.&#160;Bristol Myers Squibb Company', 'including:\\n  &#x2022;negative', 'areas.\\n  &', 'USPTO', 'consideration.\\n  &', 'periods.\\n  &', 'liability;\\n  &#x2022;disputes', '205,530\\n          &', 'The 2016 Lease', 'Regeneron Pharmaceuticals Inc.', 'candidates;\\n  &#x2022;delays', '70\\n', 'USTreasuryAndGovernmentShorttermDebtSecuritiesMember2022-12-310001501989us', 'Bristol Myers Squibb\\n        &', '\\n    &#', 'RegeneronPharmaceuticalsIncMember2022-11-162022-11-160001501989ctmx', 'Bristol Myers Squibb Company (&#', 'The Moderna Agreement', 'BMS.&#160;The Company', 'liability;\\n  &#x2022;collaborators', 'USD\\n  &', '\\n  ', 'the Amgen Other Products', 'candidates;\\n  &#', 'AbbVie, Inc.', 'AbbVieIrelandUnlimitedCompanyMember2022-07-012022-09-300001501989ctmx:', '95,952\\n          &#160;\\n          &#160;\\n', 'revenues.\\n  &#', 'candidates;\\n  &', 'versa.\\n  &#160;\\n', 'arrangements;\\n  &#160;\\n  &#x2022;our', 'the market;\\n  &#x2022;fluctuations', 'OptionsAndESPPToPurchaseCommonStockMember2023-01-012023-09-300001501989ctmx:', 'and\\n  &#x2022;our', 'OptionsAndESPPToPurchaseCommonStockMember2023', 'FTE', 'us;\\n  &#x2022;additions', 'collaborators;\\n  &#x2022;regulatory', 'Bristol', 'sublicenses.\\n  &#', 'Roche', 'Risks Related to Ownership of Our Common Stock\\n', 'WarrantMember2023-07-012023-09-300001501989ctmx:ModernatxIncMember2023-01-012023-09-300001501989ctmx:AmgenIncMemberctmx:EGFRProductsMember2023-09-300001501989us-gaap', '\\n  &#', '95,035\\n          &#160;\\n          &#160;\\n', 'the BMS Agreement and Amendment 1', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001501989ctmx:', 'LiabilitiesThe', 'candidates;\\n  &#x2022;unfavorable', 'Amgen', 'sanctions.\\n  &', 'Registrant', 'candidates;\\n  &#x2022;developments', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001501989us', 'the following:\\n  &#', 'AbbVieIrelandUnlimitedCompanyMember2022-01-012022-09-300001501989us', 'Pharma Inc.', 'EGFR Co-Development Option', 'Additional Collaboration Program Option', 'Company&#x2019;s', 'prospects.\\n  &', '47\\n', 'Magistrate', 'flows.\\n  &', 'the following:\\n  &#x2022;results', 'EGFR', 'Condensed Financial Statements', 'Price', 'PrivatePlacementMember2023-01-012023-09-300001501989us', 'the Cost Share Option', '\\n  &#x2022;We', 'the Moderna Agreement', 'Investigational New Drug Application', 'the marketplace.\\n  &#', 'BMS-986288', 'FiledHerewith', 'CollaborationAndLicenseAgreementMember2023-01-012023-03-310001501989ctmx:', 'Regeneron', '\\n  &', 'controls.\\n  &#', 'CX-904;\\n  &#x2022;collaborators', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001501989ctmx:', 'generally;\\n  &#x2022;our', 'Clinical Trial Application', 'European Union', 'states.\\n  &', 'ImmunoGen', 'x201c;Astellas', 'technologies;\\n  &#x2022;introductions', 'some stockholders.\\n  &', 'and\\n  &#x2022;general', 'Regeneron Pharmaceuticals, Inc.', 'diagnostics;\\n  &#x2022;relative', 'Medicaid Services', 'CX-2029', 'AstellasPharmaIncMember2022', 'the Astellas Agreement', 'x201c;Bristol Myers', 'community;\\n  &#', 'products;\\n  &', 'market.\\n  &', 'the Collaboration and License Agreement', 'the &#x201c;Discovery', 'the U.S. District Court', '\\n        &', 'SEC', 'Restricted', 'Collaboration and License Agreement', 'the BMS Agreement', 'UCSB', 'the Centers for Medicare &', 'calamities;\\n  &#x2022;actual', 'and\\n  &#x2022;changes', 'Halozyme', 'Probody', 'candidate.\\n  &', 'x201c;Regeneron', 'the European Union', '\\n    &', 'CollaborationAndLicenseAgreementMember2023-01-012023-01-310001501989us', 'PrivatePlacementMember2023-09-300001501989us'}"
CTSO,"{'the Company&#8217;s stockholders.&#8203;The Company', 'Fresenius', 'VAT', 'HemoDefend', 'the Term C Loans.&#8203;21\\nTable', 'The Board of Directors', 'CytoSorbents India Private Limited', 'The Breakthrough Devices Program', 'Security Agreement', 'CytoSorb&#174', 'Principal Executive Officer', 'CytoSorbents Corporation', 'CytoSorbents', 'StockCTSONasdaq Capital', 'the Term Loan', 'EUA', 'the Amended Loan', 'Breakthrough Designation', 'CytoSorbents Europe GmbH', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'the 12\\nTable of Contentscalculation', 'COVID-19', 'the FDA.The U.S. CTC (CytoSorb Therapy', 'Fresenius Medical Care Deutschland GmbH', 'ContrastSorb', 'ICU', 'EstimatesThe', 'Restated Loan', '748,381)&#8203;$ 2.96&#160', 'the United States Department', 'CytoSorbents Medical Limited', 'the Amended and Restated Loan', 'FDA', 'organization)&#160;&#160;&#8203;&#8203;&#8203;305 College Road East &', 'ContentsChange', 'ContentsThe', 'CompensationTotal', 'CytoSorb', 'the shares.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Options Outstanding &', 'the Term B Loan', 'Company', '305 College Road East', 'the Borrower', 'the CE Mark', 'DAF', 'ASU', 'DrugSorb', 'the Nasdaq Capital Market', 'the Restated Loan', 'DrugSorb-ATR Antithrombotic Removal System', 'Fresenius Medical Care', 'the Air Force', 'Employment Agreement', 'Success Fees', 'the Sale Agreement', 'the Success Fees', 'Amended Loan', 'the Company&#8217;s Board of Directors', 'CytoSorbents UK Limited', 'Form S-3', 'Bank', 'CytoSorbents Medical, Inc.', 'Black Scholes', 'the Loan Agreement', 'CytoSorbents Medical Inc.', 'the Board of Directors', 'Asklepios', 'ECMO', 'Section&#160;13', 'the Term A Loan', 'CONTINGENCIESEmployment AgreementsOn July&#160;30', 'Ms.', 'the Marketing Agreement', 'COVID-19)', 'Recognition', 'SEC', 'K+ontrol&#8482;.Impact of Inflation and Other Issues', 'Biocon', 'HemoDefend-RBC'}"
CTXR,
CUE,"{'ASC', 'Erie Laboratory', 'Leases &', 'diluted\\n    &', 'LG Chem', 'Immuno', 'Interest Income\\n  Interest', 'Restricted CashThe Company', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'CUE-102;\\n  &#x2022;leverage', 'Indicate', 'G Additional Laboratory Lease', '\\n    Research', 'this Quarterly Report on Form 10-Q.\\n  ', 'Adopted', 'Research', 'Jefferies', 'and\\n  &', 'the LG Chem Territory', 'ATM Agreement', 'the Einstein License Agreement', 'EPS', 'x2014;\\n        &', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Licensed Products', 'Ono Pharmaceuticals Co., Ltd.', 'Loan', '\\n        Laboratory equipment\\n', 'the Research Term', 'depreciation\\n        &', 'Silicon Valley Bank', 'Company', 'regulations;\\n  &#160;\\n  &#x2022;our', 'Jefferies LLC (&#34;Jefferies&#34;)', 'Collaboration Products', 'SVB', 'the &#x201c;Research', 'SVBB', 'products.\\n  &#x2022;We', 'LG', 'Loan Agreement', 'candidates;\\n  &', 'Merck', 'the Ono Collaboration and Option Agreement', 'The Loan Agreement', 'remaining)\\n        &#', 'the LG Chem Collaboration Agreement', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'License', 'Scientific and Clinical Advisory Board', '\\n  &#', 'CMC', '7,500,480\\n          &', 'Contract CostsThe Company', 'the following:&#160;\\n      \\n       \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n       \\n       \\n        &', '\\n    &', 'LG Chem\\n  Effective', 'the heading &#x201c;Collaboration Agreement', 'Tregs', 'OnoOn', 'programs.\\n  &#160;\\n  &#160;\\n  &#160;\\n  ', 'statements.\\n  &#x2022;We', 'organization)\\n    &#160;\\n', '\\n  Collaboration Agreement', 'CPS', 'charter)\\n  &#', 'the &#x201c;Closing Date&#x201d;)', 'Silicon Valley Bridge Bank', 'Form S-3', 'Neo-STATs;\\n  &#', 'the Loan Agreement', '\\n  &#x2022;We', 'the Lender', 'ATM', '\\n  &', 'LG Chem Ltd.', 'the Term Commencement Date', 'the Drug Product Candidates', 'candidates.\\n  &#x2022;We', 'we:\\n  &#x2022;continue', 'EquipmentProperty', 'and\\n  &#x2022;incur', 'agreements.\\n  &#x2022;Pay', 'G Additional Laboratory', 'U.S. Treasury', 'Albert Einstein College of Medicine', '\\n        &', 'SEC', '\\n    Interest', 'x201c;Loan', 'Ono Pharmaceutical Co., Ltd.', 'Leases', 'funding.\\n  &#160;\\n  ', 'expense.\\n  &', 'below.\\n  &#'}"
CUTR,
CVAC,
CVKD,"{'Placement', 'the\\nsymbol &', 'LLC', 'the Nasdaq Capital Market', 'the United States Renal Data System', 'AFib', 'Qualitative Disclosures', 'the\\nunderwriters (the &#', 'thromboembolism\\n(blood', 'the Underwriting Agreement', 'the Common Warrants', 'the Current Report on Form 8-K', 'net&#160;\\n', 'K\\nantagonist', 'Nasdaq Capital Market', 'Boustead Securities', 'the Investor Selling Stockholder', 'Placement Agent Warrants', 'Factors II', 'Tecarfarin', 'Financial Instruments\\n\\n&#160;\\n\\nThe Company', 'Phamace', 'Related Party', 'will\\nbe', 'the Private Placement', 'Common\\nStock (the &#', 'the Nasdaq Capital Market (&#8220;Nasdaq&#8221', 'SEC', 'the purchaser party', 'Common Stock', 'parties&#160;\\n    $&#', 'Company', 'Risk\\n\\n&#160;\\n\\nWe', 'RENAL', 'the heading &#8220;Special Note Regarding Forward-Looking', 'the Restricted Stock', 'Boustead', 'Horizon Technology Finance Corporation', 'the Common Warrants or Placement Agent Warrants', 'VKA', 'IPO', 'LLC (&#8220;Boustead&#8221;)', 'Cadrenal Therapeutics, Inc.', 'the Pre-Funded Warrants', 'the June&#160;2022 Note', '\\n    &', 'the Registration Statement on Form S-1', 'Part&#160;I,&#160;Item&#160;1A,&#160;&#8220;Risk', 'valuation\\nallowance.\\n\\n&#160;\\n\\nThe Company'}"
CVRX,"{'ASC', 'portion&#8203;&#8203;916&#8203;&#8203;117Total', 'BeAT-HF', 'the Loan Agreement', 'liabilities &', 'pronouncementsA', 'the Medical Devices Regulation (Regulation (EU', 'the Essential Requirements', 'the Board of Directors', 'ATM', 'this Quarterly Report on Form 10-Q.Changes', 'EEA', 'this Quarterly Report on Form 10-Q', 'The Loan Agreement', 'ContentsPART&#160;II&#160;&#8212', 'follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#160;&#160;&#160;&#160;September&#160;30,&#160;(in thousands)&#8203;20232023&#160;&#160;&#160;&#160;$ &#', '264,160)&#8203;&#160;10.42&#160;&#8203;&#8203;&#160;&#160;Exercised&#160', 'Loan', 'Barostim in Europe', 'DebtInnovatus Loan AgreementOn', 'the Loan Agreement.&#160;The Loan Agreement', 'Piper Sandler &amp', 'Company', 'Contentsand', 'the Quality Management System', 'and&#9679;we', 'COVID-19', 'IPO', 'the Technical File', 'Innovatus Life Sciences Fund I, LP'}"
CYCC,
CYCCP,
CYCN,"{'ASC', 'FASB', 'the Employee Matters Agreement between', 'ASU', 'the License Agreement', 'Tisento&#x2019;s', 'Financial Instruments-Credit Losses', 'Tisento Parent', '\\n', ""Tisento Parent\\'s"", 'the Board of Directors', '\\n    Diluted', '3.11\\n    &', '\\n  &', 'WeWork', 'a Common Stock Purchase Agreement', 'the Securities and Exchange Commission', 'Diluted', 'Stockholders&#x2019', 'Condensed Consolidated Statements of Operations and Comprehensive', 'this Quarterly Report on Form 10-Q', 'the Company&#x2019;s Annual Report on Form 10-K', 'x2014;\\n        &', 'Tisento', 'the Supply Agreement', 'the Asset Purchase Agreement', 'Tisento Parent\\n        &', 'Ironwood', 'performance.\\n  New Accounting Pronouncements\\n', 'Weighted Average\\n        &', 'Unaudited)\\n  &#160;\\n', '\\n  &#', 'RSU', 'RSUs\\n    &', 'the Initial Supply', 'EquipmentProperty', 'Series A Preferred Stock', 'gain)\\n    &', 'License AgreementAkebia License AgreementOn June 3, 2021,', 'the &#x201c;Exchange', 'Note 4', 'the Akebia License Agreement', '\\n    Research', 'Significant Accounting Policies', 'OverviewThe', 'plan\\n    &', '\\n    Interest', 'Condensed Consolidated Statements', '\\n        &', 'ATM Offering', 'activities\\n    &', 'Company', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Cyclerion', 'Jefferies', 'Cyclerion Therapeutics', 'Cyclerion Securities Corporation', '\\n    &', 'No &#9744;\\n  Indicate', 'the sale\\n        &'}"
CYT,"{'compensation\\n    &', 'the Delaware General Corporation Law', 'dissolution.\\n  &', '\\n  Components', 'LeasesOperating LeaseIn', '\\n    Interest income\\n    &', 'State', '\\n  &', 'x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Plan of Dissolution', 'x2014;\\n        &', 'ESPP', '\\n  &#x2022;costs', 'analysis;\\n  &#', 'dissolution.\\n  &#', 'restructuring.\\n  &#', 'the Public Company Accounting Oversight Board', '\\n  &#', 'the Lease.12&#160;\\n     &', 'EGC', 'Treasurer(Principal Financial', 'Interim Financial Information', '27\\n  &#160;\\n', '\\n    Research', 'the Sarbanes-Oxley Act;\\n  &#', 'Form S-1', '\\n        &', 'SEC', 'Restricted', 'uncertain.\\n  &#', 'the Certificate of Dissolution', 'activities\\n    &', 'Company', ""the Company\\'s Board of Directors"", 'the Securities Exchange Act', '\\n  &#x2022;facilities', 'compensation)\\n    &', 'expense)\\n    &', '\\n  Research', 'Research', 'Capital Resources.&#x201d', 'THERAPEUTICS, INC', 'Cyteir Therapeutics, Inc.', 'IPO', 'Results of Operations', 'the Delaware Court of Chancery', '\\n  &#160;\\n', '\\n  &#x2022;external', 'Nasdaq', '16\\n  &', 'Comparison', '\\n    &', 'costs.\\n  &#', '15\\n  &#160;\\n', 'and\\n  &', 'See &#x201c;&#x2014;Liquidity'}"
CYTH,"{'the Securities and Exchange Commission', 'Company', 'LLC', 'the Company&#x2019;s Board of Directors.\\n\\n&#xa0;\\n\\nOn August 1, 2023', 'NPC', 'Ashland, Inc.', 'Original Warrants', 'the Original Warrants', 'Rafael Holdings', 'the Company&#x2019;s Articles of Incorporation', 'Warrants', 'Merger', 'AMTI', '\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\tNine Months Ended \\n\\n\\t\\t\\tSeptember', 'Cyclo&#x2122'}"
CYTK,
CYTO,
DARE,
DAWN,
DBVT,"{'Marketing expenses\\n&#160;&#160;\\n&#160;\\n663\\n&#160;\\n&#160;&#160;\\n&#160;\\n159\\n&#160;\\n&#160;&#160;\\n&#160;\\n504\\n&#160;\\n&#160;&#160;\\n&#160;\\n318\\n%&#160;\\n\\n\\n&#160;&#160;\\n &', 'FASB', 'THE SECURITIES EXCHANGE ACT OF 1934', 'ASU', 'VAT', 'Marketing expenses\\n&#160;&#160;\\n&#160;\\n1,613\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,659\\n&#160;\\n&#160;&#160;\\n&#160;\\n(46\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(3\\n)%&#160;\\n\\n\\n&#160;&#160;\\n &', 'ATM', 'ContentsAccounting Pronouncements', 'DBV', 'THE SECURITIES EXCHANGE ACT OF 1934 For', 'expenses\\n&#160;&#160;\\n&#160;\\n32\\n&#160;\\n&#160;&#160;\\n&#160;\\n(50\\n)&#160;\\n&#160;&#160;\\n&#160;\\n82\\n&#160;\\n&#160;&#160;\\n&#160;\\n(165\\n%)&#160;\\n\\n Depreciation', 'Administrative expenses\\n&#160;&#160;\\n&#160;\\n6,184\\n&#160;\\n&#160;&#160;\\n&#160;\\n4,839\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,345\\n&#160;\\n&#160;&#160;\\n&#160;\\n28\\n%&#160;\\n\\n\\n&#160;&#160;\\n &', 'FDA', 'STATES SECURITIES AND EXCHANGE COMMISSION', 'costs\\n&#160;&#160;\\n&#160;\\n2,467\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,949\\n&#160;\\n&#160;&#160;\\n&#160;\\n518\\n&#160;\\n&#160;&#160;\\n&#160;\\n27\\n%&#160;\\n\\n\\n&#160;&#160;\\n &#', 'costs\\n&#160;&#160;\\n&#160;\\n1,595\\n&#160;\\n&#160;&#160;\\n&#160;\\n6,423\\n&#160;\\n&#160;&#160;\\n&#160;\\n(4,827\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(75\\n%)&#160;\\n\\n\\n&#160;&#160;\\n &', 'the General Meeting of the Shareholders', 'EPITOPE', 'STAMP', 'EUR', 'costs\\n&#160;&#160;\\n&#160;\\n7,117\\n&#160;\\n&#160;&#160;\\n&#160;\\n6,042\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,075\\n&#160;\\n&#160;&#160;\\n&#160;\\n18\\n%&#160;\\n\\n\\n&#160;&#160;\\n &#160;\\n &#160;\\n&#160;\\n&#160;&#160;\\n &', 'DBV Technologies S.A.', 'Advice/Information Request', 'Share', 'Health Sciences', 'Company', 'the Financial Accounting Standards Board', 'Contents  Note 3: Cash and Cash Equivalents', 'VITESSE', 'costs\\n&#160;&#160;\\n&#160;\\n136\\n&#160;\\n&#160;&#160;\\n&#160;\\n299\\n&#160;\\n&#160;&#160;\\n&#160;\\n(163\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(55\\n%)&#160;\\n\\n\\n&#160;&#160;\\n &', 'Consolidated Financial Statements', 'Administrative expenses\\n&#160;&#160;\\n&#160;\\n22,304\\n&#160;\\n&#160;&#160;\\n&#160;\\n17,173\\n&#160;\\n&#160;&#160;\\n&#160;\\n5,130\\n&#160;\\n&#160;&#160;\\n&#160;\\n30\\n%&#160;\\n\\n\\n&#160;&#160;\\n &', 'AdrMember', 'costs\\n&#160;&#160;\\n&#160;\\n365\\n&#160;\\n&#160;&#160;\\n&#160;\\n690\\n&#160;\\n&#160;&#160;\\n&#160;\\n(325\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(47\\n%)&#160;\\n\\n\\n&#160;&#160;\\n &'}"
DCGO,"{'ASC', 'net1,219,927&#160;(1,219,927)&#8212;&#160;&#8212;&#160;&#8212;&#160;Prepaid', 'LLC', 'this Quarterly Report on Form 10', 'the Mobile Health Services', 'the Bienstock Agreement', 'Item 408 of Regulation S-K', 'Transportation Services', 'Description of Organization and Business', 'this Quarterly Report on Form 10-Q', 'the Exchange Act.32.1**Certification', 'U.K.The Company', 'the Internal Revenue Code', 'Health Services', 'the Principal Financial Officer Pursuant', 'Consolidated Balance Sheet', 'the Revolving Facility', 'AmortizationExpense2023', 'PlanThe Company', 'Mobile Health Services and', 'COVID-19', 'Credit AgreementDuring 2022', 'The Bienstock Agreement', 'LeasesOperating LeasesThe Company', 'Motion Merger Sub Corp.', 'Holdings', 'Ambulnz, Inc.', 'ABC', 'Mobile Health Services', 'The Business Combination', 'Exceptional Medical Transportation', ': &', 'NetProperty', 'Condensed Consolidated Statement of Operations and Comprehensive Income', 'Ryan Brothers', 'the Payroll Protection Program Term', 'Condensed 9Table of ContentsDocGo Inc.', 'OverviewThe Company', 'Company', 'NPA', 'Ambulnz Holdings', 'Finance LeasesThe Company', 'Condensed Consolidated Financial Statements', 'RevenueThe', 'liabilities63,885,183&#160;&#8212;&#160;63,885,183&#160;(63,885,183)&#8212;&#160;Total', 'ContentsDocGo Inc.', 'the Condensed Consolidated Balance Sheets', 'the Annual Report on Form 10-K', 'Condensed Consolidated Statements of Operations and Comprehensive Income', 'Condensed Consolidated Balance Sheets', 'DocGo Inc.', 'The BusinessThe Company', 'equity$(38,525,805)$(2,921,958)$(41,447,763)$41,447,763&#160;$&#8212;&#160;Total', '2) Mobile Health Services', '2023).10.2*Executive Employment Agreement', 'the Transportation Services', 'CRMS', 'Corporate', 'the Mobile Health Services and', 'CostThe', 'Business Segment InformationThe Company', 'the U.K.The Company', 'Control ExpensesWe', 'ContentsCapital ResourcesWorking', 'the Consolidated Financial Statements', 'the Company (&#8220;Merger', 'LLC (&#8220;Holdings&#8221', 'EquipmentProperty', 'RND', 'Motion Acquisition Corp.', 'VendorThe Company', 'the U.S. District Court', 'SEC', 'the Business Combination', 'RMS', 'Consolidated Balance', 'Contentsestimated', 'Rule 16a-1'}"
DCPH,"{'LLC', 'AmMax Bio, Inc.', 'Sprint Biosciences AB', 'EC', 'RAS', 'BRAF', 'EMA', 'HXPharma', 'Principal Executive Officer', 'Legal ProceedingsThe Company', 'EEA', 'the Federal Reserve', 'ProductMember2023', 'Development ExpensesResearch', 'Restated Certificate of Incorporation of the Registrant (Incorporated', 'EU', 'Pfizer Inc.', 'the Sarbanes-Oxley Act of', 'WarrantMember2022-01-012022-09-300001654151us-gaap', 'UPC', 'the Registrant (Incorporated', 'the Zai Supply Agreement', 'ContentsWe', 'the Securities Exchange Act', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001654151us-gaap', 'Jefferies', 'Ownership of Our Common StockRisks Related', 'SynOx Therapeutics Ltd', 'ContentsIn', 'Pfizer', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001654151us-gaap', 'INSIGHT', 'the Personal Information Protection Law', 'the Department of Justice', 'Medicaid', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'Medicare', 'The U.S. Supreme Court', 'GDPR', 'pan-RAF', 'FDA', 'QINLOCK', 'ii)&#160;any', 'NonUsMember2022-01-012022-09-300001654151dcph', 'the Zai License Agreement', 'ContentsThe', 'Risks Related', 'CRAF', 'the Delaware Forum Provision', 'Abbisko Therapeutics Co., Ltd.', 'the International Data Transfer Agreement', 'Company', 'the Department of the Treasury', 'ContentsFunding RequirementsOur', 'USPTO', 'the Leahy-Smith Act', 'SVB', 'LetterOfCreditMember2022-12-310001654151us-gaap', 'the Delaware General Corporation Law', 'Guggenheim Securities', 'US2023-01-012023-09-300001654151us-gaap', 'ProductMembercountry', 'VPS34', 'Deciphera Pharmaceuticals', 'OperationsComparison', 'the U.S. Patent and Trademark Office', 'ValueDue', 'WarrantMember2023-01-012023-09-300001654151us-gaap', 'J.P. Morgan Securities', 'NetDuring', 'ContentsTo', 'FairValueInputsLevel1Member2022-12-310001654151us-gaap', 'WarrantMember2022-04-262022-04-290001654151us-gaap', 'KIT', 'ContentsDeciphera Pharmaceuticals', 'RAF', 'WarrantMember2022-04-2600016541512022-04-262022-04-290001654151us-gaap', 'Contentsbiologics', 'ProductMember2022', 'GIST', 'U.S.QINLOCK', 'the Consolidated Financial Statements(Unaudited)In', 'US2022-01-012022-09-300001654151us-gaap', 'FDIC', 'Federal Reserve Board', 'the Sarbanes-Oxley Act', 'IPO', 'the General Data Protection Regulation', 'the U.S. Department of Treasury', 'the Zai License Agreement and Zai Supply Agreement', 'US2023-07-012023-09-300001654151us-gaap', 'Our Financial Position', 'the licensee and/or collaborator;&#8226;a', 'Capital Needs', 'WarrantMember2023-07-012023-09-300001654151us-gaap', 'SECSchedule1209AllowanceChargebacksAndAdministrativeFeesMember2022-12-310001654151dcph', 'WarrantMember2022-07-012022-09-300001654151us-gaap', 'the Court of Chancery of the State of Delaware', 'Daiichi Sankyo Company, Limited, Dragonboat Biopharmaceutical Company Limited', 'the Amended Sales Agreement', 'US2022', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001654151us-gaap', 'PHARMACEUTICALS', 'NonUsMember2022-07-012022-09-300001654151us-gaap', 'Consolidated Financial Statements12Item&#160;2', 'the Consolidated Financial', 'the Food and Drug Omnibus Reform Act', 'SEC', 'the European Union', 'deposit&#8212;&#160;4,075&#160;&#8212;&#160;4,075&#160;Total$&#8212;&#160;$348,182&#160;$&#8212;&#160;$348,182&#160;As'}"
DCTH,
DERM,
DH,"{'LLC', '\\n', 'significant.\\n  &', 'Amortization\\n          &', 'Delaware corporation.\\n  &', 'Transaction', 'TRA', 'Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;)', 'Exhibit 99.2', 'Indicate', '1,473,093\\n          &#160;\\n         \\n        &#160;The Company', 'AIDH Management Holdings', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Class A Common Stock', 'Analytical Wizards', 'Definitive Healthcare Corp.\\n', '3,062\\n          &', 'Advent', 'Definitive Healthcare', 'FASB', 'the Company&#x2019;s Quarterly Report on Form 10-Q', 'The Definitive Healthcare Corp.', '452\\n          &', 'Equity\\n          &', 'LLC Units', 'Definitive Healthcare Corp', 'the Securities and Exchange Commission', 'x2014;\\n        &', 'Reorganization Transactions', 'LLC Unit', 'unvested)\\n        &', 'Interest Rate Risk    The Company', 'x2022;&#x201c;Reorganization', 'Interests\\n          &', 'the &#x201c;Amended', 'Company', 'Gross Profit', 'firm.\\n  &', 'x2022;&#x201c;Tax Receivable', 'L.P.', 'Spectrum Equity Management', 'Purchase Option', '6,060\\n          &', 'the Company&#x2019;s Quarterly Report on Form 10-Q (File No', '631\\n          &', '66,062\\n          &', '200\\n          &', '961,001\\n          &', 'operations\\n          &#160;\\n          &#160;\\n', 'ImpairmentGoodwill', 'Goodwill\\n          &', '336,027\\n        &', '\\n  &#', 'period:&#160;\\n        \\n         \\n', 'the &#x201c;Exchange', '1,876\\n          &', 'The Amended LLC Agreement', '\\n          &', '22C Capital', '543,003\\n          &#160;\\n          &#160;\\n', 'Definitive Healthcare Corp.', 'IPO', 'This Quarterly Report', '1,477,522\\n          &#160;\\n          &#160;\\n          &#160;\\n', '128,755\\n          &', 'Class A Common Stock of Definitive Healthcare Corp.', 'this Quarterly Report', 'Definitive OpCo', 'the &#x201c;2021 Credit', 'the Stock Purchase Agreement', 'thousands)\\n          &#160;\\n', 'data)\\n          &#160;\\n', 'DH Holdings', 'Definitive Healthcare Corp.\\n  &#x2022;&#x201c;Reorganization', 'Revenue\\n          &#160;\\n', 'the Tax Receivable Agreement', 'ARR', 'firm.\\n  &#', 'Noncontrolling\\n          &', 'Spectrum Equity', '\\n        &', 'SEC', 'TRA &', '22C Capital LLC', '9,716\\n          &', '33,564\\n          &', 'the Reorganization Transactions', 'the Series B Preferred Stock', '1,477,522\\n          &#160;\\n         \\n         \\n          Adjustment', ""Definitive Healthcare Corp.\\'s"", 'x2022;&#x201c;22C', '\\n    &'}"
DMAC,"{'FASB', 'the United States Securities and Exchange Commission', 'management&#x2019;s', 'Inputs &#', 'the Resale Registration Statement', 'Registration Rights Agreement', 'Compensation\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nAmended', 'the District Court of Northern Netherlands', 'EPS', 'the Securities and Exchange Commission', 'Internal Control over Financial', 'DM199', 'Pharmaceutical Research Associates Group B.V.', 'the United States Securities Exchange Act', 'The Resale Registration Statement', 'PRA Netherlands', 'FDA', 'Plan\\n\\n&#xa0;\\n\\nThe DiaMedica Therapeutics Inc.', 'DiaMedica USA', 'SEC File No', 'DiaMedica&#x2019;s Current Report on', 'AIS', 'DiaMedica&#x2019;s Current Report on Form 8-K', 'SEC', 'ICON', 'Company', 'Adopted Accounting Pronouncements\\n\\n&#xa0;\\n\\nIn', 'NCC', 'companies&#x2019', 'ASU No', 'CRD'}"
DMTK,"{'ASC', 'the Merger Agreement', 'the ""Transition Agreement', 'compensation$5,773&#160;$7,894&#160;Accrued', 'the Black-Scholes-Merton', 'Board', 'The Nasdaq Stock Market', 'the &#8220;Smart', 'Supply Chain and Inflationary EnvironmentGlobal', 'ProceduresOur', 'Remaining Performance', 'the Clinical Laboratory Fee Schedule', 'TERT', 'Compensation &#8211', 'Medicare', 'CostGross UnrealizedGainsGross', 'Restated Certificate of Incorporation of the Company', 'Principal Executive Officer', 'Control systems', 'this Quarterly Report on Form 10-Q', 'amended10-Q001-3811808/03/233.2Bylaws', 'GreaterTotal Fair Value Gross Unrealized LossFair ValueGross Unrealized LossFair', 'RevenueContract', 'the PLA Code', 'the Compensation Committee of the Board', 'Restructuring Plan', 'Clinical Laboratory Improvement Amendments', 'Upfront', 'Stock Compensation', 'Research and Development', 'ContentsPrepaid Expenses and Property and Equipment', 'Liquidity and Capital Resources', 'LCD', 'securities$2,623&#160;$&#8212;&#160;$(22)$2,601&#160;U.S.', 'ContentsRemaining', 'SEC', 'the Financial Accounting Standards Board', 'Company', 'the Securities Exchange Act', 'the Business Combination', 'Smart Stickers', 'ContentsThe Company', 'the Sarbanes-Oxley Act', 'the Public SPAC Warrants', 'Adopted Pursuant to Section 302', 'NPV', 'Principal Financial Officer Pursuant', 'commissions$2,591&#160;$3,257&#160;Accrued', 'The Private SPAC Warrants', 'Cowen', 'ObligationsThe', 'College of American Pathologists', 'ContentsFinancial Overview Revenue', 'Test Revenue'}"
DNLI,"{'the Longevity Business Combination', 'the Merger Agreement', 'the Sponsor Convertible Promissory Note', 'the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition', 'LLC', 'FASB', 'ASU', 'the Public Shareholders', 'Working Capital Loans', 'Working Capital', 'the Company (&#8220;Holdco&#8221', 'Principal Financial and Accounting Officer', 'Form\\nS-4', 'FutureTech', 'this Quarterly Report', 'Company&#8217;s\\nordinary', 'Longevity (the &#8220;Longevity', 'the Board of Longevity\\n(&#8220;FutureTech&#8221;)', 'Form\\n10-K', 'Denali Capital\\nGlobal Investments LLC', 'Private Placement Warrants', 'Private Placement Unit', 'and\\n  \\n&#160;\\n\\n  &#', 'Principal Executive Officer', 'entering\\ninto', 'July&#160;11', 'the Company (&#', 'the Annual Report', 'MIPA,&#160;FutureTech', 'income\\nand', 'Merger Sub, Inc.', 'the Longevity Business Combination.\\n\\n&#160;\\n\\nOn', 'the Sponsor (&', 'Cayman Islands', 'Longevity Biomedical, Inc.', 'the Sponsor and\\nFutureTech Capital LLC', 'Cerevast Medical', 'The Voting Stockholder', 'SHAREHOLDER&#8217;S DEFICIT\\n\\n&#160;\\n\\nPreference', 'a Business Combination', '\\n    &', 'Denali SPAC Holdco, Inc.', 'Update (&#8220;ASU&#8221', 'the Private Placement Units', 'Form S-1', 'Holdco (&#8220;Denali', 'Longevity (File No', 'Holdco (&#', 'SEC', 'the Company entered into\\nan Agreement', 'Growth Company Status\\n\\n&#160;\\n\\nThe Company', 'the Private Placement Warrants', 'claims.\\n\\n&#160;\\n\\nOn', 'Company', 'the Securities Exchange Act', 'Contractual', 'Holdco, Inc.', 'securities\\nlaw', 'a Business Combination does\\nnot close&#160;the Company', 'the Business Combination', 'the Private Offering', 'conversion\\nfeature &#8211', 'the Registration Statement on Form S-4', 'Sponsor,\\nin', 'Adopted Pursuant to Section 302', 'the Sarbanes-Oxley Act', 'the Trust Account', 'Company&#8217;s\\nmanagement', 'IPO', 'this Quarterly Report on Form 10-Q.\\n\\n&#160;\\n\\n\\n', 'Public Warrants', 'Longevity', 'the&#160;Longevity Business Combination.&#160;FutureTech', 'the Private Placement Units.\\nIn', 'Cerevast Medical, Inc.'}"
DNTH,"{'ASC', 'years)\\n        &', 'LLC', '\\n  &#x2022;payments', 'Contractual Obligations and Commitments \\n  Lease Obligations \\n', '\\n    Interest income\\n    &', 'the Company&#x2019;s Registration Statement', '\\n', 'Crystal Bioscience, Inc. (', 'Alloy Therapeutics', 'Note 14.Recently', 'UncertaintiesThe Company', 'arrangement\\n  &#160;\\n  45\\n  ', 'Dianthus Therapeutics', 'the Zenas Territory', 'x201c;Reverse', 'Pre-Closing Financing\\n', '\\n    Research', 'the Securities Exchange Act', 'Zenas BioPharma Limited', 'Ligand Pharmaceuticals Incorporated', 'the Zenas Agreements', 'the Merger Agreement', 'the &#x201c;CVR Agreement&#x201d', 'OpCo Inc.', 'and\\n  &#x2022;risks', 'Unbilled Receivable', 'Zenas BioPharma LimitedThe Company', 'IONTAS Limited (&#x201c;IONTAS&#x201d', 'x201c;Risk', 'x2014;\\n        &', ': &', 'FDA', 'C1s', 'OmniAb, Inc. (&#x201c;OmniAb&#x201d', 'any;\\n  &#x2022;our', 'CVR', 'Ligand', 'Note 11.Segment Information', 'Zenas License Agreement', '\\n  &#x2022;regulatory', 'Management&#x2019;s Evaluation', 'Company', 'the Dianthus Therapeutics, Inc. 2019', 'x2022;With', 'Related PartyThe', 'the Securities Act.\\n  Item 3', '\\n  &#x2022;unexpected', 'Zenas (&#', 'EquivalentsAll', 'ASU', 'x201c;Zenas License', 'Zenas BioPharma (&#', 'License Revenue &', 'Zenas', 'results;\\n  &#x2022;the', 'Procedures\\n  &', 'Exhibit 10.19', 'License', '\\n  &#', 'CMC', 'trading;\\n  &#x2022;regulatory', 'Zenas Option', 'the Company (&#x201c;Merger', 'Research and Development and Manufacturing Agreements', 'Subscription Agreement', 'The Zenas Option', 'Dianthus Therapeutics, Inc.', 'The Zenas License', 'factors:\\n  &#x2022;risks', 'Dio Merger Sub, Inc.', 'IONTAS', 'Nasdaq Capital', 'prospects.\\n  &', 'Comparison', 'the Subscription Agreement', 'Offer Letter', '\\n  &#x2022;our', 'OmniAb Antibodies', 'Investors', 'Magenta Therapeutics, Inc.', '924\\n    &', 'x201c;Zenas Agreements.&#x201d', 'events;\\n  &#x2022;changes', 'OmniAb,', 'the U.S. Food and Drug Administration', 'the Zenas Option', 'OmniAb, Inc. (&#x201c;OmniAb&#x201d;)', 'Crystal Bioscience, Inc.', 'Related Party', 'utilized.\\n', '\\n        &', 'SEC', 'Restricted', '\\n  &#x2022;potential', '\\n  External', 'IONTAS Limited', 'the Zenas License', 'the Company&#x2019;s Current Report', 'Equity Securities', 'generally;\\n  &#x2022;expectations', 'Related PartyTo', 'The Zenas License Agreement', '\\n    &', 'License Revenue &#', 'x2022;A'}"
DOMH,"{'Trump Tower Commercial\\nLLC', 'ASU', '\\n    Investment in Unusual Machines&#160;\\n    &', 'Convergent Therapeutics', 'treasury', 'SEC Uniform Net Capital Rule', 'the Grant Agreement', 'Soo Yu&#8217;s', 'Condensed', 'portion&#160;\\n    &', 'portion&#160;\\n', '\\n    Investment in Tevva Motors&#160;\\n    &', '\\n    Investment', 'Convergent Therapeutics, Inc. (&#8220;Convergent&#8221;)\\nin', 'controls\\nand', 'AerocarveUS Corporation', 'the 22nd&#160;Floor Premises', 'ASP Isotopes&#160;\\n    &', 'Convergent', 'liabilities\\nto', 'Total&#160;\\n    $', '\\n&#160;\\n\\nInvestment\\nin Unusual Machines', 'Company', '\\n    Convergent', 'the Company adopted Accounting Standards Update', 'Dividend income&#160;\\n    &', 'Dominari Financial', '\\n    Investment in Automation Anywhere&#160;\\n    &', 'portion&#160;\\n    &#160;250&#160;\\n', 'the AerocarveUS Agreement', '\\n    &', 'Grant', 'Report'}"
DRIO,"{'L.P.', 'Credit Agreement', 'Hamas', 'The Preferred Stock', 'September&#160;30,&#160;2022', 'National Health Plan&#8203;On October 1, 2021,', 'the Series A-1 Convertible Preferred Stock', 'EQUITY', 'compensation&#8203', 'the Series B-2 Preferred Stock', 'Sanofi U.S. Services Inc.', 'the Orbimed Lender', 'Contentsopportunities', 'PlanSource', 'L.P. and Avenue Venture Opportunities Fund', 'Avenue Loan Facility', 'the United States Food and Drug Administration', 'the words &#8220;may,&#8221', 'the Compensation Committee of the Board of Directors', 'Parity Securities', 'the Initial Tranche', 'OrbiMed', 'Loan', 'the ADCES23 Annual Conference', 'consumers.&#8203;In', '11,927&#160;&#160;&#160;&#160;$*)-&#160;&#160;&#160;&#160;$ 307,561&#160;&#160;&#160;&#160;$', 'Avenue Venture Opportunities Fund II', 'the Series B-1 Preferred Stock', 'the Exclusive Agreement', 'ContentsDARIOHEALTH CORP.', 'LSA', 'Company', 'the Prime Rate', 'the Series B Preferred Stock', 'PsyInnovations Inc.', 'LabStyle Innovation&#160;Ltd', 'the Senior Securities', 'Preferred Stock', 'the Avenue Loan Facility', 'September&#160;14', 'Nasdaq', 'Series B Preferred Stock', 'Sanofi'}"
DRMA,"{'Financial Statements &', 'LLC', 'Dermata Therapeutics, Inc.', 'the License Agreement', 'Contents &', 'State', 'Note 2 &#8212', 'Diluted', 'Yes &#9744', 'the State of Delaware', 'DMT410', 'equivalents&#160;$390,189&#160;&#160;$(2,731,984 )&', 'Villani, Inc.', 'technologies.&#160;Critical Accounting Policies', 'Contents &#160;We', 'registeredCommon Stock', 'Contents &#160;General and', 'Administrative Expenses&#160;General', 'Delaware C-corporation', 'Common Stock', 'Company', 'the Securities Exchange Act', 'Nasdaq Capital MarketWarrants', 'the March 2023 Offering', 'the European Union', 'any.&#160;To'}"
DRRX,"{'ASC', 'DURECT Corporation', 'Cantor Fitzgerald &amp', 'ASU', 'management&#x2019;s', 'The Innocoll Agreement', 'Form S-3', 'the Loan Agreement', 'AHFIRM', 'ALZET', 'the U.S. Patent and Trademark Office', 'Oxford Finance', 'candidates;\\n  &#x2022;costs', 'Loan Agreement', 'Earn', 'Innocoll', 'Qualitative Disclosures', 'x201c;Risk', 'the &#x201c;Indivior Agreement&#x201d', 'including:\\n  &#x2022;continued', 'the Securities and Exchange Commission', 'candidates;\\n  &#x2022;competing', 'x2014;\\n        &', 'stockholders&#x2019', 'The Loan Agreement', 'Monte-Carlo', 'Innocoll Pharmaceuticals, Ltd.', 'Nasdaq&#x2019;s', 'POSIMIR', 'FDA', 'Sold Pursuant', 'the Innocoll Agreement', 'www.perseris.com.\\n  &', 'Orient Pharma Co., Ltd.', 'Innocoll Pharmaceuticals Limited', 'the &#x201c;2021 Sales Agreement&#x201d', 'PERSERIS', '\\n  &#', 'and\\n  &#x2022;unexpected', 'the February Offering', 'Loan', 'NetThe Company', 'LiabilitiesThe', 'POSIMIR&#174', 'Manufacturing\\n        &', 'the U.S. SABER&#174', 'the &#x201c;2021 Registration', '\\n        &', 'SEC', 'Common Stock', 'x201c;Loan', 'Company', 'Collaborative Research and Development and Other RevenueThe Company', 'any;\\n  &#x2022;costs', 'candidates;\\n  &#x2022;any', 'the &#x201c;Innocoll', 'Collaborative Research and Development and Other Revenue\\n  Collaborative', 'candidates;\\n  &#x2022;success', 'the Company&#x2019;s Loan Agreement', 'this Management&#x2019;s Discussion and Analysis of Financial Condition', 'Regulation S-K', 'the 2021 Registration Statement', 'Results of Operations', 'Indivior', 'Indivior UK Limited', 'larsucosterol\\n  &#160;\\n', 'research.\\n  &', 'Registered Direct'}"
DRTS,
DRUG,"{'Sellers', 'FASB', 'Financial Reporting', 'the Black-Scholes', 'Exhibit 32.1', 'this Quarterly Report', 'Basis of Presentation', 'recognition\\nand', 'Related Information&#8221', 'the Lender', 'Original June Report', 'DEA', 'Equipment\\n\\n\\n\\n\\n&#160;\\n\\nProperty,\\nplant', 'the\\n    Securities and Exchange Commission', 'the Condensed Consolidated Financial Statements', 'Company&#8217;s\\noperations', 'the Sellers.\\n\\n&#160;\\n\\nVoting\\nAgreement\\n\\n&#160;\\n\\nThe\\nVoting Agreement', 'the Company (Note 11).\\n\\n&#160;\\n\\nIncluded\\nin', 'Transferred Shares', 'Alterola', 'the &#8220;Repayment', 'Registrant', 'Alterola or\\nthe', 'this Quarterly Report on Form 10-Q.\\n\\n&#160;\\n\\nThese\\nfactors', 'Entity&#8217;s Own Equity', 'Form S-1', 'SEC', 'in\\nthe &#8220;Risk Factors&#8221', 'cannabis\\ncommercially', 'Memorandum of Agreement', 'DEA Document', 'Company', 'the investee.\\nThe Company', 'the Securities Exchange Act', 'Grants Greenhouse Growers, Inc.', 'Adopted Accounting', 'Company,\\nto', 'RB0649383', '\\n    &', 'Compensation- Stock Compensation', 'the Bright Green Group of Companies'}"
DSGN,
DTIL,
DVAX,
DXCM,
DYAI,
DYN,"{'thousands)\\n  &', 'and\\n  &#x2022;exemptions', '\\n    Interest income\\n    &', 'justified.\\n  &', 'Good Laboratory Practices', 'may:\\n  &#x2022;issue', 'contracts.\\n  &#', '\\n', 'operations.\\n  &#160;\\n', 'The Sarbanes-Oxley Act', 'all;\\n  &#x2022;delays', 'EMA', 'agencies.\\n  &#', 'results.\\n  &', 'revenue;\\n  &#x2022;suspension', 'develop.\\n  &', '\\n  &#x2022;costs', 'protocols;\\n  &#x2022;changes', 'directors;\\n  &#x2022;require', 'programs.\\n', 'candidates;\\n  &#x2022;subjecting third-party', 'section.\\n  &', 'PCT', 'Wave Life Sciences Ltd.', 'AOC', 'financial condition.\\n  &', 'the Public Company Accounting Oversight Board', 'law:\\n  &#x2022;any', 'penalties.\\n  &', '\\n    &#160;&#160;&#160;&#160;&#160;Facility', 'Manufacturers of America', 'Chamber of Commerce', 'BPCIA', 'Novartis Pharmaceutical Corporation', 'Janssen Pharmaceuticals, Inc.', 'Pepgen, Inc.', 'CPRA', '\\n    Research', 'ACA', 'UMONS', 'revenue.\\n  &#', '\\n  &#x2022;development', 'the Securities Exchange Act', 'compensation)\\n    &', 'Research', 'FSHD', 'technologies;\\n  &#x2022;actual', 'us.\\n  &', 'REGENXBIO Inc.', 'treatments.\\n  &#160;\\n', '\\n  &#x2022;expenses', 'the law;\\n  &#', 'and\\n  &', 'Property and Equipment Property', 'REGENXBIO', 'HHS', 'Boehringer Ingelheim Pharmaceuticals', 'DYNE-251', 'liability;\\n  &#x2022;expansion', 'WVE-N531', 'the U.S. Congress', 'traits.\\n  &#', 'Exon 51', 'collaborators.\\n  &', 'BioMarin Pharmaceuticals', 'culture.\\n  &', 'approach;\\n  &#x2022;changes', 'property.\\n  &', 'letters;\\n  &#x2022;withdrawal', 'Medicare', 'Medicaid', 'manufacturers&#x2019', 'x201c;Risk', 'and\\n  &#x2022;require', 'Exon 53', 'products;\\n  &#', 'procedures.\\n  &#160;\\n  58\\n', ': &', 'design;\\n  &#x2022;delays', 'FDA', 'the U.S. Chamber of Commerce', 'and\\n  &#x2022;establishment', 'control;\\n  &#x2022;collaborations', 'the Medicaid Drug Rebate', 'and\\n  &#x2022;any', 'reimbursement;\\n  &#x2022;the', 'Novo Nordisk Inc.', '\\n        Laboratory equipment\\n', 'and\\n  &#', 'EGC', 'efforts.\\n  &', 'efforts;\\n  &#x2022;retention', '\\n        Office', 'products.\\n  &#', 'HIPAA', 'the Trade and Cooperation Agreement', 'impacted.\\n  &', 'BMN', 'results;\\n  &#x2022;delays', 'FTC', 'activities\\n    &', 'personnel.\\n  &#', 'Patient-Centered Outcomes Research Institute', 'products;\\n  &#x2022;collaborators', 'Company', 'the European Commission/EMA&#x2019;s', 'the Chamber of Commerce&#x2019;s', '\\n  &#x2022;facilities', 'analysts;\\n  &#x2022;variations', 'USPTO', 'information.\\n  &#160;\\n', 'the California Privacy Rights Act', 'candidates;\\n  &#x2022;delays', '\\n  &#160;\\n', 'all.\\n  &', 'the Chamber of Commerce', 'the so called &#34;reliance', 'challenges;\\n  &#x2022;coordination', 'the Delaware General Corporation Law', 'the Public Health Service', 'prices;\\n  &#x2022;extension', '\\n  ', 'CMS.\\n  &', 'CMS', 'us;\\n  &#x2022;seize', 'benefits;\\n  &#x2022;occurrence', 'all;\\n  &#x2022;misappropriation', 'revenues.\\n  &#', 'share.\\n  &', 'litigation;\\n  &#x2022;disputes', 'DELIVER', 'the acquisition;\\n  &#x2022;cultural', 'directors;\\n  &#x2022;limit', 'Avidity', 'the Medicare Modernization Act', 'technologies;\\n  &#x2022;regulatory', 'the market;\\n  &#x2022;refusal', 'The Patient Protection', 'indicated.\\n  &#', 'the FCPA.\\n  &#', 'IRB', 'License', '\\n  &#', 'Fab', 'and\\n  &#x2022;termination', 'Bristol Myers Squibb Company', 'payers.\\n  &#160;\\n', '\\n    &', 'sanctions.\\n  &', 'litigation;\\n  &#x2022;substantial', 'Astellas Pharma US', 'harmed.\\n  &', '\\n    &#160;Total', 'patentable;\\n  &#x2022;the', '\\n    &#160;&#160;&#160;&#160;&#160;DYNE-101', 'medications.\\n  &', 'requirements.\\n  &', 'consent;\\n  &#x2022;limit', 'noncompliance;\\n  &#x2022;a', 'terminated;\\n  &#x2022;collaborators', 'IRA', 'bylaws.\\n  &', 'directors;\\n  &#', '\\n    &#160;&#160;&#160;&#160;&#160;Total', 'prospects.\\n  &', 'into.\\n  &', 'Comparison', 'options.\\n  &', 'parties.\\n  &', 'Entrada Therapeutics, Inc.', 'DMD', 'and\\n  &#x2022;injunctions', 'company;\\n  &#x2022;changes', '\\n    &#160;Unallocated', 'Form S-3', 'this Quarterly Report', '\\n    &#160;&#160;&#160;&#160;&#160;Platform', 'commercialization.\\n  &#', 'the American Medical Association', 'the product.\\n  &#160;\\n', '\\n  &', 'policies.\\n  &', 'including:\\n  &#x2022;the', 'approved.\\n  &', 'the Court of Chancery of the State of Delaware', 'European Union', 'the Health Care and Education Affordability Reconciliation Amendment', 'the University of Mons', 'AstraZeneca L.P.', 'x2022;refuse', 'MAA', 'required.\\n  &', 'revenue;\\n  &#x2022;reduced', 'practices.\\n  &', 'Medicaid Services', 'institute a &#x201c;poison pill&#x201d', '\\n    &#160;&#160;&#160;&#160;&#160;DYNE-251', 'The Foreign Corrupt Practices Act', 'patents;\\n  &#x2022;issued', 'the Anti-Kickback Statute', 'and\\n  &#x2022;in', 'the Medicare Prescription Drug', 'collaborators;\\n  &#x2022;adverse', 'PMO', 'suspended.\\n  &#', 'the U.S. District Court', 'SEC', 'stock.\\n  &', 'candidates.\\n  &', 'Exon 44', 'investment.\\n  &', 'BLA', 'approvals;\\n  &#x2022;suspension', 'Condensed Consolidated Statements of Cash Flows', 'the Centers for Medicare &', 'include:\\n  &#x2022;diversion', 'the Biologics Price Competition and Innovation Act', 'the future;\\n  &#', 'the European Union', 'the Pharmaceutical Research', 'securities.\\n  &', 'and\\n  &#x2022;collaboration', 'policies;\\n  &#x2022;liability'}"
DYNT,
EAR,"{'the Office of Personnel Management', 'LLC', 'PSC Echo', 'the Note Purchase Agreement', 'EEA', 'this Quarterly Report on Form 10-Q', 'EU', 'the U.S. Attorney&#x2019;s Office', 'the Internal Revenue Code', 'x2022;a', 'Merger Sub', '76\\n   &', 'Form S-1', 'the Children&#x2019;s Health Insurance Program', 'the Securities Exchange Act', 'PSC Echo Merger Sub Inc.', 'the European Economic Area', 'OPM', 'Chung Actions', 'Hana Microelectronics', 'COVID-19', 'some Organisation for Economic Co-operation and', 'the Rights Offering', 'the Merger Agreement', 'the Federal Employee Health Benefits (&#', 'the United States Patent and Trademark Office (&#x201c;USPTO&#x201d', 'x201c;Risk', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'PSC Stockholder&#x2019;s', 'the Risk Factor', 'the U.S. Department of Justice', 'FDA', 'RSU', 'PSC Echo Parent', 'The PSC Resale Registration Statement', 'HIPAA', 'the PSC Stockholder', 'general &#', 'FDARA', 'FTC', 'Company', 'Pegatron Corporation', 'see &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition', 'Adopted Pursuant to Section 302', '2002.&#134;\\n     &', 'the U.S. Securities and Exchange Commission', 'SVB', ': &#x2022;decreased', 'the Delaware General Corporation Law', '44\\n   &', '2022\\n         &', 'Board of Directors', 'DOJ', 'LeasesWe', 'the Sarbanes-Oxley Act', 'IPO', 'EEA Directives', 'Eargo, Inc.', 'the &#x201c;Merger', 'companies&#x2019', 'the Company&#x2019;s Board of Directors', 'Board', 'the Civil Division of the DOJ', 'the Board of Directors', 'the Court of Chancery of the State of Delaware', 'the PSC Stockholder and Drivetrain Agency Services', 'the State of Delaware', '63\\n   &', 'an Intervening Event', 'PMA', 'the OTC Final Rule', 'the Court of Chancery', 'SEC', 'Victra', 'FEHB', 'Nasdaq'}"
ECOR,"{'\\n\\n\\n9\\n\\n\\n\\n\\n\\n &#160', '\\n\\n\\n(103\\n\\n)\\n\\n &#160', 'the Nasdaq Capital Market', 'NHS Supply Chain', 'Critical Accounting Policies and Estimates', '\\n\\n\\n &#160', 'the Securities and Exchange Commission).\\n&#160;\\n\\n\\n\\n\\n\\n30\\n\\n\\n\\n\\n\\n\\n\\n\\nItem&#160;6.&#160;EXHIBITS\\n&#160;\\n\\n\\n\\n\\nExhibit\\nNumber\\n\\n\\n&#160;\\n\\n\\nDescription\\n\\n\\n\\n10.1**\\n\\nelectroCore, Inc.', '\\n\\n\\n3,847\\n\\n\\n &', 'The 2022 Shelf Registration Statement', 'Consolidated', 'Operations\\nComparison', '\\n\\n\\n1,067\\n\\n\\n\\n\\n\\n Total', '30,\\n\\n\\n &#160', 'NJ', '\\n\\n\\n403\\n\\n\\n\\n\\n\\n Gross', 'Citibank', '\\n\\n\\n Change \\n\\n\\n &#160', 'Grant Program', 'the Securities and Exchange Commission', '\\n\\n\\n5,657\\n\\n\\n &', 'N.A', '\\n\\n\\n1,430\\n\\n\\n\\n\\n\\n Other', 'Qualitative Disclosures About Market Risk\\nWe', '\\n\\n\\n2022\\n\\n\\n &#160', 'the Shelf Securities', 'Department of Veteran Affairs', 'Principal Executive Officer Pursuant', '\\n\\n\\n1,249\\n\\n\\n &#160', '\\n\\n\\n1,617\\n\\n\\n &', 'Nasdaq Listing Rule', 'United', 'nVNS', 'the Chair of the Nominating and Governance Committee.\\n(b', '\\n\\n\\n7,973\\n\\n\\n\\n &#160', 'the Condensed Consolidated Statement of Cash Flows', 'Discussion and Analysis of Financial Condition', 'Force Research Laboratories', '\\n\\n\\n7,274\\n\\n\\n &#160', '\\n&#160;\\n\\n\\n\\n\\n\\n &', '\\n\\n\\n1,718\\n\\n\\n &#160', 'SEC', '\\n\\n\\n\\n\\n\\n &#160', 'Company', 'the Securities Exchange Act', '\\n\\n\\n(4,126\\n\\n)\\n\\n &#160', 'Sections 11', 'Department of Defense\\n\\n$\\n6,523\\n\\n\\n$\\n3,597\\n\\n\\n\\nRx gammaCore&#160;-', '\\n\\n\\n(94\\n\\n)\\n\\n &#', 'the 2022 Shelf Registration Statement', 'the Sarbanes-Oxley Act', 'Adopted Pursuant to Section 302', 'Regulation S-K', 'IPO', 'Commercial Insurance Premium Finance', 'the United States Department of Defense Biotech Optimized for Operational Solutions and Tactics', 'TAC', 'Real-Time Assessing', '\\n\\n\\n661\\n\\n\\n &', '\\n\\n\\n\\n\\n &#160', 'Licensed Products \\n\\n\\n\\n\\n\\n\\n\\n\\nThe Company'}"
EDAP,
EDIT,"{'OverviewWe', 'Juno Therapeutics, Inc. (&', 'BMS', 'Juno Therapeutics, Inc.', 'OperationsComparison', 'Principal Financial Officer', 'Bristol Myers Squibb Company (&#8220;BMS&#8221', 'the Securities and Exchange Commission', 'the Annual Report', 'this Quarterly Report on Form 10-Q', 'Immatics N.V.', 'ContentsComparison', 'Vor Biopharma Inc.', 'funds141,522&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;141,522&#160;Corporate', 'Part I, &', 'No &#9744;Indicate', 'Registrant', 'net$11,559&#160;$15,569&#160;7', 'the Bristol-Myers Squibb Company (&#8220;BMS&#8221', 'Principal Executive', 'Principal Financial Officer32.1+Certification', 'Company', 'RUBY', 'BusinessEditas Medicine, Inc.', 'the Securities Exchange Act', 'administrative14,987&#160;16,236&#160;(1,249)(8)%Total', 'Allergan Pharmaceuticals International Limited', 'Regulation S-K', 'ContentsCollaboration'}"
EDSA,
EFTR,"{'eFFECTOR Therapeutics, Inc. (&', 'years)\\n        &', 'MayTwoThousandTwentyThreeCommonStockWarrantsMember2023', 'Oxford', 'the &#34;Company&#34', 'Security Agreement', 'JuneTwoThousandTwentyThreeRegisteredDirectOfferingMember2023-01-012023-09-300001828522eftr', 'JuneTwoThousandTwentyThreePlacementAgentWarrantMember2023-09-300001828522us-gaap', 'Translational Profiling Patent', 'The Triggering Event', 'the Warrant Agreement', 'Exhibits.\\n  &#160;\\n', 'OxfordFinanceLlcMember2023-01-012023-09-3000018285222022-07-012022-09-300001828522us-gaap', '\\n  &#x2022;costs', 'Lincoln Park', 'eFFECTOR Therapeutics Operations', 'Prospectus', 'Registered Direct Offering', '\\n  Financial Operations Overview \\n  Revenue \\n', 'The Regents of the University of California', 'OxfordFinanceLlcMember2023-01-012023-09-300001828522eftr', 'OxfordFinanceLlcMember2023-01-012023-09-300001828522us-gaap', 'DARPA', '\\n    Research', 'JuneTwoThousandTwentyThreeRegisteredDirectOfferingMember2023-01-012023-09-300001828522us-gaap', '\\n      &', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'the Regents of the University of California (&#x201c;UCSF&#x201d', 'EquityPurchase AgreementOn', 'COVID-19', '\\n  &#x2022;external', 'General Instruction I.B.6', '\\n  &#x2022;expenses', 'AociIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-03-310001828522eftr', 'OxfordFinanceLlcMember2022-02-222022-02-220001828522eftr', 'the Merger Agreement', 'Company\\', 'Pfizer', 'the Pfizer Agreement', 'Locust Walk Acquisition Corp.', 'The Subaward Agreement', 'the Subaward Agreement', 'See &#x201c;Business &#', 'x2014;\\n        &', 'MaximumMember2022-01-242022-01-240001828522eftr', 'THE SECURITIES EXCHANGE ACT OF', 'BasedOnLicenseMember2023-09-300001828522eftr', 'LLC (&#34;Lincoln', 'Prospectus Supplement', 'Loan', 'MayTwoThousandTwentyThreePlacementAgentWarrantsMember2023-01-012023-09-300001828522us-gaap', 'Continental Stock Transfer  &amp', 'Company', 'MaximumMember2022', 'expense)\\n    &', '\\n    &#160;&#160;&#160;&#160;4.3\\n    &', 'Adopted Pursuant to Section 302', 'ZFA', 'JuneTwoThousandTwentyThreeCommonStockWarrantsMember2023-01-012023-09-300001828522eftr', 'OxfordFinanceLlcMember2023-07-012023-09-300001828522eftr', 'Charter)\\n  &#', '\\n  Liquidity and Capital Resources \\n', '\\n    &#', 'thereunder.\\n  &#', 'StockholdersMember2022', 'the Merger Sub', 'Cantor Fitzgerald &amp', 'MeasurementInputPriceVolatilityMember2022-12-310001828522eftr', 'DebtInstrumentTermLoanBMember2022-02-222022-02-220001828522eftr', 'Oxford Finance', 'MaximumMember2023-01-012023-09-300001828522eftr', 'Exchange Act', 'EarnoutSharesReservedForFutureIssuance1Member2022-01-012022-09-300001828522eftr', 'Stockholders&#x2019', 'the Sales Agreement', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'Trust Company', 'the Research Collaboration and License Agreement', '\\n  &#', 'Pfizer (&', 'the Research Subaward Agreement', 'DebtInstrumentTermLoanBMember2022-02-222022-02-220001828522eftr:PrivatePlacementWarrantsMember2023-09-300001828522eftr:', 'USTreasurySecuritiesMember2022-01-012022-12-310001828522us-gaap', 'ZF', 'Lincoln Park Capital Fund', 'LeaseholdImprovementsMember2022-12-310001828522us-gaap', 'FairValueMeasurementsRecurringMember2023', 'MeasurementInputPriceVolatilityMember2022-12-310001828522us-gaap', 'OxfordFinanceLlcMember2023-09-300001828522us-gaap', 'the Sarbanes-Oxley Act', 'Earn-Out Shares', 'Comparison', 'Grant', 'the Purchase Agreement', 'AociIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001828522us-gaap', 'this Quarterly Report', 'eIF4E', 'Pfizer Agreement \\n', 'LWAC', 'BuildingMember2023-01-012023-09-300001828522us-gaap', 'Cantor', 'CooperativeAgreementMember2023-07-012023-09-300001828522us-gaap', 'PrivatePlacementMember2023-01-012023-09-300001828522us-gaap', 'BuildingMember2022', 'OxfordFinanceLlcMember2022', 'UCSF', 'Continental Stock Transfer &amp', '\\n        &', 'Controlled Equity Offering Sales Agreement', 'WarrantMember2023-01-012023-09-300001828522eftr', 'SEC', 'ATM Offering', 'Oxford Loan Facility', 'the &#x201c;Purchase', 'Co (&#34;Cantor&#34', 'the Business Combination', 'TwoThousandAndTwentyOneEquityIncentivePlanMember2023', '\\n    &', 'Equity Line of Credit'}"
EGRX,"{'ASC', 'Company\\', 'the Purchase Agreement the Company', 'accounting\\nat', '2022\\n\\n(UNAUDITED)\\n\\n\\n&#160;\\n\\nNote\\n1 &#8211', 'Board', 'Android', 'Beyond Visual\\nLine of Sight (&#8220;BVLOS&#8221', 'Alpha Capital Anstalt (&#8220;Alpha&#8221', 'PBO', 'Contracts', 'Continued\\n\\n&#160;\\n\\nSegment\\nReporting &#8211', 'Intangible Assets &#8211', 'Series F Preferred Stock\\nconvertible', 'AgEagle', 'Measure Ground Control\\n    ', 'the Securities and Exchange Commission', 'RGB', 'exercisable\\non a &#8220;cashless&#8221', 'senseFly S.A.', 'the Series F Warrants', 'the Monthly Amortization Payments', 'Description of the Business and Basis of Presentation', 'Series F Convertible Preferred', 'RedEdge', 'the Maturity Date', 'COVID', 'the Warrant Shares', 'the Investors of the Warrant Shares', 'AgEagle Aerial', 'Warrant Exchange Agreement', 'senseFly Inc.', 'the Manufacturing Agreement', 'the Internal Revenue Code', 'Equity &#8211', 'the Certificate of Designation', 'Board Agreements\\n\\n&#160;\\n\\nThe\\nCompany', 'CONDENSED CONSOLIDATED FINANCIAL', 'Future Offering', 'RedEdge-P', 'Inc.;\\nMeasure Global, Inc.', 'cancelled.\\n\\n&#160;\\n\\nNote\\n8 &#8211', 'SEC', 'Significant Accounting Policies &', 'Common Stock', 'Darley', 'Company', '\\n\\n&#160;\\n\\nNote\\n6 &#8211', 'revenues\\nor', 'the Series\\nF Warrants', '2022\\n\\n(UNAUDITED)\\n\\n&#160;\\n\\nNote\\n9 &#8211', 'eBee', 'Preferred Stock', 'eBee VISION', 'the COVID Loan', 'Additional Warrant.\\n\\n&#160;\\n\\nAs\\na', 'assemble\\nproducts.\\n\\n&#160;\\n\\nUse\\nof Estimates &', '\\n    &', 'future.\\n\\n&#160;\\n\\nPurchase\\nCommitments\\n\\n&#160;\\n\\nThe\\nCompany', 'the Purchase Agreement', 'Warrants'}"
EIGR,"{'net$11,720&#160;$10,038&#160;$1,682&#160;17&#160;%Other', 'Good Manufacturing Practices', 'the Accelerated Approval Program', 'Financial Instruments &#8211', 'Innovatus', 'State', 'EMA', 'Amendment of Amended and Restated Certificate of Incorporation of Celladon Corporation', 'Principal Executive Officer', 'the EU Commission', 'Financial Instruments', 'EEA', 'this Quarterly Report on Form 10-Q', 'EU', 'The Accelerated Approval Program', 'netProduct', 'Topics', 'HTA', 'CPRA', 'pre-NDA', 'market&#8221', 'the Listing Qualifications Department', 'The Nasdaq Stock Market LLC', 'the Securities Exchange Act', 'NOL', 'Jefferies', 'COVID-19', 'PRF', 'the Office of Civil Rights', 'The Progeria Research Foundation', 'Internal Control', 'Medicaid', 'Medicare', 'Congress', 'HDV', 'Zokinvy', 'FDA', 'Loan', 'fair', 'the Medicaid Drug Rebate Program', 'Company', 'Tranche B', 'Tranche C', 'USPTO', 'the Innovatus Loan', 'federal and/or state breach notification laws', 'the Registration Statement on Form S-4', 'the Accelerated Approval Pathway', 'the Leahy-Smith Act', 'Letter Agreement/Employment Agreement', 'NIP', 'Institutional Review Board', 'the Delaware General Corporation Law', 'CMS', 'the Swiss Federal Data Protection and Information', 'OperationsComparison', 'Principal Financial Officer', 'Innovatus Life Sciences Lending Fund I, LP (Innovatus', 'this Quarterly Report on Form 10-Q.', 'TOGETHER', 'CCPA', 'the California Privacy Protection Agency', 'deemed &#8220;at', 'Orphan Drug', 'NetOur', 'PBH', 'the Department of Health and Human Services', 'Eiger BioPharmaceuticals', 'IRB', 'RiskFinancial', 'Financial ReportingThere', 'the Bid Price Requirement', 'Financial Operations OverviewProduct Revenue', 'the Common Stock', 'NDA', 'September&#160;30, 2023.The Company', 'Tranche', 'PL', 'This Quarterly Report on Form 10-Q', 'Form S-3', 'Board', 'the Swiss-U.S. Privacy', 'Accelerated Approval', 'District Court', 'FDA&#8217;s', 'the Standard Contractual Clauses', 'ContingenciesLease AgreementsIn', 'the Federal Food, Drug and Cosmetic Act', 'pre-New Drug Application', 'the Oxford Loan', 'SEC', 'GCP', 'BLA', 'Ingrid Choong.10.2**&#8224;Promotion Letter Agreement', 'Credit Losses', 'HGPS'}"
EKSO,
ELAB,"{'the Condensed Consolidated Financial Statements\\n\\n(Unaudited &', 'ASU', '\\n    Foreign exchange', 'price).\\n\\n&#160;\\n\\n\\n11.Derivative', 'the Black-Scholes Option Pricing Model', 'as\\nfollows:\\n\\n&#160;\\n\\n\\n  \\n    &', 'channel.\\n\\n&#160;\\n\\nOutlook\\n\\n&#160;\\n\\nManagement&#8217;s', '2022,\\nthe Company', 'customer\\nis', 'the Registration Statement', 'diluted&#160;\\n    &', 'YiGuoMember\\n', 'Reactive Medical Inc.', 'Empower', 'EDGAR', 'Principal Accounting', '\\n\\n\\n&#160;\\n\\nThe Company', 'Company&#8217;s\\ncommon', 'new\\nlab', 'Bensler', '\\n    Office', 'the U.S. Securities and Exchange Commission\\n(the &', '\\n    Research', 'Form S-1', 'Labs Inc.', 'Principal Executive', 'Company', 'Pursuant', 'revenues\\nor', 'Elevai Research', '\\n\\n\\n&#160;\\n\\nWe', 'Research Inc.', 'the Sarbanes-Oxley Act', 'Principal Financial Officer Pursuant', 'IPO', 'compensation&#160;\\n    &', 'GB Capital Ltd.', 'CFO', '499,311)&#160;\\n    $', '\\n    &', 'Enfinity'}"
ELDN,"{'all;\\n  &#x2022;the', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n', 'candidates;\\n  &#x2022;the', 'Board;\\n  &#x2022;require', 'the Federal Food, Drug', 'EEA', 'Significant Accounting PoliciesBasis', 'IgA Nephropathy', 'Jefferies LLC', 'EU', 'compromised.\\n  Clinical', 'our Board;\\n  &#x2022;limit', 'L.P., Biotechnology Value Fund II', 'Bristol Myers Squibb', 'Indicate', 'commercialization.\\n  Specifically', '\\n    Research', 'Securities Purchase Agreement', 'the European Economic Area', 'L.L.C.', 'the &#x201c;baby shelf &#x201d', 'COVID-19', 'Adopted Accounting PronouncementsNo', 'ALS', 'compensation\\n    &', 'the Securities Purchase Agreement', 'develop.\\n', 'ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2023-01-012023-09-300001404281stpr', 'the pandemic;\\n  &#x2022;limitations', '\\n  Collaboration Agreement with eGenesis for Xenotransplantation Studies\\n  ', 'x201c;eGenesis', 'the &#x201c;baby shelf rules&#x201d', 'CNI', 'we:\\n  &#x2022;conduct', 'the Securities and Exchange Commission', 'candidate;\\n  &#', 'Armistice Capital Master Fund Ltd.', 'letters;\\n  &#x2022;withdrawal', 'Medicare', 'and\\n  &#x2022;require', 'x2014;\\n        &', 'the &#x201c;Series X1 Exchange', 'SeriesXOnePreferredStockMember2023-09-300001404281us-gaap', '27\\n', 'Expired\\n        &', 'eGenesis', 'FDA', 'national data protection authority', 'x201c;Lonza', 'Unaudited)\\n  &#160;\\n', 'Ligand', 'and\\n  &#x2022;any', 'or\\n  &#x2022;injunctions', 'and\\n  &#', 'Cash EquivalentsThe Company', 'and\\n  &#x2022;operate', 'Anelixis Therapeutics, Inc. (&#x201c;Anelixis&#x201d;)', 'the Private Placement', 'UCB', 'use;\\n  &#x2022;requirements', 'x201c;Common', 'activities\\n    &', 'Eledon', 'Company', 'Lonza Sales AG Inc.', 'profits.\\n', 'EU&#x2019;s', 'the Pre-Funded Warrants', 'technologies;\\n  &#x2022;our', 'USD\\n  &', '\\n  ', 'CMS', 'ArmisticeCapitalMasterFundLtdMember2023', 'ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2023-01-012023-09-300001404281us-gaap', 'technologies;\\n  &#', 'diagnostics;\\n  &#x2022;the', 'the market;\\n  &#x2022;refusal', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'the ATM Program', 'ALSTherapyDevelopmentFoundationIncLicenseAgreementMember2023', '\\n  &#', 'CommonStockWarrantsMember2022-12-3100014042812022-09', 'Horizon Therapeutics', 'CommonStockWarrantsMember2022-12-310001404281eldn', 'Amgen', 'eGenesis, Inc. (&#x201c;eGenesis&#x201d;)', 'Tregs', 'consent;\\n  &#x2022;limit', 'prices;\\n  &#', 'ELEDON', '\\n    Increase', 'the Securities Purchase Agreement with Purchasers', 'Biotechnology Value Fund', 'INC', 'FairValueMeasurementsRecurringMember2023', 'Board;\\n  &#', 'candidates;\\n  &#x2022;acquire', 'organization)\\n    &#160;\\n', 'L.P., Biotechnology Value Trading Fund OS', 'Legal MattersThe Company', 'Form S-3', 'organizations;\\n  &#x2022;delays', 'Board', 'The ALS Therapy Development Institute', 'this Quarterly Report', 'Series X1 Preferred Stock', '\\n  &#9744;\\tTRANSITION', 'eGenesis, Inc.', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09', 'ESPP', 'people;\\n  &#x2022;refusal', 'eGenesis&#x2019', 'institute a &#x201c;poison pill&#x201d', 'Pre-Funded Warrants', 'Healthcare', 'x201c;Private', 'ALS TDI', '\\n        &', 'SEC', 'GAAP', '\\n    &'}"
ELEV,
ELTX,"{'ASC', 'the GI Research Foundation', 'Angion Biomedica Corp (&', 'Arkham Merger Sub, Inc.', 'THERAPEUTICS', 'InformationDuring', 'ESC', 'Elicio Securities Corporation', 'ESPP', 'Compensation ExpenseThe', 'Credit Risk and Off-Balance Sheet RiskFinancial', 'NetProperty', 'Sarbanes-Oxley Act', 'the Public Company Accounting Oversight Board', 'Administrative ExpensesGeneral', 'Sarbanes-Oxley', 'No &#9744;Indicate', 'ExpensesAccrued', 'Angion (the &#8220;Merger&#8221', 'and/or &#', 'SEC', 'Company', 'Angion (&#8220;Merger', 'Angion Biomedica Corp.', 'the period$&#8212;&#160;$&#8212;&#160;Existing Angion Warrant Liability9&#160;&#8212;&#160;Change', 'IPO', 'expenses13&#160;4&#160;Total', 'Elicio Operating Company, Inc.', 'the Gastro-Intestinal (&#8220;GI&#8221;) Research Foundation', 'Black-Scholes'}"
ELUT,
ELVN,"{'API', 'Contractual Obligations', 'Russia&#x2019;s', 'EMA', 'EEA', 'Jefferies LLC', 'federal and/or', 'EU', '\\n  &#x2022;consent', 'x2022;a', 'PIPL', 'consultants;\\n  &', 'ACA', 'the Securities Exchange Act', 'pay&#x201d', 'COVID-19', 'the Merger Agreement', 'FASB', 'activities.\\n  &', 'x2022;if', 'the Accounting for Income Taxes', 'ContingenciesLease', '\\n  &#x2022;product', '\\n  &#x2022;significant', 'the Personal Information Protection Law', '\\n  &#x2022;assimilation', '\\n  &#x2022;publicity', '\\n  &#x2022;issued', 'x201c;Risk', 'The Executive Order', 'the Securities and Exchange Commission', 'Medicaid', 'Congress', 'Medicare', 'Obtaining', 'SVB Securities', 'GDPR', 'FDA', '\\n  &#x2022;collaborations', 'NetProperty', '\\n        Laboratory equipment\\n', 'and\\n  &#', 'the &#x201c;say', 'depreciation\\n        &', 'Company Common Stock', 'include:\\n  &#x2022;payments', 'classified.&#160;Black-Scholes', '\\n  &#x2022;warning', 'HIPAA', 'stock.&#x2022;Risk-Free Interest', '\\n  &#x2022;requirements', 'private &#', 'REMS', '\\n  &#x2022;others', '\\n  &#x2022;collaboration', '\\n  &#x2022;fines', '69\\n', 'Company', '\\n  &#x2022;changes', 'management&#x2019;s attention', '\\n  &#x2022;total', 'USPTO', 'the California Privacy Rights Act', '\\n  &#160;\\n', '\\n  &#x2022;whether', 'the Delaware General Corporation Law', 'ASU', 'External', 'efforts;\\n  &#x2022;failure', 'Imara Inc.', 'FCPA', 'and\\n  26\\n', '\\n  &#x2022;the', 'the U.S. Department of Health and Human Services', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;timing', 'Dividend Yield&#x2014;The Company', '\\n  &#x2022;suspension', '\\n  &#', '\\n  &#x2022;market', '\\n  &#x2022;imposition', 'the Trans-Atlantic Data Privacy Framework', '\\n  &#x2022;collaborators', 'the &#x201c;Exchange', 'plaintiff.&#160;The Company', 'NDA', '\\n  &#x2022;additions', 'Restated Certificate of Incorporation', 'IRA', 'FDA&#x2019;s Oncology Center of Excellence', 'DOJ', 'unclear.\\n  &', '\\n  &#x2022;announcement', 'Internal', 'LeasesFacility', '\\n  &#x2022;The', 'research.\\n  &', '\\n  &#x2022;our', 'PGR', '\\n  &#x2022;announcements', 'Form S-3', '\\n  &#160;\\n  ', '\\n  &', '\\n  &#x2022;voluntary', '\\n  &#x2022;actions', '\\n  &#x2022;delays', 'the Court of Chancery of the State of Delaware', 'ESPP', 'Complaint', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', 'Medicaid Services', '\\n  &#x2022;restrictions', 'otherwise.\\n  &', 'Foreign Currency Exchange Risk \\n', 'Development\\n  Research', 'U.S. Treasury', 'the Financing Transaction', '\\n        &', 'SEC', 'stock.\\n  &', 'realized.&#160;The Company', 'Iguana Merger Sub, Inc. (&#34;Merger Sub&#34', 'candidates.\\n  &', 'Pharmaron', 'Juerling v. Imara Inc.', 'the Centers for Medicare &', '\\n  &#x2022;failure', '\\n    &', '\\n  &#x2022;sales', 'The Leahy-Smith Act', '\\n  &#x2022;expiration'}"
ELYM,"{'\\n  &#x2022;develop', 'common stock;\\n  &#x2022;provide', 'directors;\\n  &#x2022;prohibit', 'operations.\\n  &#160;\\n', 'EEA', 'resources.\\n  &#160;\\n', 'proceeding.\\n  &#', '\\n  &#x2022;attract', 'the Public Company Accounting Oversight Board', 'Trademark Office', 'the Infrastructure Investment and Jobs Act', 'decline.\\n  &#160;\\n', 'incorporation.\\n  &', 'CPRA', 'the Securities Exchange Act', 'products;\\n  &#x2022;injury', 'COVID-19', 'Principal Financial Officer Pursuant', '\\n  &#x2022;complete', 'Adopted Accounting', 'FASB', 'collaborators.\\n  &', 'and\\n  &#x2022;require', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'Congress', 'stockholders.\\n  &', 'and\\n  &#x2022;refusal', 'FDA', 'Contractual Commitments', 'and\\n  &#', 'Company', 'time.\\n  &', 'USPTO', 'unlawful.\\n  &#x2022;We', '\\n  &#x2022;impose', 'transit disruptions;\\n  &#x2022;changes', 'Adopted Pursuant to Section 302', 'quarantine;\\n  &#x2022;interruption', '\\n  &#x2022;seize', 'the Delaware General Corporation Law', 'ASU', 'stock;\\n  &#x2022;require', 'consequences.\\n  &', 'directors;\\n  &#x2022;provide', '7\\n     &#160;Recently', 'the Federal Depository Insurance Corporation and Financial Services Compensation Scheme', 'the Nasdaq Stock Market', '\\n  &#', 'Registrant', '\\n  &#x2022;require', 'LSRP', 'ContingenciesFacility LeasesThe Company', 'the Sarbanes-Oxley Act', 'Economy,&#x201d', 'IPO', '\\n  &#x2022;mandate', 'into.\\n  &', 'ASU No', 'None.\\n  &', 'vendors;\\n  &#x2022;interruption', 'litigation costs;\\n  &#x2022;substantial', 'revenue;\\n  &#x2022;diversion', 'endpoints;\\n  &#x2022;diversion', '\\n  &', '44\\n', 'the U.K. International Data Transfer Agreement', 'ROU', '299\\n        &', 'the U.S. Food and Drug Administration', '\\n  &#x2022;set', 'EU GDPR&#x2019;s', 'x2022;refuse', 'operations.\\n  &', '\\n  &#x2022;suspend', '\\n  &#x2022;obtain', 'harmed.\\n  &#160;\\n', 'Issuer Purchases of Equity', 'SEC', 'the U.S.\\n  &#', 'stock.\\n  &', 'candidates.\\n  &', 'agents.\\n  &', 'consent;\\n  &#x2022;specify', 'the Budget Control Act', 'Equity Securities', 'Schedule A thereto\\n'}"
EMBC,
ENGN,
ENLV,
ENSC,"{'FASB', 'LLC', '\\n \\n\\n\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n&#160;\\n\\nUNITED\\nSTATES\\n\\nSECURITIES\\nAND EXCHANGE', 'aggregate\\nat', 'Consolidated Statements', 'references\\nto &#8220;LACQ&#8221', 'The Prior Warrants', 'this Quarterly Report on Form 10-Q', 'The Public Warrants', 'the GEM Agreement', 'Lake Street Capital Management', 'Omnibus Incentive', 'THE SECURITIES EXCHANGE ACT OF', 'Company&#8217;s\\nrights', 'NIH', 'The Nasdaq\\nStock Market', 'Leisure Acquisition Corp.', '\\n    &', 'NIDA', 'pursuant\\nto', 'P5Y\\n  \\n', 'the holder.\\n    &', 'and\\n  \\n    &', 'Common Stock', 'Company', 'Securities Purchase Agreement', 'Certificate of Incorporation', 'GEM', '\\n\\n\\n\\n\\n\\n&#160;\\n\\nReverse\\nstock', 'Nasdaq', 'Consolidated Financial Statements', '\\n    &#'}"
ENSG,"{'\\n  &#x2022;injury', 'years)\\n        &', 'LLC', 'AMD', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n    Interest income\\n    &', '\\n  &#x2022;variations', '\\n  Commission File Number 001-39782', '\\n', 'Medicaid Innovation (&#x201c;CMMI&#x201d;)', '\\n  &#x2022;expansion', 'the University of PennsylvaniaOn April 21, 2023', 'EMA', '\\n  &#x2022;disruptions', 'the Regents of the University of California', '\\n  &#x2022;an', 'Rights Agreement', 'Uneek Mehra\\n', '\\n  &#x2022;termination', 'this Quarterly Report on Form 10-Q', 'the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program', 'the University of California The Company', 'Jefferies LLC', '223,327\\n    &', '\\n  &#x2022;costs', 'B.V. (&#x201c;uniQure&#x201d', 'Molecular Therapeutics, Inc.', 'x2022;a', 'UNITED STATES', 'Effects of Inflation\\n', 'the &#x201c;License', '\\n    Research', 'AGT the Transferred Material', 'UC Agreements', 'ACA', 'Segment Information The Company', 'the Securities Exchange Act', '\\n  &#x2022;expenditures', 'the S-3 Registration Statement', 'COVID-19', 'the License Agreement).Aevitas Therapeutics, Inc.', 'the University of Pennsylvania', 'the Company&#x2019;s 2022 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'the Funding Agreement', 'Registration Statement on Form S-1', 'FASB', '2022\\n         \\n         \\n          &#160;Customer', '\\n  &#x2022;product', 'DirectorPrincipal Executive', '\\n  &#x2022;sufficient', 'the &#x201c;UC Agreements&#x201d', '\\n  &#x2022;publicity', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'CFF', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;general', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'Licensed Products', 'requirements.\\n  &#x2022;Our', 'parties)\\n    &', 'and\\n  &#', 'Registration Statement on Form S-3', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'Center for Medicare &', '\\n  &#x2022;others', 'the Medicaid Drug Rebate Program', 'the Amended uniQure Agreement', 'x201c;CFF', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;loss', '\\n  &#x2022;new', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '99%\\n          &#160;\\n', 'Catalent', 'USPTO', '\\n  &#x2022;impose', '\\n  &#x2022;seize', 'DME', '\\n    &#', 'Report', 'the Delaware General Corporation Law', '\\n  &#x2022;diligence', '\\n  ', 'Capital Requirements \\n', 'the UC Agreements', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD', 'UK Data Protection Act 2018', '\\n  &#x2022;future', 'the Program Advisory Group', '\\n  Interest Rate Sensitivity', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'the Sales Agreement', '497\\n        &', '\\n  &#x2022;coverage', 'Roche', '\\n  &#x2022;exhaustion', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;commencement', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;retention', 'Registrant', 'the UC Regents', '\\n          &', 'technologies.\\n  &#', 'Condensed Statements of Operations', '10\\n       &', '\\n  &#x2022;announcement', 'IPO', 'AWA', '\\n  &#x2022;The', 'companies&#x2019', 'ASU No', 'the Amended uniQure Agreement or the Second uniQure Agreement', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Therapeutic Vector Evolution', 'Form S-3', '\\n  &#x2022;convenience', 'the License Agreement', 'GA', '\\n  &#x2022;We', 'the Funding Agreement Product (&#x201c;Acceptance&#x201d;)', 'the &#x201c;August 2023', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '500\\n    &', 'harmed.\\n  &#x2022;Our', 'European Union', 'Condensed Statements of Comprehensive Loss', '99%\\n          &#', 'the State of Delaware', 'x2022;refuse', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', '\\n  &#x2022;suspend', 'frames.\\n  &', '\\n  &#x2022;the FDA', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Related Party Transactions', 'the Court of Chancery', 'Significant Accounting Policies', 'the &#x201c;Funding Agreement', '\\n        &', 'SEC', 'ATM Offering', 'agreements.\\n', 'Collaboration and License Agreement', 'BLA', 'The CFF Agreement', 'the Centers for Medicare &', 'the University of California and The Trustees of the University of Pennsylvania', '\\n  &#x2022;failure', 'Aevitas Therapeutics, Inc. (&#x201c;Aevitas&#x201d;)', '\\n  &#x2022;reduced', 'the European Union', '\\n  Litigation', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
ENTA,
ENTX,"{'Consolidated Statements of Operations', 'FASB', 'products.\\n                    &', 'LLC', 'ASU', 'Analog', 'Hamas', 'the Israeli Encouragement of Research, Development and Technological Innovation', 'Prepaid', 'DILUTED', 'OPKO Biologics, Inc.', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS&#160;(U.S. dollars', 'NIS 0.0000769', 'ATM', 'GLP-2', '\\n                   &', 'statements.\\n          &', 'PTH', 'OPKO Health, Inc. (&', 'Bone Mineral Density', 'Consolidated Statements of Cash Flows', 'Delivery Technology Enabling Gastro-Mucosal Absorption of Glucagon-Like', 'FDA', 'enter.&#160;As', 'the Condensed Consolidated Financial Statements', 'OF CONTENTS&#160;&#160;PageCONDENSED CONSOLIDATED FINANCIAL STATEMENTS:&#160;Condensed Consolidated Balance Sheets', '\\n              &', 'Entera Bio Inc.', 'FLOW INFORMATION:\\n              &#160;\\n              &#160;\\n              &#160;\\n              &#160;\\n              &#160;\\n              &#160;\\n              &#160;\\n              &#160;\\n', '\\n          &#160;\\n', 'the International Journal of Peptide Research and Therapeutics, &#8220;Oral', 'Ordinary Shares', 'the European Medicines Agency', 'Amgen', 'BMD', 'Nasdaq Capital Market (&#8220;Nasdaq&#8221', 'Registration Statement on', 'ENTERA', '\\n        &', '\\n      &', '\\n          &', 'LB', 'IIA', 'Company', 'the Amgen Agreement', 'the IIA.&#160;Recent Developments Potentially Affecting Our', 'BIO', '\\n          &#', 'Consolidated Statements of Changes', 'Credit Losses on Financial Instruments.&#8221', 'IPO', 'No &', 'Item 408 of Regulation S-K.&#160;ITEM', 'RESTRICTED', 'the U.S. Securities and Exchange Commission'}"
ENVB,"{'ASC', 'FASB', 'Common Stock that\\nwe', 'ASU', 'the Distribution Agreement', 'Dividend yield&#160;\\n    &', 'Black Scholes', 'Board', 'Vogel-Nathan Purchase Agreement', 'Canada.\\nThe Company', 'Lincoln Park\\nCapital Fund', 'the Kanubaddi Separation Agreement', 'the Equity Distribution Agreement', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'RD Offering', 'the Weighted Expected Return', 'the Board of Directors', 'Akos Common Stock', 'PureForm', 'SHARE CAPITAL AND OTHER EQUITY', 'THC', 'cash&#160;\\n    $', 'the Distribution Agreement.\\nThe Company', 'the Akos\\nSeries A Preferred Stock', 'non-controlling\\ninterest', 'sections\\nin', 'the Patient Protection', 'the Annual Report', 'the European Patent Office', 'Lincoln Park', 'the United States Food and Drug Administration', 'the Nasdaq Stock Market', 'the &#8220;Registered Direct Securities Purchase', 'Intellectual Property', 'the Registration\\nRights Agreement', 'Akos Series A Preferred Stock - See Note 8&#160;\\n    &', 'Australia&#8217;s\\nTGA', 'Post-Modification Warrants&#160;\\n', 'Long-Term Incentive Plan', 'the Kanubaddi Separation Agreement,\\nMr', 'MagicMed Industries\\n                                            Inc.', 'Development and Clinical Supply Agreement', 'PureForm\\nGlobal, Inc. (&#8220;PureForm&#8221', 'Akos Series A Preferred Stock\\n\\n&#160;\\n\\nUnder\\nthe Certificate of the Designations, Preferences', 'the Common Stock', 'Entity&#8217;s Own Equity', 'Form S-1', 'Conversion and Other Options', 'Akos Series A Preferred Stock', 'SEC', 'cash&#160;\\n    &', 'Common Stock', 'under\\nthe Purchase Agreement', 'Company', 'Vendor Agreements\\n\\n&#160;\\n\\nThe\\nCompany', 'Lincoln Park&#8217;s', 'New Chemical Entities', 'future\\nfinancial', 'incurred.\\n\\n&#160;\\n\\nConcentration\\nof Credit Risk\\n\\n&#160;\\n\\nFinancial\\ninstruments', 'the Akos Purchase Agreement', 'COVID-19', 'Preferred Stock', 'Spin-Off', 'Options&#160;\\n', 'Enveric', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n&#160;\\n\\nThe\\nkey', 'Incentive Plan&#8221', 'LLC (&#8220;Lincoln', '\\n    &', 'Dividend rate&#160;\\n    &', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n&#160;\\n\\nDevelopment\\nand Clinical Supply', 'the Purchase Agreement', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n&#160;\\n\\nDuring\\nthe'}"
EOLS,"{'ASC', 'Contentsour', 'LLC', 'the Medytox/Allergan Settlement Agreements', 'LLC (&#8220;SCH&#8221;)', 'EMA', 'Board of Directors;&#8226;require', 'the Federal Food, Drug', 'ContentsProduct', 'this Quarterly Report on Form 10-Q', 'CompensationThe Company', 'Weighted-Average Life (Years)Original CostAccumulated', 'the Compensation Committee of the Board of Directors', 'the Share Issuance Agreement', 'the Medytox Litigation', 'Continued)(in', 'Loyalty Program &', 'ActivitiesCash', 'net30,464&#160;22,448&#160;Inventories17,626&#160;18,852&#160;Prepaid expenses3,655&#160;3,902&#160;Other', 'Alphaeon', 'the U.S. Settlement Agreement', 'the Evolus Founders', 'Strathspey Crown Holdings Group', 'Allergan Limited', 'COVID-19', 'Contentssufficient', 'development&#8212;&#160;&#8212;&#160;4,441&#160;2,000&#160;Revaluation', 'ContentsIn', 'Medytox, Inc.', 'the Daewoong Agreement', 'the Settlement Agreement with Medytox', 'Biopharma Credit PLC', 'SVB Securities LLC', 'Contingencies', 'Offerings of Common StockOn', 'Internal Control', 'Medicaid', 'Medicare', 'another Settlement and License Agreement', 'FDA', 'Medytox the Settlement Shares', 'RSU', 'the U.S. International Trade Commission', 'the Delaware General Corporations Law', 'the Sarbanes-Oxley', 'Risks Related', 'Evolus', 'Company', 'Evolus Founders', 'ContentsEvolus', 'a Settlement and License Agreement', 'USPTO', 'Adopted Accounting PronouncementsWe', 'Results of Operations', 'Contingent Royalty Obligation Payable', 'Unrealized', 'Consolidated Statements of Operations', 'Significant Accounting Policies-Recent Accounting Pronouncements', 'LeasesOur', 'BioPharma Credit Investments V', 'Alphaeon Corporation', 'Financial Instruments&#8212;Credit Losses', 'the Lease Agreement', 'RecognitionThe Company', 'Omnibus Incentive Plan', 'PRSU', 'RequirementsOur', 'License', 'the Settlement Shares', 'Board of Directors', 'AgreementThe Symatese Agreement', 'DevelopmentResearch', 'Medytox, Inc. (&#8220;Medytox&#8221', 'Leerink Partners', 'the Medytox Settlement Agreement', 'Consolidated Financial StatementsEvolus', 'Evolysse&#8482;.For', 'Capital', 'Sculpt', 'AgreementOn', 'Form S-3', 'the Loan Agreement', 'Condensed Consolidated Financial Statements(in', 'Board', 'EQUITY', 'Pharmakon', 'Medytox/Allergan Settlement Agreements', 'BusinessDescription of BusinessEvolus, Inc.', 'healthcare', 'the Board of Directors', 'Intangible AssetsThe', 'the Daewoong Settlement Agreement', 'Evolus FoundersThe Company', 'ATM', 'the Stock Purchase Agreement', 'IndebtednessSee &', 'BPCR Limited Partnership', 'ContentsIn February 2021', 'ROU', 'Daewoong 37Table of Contentspursuant', 'the Registration Rights Agreement', 'the State of Delaware', 'the Public Health Service Act', 'Symatese S.A.S (&#8220;Symatese&#8221;)', 'Allergan, Inc.', 'the Daewoong Arrangement', 'Jeuveau&#174;.&#8226;Our', 'the Amended Stock Purchase Agreement', 'the Symatese Agreement', 'Litigation SettlementAs', 'the U.S. District Court', 'Supply AgreementThe Daewoong Agreement', 'SEC', 'Lips and Eye', 'Equity', 'plan195&#160;539&#160;Net'}"
EPIX,
EQ,"{'International Data Transfer Agreement / Addendum', 'Biocon License', 'the Biocon License', 'License Agreements', 'regulators;\\n  &#x2022;significant', 'the product;\\n  &#', 'Asset Purchase Agreement', 'and\\n  &#x2022;provide', 'the Interest-Only Extension II Milestone', 'consent;\\n  &#x2022;provide', 'Condensed Consolidated Financial Statements\\n    &', 'the License Agreements', 'the Securities Exchange Act', 'EQ101', 'choose);\\n  &#x2022;provide', 'COVID-19', 'USE OF PROCEEDS', 'No &#', 'licensed;\\n  &', 'and\\n  &', 'the Merger Agreement', 'FASB', 'HHS', 'Biocon Collaboration and License AgreementIn', 'Medicaid', 'Organization and Accounting Pronouncements Description of BusinessEquillium, Inc.', 'Diluted', 'prices;\\n  &#x2022;convenience', 'Medicare', 'the Securities and Exchange Commission', 'Yes &#9744', 'Concentration of Credit Risk and Off-Balance Sheet RiskFinancial', 'candidates;\\n  &#x2022;a', 'Accounting for Contract Assets and Contract Liabilities', 'FDA', 'Exhibit 3.1', 'Comprehensive LossThe Company', 'reimbursement;\\n  &#x2022;the', 'Loan', 'EQUILLIUM', 'and\\n  &#', 'others;\\n  &#x2022;collaborators', 'collaborations;\\n  &#x2022;collaborators', 'Risks Related', 'Contracts with Customers (Topic', 'REMS', 'Biocon Limited', 'Company', 'Business Combinations', 'liability;\\n  &#x2022;disputes', 'and\\n  &#x2022;If', 'and\\n  &#x2022;diminished', '\\n  &#160;\\n', 'SVB', 'Condensed Consolidated Financial Statements', 'the Delaware General Corporation Law', 'the Interest-Only Extension Milestone', 'ASU', 'the Nasdaq Capital Market', 'Oxford Finance', 'Loan Agreement', 'Bioniz', 'Repriced Options', 'Contracts with Customers', 'and\\n  &#x2022;our', 'the Asset Purchase Agreement', 'directors;\\n  &#x2022;provide', 'x2022;a collaborator&#x2019;s', 'fee\\n        &', '\\n  &#', 'EQUITY SECURITIES', 'Lenders', 'TaxesThe Company', 'Registrant', 'Exhibit 3.2', 'Economy,&#x201d', '47\\n', 'Bruce D. Steel', '9746;\\n  &', 'including:\\n  &#x2022;regulatory', 'Our Financial Position', 'the Loan Agreement', 'this Quarterly Report', 'outstanding.\\n  &#', '\\n  &', 'the Court of Chancery of the State of Delaware', '44\\n', 'stock;\\n  &#x2022;provide', 'the Registrant&#x2019;s Registration Statement on Form S-1', 'Biocon SA', 'No\\n  Indicate', 'operations.\\n  &', 'Biocon Products', 'EQ102', 'OFAC', 'the Registrant&#x2019;s Current Report', 'the European Medicines Agency', 'EQ302', 'the Equillium Territory', '\\n        &', 'SEC', 'including:\\n  &#x2022;efficacy', 'discount\\n        &', 'product;\\n  &#', 'Biocon', 'CHO', 'expense.\\n  &', 'Nasdaq', '\\n    &', 'Representative'}"
ERAS,
ERNA,"{'ASC', 'the Note Warrants', 'Inputs &#8211', 'the Common Warrants', 'Somerville Sublease\\n                \\n            \\n\\n    &#160;\\n\\n    &#160;\\n\\n', 'Sublicense Fee', 'Lincoln Park', 'Bristol-Myers Squibb Company (&#8220;Sublessor&#8221;)', 'Common', 'Westman', 'Somerville Sublease\\n                 ', 'Sublicense Fees', 'the Exacis Purchase Agreement', 'L.L.C.', 'No &#', '\\n               ', 'and\\n                          \\n\\n  ', 'the Exclusive Factor License', 'Sendai', 'OTHER', 'Private Placement', 'Internal Control', 'TIA', 'the Securities and Exchange Commission', 'Diluted', 'the Original Factor License', 'us.\\n\\n    \\n    \\n\\n    Further', 'the SEC&#8217;s\\n        Disclosure Update', 'Non-Controlling Investment\\n\\n', 'C.A.', 'Hedging &', 'the Exacis Acquisition', 'Factor Bioscience', 'Zelickson et al.', 'Founders', 'Company', 'Lincoln', 'the Exclusive License Agreement Amendment', 'Eterna&#8217;s Annual Report on Form 10-K', 'Regulation S-X\\n      or', 'liabilities\\n\\n    &#160;\\n\\n', 'the Pre-Funded Warrants', 'LLC (&#8220;Lincoln', 'Disclosure Improvements &#8211', 'Exacis Biotherapeutics Inc.', 'ASU', 'Novellus Limited', 'Somerville Sublease\\n                \\n              ', 'the Company issued&#160;the Note Warrants', 'the Factor Patents (&#8220;Sublicense Fees&#8221', 'Sublease', 'Waiver', 'The Note Warrants', 'the Exacis Assets', 'the Market Cap Contingent Consideration', 'Exacis', 'Lincoln Park Capital Fund', 'Response', 'Pursuant', 'Lincoln Park&#8217;s', 'NoveCite', 'Factor Bioscience Limited', 'Contracts with Customers (&', 'MSA', 'Contracts', 'Novellus, Inc.', 'NoveCite, Inc. (&#8220;NoveCite&#8221', 'ROU', 'IPR&amp;D', 'the future (&', 'Squibb &', 'of&#160;common', 'not\\n', 'the Court of Chancery', 'SEC', 'the Option Right', 'payments\\n\\n    &', 'the Covered Claims', 'Sons', 'SEPA', 'Factor Limited', 'Contingencies&#8212;Legal', 'the\\n      Company', 'the Exclusive Factor License Agreement'}"
ESLA,"{'ASC', 'LLC', 'the Series A', 'the Black-Scholes-Merton', 'the Common Stock Purchase', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'a Services Agreement', 'the Lock-Up Agreement', 'Merger Agreement', 'the Company Registration Statement', 'JSC', 'Estrella Immunopharma, Inc.', 'Series A Preferred Stock', 'Imugene Limited', 'Plentiful Limited', 'Form S-1', 'the Common Stock Purchase Agreement', 'The Services Agreement', 'Common Stock of the Company', 'Estrella&#8217;s Series AA Preferred Stock', 'Warrants', 'the Merger Agreement', 'The Unsecured Note matures\\non', 'Yangbing Xiao(incorporated', 'Merger Sub Inc.', 'the Association of Southeast Asian', 'US Tiger Securities, Inc.', 'White Lion', 'Exhibit 10.5', 'Estrella Immunopharma', 'FDA', 'Estrella Biopharma Inc.', 'Credit', 'Eureka Therapeutics, Inc.', 'the\\nCommon Stock Purchase Agreement', 'Common Stock', 'Company', 'Common Stock of New Estrella', 'UPTD', 'and\\n\\n&#160;\\n\\n  &#160', 'this Quarterly Report on Form 10-Q.\\n\\n&#160;\\n\\n\\n  \\n    Exhibit No.\\n    &', 'Note 10.\\n\\n\\n&#160;\\n\\nEquity Financing', 'restrictive\\ncovenants.\\n\\n&#160;\\n\\nThe Company', 'White Lion Capital', 'Business Combination', 'License Agreement', 'the Current Report on Form 8-K', 'the Company Current Report', 'Omnibus Incentive Plan(incorporated', 'Lianhe World Limited', 'Estrella&#8217;s Series A Preferred Stock', 'License', 'Private Shares', 'the Subscription Agreements', 'Registrant', 'pursuant\\nto the Contribution Agreement', 'the Common Stock', 'outstanding\\ncommon', 'the Warrants.\\nThe Company', 'Smart Crest International Limited', 'White Lion\\nto', 'the Series A Preferred Stock Purchase Agreement', 'Preferred Stock', 'Estrella', 'dividends\\non', 'Capital', 'License Agreement\\n(the &#8220;License', 'the Founder Shares', 'Offer Letter', 'Smart Crest International Limited(incorporated', 'expense\\n\\n&#160;\\n\\nFor', 'Hamas', 'the License Agreement', 'the Equity Line Shares', 'this Quarterly Report', 'of\\na &', 'the Common Stock Purchase Agreement pursuant\\nto the Joinder', 'Series AA Preferred Stock of Estrella', 'Estrella&#8217;s\\nSeries A Preferred Stock', 'ASC No.&#160;450-20', 'Common Stock (&', 'the State of Delaware', 'Acquisition Corp.', 'Preferred Stock\\n\\n&#160;\\n\\nSeries AA Preferred', 'un', 'Estrella Biopharma, Inc.', 'CoFame Investments', 'the Collaboration Agreement', 'Exhibit 10.8', 'issuance.\\nThe Company', 'the Services Agreement', 'SEC', 'TradeUP Acquisition Corp.', 'Territory', 'New Estrella\\nwill', 'the Business Combination', 'the Warrants for redemption:\\n\\n&#160;\\n\\n\\n&#9679;in\\n                                            ', 'Equity Line', '\\n    &', 'Developments\\n\\n&#160;\\n\\nThe Business Combination and Public Company'}"
ESPR,"{'ASC', 'API', 'the CLEAR Outcomes', 'LLC', 'LDL-C. On', 'NILEMDO', 'the DSE Territory', 'WarrantMember2022-01-012022-09-30UNITED', 'ATM Program', 'ExhibitsThe', 'ProductMember2023', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-01-012022-12-310001434868espr', 'EU', 'netProduct', 'PBSOs661,850&#160;499,200&#160;Unvested', 'RestrictedStockUnitsRSUMember2023-09-300001434868us-gaap', 'H.C. Wainwright &amp', 'ProductSalesBulkTabletsMember2023', 'the Amendment to Security Agreement', 'DSE', 'the New ATM Program', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2023-07-012023-09-300001434868espr', 'the Securities Exchange Act', 'the European Economic Area', 'Oberland', 'Company\\', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-01-012022-09-300001434868us-gaap', 'Daiichi Sankyo Co. Ltd', 'product00014348682019-08-012019-08-31espr', 'Collaboration RevenueThe Company', 'DSE Territory', 'ConvertibleSeniorNotesDue2025Member2020-11-012020-11-300001434868espr', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'the Exchange Agreement', 'FDA', 'the DS Territory', 'CollaborationRevenueMember2022', 'the DS Agreement', 'the Specified Net Revenue', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001434868us-gaap', 'Contents &#8226;decide', 'Company', 'NEXLETOL', 'ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember2023', 'the NUSTENDI Marketing Authorisation Applications', 'the Security Agreement', 'Purchase Agreement', 'Oberland Capital', 'ProceedingsThe', 'Concentration of RiskThe Company', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-07-012022-09-300001434868espr', 'Condensed Financial Statements8Item 2', 'HeFH', 'Eiger III SA', 'NEXLIZET', 'Restricted Stock Units', 'this Quarterly Report on Form&#160;10-Q', 'Waiver', 'Benjamin HalladayBenjamin HalladayChief Financial Officer(Principal Financial Officer', 'net&#8221', 'CVD', 'Daiichi Sankyo Europe GmbH', 'Registrant', 'Exchange', 'ProductMember2022', 'Performance-Based Stock Options', 'MinimumMemberespr', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001434868us', 'Restated Certificate of Incorporation', 'RevenueThe Company', 'ConvertibleSeniorNotesDue2025Member2020-11-300001434868us-gaap', 'FairValueMeasurementsRecurringMember2023', 'ExpenseInterest', 'ex-U.S.', 'StockOptionAndIncentivePlan2022Member2022', 'the Call Option', 'the Cumulative Purchaser Payments', 'Form S-3', 'WarrantMember2023-01-012023-09-300001434868us-gaap', 'District Court', 'ATM', 'ESPP', 'CLEAR Outcomes', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001434868us-gaap', 'the Otsuka Agreement', 'Indenture', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2023-01-012023-09-300001434868espr', 'DSE JCC', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-12-310001434868espr', 'PBSOs', 'EXCHANGE', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2022-01-012022-09-300001434868espr', 'the U.S.', 'Principal Accounting Officer)44\\n\\n\\n', 'ShareBasedPaymentArrangementOptionPerformanceBasedMember2023-09-300001434868espr', 'RevenueInterestPurchaseAgreementMember2021-04-262021-04-260001434868espr', 'Eiger Partners II LP', 'FairValueInputsLevel1Member2022-12-310001434868us-gaap', 'CollaborativeArrangementMember2022'}"
ESTA,
ETAO,
ETNB,"{'compensation\\n    &', 'the Delaware General Corporation Law', 'LLC', 'Cantor Fitzgerald &amp', 'the &#x201c;Sales', 'SHTG', 'Sublicense', 'tax\\n    &', 'Unaudited Condensed Consolidated Financial Statements \\n  &#160;\\n  1', 'ConsolidationThe', 'the 2023 Loan Agreement', 'Contracts', 'Ankura Trust Company', 'BTPH', '\\n  &', 'glycoPEGylation', 'Internal Control', 'amounts)\\n  &#160;\\n', 'Teva', 'compromised.\\n  Similar', 'Condensed Consolidated Statements of Operations and Comprehensive', 'The Loan Agreement', 'ESPP', 'x2014;\\n        &', 'Teva Pharmaceutical Industries Ltd', 'the &#x201c;Sales Agreement&#x201d', 'SVB Securities', 'this Quarterly Report on Form 10-Q', 'Dear Healthcare Provider', 'FDA', '47\\n    &', 'fee\\n        &', 'the Term B Loan Facility', 'EquivalentsThe Company', 'Financial Reporting \\n', 'the U.S. Treasury Department&#x2019;s Office of Foreign Assets Controls', '\\n  &#', 'reporting.\\n  &', 'Loan', 'LossThe', '\\n    ', 'tax\\n    &#', 'Risks Related', '\\n    Research', 'Silicon Valley Bank', 'Conversion and Other Options', 'Condensed Consolidated Statements', 'SEC', 'candidates.\\n  Risks Related', 'activities\\n    &', 'agreements.\\n', 'x201c;Loan', 'Company', 'Research', 'USPTO', 'Reagent Supply and Technology Transfer Agreement', 'the ATM Facility', 'ENLIVEN', 'COVID-19', 'The Term A Loan Facility', '\\n    &', 'property.\\n'}"
ETON,"{'xa0;\\n Year &#', 'ASC', 'portion.\\n  &#', 'FASB', 'the Eyemax Agreement', 'ASU', 'Subsequent Events\\n   ', 'BSM', 'Nitisinone Capsules', 'Credit Agreement', 'Cover Page Interactive Data File', 'No &#x2610;\\n&#xa0;\\nIndicate', 'Amortization &', 'x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;believe,&#x201d;', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Securities and Exchange Commission', 'segment.\\n   &#', 'the investors.\\n   &#', 'value.\\n   &', 'Credit Losses on Financial Instruments.&#x201d', 'acquired.\\n   &#xa0;&#xa0;\\n', 'FDA', '\\n   &#', 'the Public Company Accounting Oversight Board', '\\n  &#', 'SWK Holdings', 'portion.\\n   &', 'xa0;\\n     &#', 'Condensed Financial', 'the words &', 'the &#x201c;Exchange', 'ASC&#xa0;718, Compensation &#x2014;&#xa0;Stock Compensation', 'Bausch Health', 'Significant Accounting Policies', 'September&#xa0;2022', 'Tulex Pharmaceuticals, Inc. (&', 'Company', 'Azurity', 'the Securities Exchange Act', 'the &#x201c;Excelvision', 'thereafter.\\n   &', 'the Sarbanes-Oxley Act', 'Exclusive Development &', 'Topiramate', 'IPO', 'Impairment of Long-Lived Assets\\n   &', 'the Condensed Statements of Operations', 'Supply Agreement with Excelvision SAS', 'Milestone Payments &', 'This Quarterly Report on Form 10-Q', 'Expense &#xa0;\\n', '\\n    &#', 'the Amended Agreement'}"
EUDA,
EVAX,
EVGN,
EVO,
EVOK,"{'ASC', 'LLC', 'the Company&#x2019;s Quarterly Report on Form 10-Q', 'the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;)', 'the Nasdaq Capital Market', 'ASU', 'Form S-3', '639,601\\n          &', '\\n', 'EquityAt the Market Equity Offering Program', 'Contractual Obligations', 'the Eversana Credit Facility', 'Questcor', 'ATM', 'Questcor Pharmaceuticals, Inc. (&#x201c;Questcor&#x201d;)', 'Eversana Agreement', 'and\\n  &#x2022;health', '\\n  &#x2022;per', 'the Gimoti NDA', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Questcor Pharmaceuticals, Inc.', '\\n  &#x2022;the', 'Financial Instruments', 'decrease.\\n  &', 'Commercial Services', 'FDA', 'Nasdaq Capital Market', 'Financial Instruments &#', 'Thermo Fisher Scientific Inc.', 'the Eversana Agreement', 'Research and Development Expenses', 'Credit Facility', '\\n  &#', 'the Net Profit Quarterly Termination Right', 'FBR', 'Mallinckrodt', 'Loan Agreements', 'FBR Sales Agreement', 'SEC Rule 13a-15(b', 'Indicate', 'Evoke', 'the agreement- &#', 'distribution;\\n  &#x2022;competition', 'efforts;\\n  &#x2022;the', '\\n    &', 'Principal Financial and Accounting Officer)\\n', 'Significant Accounting Policies', 'NDA', '\\n        &', 'SEC', '\\n  &#x2022;potential', 'Teva&#x2019;s', 'Company', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'WarrantsThe Company', 'Credit Losses', 'Eversana Life Science Services', 'Cosma S.p.A.', 'The Eversana Agreement', 'company.&#x201d;\\n  &#', 'Results of Operations', 'timelines;\\n  &#x2022;the', 'Nasdaq', 'the U.S. Securities and Exchange Commission', 'Eversana', '\\n  &#x2022;our'}"
EWTX,"{'ContentsIntellectual', 'MaximumMember2023', 'API', 'OverAllotmentOptionMember2022-09-162022-09-160001710072us-gaap', 'FairValueMeasurementsRecurringMember2023-01-012023-09-300001710072us-gaap', 'The Ohio State Innovation Foundation', 'EMA', 'Nasdaq Hearings Panel', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001710072us-gaap', 'Segment InformationThe Company', 'ATM Program', 'EU', 'the Audit Committee', 'Need for Additional Capital and Limited', 'ContentsWhere', 'EDG-5506', 'Public Offering of Common Stock On', 'UPC', 'CPRA', 'Form S-1', 'ContentsWe', 'the Securities Exchange Act', 'OfficeAndLaboratorySpaceInBoulderColoradoMember2023', 'COVID-19', 'Santhera Pharmaceuticals', 'BofA Securities, Inc.', 'HHS', 'BioMarin Pharmaceuticals', 'Medicaid', 'Medicare', 'Congress', 'the Unverified List', 'Notice', 'the Ohio State Innovation Foundation', 'GDPR', ': &', 'FDA', 'the New Boulder Lease', 'OSIF', 'HCM', 'No  &#9744;Indicate', 'REMS', 'Company', 'Co-Founder', 'Lexeo Therapeutics (LX2022', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001710072us-gaap', 'USPTO', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001710072us-gaap', 'the Nasdaq Listing Rule 5605(c)(2', 'expense&#8203;$', 'the U.S. Securities and Exchange Commission', 'company.&#8221', 'Founder Stock Options', 'ContentsGrant of Stock OptionsDuring', 'CMS', 'TwoThousandTwentyOneEquityIncentivePlanMember2023', 'FCPA', ': &#9679;delays', 'CDMOs', 'the U.S. Department of Health and Human Services', 'MAD', ': &#', 'the Organization for Economic Cooperation and Development', 'BofA Securities', 'Capital ResourcesThe Company', 'CDMOs);&#9679;expenses', 'the Nasdaq Stock Market LLC', 'The Nasdaq Capital Market', 'NDA', 'the Unified Patent Court', 'ContentsOur', 'DOJ', 'FairValueMeasurementsRecurringMember2023', 'the Nasdaq Listing Rule 5605', 'Contentsentitle', 'PGR', 'Hamas', 'NOTE&#160;5 &', 'Form S-3', 'ContentsAdditionally', 'this Quarterly Report', 'CJEU', 'California Privacy Protection Agency', 'USTreasurySecuritiesMember2022-01-012022-12-310001710072us-gaap', 'ReveraGen Biopharma', 'Contentson', 'the Nasdaq Listing Rules', 'the State of Delaware', 'Medicaid Services', 'CONTINGENCIESLicense AgreementsOn November&#160;20', 'USTreasurySecuritiesMember2022-12-310001710072us-gaap', 'SEC', 'the General Corporation Law', 'the Centers for Medicare &', 'Equity Securities', 'the European Union', ': &#9679;differing', 'Nasdaq', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001710072us'}"
EXAI,
EXAS,
EXEL,
EYEN,
EYPT,"{'ASC', 'LLC', 'AMD', ""Loan AgreementThe Company\\'s"", 'TSA', 'Alimera', '2025;\\n  &#x2022;our', 'Lender', 'Transaction', 'The Betta License Agreement', 'Contracts with Customers (ASC 606', 'Treasury', 'OAI', 'The Sales Services', '\\n  &#x2022;effects', 'DURASERT E&#153', 'products;\\n  &#x2022;market', 'the Equinox License Agreement', 'Note 3)\\n        &', 'goods\\n        &', 'PRA', 'x2014;\\n        &', 'cost.\\n', '27\\n', 'Official Action Indicated', 'FDA', 'Betta Pharmaceuticals Co., Ltd.', 'and\\n  &#', 'ExpensesAccrued', 'Silicon Valley Bank', 'the Alimera PRA', 'Company', 'Research Collaborations &', 'a Memorandum of Understanding for YUTIQ', 'SWK Funding', 'the ATM Facility', 'Alimera Sciences, Inc.', 'SVB', 'NPDR', 'DEXYCU', 'Upfront Payment', 'The SVB Loan Agreement', 'year.\\n  Interest', '\\n  &#x2022;the', 'the CSA.11\\n     &', 'CSA', 'License', 'Alimera&#x2019;s', '\\n  &#', 'the ESPP.The Company', 'the Amended Alimera Agreement', 'the Betta License Agreement', 'AllowancesFrom', 'Betta Pharmaceuticals, Co., Ltd.', 'the Transferred Assets', 'the Upfront Payment', 'YUTIQ&#174', '\\n  &', 'ATM', 'the SVB Loan Agreement', 'the Asset Transfer', 'ROU', 'RPA', 'ESPP', 'SWK Royalty Purchase AgreementPursuant', 'First Citizens BancShares', 'Equinox Sciences', 'DME;\\n  &#x2022;fluctuations', 'Development\\n  Research', 'U.S. Treasury', 'First Citizens', 'revenues.\\n  Research', '\\n        &', 'the Supply Transaction', 'the Original Field', 'the Betta Territory', 'VAI'}"
FATE,
FBIO,"{'the &quot;VYNE Product Acquisition Agreement&quot;)', 'Maruho', 'LLC', 'Judiciary Committee', 'InvaGen', 'Nasdaq Listing Rule 5635.Mustang 2020', 'the UTRF Litigation', 'University of Pennsylvania', 'Stockholders Agreement', 'Restricted CashThe Company', 'Aevitas', 'the Sub-Contracting CDMO Agreement', 'CompensationAs of September 30,&#160;2023', 'TGTX', 'Boston) Biosciences Inc.', 'PRV', 'Registered Direct Offering', 'the Patent Trial and Appeal Board', 'the Zydus Group', 'InvaGen Pharmaceuticals, Inc. (&#8220;InvaGen&#8221', 'the Internal Revenue Code', 'Amendment of the Amended and Restated Certificate of Incorporation', 'VYNE Therapeutics, Inc.', 'the &#8220;Avenue Registration Rights Letter', 'ProceduresUnder', 'Labor and Pensions Committee', 'SOX', 'Management Services Agreement', 'ContentsWe', 'The Contingent Subsidiary Securities', 'The Nasdaq Stock Market LLC', 'Journey Medical', 'ContentsTriplex', 'COVID-19', 'the Manufacturing Services Agreement', '8203;&#8203;Operating expenses&#8203;&#8203', 'Market Issuance Sales Agreement', 'Cyprium', 'ContentsIn', 'SUBSIDIARIESNotes&#160;to Unaudited', 'the &quot;AnnJi License Agreement&quot;)', 'the New License Agreement', 'Anti-Kickback Statute', 'EquityReverse', 'closing$ 24,963&#8203;The', 'Sentynl Therapeutics, Inc. (&', 'AnnJi Pharmaceutical Co. Ltd.', 'Private Placement', 'Monoclonal Antibody', 'Consolidated Financial Statements&#8203;The', 'PIK', 'Checkpoint', 'SentynlOn February 24,', 'Internal Control', 'revenue&#8203;&#8203', 'Medicare', 'Medicaid', '12,005)&#8203;(12)%Research and development &', 'First Tranche Shares', 'ContentsComparison', 'FDA', 'Consolidated Financial', 'the Contribution Agreement', 'Cyprium PPS', 'Avenue', 'Restated Certificate of Incorporation of Fortress Biotech, Inc.', 'Proportionate', 'the Company&#39;s Common Stock', 'ContentsThe', 'HIPAA', 'AstraZeneca', 'thereof.&#8203;As', 'Cellvation, Cyprium,', 'Common Stock', 'Company', 'Maruho Co., Ltd.', 'Baergic', 'Finance Committee', 'the Sub-Contracting CDMO Agreement.&#8203;CypriumAgreement', 'the Avenue Stockholders Agreement', 'the Avenue Private Placement Investors', 'the Leahy-Smith Act', 'the Avenue Registered Offering', 'the Minimum Commitment', 'market.&#9679;Any', 'Oaktree Fund Administration', 'the Delaware General Corporation Law', 'the Nasdaq Capital Market', 'CMS', 'Senate', 'Facility', 'Exchange Act', 'Caelum', 'the Unaudited Condensed Consolidated Financial Statements', 'License Agreement', 'Contentsassets', 'the Asset Purchase Agreement', 'the 2020 Shelf', 'Triplex', 'The Cyprium PPS', 'Contingent Subsidiary Securities', 'AssetsIntangible', 'Fortress Series A Preferred Stock', 'the Oaktree Agreement', 'PTO', 'License', 'IRB', '19,260&#8203;&#8203', 'Board of Directors', 'Placement &', 'Laboratories, Ltd (&', 'Health, Education', 'Direct Offering', 'the Common Stock', 'NDA', 'Strategic Development', 'City of Hope (&#8220;COH&#8221', 'Anti-Human Immunodeficiency Virus', 'development &', 'the Amended Asset Purchase Agreement', 'Exhibit 3.2', 'Fortress Biotech, Inc.', 'the Company&#8217;s Board of Directors', 'Qbrexza&#174', 'Molecule Stabilizing TechnologyTM &', 'UTRF', 'the Compensation Committee granted&#160;81,286&#160;and&#160;73,532&#160;shares', 'Capital ResourcesSince', 'the Share Repurchase Agreement', 'Form S-3', 'ExpenseThe', 'LTIP', 'the Avenue Registration Rights Letter Agreement', 'ContentsSales', 'MSA', '3%Total Selling', 'General &amp', 'VYNE Therapeutics, Inc. (&', 'TGTXCheckpoint', 'the Cyprium PPS', 'Administrative', 'the U.S. Food and Drug Administration', 'Manufacturing Services Agreement', 'the Biden Administration', 'entity:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#160;&#8203;Nine Months Ended &', 'DRL', 'Journey', 'Litigation&#8221;).&#160', '4DMT', 'uBriGene Group', 'Fortress', 'the Stockholders Agreement', 'CMV', '3,143&#8203;100%Total', 'AnnJi', 'Related Party Transactions', '3,536&#8203;&#8203', 'Alexion', 'SEC', 'the New Drug Application', 'Financial ReportingNo', 'VYNE', 'Pertaining to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries&#8203;&#9679;We', 'Caelum Biosciences, Inc. (&', 'Avenue&#8217;s', 'Nasdaq', 'Antigen Receptor', 'the European Union', 'Securities', 'installments:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Annual&#160;MSA&#160;Fee Partner Company', 'the Fortress Biotech,&#160;Inc'}"
FBIOP,"{'the &quot;VYNE Product Acquisition Agreement&quot;)', 'Maruho', 'LLC', 'Judiciary Committee', 'InvaGen', 'Nasdaq Listing Rule 5635.Mustang 2020', 'the UTRF Litigation', 'University of Pennsylvania', 'Stockholders Agreement', 'Restricted CashThe Company', 'Aevitas', 'the Sub-Contracting CDMO Agreement', 'CompensationAs of September 30,&#160;2023', 'TGTX', 'Boston) Biosciences Inc.', 'PRV', 'Registered Direct Offering', 'the Patent Trial and Appeal Board', 'the Zydus Group', 'InvaGen Pharmaceuticals, Inc. (&#8220;InvaGen&#8221', 'the Internal Revenue Code', 'Amendment of the Amended and Restated Certificate of Incorporation', 'VYNE Therapeutics, Inc.', 'the &#8220;Avenue Registration Rights Letter', 'ProceduresUnder', 'Labor and Pensions Committee', 'SOX', 'Management Services Agreement', 'ContentsWe', 'The Contingent Subsidiary Securities', 'The Nasdaq Stock Market LLC', 'Journey Medical', 'ContentsTriplex', 'COVID-19', 'the Manufacturing Services Agreement', '8203;&#8203;Operating expenses&#8203;&#8203', 'Market Issuance Sales Agreement', 'Cyprium', 'ContentsIn', 'SUBSIDIARIESNotes&#160;to Unaudited', 'the &quot;AnnJi License Agreement&quot;)', 'the New License Agreement', 'Anti-Kickback Statute', 'EquityReverse', 'closing$ 24,963&#8203;The', 'Sentynl Therapeutics, Inc. (&', 'AnnJi Pharmaceutical Co. Ltd.', 'Private Placement', 'Monoclonal Antibody', 'Consolidated Financial Statements&#8203;The', 'PIK', 'Checkpoint', 'SentynlOn February 24,', 'Internal Control', 'revenue&#8203;&#8203', 'Medicare', 'Medicaid', '12,005)&#8203;(12)%Research and development &', 'First Tranche Shares', 'ContentsComparison', 'FDA', 'Consolidated Financial', 'the Contribution Agreement', 'Cyprium PPS', 'Avenue', 'Restated Certificate of Incorporation of Fortress Biotech, Inc.', 'Proportionate', 'the Company&#39;s Common Stock', 'ContentsThe', 'HIPAA', 'AstraZeneca', 'thereof.&#8203;As', 'Cellvation, Cyprium,', 'Common Stock', 'Company', 'Maruho Co., Ltd.', 'Baergic', 'Finance Committee', 'the Sub-Contracting CDMO Agreement.&#8203;CypriumAgreement', 'the Avenue Stockholders Agreement', 'the Avenue Private Placement Investors', 'the Leahy-Smith Act', 'the Avenue Registered Offering', 'the Minimum Commitment', 'market.&#9679;Any', 'Oaktree Fund Administration', 'the Delaware General Corporation Law', 'the Nasdaq Capital Market', 'CMS', 'Senate', 'Facility', 'Exchange Act', 'Caelum', 'the Unaudited Condensed Consolidated Financial Statements', 'License Agreement', 'Contentsassets', 'the Asset Purchase Agreement', 'the 2020 Shelf', 'Triplex', 'The Cyprium PPS', 'Contingent Subsidiary Securities', 'AssetsIntangible', 'Fortress Series A Preferred Stock', 'the Oaktree Agreement', 'PTO', 'License', 'IRB', '19,260&#8203;&#8203', 'Board of Directors', 'Placement &', 'Laboratories, Ltd (&', 'Health, Education', 'Direct Offering', 'the Common Stock', 'NDA', 'Strategic Development', 'City of Hope (&#8220;COH&#8221', 'Anti-Human Immunodeficiency Virus', 'development &', 'the Amended Asset Purchase Agreement', 'Exhibit 3.2', 'Fortress Biotech, Inc.', 'the Company&#8217;s Board of Directors', 'Qbrexza&#174', 'Molecule Stabilizing TechnologyTM &', 'UTRF', 'the Compensation Committee granted&#160;81,286&#160;and&#160;73,532&#160;shares', 'Capital ResourcesSince', 'the Share Repurchase Agreement', 'Form S-3', 'ExpenseThe', 'LTIP', 'the Avenue Registration Rights Letter Agreement', 'ContentsSales', 'MSA', '3%Total Selling', 'General &amp', 'VYNE Therapeutics, Inc. (&', 'TGTXCheckpoint', 'the Cyprium PPS', 'Administrative', 'the U.S. Food and Drug Administration', 'Manufacturing Services Agreement', 'the Biden Administration', 'entity:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#160;&#8203;Nine Months Ended &', 'DRL', 'Journey', 'Litigation&#8221;).&#160', '4DMT', 'uBriGene Group', 'Fortress', 'the Stockholders Agreement', 'CMV', '3,143&#8203;100%Total', 'AnnJi', 'Related Party Transactions', '3,536&#8203;&#8203', 'Alexion', 'SEC', 'the New Drug Application', 'Financial ReportingNo', 'VYNE', 'Pertaining to Legislation and Regulation Affecting the Biopharmaceutical and Other Industries&#8203;&#9679;We', 'Caelum Biosciences, Inc. (&', 'Avenue&#8217;s', 'Nasdaq', 'Antigen Receptor', 'the European Union', 'Securities', 'installments:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Annual&#160;MSA&#160;Fee Partner Company', 'the Fortress Biotech,&#160;Inc'}"
FBRX,"{'Preferred Stock Rights Agreement', 'Fortune Business Insights).\\n  &', 'Advisory Committee', 'EMA', 'Nasdaq;\\n  &#x2022;sales', 'Phase 4', 'Tocagen, Inc.', 'decline.\\n  &#160;\\n', 'Series A Preferred Stock', 'EASI', 'Indicate', '\\n    Research', 'liability;\\n  &#', 'the Securities Exchange Act', 'Plaintiff', 'COVID-19', 'and\\n  &', 'Anti-Kickback Statute', 'reimbursement;\\n  &#x2022;enforcing', 'Preclinical Services The Company', 'Medicaid', 'Medicare', 'a Securities Purchase Agreement', 'Congress', 'technologies.\\n', 'FDA', 'claims;\\n  &#x2022;the', 'and\\n  &#', 'stock;\\n  &#x2022;announcements', 'the Private Placement', 'REMS', 'Company', 'expensive;\\n  &#x2022;current', 'payroll taxes;\\n  &#x2022;foreign', 'USPTO', 'the ATM Facility', 'Adopted Pursuant to Section 302', 'stockholder litigation;\\n  &#x2022;claims', 'FB-102;\\n  &#x2022;establishing', '\\n  &#160;\\n', 'the Annual Meeting', 'and\\n  &#x2022;business', 'Contract Research Organizations', 'Defendants', 'Legal Proceedings &', 'the public;\\n  &#x2022;failure', 'the Rights Agreement', 'Purchasers', 'products;\\n  &#x2022;disagreements', '\\n  &#', 'and\\n  &#x2022;current', 'and\\n  &#x2022;maintaining', 'harmed.\\n', 'patentable;\\n  &#x2022;the', 'own;\\n  &#', 'prices;\\n  &#', 'the Sarbanes-Oxley Act', 'factors.\\n  &', 'Forte&#x2019;s', 'Forte', 'Computershare Trust Company', 'patents;\\n  &#x2022;future', 'capital commitments;\\n  &#x2022;adverse', 'Form S-3', 'product;\\n  &#x2022;current', 'the United States;\\n  &#x2022;production', 'technologies;\\n  &#x2022;additions', 'markets;\\n  &#x2022;compliance', '\\n  &', 'including:\\n  &#x2022;the', 'The Amended Complaint', 'The Anti-Kickback Statute', 'Forte;\\n  &#x2022;changes', '\\n  Research and Development Expenses\\n  Research', 'Complaint', 'conditions;\\n  &#', 'the Registrant&#x2019;s Current Report', 'FB-102;\\n  &#x2022;Forte&#x2019;s', 'including:\\n  &#x2022;efficacy', 'SEC', 'Investors&#x2019', 'the future;\\n  &#', 'Nasdaq', 'harmed.\\n  Preclinical', '\\n    &', 'property.\\n', 'FB-102;\\n  &#x2022;launching'}"
FDMT,
FEMY,
FENC,
FGEN,
FHTX,"{'FASB', 'the Discovery Programs', 'Consolidated Statements of Cash Flows4Notes to Unaudited', 'ContentsPART I&#8212;FINANCIAL INFORMATIONItem&#160;1', 'ArrangementsWe', 'Consolidated Statements', 'the Merck Collaboration Agreement', 'Merck', 'ContentsTable of ContentsPagePART I.FINANCIAL', 'Adopted Pursuant', 'the Securities and Exchange Commission', 'the Lilly Collaboration Agreement', 'compensation)9,560&#160;8,705&#160;855&#160;29,787&#160;24,706&#160;5,081&#160;Facilities', 'Lilly', 'NetProperty', 'the Joint Programs', 'Ex-U.S.', 'Gene Traffic Control', 'Company', 'BRM Selective', 'the Sarbanes-Oxley Act', 'BRM'}"
FIXX,"{'consistently;\\n  &#x2022;delay', 'LLC', 'MHRA', '\\n    Interest income\\n    &', 'EC', '\\n  &#x2022;variations', '\\n', 'this Quarterly Report on Form 10-Q.\\n', 'Oxford', 'The Sarbanes-Oxley Act', '\\n  &#x2022;expansion', 'EMA', 'the UK Medicines', 'Interest Income\\n  Interest', 'AAVHSC platform.\\n  &#x2022;The', '\\n  &#x2022;an', '\\n  &#x2022;developments', 'Oxford Biomedica Solutions', 'City of Hope', 'this Quarterly Report on Form 10-Q', 'Homology', '\\n  &#x2022;having', 'any.\\n  &#', 'the Supply Agreement', '\\n  &#x2022;costs', 'EU', 'capacity;\\n  &#x2022;issues', 'the Public Company Accounting Oversight Board', 'markets.\\n  &#', 'the Internal Revenue Code', 'x2022;a', 'Pfizer Inc.', 'unpredictable.\\n  &#x2022;Our', 'the &#x201c;Services Agreement&#x201d', 'Options', '\\n    Research', 'ACA', '\\n  &#x2022;development', '\\n  &#x2022;not', 'Research', 'costs.\\n  Research and Development Expenses \\n  Research', '\\n  &#x2022;recall', 'COVID-19', 'Misconduct', '\\n  &#x2022;adding', '\\n  &#x2022;effectiveness', 'The Information Committee', '\\n  &#x2022;obtaining', '\\n  &#x2022;expenses', 'Pfizer', '\\n  &#x2022;significant', '\\n  &#x2022;product', '\\n  &#x2022;substantial', '\\n  &#x2022;exemptions', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;a', '\\n  &#x2022;refusal', 'Medicaid', 'Medicare', '\\n  &#x2022;extension', 'Congress', '\\n  &#x2022;any', 'x2014;\\n        &', 'the Federal Trade Commission', 'GDPR', '\\n  &#x2022;general', 'FDA', 'the Contribution Agreement', 'GMP', '\\n  &#x2022;clinical', 'Transitional Services', '\\n        Laboratory equipment\\n', 'and\\n  &#', '30\\n', 'Registration Statement on Form S-3', 'the UK Government', '\\n  &#x2022;warning', '\\n  &#x2022;loss', '77\\n', 'the Medicaid Drug Rebate Program', '\\n  &#x2022;others', '\\n  &#x2022;requirements', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;fines', 'FTC', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '\\n  &#x2022;changes', 'Units', '\\n  &#x2022;salaries', 'USPTO', '\\n  &#x2022;addressing', 'all.\\n  &#x2022;If', 'profits.\\n', '\\n  &#x2022;injunctions', '\\n  &#x2022;distraction', '50\\n', 'Condensed Consolidated Financial Statements', 'GLP', 'CRO', 'the European Commission', 'products.\\n  &#x2022;We', 'CAT', 'CMS', 'Healthcare Regulatory Agency', '\\n  &#x2022;recruiting', '\\n  &#x2022;establishment', 'COH', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'Stockholders&#x2019', 'IRB', '\\n  &#x2022;suspension', '\\n  &#', 'Board of Directors', 'the Amended and Restated Limited Liability Company Agreement', '\\n  &#x2022;market', 'the following:&#160;\\n      \\n       \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n       \\n       \\n        &', '\\n  &#x2022;decreased', 'the Transferred Assets', '\\n  &#x2022;reaching', 'and\\n  &#x2022;allocated', 'x201c;anticipate,&#x201d; &#', '\\n  &#x2022;inability', 'IPO', 'Comparison', 'Jumpstart Our Business Startups Act', '\\n  &#x2022;impairment', '\\n  &#x2022;our', 'NHPs', '\\n  &#x2022;announcements', 'and/or marketing authorization application supplement', 'the &#x201c;Windsor', 'Medicaid Innovation', 'Comparison of Nine Months Ended September 30, 2023', 'ATM', 'the Court of Chancery of the State of Delaware', ""OXB Solution\\'s"", 'OXB Solutions', 'the Stock Purchase Agreement', 'Nasdaq&#x2019;s', 'the State of Delaware', 'CTR', 'the OXB Solutions Operating Agreement', 'the &#34;OXB Solutions', 'periods.\\n  Research and Development Expenses\\n  &', '\\n  &#x2022;restrictions', 'Medicaid Services', 'the &#34;Options&#34;)', 'capacity.\\n  &#x2022;Even', '\\n  &#x2022;the FDA', '\\n  &#x2022;withdrawal', 'Issuer Purchases of Equity', '\\n        &', 'agreements.\\n', 'GCP', 'the COH License', 'OXB', 'BLA', 'cost\\n        &', 'the Federal Trade Commission Act', 'the Budget Control Act', 'PNH', '\\n  &#x2022;manufacturing', 'Equity Securities', 'the Centers for Medicare &', 'the OXB Solutions Transaction', '\\n  &#x2022;failure', '\\n  &#x2022;reduced', '\\n  &#x2022;actual', 'Nasdaq', '\\n    &', 'the Transferred Units'}"
FLGC,"{'Company\\', 'LLC', 'Liberacion e Inversiones S.A.', 'this Quarterly Report', 'Compensation Expenses \\n                        Share', 'Flora Growth', 'the Reverse Stock Split', 'Phatebo', '42,420\\n                                    &', 'income)\\n                                    &', '(16,187\\n                            )\\n', '\\n                                    &', 'Corporate &', 'equipment.\\n                            Depreciation', 'the house of brands', 'activities\\n                            &#160;\\n', 'the Ontario Superior Court of Justice', 'Goodwill\\n                                                ', 'Lisan', 'combinations.\\n                        \\n                            ', 'Flora Growth Corp.Notes', 'the business.\\n                        The reconciliation', 'activities\\n                            &#', 'JustCBD.\\n                        \\n                        ', 'Accounting Standards Codification', 'Discussion and Analysis of Financial Condition', 'options\\n                            &#', '\\n                                            &', 'Flora', 'Flora Growth Corp.', 'Wholesale', 'Flora Growth Corp.\\n', 'United States dollars', 'ClassicPlan Premium Financing, Inc', '1,173\\n                                                &', '\\n                                                        &#', 'Company', 'development.\\n                            Professional', '\\n                                                ', 'the Act).Yes &#9744;&#160', '\\n                            &', 'disposals\\n                            &#160;\\n', 'FGH', 'Share Purchase Agreement', 'employees.\\n                            Travel', '2022 Annual Report', 'Inventory\\n                                                &', '31\\n                                                &', 'No &#', '\\n                        Consulting and Management', 'the house of brands segment', '\\n                                                &', 'Vessel'}"
FLGT,"{'FASB', 'ROU assets\\n', 'this Quarterly Report on Form', 'treasury', 'Allowance for Credit Losses Trade', 'Board', 'Critical Accounting Policies', 'the Clinical Laboratory Improvement Amendments', 'investments.7\\n       &', '\\n  &#94', 'the Securities and Exchange Commission', 'the Condensed Consolidated Balance Sheets', 'Chairperson of the Board', 'Stockholders&#x2019', 'x2014;\\n        &', 'The Amended and Restated Incentive Compensation Recoupment Policy', 'Geographic InformationThe Company', '\\n  &#', 'Restated Incentive Compensation Recoupment Policy', 'the Compensation Committee of the Board', 'the BusinessFulgent Genetics, Inc.', 'Development\\n  Research', 'COVID-19 tests.\\n  Revenue', 'Significant Accounting Policies', 'ShareThe', '\\n        &', 'SEC', 'Condensed Consolidated Statements', 'the U.S. Health Resources and Services Administration', 'LeasesLesseeThe Company', 'Condensed Consolidated Balance Sheets', 'Company&#x2019;s', 'the Financial Accounting Standards Board', 'Company', 'CAP', 'HRSA', 'ANP', 'RevenueThe Company', 'COVID-19', 'AHMC', 'the State of California Department of Public Health', 'Tenants\\n        &', 'data)\\n        &', 'Recent Accounting', 'ANP Technologies, Inc.', 'the College of American Pathologists', 'Recent Accounting Pronouncements\\n  See Note 2', '\\n    &', 'HRSA COVID-19 Uninsurance Program', 'Unaudited Interim Financial Information'}"
FNCH,
FOLD,
FONR,"{'Diagnostic Center, Inc.', 'AIRS Medical', 'Health Management Corporation of America', 'the Securities Exchange', 'this Quarterly Report on Form 10-Q', 'the &#8220;percentage', 'COVID-19', 'facilities\\nHMCA', 'Stand Up MRI &', 'Health Diagnostics\\nManagement', 'LLC (&#8220;HDM&#8221;)', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\nSEPTEMBER\\n30', 'completion&#8221', 'Facility Competition', 'Fonar', 'Company', 'carryforwards.\\n\\n&#160;\\n\\nASC\\nTopic'}"
FORA,"{'ASC', 'BioTrack', 'FASB', 'the Note Purchase Agreement', 'Stockholders Agreement', 'the Board of Directors', 'Contracts with Customers (&#', 'and\\n              ', 'United States', 'Accounting for Contract Assets and Contract Liabilities', 'Treasury', 'SEC', 'Company', 'the Securities Exchange Act', 'Exhibit 3.2', '\\n                      &', 'Nasdaq', '\\n               ', 'Warrants'}"
FRES,
FRLN,
FRTX,"{'Carna Biosciences, Inc. (&', 'BotanixOn', 'the Potential Treatment of Autoimmune, Inflammatory', 'Yonder Partners', 'Botanix Pharmaceuticals', 'development$273&#160;$104&#160;$468&#160;$320&#160;General', 'ContentsOn May&#160;25', 'Principal Executive Officer', 'TSA', 'Post-Closing Payment', 'Financial ReportingManagement', 'General Risk FactorsProvisions', 'Asset Purchase Agreement', 'No &#9744;Indicate', 'Nasdaq Staff', 'the Series A Preferred Stock', 'Rare Genetic', 'Key Components', 'ProceduresUnder', 'the Listing Qualifications Department', 'Nasdaq Listing Rule Series 5100', 'the Financial Accounting Standards Board', 'BodorIn', 'Botanix SB Inc.', 'McAvoy Law LLC&#215;10.7Separation', 'the Securities Exchange Act', 'the Company&#8217;s Board', 'TTK', 'L.L.C.', 'Kaken Pharmaceutical Co., Ltd.', 'Market Issuance Sales Agreement', 'Exclusive License and Development Agreement', 'Asset', 'the Company for FRTX-02', 'Payments&#8221;).The Asset Purchase Agreement', 'ProceduresWe', 'Deepak', 'Bodor Laboratories, Inc. (&#8220;Bodor&#8221', 'ATM Agreement', 'Internal Control', 'the Carna License Agreement', 'TSA&#8212;&#160;372&#160;9&#160;730&#160;Upfront', 'NetTotal', 'the Restated Certificate of Incorporation', 'FDA', 'The Securities Purchase Agreement', 'Botanix Asset Purchase Agreement', 'the U.S. NDA', 'Botanix SB', 'ContentsThe', '907,804&#160;843,982&#160;LeasesThe Company', 'The Asset Purchase Agreement', 'Sublicense Income', 'License and Development Agreement', 'Company', 'CLK', 'The Series A Preferred Stock', 'Brickell Subsidiary, Inc.', 'LLC (&#8220;Lincoln', 'Kaken', 'Market Issuance Sales AgreementsIn', 'Oppenheimer &amp', 'The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'the Asset Purchase Agreement, Botanix', 'Exclusive License Agreement', 'Dissolution', 'Botanix Asset Purchase Agreement with Botanix', 'Principal Financial Officer', ': &#8226;impairment', 'Botanix', 'ContentsContract', 'Co. Inc.', 'Release Agreement', 'Bodor Laboratories', 'the Asset Purchase Agreement', 'Brickell Subsidiary, Inc. (&#', 'the Asset Purchase Agreement Amendment with Botanix', 'Oppenheimer', 'Botanix (the &#', 'the Asset Purchase Agreement Amendment', 'NDA', 'Lincoln Park Capital Fund', 'DevelopmentResearch', 'September&#160;18', 'authority&#160;to', 'Restated Certificate of Incorporation', 'OperationsAs', 'the Botanix AgreementsThe Company', 'Kaken Agreement', 'the Purchase Agreement', 'Contentsany', 'the Voronoi License Agreement', 'Board', 'this Quarterly Report', 'OPERATIONS', 'Voronoi Inc.', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'Transition Services Agreement', 'The Voronoi License Agreement', 'License, Development', 'LRRK2', 'Conclusion Regarding the Effectiveness of Disclosure Controls', 'SEC', 'ContentsStock-Based Compensation ExpenseTotal', 'Commercialization Agreement', 'the &#8220;Effective', 'BotanixIn', 'Botanix Pharmaceuticals Limited', 'Asset Purchase Agreement and Amended and Restated License Agreement', 'FilingExhibit NumberFiled Herewith2.1Plan of Dissolution of Fresh Tracks Therapeutics', 'Nasdaq'}"
FTRE,"{'Fortrea Holdings Inc.', 'the Black-Scholes', 'the Clinical Services', 'the Transition Services Agreement', '20233.00.1$32.9&#160;$43.8&#160;All PlansTotal', 'Exchange Act', 'the Securities and Exchange Commission', 'the Employee Matters Agreement', 'Omnibus Incentive Plan', 'Labcorp Drug Development', 'ExhibitsThe', 'Business Segment Information', 'the Financial Institution', '2002.X32.1Certification of Chief Executive Officer', 'The Enabling Services', 'Derivative InstrumentsThe Company', 'the Laboratory Corporation of America Holdings', 'Information Statement', 'Enabling Services', 'Basis of Financial Statement Presentation', 'FORTREA HOLDINGS INC', 'LabcorpOn June 30, 2023', 'Incremental Independent Public Company ExpensesThe', 'the Credit Agreement', 'Board of Directors of Fortrea', 'ContentsThe', '19INDEX                                                                             FORTREA HOLDINGS INC', 'the Tax Matters Agreement', 'Form 10.Company OverviewFortrea Holdings Inc.', 'SEC', '9INDEX                                                                             FORTREA HOLDINGS INC', 'Company', 'see &', 'Internal Control Over Financial ReportingNo', 'Fortrea&#8217;s Board of Directors', 'data)Unrecognized Compensation CostAs of September&#160;30', 'the &#8220;Risk Factors&#8221', 'the Sarbanes-Oxley Act', 'Labcorp', 'CFO', '14INDEX                                                                             FORTREA HOLDINGS INC', 'CODM', 'Fortrea'}"
FULC,
FUSN,"{'\\n  &#x2022;injury', 'LLC', '4,169\\n        &', 'Men1', 'AML', '\\n', 'Financial Statements&#x2014;Recent', 'Financial Instruments', 'the Federal Reserve', 'this Quarterly Report on Form 10-Q', '\\n  &#x2022;making', '\\n  &#x2022;costs', 'Stock-Based Compensation ExpenseTotal', 'x2022;a', 'Sensitive Information', 'FUSIONTM System', '\\n  &#x2022;completion', 'Form S-1', 'Point Sur Investors Fund I', '\\n  &#x2022;establishing', 'IndemnificationThe Company', 'COVID-19', '\\n  &#x2022;whether BMF-219', '\\n  &#x2022;obtaining', 'Ramses Erdtmann', '\\n  &#x2022;expenses', 'FASB', '\\n  &#x2022;product', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', '\\n  &#x2022;initiation', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'FDA', '\\n  &#x2022;collaborations', 'NetProperty', 'statements.\\n  &', '\\n        Laboratory equipment\\n', '3,847\\n        &', '\\n  &#x2022;Our', '\\n  &#x2022;maintaining', '\\n  &#x2022;relative', 'depreciation\\n        &', '\\n  &#x2022;others', '\\n  &#x2022;loss', 'HIPAA', 'REMS', 'Company', 'the Department of the Treasury', 'USPTO', 'General Risk Factors \\n', '\\n  &#x2022;laboratory', '\\n  &#x2022;limitations', 'Biomea Fusion, Inc.', '\\n  &#x2022;whether', 'SVB', 'Signature Bank', '\\n  &#x2022;physicians', 'the Delaware General Corporation Law', 'ASU', 'The Shelf Registration Statement', 'Restricted Cash&#160;The Company', '\\n  &#x2022;the', 'x2022;we', '\\n  &#x2022;exhaustion', 'Financial Instruments &#', '\\n  &#', '\\n  &#x2022;collaborators', 'KRAS', '\\n  &#x2022;retention', 'estimates.6\\n     &#160;&#160;&#160;Segments&#160;The Company', '\\n  &#x2022;decreased', 'NDA', 'NPM1', 'CMO', 'Capital StructureCommon Stock', 'FDIC', 'the Sarbanes-Oxley Act', 'the indemnified party', 'noted.\\n  &', 'IPO', 'This Quarterly Report on Form 10-Q', 'companies&#x2019', '\\n  &#x2022;our', '\\n  &#x2022;pricing', 'Form S-3', 'iii\\n', '\\n  &', 'HITECH', 'the Court of Chancery of the State of Delaware', 'combination.\\n  &', '\\n          Laboratory', 'Biomea', '4th Floor', 'the State of Delaware', '\\n  &#x2022;risks', 'Sarbanes-Oxley Act', 'BMF-219\\n  &#160;\\n', '\\n  &#x2022;withdrawal', '\\n  &#x2022;successful', 'the Court of Chancery', '5,575\\n        &', '\\n        &', 'SEC', 'the Shelf Registration Statement', 'Cormorant Asset Management', 'stock.\\n  &', '42\\n  \\n  &#', 'Credit Losses', 'payors;\\n  &#x2022;effectively', 'Equity Securities', 'MLL', '\\n  &#x2022;receipt', 'property.\\n'}"
FWBI,
GALT,
GANX,
GBIO,
GBNH,
GCTK,"{'reporting.\\n\\n&#160;\\n\\nManagement\\nhas', 'Aegis Capital Corp.', 'immediately.\\n\\n&#160;\\n\\nJames\\nCardwell', 'The Nasdaq Stock Market', 'Nasdaq&#8217;s Listing Rules\\n(the &#8220;Rules&#8221', 'GlucoTrack, Inc.', 'expenses\\n\\n&#160;\\n\\nGeneral\\nand', 'Company&#8217;s\\noperations', 'CGM', 'the CFO Squad', 'Regulation S-K.\\n\\n&#160;\\n\\nOn\\nOctober 11,', 'SEC', 'Company', 'The Nasdaq Stock Market LLC', 'the Securities Exchange Act', 'the Evaluation Date', 'the Sarbanes-Oxley Act', 'The Cardwell Consulting', 'Nasdaq', '\\n    &'}"
GDRX,"{'FASB', 'Issuer Repurchases of Equity SecuritiesThe', 'NDCA', 'ASU', 'ProceedingsThe', 'Babak Azad', 'RevenueFor', 'Board', 'this Quarterly Report on Form 10-Q.', 'Holdings, Inc.', 'PBM', 'Kroger Savings', 'vitaCare\\', 'Walmart', 'the Securities and Exchange Commission', 'Contentson', 'this Quarterly Report on Form 10-Q', 'Revolving Credit Facility', 'Investments &#8211', 'Trevor Bezdek', 'Accounting Standards Codification Topic 321', 'Kroger', 'Restructuring Plan', 'the Credit Agreement', 'Rule 10b5-1', 'Meta', 'ContentsThe', 'Google', 'Gold', 'vitaCare', 'Board on February&#160;23', 'the Revolving Credit Facility', 'Form S-1', 'SEC', 'FTC', 'GoodRx, Inc.', 'Total RevenueChange', 'Monthly Active Consumers', 'the Financial Accounting Standards Board', 'DollarValue of Shares', 'COVID-19', 'Equity Securities', 'Regulation S-K', 'Fair Value Measurement', 'CVS', 'IPO', 'RepurchasedUnder', 'MedImpact', 'Board (the &#8220;Transition&#8221', 'Navitus', 'Release'}"
GDTC,
GEHC,
GENE,
GERN,
GH,"{'Adicon Holdings Limited', 'Company\\', 'Development Services', 'the Clinical Laboratory Improvement Amendments', 'MSU', 'Labour', 'Welfare', 'RecognitionThe Company', 'December&#160;31', ""Japan\\'s Ministry of Health"", 'this Quarterly Report on Form 10-Q', 'SoftBank', 'ContentsValuation of Stock OptionsThe', 'Lunit, Inc.', 'Geographic InformationThe Company', 'ContentsGeneral', 'the New York State Department of Health', 'GuardantOMNI', 'NYSDOH', 'Shield', 'Guardant Galaxy', 'GoodwillThe', 'financial and/or operational metrics', 'administrative$118,135&#160;$126,068&#160;$(7,933)(6)%General', 'ContentsThe', 'released(3,435)32.86&#160;Canceled(40,142)94.56&#160;Balance', 'Illumina, Inc.', '6.105.50 &#8211', 'Joint Venture', 'Guardant Reveal', 'ContentsWe', 'LDT', '6.025.50 &#8211', 'Company', 'CAP', 'IVD', 'Guardant Health, Inc.', 'ContentsTotal', 'the Securities Exchange Act', 'Collaboration and Settlement Agreement', 'the Joint Venture', 'ContentsThe Company', '2023,&#160;and&#160;2022', 'the College of American Pathologists', 'CFO', 'ORACLE', 'The Royal Marsden NHS Foundation Trust'}"
GHRS,
GHSI,"{'operations.\\n\\n&#160;\\n\\n7.\\nRedeemable Preferred Stock (Temporary Equity', 'LLC', 'Regulation S-K.\\n\\n&#160;\\n\\nITEM\\n6', 'Guardion Health Sciences, Inc.', 'ASU', 'the U.S. Securities and Exchange Commission', 'the Series C Preferred Stock', 'this Quarterly Report on Form 10-Q.', 'the Board of Directors', 'the Series B Warrants', 'the Company&#8217;s Series D Redeemable Preferred Stock\\n(the &#', 'Delaware Certificate of Incorporation', 'Maxim Group', 'Yes &#9744', 'this Quarterly Report on Form 10-Q', 'Unobservable', 'Non Vested Restricted Common Stock', 'the State of Delaware', 'reporting.\\n\\n&#160;\\n\\nLimitations\\non Effectiveness of Controls', 'forced\\nto', 'appropriate.\\n\\n&#160;\\n\\nChanges\\nin Internal Control Over Financial Reporting\\n\\n&#160;\\n\\nThere\\nhave', 'the Compensation\\nCommittee of the Board of Directors', 'Roth Capital\\nPartners LLC (&#8220;Roth&#8221', 'PROCEDURES\\n\\n&#160;\\n\\nEvaluation\\nof Disclosure Controls', 'The Nasdaq Capital Market', 'Accounting Standards Update', 'the Common Stock', 'Adare\\n    Pharmaceuticals, Inc. (&#8220;Adare&#8221', 'SEC', 'Health Sciences', 'Company', 'the Financial Accounting Standards Board', 'the Company&#8217;s Series C Convertible Redeemable\\nPreferred Stock', 'Securities and Exchange Act', 'Certificate of Incorporation', 'Measurement of Credit Losses on Financial Instruments', 'Stock&#8221;).&#160;\\n\\n&#160;\\n\\n\\n\\n    &', 'data.\\n\\n&#160;\\n\\nLevel\\n3 &#8211', 'Guardion Health Sciences', 'respectively.\\n\\n&#160;\\n\\nCost\\nof Goods Sold\\n\\n&#160;\\n\\nCost\\nof', 'The Series A Warrants', 'Nasdaq', 'Credit Losses &#8211', '\\n    &'}"
GILD,
GLMD,
GLPG,
GLSI,
GLTO,"{'compensation\\n    &', 'LOXL2', 'None.\\n  &', 'CRO', 'Form S-3', 'Rule 424(b)(4', 'Item 10 of Regulation S-K', '\\n    Consultants', 'noncurrent\\n    &', '\\n  &', '\\n    Preclinical', 'ATM Program', 'net.\\n', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'Roche', 'operations.\\n  &', 'the Nasdaq Stock Market', 'Nasdaq&#x2019;s Listing Qualifications Department', 'FAIR VALUE MEASUREMENTSFair', '\\n  &#', 'the Public Company Accounting Oversight Board', 'Nasdaq Delisting Notice\\n', 'EGC', 'Condensed Consolidated Statements of Changes', 'NSCLC', 'The Nasdaq Capital Market', '\\n    Research', 'Form S-1', 'Euro', 'SEC', '\\n    Adjustment', 'RECIST', 'activities\\n    &', 'Company', 'Condensed Consolidated Statements of Cash Flows \\n', 'Research', '\\n  Research', 'the Sarbanes-Oxley Act', '\\n    Chemistry', 'IPO', 'Comparison', 'GALECTO', 'Nasdaq', 'Nasdaq Listing Rule 5450(a)(1', '\\n    &', 'the Registration Statement'}"
GLUE,
GLYC,
GMAB,
GMDA,
GNFT,
GNLX,
GNPX,"{'University of Texas', '\\n      &#', '\\n      &#x25cf', 'the Equity Distribution Agreement', 'Rules 13a-15(b', '2023 &#', 'xa0;\\n\\n', 'the Patent and Technology License Agreement', 'the National Institutes of Health.\\n   &#', 'expense&#xa0;from', 'AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics&#xa0;the Phase 1', 'The University of Texas', '\\n   &#', 'the Public Company Accounting Oversight Board', 'the Internal Revenue Code', 'Research and Development Expense\\n  &#xa0;\\n  Research and Development', 'the trial.&#xa0;\\n  &#', 'IRI', 'NSCLC', 'Anderson Cancer Center', 'life.\\n  &#', 'of:\\n  &#', 'Except', 'the University of Pittsburgh', 'The Board of Regents of the University of Texas System', 'Critical Accounting Estimates\\n  &#', 'reporting.\\n  &#', 'Registered Direct Offerings\\n   &', 'Company\\', 'Internal Control', 'our&#xa0;common', 'FDA', 'Specifically', 'RSU', 'Original', 'immunotherapies.&#xa0;\\n   &', 'the Sarbanes-Oxley', 'JMP Securities', 'the ""ATM Facility', '\\n    &#', 'NPRL2', 'REQORSA', 'for&#xa0;gross', 'ATM Facility', 'NHP', 'University of Pittsburgh\\n   &#', 'results.\\n  &#', '\\n  &#', 'the Safety Review Committee', 'University of Pittsburgh).\\n   &', 'Commitments &', 'Anderson License Agreement', 'SCLC', 'Procedures\\n  &#', 'FDIC', 'IPO', 'Fair Value of Financial Instruments\\n   &', 'Financial Reporting\\n  &#', 'the University of Pittsburgh&#xa0;relating', 'Comparison', 'operations.\\n  &#', ': &#xa0', 'our&#xa0;2018 Equity Incentive Plan', 'the glucagon technology (See Note 7 &#', 'JMP Securities LLC&#xa0;(""JMP Securities', 'this Quarterly Report', 'impacted.\\n  &#', 'xa0;\\n     &', 'ATM', 'Commitments and Contingences &#', 'Tagrisso', 'Nasdaq&#x2019;s', '2023.&#xa0;\\n  &#', 'xa0;\\n     &#', 'x201c;anticipate,&#x201d', 'Black-Scholes-Merton', 'SEC', 'agreements.\\n', 'Nasdaq', '\\n    &', 'concern.\\n  &#'}"
GNTA,
GOSS,"{'Consolidated Statements of Operations', 'ProceduresWe', 'the Nasdaq Capital Market', 'Fair Value of Other Financial InstrumentsAs of September&#160;30', 'Form S-3', 'Unaudited Condensed Consolidated Financial Statements9Item&#160;2Management&#8217;s Discussion and Analysis of Financial Condition', 'Rule&#160;15d-14(a', 'Results of Operations23Item&#160;3Quantitative', 'the Eligible Options', 'Critical Accounting Policies', 'Consolidated Statements', '2022.The Company', 'GOSSAMER BIO', 'EstimatesOur', 'Pulmokine', 'the Private Securities Litigation Reform Act', 'the Option Repricing, &', 'Wilmington Trust', 'this Quarterly Report on Form 10-Q', 'ESPP', 'Liabilities Measured at Fair Value', 'Consolidated Statements of Cash Flows', 'FDA', 'ContentsAssets', 'ContentsUnder', 'funds$54,662&#160;$54,662&#160;$&#8212;&#160;$&#8212;&#160;U.S. Treasury', 'BasisThe', 'Registrant', 'Pulmokine, Inc.', 'SEC', 'the 2020 Shelf Registration Statement', 'Company', 'Restated Certificate of Incorporation', 'the Securities Exchange Act', 'funds$19,885&#160;$19,885&#160;$&#8212;&#160;$&#8212;&#160;U.S. Treasury', 'Eligible Options', 'the Sarbanes-Oxley Act', 'Consolidated Balance Sheets', 'PAH', 'IPO', 'Nasdaq', 'Consolidated Financial Statements', 'the Credit Facility', 'Exhibit 4.4).8-K5/21/20204.34.6Form'}"
GOVX,"{'Options\\n\\n&#xa0;\\n\\nWe', 'Outside the Box Capital', 'LLC', 'GP', 'Reston ebolavirus.\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\n\\n\\n\\n9\\n\\n\\n\\n\\n\\n\\n&#xa0;\\n\\n\\n\\n\\n&#xa0;\\n\\nGeneral Corporate\\n\\n\\n\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#x25cf;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tIn', 'Nasdaq Capital Market\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tWarrants', 'the U.S. Patent and Trademark Office', 'Acorn Management Partners', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Activities &#', 'GEO-CM04S1', 'Yes&#xa0;&#x2612', 'GeoVax&#x2019;s', 'Results of Operations (&#x201c;MD&amp;A&#x201d;)', 'Registered\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tCommon Stock', 'Trademark Office', 'Board of Directors', 'Nasdaq Capital Market\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nIndicate', 'the &#x201c;Company&#x201d;.\\n\\n&#xa0;\\n\\nThe Company', 'Rule 12b-2', 'Registrant', 'Exchange', 'GEO', 'The Nasdaq Capital Market', 'GeoVax Labs, Inc.', 'No &#x2610;\\n\\n&#xa0;\\n\\nIndicate', 'the Listing Qualifications Department', '&#x201c;Replication', 'Company', 'Rule 405 of Regulation S', 'the Securities Exchange Act', 'MVA', 'Capital Resources\\n\\n&#xa0;\\n\\nThe', 'Share\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nBasic', 'Interactive Data File', 'Equity\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nCommon Stock', 'GeoVax, Inc.'}"
GPCR,
GRCL,
GRFS,
GRI,
GRPH,"{'LLC', 'Stanford', 'x201c;IDT License', 'Exhibits.\\n  &#160;\\n', 'Soleil Labs', 'ConsolidationThe Company', 'candidates;\\n  &#x2022;estimates', 'the Public Company Accounting Oversight Board', 'Lease Agreement', 'ContingenciesResearch', '26\\n', 'the &#x201c;License', 'Non-Genotoxic Targeted Conditioning Technology AssetsOn', 'Form S-1', 'the Leland Stanford Junior University', 'the Securities Exchange Act', 'License AgreementsThe Company', 'x201c;continue,&#x201d', 'COVID-19', 'Principal Financial Officer Pursuant', 'The Board of Trustees', 'No &#', 'the &#x201c;First Option', 'the IDT License Agreement', 'the Subleased Haskins Premises', 'LCGM', 'candidates;\\n  &#x2022;our', 'LCGM Service', 'securities;\\n  &#x2022;our', 'the Laboratory for Cell &', 'the Stanford Adjustment Repurchase', 'activities\\n    &', 'Company', 'Adopted Pursuant to Section 302', 'we:\\n  &#x2022;advance', 'the Second Option Agreement', '\\n  LCGM Service Agreement\\n', 'Critical Accounting Policies', 'Stanford (&#x201c;LCGM', 'Grant PlanPrior', 'Release Agreement', 'and\\n  &#x2022;our', 'x201c;expects,&#x201d', 'Integrated DNA Technologies, Inc. (&#', 'performance;\\n  &#x2022;our', 'Gene Medicine (&', '\\n  &#', 'Non-Genotoxic Targeted Conditioning Technology Assets\\n', 'APA', 'the ARE Master Lease', 'Registrant', 'respectively.\\n  &#', 'the Sarbanes-Oxley Act', 'IPO', 'any;\\n  &#', 'Condensed Financial Statements', 'Form S-3', 'the License Agreement', 'Bayside Area Development', 'x201c;Second Option', 'Explora Agreements', 'Inherent Limitations on Effectiveness', 'outstanding.\\n  &#', '\\n  &', 'the First Option Agreement', 'the Registrant&#x2019;s Registration Statement on Form S-1', 'The First Option Agreement', 'the Registrant&#x2019;s Current Report', 'Adopted Accounting Pronouncements\\n', 'and\\n  &#x2022;obtain', '\\n        &', 'SEC', 'CA', 'Development AgreementsThe Company', 'relationships;\\n  &#x2022;our', '\\n    &', 'No &#9744;\\n  Indicate', 'Internal Control Over Financial Reporting\\n'}"
GRTS,
GRTX,"{'L.P.', 'FASB', 'ASU', 'reference.\\n  &', '\\n    Interest income\\n    &', 'Research and Development Expense \\n  &#', 'Critical Accounting Policies', 'this Quarterly Report', 'the Royalty Agreement', 'this Quarterly Report on Form 10-Q.', 'Contracts', 'SBRT', '\\n  &', 'ATM', 'x201c;Risk', 'Royalty', 'the Royalty Purchase Price', '\\n  &#x2022;the', 'Obtaining', 'Nasdaq&#x2019;s', 'x2014;\\n        &', 'Blackstone', 'Jefferies LLC', 'TD Bank', 'PDUFA', 'FDA', 'The U.S. Food and Drug Administration', 'the Product Payments', '\\n  &#', '\\n  &#x2022;our', '\\n        Laboratory equipment\\n', 'Nasdaq Listing Notification\\n  &', 'and\\n  &#', 'Market Value of Listed Securities', 'The Nasdaq Capital Market', '\\n    Research', 'L.P. (the Blackstone Purchaser', 'NDA', '\\n        &', 'SEC', 'Restricted', 'Accounting for Convertible Instruments', '\\n          &', 'Blackstone Life Sciences', 'CRL', '\\n  Royalty Agreement', 'Company', 'Pursuant', 'The Nasdaq Stock Market LLC', 'the MVLS Requirement', 'Notices', 'the Securities Exchange Act', 'Research', 'Jefferies', 'the Sarbanes-Oxley Act', 'COVID-19', '\\n    Interest expense\\n    &', 'the Workforce Reduction', 'enrollment.\\n  &', 'liability.\\n  Liquidity and Capital Resources', 'Adopted Pursuant to Section 302', 'GAAP', 'GALERA THERAPEUTICS', 'Nasdaq', 'Comparison', 'the MVPHS Requirement', '\\n    &', 'Property'}"
GTBP,
GTH,
GTHX,
HALO,
HARP,"{'Reliance', 'the Nasdaq Hearings Panel', '\\n', '\\n  &#x2022;incur', 'candidates;\\n  &#x2022;the', 'Restricted Stock Units  A', 'the Cove Lease', 'Financial Instruments', 'any.\\n  &#', 'EU', 'approvals;\\n  &#x2022;the', 'PCT', 'Phase 4', '\\n    Laboratory', 'the period.\\n  Research and Development \\n', 'Series A Preferred Stock', 'Nasdaq Staff', 'the Series A Preferred Stock', 'CPRA', '\\n    Research', ""the Company\\'s Board"", 'the Financial Accounting Standards Board', 'the Effectiveness of Internal Control\\n', 'Research', 'AbbVie', 'results.\\n  &#x2022;We', '\\n  &#x2022;prohibit', 'the Series A Preferred', '\\n  &#x2022;provide', 'Liquidity and Capital Resources \\n  Liquidity \\n', 'FASB', 'the Development and Option Agreement', 'Anti-Kickback Statute', 'HHS', 'Internal Control', 'Note 11 Subsequent', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'HPN601', 'x2014;\\n        &', 'GDPR', ': &', 'FDA', 'Financial Reporting \\n', '\\n        Laboratory equipment\\n', '\\n  &#x2022;difficulties', 'performed.\\n  Collaboration', 'Nasdaq;\\n  &#x2022;the', 'Development and Option Agreement', 'the Certificate of Amendment', 'stock.\\n  Ensuring', 'Company', 'Equipment, Net Property', 'BCMA', 'and\\n  &#x2022;the', 'Principal Financial and Accounting Officer', 'the Nasdaq Capital Markets', 'General Risk Factors \\n', '\\n  &#x2022;impose', 'the California Privacy Rights Act', '\\n  &#x2022;seize', 'Purchase Agreement', 'ASU', '\\n  ', 'AIA', 'the U.S. Patent and Trademark Office', 'Stockholders&#x2019', '\\n  &#x2022;disruption', 'Roche', 'Financial Instruments &#', 'Sales Agreement', '\\n  &#', '\\n  &#x2022;restrict', 'Investigational New Drug', '\\n  &#x2022;possible', '\\n  &#x2022;retention', 'TCR', '\\n  &#x2022;diversion', '\\n  &#x2022;require', 'all.\\n  &#x2022;Interim', 'SCLC', 'Economy,&#x201d', 'TROP2', 'the HTA Regulation', 'issue.\\n  Financial Operations Overview \\n', 'The Development and Option Agreement', '\\n  &#x2022;our', 'Form S-3', 'commercialize.\\n  &#x2022;We', '\\n  &#x2022;We', 'Investigational New Drug Application', '\\n  &#160;\\n  ', '\\n  &', 'the Restated Collaboration Agreement', 'Nasdaq&#x2019;s', 'candidates.\\n  &#x2022;We', 'x2022;refuse', '\\n  &#x2022;unanticipated', '\\n  &#x2022;increases', '\\n  &#x2022;suspend', 'Pre-Funded Warrants', 'Condensed Financial', '\\n  &#x2022;authorize', '\\n        &', 'SEC', 'RECIST', 'stock.\\n  &', 'GCP', 'Credit Losses', 'additional capital;\\n  &#x2022;the', 'FINANCIAL INFORMATION\\n    &', '\\n  &#x2022;permit', 'Nasdaq', 'the European Union', '\\n    &', '\\n  &#x2022;eliminate'}"
HBIO,"{'Harvard Apparatus Regenerative Technology, Inc.', 'State', 'the Registration Statement on Form 10-12B', 'the Company\\nand HBIO', 'the Current Report on Form 8-K', 'Administrative\\n\\n&#160;\\n\\nGeneral\\nand', 'Administrative Expense\\n\\n&#160;\\n\\nGeneral\\nand', 'this Quarterly Report on Form 10-Q', 'Harvard', 'the State of Delaware', 'HBIO', 'Biostage, Inc.', 'certifications.\\n\\n&#160;\\n\\n\\n\\n\\n\\n\\n\\nEvaluation\\nof Disclosure Controls', 'the Registration Statement on Form 8-A', 'Significant Accounting Policies', 'the Annual Report on Form 10-K', 'the Series C Convertible Preferred Stock', 'SEC', 'Total&#160;\\n    $', 'YES &#9744', 'Company', 'the Securities Exchange Act', 'prepared\\nin', 'the Securities and Exchange Commission&#8217;s\\nrules and forms.\\n\\n&#160;\\n\\nChanges\\nin Internal Control', 'Development Expense\\n\\n&#160;\\n\\nResearch\\nand', 'Harvard Bioscience, Inc.', 'the Sarbanes-Oxley Act', 'guidance.\\nShare', '\\n    &', 'Harvard Bioscience', 'Series E Convertible Preferred Stock', 'Condensed Consolidated Financial Statements'}"
HCAT,
HCM,
HCSG,
HCTI,
HCWB,"{'Prime Capital Ventures', 'Company\\', 'LLC', 'the University of Minnesota', 'LLC (&#34;Prime&#34;)', 'Development Line of Credit Agreement', 'HCW Biologics', 'the Principal Investigator', 'the 2023 Loan Agreement', 'Critical Accounting Policies', 'this Quarterly Report', 'Professor', 'MSA', 'Legal &', 'LLC (&#x201c;Prime&#x201d;)', 'the Prime Maturity Date', '\\n  Salaries', 'x2014;\\n        &', 'Procedures\\n  &', 'Altor/NantCell&#x2019;s', 'the Department of Obstetrics, Gynecology', 'Recent Accounting Pronouncements\\n  &', 'Cogent Bank', 'GMP', '\\n  &#', 'Court', 'NantCell, Inc. (&#x201c;Altor/NantCell&#x201d', 'the Wugen License', 'Indicate', '\\n    Research', 'the U.S. District Court', '\\n        &', 'NantCell, Inc.', 'UMN', 'Division', 'Company', 'period.&#160;The Company', 'the 2022 Loan Agreement', 'procedures.\\n  &', 'x201c;anticipate,&#x201d; &#', '\\n    Interest expense\\n    &', 'Regulation S-K', 'CFO', 'Gynecologic Oncology', 'Comparison', 'HCW9218', '\\n    &'}"
HEPA,"{'ASC', 'U.S.C', 'Basis of PresentationBasis of', 'Principal Financial Officer', 'the Edison Lease', 'InformationDuring', 'the Securities and Exchange Commission', 'the Interactive Data File', 'FDA', 'Pre-Funded Warrant', 'PHARMACEUTICALS', 'Board of Directors', 'ROBERT FOSTERRobert FosterChief Executive', 'Research and Development', 'Condensed Consolidated Financial Statements(Unaudited)At September&#160;30', 'Registrant', 'Exhibit 4.3', 'DevelopmentResearch', 'the Securities Exchange Act', 'Securities Purchase Agreement', 'the Sarbanes-Oxley Act', 'Regulation S-K', 'ASC Topic', 'Nasdaq', 'Condensed Consolidated Financial'}"
HITI,
HLTH,"{'ASC', 'Erie Laboratory', 'Leases &', 'diluted\\n    &', 'LG Chem', 'Immuno', 'Interest Income\\n  Interest', 'Restricted CashThe Company', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'CUE-102;\\n  &#x2022;leverage', 'Indicate', 'G Additional Laboratory Lease', '\\n    Research', 'this Quarterly Report on Form 10-Q.\\n  ', 'Adopted', 'Research', 'Jefferies', 'and\\n  &', 'the LG Chem Territory', 'ATM Agreement', 'the Einstein License Agreement', 'EPS', 'x2014;\\n        &', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Licensed Products', 'Ono Pharmaceuticals Co., Ltd.', 'Loan', '\\n        Laboratory equipment\\n', 'the Research Term', 'depreciation\\n        &', 'Silicon Valley Bank', 'Company', 'regulations;\\n  &#160;\\n  &#x2022;our', 'Jefferies LLC (&#34;Jefferies&#34;)', 'Collaboration Products', 'SVB', 'the &#x201c;Research', 'SVBB', 'products.\\n  &#x2022;We', 'LG', 'Loan Agreement', 'candidates;\\n  &', 'Merck', 'the Ono Collaboration and Option Agreement', 'The Loan Agreement', 'remaining)\\n        &#', 'the LG Chem Collaboration Agreement', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'License', 'Scientific and Clinical Advisory Board', '\\n  &#', 'CMC', '7,500,480\\n          &', 'Contract CostsThe Company', 'the following:&#160;\\n      \\n       \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n       \\n       \\n        &', '\\n    &', 'LG Chem\\n  Effective', 'the heading &#x201c;Collaboration Agreement', 'Tregs', 'OnoOn', 'programs.\\n  &#160;\\n  &#160;\\n  &#160;\\n  ', 'statements.\\n  &#x2022;We', 'organization)\\n    &#160;\\n', '\\n  Collaboration Agreement', 'CPS', 'charter)\\n  &#', 'the &#x201c;Closing Date&#x201d;)', 'Silicon Valley Bridge Bank', 'Form S-3', 'Neo-STATs;\\n  &#', 'the Loan Agreement', '\\n  &#x2022;We', 'the Lender', 'ATM', '\\n  &', 'LG Chem Ltd.', 'the Term Commencement Date', 'the Drug Product Candidates', 'candidates.\\n  &#x2022;We', 'we:\\n  &#x2022;continue', 'EquipmentProperty', 'and\\n  &#x2022;incur', 'agreements.\\n  &#x2022;Pay', 'G Additional Laboratory', 'U.S. Treasury', 'Albert Einstein College of Medicine', '\\n        &', 'SEC', '\\n    Interest', 'x201c;Loan', 'Ono Pharmaceutical Co., Ltd.', 'Leases', 'funding.\\n  &#160;\\n  ', 'expense.\\n  &', 'below.\\n  &#'}"
HLVX,"{'ASC', 'FASB', 'the Takeda License', 'the Loan Agreement', 'this Quarterly Report', 'Hercules Capital, Inc.', 'Loan Agreement', 'Security Agreement', 'PIK', '\\n  &', 'Credit Risk Financial', 'results.\\n  &', 'Transitional Services Agreement', 'the Existing Loan Agreement', 'the Private Securities Litigation Reform Act', 'HilleVax Security Corporation', 'TSA', 'x2014;\\n        &', 'Hercules Capital', 'Condensed Consolidated Financial Statements &', 'Lenders)&#xb8', 'NetProperty', 'EquivalentsThe Company', '\\n  &#', 'Takeda Vaccines, Inc.', '\\n          &#160;\\n', 'Loan', 'Lenders', 'Sarbanes-Oxley', '\\n    &', 'ContingenciesLicense AgreementOn July 2, 2021', 'U.S. Treasury', 'MokshaCo', 'HilleVax GmbH', 'Exhibit Index\\n  &', 'Form S-1', '\\n        &', 'Company', '232,869\\n        &', 'Territory', 'Second Amendments', 'the Securities Exchange Act', 'YamadaCo III', 'HilleVax', 'the Sarbanes-Oxley Act', 'Equity Securities', 'Adopted Pursuant to Section 302', 'IPO', 'Significant Accounting', 'LeasesOperating Leases', 'Compensation - Retirement Benefits', 'Takeda Pharmaceutical Company Limited', 'TakedaAs', 'the Takeda Warrants', '\\n  Transitional Services Agreement'}"
HOLX,
HOOK,"{'ASC', 'FASB', 'LeasesThe', 'LLC', 'Results of Operations - Critical Accounting', 'ContentsHOOKIPA PHARMA&#160;INC.NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS', 'September&#160;30,&#160;2022', 'Form S-3', 'Contentscollaborations', 'the Chief Financial and Accounting Officer', 'Investigational New Drug Application', 'Contracts', 'Incentive Plan', 'Gilead Collaboration AgreementOn June&#160;4,&#160;2018', 'FFG', 'U.S. Food and Drug Administration', 'the Registration Statement', 'Grant Plan', 'the Stock Purchase Agreement', 'the Securities and Exchange Commission', 'Restated Certificate of Incorporation of the Company', 'ContentsOther', 'this Quarterly Report on Form&#160;10-Q', 'HBV', 'Statements of Operations', 'THE SECURITIES EXCHANGE ACT', 'Roche', 'European Medicines Agency', 'IncomeIn', 'the Human Papillomavirus (&#8220;HPV&#8221', 'Hoffmann-La Roche Inc.', 'Board of Directors', 'Software Development CostThe Company', 'ContentsHOOKIPA PHARMA&#160;INC.NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL', 'September&#160;30,&#160;2023&#8203;&#160;&#160;&#160;&#160;2018 Plan&#160;&#160;&#160;&#160;2019 Plan&#160;&#160;&#160;&#160;Inducement', 'Derivatives and Hedging &#8211', 'Smaller Reporting CompanyAs', 'option&#8217;s', 'Accounting Standards Codification', 'Registrant', 'the Roche Collaboration 28\\nTable of ContentsAgreement', 'this Quarterly Report on Form&#160;10-', 'Principal Financial and Accounting', 'the Roche Collaboration Agreement', 'Entity&#8217;s Own Equity', 'Statements of Convertible Preferred Stock', 'Principal Executive', 'SEC', 'valuationThe Company', 'Collaboration and License Agreement', 'Company', 'the Financial Accounting Standards Board', 'software&#160;2 - 4', 'the Securities Exchange Act', 'The Registration Statement', 'HPV16+', 'Gilead Sciences, Inc. (&', 'Gilead', 'IPO', 'ExpenseInterest', 'Nasdaq', 'the Restated Gilead Collaboration Agreement', 'Finance LeasesThe Company', 'the Austrian Research Promotion Agency', 'the Gilead Collaboration Agreement', 'customersThe Company'}"
HOTH,"{'agreement\\nwith Virginia Commonwealth University', 'Hoth Therapeutics Australia Pty Ltd', 'the American Recovery and Reinvestment Act', 'Fair Value of Financial Assets\\nand Liabilities\\n\\n&#160;\\n\\nThe', 'the Exclusive Sublicense Agreement).\\nZyl&#246', 'necessary.\\n\\n&#160;\\n\\nIn', 'defined\\nin the Exclusive Sublicense Agreement', 'Identification No.', 'Level\\n3)&#160;\\n  \\n    Assets&#160;\\n    &', 'State University', 'Novotech', 'Company&#8217;s\\nsignificant', 'controls\\nand', 'entering\\ninto', 'VCU Agreement', 'the Net Sales', 'ventures\\n\\n&#160;\\n\\nThe Company', 'Development Expenses\\n\\n&#160;\\n\\nFor', 'The December Wainwright Warrants', 'GW', 'the Exclusive Sublicense Agreement', 'License', 'the September Common Stock Warrants', 'prepaids.\\n\\n&#160;\\n\\nTo', 'the University of Cincinnati\\n\\n&#160;\\n\\nDuring the three and nine months ended September\\n30, 2023, the Company', 'Biosciences, Inc.', 'VCU', 'investment\\nin', 'Hoth Therapeutics Australia\\nPty Ltd', 'and\\n  \\n&#160;\\n\\n\\n  \\n    &', 'HIPAA', 'VCU License Agreement.&#160;\\n\\n\\n\\n\\n\\n\\n', 'SEC', 'Company', 'Company&#8217;s\\nnet', 'Standards Update', 'George Washington University', 'Territory', 'Therapeutics', 'the Securities Exchange Act', 'Total&#160;\\n    &', 'to\\nthe Virginia Commonwealth University Intellectual Property Foundation', 'Adopted Pursuant to Section 302', 'the Sarbanes-Oxley Act', 'Effectiveness of Controls', 'the Hoth Therapeutics, Inc.', 'Company&#8217;s\\nassets', '\\n    &'}"
HOWL,"{'administrative1,089&#160;1,027&#160;3,088&#160;2,962&#160;Total', 'MHRA', 'Physician Payments Sunshine Act', 'development$1,008&#160;$909&#160;$3,047&#160;$2,496&#160;General', 'Crossbow Therapeutics, Inc. (&#8220;Crossbow&#8221;)', 'The Sarbanes-Oxley Act', 'the Federal Food, Drug', 'EU', 'RSA', 'CPRA', 'ContentsWe', 'ContentsRevenueRevenue', 'institute a &#8220;poison', 'COVID-19', 'ContentsIn', 'HHS', 'Sources of Liquidity &', 'Medicaid', 'Medicare', 'Operations Comparison', 'Congress', 'GDPR', ': &', 'Harpoon Therapeutics, Inc. for', 'FDA', 'the Success Fee of $1.6&#160;million', 'the Licensed Products', 'Licensed Products', 'Loan', 'ContentsStock-Based Compensation Expense Total', 'Risks Related', 'ContentsThe', 'HIPAA', 'FTC', 'Company', 'Lease AgreementsTotal', 'the California Privacy Rights Act', 'MPM Capital (&', 'the Delaware General Corporation Law', 'Operations &#8211', 'the European Commission', 'CMS', 'NetInterest', 'Loan Agreement', 'Interferon', 'Pacific Western Bank', 'ActivityThe Company', 'FCPA', 'Success', 'ActivitiesNet', 'The Loan Agreement', 'PWB', 'Smaller Reporting Company ImplicationsWe', 'PeriodEnd', 'Harpoon', ': &#', 'the Children&#8217;s Health Insurance Program', 'the Success Fee Event', 'ContentsOur', 'IRA', 'the U.S. Senate', 'Leerink Partners', 'the Sarbanes-Oxley Act', ': &#8226;delay', 'KEYTRUDA', 'IPO', 'Capital', 'Capital Resources &', 'ContentsSuccess Fee', 'the Loan Agreement', 'this Quarterly Report', ': &#8226;regulatory', 'The Success Fee Event', 'European Union', 'ESPP', 'Sarbanes-Oxley Act', 'Success Fee', 'the Harpoon Agreement', 'Research and Development', 'Jazz Pharmaceuticals Ireland Limited', 'SEC', 'non-U.S.', 'BLA', 'IncomeOther (Expense) Income', 'Crossbow Therapeutics, Inc.', 'the European Union', 'Nasdaq'}"
HQY,
HRMY,"{'LLC', 'Credit Agreement', 'the Blackstone Credit Agreement', 'Zynerba Pharmaceuticals', 'LLC (&#8220;Paragon&#8221;)', 'the Ticking Fee', 'JPMorgan Chase Bank', 'NetInterest', 'Paragon', 'Intellectual PropertyIn', 'Security Agreement', 'ConSynance Therapeutics, Inc.', '0.7&#8203;Valuation allowance &', 'the Securities and Exchange Commission', 'Blackstone', 'Xylophone Acquisition Corp.', 'this Quarterly Report on Form&#160;10-Q', 'Consolidated Statements of Cash Flows', 'LLC (&#8220;Paragon&#8221', 'Debt ExtinguishmentLoss', 'FDA', 'LCA', 'the OrbiMed Credit Agreement', 'WAKIX', 'Note&#160;3', 'Incremental Amendment', 'Note&#160;18', 'Consolidated Statements of Operations and Comprehensive Income', 'EDS', '0.2)&#8203;Other 0.6&#8203; &', 'Harmony Biosciences Holdings', 'Regulation S-K. Item&#160;6', '2023&#8203;10.110.2&#8203;Restricted Stock Unit Award Agreement', 'Share RepurchasesThe Company', 'statements.&#8203;Recently Issued Accounting PronouncementsThe Company', 'DDTL', 'Ticking Fee', 'Regulation S-K.', 'Bioprojet whereby Harmony', 'Bioprojet', 'Orphan Drug Designation', 'Company', 'TaxesIncome', 'the Securities Exchange Act', 'ContentsParagon AgreementsWe', 'Credit AgreementIn', 'Bank of America', 'Contentscentral', 'the Sarbanes-Oxley Act', 'Consolidated Balance Sheets', 'the TLA Credit Agreement', 'compensation &', 'RELATED-PARTY TRANSACTIONSThe Company', 'IPO', 'ContentsSupplemental', 'Sandip Kapadia &', 'Restated Certificate of Incorporation of Harmony Biosciences', 'see &#8220;Recent', 'Condensed Consolidated Financial Statements'}"
HROW,
HRTX,
HSCS,
HSDT,
HSIC,
HSTM,
HUGE,
HUMA,"{'ASC', 'inception$&#8212;&#160;Proceeds', 'Yale University', 'Global in exchange', 'Duke', 'the Public Warrants', 'Legal ProceedingsThe Company', 'the Option Agreement', 'ExhibitsThe', 'the Contingent Earnout', 'EU', 'Condensed Consolidated Financial Statements(unaudited)Option AgreementIn', 'the Sarbanes-Oxley Act of', 'the BVP License Agreement', 'Note 8 &#', 'FlowsThe', 'Option', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'the PIPE Financing', 'SVB Innovation Credit Fund VIII', 'First-Citizens Bank &amp', 'the Merger Agreement', 'Global', 'AV', 'the BVP License Agreement and Tubular Prosthesis License Agreement', 'Contingencies', 'the Common Stock Warrants', 'Note 11 &', ': &', 'Organization and Description of Business', 'FDA', 'Humacyte, Inc.', 'Condensed Consolidated Financial Statements(unaudited)The', 'Oberland Capital Management', 'Contingent Earnout Liability', 'Silicon Valley Bank', 'RevenueThere', 'Duke University', 'Common Stock', 'the Private Placement Warrants', 'Company', 'October&#160;13', 'Industry Discovery and Development Partnership Agreement', 'HAV', 'the JDRF Agreement Disposition Payment', 'SVB', 'Condensed Consolidated Financial Statements(unaudited)WarrantsThe Company', 'Condensed Consolidated Financial Statements', 'L.P.', 'JDRF International (&#8220;JDRF,&#8221', 'Fresenius Medical Care&#8217;s', 'Purchase Agreement', 'Risks and UncertaintiesThe Company', 'Second Amended', 'Loan Agreement', 'Fresenius Medical Care', 'Note 6 &#', 'LiabilityThe', 'this Quarterly Report on Form 10-Q.ExhibitNumberDescription31.1*Certification', 'September&#160;30,', 'Purchasers', 'Trust Company', 'Yale', 'Condensed Consolidated Statements of Changes', 'Credit RiskFinancial', 'Inline XBRL (Inline eXtensible Business Reporting Language', 'the Common Stock', 'Humacyte', 'AHAC', 'the Biovascular Pancreas (&#8220;BVP&#8221;)', 'Condensed Consolidated Balance Sheets', 'Restated Certificate of Incorporation', 'FASB ASC Topic', 'FDIC', 'The Contingent Earnout Shares', 'AgreementOn May 12, 2023', 'the Sarbanes-Oxley Act', 'Adopted Accounting PronouncementsThe Company', 'Related Party TransactionsFresenius Medical Care', 'the Purchase Agreement', 'Duke:&#8226;a', 'the Loan Agreement', 'this Quarterly Report entitled &#8220;Risk Factors&#8221', 'this Quarterly Report', 'Condensed Consolidated Statements of Operations and Comprehensive Loss', 'Condensed Consolidated Financial Statements(unaudited)Revenue Interest', 'CashThe Company', 'Fresenius Medical Care Holdings, Inc. (&', 'European Union', 'SegmentsThe Company', 'Public WarrantsThe Public Warrants', 'the U.S. Food and Drug Administration', 'TPC Investments III LP', 'ContentsHumacyte', 'Condensed Consolidated Financial Statements(unaudited)Concentration of', 'the European Medicines Agency', 'Related Party Transactions', 'The Option Agreement', 'Issued Accounting PronouncementsThe Company', 'Duke University (&#8220;Duke&#8221', 'Inc.&#8217;s Quarterly Report on Form 10-Q', 'Humacyte Common Stock Warrants&#8221', 'BLA', 'Condensed Consolidated Statements of Cash Flows', 'Yale University (&#8220;Yale&#8221', 'ProceduresDisclosure', 'Condensed Consolidated Financial Statements(unaudited)3', 'Page Interactive Data File', 'Diameter Vessel License', 'the Contingent Earnout Liability', 'Holders'}"
HYPR,"{'ASC', 'Cover Page Interactive Data File', '\\n    Interest income\\n    &', 'EQUIPMENT', 'Hyperfine, Inc.', 'thereafter.\\n  &', '\\n  &', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Securities and Exchange Commission', 'the Interactive Data File', '\\n  &#', '\\n        Laboratory equipment\\n', 'Common Control Arrangements', 'Brett Hale\\n    &', 'BMGF', 'Indicate', 'AI', '\\n    Research', 'DWI', 'Exhibit 101).\\n    &', 'the heading &#x201c;Recently Issued Accounting', '\\n        &', 'Technology and Services Exchange Agreements', 'Company', 'the Securities Exchange Act', 'Expand', '9\\n       HYPERFINE, INC.', 'the Sarbanes-Oxley Act', 'NET Property', 'Liminal', 'COVID-19', '\\n  &#160;\\n', '\\n    &', 'sites.\\n  &'}"
IART,
IBRX,"{'U.S.&#160;treasury', 'the &#8220;Notes', 'RNA', 'LLC', 'The Dunkirk Facility', 'the nine&#160;months&#160;ended &#160;&#160;&#160;September&#160;30,&#160;2023)$&#8212;&#160;$&#8212;&#160;$10,197&#160;$34,100&#160;$44,297&#160;202430,000&#160;505,000&#160;30,732&#160;67,829&#160;633,561&#160;2025&#8212;&#160;&#8212;&#160;26,629&#160;&#8212;&#160;26,629&#160;2026200,000&#160;&#8212;&#160;18,531&#160;&#8212;&#160;218,531&#160;Total', 'EMA', 'Nant Capital', 'Principal Executive Officer', 'BCG', 'EU', 'July&#160;8,&#160;2022', 'a Specified Transaction', 'ContentsReliance', 'October&#160;1,&#160;2021', 'Sarbanes-Oxley', 'the Amended and Restated Promissory Note', 'Treasury', 'the Open Market Sale Agreement', 'AAHI', 'ContentsWe', 'ACA', 'the Fort&#160;Schuyler Management Corporation Lease', 'the Athenex Proceedings', 'Duley Road,&#160;LLC', 'COVID-19', 'ISO', 'ContentsUpon', 'the Dunkirk Lease', 'Shenzhen Beike Biotechnology Co. Ltd.', 'Immuno-Oncology Clinic', 'International Court of Arbitration', 'the Initial Premises', 'Related-Party Agreements', 'ContentsIn', 'ContentsFor', 'Consolidated Financial Statements', 'PaymentsInterest Payments', 'in&#160;thousands):September&#160;30', 'ASU 2018-07', 'ImmunityBio, Inc.', 'March&#160;1,&#160;2023', 'Fair', 'FASB', 'the International Chamber of Commerce', 'FTO', 'NantCell', 'El&#160;Segundo', 'Unaudited Condensed Consolidated Financial', 'ContentsLater', 'the Superior Court', 'TLR7/8', 'CIS', 'Medicare', 'Diluted', 'ContentsFurthermore', 'Congress', 'Facility Agreements', 'GDPR', 'Contents23&#160;Alaska', 'the U.S. Filing', 'Clinic', 'FDA', 'July&#160;21,&#160;2023).&#160;&#160;10.1Securities Purchase Agreement', 'Anktiva', 'GMP', 'Superior Court', 'NMIBC', 'Dunkirk', '60%&#160;owned', 'ContentsThe', 'Risks Related', 'HIPAA', 'ImmunityBio', 'Revised Accounting Standards &', 'July&#160;20', 'REMS', 'Contents_______________(1)Third-Party', 'NCSC', 'USPTO', 'Corporate Governance Committee', 'FCA', 'Condensed Consolidated Financial', 'ValuationsFinancial', 'NantBio', 'ContentsFactors', 'Purchase Agreement', 'an&#160;ATM', 'ASU', 'Altor', 'Principal Financial Officer', 'Exchange Act', 'ControlsManagement', 'this Quarterly Report on Form&#160;10-Q', 'Purchasers', 'License', 'Related PartiesOur Executive', 'Duley Road', 'Board of Directors', 'the Stipulation of Settlement', 'Sorrento', 'NANTibody', 'ContentsForward', 'AcquisitionDunkirk', 'the AAHI&#160;RNA License Agreement', 'NDA', 'the Superior Court of the State of California', 'Executive', 'ContentsOur', 'the Sarbanes-Oxley Act of 2002.143Table', 'December&#160;31,&#160;2024.As', 'ContentsRecent Accounting PronouncementsApplication of New', 'Related-Party Convertible Note', 'the Sarbanes-Oxley Act', 'May&#160;6,&#160;2022', 'CFO', 'This Quarterly Report', 'ContentsUnless', 'national and/or international data protection laws', 'IgDraSol', 'LLCEffective', 'Dunkirk Lease', 'this Quarterly Report', 'ProceduresOur', 'the Board of Directors', 'ATM', 'NantWorks', 'the Dunkirk Facility', 'February&#160;2023 Warrants', 'Global Chief Scientific', 'Fair Value', 'August&#160;2022', 'this Quarterly Report on Form&#160;10-Q.', 'Healthcare', 'LLCShared Services', 'ContentsFurther', 'Unamortized DiscountsTotal(Unaudited)Related-Party Nonconvertible Notes', 'the AAHI Adjuvant Formulation License Agreement', 'Significant Accounting Policies', 'The Stipulation of Settlement', 'The Superior Court', 'combination&#8221', 'SEC', 'GCP', 'FSMC', 'the Implementing Order', 'December&#160;12,&#160;2022', 'BLA', 'Beike', 'ContentsInformation', 'Fair Value Measurement', 'HCW', 'SettlementIn 2019', 'NantPharma', 'Nasdaq', 'the Promissory Note'}"
ICAD,
ICCC,
ICCM,
ICCT,"{'the Merger Agreement', 'Goodwill&#160;The Company', 'Segregated Portfolio #8 &#8211', 'ASU', 'the Nasdaq Capital Market', 'the Satisfaction Guarantee', 'Arena Business Solutions Global SPC II, Ltd.', 'profitability.&#160;The', 'years.&#160;Long-Lived Assets', 'Board', 'net &', 'State Associations', 'Old iCore', 'this Quarterly Report', 'Health Insurance Portability', 'Item 408 of Regulation S-K', 'methods.&#160;The Company', 'The Satisfaction Agreement', 'Contracts with Customers', 'amortization&#160;&#160;320,427&#160;&#160;&#160;286,622&#160;&#160;&#160;12%Total', 'stockholders&#160;$(3,910,316 )&', 'the Court of Chancery of the State of Delaware', 'Deposit Account Control Agreement', 'the Securities and Exchange Commission', 'operations&#160;&#160;(2,423,104 )&', 'EPS', 'FG Merger Sub Inc.', 'Financial Instruments', 'the Company&#160;Company History&#160;The Company', 'Common Old iCore Stock', 'Hospitals', 'thereof.&#160;8', 'Nasdaq Capital Market', 'subscriptions.&#160;iCoreRx &', 'FG Merger Corp.', 'No &#9744;&#160;Indicate', 'Financial Instruments &', 'share.&#160;The Business Combination', 'PDF', 'Credit', 'Series A Preferred Stock.&#160;&#160;&#160', 'Preferred Stock &#160;and $', 'Arena', 'Accounting Standard Codification Topic', 'the Merger Agreement and Plan of Reorganization', 'HIPAA', 'most Electronic Health Record', 'the Nasdaq Capital', 'the Common Stock', 'SEC', 'the Registration Statement effective.&#160;As', 'MSP', 'Practice Management', 'Common Stock', 'Company', 'FGMC', 'the Securities Exchange Act', 'JPEG', 'the Convertible Promissory Note', 'period.&#160;The Company', 'SEGMENT INFORMATION&#160;The Company', 'the Business Combination', 'FDIC', 'Contracts with Customers (&#8220;Topic 606&#8221;)&#8221', 'SPC #8 (&#8220;Arena&#8221', 'Satisfaction Agreement', 'HIPAA Compliant', 'COVID-19', 'the Sarbanes-Oxley Act', 'Nasdaq', 'the Purchase Agreement', 'Old iCore Common Stock'}"
ICLR,"{'STA', 'FASB', 'Huawei', 'BEAT', 'ASU', 'Company\\', 'The JV Company', 'RevenueThe', 'the Altera Corporation Tax Court', 'AOS SH', 'Jireh Semiconductor Incorporated', 'the U.S. Tax Court', 'the U.S. Department of Justice', 'the JV Company', 'Agape Package Manufacturing', 'the Department of Commerce (&#8220;DOC&#8221', 'ESPP', 'EarningsTotal', 'Omega Semiconductor', 'Altera Corp.', 'DOC', 'Shanghai) Ltd.', 'OMEGA SEMICONDUCTOR LIMITEDCONDENSED', 'License and Development Revenue Recognition', 'Silicon Carbide', 'Worldwide Sales', 'the Science and Technology Innovation Board', 'Shanghai Banking Corporation Limited', 'Company', 'AOS', 'the Securities Exchange Act', 'the Tax Court', 'DOJ', 'Segment and Geographic Information', 'the Shanghai Stock Exchange', 'revenue)Computing$70,350&#160;$89,265&#160;38.9&#160;%42.8&#160;%Consumer31,090&#160;45,280&#160;17.2&#160;%21.7&#160;%Communication31,027&#160;31,421&#160;17.2&#160;%15.1&#160;%Power Supply', 'XueExecutive', 'HSBC', '42.2%.The Company', 'Adopted Accounting', 'Alpha &', 'the ""Bank', 'MOSFET', 'ContentsALPHA', 'ASU No'}"
ICU,"{'compensation\\n    &', 'Segment informationThe Company', 'LLC', '1,400\\n          &', 'the Securities Purchase Agreement', 'Tumim', 'Prepaid\\n          &', 'SeaStar Medical', 'Payments\\n          &', 'State', '52\\n    &', '4,898\\n    &', 'amounts)\\n  &#', '\\n  &', 'LMFA', 'SCD', '558\\n          &', 'SeaStar Medical, Inc.', '\\n  &#x2022;a', 'benefit)\\n    &', 'credit\\n    &', 'Maxim Group', 'Condensed Consolidated Balance Sheets\\n', 'the SEC Division of Corporation Finance&#x2019;s Regulation S-K Compliance &', 'the \\n  &#', 'the State of Delaware', 'FDA', '47\\n    &', 'statements.\\n  &', 'Report on Internal Control', '\\n  &#', 'Note 7)\\n          &', 'RSUs\\n    &', 'Lease agreementsThe Company', 'x2022;a', 'LMAO', 'Condensed Consolidated Statements of Changes', '\\n    ', 'the &#x201c;Exchange', 'the Condensed Consolidated Financial Statements\\n', 'the Selective Cytopheretic &', '\\n    Research', '\\n    Warrants liability\\n    &', '4,405\\n          &#160;\\n          &#160;\\n', '\\n        &', 'Condensed Consolidated Statements', 'the Condensed Consolidated Financial Statements(in', 'activities\\n    &', '\\n          &', 'Company', 'the Securities Exchange Act', 'NASDAQ', 'expense)\\n    &', 'the Business Combination', '\\n  Research and Development Expenses \\n', '\\n  Research', 'the Sarbanes-Oxley Act', '\\n    Interest expense\\n    &', 'Adopted Pursuant to Section 302', 'and\\n  &#x2022;delays', 'the Forward Purchase Agreements', 'SeaStar Medical Holding', 'Restated Certificate of Incorporation of SeaStar Medical Holding Corporation', 'FVO', '\\n    &', 'ContingenciesLicense', 'payments\\n          &#160;\\n          &#160;\\n          &#x2014;\\n          &#160;\\n          &#160;\\n          &#160;\\n', 'subjects;\\n  &#'}"
ICUI,
ICVX,"{'and\\n  &#x2022;exemptions', 'the Grant Agreement', 'operations.\\n  &#160;\\n', 'the Equity Distribution Agreement', 'Respect to Influenza&#160;The Company', '\\n  &#x2022;an', 'the Annual Report', 'Financial Instruments', '\\n  &#x2022;costs', 'Unregistered Sales of Equity', 'candidates;\\n  &#x2022;subjecting third-party', 'financial condition.\\n  &', 'the Public Company Accounting Oversight Board', 'foreign countries;\\n  &#x2022;reduced', 'University of Washington &#160;License Agreement', 'Sarbanes-Oxley', '\\n    Research', 'the Institute for Protein Design', 'Form S-1', 'ACA', 'Research', 'the public;\\n  &#x2022;reduced', 'pay&#x201d', 'COVID-19', 'individuals;\\n  &#x2022;regulatory', 'the UW Flu License Agreement', 'Our Business Operations', '\\n  &#x2022;expenses', 'the University of Texas', 'approvals;\\n  &#x2022;warning', 'and\\n  &#x2022;collaborations', 'FASB', 'x2022;if', '&#x201c;License Agreement', 'the National Institutes of Health', 'Medicaid', 'Medicare', 'x2014;\\n        &', 'candidates;\\n  &#x2022;a', 'GDPR', 'FDA', 'RSU', 'others;\\n  &#x2022;collaborators', 'experience.\\n  &', 'the University of Texas &#160;The Company', 'Respect to COVID-19&#160;The Company', 'surveillance;\\n  &#x2022;we', 'REMS', 'the University of Washington (&#x201c;UW&#x201d;)', 'Company', 'requirements;\\n  &#x2022;economic', 'and\\n  &#x2022;the', 'USPTO', 'profits.\\n', 'delayed.\\n  &#x2022;We', 'and\\n  &#x2022;diminished', 'and\\n  &#x2022;business', 'U.S. Agency', 'Oppenheimer &amp', 'herein.\\n  &', 'GLP', 'liability;\\n  &#x2022;collaborators', 'ASU', 'candidates;\\n  &#', 'Critical Accounting Policies', 'UW (&', 'all;\\n  &#x2022;misappropriation', 'ASU 2020-02', 'litigation;\\n  &#x2022;collaborators', 'Other Pathogens&#160;The Company', 'Co. Inc.', 'RSV', 'organizations;\\n  &#x2022;determinations', 'and\\n  &#x2022;our', '\\n  &#x2022;the', 'License Agreement', 'Grant Agreement &', 'agreements.\\n  &#160;\\n', 'Procedures\\n  &', 'thousands):&#160;&#160;16\\n       &', 'this Annual Report', 'x2022;a collaborator&#x2019;s', 'VLP', '\\n  &#', 'adults;\\n  &#x2022;unexpected', 'the &#x201c;Grant', '\\n  &#x2022;collaborators', 'and\\n  &#x2022;termination', 'products.\\n  &', 'x201c;Business&#x2014;Material', 'candidates;\\n  &#x2022;maintaining', '\\n  &#x2022;different', 'distribution;\\n  &#', 'individuals;\\n  &#', 'the University of Washington', 'and\\n  &#x2022;maintaining', '\\n          &', 'strategy.\\n  &#160;\\n', 'candidates.\\n  &#x2022;Our', 'results;\\n  &#x2022;demonstrating', 'General Risk Factors\\n  &', 'prospects.\\n  &', 'Comparison', 'companies&#x2019', 'Grant', 'the Sarbanes-Oxley Act of 2002', 'regulations;\\n  &#x2022;foreign', 'UW', 'Adopted Accounting Standards &', 'and\\n  &#x2022;injunctions', 'including:\\n  &#x2022;regulatory', 'Grant Revenue \\n  &#160;\\n', 'None.\\n  &', 'Melinda Gates Foundation', 'the CDC&#x2019;s National Immunization Program', 'markets;\\n  &#x2022;compliance', 'the UT Agreement', '\\n  &', 'common;\\n  &#x2022;differing', 'harmed.\\n  &#x2022;Our', 'ROU', 'ESPP', 'Risks Related to', '\\n  &#x2022;restrictions', 'BMGF', 'and\\n  &#x2022;in', 'U.S. Treasury', 'Conclusion Regarding the Effectiveness of Disclosure Controls', 'expensive;\\n  &#x2022;collaborators', '\\n        &', '\\n    Interest', 'Restricted', 'SEC', 'vaccine products;\\n  &#x2022;production', 'BLA', '\\n  &#x2022;being', 'markets.\\n  &', 'fires.\\n  &', 'Austin (&#x201c;UT&#x201d;)', '\\n  &#x2022;failure', '\\n    &', 'the Bill &'}"
IDXX,"{'IDEXX B.V. and IDEXX Operations, Inc.', 'ASU', 'IDEXX Points', 'R$5.14', 'Program Combinations', 'Euro-Denominated NotesIn', 'Poultry', 'Fair Value Measurements&#8221', 'ERISA', 'this Quarterly Report on Form 10', 'TERMS', 'the Board of Directors', 'Dairy', 'efficiencyOPTI MedicalOPTI Medical Systems', 'SELECTED', 'Interest Rate Impacts', 'Diagnostic Products', 'CAG Diagnostics Recurring Revenue', 'GuaranteesWe', 'Assumptions.&#8221; &', 'derivatives:(in thousands)&#160;Three Months EndedSeptember', 'Credit Facility', 'operations$275,283&#160;30.1&#160;%$244,828&#160;29.1&#160;%$30,455&#160;12.4&#160;%Gross Profit', 'OPTI Medical', 'OPTI', 'IDEXX Laboratories Inc.', 'Results of Operations - Critical Accounting Estimates', 'this Quarterly Report on Form 10-Q.Non-GAAP Financial MeasuresThe', 'Ortho-Clinical Diagnostics, Inc.', 'FacilityOur', 'Cross Currency SwapsWe', 'Up-Front Customer Loyalty Programs', 'growth.39WaterThe', 'Company', 'CAG Diagnostics', 'revenue:$2,223,336&#160;$2,017,532&#160;$205,804&#160;10.2&#160;%(0.6&#160;%)&#8212;&#160;10.8&#160;%IDEXX VetLab', 'IDEXX', 'accessories30,060&#160;28,357&#160;1,703&#160;6.0&#160;%1.3&#160;%&#8212;&#160;4.7&#160;%CAG Diagnostics capital - instruments32,254&#160;35,176&#160;(2,922)(8.3&#160;%)1.9&#160;%&#8212;&#160;(10.2&#160;%)Veterinary software', 'I.', 'Organic', 'Regulation S-K', 'Customer Commitment Programs', 'growth.48OtherThe', 'administrative89,034&#160;9.7&#160;%83,764&#160;10.0&#160;%5,270&#160;6.3&#160;%Research', '1)CAG Diagnostics', 'No &#160;&#168;&#160;&#160;&#160;&#160;Indicate', 'Financial Accounting Standards', 'CAG', 'the Credit Facility'}"
IDYA,"{'ASC', 'LLC', 'Clinical Trial Collaboration and Supply Agreement with Amgen', 'MAF', 'Novartis International Pharmaceuticals Ltd.', 'CDK4/6', 'Reliance', '\\n  IDE161', 'PARG', '\\n', 'maturity.\\n  &', 'EMA', '\\n  &#x2022;an', 'Cancer Research Technologies Ltd.', 'and\\n  &#x2022;developments', 'Financial Instruments', 'this Quarterly Report on Form 10-Q', 'Amgen Clinical Trial Collaboration and Supply Agreement', '\\n  &#x2022;having', '\\n  &#x2022;termination', 'the Supply Agreement', 'programs.\\n', 'BRCA', 'EU', 'C.F.R', '\\n  Darovasertib &#', '\\n  &#x2022;analogous', 'x2022;a', 'Pol Theta Helicase Inhibitor DC', '\\n  &#x2022;uncertainties', 'Financial Instruments&#x2014;Credit Losses', 'Pfizer Inc.', 'Codification Improvements to Topic 326', 'additional capital;\\n  &#x2022;our', '26\\n', 'x201c;well', 'NSCLC', '\\n    Research', 'Werner Helicase Inhibitor Development Candidate', 'ACA', 'satisfied\\n        &', 'University of Manchester', 'the Children&#x2019;s Health Insurance Program', 'the Financial Accounting Standards Board', 'Significant Accounting PoliciesThere', 'MUM', 'IDEAYA', 'Jefferies', '\\n  &#x2022;expenditures', 'The Fast Track Designation', 'COVID-19', 'the WRN program.\\n  &', '\\n  &#x2022;adding', '\\n  &#x2022;misappropriation', 'a New Drug Application', '\\n  &#x2022;obtaining', 'Cell Press - iScience', 'FASB', 'Outstanding Warrants\\n       \\n       \\n        ', 'the Second Pfizer Agreement', 'Pfizer', 'Clinical Trial Collaboration and Supply Agreement', 'Concentration of Credit Risk &', '\\n  &#x2022;product', '\\n  &#x2022;assimilation', 'Clinical Trial and Supply Agreement with Amgen Inc.', '\\n  &#x2022;a', '\\n  &#x2022;refusal', 'Medicaid', 'Medicare', 'Risks Related to Government Regulation', 'x2014;\\n        &', 'Limited (&#x201c;GSK&#x201d;)', 'MSS', 'GDPR', '\\n  &#x2022;have', 'FDA', 'WRN', 'NetProperty', 'the Data Safety Monitoring Board', 'Unaudited)\\n  &#160;\\n', 'the Amgen CTCSA', '\\n  &#x2022;clinical', 'Comparison of Nine Months Ended September 30, 2023 and September 30,', 'injected;\\n  &#x2022;expansion', 'Research and Development Expenses \\n  Research', 'the American Association for Cancer Research', 'HLA-A2(+),MUM patients.\\n  &', 'candidates;\\n  &#x2022;our', 'expectations;\\n  &#x2022;our', '\\n  &#x2022;continue', '\\n  &#x2022;others', '\\n  &#x2022;loss', 'candidates;\\n  &#x2022;The', 'the Medicaid Drug Rebate Program', 'Registration Statement on', 'REMS', '\\n  &#x2022;fines', 'IDEAYA Biosciences', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n        6,192\\n        &', 'MTA', 'USPTO', '\\n  &#x2022;addressing', '11\\n       &', 'BCC', 'Balance Sheet Components Property and Equipment', 'the U.S. FDA', '\\n  &#x2022;injunctions', '\\n  &#160;\\n', 'AE', 'Financial Instruments&#x2014;Credit', 'AMG', '\\n  &#x2022;breach', 'GLP', '\\n  &#x2022;diligence', 'the Delaware General Corporation Law', 'ASU', '\\n  ', ""the Pol Theta program\\'s IND"", 'Varian Biopharmaceuticals', 'CMS', 'candidates;\\n  &#', '\\n  &#x2022;recruiting', '\\n  &#x2022;establishment', 'IND-', 'affected;\\n  &#', '\\n  &#x2022;future', '\\n  &#x2022;the', 'License Agreement', 'Stockholders&#x2019', 'the Company.&#160;Pfizer Clinical Trial Collaboration and Supply Agreements', 'Orphan Drug', 'including:\\n  &#', 'x2022;we', '\\n        Laboratory', '\\n  &#x2022;coverage', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', 'License', '\\n  &#x2022;suspension', '\\n  &#', 'Second Pfizer Agreement', '\\n  &#x2022;collaborators', 'CDX', 'PARG Inhibitor', 'Amgen', 'biomarkers.\\n  &#160;\\n', 'pathway.\\n', 'NDA', 'candidates;\\n  &#x2022;In', 'Orphan Drug Designation', 'NADOM', 'Preclinical', '\\n  &#x2022;reaching', 'CRT and University of Manchester', 'inadequate;\\n  &#x2022;regulators', 'costs;\\n  &#', 'Limited (&#x201c;GSK&#x201d;);\\n  &#x2022;our', 'Comparison', '\\n  &#x2022;our', 'MAT2A', 'Condensed Financial Statements', 'Condensed Statements of Operations and Comprehensive', '\\n  &#x2022;obtaining IRB', 'PCK', 'Cancer Research United Kingdom', 'the License Agreement', 'Medicaid Innovation', '\\n  &', 'the Court of Chancery of the State of Delaware', 'Amgen Inc.', 'European Union', 'the U.S. Food and Drug Administration', 'GSK101', '\\n  &#x2022;identify', 'Required for the Survival of Cancer Cells', 'Microsatellite Instability', '\\n  &#x2022;the U.S. Foreign Corrupt Practices Act', 'Risks Related to', 'HRD', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', 'DW LSP 5000 Shoreline', '\\n  &#x2022;obtain', 'University of Manchester;\\n  &#x2022;the', '\\n  &#x2022;the FDA', 'patents;\\n  &#x2022;issued', 'NCCN Clinical Practice Guidelines', 'GSK plc', 'ATPase', '\\n  Interest Rate Sensitivity\\n', 'GSK;\\n  &#x2022;timing', 'things:\\n  &#x2022;suspension', 'may:\\n  &#x2022;incur', 'Recognition', 'Clinical Trial Collaboration and Supply Agreements', '\\n        &', 'SEC', 'GCP', '\\n  &#x2022;similar', 'Life\\n        &', '\\n  &#x2022;manage', 'Novartis', '\\n  &#x2022;accessing', 'the Centers for Medicare &', 'GSK', '\\n  &#x2022;failure', '\\n    &', 'MUM.\\n  &#160;\\n'}"
IFRX,
IGMS,
IINN,
IKNA,"{'ASC', 'API', 'LLC', 'MHRA', 'Bristol-Myers Squibb Company (&#', 'CMOs', '\\n  &#x2022;payments', 'the Pionyr Acquisition', 'Physician Payments Sunshine Act', 'RAS', 'Reliance', '\\n  &#x2022;expand', 'EMA', 'the Society for Worldwide Interbank Financial Telecommunication', 'the EU Commission', 'EEA', 'this Quarterly Report on Form 10-Q', '\\n  &#x2022;costs', 'programs.\\n', 'EU', 'Phase 4', 'Series A Preferred Stock', 'the Company (&#x201c;Merger Sub I&#x201d;)', 'Accounting Standards Update', '\\n    Research', 'Form S-1', 'ACA', 'the &#x201c;Sunshine', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'the Pionyr Acquisition Agreement', '\\n  Research', '\\n  &#x2022;acquisition', '\\n  &#x2022;expenses', 'the University of Texas', 'x2022;a court', 'the United States.&#160;\\n  Laws', 'Pionyr Immunotherapeutics, Inc.', 'FASB', 'x2022;if', '\\n  &#x2022;substantial', 'Internal Control', 'manufacturers&#x2019', 'aryl hydrocarbon receptor (&#', 'Medicare', 'The Executive Order', 'Medicaid', 'the Delaware General Corporate Law', 'GDPR', 'the European Patent Office', '\\n  &#x2022;there', 'Principal Accounting', 'FDA', '\\n  &#x2022;collaborations', 'University', 'CVR', 'Restated Certificate of Incorporation of Ikena Oncology, Inc.', 'and\\n  &#', '30\\n', '\\n  &#x2022;continue', '\\n  &#x2022;collaboration', '77\\n', 'REMS', 'AstraZeneca', 'Company', '\\n  &#x2022;facilities', 'URO', 'USPTO', 'the Leahy-Smith Act', 'Ikena Oncology, Inc.', 'FCA', 'the &#x201c;Pionyr Acquisition', 'AKS', 'CRO', 'CMS', 'Patent and Trademark Office (&#x201c;USPTO&#x201d', 'Pionyr 1,800,652', 'Celgene Corporation', '\\n  &#x2022;initiate', '\\n  &#x2022;acquire', '\\n  &#x2022;advance', '\\n  &#x2022;the', 'Contractual Obligations \\n', '\\n  &#x2022;infringement', '\\n  &#', '\\n  &#x2022;collaborators', 'the Children&#x2019;s Health Insurance Program (&#', 'Registrant', '\\n  &#x2022;require', 'Computershare Trust Company N.A', 'Series A Non-Voting Convertible Preferred Stock (&#x201c;Series A Preferred', 'CMO', 'Bristol-Myers Squibb Collaboration Agreement', 'Fortis Advisors LLC', 'the Sarbanes-Oxley Act', 'IPO', 'Centers for Medicare', 'EGFR', '\\n  &#x2022;our', '\\n  &#x2022;add', 'Form S-3', '\\n  &#x2022;reliance', 'the Accounting Standards Codification', 'ATM', '\\n  &', 'the Stock Purchase Agreement', 'the Registrant&#x2019;s Registration Statement on Form S-1', 'the U.S. Food and Drug Administration', 'the UT Austin License', '\\n  &#x2022;disputes', 'Medicaid Services', 'Pionyr', 'the Company (&#x201c;Merger Sub II&#x201d;)', '\\n  &#x2022;redesigning', 'the Registrant&#x2019;s Current Report', '\\n  &#x2022;If', 'Bristol-Myers Squibb', 'SEC', 'agreements.\\n', 'harmed.\\n  &#x2022;We', 'the Registrant&#x2019;s Registration Statement', 'the European Union', 'x201c;Bristol-Myers', 'Nasdaq', '\\n    &'}"
IKT,
ILMN,
IMAB,
IMCC,
IMCR,
IMGN,"{'ASC', 'ELAHERE.License', 'Note C', 'J.LeasesThe Company', 'the Consolidated Statements of Operations and Comprehensive Loss', 'Lilly', 'Qualitative Disclosure', 'ELAHERE.The Company', 'Series A Preferred Stock', 'OBT', 'the Consolidated Balance Sheets', 'Options', 'the Series A Preferred Stock', 'NSCLC', 'Future Capital RequirementsWe', 'Principal Executive', 'the Conversion Blocker', 'KADCYLA', 'the Securities Exchange Act', 'ContentsDuring', 'License AgreementsThe Company', 'Adopted Accounting', 'Takeda Pharmaceutical Company Limited', 'Note&#160;F, &#8220;Liability Related', 'this Quarterly Report on Form 10-Q.&#8224;Furnished', 'the Consolidated Statements of Cash Flows', 'net &', 'the Royalty Obligation', 'ITEM 6.&#160;&#160;&#160;&#160;&#160;&#160;ExhibitsExhibit&#160;No.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Description10.1&#177;Change', '9,534)&#8203;$ &#', 'EPS', 'Ergomed PLC', 'FDA', 'Consolidated Financial', '2022.&#160;With', 'EPS &#8212', 'Cash EquivalentsThe Company', 'ContentsThe', 'Qualitative Disclosures About Market Risk&#8221', 'PrimeVigilance USA, Inc.', 'Control Severance Agreement', 'Company', 'BioPharma Credit Investments V', 'this Quarterly Report on Form 10-Q.', 'Genentech, Inc. &', 'Eli Lilly and Company (Lilly', 'Recent Accounting PronouncementsThe', 'the Series A Convertible Preferred Stock', 'Vertex Pharmaceuticals Incorporated', 'Roche', 'License', 'Convertible Preferred Stock', 'ContentsHuadong', 'Registrant', 'Preclinical', 'CustomersThe', 'ContentsThird-Party', 'Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.', 'Series A Convertible Preferred', '3,000)&#8203;$ &#8212;&#8203;$ &#', 'the Sarbanes-Oxley Act', 'B)&#8203;&#8203', 'Months Ended &', 'BioPharma Credit PLC', 'treasury', 'Ergomed Clinical Research, Inc.', 'Board', 'ContentsAdditionally', 'Note K', 'FASB Accounting Standards Updates', 'Pharmakon', 'Contracts', 'Pharmakon Advisors, LP', 'the Board of Directors', 'equivalents&#8203;&#8203', 'BPCR Limited Partnership', '43,961)&#8203;$ &#', 'the Consolidated Statements of Shareholder&#8217;s Equity (Deficit', 'thousands):&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Three Months Ended &#', 'C / D)&#8203;$ 0.1010\\nTable', 'Instruments and Concentration of Credit RiskCash', 'ImmunoGen, Inc.', 'Adopted Accounting PronouncementsThere', 'TakedaOn', 'SEC', 'Novartis', 'Novartis Institutes for BioMedical Research,&#160;Inc.&#8217;s', 'year.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Three Months Ended &', 'Ended &#160;&#160;&#160;&#160;&#8203;&#8203;&#8203;September&#160;30, &', 'RA Capital'}"
IMMP,
IMMX,"{'L.P.', 'Graham Ross Oncology Consulting Services', 'LLC', 'Alwaysraise', 'the Securities Purchase Agreement', 'Hadasit Medica Research Services &', 'Board', 'Immix Biopharma', 'Prepaid Expenses', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', '\\n\\n\\n\\n&#160;\\n\\nNote\\n6 &#8211', 'PIK', 'Clawback Policy,\\na', 'the\\nCompany without &#8220;cause&#8221', 'The Nexcella Founders Agreement\\nhas', 'Outstanding&#160;&#160;\\n', 'Covered Officer engaged\\nin', 'BeiGene Ltd.', 'this Quarterly Report on Form 10-Q', 'Prepaid Expenses and Other Current\\nAssets\\n\\n&#160;\\n\\nPrepaid', 'The Securities Purchase Agreement', 'Company&#8217;s\\ncommon', 'the Compensation Committee of the Board of Directors', 'Form of Stock Option Grant Notice and Option Agreement', 'the Company without &#8220;cause&#8221', 'Principal Executive Officer Pursuant', 'the Company&#8217;s\\nRegistration Statement on Form S-3', 'Class A Preferred Stock', 'Nexcella&#8217;s Class\\nA Preferred Stock', 'Pre-Funded Warrants', 'Stock Option', 'the Rachman Employment Agreement', 'the Nexcella COI', 'pursuant\\nto', 'Principal Executive Officer Pursuant to Rules', 'The Nasdaq Capital Market', 'Exchange', 'the Nexcella Founders Agreement', 'Accounts Payable', 'AxioMx, Inc. (&#8220;AxioMx&#8221;).\\nAxioMx', 'services&#160;\\n    &', 'Form of Stock Option Grant Notice and Option Agreement (Executive Officers &#8211', 'SEC', 'Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation\\n', 'Principal Financial Officer Pursuant to Rules', 'Management Services Agreement', 'Form of Stock Option Grant Notice and Option Agreement (Effective', 'Adopted', 'date.\\n\\n&#160;\\n\\nOther\\nCommon Stock Issuances\\n\\n&#160;\\n\\nOn\\nMarch 9, 2023', 'Company', 'the Securities Exchange Act', 'a Change of Control', 'the Sarbanes-Oxley Act', 'funds\\nheld', 'the Company&#8217;s Board of Directors', 'period\\nof', 'ThinkEquity', 'Gabriel Morris', 'the Clawback Policy', 'Immix Biopharma, Inc.', '\\n    &', 'Report'}"
IMNM,
IMNN,"{'RNA', 'Purchase Agreement', 'LLC', 'Hisun', 'Imunon', 'this Quarterly Report', 'the Technology Development Contract', 'SLL', 'diluted.\\n\\n&#160;\\n\\nFinancing\\nOverview\\n\\n&#160;\\n\\nEquity,\\nDebt', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Preferred', 'Registered Direct Offering\\n\\n&#160;\\n\\nOn\\nApril 6, 2022', 'HEAT', 'Horizon Technology', 'the SVB Loan Facility', 'the Market Offering Agreement', 'Incorporation', 'the Preferred Stock Purchase Agreement', 'MRD', 'net&#160;\\n', 'the Gynecologic Cancer Immunotherapy Program', 'IPR&amp;D', 'Imunon, Inc.', 'the State of Delaware', 'FDA', 'NIH', 'regulatory&#160;\\n    &', 'Vaccine&#160;\\n    &', 'the Nasdaq Stock Market', 'the Ovarian Cancer Indication', 'the Laboratory of Virology', 'EGWU', 'Loan', 'Zhejiang Hisun Pharmaceutical Co. Ltd.', 'Series A Preferred Stock', 'the Board of Directors of the Company (the &#8220;Reverse Stock Split&#8221;)', 'Registrant', 'NIAID', 'the Series A Preferred Stock', '\\n    Research', 'the Preferred Offerings', 'Silicon Valley Bank', 'cash&#160;\\n    &', 'Restricted', 'each Preferred Offering', 'the China State Food and Drug', 'Net Realized Losses on Sales of Available for Sale Securities and Investment Income Interest', 'Common Stock', 'the Department of Gynecologic\\nOncology and Reproductive Medicine', 'Company', 'the Financial Accounting Standards Board', 'A Preferred Stock', 'Delta', 'the National Institute of Allergy', 'H.C. Wainwright &amp;\\n    Co.', 'the Placement Agent&#8217;s', 'Decrease)&#160;\\n  \\n    &', 'the Series B Preferred Stock', 'Cooperative Research and Development Agreement', 'Yakult', 'the Securities Exchange Act', 'Preferred Stock', 'the Board of Directors of the Company (the &#8220;Reverse Stock Split&#8221;).\\n\\n\\n    &', 'the New Jersey State Legislature', 'CMC&#160;\\n    &', 'HCC', '\\n    &', 'Series B Preferred Stock', 'New Accounting Pronouncements', 'gross\\nproceeds of'}"
IMPL,
IMRN,
IMRX,"{'PGR', 'leases10.0&#160;%9.3&#160;%As the Company&#8217;s', 'API', 'FASB', 'the 340B Drug Pricing Program', 'Anti-Kickback Statute', 'Physician Payments Sunshine Act', 'BioArkive', 'RAS', 'CMS', 'Medicaid Innovation', 'ProceduresOur', 'Co', 'the Separation Agreement', 'IMM-1-104', 'Medicaid', 'Medicare', 'ATM Program', 'ManufacturingThe', 'Principal Executive Officer', 'this Quarterly Report on Form 10-Q', 'September&#160;30,', 'the U.S. Food and Drug Administration', 'FDA', 'RevenueHistorically', 'Piper Sandler &', 'the Public Company Accounting Oversight Board', 'Medicaid Services', 'RAF', 'RevenueCost', 'ContentsAct', 'EGC', 'ProceduresManagement', 'Risks Related', 'the Children&#8217;s Health Insurance Program', 'HIPAA', 'the Medicaid Drug Rebate Program', 'Center for Medicare &', 'Immuneering Corporation', 'Piper Sandler &amp', 'FlowsThe', 'market&#8221', 'REMS', 'SEC', 'Restated Certificate of Incorporation of Immuneering Corporation10-Q001-406753.19/9/20213.2Amended', 'ContentsWe', 'ISC', 'ACA', 'Patient-Centered Outcomes Research Institute', 'Company', 'the European Economic Area', 'the 2022 Shelf Registration Statement', '7 - Common StockThe Company', 'USPTO', 'the Sarbanes-Oxley Act', 'COVID-19', 'the Centers for Medicare', 'IPO', 'the Health Information Technology for Economic and Clinical Health Act', 'the European Union', 'Nasdaq', 'ContentsFor', 'The Leahy-Smith Act'}"
IMTX,
IMUX,
IMVT,"{'ASC', 'Samsung Biologics Co., Ltd.', 'the Utah Consumer Privacy Act', 'D] Concentration of Credit RiskFinancial', 'EEA', 'ContentsItem&#160;6', 'ContentsFailures', 'IgG', 'HTA', 'ISL', 'CPRA', 'The Sarbanes-Oxley Act of 2002', 'ContentsWhile', 'ContentsWe', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'the United Kingdom Bribery Act 2010', 'Restated Bylaws of Immunovant', 'Restated Certificate of Incorporation of Immunovant', 'ContentsProduct Service Agreement and Master Services', 'ContentsIn', 'the Share Exchange Agreement', 'Roivant Sciences Ltd.', 'HanAll', 'Roivant Sciences GmbH', 'FASB', 'HHS', 'Adopted Pursuant to Section 906', 'HanAll Biopharma Co., Ltd.', 'plasma exchange', 'Medicaid', 'Medicare', 'GDPR', 'CIDP', 'FDA', 'Legal Proceedings', '5 - Related Party', '2 &#8211', 'ContentsThe', 'Leerink Partners LLC (&#8220;Leerink', 'Company', 'Party', 'USPTO', 'ContentsThe Company', 'Adopted Pursuant to Section 302', 'the International Data Transfer Agreement (&', 'Health Technology Assessment', 'the Delaware General Corporation Law', 'ContentsRSL Information Sharing and Cooperation Agreement', 'the European Commission', 'CCPA', 'Recent Accounting PronouncementsRecent', 'the Sales Agreement', 'Series A Preferred Directors', 'ISG', 'IRB', 'the &#8220;HanAll', 'MG', 'OECD', 'HSAC', 'Immunovant Sciences Ltd.', 'ContentsOur', 'See &#', 'Leerink Partners', 'the Sarbanes-Oxley Act', 'the Colorado Privacy Act', 'Regulation S-K', 'the European Commission&#8217;s', 'Our Certificate of Incorporation', 'the American Institute of Certified Public Accountants', 'RSL', 'PSA', 'Form S-3', 'RSI', 'this Quarterly Report', 'California Privacy Protection Agency', 'the Accounting Standards Codification', 'Base Erosion and Profit Shifting (&', 'ATM', 'the Court of Chancery of the State of Delaware', 'The Cooperation Agreement', 'Health Sciences Acquisitions', 'IPR&amp;D', 'the Organization for Economic Co-operation and Development (&#', 'Consumer Data Protection Act', 'RYSTIGGO', 'XBRL Instance', 'These Regulatory Proceedings', 'the Court of Chancery', 'SEC', 'GCP', 'BLA', 'the U.S. Failure', 'Bermuda', 'FcRn', 'the Foreign Corrupt Practices Act', 'the U.K.', 'Samsung', 'the HanAll Agreement', 'GD', 'RSG', 'Nasdaq', 'Notified Bodies', 'The HanAll Agreement'}"
INAB,
INBS,"{'ASC', 'percentages)\\n    &', 'years)\\n        &', 'Credit Agreement', 'ASU', 'No &#9744;\\n  &#', 'management&#x2019;s', 'the Wall Street Journal', 'PRETAX', 'tax\\n    &', 'Fair Value of Other Financial Instruments&#x2014;The', 'British Pounds Sterling', 'enhancements.\\n  Research and Development \\n  Research', '\\n', 'the Business Combination Agreement', 'Safekeep, Inc. (&#34;Safekeep&#34;)', 'Obligations&#x2014;The Company', '\\n  &', 'Unaudited)\\n  &#', 'Principal Executive Officer', 'the Stock Purchase Agreement', 'the &#34;2021 Credit', 'The Sponsor Vesting Shares', 'Business Combination', 'x2014;\\n        &', 'stockholders&#x2019', 'ESPP', 'CCC', 'Cypress Holdings Inc.', 'shares)\\n', 'Outstanding\\n    &', '\\n  &#', 'HOLDINGS INC', 'Indicate', 'Non-Controlling\\n    &', 'CCC Intelligent Solutions Holdings', '26\\n', 'LOSS)\\n    &', 'tax\\n    &#', 'Accounting Standards Update', 'the 2021 Revolving Credit Facility', '\\n    Research', 'AI', 'CONDENSED CONSOLIDATED', 'plan\\n    &', 'the Private Warrants', '\\n        &', 'the Term B Loan', 'activities\\n    &', 'Executive', 'thousands)\\n    &', 'Company', 'the Financial Accounting Standards Board', 'the Secured Overnight Financing Rate (&', 'the Securities Exchange Act', 'ESPP.The', 'CCC INTELLIGENT SOLUTIONS HOLDINGS INC.', 'Principal Financial and Accounting Officer', 'Gross Profit', 'data)\\n  &#160;\\n', 'CCC Intelligent Solutions Inc.', 'this Quarterly Report on Form 10-Q.\\n  &#160;\\n', 'Business Combinations', 'Adopted Pursuant to Section 302', 'the Sarbanes-Oxley Act', 'Investor&#x2019;s', 'Adjusted Gross Profit', 'ASC Topic', '\\n    &', 'DWP', 'the Preferred Shares'}"
INBX,"{'FASB', 'the Amended Maturity Date', 'LLC', 'ASU', 'ProceduresWe', 'the Chiesi Option Agreement', 'this Quarterly Report', 'Oxford Finance', 'LitigationThe Company', 'Oxford', 'the 2020 Loan Agreement', 'Chicago Mercantile Exchange', 'Financial Officer(Principal Financial and Accounting Officer)43\\n\\n\\n', 'EMA', 'Financial Instruments', 'Chiesi', 'Purchasers', 'Jefferies LLC', 'the Compensation Committee', 'Chiesi Farmaceutici S.p.A.', 'FDA', 'Phylaxis BioScience', 'Contribution Agreement,', ': &#', 'Board of Directors', 'the Amended 2020 Loan Agreement', 'Phylaxis', 'Instruments - Credit Losses', 'the Nasdaq Stock Market LLC', 'the European Medicines Agency', 'U.S. Treasury', 'the Private Placement', 'AATD', 'Company', 'Capital Resources and Financial Condition Sources', 'the Securities Exchange Act', 'LiquidityTo', '*&', 'LEASESOperating Leases', 'the Clawback Policy', 'ASC Topic', 'the Purchase Agreement'}"
INCR,
INCY,
INDP,"{'GLP', 'LLC', 'interest&#160;\\n    &', 'the Nasdaq Capital Market', 'unrealized.\\n\\n&#160;\\n\\nDisruptions\\nat', 'this Quarterly Report', 'The Market Offering Agreement', 'efforts\\nand', 'EMA', 'ATM', 'FDA&#8217;s', 'operations.\\n\\n&#160;\\n\\nGoing\\nconcern', 'replace\\nthem', 'Medicaid', 'Medicare', 'Regulation S-K.\\n\\n&#160;\\n\\nItem\\n6', 'to\\nbe', 'Request', 'FDA', 'Lincoln Park', 'laws\\nis', 'this Quarterly Report and &#', 'not\\n', 'business.\\n\\n&#160;\\n\\nFailure\\nto', 'demands.\\n', 'the Safety Review Committee.\\nThe', 'payments&#160;\\n    &', 'the Medicaid Drug Rebate Program', 'company.&#8221', 'Lincoln Park Capital Fund', 'Form S-1', 'REMS', 'systems\\nin', 'SEC', 'GCP', 'and\\n  \\n    &', 'Company', 'concern.\\n  \\n    &', 'Lincoln Park&#8217;s', 'issuance\\nand', 'Exhibit 3.2', 'collaborations.\\n\\n&#160;\\n\\nDisagreements\\nbetween', 'the Sarbanes-Oxley Act', 'COVID-19', 'NO &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'the Health Insurance Portability', 'LLC (&#8220;Lincoln', 'Information Technology for Economic and Clinical Health Act', '\\n    &', 'YES &#9746', 'the United States Patent and Trademark Office (&#8220;USPTO&#8221'}"
INDV,
INGN,"{'ASC', 'Reference\\n    &', 'Offer Letter', 'x201c;Live Life', 'tender uncertainty.\\n  &#', 'Inogen, Inc.', 'the United States Patent and Trademark Office of Inogen, Inc.', 'tax\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n', 'sources.\\n  &#x201c;Inogen,&#x201d', 'between Inogen, Inc.', 'Medicaid', 'Medicare', 'Diluted', '44\\n', 'this Quarterly Report on Form 10-Q', 'Assignment and Assumption of Lease Agreement', 'tax\\n    &#160;\\n', '\\n  &#', 'Sonos', 'Physio-Assist', 'the &#x201c;Exchange', '\\n    Research', 'Medicare Advantage', 'Goodwill', '\\n        &', 'SEC', 'Company', 'the Securities Exchange Act', 'the United States Patent and Trademark Office', 'expense)\\n    &', 'the mark &#', 'the Sarbanes-Oxley Act', 'Form\\n    &', 'Adopted Pursuant to Section 302', 'De Capital Risque Provencale Et Corse', 'Minutes,&#x201d', 'Physio-Assist SAS', 'The Health Information Technology for Economic and Clinical Health Act', '\\n    &', 'Consolidated Statements of Comprehensive', 'Inogen, Inc. \\n'}"
INKT,"{'the Company&#x2019;s Board of Directors', 'Compensation Plans The Company', 'Principal Financial Officer', 'the New Intercompany Agreement', 'x201c;Risk', 'Principal Executive Officer', 'the Society of Immunotherapy for Cancer (&', '2,359\\n        &', 'SITC', 'B. Riley Securities, Inc.', 'License', 'Co. Incorporation', 'the &#x201c;Prior Intercompany', 'INKT', 'the &#x201c;Exchange', 'the Walloon Region', 'Intellectual Property Assignment', '\\n        &', 'Administrative Agreement', 'Company', 'Initial Public Offering', 'the Securities Exchange Act', 'the American Society of Cell', 'the American Association for Cancer Research (&#x201c;AACR&#x201d', 'the Intercompany General &amp', 'Amended and Restated Intercompany Services Agreement'}"
INM,"{'Industrial Research Assistance\\nProgram', 'LLC', 'the University of British Columbia', 'BayMedica&#160;&#160;\\n', 'the License Agreement', 'Company&#8217;s\\nbest', 'National Research Council Canada', 'InMed Pharmaceuticals Inc.', 'NRC', 'BayMedica, Inc.', 'the Board of Directors', 'Internal Control Over Financial\\nReporting\\n\\n&#160;\\n\\nThere', 'the BayMedica segment.\\nThe', 'NRF', 'BM REP', 'this Quarterly Report on Form 10-Q', 'InMed', 'the U.S. Dollar', 'goods&#160;\\n    &', 'NRC-IRAP', 'Expenses\\n\\n&#160;\\n\\n&#160;Research and Development and Patent', 'controls\\nare', 'PCT', 'FDA', 'Diluted EPS', 'To\\ndate', 'Form S-1', 'SEC', 'Biogen\\nSciences Inc.', '\\n\\n&#160;\\n\\nRecent Accounting Pronouncements\\n\\n\\n&#160;\\n\\nThe Company', 'Company', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'BayMedica', 'Total&#160;\\n', 'period\\nof', 'Nasdaq', '\\n    &', '\\n&#160;\\n\\nThe Company', 'is\\na'}"
INMB,
INMD,
INNV,"{'L.P.', 'the Delaware General Corporation Law', 'FASB', 'ASU', 'Pinewood Lodge', 'SB', 'Senior Housing', 'Continental Community Housing (&#8220;CCH&#8221;)', 'Note 2 &#', 'the Board of Directors', 'Financial Instruments&#8212;Credit Losses', 'Medicaid', 'Medicare', 'PWD', 'PACE', 'Congress', 'Financial Instruments', 'ExhibitsThe', 'InnovAge Holding Corp.', 'the National Labor Relations Board', 'LesseeThe Company', 'LLC (&#8220;SH1&#8221;)', 'Anderson &', 'InnovAge', 'between TCO Group Holdings', 'Income Taxes226&#160;(3,470)Net Loss$(10,962)$(13,699)Less', 'Total Community Options, Inc.', 'L.P. and Welsh,', 'InnovAge Holding', 'Medicare Parts C', 'the Revolving Credit Facility', 'Related Party', 'Veterans Affairs', 'DispatchHealth Holdings, Inc.', 'the PWD Amended and Restated Agreement of Limited Partnership', 'Condensed Consolidated Financial Statements', 'SEC', 'Company', 'Total Community Options Inc.', 'the Securities Exchange Act', 'Apax Partners', 'Restated Bylaws of InnovAge Holding Corp.', 'the Company&#8217;s Board', 'Stowe', 'COVID-19', 'Public Trustee', 'the Sarbanes-Oxley Act', 'Note 9 &#', 'Significant Accounting', 'Results of Operations', 'amortization55,097&#160;153&#160;55,250&#160;53,411&#160;146&#160;53,557&#160;Center-Level Contribution Margin27,804&#160;73&#160;27,877&#160;21,360&#160;64&#160;21,424&#160;Overhead', 'GAAP', 'LLP (&', 'Recently Adopted Accounting PronouncementsFinancial', 'LLC Limited Liability Company Agreement', 'Series B Preferred Stock', 'Corporate', 'Report'}"
INO,
INSM,
INTS,
INVA,"{'ICAV (&#x201c;Royalty', 'LLC', 'the Black-Scholes-Merton', '0001080014--12-31falseQ3http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Memberhttp://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Memberhttp://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member2023-03-310001080014inva:IspFundLpMember2023-09-300001080014us-gaap:LicenseMember2022-01-012022-09-300001080014us-gaap:CollaborativeArrangementMember2023-07-012023-09-300001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2023-09-300001080014inva:IspFundLpMember2021-05-310001080014inva:ArmataPharmaceuticalsIncMemberinva:ArmataTermLoanMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel2Memberinva:IspFundLpMemberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:IncardaMemberinva:SeriesD1AndD2PreferredStockAndCommonStockMember2023-09-300001080014us-gaap:CommonStockMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-01-012022-03-310001080014us-gaap:TreasuryStockCommonMember2021-12-310001080014us-gaap:OverAllotmentOptionMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-03-310001080014us-gaap:EmployeeStockOptionMemberinva:InnovivaMembersrt:WeightedAverageMember2022-07-012022-09-300001080014inva:LaJollaPharmaceuticalCompanyMember2022-07-012022-09-300001080014inva:NanoliveMember2022-12-310001080014us-gaap:AdditionalPaidInCapitalMember2023-06-300001080014us-gaap:SalesRevenueNetMemberinva:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMember2023-07-012023-09-300001080014us-gaap:CommonStockMemberus-gaap:SubsequentEventMember2023-10-012023-10-260001080014us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:AdditionalPaidInCapitalMember2021-12-3100010800142021-12-310001080014inva:InnovivaMemberus-gaap:EmployeeStockOptionMember2022-07-012022-09-300001080014us-gaap:CommonStockMember2022-03-310001080014us-gaap:FairValueInputsLevel2Memberinva:IncardaMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2023-07-012023-09-300001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2023-01-012023-09-300001080014inva:ArmataPharmaceuticalsIncMember2023-01-012023-06-300001080014inva:GSKMembersrt:MinimumMemberinva:LabaCollaborationMemberinva:LongActingBeta2AgonistAnoroMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:XeravaMember2023-07-012023-09-300001080014inva:GateNeuroscienceMember2022-12-310001080014inva:GSKMemberinva:LabaCollaborationMemberinva:LongActingBeta2AgonistRelvarBreoMember2023-01-012023-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:TwoThousandTwentyFiveNotesMemberinva:SeniorUnsecuredConvertibleNotesMember2022-12-310001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMemberinva:OtherAccruedLiabilitiesMember2022-12-310001080014inva:GSKMemberinva:LongActingBeta2AgonistRelvarBreoMember2023-07-012023-09-300001080014us-gaap:ConvertibleDebtMemberinva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:EverestMedicinesLimitedMember2023-07-012023-09-300001080014srt:MinimumMemberus-gaap:EmployeeStockOptionMemberinva:InnovivaMember2023-01-012023-09-300001080014us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001080014inva:NoteAmendmentAgreementMemberinva:GateNeuroscienceMember2023-02-020001080014inva:GateNeuroscienceMember2023-01-012023-09-300001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2022-12-310001080014us-gaap:NoncontrollingInterestMember2022-03-310001080014us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014us-gaap:FairValueInputsLevel2Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:OtherNoncurrentLiabilitiesMemberinva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2023-09-300001080014inva:TermLoanInvestmentMemberinva:ArmataTermLoanMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:XeravaMember2023-01-012023-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:LaJollaPharmaceuticalCompanyMember2023-01-012023-06-300001080014inva:SeriesD1WarrantMemberinva:IncardaMember2022-06-150001080014inva:LicenseRevenueMember2022-01-012022-09-300001080014inva:GSKMember2022-07-012022-09-3000010800142023-01-012023-03-310001080014inva:TwoThousandTwentyFiveNotesMember2023-01-012023-09-300001080014us-gaap:SalesRevenueNetMemberinva:CustomerThreeMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMember2023-01-012023-09-300001080014inva:TwoThousandTwentyThreeNotesMember2023-07-012023-09-300001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-12-310001080014us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel1Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014srt:MaximumMember2023-09-300001080014us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014inva:GSKMember2023-07-012023-09-3000010800142023-06-300001080014us-gaap:NoncontrollingInterestMember2021-12-310001080014srt:MinimumMemberus-gaap:EmployeeStockOptionMemberinva:InnovivaMember2023-07-012023-09-3000010800142022-07-012022-09-300001080014inva:IncardaMemberus-gaap:FairValueInputsLevel1Memberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:AdditionalPaidInCapitalMember2022-03-310001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyFiveNotesMember2023-09-300001080014us-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:GateNeuroscienceMember2021-11-242021-11-240001080014us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2013-01-310001080014inva:ConvertibleNoteAndWarrantsMemberinva:IncardaMember2022-03-092022-03-090001080014us-gaap:NoncontrollingInterestMember2022-09-300001080014inva:ArmataPharmaceuticalsIncMember2022-04-012022-06-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:GSKMemberinva:LongActingBeta2AgonistAnoroMember2022-01-012022-09-300001080014us-gaap:CommonStockMember2023-07-012023-09-300001080014inva:ImaginabMemberinva:SeriesC2PreferredStockMember2023-09-140001080014us-gaap:RetainedEarningsMember2023-09-300001080014inva:IncardaMemberus-gaap:WarrantMember2023-01-012023-09-300001080014inva:ArmataPharmaceuticalsIncMember2023-09-300001080014inva:GSKMembersrt:MaximumMemberinva:LabaCollaborationMemberinva:LongActingBeta2AgonistAnoroMember2023-01-012023-09-300001080014us-gaap:MoneyMarketFundsMember2023-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMemberus-gaap:WarrantMember2021-03-310001080014inva:IspFundLpMember2022-01-012022-12-310001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:IspFundLpMemberus-gaap:FairValueInputsLevel3Memberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:RetainedEarningsMember2023-01-012023-03-310001080014us-gaap:RetainedEarningsMember2022-12-310001080014inva:IncardaMemberinva:SeriesDWarrantsMember2023-09-300001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel3Memberus-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:PaionAgMemberinva:CostReimbursementMember2023-07-012023-09-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMemberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014inva:TwoThousandTwentyFiveNotesMemberinva:SeniorUnsecuredConvertibleNotesMember2022-01-012022-09-300001080014us-gaap:InProcessResearchAndDevelopmentMember2023-05-310001080014inva:IspFundLpMember2023-07-012023-09-300001080014inva:IspFundLpMember2023-01-012023-09-300001080014inva:WarrantsPurchasedIn2020Memberinva:ArmataPharmaceuticalsIncMember2023-01-100001080014us-gaap:RetainedEarningsMember2022-06-300001080014us-gaap:SalesRevenueNetMemberinva:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMember2023-07-012023-09-300001080014us-gaap:CommonStockMember2022-07-012022-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:ArmataConvertibleNoteMember2023-07-012023-09-300001080014inva:CreditAndSecurityAgreementMemberinva:ArmataPharmaceuticalsIncMember2023-07-100001080014inva:EntasisTherapeuticsHoldingsIncMember2022-01-012022-09-300001080014us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001080014inva:IspFundLpMember2023-01-012023-09-300001080014us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:CollaborativeArrangementMember2023-01-012023-06-300001080014us-gaap:OtherNoncurrentLiabilitiesMemberinva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2022-12-310001080014us-gaap:RoyaltyMemberinva:TheravanceRespiratoryCompanyLlcMember2022-01-012022-09-300001080014inva:ConvertiblePromissoryNotePurchaseAgreementMemberinva:GateNeuroscienceMember2021-11-240001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2022-07-012022-09-300001080014inva:CommonStockAndWarrantsMemberinva:ArmataPharmaceuticalsIncMember2020-01-012020-03-310001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-07-012022-09-300001080014us-gaap:FairValueInputsLevel2Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:SeriesCPreferredStockAndWarrantsMemberinva:IncardaMember2020-07-012020-09-300001080014us-gaap:FairValueInputsLevel2Memberinva:IspFundLpMemberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:GSKMember2022-07-132022-07-130001080014inva:IncardaMember2023-01-012023-09-300001080014us-gaap:ProductMember2022-01-012022-09-300001080014inva:GSKMemberinva:TrelegyElliptaMember2022-07-012022-09-300001080014us-gaap:CollaborativeArrangementMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:ImaginabMemberus-gaap:SeriesCPreferredStockMember2021-03-180001080014srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:NoncontrollingInterestMember2022-03-310001080014us-gaap:RetainedEarningsMember2023-03-310001080014us-gaap:TreasuryStockCommonMember2022-12-310001080014inva:GSKMemberinva:LongActingBeta2AgonistRelvarBreoMember2022-07-012022-09-300001080014us-gaap:CommonStockMember2022-12-310001080014inva:ArmataPharmaceuticalsIncMember2023-01-012023-09-300001080014inva:EntasisTherapeuticsHoldingsIncMemberus-gaap:CommonStockMember2022-02-170001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMember2023-09-300001080014inva:IncardaMemberinva:SeriesD1PreferredStockMember2022-06-152022-06-150001080014inva:IncardaMemberinva:SeriesD2PreferredStockMember2022-06-152022-06-150001080014us-gaap:TreasuryStockCommonMember2023-09-300001080014us-gaap:RetainedEarningsMember2021-12-310001080014us-gaap:NoncontrollingInterestMember2022-06-3000010800142023-09-300001080014inva:ArmataPharmaceuticalsIncMember2023-04-012023-06-300001080014inva:IncardaMember2023-09-300001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMemberinva:OtherAccruedLiabilitiesMember2023-09-300001080014us-gaap:TreasuryStockCommonMember2023-03-310001080014srt:MaximumMemberus-gaap:EmployeeStockOptionMemberinva:InnovivaMember2023-07-012023-09-300001080014us-gaap:AdditionalPaidInCapitalMember2022-06-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:IncardaMemberus-gaap:SeriesCPreferredStockMember2022-06-152022-06-150001080014us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel1Memberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:MoneyMarketFundsMember2022-12-310001080014inva:PrivatelyNegotiatedCappedCallOptionMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-01-012022-03-310001080014inva:GateNeuroscienceMember2023-09-300001080014inva:LaJollaPharmaceuticalCompanyMember2023-08-312023-08-310001080014inva:EntasisTherapeuticsHoldingsIncMember2022-07-012022-09-300001080014inva:NanoliveMember2023-09-300001080014inva:EntasisTherapeuticsHoldingsIncMember2023-09-300001080014inva:ArmataPharmaceuticalsIncMember2022-02-092022-02-090001080014inva:IncardaMemberinva:SeriesD1AndD2PreferredStockAndCommonStockMember2022-12-310001080014inva:GSKMember2022-01-012022-09-300001080014inva:GSKMemberinva:TrelegyElliptaMember2023-01-012023-09-3000010800142022-01-012022-09-300001080014us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:SeriesCPreferredStockMemberinva:NanoliveMember2022-02-180001080014inva:LaJollaPharmaceuticalCompanyMember2022-08-220001080014inva:EntasisTherapeuticsHoldingsIncMemberinva:SecuritiesPurchaseAgreementMemberinva:ConvertiblePromissoryNoteMember2022-02-172022-02-170001080014us-gaap:NoncontrollingInterestMember2022-01-012022-03-3100010800142022-06-300001080014inva:TermLoanInvestmentMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:XeravaMemberinva:LaJollaMember2022-08-222022-09-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:ConsolidatedInvesteesMember2023-09-300001080014inva:ImaginabMemberinva:SeriesC2PreferredStockMember2023-09-142023-09-140001080014inva:LicenseRevenueMember2023-07-012023-09-300001080014inva:LaJollaPharmaceuticalCompanyMember2023-07-012023-09-300001080014inva:CommonStockAndWarrantsMemberinva:ArmataPharmaceuticalsIncMember2022-07-012022-09-300001080014us-gaap:TradeAccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMemberinva:CustomerOneMember2023-01-012023-09-300001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2023-01-012023-09-300001080014inva:NanoliveMember2022-02-182022-02-180001080014us-gaap:PrivatePlacementMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyFiveNotesMember2017-08-070001080014inva:TheravanceRespiratoryCompanyLlcMember2022-01-012022-09-300001080014inva:SecuredConvertibleCreditAgreementMemberinva:ArmataPharmaceuticalsIncMember2023-01-102023-01-100001080014inva:LaJollaPharmaceuticalCompanyMember2022-01-012022-09-300001080014us-gaap:CollaborativeArrangementMemberinva:EntasisTherapeuticsHoldingsIncMember2023-09-300001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyFiveNotesMember2023-01-012023-09-300001080014us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:LaJollaPharmaceuticalCompanyMember2023-09-300001080014inva:LicenseRevenueMember2023-01-012023-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:ArmataConvertibleNoteMember2023-09-300001080014us-gaap:NoncontrollingInterestMember2022-07-012022-09-300001080014inva:SeriesD1WarrantMemberinva:IncardaMember2022-06-152022-06-150001080014us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001080014inva:GiaprezaMember2023-07-012023-09-300001080014us-gaap:FairValueInputsLevel1Memberinva:IspFundLpMemberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2023-01-012023-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:IncardaMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:InProcessResearchAndDevelopmentMemberinva:EntasisTherapeuticsHoldingsIncMember2023-09-300001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2023-07-012023-09-3000010800142023-10-260001080014inva:IncardaMemberus-gaap:CommonStockMember2022-06-152022-06-150001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMember2023-07-012023-09-300001080014inva:ImaginabMemberinva:SeriesC2PreferredStockMember2023-03-140001080014inva:NoteAmendmentAgreementMemberus-gaap:SubsequentEventMemberinva:GateNeuroscienceMember2023-10-060001080014us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001080014us-gaap:TreasuryStockCommonMember2022-07-012022-09-300001080014inva:LaJollaPharmaceuticalCompanyMember2022-12-310001080014inva:IspFundLpMember2020-12-310001080014srt:MinimumMemberus-gaap:EmployeeStockOptionMemberinva:InnovivaMember2022-01-012022-09-300001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2022-01-012022-03-310001080014inva:ArmataPharmaceuticalsIncMemberinva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMemberus-gaap:WarrantMember2022-02-090001080014inva:GeorgeWashingtonUniversityMember2023-01-012023-09-300001080014us-gaap:CommonStockMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyFiveNotesMember2017-08-070001080014us-gaap:CommonStockMember2021-12-310001080014inva:ArmataPharmaceuticalsIncMemberinva:ArmataTermLoanMember2023-09-300001080014inva:ImaginabMember2021-03-182021-03-180001080014us-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014inva:IncardaMemberinva:ConsolidatedInvesteesMember2023-09-300001080014us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001080014inva:IncardaMemberus-gaap:SeriesCPreferredStockMember2022-12-310001080014inva:TheravanceRespiratoryCompanyLlcMember2022-07-200001080014srt:CumulativeEffectPeriodOfAdoptionAdjustmentMemberus-gaap:TreasuryStockCommonMember2022-03-310001080014inva:GSKMemberus-gaap:RoyaltyMember2023-07-012023-09-3000010800142023-07-012023-09-300001080014inva:TheravanceRespiratoryCompanyLlcMember2022-07-012022-09-300001080014inva:GSKMemberus-gaap:RoyaltyMember2022-01-012022-09-300001080014us-gaap:RetainedEarningsMember2022-03-310001080014srt:MinimumMember2023-09-300001080014inva:IspFundLpMember2022-01-012022-09-300001080014inva:IncardaMemberus-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:TreasuryStockCommonMember2022-09-300001080014inva:IncardaMemberinva:ConsolidatedInvesteesMember2022-12-310001080014us-gaap:EmployeeStockOptionMemberinva:InnovivaMembersrt:WeightedAverageMember2022-01-012022-09-300001080014inva:TwoThousandTwentyEightNotesMember2023-07-012023-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:TreasuryStockCommonMember2023-04-012023-06-300001080014us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001080014inva:GSKMemberinva:TrelegyElliptaMember2022-01-012022-09-300001080014us-gaap:EmployeeStockOptionMemberinva:InnovivaMembersrt:WeightedAverageMember2023-07-012023-09-300001080014inva:LicenseRevenueMember2022-07-012022-09-300001080014inva:IspFundLpMember2023-09-300001080014us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:IspFundLpMember2022-03-300001080014inva:LaJollaPharmaceuticalCompanyMember2023-01-012023-09-300001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyFiveNotesMember2023-07-012023-09-300001080014inva:HealthCareRoyaltyPartnersMember2023-01-012023-09-300001080014inva:WarrantsPurchasedIn2022Memberinva:ArmataPharmaceuticalsIncMember2023-01-100001080014inva:GSKMember2023-01-012023-09-300001080014inva:IncardaMemberinva:SeriesDWarrantsMember2022-12-310001080014us-gaap:CommonStockMember2022-04-012022-06-300001080014us-gaap:FairValueInputsLevel1Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:ImaginabMemberinva:ConsolidatedInvesteesMember2023-09-300001080014us-gaap:RetainedEarningsMember2023-04-012023-06-3000010800142022-12-310001080014inva:IspFundLpMemberus-gaap:MoneyMarketFundsMember2023-09-300001080014us-gaap:ProductMember2023-07-012023-09-300001080014us-gaap:CommonStockMember2023-01-012023-09-300001080014us-gaap:ConvertibleDebtMemberinva:IspFundLpMember2023-09-300001080014inva:EntasisTherapeuticsHoldingsIncMemberinva:LaJollaPharmaceuticalCompanyMember2022-07-012022-09-300001080014us-gaap:SalesRevenueNetMemberinva:CustomerTwoMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMember2023-01-012023-09-300001080014us-gaap:RetainedEarningsMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-03-310001080014us-gaap:TreasuryStockCommonMember2022-03-310001080014inva:CustomerThreeMemberus-gaap:TradeAccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMember2023-01-012023-09-300001080014srt:MaximumMemberinva:ArmataPharmaceuticalsIncMemberinva:OneDirectorMember2022-02-092022-02-090001080014inva:LaJollaMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel1Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:TheravanceRespiratoryCompanyLlcMember2022-01-012022-12-310001080014inva:TheravanceRespiratoryCompanyLlcMember2022-07-2000010800142023-01-012023-09-300001080014inva:GateNeuroscienceMember2022-01-012022-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:TwoDirectorsMember2022-02-092022-02-090001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-01-012022-03-310001080014us-gaap:FairValueInputsLevel3Memberus-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014us-gaap:CommonStockMemberinva:TwoThousandTwentyFiveNotesMemberinva:SeniorUnsecuredConvertibleNotesMember2017-08-072017-08-070001080014inva:TwoThousandTwentyFiveNotesMember2022-07-012022-09-300001080014inva:CommonStockAndWarrantsMemberinva:ArmataPharmaceuticalsIncMember2022-01-012022-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMember2020-01-012020-03-310001080014us-gaap:RetainedEarningsMember2022-07-012022-09-300001080014inva:IncardaMember2022-01-012022-09-300001080014us-gaap:AdditionalPaidInCapitalMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-03-310001080014us-gaap:TreasuryStockCommonMember2023-06-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:CommonStockMemberinva:TwoThousandTwentyFiveNotesMember2017-08-010001080014us-gaap:PrivatePlacementMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-03-310001080014us-gaap:CommonStockMember2023-09-300001080014inva:IspFundLpMember2022-07-012022-09-300001080014inva:EntasisTherapeuticsHoldingsIncMember2022-02-170001080014us-gaap:RoyaltyMember2022-01-012022-09-300001080014inva:EquityIncentivePlansAndESPPMember2023-07-012023-09-300001080014us-gaap:AdditionalPaidInCapitalMember2023-09-300001080014inva:EntasisTherapeuticsHoldingsIncMember2022-07-112022-07-110001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMember2022-12-310001080014inva:OptionPricingModelBacksolveValuationMemberinva:IncardaMemberus-gaap:FairValueInputsLevel3Member2023-04-012023-06-300001080014inva:EntasisTherapeuticsHoldingsIncMember2023-01-012023-09-300001080014inva:CustomerTwoMemberus-gaap:TradeAccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMember2023-01-012023-09-300001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2023-09-300001080014us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:ArmataPharmaceuticalsIncMember2021-10-012022-06-300001080014us-gaap:RetainedEarningsMember2023-07-012023-09-300001080014inva:GSKMemberinva:LongActingBeta2AgonistRelvarBreoMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel1Memberinva:IspFundLpMemberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:CollaborativeArrangementMemberus-gaap:InProcessResearchAndDevelopmentMember2023-05-012023-05-310001080014us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Memberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:RetainedEarningsMember2022-04-012022-06-300001080014inva:TwoThousandTwentyThreeNotesMember2023-09-300001080014srt:MinimumMemberinva:ArmataPharmaceuticalsIncMemberinva:OneDirectorMember2022-02-092022-02-090001080014srt:MaximumMemberinva:InnovivaMemberus-gaap:EmployeeStockOptionMember2022-01-012022-09-3000010800142023-03-310001080014us-gaap:CollaborativeArrangementMember2022-01-012022-09-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMemberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMemberinva:CustomerOneMember2023-07-012023-09-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMemberinva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:TwoThousandTwentyThreeNotesMember2022-01-012022-09-300001080014inva:EntasisTherapeuticsHoldingsIncMemberinva:ConsolidatedInvesteesMember2022-02-170001080014us-gaap:CommonStockMember2023-06-300001080014us-gaap:OverAllotmentOptionMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyFiveNotesMember2017-08-070001080014inva:PrivatelyNegotiatedCappedCallOptionMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-03-310001080014inva:EquityIncentivePlansAndESPPMember2023-01-012023-09-300001080014inva:ZaiLabMemberinva:ResearchAndDevelopmentSupportMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel2Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:TwoThousandTwentyEightNotesMember2022-01-012022-09-300001080014inva:PaionAgMember2023-09-300001080014us-gaap:ConvertibleDebtMemberinva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:ZaiLabMemberinva:ResearchAndDevelopmentSupportMember2023-09-300001080014srt:MinimumMember2022-12-310001080014srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-03-310001080014inva:IspFundLpMemberus-gaap:MoneyMarketFundsMember2022-12-310001080014us-gaap:SubsequentEventMemberinva:ConvertiblePromissoryNotePurchaseAgreementMemberinva:GateNeuroscienceMember2023-10-060001080014us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-01-012022-09-300001080014inva:IncardaMemberus-gaap:WarrantMember2020-09-300001080014us-gaap:GeographicConcentrationRiskMemberus-gaap:SalesRevenueNetMembercountry:US2023-07-012023-09-300001080014us-gaap:FairValueInputsLevel1Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:GSKMemberinva:LongActingBeta2AgonistAnoroMember2023-07-012023-09-300001080014us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberinva:LaJollaMemberinva:CustomerOneMember2023-01-012023-09-300001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2022-01-012022-09-300001080014inva:TwoThousandTwentyThreeNotesMember2022-07-012022-09-300001080014us-gaap:TreasuryStockCommonMember2022-04-012022-06-300001080014inva:HarvardUniversityMember2023-01-012023-09-300001080014us-gaap:FairValueInputsLevel1Memberus-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:GateNeuroscienceMember2023-07-012023-09-300001080014inva:ImaginabMemberus-gaap:CommonStockMemberinva:OneOfImaginabsCommonStockholderMember2021-03-182021-03-180001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommonStockMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:CollaborativeArrangementMember2022-07-012022-09-300001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2022-12-310001080014us-gaap:CommonStockMember2023-01-012023-03-310001080014us-gaap:CommonStockMembersrt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-03-310001080014us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001080014us-gaap:FairValueInputsLevel1Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:CommonStockMember2022-06-300001080014inva:GeorgeWashingtonUniversityMember2023-07-012023-09-300001080014inva:OutstandingStockWarrantMember2022-07-012022-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMemberus-gaap:CommonStockMember2021-10-012021-12-310001080014us-gaap:CommonStockMember2022-10-310001080014us-gaap:AdditionalPaidInCapitalMember2022-12-3100010800142023-01-012023-06-300001080014us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:TwoThousandTwentyThreeNotesMember2023-01-012023-09-300001080014inva:LaJollaPharmaceuticalCompanyMember2022-08-222022-08-220001080014inva:GSKMemberus-gaap:RoyaltyMember2023-01-012023-09-300001080014inva:IspFundLpMember2022-12-310001080014inva:PaionAgMemberinva:CostReimbursementMember2023-01-012023-09-3000010800142022-01-012022-03-310001080014inva:IspFundLpMemberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:EmployeeStockOptionMemberinva:InnovivaMember2022-01-012022-03-310001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:FairValueInputsLevel3Memberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:GSKMemberus-gaap:RoyaltyMember2022-07-012022-09-300001080014us-gaap:CommonStockMember2023-04-012023-06-300001080014inva:EntasisTherapeuticsHoldingsIncMemberus-gaap:WarrantMember2022-02-170001080014us-gaap:CommonStockMember2022-09-300001080014inva:GSKMemberinva:LongActingBeta2AgonistRelvarBreoMember2022-01-012022-09-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2023-07-012023-09-300001080014us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:TheravanceRespiratoryCompanyLlcMember2023-01-012023-09-300001080014inva:CommonStockAndWarrantsMemberinva:ArmataPharmaceuticalsIncMemberinva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember2021-01-012021-03-310001080014inva:CreditAndSecurityAgreementMemberinva:ArmataPharmaceuticalsIncMember2023-07-102023-07-100001080014us-gaap:ConvertibleDebtMemberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:TreasuryStockCommonMember2022-01-012022-03-310001080014inva:XacduroMember2023-01-012023-09-300001080014srt:MaximumMember2022-12-310001080014inva:ImaginabMember2022-12-310001080014inva:NanoliveMemberinva:ConsolidatedInvesteesMember2023-09-300001080014us-gaap:CommonStockMemberinva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-03-310001080014us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001080014us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel3Memberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:GiaprezaMember2023-01-012023-09-300001080014inva:EverestMedicinesLimitedMember2023-01-012023-09-300001080014inva:TwoThousandTwentyFiveNotesMember2022-01-012022-09-300001080014us-gaap:ProductMember2022-07-012022-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:ArmataTermLoanMember2023-07-012023-09-300001080014us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001080014us-gaap:TreasuryStockCommonMember2023-07-012023-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMember2023-01-012023-09-300001080014inva:NanoliveMemberinva:ConsolidatedInvesteesMember2022-12-310001080014inva:ArmataPharmaceuticalsIncMemberinva:ConsolidatedInvesteesMember2022-12-310001080014inva:LaJollaPharmaceuticalCompanyMember2022-01-012022-12-310001080014inva:TheravanceRespiratoryCompanyLlcMember2022-07-202022-07-2000010800142022-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMember2023-09-300001080014inva:GSKMemberinva:TrelegyElliptaMember2023-07-012023-09-300001080014inva:EquityIncentivePlansAndESPPMember2022-01-012022-09-300001080014us-gaap:LicenseMember2022-07-012022-09-300001080014us-gaap:CommonStockMember2022-01-012022-03-310001080014inva:SeniorUnsecuredConvertibleNotesMemberinva:TwoThousandTwentyEightNotesMember2022-03-310001080014inva:LaJollaPharmaceuticalCompanyMember2023-01-012023-09-300001080014us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100010800142023-04-012023-06-300001080014us-gaap:AdditionalPaidInCapitalMember2023-03-310001080014inva:EverestMedicinesLimitedMember2023-09-3000010800142022-03-310001080014inva:OutstandingStockWarrantMember2022-01-012022-09-300001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2022-03-310001080014inva:OutstandingStockWarrantMember2023-07-012023-09-300001080014us-gaap:CommonStockMember2023-03-310001080014inva:GSKMemberinva:LongActingBeta2AgonistAnoroMember2023-01-012023-09-300001080014inva:ImaginabMemberinva:SeriesC2PreferredStockMember2023-03-142023-03-140001080014inva:IncardaMemberus-gaap:SeriesCPreferredStockMember2022-04-012022-06-300001080014us-gaap:FairValueInputsLevel2Memberus-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014us-gaap:ConvertibleDebtMemberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014us-gaap:SeriesCPreferredStockMember2023-04-012023-06-300001080014inva:ArmataPharmaceuticalsIncMember2022-10-012023-06-300001080014us-gaap:TreasuryStockCommonMember2022-06-300001080014inva:IspFundLpMemberus-gaap:EquitySecuritiesMember2023-09-300001080014us-gaap:FairValueInputsLevel2Memberinva:ArmataPharmaceuticalsIncMemberus-gaap:WarrantMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:ProductMember2023-01-012023-09-300001080014inva:IspFundLpMember2022-12-310001080014inva:IncardaMemberus-gaap:SeriesDPreferredStockMember2022-06-152022-06-150001080014us-gaap:RoyaltyMember2023-07-012023-09-300001080014inva:GateNeuroscienceMember2022-07-012022-09-300001080014us-gaap:RetainedEarningsMember2023-06-300001080014inva:ImaginabMemberinva:ConsolidatedInvesteesMember2022-12-310001080014us-gaap:SubsequentEventMemberinva:GateNeuroscienceMember2023-10-062023-10-060001080014inva:ImaginabMemberus-gaap:CommonStockMemberinva:OneOfImaginabsCommonStockholderMember2021-03-180001080014us-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:LaJollaPharmaceuticalCompanyMember2023-09-300001080014us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001080014srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember2022-01-012022-03-310001080014inva:ArmataPharmaceuticalsIncMemberinva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMemberus-gaap:CommonStockMember2022-02-090001080014inva:IncardaMember2022-07-012022-09-300001080014inva:LaJollaMember2022-08-222022-09-300001080014us-gaap:ConvertibleSubordinatedDebtMemberinva:TwoThousandTwentyThreeNotesMember2023-09-300001080014inva:IncardaMemberus-gaap:SeriesCPreferredStockMember2023-09-300001080014inva:CommercialSupplyAgreementMemberinva:EverestMedicinesLimitedMember2023-01-012023-09-300001080014inva:WarrantsPurchasedIn2020Memberinva:ArmataPharmaceuticalsIncMember2020-01-012020-03-310001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2022-01-012022-09-300001080014inva:IncardaMemberinva:OptionPricingModelBacksolveValuationMemberus-gaap:FairValueInputsLevel3Member2022-04-012022-06-300001080014us-gaap:FairValueInputsLevel1Memberus-gaap:DebtMemberus-gaap:FairValueMeasurementsNonrecurringMember2022-12-310001080014us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:SecuredConvertibleCreditAgreementMemberinva:ArmataPharmaceuticalsIncMember2023-01-100001080014us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:ImaginabMemberus-gaap:SeriesCPreferredStockMember2021-03-182021-03-180001080014inva:TermLoanInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:GateNeuroscienceMember2023-02-022023-02-020001080014us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001080014inva:ParatekPharmaceuticalsIncMember2023-01-012023-09-300001080014inva:IspFundLpMemberus-gaap:FairValueInputsLevel3Memberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:IncardaMemberus-gaap:SeriesCPreferredStockMember2020-07-012020-09-300001080014inva:GSKMemberinva:LongActingBeta2AgonistAnoroMember2022-07-012022-09-300001080014inva:OutstandingStockWarrantMember2023-01-012023-09-300001080014us-gaap:RetainedEarningsMember2022-09-300001080014us-gaap:ConvertibleDebtMemberus-gaap:FairValueInputsLevel1Memberinva:GateNeuroscienceMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014inva:CommonStockAndWarrantsMemberinva:ArmataPharmaceuticalsIncMemberinva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMember2022-02-092022-02-090001080014us-gaap:FairValueInputsLevel2Memberinva:TermLoanInvestmentMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:EntasisTherapeuticsHoldingsIncMemberinva:SecuritiesPurchaseAgreementMemberinva:ConvertiblePromissoryNoteMember2022-02-170001080014us-gaap:TreasuryStockCommonMember2023-01-012023-03-310001080014us-gaap:RoyaltyMemberinva:TheravanceRespiratoryCompanyLlcMember2022-07-012022-09-300001080014inva:IncardaMemberinva:SeriesA1PreferredStockMember2022-06-152022-06-150001080014us-gaap:AdditionalPaidInCapitalMember2022-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:ArmataConvertibleNoteMember2023-01-012023-09-300001080014inva:TwoThousandTwentyEightNotesMember2022-07-012022-09-300001080014us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001080014srt:MaximumMemberus-gaap:EmployeeStockOptionMemberinva:InnovivaMember2023-01-012023-09-300001080014inva:IspFundLpMemberinva:PrivatePlacementPositionsAndConvertibleNotesMember2022-12-3100010800142022-04-012022-06-300001080014inva:EntasisTherapeuticsHoldingsIncMember2023-01-012023-09-300001080014us-gaap:LicenseMember2023-07-012023-09-300001080014us-gaap:RoyaltyMember2022-07-012022-09-300001080014inva:TwoThousandTwentyEightNotesMember2023-01-012023-09-300001080014inva:IspFundLpMemberus-gaap:EquitySecuritiesMember2022-12-310001080014inva:InnovivaMemberus-gaap:EmployeeStockOptionMembersrt:WeightedAverageMember2023-01-012023-09-300001080014inva:GiaprezaMemberinva:LaJollaMember2022-08-222022-09-300001080014inva:LaJollaMember2023-07-012023-09-300001080014inva:XacduroMember2023-07-012023-09-300001080014inva:ArmataPharmaceuticalsIncMemberinva:WarrantsPurchasedIn2021Member2023-01-100001080014us-gaap:LicenseMember2023-01-012023-09-300001080014inva:EntasisTherapeuticsHoldingsIncMemberinva:LaJollaPharmaceuticalCompanyMember2022-01-012022-09-300001080014inva:IncardaMemberus-gaap:SeriesCPreferredStockMember2022-06-150001080014inva:ArmataPharmaceuticalsIncMemberinva:InnovivaStrategicOpportunitiesLimitedLiabilityCorporationMemberus-gaap:CommonStockMember2021-03-310001080014us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001080014us-gaap:SeriesCPreferredStockMemberinva:NanoliveMember2022-02-182022-02-180001080014inva:IspFundLpMemberinva:EquityInvestmentsAndMoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001080014us-gaap:FairValueMeasurementsRecurringMember2023-09-300001080014inva:TwoThousandTwentyFiveNotesMember2023-07-012023-09-300001080014us-gaap:RoyaltyMember2023-01-012023-09-300001080014us-gaap:FairValueMeasurementsNonrecurringMember2023-09-300001080014inva:ImaginabMember2023-09-300001080014us-gaap:RetainedEarningsMember2022-01-012022-03-310001080014inva:HealthCareRoyaltyPartnersMemberus-gaap:LoansPayableMemberinva:RoyaltyFinancingAgreementMember2022-07-012022-09-300001080014inva:EquityIncentivePlansAndESPPMember2022-07-012022-09-300001080014inva:ArmataPharmaceuticalsIncMemberus-gaap:CommonStockMember2022-12-310001080014inva:TwoThousandTwentyFiveNotesMemberinva:SeniorUnsecuredConvertibleNotesMember2022-07-012022-09-300001080014inva:IspFundLpMember2022-03-302022-03-300001080014us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-30inva:Directoriso4217:USDinva:Itemxbrli:purexbrli:sharesinva:Customeriso4217:USDxbrli:sharesiso4217:CHFinva:Trancheiso4217:USD\\n  &', 'COPD', 'this Quarterly Report on Form 10-Q', 'Armata&#x2019;s', '42\\n  \\n  &#160;\\n', 'the Paratek Pharmaceuticals, Inc. (&', 'Entasis', '\\n    Receivables', 'La Jolla Royalty Agreement', 'the Condensed Consolidated Financial Statements', 'LABA', 'XACDURO&#174', 'The La Jolla Royalty Agreement', 'Indicate', 'Pro Forma Financial InformationThe', '\\n    Research', 'Treasury', 'BREO&#174', 'the Securities Exchange Act', 'NYSE', 'data)\\n  &#160;\\n', 'ISO', 'ImaginAb Series C-2', 'purposes.\\n  Item 3', 'La Jolla Pharmaceutical Company,&#160;&#160;&#160;net', 'Armata\\', 'Innoviva Specialty Therapeutics', 'Unregistered Securities \\n  &#', 'compensation\\n    &', 'ISP Fund LP', 'Nanolive Series C', 'x201c;Risk', 'LABA Collaboration\\n  ', 'associated &', 'Medicaid', 'the Securities and Exchange Commission', 'LLC (&#x201c;ITH&#x201d', 'the La Jolla Royalty Agreement', 'Harvard', 'Theravance', 'THE SECURITIES EXCHANGE ACT OF', 'FDA', 'Unaudited)\\n  &#160;\\n', 'the Hatch-Waxman Act', 'the District Court', 'Charter)\\n  &#160;\\n', 'Development Partnership', 'GARDP', 'Notice Letter', 'CONDENSED CONSOLIDATED', 'ELLIPTA&#174', 'Goodwill', 'activities\\n    &', 'Company', 'the &#x201c;Everest Supply', 'TRC&#x2019;s', 'the Armata Convertible Note', '\\n    Interest expense\\n    &', 'satisfy &#160;&#160;&#160;tax', '27\\n     &#160;ImaginAb', 'the &#x201c;InCarda Convertible Note&#x201d;)', 'Innoviva stockholders\\n        &', '3.81\\n    &', 'Innoviva', 'ASU', 'Royalty Pharma Investments', 'InCarda', 'Nanolive SA', 'LLC (&#x201c;TRC&#x201d;)\\n    &', 'the LABA Collaboration Agreement', 'ITH', 'Innoviva&#x2019;s', 'Stockholders&#x2019', 'Zai Lab', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'Secured Convertible Credit Agreement', 'Development Expenses&#160;Research', 'License', '\\n  &#', 'the &#x201c;Armata Term Loan&#x201d;)', 'Therapeutics Holdings', 'the &#x201c;Gate Convertible Note&#x201d', 'The Replacement Warrants', 'Gate Neurosciences, Inc. (&#x201c;Gate&#x201d;)', 'NDA', 'ImaginAb Series C', 'and\\n  &#x2022;TRELEGY&#174', 'The Global Antibiotic Research &', 'x201c;InCarda', 'Innoviva Strategic Opportunities', 'Armata Pharmaceuticals', 'CHF', 'SUL-DUR', 'Credit and Security Agreement', 'None.\\n  &', 'ICS', 'Restricted Cash:\\n    &', 'License and Collaboration Arrangements\\n  Out-License AgreementsZai LabEntasis', 'Gate', 'Armata Pharmaceuticals, Inc.', 'No  &#9744;\\n  &#', 'InCarda Therapeutics, Inc. (&#x201c;InCarda&#x201d;)', 'Innoviva TRC Holdings', 'ISP Fund LP\\n', 'TRC', 'HCR', 'the Harvard University (&#x201c;Harvard&#x201d;)', 'HABP/VABP', '\\n    Interest', 'SEC', 'Restricted', 'Public Offering of Common Stock\\n  &#', 'XERAVA&#174', 'the Zai Agreement', 'ImaginAb, Inc. (&', 'Phase 3', 'Equity Securities', 'Paratek Pharmaceuticals', 'GSK', 'GIAPREZA&#174', 'Acinetobacter.\\n  &#', '\\n    &'}"
INVO,"{'the Listing Qualifications', 'LLC', 'the Resale Registration\\nStatement', 'The Placement Agent Warrants', 'IVF', 'the Mexico JV', 'the Nasdaq Hearings Panel', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'the RLSA Loan', 'State', 'INVO CTR', 'Common Stock,\\nat', 'Pre-Incorporation', 'The RSLA Loan', 'Armistice\\nCapital Markets Ltd.', 'Lender', 'JAG', 'the RSLA Loan', 'Hepatocellular Carcinoma and Multiple Myeloma\\nfrom Cytovia Therapeutics (&#8220;Cytovia&#8221;)', 'Nasdaq Rule 5635(d', 'the Securities Exchange Act', 'the RD Offering', 'Consolidated Financial Statements', 'the Merger Agreement', 'NAYA', 'centers\\nin North America', 'Country\\n  \\n    &', 'ELOC', 'the Resale Registration Statement', 'RD Offering', 'the Securities and Exchange Commission', 'FDA', '0%.\\n\\n&#160;\\n\\n&#160;\\n\\nNote\\n16 &#8211', 'the (&#8220;Price\\nRule&#8221', 'Loan', 'the Private Warrants', 'Common Stock', 'Bio X Cell, Inc', 'Company', 'deducting\\nplacement', 'the Common Stock Purchase Warrants issued\\nto Armistice', 'HRCFG', 'Shareholders', 'the CE Mark', 'The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', '\\n    &#', 'the Georgia JV', 'Purchase Agreement', 'Leases\\n\\n&#160;\\n\\nThe\\nCompany', 'Panel', 'The March Warrant', 'Envimed Co.', 'Mexico.\\nThe Shareholders', 'Alabama JV recorded\\na', 'the Atlanta Clinic', 'IVC', 'Articles of Incorporation', 'Waiver', 'INVO Center', 'the Nasdaq\\nHearings Panel', 'INVOcell', 'Wood Violet Fertility', 'Registrant', '\\n\\n&#160;\\n\\nNote\\n4 &#8211', 'The Nasdaq Capital Market', 'INVO', 'the Resale\\nRegistration Statement', 'Bloom Fertility,\\nLLC (&#8220;Bloom&#8221', 'Armistice', 'Medical Equipment Import\\n    &', 'S.A. de C.V.\\n\\n&#160;\\n\\nOn\\nSeptember 24, 2020', 'the Subsequent Equity Financing Provision', '\\n\\n&#160;\\n\\nNote\\n9 &#8211', 'Form S-3', 'the Loan Agreement', 'the Placement Agent Warrants', 'shares\\nof Common Stock', 'Armistice Capital Markets Ltd.', 'year.\\n\\n&#160;\\n\\nResearch\\nand Development', 'amendment\\nor', 'Wisconsin Fertility Institute (&#8220;WFI&#8221', 'the &#8220;Shareholders&#8221;)\\nunder', 'NAYA&#8217;s stockholders\\nand', 'WFRSA', 'CTR', 'Decathlon Alpha V LP', 'Cedar', 'The Georgia JV', 'Registered Direct Offering\\n\\n&#160;\\n\\nOn\\nMarch 23,', 'Variable Interest Entities\\n\\n&#160;\\n\\nConsolidated\\nVIEs\\n\\n&#160;\\n\\nBloom\\nINVO', 'LLC (&#8220;HRCFG&#8221', 'SEC', 'and\\n  \\n    &', 'Ltd.\\n    &', 'of\\nCommon Stock', 'MD PLLC (&', 'certain\\ninstitutional', 'WFI', 'the February Debentures', 'Company&#8217;s\\nnon', 'Advance LLC (&#8220;Cedar&#8221', 'Nasdaq', '\\n    &', 'Cosmetics &'}"
INZY,"{'compensation\\n    &', 'BofA Securities, Inc.', 'Company\\', 'LLC', 'Cowen and Company', 'The Wall Street Journal', 'The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &', 'Form S-3', 'the Loan Agreement', '\\n', 'Management&#x2019;s', 'Loan Agreement', 'Ankura Trust Company', 'Contractual Obligations', 'iii\\n', 'Unaudited Condensed Consolidated Financial Statements\\n    ', 'Exhibits.\\n  &#160;\\n', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'ENPP1', 'Stockholders&#x2019', 'this Quarterly Report on Form 10-Q', 'the Company&#x2019;s Annual Report on Form 10-K', 'The Loan Agreement', 'x2014;\\n        &', 'Jefferies LLC', 'FDA', 'Lender', 'Yale', 'Unaudited)\\n  &#160;\\n', '\\n  &#', 'Stockholders&#x2019;', 'Loan', 'Lenders', 'the Registrant&#x2019;s Current Report', 'INOZYME PHARMA, INC', '\\n    Research', 'Significant Accounting Policies', 'Piper Sandler &amp', 'Equity &', 'the Open Market Sale Agreement', 'Restricted', 'Yale University (&#x201c;Yale&#x201d;)', 'Jefferies LLC (&#x201c;Jefferies&#x201d;)', 'x201c;Loan', 'the Financial Accounting Standards Board', 'Company', 'GIC', 'Restricted CashRestricted', 'Liquidity and Capital Resources \\n', 'compensation)\\n    &', '\\n  Research', 'the Final Fee', 'Capital Resources.&#x201d', 'Comparison', '\\n    &', 'See &#x201c;Liquidity', '\\n    &#', 'the Registration Statement'}"
IOBT,
IONM,
IONS,
IOVA,
IPA,
IPHA,
IPSC,
IRIX,"{'Glaukos Corporation', 'the Delaware General Corporation Law', 'these &#x201c;underwater&#x201d', 'CW', 'ASU', 'SVBB', 'the Distribution Agreement', 'the Loan Agreement', 'x201c;Compensation &#', 'Principal Financial Officer', 'this Quarterly Report on Form 10', 'Security Agreement', 'Intangible AssetsThe', 'the Cyclo G6 Laser System', 'x201c;Risk', '2023 &#', '1,244\\n         &', 'Ivantis, Inc. Pharmaceuticals', 'Principal Executive Officer', 'Medicare', 'Medicaid', 'the Unaudited Condensed Consolidated Financial Statements', 'the Asset Purchase Agreement', 'CompensationThe Company', 'the U.S. Dollar', 'First Citizens BancShares, Inc. (&#x201c;First', 'Alcon, Inc.', 'FDA', '2022\\n         &', '371\\n         &', 'Part II and &#x201c;Subsequent', 'the Nasdaq Stock Market', 'AccumulatedAmortization\\n         &', 'PASCAL', 'Topcon', 'Loan', 'WPS', '3,042\\n     &', 'SEC Rule 13a-15(b', 'the Anti-Kickback Statute', 'TMLS', '377\\n         &', 'the Federal Deposit Insurance Corporation', 'this Quarterly Report on Form 10-Q entitled &#x201c;Risk Factors.&#x201d', 'Allergan, Inc.', 'New World Medical, Inc.', 'LCD', 'OperationsThe', 'Silicon Valley Bank', 'SEC', 'x201c;Loan', 'TruFocus LIO', 'Company', 'FASB ASC Topic', 'FDIC', 'the Quality System Regulation (&#x201c;QSR&#x201d', 'Topcon Corporation', '340\\n         &', 'COVID-19', 'MicroPulse', 'SummaryOur', '\\n     &', 'SVB', 'TLT&#x2019;s'}"
IRMD,
IRON,
IRTC,"{'ASC', 'Ending December 31,2023', 'the Delaware General Corporation Law', 'Factors &', 'RevenueThe', 'the California Department of Financial Protection and Innovation', 'Anti-Kickback Statute', 'Board', 'CMS', 'The Development Agreement', 'SOX Steering Committee', 'The SVB Loan Agreement', '2024.The Development Agreement', 'the Development Agreement with Verily', 'this Quarterly Report on Form 10-Q.', 'Contingencies', 'Security Agreement', 'the European Union;&#8226;compliance', 'BSI', 'the U.S. Internal Revenue Service', 'diluted30,607&#160;30,055&#160;30,470&#160;29,837&#160;Net', 'the UK MDR', 'ECG', 'the SVB Loan Agreement', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls and Procedures', 'the Development Agreement', 'the Unaudited Condensed Consolidated Financial Statements', 'EQUITYCommon StockThe', 'PRSUs', 'Medicare', 'Medicaid', 'Software', 'BioTelemetry, Inc.', 'National Standards Authority', '20236,728&#160;1 Awards', 'EU', 'AssetsOther', 'FDA', 'investment3,000&#160;&#8212;&#160;Other845&#160;1,130&#160;Total$47,048&#160;$22,252&#160;The Company', 'Trust Company', 'Verily', 'Medicaid Services', 'UKCA', 'AMA&#8217;s', 'British Standards Institution', 'United', 'healthcare stakeholders &#8211', 'Research and Development', 'MCT', 'the Federal Deposit Insurance Corporation', 'Risks Related', 'revenue.11IRHYTHM TECHNOLOGIES', 'September&#160;30', 'Silicon Valley Bank', 'the Trade and Cooperation Agreement', 'September&#160;30, 2023.The Company', 'Company', 'the Zio Services', 'ReimbursementThe Company', 'the Centers for Medicare &', 'COVID-19', 'UK Bribery Act', 'Results of Operations', 'ExpenseInterest', 'SVB', 'CFO', 'Zio Systems', 'the General Data Protection Regulation', 'the European Union', 'FCA', 'Bank DebtIn October 2018', 'Zio Services', 'CE', 'First-Citizens Bank &amp', 'Continued)10'}"
IRWD,
ISPC,"{'the Ianelli Separation Date', 'the Ianelli Separation Agreement', 'ContentsiSpecimen&#160;Inc', 'The Underwriter Warrant', 'Principal Executive Officer', 'Yes &#9744', 'Principal Executive Officer Pursuant to Securities Exchange Act', 'Fordham Financial Management, Inc.', 'Voluntary Disclosure Agreements', 'October&#160;24', 'PCAOB', 'Company', 'Pursuant', 'Common Stock WarrantsThe Company', 'ShortagesOur', 'the Sarbanes-Oxley Act', 'Principal Financial Officer Pursuant', 'IPO', 'ThinkEquity', 'Principal Financial Officer Pursuant to Securities Exchange Act', 'Curley', 'Executive Employment Agreement', 'Description of Exhibit31.1*Certification'}"
ISRG,
ITCI,"{'API', 'March&#160;1', 'BMS', 'Critical Accounting Policies', '2022 Product Sales', 'Item 408 of Regulation S-K', 'General Counsel', 'License Agreement', 'The Vehicle Lease', 'FDA', 'Bristol Myers Squibb', 'Rule 10b5-1', 'Inventory Inventory', 'Indicate', 'Exchange', 'Recent Accounting Pronouncements Management', 'ContentsWe', 'Company', 'CNS'}"
ITOS,"{'ASC', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001808865us-gaap', '\\n  &#x2022;injury', 'LLC', 'BE2023-01-012023-09-300001808865us-gaap', '\\n    Interest income\\n    &', 'Exhibits.\\n  &#160;\\n', 'ProductMember2023', 'ADCC', 'MSD International GmbH', '\\n  &#x2022;research', '26\\n', '\\n    Research', 'WuXiAgreementMember2023-09-3000018088652022-01-012022-09-300001808865srt', 'UBS Optimus Foundation', '\\n  Research', 'Certificate of Incorporation', 'MaximumMember2023-07-012023-09-300001808865itos', 'MaximumMember2023-09-300001808865itos', 'USTreasurySecuritiesMember2022-12-310001808865itos', 'the Granting Agencies', 'WuXi', 'GlaxoSmithKline Intellectual Property', 'Bristol Myers Squibb&#x2019;s', 'WuXiAgreementMember2023-01-012023-09-300001808865us-gaap', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001808865us-gaap', 'the Amended Adimab Agreement', 'MaximumMember2023-01-012023-09-300001808865itos', '\\n  &#x2022;significant', '\\n  &#x2022;product', 'LeaseholdImprovementsMember2022-12-310001808865us-gaap', '\\n  &#x2022;substantial', 'prospects.\\n  &#x2022;We', '\\n  &#x2022;initiation', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'x2014;\\n        &', 'Fc&#x3b3;R', 'the United States;\\n  &#', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Fred Hutchinson Cancer Research Center', 'and\\n  &#', 'candidates.\\n  Healthcare', '\\n  &#x2022;loss', 'MPM Oncology Charitable Foundation', 'Merck &', '\\n  Commission File Number', 'Company', 'MaximumMember2022', 'Charter)\\n  &#', 'Cowen', 'iTeos Belgium S.A.', '\\n    &#', 'USD\\n  &', 'the GSK Collaboration Agreement', 'Merck', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001808865us-gaap', 'Contracts with Customers', 'FCPA', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'License', 'BE2023-01-012023-06-300001808865us-gaap', '\\n  &#', 'LiabilitiesThe', 'x2022;GSK', '\\n  &#x2022;decreased', 'employees.\\n  Risks', '\\n  &#x2022;subject', 'FairValueMeasurementsRecurringMember2023', 'Fc', 'organization)\\n    &#160;\\n', 'prospects.\\n  &', 'the Adimab Agreement', 'Comparison', 'This Quarterly Report on Form 10-Q', '\\n  &#x2022;delay', '\\n  &#x2022;our', 'Cowen and Company', 'Form S-3', 'EOS-448).\\n  &#x2022;We', 'Management&#x2019;s', 'ATM', '44\\n', 'our prospects;\\n  &#', '\\n  &#x2022;identify', 'Co., Inc.', 'WuXi Biologics Hong Kong Limited', 'Sarbanes-Oxley Act', 'Revenue\\n        &', 'TIGIT', 'the Registrant&#x2019;s Current Report', '\\n  &#x2022;withdrawal', '\\n        &', 'SEC', 'Collaboration and License Agreement', 'MSD', 'the WuXi Agreement', 'AccruedExpensesAndOtherCurrentLiabilitiesMember2022-12-310001808865us-gaap', 'the Registrant&#x2019;s Registration Statement', 'GSK', 'ASC Topic', '\\n    &', '\\n  &#x2022;manage', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001808865itos'}"
ITRM,"{'ASC', 'non-compliance;\\n  &#x2022;suspend', 'Limited Recourse Royalty-Linked Subordinated Notes', 'the Exchangeable Notes Indenture', 'LLC', 'Fair Value of Financial Assets', 'Reliance', 'may:\\n  &#x2022;issue', 'EMA', 'Iterum Therapeutics Bermuda Limited', 'EU', 'Warrants\\n          &', '1,270,094\\n          &', 'Registered Direct Offering', 'all;\\n  &#x2022;the FDA', 'x2022;a', 'Intangible Asset', 'RLN', 'UPC', 'Nasdaq Listing Rule 5550(a)(2', 'Exchangeable Notes', 'Iterum Therapeutics US Holding Limited and Iterum Therapeutics US Limited', 'the Pfizer License', '340B Program', 'the Bid Price Rule', 'Iterum US Limited', 'Shelf Registration Statement', 'the Private Placement, Iterum Bermuda', 'and\\n  &', 'the Rights Offering', 'and\\n  &#x2022;collaborations', 'Pfizer', 'REnewed ASsessment', 'U.S. Holder&#x2019;s', 'Iterum Therapeutics International Limited', 'Private Placement', 'the Exchangeable Notes (Exchangeable Notes Indenture', 'the Underwriting Agreement', 'Medicaid', 'Medicare', 'healthcare practitioners;\\n  &#x2022;impose', 'risk.\\n  Inflation', 'Obtaining', 'x2014;\\n        &', 'products;\\n  &#', 'candidates;\\n  &#x2022;a', 'GDPR', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator', 'Underwritten Offering', 'ContingenciesLicense AgreementOn', 'Risks Related to Regulatory Approval', 'Loan', 'and\\n  &#', 'us;\\n  &#x2022;the', 'Risks Related', '77\\n', 'the Bermuda Stock Exchange', 'the Medicaid Drug Rebate Program', 'all;\\n  &#x2022;obtain', 'the Private Placement', 'Silicon Valley Bank', 'the product;\\n  &#x2022;the', 'REMS', 'Company', 'Units', 'USPTO', '\\n  &#160;\\n', 'Boston University', 'Resistant Enterobacterales', 'SVB', '\\n    &#', 'Purchase Agreement', 'approvals;\\n  &#', 'the Nasdaq Capital Market', 'SBA', 'AIA', 'National Health Authorities', 'CMS', 'grows.\\n', 'litigation;\\n  &#x2022;collaborators', '\\n  &#x2022;the', 'financial condition.\\n  &#160;\\n', 'U.S. Holder', 'the product;\\n  &#x2022;impose', 'the Sales Agreement', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'products;\\n  &#x2022;disagreements', 'PPP', '\\n  &#', 'CMC', 'Unaudited Condensed Consolidated Financial Statements(In', '329,799\\n          &#160;\\n         \\n         \\n          Unvested', 'Rights Offering', 'Other InformationThe Company', 'LiabilitiesThe', 'payable.\\n  &', 'The Nasdaq Capital Market', 'derivatives.\\n  &#', 'NDA', 'IRA', 'Registered Direct Offerings\\n  On', 'the Listing Qualifications Department of The Nasdaq Stock Market', 'IPO', 'costs;\\n  &#', 'REMS;\\n  &#x2022;whether', 'This Quarterly Report', 'use;\\n  &#x2022;require', 'charter)\\n  &#', 'including:\\n  &#x2022;although', 'the Company&#x2019;s Board of Directors', '1.04\\n        &', 'Form S-3', 'candidates;\\n  &#x2022;not', 'SPA', '3,028,527\\n          &', '\\n  &', 'Grant Date FairValue', 'the Paycheck Protection Program', 'European Union', 'the product;\\n  &#x2022;require', 'Liquidity and Going ConcernSince', 'x2022;refuse', 'Agency', 'Exchangeable Notes.&#160;2025 Exchangeable', 'LSF', '\\n        &#160;&#160;U.S.', 'Iterum Bermuda', 'Articles of Association', 'Employee Matters', 'the product;\\n  &#x2022;seize', '\\n        &', 'SEC', '160;&#160;Commercial paper\\n        &', 'CRL', '7\\n       ITERUM THERAPEUTICS PLCNotes', 'QIDP', 'Share Units', 'Pfizer License', 'Years\\n        &', '\\n  &#x2022;manufacturing', 'Iterum Therapeutics plc', 'the European Union', 'Nasdaq', '\\n    &', 'No &#9744;\\n  Indicate'}"
IVA,
IVVD,"{'INVIVYD', 'Unaudited Interim Financial InformationThe', 'Form S-3', 'treasury', 'HHS', 'commercial use;\\n  &#x2022;our', 'Sequencing Services', 'Commercial Manufacturing Services Agreement', 'Contractual Obligations', 'mAbs', 'Research Collaboration and License Agreement', 'NVD200', 'x2018;serial', 'Invivyd, Inc.', 'The Scripps Research Institute', 'the U.S.;\\n  &#', 'x201c;Commercial Manufacturing', 'ASC 842\\n    &', 'CoV Antibodies', 'the &#x201c;PHP', 'the PHP Work Order', 'the &#x201c;Clinical Master Services', '\\n  &#x2022;the', 'the 2020 Plan.2021 Equity Incentive', 'this Quarterly Report on Form 10-Q', 'the Federal Food, Drug', 'the Securities and Exchange Commission', '\\n  Research and Development Expenses\\n', 'PHP', 'IPR&amp;D', 'the Amended and Restated Bylaws', 'the CoV Antibodies and Products', 'FDA', 'the &#', 'WuXi Biologics', 'Population Health Partners', '\\n  &#', 'Stock-Based Compensation Expense The Company', 'the &#x201c;PHP Effective', 'Clinical Master Services Agreement', 'CANOPY', 'L.P. (&#x201c;PHP&#x201d;)', 'the Commercial Manufacturing Agreement', 'Omicron', 'candidates;\\n  &#x2022;our', 'MA Lease', 'The Commercial Manufacturing Agreement', 'this Quarterly Report on Form 10-Q;\\n  &#x2022;our', 'EUA', '30\\n', '\\n    Research', 'plan\\n    &', 'the Adimab Platform Transfer Agreement', 'SEC', '\\n        &', 'the PHP Warrant', 'activities\\n    &', 'INVYMAB&#153', 'Company', '\\n  Emerging Growth Company Status \\n', 'Condensed Consolidated Statements of Cash Flows \\n', '\\n  Research', 'Research', 'Exhibit 3.2', 'the Company&#x2019;s Current Report', 'COVID-19', 'TSRI', '5,116\\n        &', 'IPO', 'Comparison', 'and\\n  &#x2022;business', '\\n    &', 'the Adimab Assignment Agreement', '\\n  &#x2022;our', 'Products'}"
IXHL,
JAGX,
JANX,"{'MHRA', 'the European Union Parliament', 'candidates;\\n  &#x2022;the', 'and\\n  &#x2022;not', 'EMA', 'the UK Medicines', 'the 2021 Support Services Agreement', 'EEA', 'EU', 'Phase 4', 'the Public Company Accounting Oversight Board', 'x2022;a', 'regulations;\\n  &', 'HTA', 'CPRA', '\\n    Research', 'Form S-1', 'costs.\\n  ', 'the Securities Exchange Act', 'Jefferies', 'COVID-19', 'consistently;\\n  &#x2022;an', 'Principal Financial Officer Pursuant', 'the Merck Agreement', 'licensed;\\n  &', 'BofA Securities, Inc.', 'HHS', 'Merck Sharp &', 'the WuXi Biologics Licensed Technology', 'Avalon BioVentures, Inc.', 'the &#x201c;Merck', 'Medicaid', 'Medicare', 'prices;\\n  &#x2022;convenience', 'FDA', 'WuXi Biologics', 'the Collaboration Targets', 'Jefferies LLC (&#x201c;Jefferies&#x201d', '\\n        Laboratory equipment\\n', 'and\\n  &#', 'the UK Government', 'depreciation\\n        &', 'REMS', 'WuXi Biologics&#x2019', 'Company', 'management&#x2019;s attention', 'UK&#x2019;s', 'USPTO', 'Adopted Pursuant to Section 302', 'the Leahy-Smith Act', 'reimbursement;\\n  &#', 'the Delaware General Corporation Law', 'infringed;\\n  &#', 'and\\n  &#x2022;advance', 'the Cell Line License Agreement (&', 'the European Commission', 'property;\\n  &#', 'innovator&#x2019;s', 'UK&#x2019;s International Data Transfer Agreement / Addendum', 'Roche Holding', 'the Second Collaboration Target', 'acquirer;\\n  &#x2022;the', 'Merck', 'Regulation S-K).\\n  76\\n', 'Our Industry and Business Operations\\n', 'Avalon BioVentures, Inc. (&', 'ContingenciesLicense Agreement', 'concerns;\\n  &#x2022;countries', 'Merck Agreement', 'Support Services Agreement', 'Condensed Financial Statements &', 'Registrant', 'endpoints;\\n  &#x2022;obtaining', 'Akrevia Therapeutics, Sanofi', 'TCA', 'Avalon', 'Genentech', 'directors;\\n  &#', 'the Sarbanes-Oxley Act', 'Dohme Corp.', 'COI Pharmaceuticals', '47\\n', 'Comparison', 'collaborators.\\n  Collaborations', 'Collaboration Target', 'PGR', 'this Quarterly Report', 'California Privacy Protection Agency', 'the First Collaboration Target', '\\n  &', 'including:\\n  &#x2022;the', 'lose;\\n  &#', 'the Registrant&#x2019;s Registration Statement on Form S-1', 'ESPP', 'The Merck Agreement', 'Chugai Pharmaceutical', 'Healthcare', 'European Commission', 'including:\\n  &#x2022;being', 'patents;\\n  &#x2022;issued', 'the Registrant&#x2019;s Current Report', 'all;\\n  &#x2022;loss', 'and\\n  &#x2022;in', 'Related Party', '\\n        &', 'LeasesThe Company', 'SEC', 'including:\\n  &#x2022;efficacy', 'BLA', 'the &#x201c;Collaboration', '\\n  &#x2022;allocated', 'Equity Securities', 'the Northern Ireland Protocol', 'the Registrant&#x2019;s Registration Statement', 'Harpoon Therapeutics', 'the European Union', '\\n    &', 'litigation;\\n  &#x2022;distraction'}"
JAZZ,"{'EC', 'Sumitomo Pharma Co., Ltd', 'the U.S. Attorney&#8217;s Office', 'Lupin Pharmaceuticals, Inc.', 'EU', 'GW', 'HSCT', 'the Term Loan', 'Avadel\\', 'Court', 'Axsome', 'non-FDA', 'Lupin Ltd.', 'ArrangementsThe', 'ContentsWe', 'Jazz Pharmaceuticals plc', 'Lennox-Gastaut', 'the Securities Exchange Act', 'GW Pharmaceuticals PLC', 'Xywav', 'markets).Oncology&#8226;Rylaze&#174', 'ContentsIn', 'Consolidated Financial Statements', '2022.Acquired In-Process Research and Development', 'Alkem', 'the Transaction Litigation', 'the Orange Book', 'this Quarterly Report on Form&#160;10&#8209;Q.', 'Jazz Pharmaceuticals', 'Xyrem REMS', 'AML-MRC', 'Avadel', 'LGS', 'Tecentriq', 'Hikma Labs, Inc.', 'the Securities and Exchange Commission', 'Contingencies IndemnificationIn', 'Epidiolex', 'July&#160;15,&#160;2022', 'Hikma Pharmaceuticals USA Inc.', 'Aetna', 'FDA', 'the Medicaid Drug Rebate', 'the Company Defendants', 'Research and Development Expenses Research', 'GW Pharmaceuticals plc', 'Hikma AG', 'REMS', 'Sumitomo', 'Company', 'TSC', 'Health Care Service Corporation', 'the U.S. Securities and Exchange Commission', 'Intangible Asset Amortization Intangible', 'Amneal Pharmaceuticals', 'Padagis US', 'Lupin Inc', 'Par Pharmaceutical, Inc.', 'filer', 'Jazz Pharmaceuticals UK Holdings Limited', 'June&#160;2020', 'Contents10', 'May&#160;2022', 'NetXywav', 'Euro Term Loan &', 'Roche', 'the U.S. Federal Government', '30,Foreign Exchange Forward Contracts:2023202220232022Loss', 'RiskFinancial', 'the Credit Agreement', 'December&#160;31,&#160;2022.Critical Accounting EstimatesTo', 'the Revolving Credit Facility', 'NDA', 'MSP', 'SCLC', 'Eurohealth (USA),', '30,2023202220232022United States$884,579&#160;$867,835&#160;$2,579,401&#160;$2,466,758&#160;Europe68,971&#160;60,024&#160;194,198&#160;181,831&#160;All other18,590&#160;12,793&#160;48,670&#160;38,662&#160;Total', 'September&#160;30,&#160;2022', 'this Quarterly Report', 'District Court', 'IPR&amp;D', 'Padagis', 'PharmaMar', 'Jazz Pharmaceuticals Public Limited Company', 'OperationsThe', 'the Proxy Statement', 'Zymeworks Inc.', 'the New Drug Application', 'Hikma Pharmaceuticals plc', 'AG', 'SoldBruce', 'the United States Department of Justice', 'the European Union', 'IH'}"
JSPR,
JYNT,"{'\\n  &#x2022;injury', 'years)\\n        &', 'LLC', 'AMD', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n    Interest income\\n    &', '\\n  &#x2022;variations', '\\n  Commission File Number 001-39782', '\\n', 'Medicaid Innovation (&#x201c;CMMI&#x201d;)', '\\n  &#x2022;expansion', 'the University of PennsylvaniaOn April 21, 2023', 'EMA', '\\n  &#x2022;disruptions', 'the Regents of the University of California', '\\n  &#x2022;an', 'Rights Agreement', 'Uneek Mehra\\n', '\\n  &#x2022;termination', 'this Quarterly Report on Form 10-Q', 'the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program', 'the University of California The Company', 'Jefferies LLC', '223,327\\n    &', '\\n  &#x2022;costs', 'B.V. (&#x201c;uniQure&#x201d', 'Molecular Therapeutics, Inc.', 'x2022;a', 'UNITED STATES', 'Effects of Inflation\\n', 'the &#x201c;License', '\\n    Research', 'AGT the Transferred Material', 'UC Agreements', 'ACA', 'Segment Information The Company', 'the Securities Exchange Act', '\\n  &#x2022;expenditures', 'the S-3 Registration Statement', 'COVID-19', 'the License Agreement).Aevitas Therapeutics, Inc.', 'the University of Pennsylvania', 'the Company&#x2019;s 2022 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'the Funding Agreement', 'Registration Statement on Form S-1', 'FASB', '2022\\n         \\n         \\n          &#160;Customer', '\\n  &#x2022;product', 'DirectorPrincipal Executive', '\\n  &#x2022;sufficient', 'the &#x201c;UC Agreements&#x201d', '\\n  &#x2022;publicity', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'CFF', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;general', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'Licensed Products', 'requirements.\\n  &#x2022;Our', 'parties)\\n    &', 'and\\n  &#', 'Registration Statement on Form S-3', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'Center for Medicare &', '\\n  &#x2022;others', 'the Medicaid Drug Rebate Program', 'the Amended uniQure Agreement', 'x201c;CFF', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;loss', '\\n  &#x2022;new', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '99%\\n          &#160;\\n', 'Catalent', 'USPTO', '\\n  &#x2022;impose', '\\n  &#x2022;seize', 'DME', '\\n    &#', 'Report', 'the Delaware General Corporation Law', '\\n  &#x2022;diligence', '\\n  ', 'Capital Requirements \\n', 'the UC Agreements', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD', 'UK Data Protection Act 2018', '\\n  &#x2022;future', 'the Program Advisory Group', '\\n  Interest Rate Sensitivity', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'the Sales Agreement', '497\\n        &', '\\n  &#x2022;coverage', 'Roche', '\\n  &#x2022;exhaustion', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;commencement', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;retention', 'Registrant', 'the UC Regents', '\\n          &', 'technologies.\\n  &#', 'Condensed Statements of Operations', '10\\n       &', '\\n  &#x2022;announcement', 'IPO', 'AWA', '\\n  &#x2022;The', 'companies&#x2019', 'ASU No', 'the Amended uniQure Agreement or the Second uniQure Agreement', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Therapeutic Vector Evolution', 'Form S-3', '\\n  &#x2022;convenience', 'the License Agreement', 'GA', '\\n  &#x2022;We', 'the Funding Agreement Product (&#x201c;Acceptance&#x201d;)', 'the &#x201c;August 2023', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '500\\n    &', 'harmed.\\n  &#x2022;Our', 'European Union', 'Condensed Statements of Comprehensive Loss', '99%\\n          &#', 'the State of Delaware', 'x2022;refuse', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', '\\n  &#x2022;suspend', 'frames.\\n  &', '\\n  &#x2022;the FDA', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Related Party Transactions', 'the Court of Chancery', 'Significant Accounting Policies', 'the &#x201c;Funding Agreement', '\\n        &', 'SEC', 'ATM Offering', 'agreements.\\n', 'Collaboration and License Agreement', 'BLA', 'The CFF Agreement', 'the Centers for Medicare &', 'the University of California and The Trustees of the University of Pennsylvania', '\\n  &#x2022;failure', 'Aevitas Therapeutics, Inc. (&#x201c;Aevitas&#x201d;)', '\\n  &#x2022;reduced', 'the European Union', '\\n  Litigation', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
KA,
KALA,"{'the CIRM Award', 'DEBT&#8203;On', 'IncomeInterest', 'the Health Insurance Marketplace', 'LLC', 'candidates;&#9679;a', 'the First Extension Prepayment', 'The Nasdaq Stock Market', 'Commercial BusinessThere', 'Stanford', 'The Sarbanes-Oxley Act', 'Security Agreement', 'benefits&#8203;$', 'the Option Exchange Program', 'Commercial Business&#8203;$ 46,995&#8203;The Company', 'this Quarterly Report on Form 10-Q', 'the Compensation Committee', '453Commercial costs&#8203;&#8203', 'the California Institute for Regenerative Medicine', 'the &#', 'Lender', 'the Transition Agreement', 'The U.S. Patent and Trademark Office', 'Manufacturers of America', 'Chamber of Commerce', 'Novartis Pharmaceutical Corporation', 'manufacturing&#8203;&#8203', 'candidate.&#8203;KPI-012', 'Janssen Pharmaceuticals, Inc.', 'net&#8203;&#8203', 'CPRA', 'the Open Market Sale Agreement', 'ContentsWe', 'ACA', 'institute a &#8220;poison', 'Need for Additional CapitalWe', 'Jefferies', 'COVID-19', '4&#8203;$ &#', 'Kala Bio, Inc.', 'Combangio', 'ContentsIn', 'the Merger Agreement', 'the Securities Purchase Agreement', 'HHS', 'the Alcon Transaction', 'Boehringer Ingelheim Pharmaceuticals', 'Customers', 'Private Placement', 'the Second Loan Amendment', 'revenues&#8203;$ &', 'Medicare', 'Congress', 'Medicaid', 'the U.S. Dollar', 'FDA', 'the U.S. Chamber of Commerce', 'Loan', 'Novo Nordisk Inc.', 'Note 11', 'Risks Related', 'a&#160;PRIME', 'HIPAA', 'the Private Placement', 'FTC', 'Company', 'INVELTYS', 'Stanford University License Agreement', 'the Fourth Loan Amendment', 'Commercial', 'the California Privacy Rights Act', 'The Remaining Inventory', 'Department of Justice', 'the California Institute for Regenerative Medicine (&#8220;CIRM&#8221', 'the Delaware General Corporation Law', 'CMS', 'the U.S. Patent and Trademark Office', 'Oxford Finance', 'Loan Agreement', 'the 2023 Shelf Registration', 'Commercial Business', 'Prepayments', 'the Medicare Modernization Act', 'the Third Loan Amendment', 'CIRM', '2022:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Three Months Ended &#', 'The Nasdaq Global Select Market to The Nasdaq Capital Market', 'claims.&#8203;In', 'the Dosing Milestone', 'the Committee for Medicinal Products for Human Use', 'Board of Directors', 'ContentsIn March', 'the 2020 Shelf Registration', 'Stanford University', 'Bristol Myers Squibb Company', 'The Board of Trustees of The Leland Stanford Junior University', 'The Nasdaq Capital Market', 'Astellas Pharma US', 'ContentsSince', 'ContentsOur', 'Ceres Merger Sub, Inc.', 'Restated Certificate of Incorporation', 'IRA', 'Combangio, Inc. (&#8220;Combangio&#8221', 'Fortis Advisors LLC', 'Transition Agreement', 'IPO', 'No  &#9744;&#8203;Indicate', 'ExpenseInterest', 'Months Ended &', 'Limbal Stem Cell Deficiency', 'Our Financial Position', 'Form S-3', 'the Loan Agreement', 'the Second Extension Prepayment', 'the Court of Chancery of the State of Delaware', 'ContentsKALA BIO,', 'European Union', 'the U.S. Food and Drug Administration', 'the Biden Administration', 'AstraZeneca L.P.', 'the State of Delaware', 'CHASE', 'the Series E Preferred Stock', 'the Internal Revenue Service', 'Public Offering of Common Stock None', 'the European Medicines Agency', 'the Medicare Prescription Drug', 'Trade Control', 'SEC', 'ATM Offering', 'the General Corporation Law', 'the Budget Control Act', ': &#9679;We', 'Kala Pharmaceuticals, Inc.', 'Nasdaq', 'the European Union', 'the Pharmaceutical Research', 'the Amended and Restated Sales Agreement', 'the European Union.&#8203;93\\nTable', 'due.&#9679;The'}"
KALV,"{'the &#x201c;Sales Agreement&#x201d;)', 'Cantor Fitzgerald &amp', 'others.\\n  Other Income\\n  Other', 'April 2028.The Company', 'U.S. Federal', 'Diluted', 'this Quarterly Report on Form 10-Q', 'FDA', 'February 2032.The Company', '\\n  &#', 'Indicate', '\\n    Research', 'NDA', '\\n    Interest', 'LeasesThe Company', 'SEC', 'KalVista Pharmaceuticals, Inc.', 'Company', 'the Interim Financial Statements', 'HAE', 'Comparison', '\\n    &'}"
KERN,"{'LLC', 'Akerna Exchange', 'Solo and Trellis', 'the Bid Price Notice', 'the SPA.\\n\\n&#160;\\n\\nThe\\nSPA contains &', 'ATM Program', 'the Common Warrants', 'Akerna Merger Co.', 'noncurrent&#160;\\n    &', 'the MJA Note', 'GAAP.\\n\\n&#160;\\n\\nInvestors\\nare', 'the Original Note', 'respectively.\\n\\n&#160;\\n\\nCost\\nof', 'Merger Sub', 'Form S-1', 'Principal Executive', 'Commission', 'MJF', 'the Securities Exchange Act', 'Securities Purchase Agreement', 'POSaBIT Systems Corp', 'Accounting Standard Update', 'The Special Voting Preferred Stock', 'SaaS', 'Gryphon Digital Mining, Inc.', 'the Securities Purchase Agreement', 'the Discontinued Group', 'the Financial Accounting Standards', 'MTech', 'the Subordination Agreement', 'Security', 'Ample', 'Principal Financial', '\\n\\n&#160;\\n\\n\\n', 'Exhibit 3.1', 'Akerna Corp.', 'MJ Freeway Acquisition Co (&', 'SMB', 'the Private Warrants', 'Exhibit 4.3', 'sciences, inc.', 'HT\\nInvestments MA', 'the Company under\\nthe Amended', 'Common Stock', 'Ancillary Agreements\\n\\n&#160;\\n\\nOn\\nMay', 'Permitted Indebtedness', 'Securities Litigation Reform Act', 'net&#160;\\n    &', '2023\\n(the &#', 'MJA', 'the Security Agreement', 'ASU', 'Permitted Liens', 'the Quarterly Report on Form 10-Q', 'the Current Report on Form 8-K', 'the Senior Debt Documents', 'HT Investments MA', 'Board of Directors', 'the Guaranty Agreement', 'Restated New Note Transaction', 'the Holders of the Senior Convertible Notes', 'Exhibit 2.4', 'Ample, Trellis', 'Gryphon Digital Mining, Inc. (&', 'the New Note Transaction Documents', 'cash&#160;\\n    $&#', 'MJ Acquisition', 'the Underwriter Warrants', 'TreCom', 'Viridian Sciences Inc.', 'SPA', 'this Quarterly Report', 'Basis of Presentation', 'Common Stock&#160;\\n    &', 'MJ Freeway Acquisition Co.', 'the Current Report on Form', 'Alleaves', 'the Sale Transaction', 'marketing&#160;\\n    &', 'LCA', 'the Exchange Agreements', 'the Subordinated Debt Documents', 'tax&#160;\\n    &#', 'solely\\nto', 'the Exchangeable Share Support Agreement', 'revenue.\\n\\n&#160;\\n\\nProduct\\nDevelopment Expenses', 'rights.\\n\\n&#160;\\n\\nWe', 'GAAP', '\\n    &', 'the Original Security Agreement'}"
KIDS,
KMDA,
KNSA,"{'2022.Legal ProceedingsThe Company', 'MHRA', 'EMA', 'Contentsmanufacture', 'the &#8220;Primatope', 'ContentsCollaboration Expenses Collaboration', 'EU', 'SJIA', 'the BIDMC Agreement', 'BIDMC', 'Tumor Necrosis Factor', 'Regeneron Pharmaceuticals,&#160;Inc', 'the Genentech License AgreementAs', 'ContentsWe', 'the Huadong Collaboration Agreements', 'COVID-19', '99,135&#8203;&#8203', 'ContentsIn', 'the Organization for Economic Cooperation and Development&#39;s (&quot;OECD&quot', 'Biogen Agreement', 'the Second Biogen Amendment', 'Anti-Kickback Statute', 'Base Erosion and Profit Shifting', 'Genentech, Inc.', 'ContentsKINIKSA PHARMACEUTICALS', 'Beth Israel Deaconess Medical Center License AgreementIn 2019', 'Medicaid', 'Medicare', 'labs (&#8220;CTLs&#8221', 'GDPR', 'the European Patent Office', 'ContingenciesLicense AgreementsThe Company', 'FDA', 'ContentsAny', 'the Licensed Products', 'GMP', 'ContentsLicense and Collaboration Revenue &#8203;We', 'the Regeneron Agreement', 'Consolidated Financial Statements11Item&#160;2', 'Risks Related to Ownership of Our Common SharesThe', 'the UK Government', 'Indemnification AgreementsThe Company', 'Risks Related', 'the Medicaid Drug Rebate Program', 'REMS', 'FTC', 'Company', 'ContentsItem&#160;2.&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition', 'United States;&#9679;a', 'USPTO', 'Huadong Collaboration Agreement', 'Results of Operations', 'the Leahy-Smith Act', 'The Regeneron Agreement', 'amounts)(Unaudited)The MedImmune Agreement', 'the California Consumer Privacy Act', 'GLP', 'CRO', 'the European Commission', 'ESG', 'CMS', 'UK Data Protection Act 2018', 'deductible.&#8203;In', 'the Biogen Agreement', 'non-EU', 'Orphan Drug', 'Genentech License Agreement', 'the U.S. Internal Revenue Code', 'the Genentech Effective Date', 'U.S. Holder', 'CommitmentsThe Company', 'ContentsIn February 2022', 'the Organization for Economic Cooperation and Development', 'Contentsresult', 'uncertainties.&#8221', 'GM', 'the Genentech License Agreement', 'FMF', 'Novartis Pharmaceuticals Corporation', 'Genentech', 'Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.', 'ContentsResults of Operations Comparison', 'No  &#9744;&#8203;Indicate', 'ARCALYST', 'Months Ended &', 'Our Financial Position', 'September&#160;30,&#160;2022', 'to&#160;develop', 'this Quarterly Report', 'Regeneron', 'FDA&#8217;s', 'Regeneron Pharmaceuticals, Inc. (&', 'the U.S. Food and Drug Administration', 'MAA', 'MKD', 'GCP', 'BLA', 'Territory', 'the Bermuda Register of Companies', 'the Federal Trade Commission Act', 'Bermuda', 'MedImmune', 'Contentsthe Company', 'The Genentech License Agreement', 'ContentsCollaboration', 'Biogen'}"
KNTE,"{'PGR', 'API', 'Anti-Kickback Statute', 'CMS', 'the Personal Information Protection Law', 'EMA', 'Loxo Oncology', 'this Quarterly Report on Form 10&#8209;Q', 'Medicaid', 'Medicare', 'Congress', 'FCPA', 'Form', 'this Quarterly Report on Form 10-Q', 'the Global Colon Cancer Association', 'the U.S. Food and Drug Administration', 'the Consolidated Statements of Cash Flows\\n', 'ESPP', 'FGFR3', 'GDPR', 'FDA', 'the Kinnjiu Transaction', 'Medicaid Services', 'the U.S. Foreign Corrupt Practices Act', 'RAF', 'the Organization for Economic Cooperation and Development', 'the Securities Markets and Ownership of Our Common', 'Financial Position', 'FGFR2-', 'Healthcare', 'U.S. Treasury securities\\n\\n    &', 'Manufacturers of America', 'Chamber of Commerce', 'To\\n        ', 'CPRA', 'PIPL', 'REMS', 'SEC', 'the following:\\n\\n      &#160;\\n\\n      Risks Related', 'ATM Offering', 'Company', 'NOL', 'the U.S.', 'USPTO', 'the National Infusion Center Association', 'COVID-19', 'KIN-3248', 'the Pharmaceutical Research', 'Nasdaq', 'the European Union', 'company.&#8221', 'property.\\n'}"
KOD,
KPRX,
KPTI,"{'\\n  &#x2022;obtain and/or', '\\n  &#x2022;injury', 'all;\\n  &#x2022;the', 'LLC', '\\n  &#x2022;effectively', 'markets;\\n  &#x2022;workforce', 'EC', 'Reliance', '\\n', 'Antengene Therapeutics Limited', '\\n  &#x2022;expand', 'EMA', 'HCR Potomac Fund', '\\n  &#x2022;potentially', 'EEA', 'EU', 'requirements;\\n  &#x2022;collaborators', 'x201c;Long-Term', 'x2022;a', 'Indicate', 'the &#x201c;Revenue', '26\\n', 'CPRA', 'The Biden Administration', 'Commission', '340B Program', 'stock.\\n  Provisions', '\\n  &#x2022;not', '\\n  &#x2022;commercialize XPOVIO', '\\n  &#x2022;production', 'Jefferies', '\\n  &#x2022;establishing', 'COVID-19', 'L.P. (&#x201c;HCR&#x201d;)', '\\n  &#x2022;obtaining', 'disruptions.\\n', '\\n  &#x2022;adverse', 'management&#x2019;s', 'Cover Page Interactive Data File', 'Chamber', '\\n  &#x2022;significant', '\\n  &#x2022;product', '&#x201c;our&#x201d;)', 'U.S. Food and Drug Administration', 'manufacturers&#x2019', 'goods\\n        &', 'Medicaid', 'the Securities and Exchange Commission', 'Congress', '\\n  &#x2022;any', 'Medicare', '\\n  &#x2022;allow', '\\n  &#x2022;have', 'FDA', '\\n  &#x2022;collaborations', '\\n  &#x2022;clinical', '\\n  &#x2022;disagreements', '\\n  &#x2022;maintaining', 'and\\n  &#', 'the Revenue Interest Agreement', '\\n  &#x2022;loss', 'the Medicaid Drug Rebate Program', '\\n  &#x2022;regulatory', 'HIPAA', 'HCR Collateral Management', 'the FDA&#x2019;s Accelerated Approval Program', 'the &#x201c;Amended', 'the &#x201c;Amended Revenue Interest Agreement&#x201d;).\\n  ', 'and\\n  &#x2022;negative', '\\n  &#x2022;initiating', 'losses.\\n  &', 'the California Privacy Rights Act', '\\n  &#160;\\n', 'FCA', '\\n  &#x2022;unexpected', 'L.P., HealthCare Royalty Management', 'Note 10', 'L.P.', 'the Delaware General Corporation Law', '\\n  ', 'Chamber&#x2019;s', 'CMS', '\\n  &#x2022;interruptions', 'cancer;\\n  &#x2022;any', 'the conditional marketing authorization', 'Contracts with Customers', '\\n  &#x2022;manufacture XPOVIO', 'the &#x201c;Menarini', '\\n  &#x2022;the', '340B Programs', 'the U.S. Patent and Trademark Office (&#', 'HCRP Overflow Fund', 'Promedico Ltd.', '\\n  &#', '\\n  &#x2022;enrollment', '\\n  &#x2022;collaborators', 'L.P. and HealthCare Royalty Partners IV', 'Amended Revenue Interest Agreement', '\\n  &#x2022;patients', 'Registrant', '\\n  &#x2022;navigating', '\\n  &#x2022;decreased', '\\n  &#x2022;require', 'NDA', 'L.P. (&#x201c;HCR&#x201d', 'Office of Foreign Asset Control', 'consent;\\n  &#x2022;limit', 'Healthcare Royalty Partners III', '\\n  &#x2022;negative', 'the Amended Revenue Interest Agreement', 'Orphan Drug Designation', 'IRA', '47\\n', '\\n  &#x2022;our', 'Berlin-Chemie AG', 'HCR Stafford Fund', 'Hamas', '\\n  &#x2022;reliance', '\\n  &#x2022;current', '\\n  &#x2022;regulators', 'L.P., HealthCare Royalty Partners IV', 'the Menarini Group', 'CJEU', 'healthcare', '\\n  &', 'Regulation S-K).\\n  &', '\\n  &#x2022;delays', 'the Pediatric Research Equity Act', 'Nasdaq&#x2019;s', 'HealthCare Royalty Partners III', 'HCR', '\\n  &#x2022;business', '\\n  &#x2022;interruption', 'FORUS Therapeutics Inc.', 'the Interactive Data File', 'Risks Related to', 'institute a &#x201c;poison pill&#x201d', 'Good Manufacturing Practice', 'prospects.\\n  Efforts', '\\n  &#x2022;equipment', 'HCR Canary Fund', '\\n  &#x2022;obtain', 'Healthcare', 'Accounting Standards Codification', '\\n  &#x2022;authorize', 'Employee Matters', 'HCR Molag Fund', '\\n        &', 'SEC', 'XPOVIO', '2025;\\n  &#', 'the Foreign Corrupt Practices Act', 'the Menarini Agreement', '\\n  &#x2022;failure', '\\n  &#x2022;reduced', '\\n  &#x2022;actual', 'Nasdaq', '\\n    &'}"
KRMD,"{'FASB', 'LLC', 'STOCK-BASED COMPENSATION\\n\\n&#160;\\n\\nThe Company', 'the Private Securities Litigation\\nReform Act', 'achieved.\\n\\n&#160;\\n\\nWe', '&#8220;expect&#8221', 'Number\\nExercisable\\n    &', 'the words &#8220;estimate,&#8221', '\\n    &', 'ASU No', 'Company', 'AON Premium Finance'}"
KRON,"{'ASC', 'Condensed Financial Statements', 'IndemnificationIn', 'the Delaware General Corporation Law', 'LLC', 'Securities Act).The', 'ProceduresWe', 'the Roche Group (&#8220;Genentech&#8221', 'Anti-Kickback Statute', 'Physician Payments Sunshine Act', 'ESG', 'CMS', 'this Quarterly Report', 'AML', 'Contractual Obligations', 'section &#8220;Impairment', 'The Sarbanes-Oxley Act', 'Genentech, Inc.', 'the Board of Directors', 'Recent Accounting PronouncementsThe Company', 'Gilead Sciences, Inc.', 'the Court of Chancery of the State of Delaware', 'CONTINGENCIESAmended Research and Development Services', 'FCPA', 'Medicaid', 'Medicare', 'SYK', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'Tempus Research and Development Services', ': &', 'Hit Program', 'Dear Healthcare Provider', 'EU', 'FDA', 'the Gilead Asset Purchase Agreement', 'Tempus Labs, Inc.', 'Operating Lease Right-of-Use Asset', 'Healthcare', 'Condensed Financial', 'Yes or &#9744', 'Risks Related', 'the Children&#8217;s Health Insurance Program', 'the Collaboration and License Agreement', 'HIPAA', 'CPRA', 'AI', 'Accrued Research and', 'Bellco Capital', 'ExpensesOur', 'REMS', 'SEC', 'Form S-1', 'Gilead Asset Purchase Agreement', 'the Financial Accounting Standards Board', 'Company', 'Collaboration and License Agreement', 'the Securities Exchange Act', 'Restated Certificate of Incorporation', 'BIO', 'Genentech', 'Tempus', 'Research', 'USPTO', 'COVID-19', 'IPO', 'Gilead', 'the Health Information Technology for Economic and Clinical Health Act', 'Development ExpensesThe', 'the Amended Tempus Agreement', 'Department of Justice', 'Development ExpensesAs', 'Restated Bylaws', 'The Leahy-Smith Act', 'GLP-Tox-ready', 'Qualitative Disclosures About Market'}"
KROS,"{'The Sarbanes-Oxley Act', 'The General Hospital', 'the Annual Report', 'this Quarterly Report on Form 10-Q', 'EU', 'Phase 4', 'KER-065', 'HTA', 'CPRA', 'FlowsThe', 'Form S-1', 'market&#8221', 'ACA', 'Licensing Agreements2016', 'Operating Expenses Research and Development Expenses Research', 'COVID-19', 'The Tech Transfer Agreement', 'Sarbanes-Oxley Act Section 404(b', 'Santhera Pharmaceuticals', 'Waltham Lease', 'the &#8220;Hansoh', 'HHS', 'the ""Shelf Registration Statement', 'the Tech Transfer Agreement,', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'NetTotal', 'SVB Securities', 'FDA', 'Health Canada', 'FAIR VALUE', 'The General Hospital Corporation', 'Center for Medicare &', 'Healthtech Co., Ltd.', 'the Medicaid Drug Rebate Program', 'REMS', 'Silicon Valley Bank', 'GDF8', 'Regulation S-K.81ITEM 6', 'Company', 'ReveraGen Biopharma, Inc', 'the California Privacy Rights Act', 'Keros Therapeutics, Inc.', 'GLP', 'the Delaware General Corporation Law', 'the European Commission', 'CRO', 'Italfarmaco', 'the Hansoh Agreement', 'CMS', 'the MGH Agreement', 'MGH', 'the Tech Transfer Agreement', ': &#9632;decreased', 'the Nasdaq Stock Market', 'the Safety Review Committee', 'Duchenne', 'Swedish Orphan Biovitrum AB', 'CMO', 'CTI BioPharma Corp.', 'Leerink Partners', 'the Sarbanes-Oxley Act', 'IPO', 'Bristol-Myers Squibb Company', 'DMD', 'The Health Technology Assessment', 'Form S-3', 'CONTRACTS', 'Exclusive Patent License Agreement', 'MDS', 'Medicaid Innovation', 'ATM', 'Acceleron', 'the U.S. Food and Drug Administration', 'CTR', 'HDAC', ': &#9642;salaries', 'Medicaid Services', 'The Hansoh Agreement', 'development(34,140)(21,039)General', 'SEC', 'the Shelf Registration Statement', 'GCP', 'Territory', 'the Federal Trade Commission Act', 'the Centers for Medicare &', 'the Registration Statement'}"
KRRO,
KRTX,"{'LLC', 'The Arch Street Lease', 'Form S-3', 'the Arch Street Subleases', 'Goldman Sachs &', 'Fair Value of Financial Assets', 'LLC (&#34;GFB&#34;)', '\\n', 'Goldfinch', 'Incentive Plan', 'the 2023 Registration Statement', 'ABC', 'Contractual Obligations and Other Commitments \\n', 'ATM Program', 'the High Street Premises', 'Stockholders&#x2019', 'x2014;\\n        &', 'stockholders&#x2019', '27\\n', 'EMERGENT', 'the Lilly License Agreement', 'KarXT', 'the &#x201c;Patent License', 'License', '\\n  &#', 'the Patent License Agreement', 'PureTech Health', 'the Zai License Agreement', 'the Zai License Agreement, Zai', 'Adopted Accounting Pronouncements \\n', '\\n        &', 'SEC', 'the 2023 Distribution Agreement', 'activities\\n    &', 'Eli Lilly', 'Company', 'Milestone Payments', 'the Securities Exchange Act', '\\n  Research', 'Certificate of Incorporation', 'Leerink Partners', 'the Sarbanes-Oxley Act', 'CNS', 'Regulation S-K', 'Adopted Pursuant to Section 302', 'Principal Financial Officer Pursuant', 'IPO', 'Future Funding Requirements \\n', 'Goldfinch Bio', '\\n  &#160;\\n', '34;non-Rule 10b5-1', '\\n    &', 'The Lilly License Agreement', 'TRPC4/5 channel', 'other:\\n        &', 'License AgreementsAcquisition of'}"
KRYS,"{'ASC', 'FASB', 'CGMP', 'Form S-3', 'Anti-Kickback Statute', '2022.LeasesThe Company', 'Consolidated Statements', 'ContingenciesAgreements', 'PeriphaGen', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'Periodic Report', 'this Quarterly Report on Form 10-Q', 'Development ExpensesResearch', ': &', 'Consolidated Statements of Cash Flows', 'Diluted$2.79&#160;$(1.17)$0.08&#160;$(4.24)5.&#160;&#160;&#160;&#160;Fair Value InstrumentsThe', 'FDA', 'Qualitative Disclosures About Market Risk&#160;36Item', 'Phase 4', 'the Physician Payments Sunshine Act', 'Consolidated Statements of Operations and Comprehensive Income', 'netProduct', 'Krystal Biotech, Inc.', 'No &#9744;Indicate', 'Risks Related', 'Delaware C-corporation', 'SEC', 'the New Placement Shares', 'VYJUVEK; &', 'Krystal Biotech', 'Company', 'USE OF PROCEEDSNone', 'CostGrossUnrealizedGainsGrossUnrealized(Losses)Aggregate', 'the Sarbanes-Oxley Act', 'Consolidated Balance Sheets', 'FCA', 'The New Placement Shares', 'VYJUVEK', 'Our Business Operations', 'Financial Accounting Standards Board', 'Condensed Consolidated Financial Statements'}"
KTRA,"{'Series C Convertible Preferred Stock', 'LLC', 'CRO', 'CMBC', 'Performance Stock Unit Award Agreement', 'LLC AgreementsOne', 'Valent', '\\n    Research and development &', 'the National Institutes of Health', 'the Company&#x2019;s Articles of Incorporation', 'Valent&#x2019;s', 'GAAP\\n    &#160;\\n    &#160;\\n    1,859\\n    &#160;\\n    &#160;\\n    &#160;\\n    3,171\\n    &', 'EXHIBIT INDEX\\n  &', 'deemed &#x201c;filed&#x201d', 'reference.\\n  &', 'this Quarterly Report on Form 10-Q.\\n  &#', 'Global Partners', 'Kintara Therapeutics, Inc.', 'DelMar Pharmaceuticals, Inc.', 'Exhibits.\\n  &#160;\\n', 'results.\\n  &', 'The Series C Preferred Stock', 'United States', 'Adgero Biopharmaceuticals, Inc. (&', 'the Interactive Data File', 'The Nasdaq Capital Market LLC', 'FDA', 'Valent Technologies', '\\n  &#', 'thousands)\\n        &', 'BC) Ltd.', 'BC', 'Stock\\n        &', 'Restricted Stock Unit', 'Non-GAAP\\n    &', 'GAAP\\n    &#160;\\n    &#160;\\n    1,103\\n    &', 'the &#x201c;Valent Exchange', 'and\\n  &#', 'ended\\n  &', '\\n    &', 'the &#x201c;Exchange', 'Development\\n  Research', 'The Nasdaq Capital Market', 'capabilities;\\n  &#x2022;the', '\\n    Research', 'Principal Financial and Accounting', 'technologies;\\n  &#x2022;the', '\\n        &', '\\n    Interest', 'Berry Only Inc.', 'SEC', 'the Valent Assignment Agreement', 'Company', 'Del Mar Pharmaceuticals', 'the Securities Exchange Act', 'Research', 'the ATM Facility', 'the Sarbanes-Oxley Act', 'No &#', 'Comparison', 'Berry Only, Inc.'}"
KTTA,"{'Medicaid', 'Medicare', 'Company', 'the Public Warrants', 'the Representative Warrants', 'approval.\\n\\n&#160;\\n\\nWe', 'See &#', 'net&#160;\\n', 'Pasithea Clinics Corp.', 'Regulation S-K', 'Exchange', 'meet\\noperational', 'Significant Accounting', 'Unaudited Condensed Consolidated Financial Statements', 'Consolidated Financial Statements', '2 &#8211;\\nSummary', 'statements\\nare', 'LEASES\\n\\n&#160;\\n\\nLaboratory Lease &#8211'}"
KURA,"{'the Approval Milestone', '\\n  &#x2022;injury', 'HCT', 'LLC', 'Janssen&#x2019;s', 'AML', 'DS', 'candidates;\\n  &#x2022;the', 'Security Agreement', 'the Tranche 1 Loan', '42\\n  \\n  &#160;\\n  &#x2022;product', 'Novartis Pharma AG', 'EU', 'biologics.\\n  &#x2022;Our', 'the Prior Agents', 'Credit Suisse Securities', 'commercialization.\\n  Specifically', 'NSCLC', 'Principal Executive', 'Comprehensive Loss &', 'the Financial Accounting Standards Board', 'Breakthrough Therapy Designation', 'results.\\n  &#x2022;We', '\\n  &#x2022;recall', 'IRF', 'COVID-19', 'candidates;\\n  &#x2022;competition', 'KOMET-001', 'HRAS', 'Financial Officer', 'HHS', '\\n  &#x2022;significant', '\\n  &#x2022;substantial', 'Internal Control', '\\n  &#x2022;refusal', 'Medicaid', 'Medicare', '\\n  &#x2022;any', 'the Delaware General Corporate Law', 'the University of Michigan', '\\n  &#x2022;there', 'FDA', 'the Overallotment Option', '\\n  &#x2022;clinical', '\\n  &#x2022;may', 'and\\n  &#', 'SEC Rule 13a-15(b', 'development.\\n  &#x2022;Failure', 'candidates;\\n  &#x2022;initiate', 'candidates;\\n  &#x2022;our', '\\n  &#x2022;warning', '\\n  &#x2022;continue', '\\n  &#x2022;loss', '\\n  &#x2022;requirements', 'AI', '\\n  &#x2022;fines', '\\n    &#160;&#160;&#160;&#160;4.3\\n    &', 'profits.\\n', 'the Leahy-Smith Act', '\\n  &#x2022;injunctions', 'the Tranche 4 Loan', 'this Quarterly Report on Form', 'Cantor Fitzgerald &amp', 'Critical Accounting Policies and Management Estimates\\n', 'CMS', 'BMS', 'Critical Accounting Policies', 'candidates;\\n  &#', 'and\\n  &#x2022;manage', 'Oxford Finance', 'University of Michigan', '\\n  &#x2022;the', 'Mirati Therapeutics, Inc.', 'and\\n  &#x2022;our', 'This Quarterly Report on Form 10', 'the Sales Agreement', 'the Maturity Date', 'the Commercialization of Our Product Candidates \\n  ', 'Cantor Fitzgerald &', '\\n  &#x2022;suspension', '\\n  &#', 'Lenders', '\\n  &#x2022;catastrophic', 'FINRA', 'candidates;\\n  &#x2022;establish', 'NDA', 'NPM1', 'the European Union&#x2019;s General Data Protection Regulation', 'Leerink Partners', 'the Sarbanes-Oxley Act', '\\n  &#x2022;inability', 'Economy,&#x201d', 'Agents', 'Bristol-Myers Squibb Company', '\\n  &#x2022;delay', 'Results of Operations &', 'relationships;\\n  &#x2022;the', '\\n  &#x2022;our', 'Condensed Financial Statements', 'Form S-3', 'the Loan Agreement', '\\n  &#x2022;regulators', 'this Quarterly Report', 'Hercules Capital, Inc.', 'Stockholders&#x2019; Equity &#', 'Management&#x2019;s', 'Accelerated Approval', 'the market;\\n  &#x2022;any', '\\n  &', 'ATM', 'including:\\n  &#x2022;the', '\\n  &#x2022;delays', 'Hercules Capital', 'ESPP', 'Canada&#x2019;s Personal Information Protection and Electronic Documents Act', 'Co.', 'candidates.\\n  &#x2022;We', 'the Federal Food, Drug and Cosmetic Act', 'PIK3CA', 'the future development and/or commercialization', '\\n  &#x2022;restrictions', 'representatives.\\n', 'capabilities.\\n', 'efforts;\\n  &#x2022;incur', '\\n  &#x2022;withdrawal', '\\n        &', 'SEC', '\\n  &#x2022;lack', 'Novartis', 'the U.S. PTO', '\\n  &#x2022;reduced', 'The University of Michigan', 'the European Union', 'period.\\n  &#x2022;We', '\\n    &', 'cutoff.\\n  Durable'}"
KYMR,"{'ASC', '\\n  &#x2022;payments', 'the 2021 Lease', 'Vertex&#x2019;s', 'Intellectual Property Litigation and Infringement Claims\\n', 'the Original Sanofi Agreement', 'The Sanofi Agreement', 'the Federal Reserve', 'the Company&#x2019;s Annual Report on Form 10-K', '\\n  &#x2022;costs', 'EU', 'the Vertex Agreement', 'Phase 4', 'Collaboration Target 2', 'the Internal Revenue Code', 'x2022;a', 'Accounting Standards Update', '\\n    Research', 'Collaboration Target 2.10\\n     &', 'Form S-1', 'The Amended Sanofi Agreement', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Collaboration Target 1.The Company', '\\n  &#x2022;expenses', 'Sanofi', 'x2022;a court', 'HHS', 'x2022;if', 'MDM2 programs.\\n  General', '\\n  &#x2022;substantial', 'success.\\n  &#x2022;If', '\\n  &#x2022;contract', 'Risks Related to Drug Development and Regulatory', 'the Securities and Exchange Commission', 'Medicare', 'Medicaid', 'Series B-1 Preferred Stock', 'the Delaware General Corporate Law', 'x2014;\\n        &', 'PIPE', 'the European Patent Office', '\\n  &#x2022;there', 'FDA', 'the Sanofi Agreement, Sanofi', 'any.\\n  &#x2022;Even', 'realized.\\n  Item 4', 'the Amended Sanofi Agreement', 'Related-Party Transactions Other', 'products.\\n  &#', '\\n  &#x2022;regulatory', 'the U.S Food and Drug Administration', 'REMS', 'Company', 'the Department of the Treasury', '\\n  &#x2022;facilities', 'USPTO', 'periods.\\n  &', '\\n  &#160;\\n', '70\\n', 'Cowen', 'IRAK4', 'SVB', 'Patent and Trademark Office', 'Signature Bank', 'CMS', 'the &#x201c;Indemnified', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', 'the U.S. Department of Health and Human Services', '\\n  &#x2022;infringement', 'prevented.\\n  &#x2022;Our', 'the Sanofi Agreement', '\\n  &#', 'Vertex', '\\n  &#x2022;collaborators', 'the United States.&#160;The Sanofi Agreement', 'Orphan Drug Designation', 'CMO', 'FDIC', 'Share Purchase Agreement', 'factors.\\n  &', 'the indemnified party', 'IPO', '47\\n', 'Comparison', 'This Quarterly Report', 'Collaboration Target', '\\n  &#x2022;our', 'Collaboration Target 1', 'the Accounting Standards Codification', 'Organization and Nature of Business Kymera Therapeutics, Inc.', 'Unaudited Condensed Consolidated Financial Statements\\n    ', 'harmed.\\n  &#x2022;If', 'harmed.\\n  &#x2022;Our', 'Risks Related to', 'the Indemnified Parties', '\\n  &#x2022;disputes', 'Medicaid Services', 'the Internal Revenue Service', 'expense.\\n  &#x2022;We', '\\n        &', 'SEC', 'Kymera Securities Corporation', 'agreements.\\n', 'GCP', 'the Centers for Medicare &', 'Collaboration Targets 1 and', 'the European Union', '\\n    &'}"
KZIA,
KZR,"{'ASC', 'years)\\n        &', 'LLC', 'the ATM Agreement', 'consistently;\\n  &#x2022;delay', '\\n    Interest income\\n    &', 'candidates;\\n  &#x2022;the', 'Oxford', 'collaboration.\\n  &', 'and\\n  &#x2022;other', '\\n  &#x2022;developments', 'PALIZADE', 'the Center for Medicare', 'Condensed Consolidated Financial StatementsThe', 'the Compensation Committee', 'directors;\\n  &#x2022;require', 'Status', 'Phase 4', 'capacity;\\n  &#x2022;issues', 'the Internal Revenue Code', '26\\n', 'therapies;\\n  &#x2022;the', '\\n    Research', 'factors.\\n  Research and Development Expenses\\n  Research', 'zetomipzomib.\\n  &#x2022;If', 'candidates;\\n  &#x2022;general', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'NOL', 'Outstanding\\n        &', 'candidates;\\n  &#x2022;operations', 'Secured Overnight Financing Rate', 'The Wall Street Journal', 'HHS', 'candidates;\\n  &#x2022;obtaining', 'gain.\\n  ', 'and\\n  &#x2022;require', 'include:\\n  &#', 'Medicare', 'Diluted', 'Congress', 'Medicaid', 'x2014;\\n        &', 'LLC (&#x201c;Oxford', 'all;\\n  &#x2022;breach', 'FDA', 'Financial Operations Overview\\n', 'millions):\\n  &#160;\\n', 'collaborators.\\n  &#x2022;Success', 'and\\n  &#x2022;any', 'reimbursement;\\n  &#x2022;the', 'Loan', 'the Advisor Agreement', 'and\\n  &#', 'EGC', 'candidates;\\n  &#x2022;our', 'International Council for Harmonisation', 'REMS', 'the \\n  &#160;\\n', 'the Onyx License Agreement', 'Company', 'requirements;\\n  &#x2022;economic', 'and\\n  &#x2022;the', 'licenses;\\n  &#x2022;the', 'USPTO', 'Canada&#x2019;s Anti-Spam Legislation', 'the board;\\n  &#', '\\n    Interest expense\\n    &', 'Adopted Pursuant to Section 302', 'the Workforce Reduction', 'effort;\\n  &#x2022;expenses', 'and\\n  &#x2022;business', 'Cowen', 'Onyx Therapeutics, Inc.', 'Onyx License Agreement', 'the Delaware General Corporation Law', 'ASU', 'CRO', 'candidates;\\n  &#', 'Principal Financial Officer', 'relationships;\\n  &#x2022;risks', 'Oxford Finance', 'Loan Agreement', 'manufacturing;\\n  &#x2022;costs', 'candidates;\\n  &', 'directors;\\n  &#x2022;limit', 'community;\\n  &#x2022;effectively', 'Success', 'and\\n  &#x2022;our', 'liabilities.\\n  &#', 'the London Interbank Offered Rate (&#', 'The Loan Agreement', 'the Personal Information Protection and Electronic Documents Act', 'KZR-261\\n    &', 'reimbursement;\\n  &#x2022;our', 'zetomipzomib;\\n  &#x2022;Everest', 'company;\\n  &#', '\\n  &#', 'the Kirk Agreement', 'the Common Stock', 'NDA', 'The U.S. Department of Health and Human Services', 'the &#x201c;Option Repricing&#x201d;)', 'consent;\\n  &#x2022;limit', 'time.\\n  &#x2022;We', 'prices;\\n  &#', 'CMO', 'the Sarbanes-Oxley Act', 'and\\n  &#x2022;facilities', 'prospects.\\n  &', '47\\n', 'Comparison', 'compensation;\\n  &#x2022;fees', 'the Company&#x2019;s Board of Directors', '\\n  &#x2022;Patent', 'Cowen and Company', 'Our Financial Position', 'Form S-3', 'the Loan Agreement', '\\n  &#x2022;We', 'Medicaid Innovation', 'markets;\\n  &#x2022;compliance', '\\n  &', 'products.\\n  Disputes', 'harmed.\\n  &#x2022;If', '44\\n', 'development programs;\\n  &#', 'x2022;strategic', 'EU GDPR&#x2019;s', 'Onyx', 'CME', 'operations.\\n  &', 'Healthcare', 'litigation;\\n  &#x2022;business', '\\n    ', 'Everest License Agreement', 'Advisor Agreement', 'Related Party', '\\n        &', 'the Everest License Agreement', 'SEC', 'SOFR', 'GCP', 'x201c;Loan', 'cGMP;\\n  &#x2022;establishing', 'the Fowler Agreement', 'price.\\n  &', 'efforts;\\n  &#', 'communities;\\n  &#', 'candidates.\\n  Success', '\\n    &', 'regulations;\\n  &#x2022;developments', 'Onyx Therapeutics', 'decline.\\n  &#', 'and\\n  &#x2022;securing'}"
LAB,
LABP,"{'costs.\\n  &', 'the Company&#x2019;s Registration Statement on Form S-1', 'Form S-3', 'the Securities Purchase Agreement', 'reference.\\n  &', 'The 2022 Shelf Registration Statement', 'this Quarterly Report', 'Internal Control Over Financial Reporting\\n', '\\n  &', 'Redemption Agreement', 'Crohn&#x2019;s', 'Retained Compounds Royalty AgreementPursuant', 'the Acquired Compounds', 'Organization and Description of the Business', 'IR', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Securities and Exchange Commission', 'Significant Accounting PoliciesBasis', 'LABP-111', 'ROU', 'Purchasers', 'NLRX1', '\\n  &#', 'x201c;Private', '4,862\\n    &', 'the &#x201c;Acquired Compounds&#x201d;)', '\\n    Research', 'the Private Placement', '\\n    Interest', 'LeasesThe Company', 'SEC', 'Principal Executive', 'Company', 'Territory', 'the &#x201c;Company&#x201d;)', 'the Listing Qualifications Department of The Nasdaq Stock Market (&#x201c;Nasdaq&#x201d;)', 'NOD', 'the Securities Exchange Act', 'costs.\\n  Research', 'the 2022 Shelf Registration Statement', 'NX-13', 'Landos Biopharma Australia Pty Ltd.', 'IPO', 'Results of Operations', 'Inherent Limitations on Effectiveness of Internal', 'the Pre-Funded Warrants', 'Comparison', 'Nasdaq', 'General Instruction I.B.6', '\\n    &', 'the Purchase Agreement', 'Products'}"
LBPH,"{'candidates;\\n  &#x2022;the', 'and\\n  &#x2022;state', 'EEA', 'companies;\\n  &#x2022;selection', 'EU', 'and\\n  &#x2022;provide', 'reputation.\\n', 'Phase 4', 'Suite', 'x2022;a', '\\n  &#x2022;uncertainties', 'therapies;\\n  &#x2022;the', 'the CAMELLIA-TIMI', 'the Children&#x2019;s Health Insurance Program', 'revenue.\\n  &#', 'the Arena License Agreement', 'the European Economic Area', '\\n  Research', 'choose);\\n  &#x2022;provide', 'COVID-19', 'Our Business Operations', 'products;\\n  &#x2022;effectiveness', 'operations.\\n  &#x2022;We', 'Pfizer', 'Anti-Kickback Statute', 'and\\n  &#x2022;collaborators', '\\n  &#x2022;significant', 'candidates;\\n  &#x2022;collaborators', 'x201c;Risk', 'Medicaid', 'Medicare', 'Eisai Inc.', 'the trial;\\n  &#x2022;delays', 'x2014;\\n        &', 'GDPR', 'candidates;\\n  &#x2022;a', 'FDA', 'EquivalentsThe Company', 'and\\n  &#x2022;any', 'experience;\\n  &#', 'reimbursement;\\n  &#x2022;the', 'and\\n  &#', 'BELVIQ', 'Arena', 'Arena License Agreement', 'Arena Pharmaceuticals, Inc.', 'HIPAA', 'REMS', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Company', 'management&#x2019;s attention', 'USPTO', 'liability;\\n  &#x2022;disputes', 'the Leahy-Smith Act', '\\n  &#160;\\n', 'SVB', '50\\n', 'the Delaware General Corporation Law', 'Cantor Fitzgerald &amp', 'CMS', 'benefits;\\n  &#x2022;occurrence', '\\n  &#x2022;the', 'directors;\\n  &#x2022;provide', 'Risks Related to Ownership of Our Common Stock\\n', 'the Royalty Purchase Agreement', 'x2022;a collaborator&#x2019;s', 'Pfizer, Inc.', 'Series A Preferred Stock outstanding.11\\n     &#160;Amended', '\\n  &#', 'and\\n  &#x2022;maintaining', 'NDA', 'prices;\\n  &#', 'regulators;\\n  &#x2022;the', 'IPO', 'relationships;\\n  &#x2022;whether', 'The Arena License Agreement', 'candidates;\\n  &#x2022;per', '\\n  &#x2022;We', 'Voting Common Stock and', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '4275 Executive Square', 'the U.S. Food and Drug Administration', 'Royalty Purchase Agreement', 'DEA', 'ESPP', 'shares)\\n        &', 'Medicaid Services', 'insurance;\\n  &#x2022;significant', 'results;\\n  &#x2022;collaborators', 'candidates;\\n  &#x2022;establishing', 'Equity\\n        &', 'Employee Matters', '\\n        &', 'arrangements;\\n  &#x2022;the', 'SEC', '\\n  &#x2022;potential', 'GCP', 'Data Safety Monitoring Board', 'revenue;\\n  &#x2022;substantial', 'communities;\\n  &#', 'EquityThe', 'the Centers for Medicare &', 'the Registrant&#x2019;s Registration Statement', 'Nasdaq', '\\n    &', 'property.\\n'}"
LEGN,
LEXX,
LFCR,
LFLY,"{'ASC', 'the Merger Agreement', 'compensation\\n    &', 'years)\\n        &', 'the Nasdaq Capital Market', 'Board', 'the New Leafly 2021 Equity Incentive Plan', 'Business Overview\\n  ', 'costs.\\n  Operating Expenses\\n', 'this Quarterly Report', 'deemed &#x201c;filed&#x201d', 'the Reverse Stock Split', 'amounts)\\n  &#', '\\n  &', 'THC', 'the Public Warrants', 'x2014;\\n        &', 'ESPP', 'The Public Warrants', 'Leafly', 'costs.\\n  Sales', 'Continued(in', 'the New Leafly 2021 Employee', '\\n  &#', 'Taxes', 'and\\n  &#', 'the New Leafy Earn-Out Plan', 'the Bid Price Requirement', 'Retail and Brands', 'the Legacy Leafly 2018 Equity Incentive Plan', '10\\n', '\\n        &', 'Legacy Leafly', 'Restricted', '\\n    Interest', '\\n  Liquidity and Capital Resources\\n', 'oAll', 'NotesMerida', 'Company', 'Equity Incentive and Other PlansThe Company', 'seed.\\n  &', 'the Business Combination', 'Securities Exchange Act', 'GAAP', 'AdoptedManagement', '\\n  &#160;\\n', 'Nasdaq', 'the &#x201c;Merger', '42\\n  \\n  Table of Contents\\n  &', '\\n    &', 'and\\n  &', 'Adopted Accounting Pronouncements\\n  Reference'}"
LFMD,"{'ASC', 'LLC', 'The Nasdaq Stock Market', 'Company&#8217;s\\nskincare', 'ownership.\\n\\n&#160;\\n\\nConcurrently\\nwith', 'Conversion Labs PR', 'LLC (&#8220;Pilaris&#8221;)\\nrelating', 'the &#', 'LifeMD, Inc.', 'Gallagher Risk Management Services', 'the United States\\n(&#8220;U.S. GAAP&#8221;)', 'the CRG Financial', 'Court', 'PURPUREX', 'Immudyne, Inc.', 'the Alphabet Agreement', 'Cancelled/Forfeited', 'the Securities Exchange', 'the Securities Act.\\n\\n&#160;\\n\\nITEM\\n3', 'Market Issuance Sales Agreement', 'Series B Preferred Stock', 'The Credit Agreement', 'M.ALPHABET', 'the Securities Purchase Agreement', 'NOTES PAYABLE\\n\\n&#160;\\n\\nWorking\\nCapital', 'Conversion Labs', 'Avenue Credit Agreement\\n\\n&#160;\\n\\nOn\\nMarch', 'WSS', 'LLC (&#8220;PA001', 'Amazon', 'Immudyne PR', 'WorkSimpli', 'successful\\nin', 'Company', '\\n\\n&#160;\\n\\nNOTE\\n6 &#8211', 'The Blair Complaint', 'the Avenue First Amendment', 'Credit Agreement', 'Cantor Fitzgerald &amp', 'Pathak Options', 'LLC (&#8220;Alphabet&#8221;),\\npursuant', 'VIE.\\n\\n&#160;\\n\\nThe\\nCompany', 'B. Riley Securities, Inc.', 'the 2021 Shelf', 'ACCRUED', 'the Avenue Facility terms.\\n\\n&#160;\\n\\nSeries\\nB Preferred Stock', 'Fitzpatrick Option Agreement the &#8220;Option Agreements&#8221;),\\npursuant', 'the Credit Agreement', 'Avenue Venture Opportunities Fund II', 'respectively.\\nTotal interest', 'L.P. and Avenue Venture', 'goods\\nsold &#8211', 'the Black-Scholes\\nPricing Model', 'Specialty Medical Drugstore,\\nInc', 'Option Agreement', 'CRG Financial', 'LifeMD Southern Patient Medical Care', 'CloudBoson', 'Form S-3', 'Restructuring', 'Going Concern Evaluation\\n\\n&#160;\\n\\nThe\\nCompany', 'PA001 Holdings', 'Company\\nand', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n7 &#8211', 'ATM', 'the Stock Purchase Agreement', 'Pilaris', 'Telehealth', 'the Bowlin Option Agreement', 'Pilaris Laboratories', 'the aggregate\\nwith Conversion Labs PR', 'the First Amendment.\\n\\n&#160;\\n\\nFirst\\nAmendment to', 'The\\nCredit Agreement', 'SEC', 'Immudyne PR LLC (&#', 'CRG', 'LONG-TERM DEBT\\n\\n&#160;\\n\\nAvenue\\nCapital Credit', '\\n    &'}"
LFMDP,"{'ASC', 'LLC', 'The Nasdaq Stock Market', 'Company&#8217;s\\nskincare', 'ownership.\\n\\n&#160;\\n\\nConcurrently\\nwith', 'Conversion Labs PR', 'LLC (&#8220;Pilaris&#8221;)\\nrelating', 'the &#', 'LifeMD, Inc.', 'Gallagher Risk Management Services', 'the United States\\n(&#8220;U.S. GAAP&#8221;)', 'the CRG Financial', 'Court', 'PURPUREX', 'Immudyne, Inc.', 'the Alphabet Agreement', 'Cancelled/Forfeited', 'the Securities Exchange', 'the Securities Act.\\n\\n&#160;\\n\\nITEM\\n3', 'Market Issuance Sales Agreement', 'Series B Preferred Stock', 'The Credit Agreement', 'M.ALPHABET', 'the Securities Purchase Agreement', 'NOTES PAYABLE\\n\\n&#160;\\n\\nWorking\\nCapital', 'Conversion Labs', 'Avenue Credit Agreement\\n\\n&#160;\\n\\nOn\\nMarch', 'WSS', 'LLC (&#8220;PA001', 'Amazon', 'Immudyne PR', 'WorkSimpli', 'successful\\nin', 'Company', '\\n\\n&#160;\\n\\nNOTE\\n6 &#8211', 'The Blair Complaint', 'the Avenue First Amendment', 'Credit Agreement', 'Cantor Fitzgerald &amp', 'Pathak Options', 'LLC (&#8220;Alphabet&#8221;),\\npursuant', 'VIE.\\n\\n&#160;\\n\\nThe\\nCompany', 'B. Riley Securities, Inc.', 'the 2021 Shelf', 'ACCRUED', 'the Avenue Facility terms.\\n\\n&#160;\\n\\nSeries\\nB Preferred Stock', 'Fitzpatrick Option Agreement the &#8220;Option Agreements&#8221;),\\npursuant', 'the Credit Agreement', 'Avenue Venture Opportunities Fund II', 'respectively.\\nTotal interest', 'L.P. and Avenue Venture', 'goods\\nsold &#8211', 'the Black-Scholes\\nPricing Model', 'Specialty Medical Drugstore,\\nInc', 'Option Agreement', 'CRG Financial', 'LifeMD Southern Patient Medical Care', 'CloudBoson', 'Form S-3', 'Restructuring', 'Going Concern Evaluation\\n\\n&#160;\\n\\nThe\\nCompany', 'PA001 Holdings', 'Company\\nand', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n7 &#8211', 'ATM', 'the Stock Purchase Agreement', 'Pilaris', 'Telehealth', 'the Bowlin Option Agreement', 'Pilaris Laboratories', 'the aggregate\\nwith Conversion Labs PR', 'the First Amendment.\\n\\n&#160;\\n\\nFirst\\nAmendment to', 'The\\nCredit Agreement', 'SEC', 'Immudyne PR LLC (&#', 'CRG', 'LONG-TERM DEBT\\n\\n&#160;\\n\\nAvenue\\nCapital Credit', '\\n    &'}"
LFST,"{'ASC', 'FASB', 'Credit Agreement', 'ASU', 'Lynnwood Intermediate Holdings', 'operations;\\n  &#x2022;performing', 'resources.\\n  Item 2', 'STR', 'increases.\\n', '\\n  &', 'Capital One', 'Regulation S-K).\\n  &', 'Medicaid', 'Medicare', 'Financial Instruments', 'names&#160;(1)\\n        &', 'x2014;\\n        &', 'National Association', 'centers.\\n  Center', 'the Public Company Accounting Oversight Board', 'Nayani', '\\n  &#', 'increases.\\n  Total', 'and\\n  &#', 'BasisThe', 'periods.\\n  Depreciation', '26\\n', 'TRPV', 'Fair Value\\n        &', 'entries;\\n  &#x2022;developed', 'GoodwillGoodwill', 'Credit Losses on Financial Instruments', '\\n        &', 'SEC', 'Company', 'the Securities Exchange Act', 'FPE', 'LifeStance Health Holdings, Inc.', '\\n  &#x2022;Adjusted EBITDA', 'and\\n  &#x2022;development', 'the Sarbanes-Oxley Act', 'clinician&#x2019;s', 'Center Margin', 'Adopted Accounting'}"
LGMK,"{'LogicMark', 'FASB', 'States General Services Agreement', 'related\\ncosts', 'EQUITY', 'COSO', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', '\\n    Dividends &#8211', 'Inc.\\n\\nNOTES TO CONDENSED FINANCIAL', 'issued\\nas', 'a Certified Public Accountant', 'SEC', 'noted.\\n\\n&#160;\\n\\nOTHER INTANGIBLE ASSETS\\n\\n&#160;\\n\\nThe', 'Common Stock', 'Company', '\\n\\n\\n&#160;\\n\\nWe', 'VHA', 'Results of Operations', '\\n    &'}"
LGND,
LGVN,"{'the National Heart', 'Development', 'LLC', 'the National Institutes of Health', 'operations.&#160;Changes\\nin', 'Registry', 'The\\nBahamas', 'exclusive\\nlicense', 'Lomecel-BTM\\nin', 'Co. Inc.', 'HLHS', 'below.\\n\\n&#160;\\n\\nSelling\\nand Marketing', 'UM of', 'Offering', 'Clinical Development', 'NIH', 'Bahamas Registry', 'RSU', 'Research and Development', 'and\\n  \\n&#160;\\n\\n  &#160', 'The UM License', 'Maryland Stem Cell Research Fund', '\\n    Research', 'MD Holdings,\\nLLC', 'the University of Miami', 'CSO', 'SEC', 'Company', 'the Bahamas Registry Trial', 'Development Expenses\\n\\n&#160;\\n\\nResearch\\nand', 'The Purchaser Warrants', 'JMH', 'Total&#160;\\n    &', 'Longeveron Inc.', 'Optimal Networks, Inc.', 'IPO', 'Lafferty &', 'consultants.\\n\\n&#160;\\n\\nThe accompanying\\ninterim', 'net&#160;\\n    &', '\\n    &', 'The Bahamas Registry Trial', 'Financial Accounting Standards Board', 'Blood Institute (&'}"
LIAN,"{'QED Therapeutics, Inc.', 'Capital Resources Sources', 'the National Information Security Standardization Technical Committee', 'LLC', 'Pfizer', 'Tarsus Pharmaceuticals, Inc. (&#8220;Tarsus&#8221', 'The HGR Regulation', 'the Draft Data Security Management Regulations', 'CRO', 'BMS', 'the Pfizer Commercial Agreement', 'Navire Pharma, Inc. (&#8220;Navire&#8221', 'Nanobiotix S.A. (&', 'Parent Company Shares', 'HGRAC', 'Mainland China&#8217;s', 'UncertaintiesThe', 'HGR', 'Shanghai LianBio Development Co., Ltd.', 'the Termination Agreement', 'the Termination Effective Date', 'the Tarsus Supply Agreement', 'the Tarsus License Agreement', 'the MyoKardia License Agreement', 'QED', 'NImmune', 'License Agreement', 'Internal Control', 'this Quarterly Report on Form 10-Q', 'CAC', 'Landos BioPharma, Inc. (&#8220;Landos&#8221', ': &', 'this Quarterly Report on Form 10-Q.4Table', 'the Lyra License Agreement', 'MyoKardia, Inc.', 'Contents(i) Concentration of Credit Risk and Other Risks', 'the Tarsus Warrants', 'NLRX1', 'Meibomian Gland Disease', 'Cayman', 'NImmune Biopharma, Inc (&#8220;NImmune&#8221', 'Bristol Myers Squibb', 'Financial ReportingThere', 'Indicate', 'Material Agreements License Agreement', 'SCNPC', 'the Company (&#8220;Parent Company Shares&#8221', 'LianBio', 'PIPL', 'New Accounting StandardsThe', 'the Black-Scholes Model', 'Lyra Therapeutics, Inc. (&#8220;Lyra&#8221', 'QED Therapeutics, Inc. (&#8220;QED&#8221', 'Company', 'BridgeBio', 'Data Security Law', 'Lian Ophthalmology', 'MyoKardia', 'the Lian Ophthalmology', 'the Securities Exchange Act', 'NX-13', 'MOST', 'IPO', 'the Landos License Agreement', 'Lian Cardiovascular Limited', 'ContentsIn', 'Navire', 'Nanobiotix', 'the Certification Specification', 'NBTXR3'}"
LIFE,
LIFW,
LIPO,
LIVN,"{'DRE', 'Item 408 of Regulation S-K', 'Neuromodulation', 'InformationDuring', 'ImThera of', 'Bankruptcy Court of Milan', 'Site Management S.r.l', 'Consolidated Interest Expense', 'Targeted Hypoglossal', 'the Condensed Consolidated Balance Sheet', 'LivaNova PLC', 'Regulation S-K.ExhibitNumberDocument', 'OCIGains Reclassified', 'ArrangementsThe', 'Sorin', 'LSM', 'the Securities Exchange Act', 'the Italian Ministry of the Environment', 'income/(expense)$&#8212;&#160;$&#8212;&#160;$(1,345)$3,517&#160;FX', 'the Condensed Consolidated Statements of Income (Loss', 'Amended &', 'DTD', 'Statistical Analysis Committee', 'Essenz In-Line Blood Monitor', 'the Condensed Consolidated Financial Statements104*Cover Page Interactive Data File', 'SNIA Litigation Guarantee', 'Restated Purchase Agreement', 'the Amended &', 'DevelopmentOrderAdministrative', 'FDA', 'AdministrationsThe Italian Ministry of the Environment', 'the Initial Term Facility', 'Data Files Pursuant', 'Fair Value of ConsiderationCash', 'LossGains Recognized', 'Indemnity Letter', 'Company', 'SNIA', 'Technical Guide', 'the Public Administrations', 'the Civil Court of Milan', 'the Italian Ministry of Economic', 'RECOVER', 'the Condensed Consolidated Statements of Cash Flows', 'CMS', 'Barclays', 'this Quarterly Report on Form 10-Q.', 'r.l.Notes$287.5 million', 'SalesCost', 'CE Mark', 'CapitalCurrent', 'LivaNova', 'the Supreme Court', 'the Condensed Consolidated Statements of Comprehensive Income', 'Order', 'this Quarterly Report on Form 10-Q.CardiopulmonaryLivaNova&#8217;s Cardiopulmonary', 'Centers for Medicare &', 'the aforementioned Court of Appeal', 'CPB', 'ALung', 'the Bridge Loan Facility', 'the Sarbanes-Oxley Act', 'the cross symbol (&#8224;)', 'the SNIA Litigation Guarantee', 'AllocationDeveloped', 'Barclays in USD', 'treasury', 'Model 106', 'LossLosses Recognized', 'Consolidated Senior Secured', 'ISIN', 'ExpensesThe', 'Issuer Purchases of Equity', 'the U.S. District Court', 'SEC', 'Inspectorate for Nuclear Safety and Radiation Protection', 'the Delayed Draw Term Facility', 'Equity Securities', 'Consolidated EBITDA', 'Medicaid ServicesCourt', 'FX'}"
LIXT,
LMAT,
LMDX,
LNSR,"{'\\n  &#x2022;management', 'x201c;ALLY', 'the Series A Redeemable Convertible Preferred Stock', 'PID', '\\n', 'ALLY System', 'the EU Medical Devices Regulation', 'EEA', 'CE marks', 'EU Active Implantable Medical Devices Directive', 'EU', 'the Public Company Accounting Oversight Board', 'The U.S. Patent and Trademark Office', 'LENSAR, Inc', 'x2022;a', '\\n  &#x2022;criminal', 'QSR', 'CPRA', 'the Securities Exchange Act', 'Oertli', 'COVID-19', '\\n  &#x2022;withdrawals', 'LENSAR Laser System', 'NR-GRI Partners', 'Warrants', 'FASB', 'Company\\', '\\n  &#x2022;additional', 'the Securities Purchase Agreement', 'amounts)\\n  &#', 'Medicaid', 'Medicare', 'the Patient Interface Device (&#x201c;PID&#x201d;)', 'x2014;\\n        &', 'GDPR', 'Adaptive Cataract Treatment System', 'the ALLY System', 'FDA', '\\n  &#x2022;customer', 'BioPharma, Inc.', 'HIPAA', 'the Schaper Action', '\\n  &#x2022;fines', '\\n  &#x2022;entry', 'FTC', 'ALLY Adaptive Cataract Treatment System', 'Company', 'USPTO', 'ALLY&#174', 'the Health Insurance Portability', 'EU&#x2019;s', 'the California Privacy Rights Act', '\\n  &#x2022;limitations', 'the EU Medical Devices Directive', '\\n    &#', 'the California Consumer Privacy Act', '\\n  ', 'ESG', 'OrganizationLENSAR, Inc. (&#', 'the Fundamental Transaction', 'FCPA', '\\n    &#160;&#160;3.3\\n', '\\n  &#x2022;the', '\\n  &#x2022;untitled', '\\n  &#x2022;advance', '\\n    &#160;&#160;4.3\\n', 'the Nasdaq Stock Market', '\\n  &#x2022;recalls', '\\n  &#', 'the Separation and Distribution Agreement', 'Series A Redeemable Convertible Preferred Stock', '\\n    &#160;&#160;4.4\\n', 'the Spin-Off', 'stock.\\n  Pursuant', 'x201c;anticipate,&#x201d; &#', 'the Sarbanes-Oxley Act', 'EU Medical Devices Directive', 'CE', '\\n    &#160;&#160;4.1\\n    Form of Certificate of Common Stock\\n    Form 10/A\\n    001-39473\\n    4.1\\n', '\\n  &#x2022;increased', 'Form S-3', 'SPA', 'and\\n  &#x2022;transitioning', 'this Quarterly Report', 'ATM', '\\n  &#x2022;delays', 'the Medical Devices Directive', 'Good Manufacturing Practice', 'Oertli Instrumente AG', 'the Internal Revenue Service', '\\n  &#x2022;operating', 'Contingencies Purchase Obligation LENSAR', '\\n    &#160;&#160;2.1+\\n    Separation and Distribution Agreement', 'Significant Accounting Policies', 'Issuer Purchases of Equity', '\\n        &', 'SEC', 'GCP', 'the &#x201c;Company&#x201d;)', 'the Federal Trade Commission Act', 'LENSAR', 'IRS', 'the FDA&#x2019;s Quality System Regulation', 'Equity Securities', 'the Amended Complaint', 'the Health Information Technology for Economic and Clinical Health Act', 'the European Union', 'Nasdaq', '\\n    &', 'the Registration Statement'}"
LNTH,"{'Ratio Therapeutics', 'Precision Diagnostics', 'RELISTOR Licensed Intangible Asset Associated with Net Sales RoyaltiesOn', 'Novartis Pharma AG', 'this Quarterly Report on Form 10-Q', 'RELISTOR', 'the Novartis Agreement', 'Endocyte, Inc. (&', 'Bayer AG', 'POINT Biopharma Global Inc.', 'Progenics, Lantheus Holdings', 'Advanced Accelerator Applications USA, Inc. (&', 'Marketing, Reimbursement, Quality and Medical Affairs', 'the European Association of Urology', 'the &#8220;2022 Credit', 'IRONMAN Registry', 'Lantheus Holdings', 'Novartis Pharma AG.The Company', 'the &#8220;Progenics Acquisition&#8221;).In', 'IRE', 'Cerveau', 'the European Association of Nuclear Medicine', 'Citizens Bank', 'Guarantor', 'SupplyWe', 'U.S. Food and Drug Administration', 'TreatmeNt Enhancement', 'CompensationThe', 'PSMA', 'NTP', 'FDA', 'Strategic Partnerships', 'AI', 'Company', 'ObligationsThe Company', 'Credit Agreement', 'PNT2002', 'BMS', 'Contents15', 'the Power of Big Data', 'Digital Solutions', 'PolicyWe', 'SonoThera, Inc. (&#8220;SonoThera&#8221', 'the Additional Premises', 'Strategic Partnerships and Other Revenue', 'POINT', 'Unobservable', 'this Quarterly Report on Form&#160;10-Q', 'the Securities Exchange Commission', 'ContentsLiquidity', 'Board of Directors', 'the &#8220;P&amp;S&#8221', 'DevelopmentResearch', 'the Amended and Restated Agreement and Plan of Merger', 'the Australian Nuclear Science and Technology Organisation', 'ExpenseInterest', 'ex-U.S.', 'PYLARIFY', 'the Prostate Cancer Clinical Trial Consortium', 'ExpenseOur', 'the International Registry for Men with Advanced Prostate Cancer', 'NTP Radioisotopes', 'Plato Merger Sub, Inc.', 'Registry', 'MSA', 'Bausch Health Companies, Inc. (&#8220;Bausch&#8221', 'PIONEER', 'Our Digital Solutions', 'the Progenics Acquisition', 'Institute for Radioelements (&#8220;IRE&#8221', 'the 2022 Revolving Facility', 'Bausch', 'Bristol-Myers Squibb', 'development1,904&#160;1,099&#160;5,097&#160;2,665&#160;Total', 'Internal Revenue Code Section 382', 'PYLARIFY AI', 'Pharma Solutions', 'February&#160;23', 'Novartis', 'Equity Securities', 'ContentsItem&#160;2', 'ContentsGlobal', 'Progenics'}"
LPCN,"{'ASC', 'LLC', 'Halozyme Therapeutics', 'The Antares License', 'LPCN 1154', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Security Agreement', 'Lipocine', 'Company&#8217;s\\npotential', 'Antares Pharma Inc.', 'this Quarterly Report on Form 10-Q', 'Court', 'LPCN 1148,\\nor LPCN', 'the Initial Redemption', '\\n    Research', 'the Securities Exchange Act', 'the Company&#8217;s Board', 'CNS', 'the Registration Statement on Form S-3', 'the ATM Offering', 'classified\\nas', 'General Instruction I.B.6', 'LPCN 1111 to June 30, 2022', 'Series B Preferred Stock', 'goods\\nin', 'the Certificate of Incorporation', 'Makena', 'the Antares License Agreement for TLANDO', 'Antares', 'Abbott Products, Inc. (&#8220;Abbott&#8221', 'LPCN 1154 for PPD', 'the Securities and Exchange Commission', 'Principal Financial', 'the Securities and Exchange\\nCommission', 'FDA', 'Company&#8217;s\\nrights', 'us.\\n\\n&#160;\\n\\n\\n\\n\\n', 'candidates\\nand', 'GABAA', 'Loan', 'the Final Payment Charge', 'the Antares Licensing Agreement', 'hypogonadism\\n(congenital', 'TLANDO\\nwill', 'Company', 'the FASB ASC Topic', 'the Prime Rate', 'Field\\ninside', 'the State of Delaware.\\n\\n&#160;\\n\\n(12)\\nAgreement', 'the Company.\\n\\n&#160;\\n\\n\\n\\nOur\\nDevelopment Pipeline Product Candidates\\n\\n&#160;\\n\\nOur\\npipeline', 'SVB', 'PTB', 'NAS', 'Summary Judgment', 'Halozyme.\\n\\n&#160;\\n\\nThe\\nCompany', 'The Amended Settlement Agreement', 'TRT', 'Principal Financial Officer', 'New Drug Application', 'Security Agreements\\n\\n&#160;\\n\\nSilicon\\nValley Bank', 'the inhibitory neurotransmitter &', 'License Agreement', 'ASM', '\\n&#160;\\n\\n\\n\\n\\n\\n', 'the Antares License Agreement with Antares', 'the Antares License Agreement', 'AMAG Pharmaceuticals', 'the Endocrine Society', 'Solvay Pharmaceuticals, Inc.', 'concern.\\n\\n&#160;\\n\\nGeneral\\nand Administrative Expenses', 'Registrant', 'NDA', 'the FDA&#8217;s Center for Drug Evaluation and Research (&#8220;CDER&#8221', 'Restated Certificate of Incorporation', 'transaction\\non', 'Administrative Expenses', 'the License Agreement', 'Board', 'TLANDO XR', 'LPCN 1111', 'the Securities and Exchange Commission\\n    &', 'Postpartum Depression', 'Spriaso', 'significant\\ncapital', 'Development Expenses', 'the U.S. Food and Drug Administration', 'LPCN 1148', 'Cantor', 'expense.\\n\\n&#160;\\n\\nInterest\\nand Investment', 'Bioidentical Testosterone Product Candidate for the Treatment of NASH\\n\\n&#160;\\n\\nWe\\nare', 'the Global Agreement.\\n\\n&#160;\\n\\nLiquidity\\nand Capital Resources', 'Distinguishing Liabilities', 'U.S. Treasury', 'the License Agreement of approximately\\n$3.1\\nmillion', 'will\\nbe', 'SEC', 'and\\n  \\n    &', 'Silicon\\nValley Bank (&#8220;SVB&#8221', 'Halozyme', 'directors\\nof Lipocine Inc.', 'no\\npartnering', '\\n    &', 'not\\nshow Makena'}"
LPTX,
LQDA,"{'ASC', 'The University of North Carolina', 'LLC', 'Federal Deposit Insurance Corporation', 'LGM', 'PBM', 'Rule&#160;12b-2', 'InjectionUnited Therapeutics', 'No &#9744;&#8203;Indicate', 'LLC (&#8220;Liquidia', 'Prepare Treprostinil', 'Treprostinil', 'the Patient Protection', 'Phase 4', 'The Indemnification Agreement', 'PRINT', 'UNC License AgreementWe', 'Liquidia PAH', 'the Hatch-Waxman Litigation', 'Smaller Reporting CompanyAs a &#8220;smaller', 'ContingenciesWe', 'FlowsThe', 'L606', 'ContentsWe', 'ACA', 'the Company of U.S. Patent Nos', 'G&amp;W Laboratories, Inc.', 'the Financial Accounting Standards Board', 'L.P. (&#8220;HCR&#8221', 'the Securities Exchange Act', 'CommitmentsMilestone', 'Orphan Disease Designation', 'contracts.&#8203;Any', 'COVID-19', 'SVB Innovation Credit Fund VIII', 'ContentsIn', 'Medicaid programs.&#160;&#9679;The', 'LLC (&#8220;Henderson&#8221;)', 'the Merger Agreement', 'LGM Pharma', 'Anti-Kickback Statute', 'HHS', 'LLC (&#8220;RareGen&#8221;).We', 'Hatch-Waxman', '2022&#8203;6&#8203;&#8203;Condensed Consolidated Statements of Operations', 'Medicaid', 'Medicare', 'ContentsContractual Obligations', 'ContingenciesPharmosa License Agreement', 'CustomersIn', 'FDA', 'the Revenue Interest Financing Agreement', 'Sandoz', 'a Litigation Funding and Indemnification Agreement (&#8220;Indemnification', 'RevenueCost', 'United Therapeutics and Smiths Medical', 'the World Health Organization', 'the Active 28\\nTable of ContentsIngredient', 'ContentsThe', 'Risks Related', 'FINANCIAL INFORMATION&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Item 1.&#8203;Condensed Financial Statements', 'REMS', 'the Original Agreement', 'Patient-Centered Outcomes Research Institute', 'Company', 'Merger Transaction', 'Healthcare RegulationThe', 'Liquidia Corporation Common Stock', 'Mainbridge Health Partners', 'Critical Accounting EstimatesWe', 'Contentsamended', 'Condensed Consolidated Financial', 'SVB', 'AKS', 'the Term Sheet and Settlement Agreement, Smiths Medical', 'the California Consumer Privacy Act', 'Qualitative Disclosures About Market', 'the Delaware General Corporation Law', 'Caligan', 'UNC', 'the Public Health Service', 'Liquidia', 'ESG', 'CMS', 'Chapel Hill', 'the Company of the &#8216;793 Patent', 'the UNC License Agreement', 'the Indemnification Agreement', 'Contents10', 'the Medicaid Drug Rebate Program;&#9679;a', 'the Active Ingredient', 'ActivitiesNet', 'the Financing Agreement', 'IRB', 'RareGen Litigation', 'Board of Directors', 'YUTREPIA.&#160;In', 'Pharmosa Biopharm Inc.', 'Chasm Technologies, Inc.', 'Net Profits', 'the RareGen Litigation', 'LLC (&#8220;Mainbridge&#8221;)', 'Months Ended &#', 'the Development and Regulatory Approval', 'NDA', 'RIFA', 'Liquidia Technologies, Inc. (&', 'the Pump Development Agreement', 'L.P. (&#8220;Innovation&#8221', 'the &#8220;Risk Factors&#8221', 'PAH', 'United Therapeutics', 'Tranche', 'The Pump Development Agreement', 'Chasm', 'Contentsamended (the &#8220;RIFA&#8221', 'LeasesOperating LeasesWe', 'HealthCare Royalty Management', 'protocols.&#8203;In', 'i)&#160;whereby Smiths Medical', 'New Chemical Entity', 'Hamas', 'the Promotion', 'September&#160;30,&#160;2022', 'New Clinical Investigation', 'Board', 'Consolidated Statements', 'District Court', 'Smiths Medical', 'HCR', 'any.&#8203;See &', 'YUTREPIA.&#8203;It', 'YUTREPIA', 'ContentsIssuance of Common Stock', 'Medicaid Services', 'the Health Care and Education Affordability Reconciliation Act', 'RareGen', 'the UNC License', 'the Promotion Agreement', 'Administrative ExpensesGeneral', 'United', 'Mainbridge', 'Discussion and Analysis of Financial Condition', 'Sandoz Inc.', 'Related Party', 'Pharmosa', 'ContentsResearch', 'the Centers for Medicare', 'Consolidated Balance Sheets', 'the Pharmosa License Agreement', 'GSK', 'ContentsInjection'}"
LRMR,"{'No &#9744', '\\n  &#x2022;payments', 'OLE', 'CostsAll', 'ATM Agreement', 'ATM', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Securities and Exchange Commission', 'this Quarterly Report on Form 10-Q', 'Purchasers', 'MAD', 'FDA', 'the Company&#x2019;s Certificate of Incorporation', '\\n  &#', 'Massachusetts Municipal Association, Inc.', 'The Company&#x2019;s Registration Statement on', 'Indicate', 'ProceedingsThe Company', '\\n    Research', '\\n        &', 'SEC', 'of:\\n  &#', 'Company', 'CPP', '\\n  Research', '\\n  &#x2022;allocated', 'WFUHS', 'activities;\\n  &#', 'Results of Operations \\n', 'the Company&#x2019;s Registration Statement on', 'expense.\\n  &', 'Equity and Stock OptionsCommon Stock', 'Comparison', '\\n    &'}"
LSDI,
LSTA,
LTRN,
LUCD,"{'ASC', '\\n    Research &', 'the Lucid Diagnostics 2018 Equity Plan', 'the Amended CWRU License Agreement', 'loss.\\n\\n&#160;\\n\\nRecently\\nAdopted Accounting Pronouncements\\n\\n&#160;\\n\\nIn\\nJune 2016', '- Management Services', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'LLC (&#8220;CapNostics&#8221', 'Incurred Expenses of Minority', '\\n    Laboratory', 'Agreement and Management Services', 'Series A Preferred Stock', 'Stock-Based Compensation - continued\\n\\n&#160;\\n\\nLucid\\nDiagnostics Stock Options\\n\\n&#160;\\n\\nLucid\\nDiagnostics', 'Company\\nconsiders', '\\n    Sales &', 'Management Services Agreement', 'CAP', 'the financing\\nterms the Company', 'software&#160;\\n', 'Physician Inventors', 'classified\\nas', 'EsoGuard Esophageal DNA Test', 'operations.\\n\\n&#160;\\n\\nCost\\nof', 'FASB', 'Prepaid Expenses and Other Current Assets\\n\\n\\n  \\n    &', 'Company&#8217;s\\nunaudited', '\\n\\n&#160;\\n\\nNote\\n4 &#8212', 'the EsoGuard Commercialization Agreement', 'Intangible Assets', 'LucidDx Labs Inc', 'FDA', 'LucidDx Labs Inc.', 'SEC File No', 'Lucid Diagnostics', 'supplies.\\n\\n&#160;\\n\\nSales\\nand marketing expenses\\n\\n&#160;\\n\\nSales\\nand marketing', 'MSA Fees', 'Company', 'respect\\nto the March 2023', '\\n\\n&#160;\\n\\nNote\\n8 &#8212', 'The EsoGuard Commercialization Agreement', 'Management Services Agreement and Modification of Other Payment Obligations - ResearchDx', 'The Series A Preferred Stock', 'provider,\\nResearchDx Inc.', 'Significant Accounting', 'statements.\\n\\n\\n\\n&#160;\\n\\nNote\\n3 &#8212', 'net&#160;\\n    &', 'Cantor Fitzgerald &amp', 'ASU', '2022.\\n\\n&#160;\\n\\nNote\\n4 &#8212', 'Related Party Transactions - continued\\n\\n&#160;\\n\\nPAVmed\\nInc', 'Prepaid Expenses', 'market.\\n\\n&#160;\\n\\nNote\\n9 &', 'Contracts with Customers', 'Internal Controls Over Financial', 'CE Mark', 'Co. (&', 'summarized\\nas follows:\\n\\n&#160;Schedule\\nof Stock Options Issued', 'CWRU', 'net&#8221', 'EsoGuard NGS', 'APA', 'License Agreement - reimbursement', 'Exchange', 'Marketing&#160;\\n    &', 'the Lucid Diagnostics', 'EsoGuard Commercialization Agreement', 'IPO', 'EsoCheck', '\\n    Amended CWRU &', '\\n    Research and Development Expense&#160;\\n    &', 'Granted(1)&#160;\\n    &', 'CapNostics', 'the United States Securities and Exchange Commission', 'the Lucid Diagnostics\\nInc 2018 Equity Plan', 'MSA', 'Contracts', 'respect\\nto the Amended CWRU License Agreement', 'expense\\non', 'Centers', 'Intangible Assets\\n\\n\\n  \\n    &', 'APA-RDx,\\nLucidDx Labs Inc.', 'Contracts with Customers - continued\\n\\n&#160;\\n\\nRevenue\\nRecognized\\n\\n&#160;\\n\\nIn\\nthe three and nine months ended September 30, 2023', 'Related Party Transactions', 'Significant Accounting Policies', 'PAVmed', 'SEC', 'Related Party Transactions\\n\\n&#160;\\n\\nCase\\nWestern Reserve University', 'PAVmed Inc.', 'agreements&#160;\\n    &', 'termination.\\n\\n&#160;\\n\\nNote\\n7 &#8212', 'Equity Securities', 'EsoGuard&#174', 'the Company from\\nPAVmed Subsidiary Corp', 'Fair Value Measurement', '\\n    General &', 'Lucid Diagnostics Inc.', '\\n    &', 'Restricted Stock Awards\\n\\n&#160;\\n\\nLucid\\nDiagnostics', 'EsoGuard'}"
LUCY,"{'Principal Executive Officer', 'License', 'the Securities and Exchange Commission', 'the Securities and Exchange Act', 'Defiant Technologies\\nInc', 'the License Agreement', 'the Patent Rights and Materials', 'Registrant', 'Alexandria Advantage', 'Principal Accounting', 'Issued Accounting Pronouncements\\n\\n&#160;\\n\\nWe', '2021.\\n\\n(4', 'the Board of Directors', 'Licensed Products', 'Company'}"
LUMO,
LUNG,"{'Swiss Federal Government', 'the Zephyr Valves', 'the Delaware General Corporation Law', 'FASB', 'Credit Agreement', 'ASU', 'Anti-Kickback Statute', 'United Healthcare', 'the Sublease Agreement', 'Financial Instruments &#8211', 'CMS', 'Commerce', 'International Organization for Standardization (&#8220;ISO&#8221', 'this Quarterly Report on Form 10-Q.', 'this Quarterly Report on Form 10', 'State', 'Pulmonx International S&#224;rl', 'The Sarbanes-Oxley Act', '2023.Recent Accounting PronouncementsSee &', 'NCD', 'Interim Condensed Consolidated Financial Statements', 'Sublease Agreement', 'Medicare', 'CIBC', 'Medicaid', 'the Spiration Valve System', 'Yes &#9744', 'this Quarterly Report on Form 10-Q', 'the CIBC Loan', 'Blue Cross Blue Shield', 'ActivitiesNet', 'the InterVapor System', 'Risks Related to Government Regulation', 'GDPR', 'Aetna', 'FDA', 'Anthem, Health Care Service Corporation', 'Accounting for Implementation Costs Incurred', 'LiabilitiesAccrued', 'the U.S. Foreign Corrupt Practices Act', 'the Internal Revenue Code', 'the Office of Foreign Assets Control (&#8220;OFAC&#8221;)', 'Loan', 'Amount2023', 'Healthcare', 'Departments of Justice', 'Restated CIBC Agreement', 'PMA', 'Broncus Medical, Inc.', 'OIG', 'CPRA', 'the lender.36Summary Statement of Cash', 'decline.77We', 'HIPAA', 'Humana', 'LCD', 'Treasury', 'COVID-19 Credit Agreement', 'SEC', 'GCP', 'Company', 'BCBS Michigan', 'DOJ', 'Credit Losses', 'the Budget Control Act', 'Canadian Imperial Bank of Commerce (&#8220;CIBC&#8221', 'USPTO', '0.5&#160;million Swiss Francs', 'COVID-19', 'Medicare/Medicaid', 'Tranche', 'RecognitionThe', 'FCA', 'Zephyr Valves', 'UBS Switzerland AG', 'Zephyr Valve'}"
LVTX,
LXEO,"{'HIPPA', 'LLC', 'LEASESOperating Lease Right-of-Use AssetIn', 'No &#9744;\\n  &#', 'facilities;\\n  &#x2022;payments', 'TwoThousandTwentyOneEquityIncentivePlanMember2021-02-160001907108lxeo', 'Reliance', 'LX2006, LX1001', 'candidates;\\n  &#x2022;the', 'The Sarbanes-Oxley Act', 'and\\n  &#x2022;other', 'EMA', 'Cornell University (&#x201c;Cornell&#x201d;)', 'the New York Stock Exchange', 'the First Cornell License Agreement', 'the My Health My Data Act', 'TwoThousandTwentyThreeEquityIncentivePlanMember2023-11-070001907108lxeo', 'Neurocrine Biosciences', 'this Quarterly Report on Form 10-Q', 'EEA', 'The Third UCSD Agreement', 'Unregistered Sales of Equity', 'The First Cornell License Agreement', 'NY', 'the &#', 'strategy.\\n  &#x2022;Our', 'the patient&#x2019;s health', 'EU', 'the Securities Act.\\n  Use of Proceeds\\n  On', 'the U.S. Foreign Corrupt Practices Act', 'EquipmentMember2023', 'SeriesAPreferredStockMember2021', 'Indicate', '\\n    Research', 'TwoThousandTwentyOneEquityIncentivePlanMember2021-11-302021-11-300001907108lxeo', 'and\\n  &#x2022;authorize our Board of Directors', 'Board of Directors;\\n  &#', 'the License Agreements', 'the European Economic Area', 'ScenarioForecastMemberlxeo', 'the Cornell License Agreements', 'Research', 'Weill Cornell Medicine&#x2019;s Department of Genetic Medicine', 'Rocket Pharmaceuticals', 'TwoThousandTwentyOneEquityIncentivePlanMember2021-08-310001907108us-gaap', 'The Second Cornell License Agreement', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001907108lxeo', 'WCM', 'Takeda Pharmaceutical Company Limited', 'and\\n  &#x2022;collaborations', 'WCM Agreement', 'management&#x2019;s', 'CornellLicenseAgreementsMemberlxeo', 'LX2006', 'the U.S. Congress', 'Medicaid', 'Medicare', 'Exhibit 10.5', 'ThirdUcsdLicenseAgreementMember2023-01-012023-09-300001907108lxeo', 'SAFE', 'candidates;\\n  &#x2022;a', 'GDPR', 'the Second UCSD Agreement', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'the &#x201c;Second UCSD', 'Rule 701', 'and\\n  &#x2022;any', 'Risks and Uncertainties&#x2014;The Company', 'StrideBio', 'and\\n  &#', 'Charter)\\n  &#160;\\n', 'the Hatch-Waxman Amendments', 'HIPAA', 'REMS', 'The First UCSD Agreement', 'Company', 'the &#x201c;First UCSD', 'stockholder meeting;\\n  &#x2022;allow', 'requirements;\\n  &#x2022;economic', 'expense)\\n    &', 'TwoThousandTwentyOneEquityIncentivePlanMember2021-11-300001907108lxeo', '\\n    Interest expense\\n    &', 'CLN2 Batten', 'including:\\n  &#x2022;their efficacy', 'LX2020', 'the Delaware General Corporation Law', 'the European Commission', 'CAT', 'CMS', 'shares.8\\n       &#', 'Lacerta Therapeutics, Inc.', 'litigation;\\n  &#x2022;collaborators', 'Undue', 'CCPA', 'Cornell', 'FCPA', 'IPO Proceeds', 'the U.S. Department of Health and Human Services', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'the Nasdaq Stock Market', 'PTC Therapeutics, Inc.', 'Lexeo Therapeutics', '\\n  &#', 'the Regents of UCSD', 'Board of Directors', 'The Adverum Agreement', 'OfficeFacilityAndLaboratorySpaceMember2029-08-012034-07-310001907108us-gaap', 'Upfront', 'SteliosTherapeuticsIncMember2022-07-012022-09-300001907108lxeo', 'GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001907108srt', 'IRA', 'LeaseholdImprovementsMember2022-12-310001907108us-gaap', 'FairValueMeasurementsRecurringMember2023', 'Stelios', 'the Sarbanes-Oxley Act', 'Lexeo Therapeutics, Inc', 'reporting.\\n', 'IPO', 'the Cornell Second License Agreement', '47\\n', 'the WCM Agreement', 'Comparison', 'the General Data Protection Regulation', 'Lexeo Therapeutics, Inc.', 'the Company&#x2019;s Board of Directors', 'Voyager Therapeutics, Inc.', 'CornellUniversityMember2023-07-012023-09-300001907108srt', 'QUARTERLY REPORT PURSUANT TO', 'the First UCSD Agreement', 'may:\\n  &#x2022;lose', 'TwoThousandTwentyOneEquityIncentivePlanMember2021-02-162023-09-300001907108us-gaap', 'markets;\\n  &#x2022;foreign', 'this Quarterly Report', 'Board of Directors;\\n  &#x2022;limit', 'the Second Cornell License Agreement', 'the Regents of UCSD.On', 'the University of California, San Diego&#x2014;Stelios', 'APOE', 'including:\\n  &#x2022;the', 'the Company of Cornell&#x2019;s IND', 'the Third UCSD Agreement', 'European Union', 'the Nasdaq Stock Market&#x2019;s National Market', 'TwoThousandTwentyThreeEquityIncentivePlanMember2023-11-072023-11-070001907108srt', 'CMOs;\\n  &#x2022;costs', 'MAA', 'MinimumMemberlxeo', 'First License', 'Medicaid Services', 'SPAC', 'institute a &#x201c;poison pill&#x201d', 'Sarepta Therapeutics, Inc.', 'benefits.\\n  &', 'ThirdUcsdLicenseAgreementMemberlxeo', 'the Registrant&#x2019;s Current Report', 'the European Medicines Agency', '\\n    ', 'consuming.\\n  Regulatory', 'Simple Agreement for Future Equity', 'expensive;\\n  &#x2022;collaborators', 'candidates.\\n  Collaboration', '\\n        &', 'SEC', 'UCSD', 'BLA', 'Aavanti Bio, Inc.', 'Novartis', 'the Federal Trade Commission Act', 'requirements;\\n  &#x2022;limit', 'REMS;\\n  &#x2022;the', 'the Centers for Medicare &', 'Equity Securities', 'the Health Information Technology for Economic and Clinical Health Act', 'prices;\\n  &#x2022;their', 'the European Union', '\\n    &', 'CornellUniversityMember2022'}"
LXRX,
LYEL,"{'N=18', 'Stanford', 'the Equity Distribution Agreement', 'Principal Executive Officer', 'the GSK Agreement', 'this Quarterly Report on Form 10-Q', 'Goldman Sachs', 'Note&#160;3', 'this Quarterly Report on Form 10-Q.Reduction', 'AdministrativeGeneral', 'Hutch Collaboration', 'No &#9744;Indicate', 'NSCLC', 'FlowsThe', 'ContentsWe', 'the Financial Accounting Standards Board', 'the&#160;Company', 'The Nasdaq Stock Market LLC', 'the Securities Exchange Act', 'NetOther', 'ContentsGSK Agreement', 'COVID-19', 'Principal Financial Officer Pursuant', 'the Amended Bylaws', 'this Quarterly Report on Form&#160;10&#8209;Q.In', 'ContentsIn', 'EnvironmentOur', 'GlaxoSmithKline Intellectual Property', 'HHS', 'License, Collaboration and Success Payment Agreements &', 'FDA&#8217;s GCP', 'Medicaid', 'Medicare', 'December&#160;24', 'FDA', 'the Data Safety Monitoring Board', 'the PACT Commitment Agreement', 'ContentsOperating Expenses Research', 'PACT Pharma, Inc.', 'The GSK Agreement', 'ContentsThe', 'Risks Related', 'Principal Executive Officer Pursuant to Rules', 'Co. LLC (&', 'Company', 'TNBC', 'USPTO', 'Placement Shares', 'the Health Insurance Portability', 'LYL797', 'Condensed Consolidated Financial Statements', 'the Delaware General Corporation Law', 'Compensation2021 Equity Incentive PlanIn', 'the Sonoma Sublease', 'the Condensed Consolidated Balance Sheets', 'CAR', 'Condensed Consolidated Balance Sheet', 'the Condensed Consolidated Statements of Operations and Comprehensive Loss.8', 'Good Clinical Practice', 'IRB', 'LYL331', 'Registrant', 'License, Collaboration and Success Payment AgreementsFred', 'Condensed Consolidated Balance Sheets', 'the Data Monitoring Committee', 'IPO', 'Agents', 'Our Financial Condition', 'T&#8209;cell', 'Fred Hutchinson Cancer Center (&', 'PACT Pharma, Inc. (&#8220;PACT&#8221', 'License, Collaboration and Success Payment', 'Goldman Sachs &', 'DevelopmentTo', 'the 2021 Plan.2021 Employee Stock Purchase PlanIn', 'PACT', 'this Quarterly Report on Form 10&#8209;Q', 'BofA Securities, Inc. (&#8220;BofA&#8221', 'Administrative ExpensesGeneral', 'the Collaboration and License Agreement', 'the Condensed Consolidated Statements of Operations', 'this Quarterly Report on Form 10&#8209;Q.', 'SEC', 'GCP', 'License, Collaboration and Success Payment Agreements', 'the Health Information Technology for Economic and Clinical Health Act', 'GSK', 'Acquisitions', 'Restated Bylaws'}"
LYRA,"{'ASC', 'LLC', 'below);\\n  &#x2022;our', '\\n    Interest income\\n    &', 'tax\\n    &#160;\\n    &#160;\\n    20\\n    &', 'The Sarbanes-Oxley Act', '\\n  &#x2022;expansion', 'EMA', 'MCSA', '\\n  &#x2022;an', '\\n  &#x2022;developments', 'Exhibits.\\n  &#160;\\n', '\\n  &#x2022;termination', 'Condensed Consolidated Statements of Operations and Comprehensive', '\\n  &#x2022;costs', 'EU', 'Litigation', 'Trademark Office', 'the Public Company Accounting Oversight Board', 'the U.S. Foreign Corrupt Practices Act', 'x2022;a', 'Material Weakness', '\\n  &#x2022;foreign', 'LianBio', '\\n    Research', 'ACA', 'the Children&#x2019;s Health Insurance Program', '\\n  &#x2022;development', 'Perceptive Advisors', '\\n  &#x2022;not', '\\n  &#x2022;misappropriation', '\\n  &#x2022;expenses', 'the LianBio License Agreement', 'HHS', '\\n  &#x2022;significant', '\\n  &#x2022;product', '\\n  &#x2022;substantial', '\\n  Research and Development Expenses \\n  Research', 'x201c;Risk', 'Internal Control', '\\n  &#x2022;a', '\\n  &#x2022;extension', 'Medicaid', 'the Securities and Exchange Commission', '3,604\\n        &', 'COVID-19 pandemic;\\n  &#x2022;our', 'Medicare', 'Congress', 'x2014;\\n        &', 'the Master Clinical Supply Agreement (&#x201c;MCSA&#x201d;)', '\\n  &#x2022;developing', 'FDA', 'Audit Committee', 'and\\n  &#', 'activities;\\n  &#x2022;general', '\\n  &#x2022;changes', '\\n  &#x2022;loss', 'the Medicaid Drug Rebate Program', '\\n  &#x2022;regulatory', 'HIPAA', 'REMS', '\\n  &#x2022;new', 'Common Stock', 'Patient-Centered Outcomes Research Institute', 'Company', 'USPTO', '\\n  &#x2022;import', '\\n  &#x2022;longer', 'the Leahy-Smith Act', 'customs', 'future operations.\\n  &#160;\\n', '70\\n', '\\n  &#x2022;language', '\\n  &#x2022;obtaining NDA', '\\n  &#x2022;distraction', '\\n  &#x2022;breach', '\\n    &#', '\\n  ', 'CMS', 'revenue.\\n  &', 'LianBio License Agreement', '\\n  &#x2022;establishment', '\\n  &#x2022;foreign currency exchange', '\\n  &#x2022;the', 'the Sales Agreement', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#x2014', 'Center for Medicare Innovation', '\\n  &#x2022;launching', '\\n  &#x2022;short', '\\n  &#', 'the Superior Court of the State of Delaware', 'Board of Directors', 'actions:\\n  &#x2022;Enhance', '\\n  &#x2022;formulating', '\\n  &#x2022;market', 'operations;\\n  &#x2022;our', 'Leases (&', 'CRS', '\\n  &#x2022;different', '\\n  &#x2022;decreased', 'manner;\\n  &#x2022;managing', 'CMO', '\\n  &#x2022;cultural', 'x201c;anticipate,&#x201d; &#', '\\n  &#x2022;inability', 'General Risk Factors\\n', 'prospects.\\n  &', 'the Company&#x2019;s Registration Statement on', 'Comparison', '\\n  &#x2022;impairment', '\\n  &#x2022;our', 'costs.\\n  &', '\\n  &#x2022;announcements', 'LYRA THERAPEUTICS', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &#', 'Form S-3', 'Management&#x2019;s', '\\n  &', 'the State of Delaware', 'Cantor', '\\n  &#x2022;foreign exchange', 'Healthcare', '\\n  &#x2022;facility', 'costs.\\n  Failure', '\\n  &#x2022;withdrawal', 'Adopted Accounting Pronouncements\\n', '80\\n', '\\n  &#x2022;consulting', '\\n        &', 'SEC', '9,492\\n', 'GCP', 'Territory', 'the Budget Control Act', '\\n  &#x2022;manufacturing', '\\n  &#x2022;undertaking', 'the Health Information Technology for Economic and Clinical Health Act', '\\n  &#x2022;failure', '\\n  &#x2022;reduced', 'ASC Topic', 'the European Union', '\\n  &#x2022;actual', '\\n  Interest Income\\n  Interest', '\\n    &', 'The Leahy-Smith Act', 'the Registration Statement'}"
MACK,
MASI,
MASS,
MBIO,"{'the Initial Public Offering.22\\nTable of ContentsCritical Accounting PoliciesThe', 'BofA Securities, Inc.', 'Months Ended &', 'Working Capital Loans', 'LLC', 'Goldman Sachs &', 'American LLCRedeemable', 'UncertaintiesThe', 'Results of OperationsReferences', 'Private Placement Warrants', 'FL', 'Business Combination', 'The Public Warrants', 'the Initial Public Offering', 'AgreementThe', 'a Business Combination', 'Credit RiskFinancial', 'the Federal Deposit Insurance Corporation', 'SEC', 'the Private Placement Warrants', 'Company', 'FASB ASC Topic', 'the Business Combination', 'ProceduresDisclosure', 'this Quarterly Report on Form 10-Q.&#8203;No.&#160;&#160;&#160;&#160;Description of', 'IPO', 'the Founder Shares', 'Jaws Mustang Acquisition Corporation References'}"
MBOT,"{'Nitiloop Ltd.', 'required\\ndisclosures.\\n\\n&#160;\\n\\nChanges\\nin Internal Control Over Financial', 'the Securities Purchase Agreement', 'the CardioSert Agreement', 'CardioSert Ltd.', 'SPA', 'the Second May Offering', 'this Quarterly Report on Form 10-Q.', 'Microbot\\nMedical Ltd.', 'October\\n25', 'adoption.\\n\\n&#160;\\n\\nNOTE\\n3 &#8211', 'the Israeli Innovation Authority\\nand', 'Incorporation', 'the Series B Preferred Investment Options', 'U.S. Securities and Exchange Commission', 'Nitiloop', 'FDA', 'the words &#8220;may,&#8221', 'substantial\\ndoubt', 'Stryker', 'NIS', 'the Israeli Innovation Authority', 'the Existing Preferred Investment Options', 'the Securities Purchase\\nAgreement', 'Libor per annum.\\n\\n&#160;\\n\\nThe\\nrepayment', 'Certificate', 'SEC', 'IIA', 'Company&#8217;s\\nlease', 'Common Stock', 'Company', 'the Financial Accounting Standards Board', 'the State of Israel', 'CardioSert', 'Cyto Therapeutics, Inc.', 'the Engagement Letter', 'the New Israeli Shekel', 'the LIBERTY Robotic System', 'October\\n2022', 'the State of Israel (&', 'StemCells', '\\n    &'}"
MBRX,"{'\\n       Financial Statements', 'Equity&#xa0;\\n', 'the Company&#x2019;s Board of Directors', 'x2014;\\n     &#', 'No &#x2610;\\n&#xa0;\\nIndicate', 'AML', 'this Quarterly Report', 'Condensed Consolidated Statements of Operations and Comprehensive Loss', 'Item 408 of Regulation S-K', 'the Company and Exploration Invest Pte Ltd.', 'xa0;\\n     &', 'the US Food &amp', 'Research and Development Expense', 'the Sponsored Research Agreement', 'Unaudited)\\n  &#', ""BMA\\'s).&#xa0;\\n  &#"", 'HEPA', 'party &', 'License Agreements', 'PROCEDURES\\n  &#', '2022 &#', 'FDA', 'Lincoln Park', '\\n   &#', 'Houston Pharmaceuticals, Inc.', 'HPI', 'the Management&#x2019;s Discussion and Analysis of Financial Condition', 'Clinicaltrials.gov', '\\n  &#', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'these statements.\\n  &#', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', 'Anderson - Total', 'INFORMATION.&#xa0;\\n  &#', 'the WPD Agreement', 'Sponsored Research Agreements', '\\n     &#', 'Condensed Consolidated Statements', 'Condensed Consolidated Financial Information', 'SEC', 'about:&#xa0;\\n  &#', 'Condensed Consolidated Balance Sheets', 'subsidiaries.&#xa0;All', 'Company', 'Cardiac', 'the Securities Exchange Act', 'Condensed Consolidated Statements of Cash Flows', 'WP1122\\n  &#', '\\n \\n \\n \\n', 'Procedures\\n  &#', 'WPD', 'Lincoln Park Agreement', 'Presentation &#', 'the Bid Price Rule', '7,765\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Results of Operations', 'Lincoln Park Equity Line\\n   &#', 'CFO', 'amended).\\n  &#', 'Northwestern University', 'the U.S. Securities and Exchange Commission', 'Drug Administration', '\\n    &#', 'the Company&#xa0;and WPD Pharmaceuticals', 'STS', 'Condensed Consolidated Financial Statements'}"
MCRB,"{'ASC', 'PayableOn', 'LLC', 'shortened.\\n', '\\n    Interest income\\n    &', 'the Original Credit Facility', 'Mayo Collaborative Services', 'costs.\\n  Collaboration (Profit', 'candidates;\\n  &#x2022;the', 'The Sarbanes-Oxley Act', 'EMA', 'discount\\n    &', 'S.A. (Nestl&#xe9;)Summary', 'and\\n  &#x2022;experience', 'Health Science', 'the Patient Protection', 'control;\\n  &#x2022;entrench', 'EU', 'Bacthera', 'collaborators;\\n  &#x2022;unfavorable', 'the Applicable Funding Date', 'the Company&#x2019;s Common Stock', 'the Term Loan', 'Condensed Consolidated Financial Statements\\n    &', 'x2022;a', 'Restructuring Plan', 'the &#x201c;Share Increase', 'Nestec, Ltd.', 'the Oaktree Credit', 'Pharma Partners', 'UPC', '\\n    Research', 'Chr', 'activities\\n        &', 'ACA', 'S.A.', 'VOWST', 'Clostridioides', 'Accounting Standard Update', '\\n  &#x2022;VOWST', 'medications;\\n  &#x2022;interactions', 'directors.\\n  These', 'Soci&#xe9;t&#xe9', 'the Oaktree Credit Agreement', 'Alice Corp.', 'investments.\\n  Interest Expense\\n  Interest', 'HHS', 'liability;\\n  &#x2022;expansion', '\\n  &#x2022;by', 'manufacturers&#x2019', 'goods\\n        &', 'letters;\\n  &#x2022;withdrawal', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'Lonza Group', 'x2014;\\n        &', 'IP', 'Bacthera.\\n  The Bacthera Agreement', 'the Restated Certificate of Incorporation', 'collaborators;\\n  &#', 'FDA', 'NetProperty', 'the Medicaid Drug Rebate', 'control may:\\n  &#x2022;delay', 'Loan Documents', 'Loan', '\\n        Laboratory equipment\\n', 'the Tranche A Warrant', 'and\\n  &#', 'Association for Molecular Pathology', 'Prometheus Laboratories', 'lines;\\n  &#x2022;unforeseen', 'the UK Government', 'Risks Related', '77\\n', 'HIPAA', 'Contracts with Customers (Topic', 'CONDENSED CONSOLIDATED', 'LossLicense Agreement', 'use;\\n  &#x2022;requirements', 'Health Science (&#x201c;Nestl&#xe9;&#x201d;)', 'consequences.\\n  Failure', 'activities\\n    &', 'BacThera AG', 'Patient-Centered Outcomes Research Institute', 'Company', 'methodology.\\n  &', 'management&#x2019;s attention', 'expense)\\n    &', 'USPTO', 'the Hercules Loan Agreement', 'Bacthera&#x2019;s', '\\n    Interest expense\\n    &', 'Compensation ExpenseThe Company', 'the Oaktree Closing Date', 'including:\\n  &#x2022;their efficacy', 'abroad.\\n  &#x2022;The', '70\\n', 'Cowen', '59,107\\n', 'the Hercules Lenders', 'detention;\\n  &#x2022;injunctions', 'Condensed Consolidated Financial Statements', 'Oaktree Fund Administration', 'the Oaktree Term Loan', 'the European Commission', 'the Public Health Service', 'prices;\\n  &#x2022;extension', 'the Bacthera Agreement', 'candidates.\\n  Foreign', 'all;\\n  &#x2022;misappropriation', 'Contracts with Customers', 'the Tranche A Loan', 'Licensed Territory', 'companies;\\n  &#x2022;additional', 'the Hercules Credit Facility', 'License Agreement', 'Stockholders&#x2019', 'Credit Agreement and Guaranty', 'CLS Bank International', 'the U.S. Internal Revenue Code', 'approvals;\\n  &#x2022;damage', 'Note 16)\\n        &', '\\n  &#', 'Nestl&#xe9;;\\n  &#x2022;continue', 'SER-287', 'IBD', 'Lenders', 'and\\n  &#x2022;termination', 'Nestec Ltd.', 'Myriad Genetics, Inc.', 'the &#x201c;Tranche', 'Memorial Sloan Kettering Cancer Center', 'operations.\\n  Acquisitions', 'plan\\n        &', '\\n  &#x2022;make', '\\n  Liquidity and Capital Resources\\n', 'capabilities;\\n  &#', 'Restated Certificate of Incorporation', 'Tranche B Loan', 'x201c;anticipate,&#x201d; &#', 'the Letter Agreement', 'Bacthera Agreement', 'Hercules Capital, Inc. (&', 'Nestl&#xe9;\\n    &', 'partnerships;\\n  &#x2022;make', 'the market;\\n  &#x2022;suspension', 'challenges;\\n  &#x2022;increases', 'The Bacthera Agreement', 'Cowen and Company', 'the requirements.\\n  Efforts', '\\n  &#x2022;1,513', 'including:\\n  &#x2022;litigation', 'this Quarterly Report', 'Hercules Capital, Inc.', 'Comparison of Nine Months Ended September 30, 2023', 'Contracts', '\\n  &', 'Crohn&#x2019;s', '\\n  &#x2022;commercialize', 'the Paycheck Protection Program', 'sources.\\n', 'ESPP', 'the U.S. Food and Drug Administration', 'CTR', 'CustomersLicense Agreement', 'and\\n  &#x2022;inability', 'the Share Increase Amendment', 'Unified Patent Court', 'the Health Care and Education Affordability Reconciliation Act', 'Healthcare', 'Rx License GmbH', '\\n    ', '\\n        &', 'Nestl&#xe9', 'The Oaktree Credit Agreement', 'Collaboration Profit', 'the &#x201c;Hercules', 'Collaboration and License Agreement', 'BLA', 'CI', 'drugs.\\n  &#', 'CDI', 'prices;\\n  &#x2022;their', 'the European Union', '\\n    &', 'property.\\n', 'Nestl&#xe9;\\n        &', 'the &#x201c;Hercules Loan'}"
MDAI,"{'ASC', 'Committed Stock', 'this Quarterly Report', 'Yes\\n&#9746', 'the Board of Directors', 'Rosecliff Acquisition Corp I', 'the MTEC Agreement', 'Department of Health and Human Services', 'Rosecliff', 'No &#9744;\\n\\n&#160;\\n\\nIndicate', 'Financial Instruments', 'Spectral MD Holdings, Ltd.', 'the National Association of Securities Dealers Automated Quotations (&#8220;NASDAQ&#8221;),\\nthe', 'manufacturing\\nof', 'Spectral', 'Spectral MD Holdings Ltd.', 'Spectral MD, Inc.', 'Contingencies (&', 'Condensed Financial', 'this Quarterly Report on Form 10-Q:\\n\\n&#160;\\n\\n\\n', 'Spectral AI;\\n  \\n&#160;\\n\\n\\n  \\n    &', 'subsidiaries\\nin', 'the Business Combination the Company', 'Medical Technology Enterprise\\nConsortium', '\\n    Research', 'Rosecliff Acquisition Corp', 'Because\\nthe Company', 'SEC', 'Holdings, Ltd.', 'Company', 'Spectral AI.\\n', 'the Business Combination', 'the Registration Statement on Form S-4', 'PBS', 'Spectral AI, Inc.', 'recorded.\\n\\n&#160;\\n\\nIn', 'net&#160;\\n    &', '\\n    &', 'the Biomedical Advanced Research and Development Authority'}"
MDGL,
MDGS,
MDRX,
MDVL,
MDWD,
MDXG,
MDXH,
ME,"{'ASC', 'LLC', 'PGS', 'Contractual Obligations', 'Time', '23andMe Holding Co.', 'Segment InformationThe Company', 'Mother&#x2019;s Day', 'the GSK Agreement', 'the New Data', 'this Quarterly Report on Form 10-Q', 'the Compensation Committee', 'the &#x201c;Business Combination&#x201d;).The Company', 'category:&#160;\\n      \\n       \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n        \\n       \\n       \\n        &', 'Indicate', 'VGAC (&#x201c;Merger', 'Exhibit Index\\n  &', '\\n    Research', 'GlaxoSmithKline plc', '\\n      &', 'the-Market (&#', 'Therapeutics', 'Research', 'IndemnificationThe Company', 'ObligationsThe', 'the &#x201c;Agent&#x201d;)', 'the &#x201c;Lemonaid', 'Lemonaid Health', 'VGAC', 'x2014;\\n        &', 'the &#x201c;Protection', 'the 23andMe Holding Co.', 'NetProperty', 'Amazon', 'the Consumer and Research Services', 'Consumer and Research Services', '456\\n    &', 'Company', 'companies.\\n  Expansion', 'The Consumer and Research Services', 'the California Consumer Privacy Act', '23andMe, Inc.', 'RevenueThe', 'percentages)\\n        &', 'Lemonaid Health, Inc. (&#x201c;Lemonaid', 'the Lemonaid Health, Inc. (&#x201c;Lemonaid', 'the &#x201c;Company,&#x201d', 'EBITDA\\n        &', '\\n        Laboratory', 'Research Services', 'intensify.\\n  Engagement of Research Participants\\n', '\\n  &#', 'x201c;GSK', 'Board of Directors', 'the Lemonaid Health', 'Registrant', 'Lemonaid Health Limited', 'the Lemonaid Acquisition', 'costs&#160;(3)\\n        &', 'Merger', 'The Earn-Out Shares', 'Consumer Services', 'the Company&#x2019;s Board of Directors', 'percentages)\\n    &', 'Cowen and Company', 'VG Acquisition Corp.', 'New Data', '\\n    Provision', 'the Registration Statement on Form S-8 (File No', 'GSK&#x2019;s', 'ATM', 'ESPP', 'the State of Delaware', 'Revenue\\n        &', 'IssuanceThe Company', 'GSK Agreement', 'ContingenciesNon', 'Discussion and Analysis of Financial Condition', '\\n        &', 'the Shelf Registration Statement', 'GSK', 'Adjusted EBITDA:\\n        &', '\\n    &'}"
MEDP,"{'LLC', 'ContentsControl', 'the Loan Agreement', 'Guarantor', 'Prepaid', 'SoldDuration/Expiration DateRule', 'The Aircraft Management Company', 'OperationsThree Months Ended September 30, 2023', 'InformationDuring', 'EPS', 'AmortizationDepreciation', 'percentages)20232022Change &', 'administrative41,407&#160;35,418&#160;5,989&#160;16.9&#160;%Depreciation6,329&#160;4,951&#160;1,378&#160;27.8&#160;%Amortization549&#160;838&#160;(289)(34.5)%Total', 'Related Party', 'ExpensesOur', 'Treasury', 'Company', 'the Aircraft Management Company', '-16-Table of Contentsaircraft', 'Regulation S-K', 'Medpace, Inc.', 'the Credit Facility'}"
MEDS,
MEIP,
MESO,
MGNX,
MGRM,
MGRX,
MGTX,"{'ASC', 'MHRA', 'the Note Purchase Agreement', 'EC', 'The Sarbanes-Oxley Act', 'EMA', 'UncertaintiesThe Company', 'IRD', 'EU', 'the &#', 'the Public Company Accounting Oversight Board', 'ContentsWe', 'ACA', 'Contentscovenants', 'the Securities Exchange Act', 'IDA Ireland', 'Restricted CashRestricted', 'COVID-19', 'CNS', 'ContentsIn', 'Sanofi', 'Contentsliterature', 'FASB', 'Perceptive', 'liability;&#8203;&#9679;a', 'Note Purchase Agreement', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'the Sanofi Private Placement', 'GDPR', 'FDA', 'the Data Safety Monitoring Board', 'GMP', 'Cayman Islands', 'requirements;&#8203;&#9679;a', 'the UK Government', 'the Cayman Islands Companies Act', 'ContentsThe', 'Center for Medicare &', 'the Medicaid Drug Rebate Program', 'HIPAA', 'the Janssen Pharmaceuticals Companies of Johnson&#160;&amp', 'Patient-Centered Outcomes Research Institute', 'Company', 'MeiraGTx Limited', 'USPTO', 'the Consent and Amendment', 'Sanofi Foreign Participations B.V.', 'Investment Agreement', 'InformationManagement', 'ContentsThere', 'the Access Consortium', 'ASU', 'the European Commission', 'CAT', 'CMS', 'ContentsTo', 'Central Nervous System', 'the Financing Agreement', 'License', 'IRB', 'as:&#8203;&#9679;a', 'Leases (&', 'the Children&#8217;s Health Insurance Program', 'Response', 'TCA', 'License AgreementsJanssen Pharmaceuticals,&#160;Inc', 'ExpenseInterest', 'Capital Resources.&#8221', 'downsizing;&#8203;&#9679;a', 'ContentsAgreement', 'Impairment', 'the words &#8220;expect,&#8221; &#', 'Medicaid Innovation', 'ContentsFair Value MeasurementsFair', 'SEC Regulation S-X and Regulation S-K.', 'AAV-CNGA3', 'FDA&#8217;s', 'ROU', 'Milestone Payments:&#160;At', 'authorized.&#8203;&#8203;&#160;&#160;&#160;&#160;MeiraGTx Holdings plc', 'MAA', 'Medicaid Services', 'Good Manufacturing Practice', 'European Commission', 'Research and Development', 'the Collaboration Agreement', 'potential.&#8203;In', 'Trade Control', 'LeasesThe Company', 'SEC', 'GCP', 'BLA', 'the FASB&#8217;s Accounting Standards Codification', 'the Centers for Medicare &', 'the Subsidiary Guarantors', 'ContentsItem&#160;2', 'Nasdaq', 'The Note Purchase Agreement'}"
MHUA,
MIRA,"{'Loan Association', 'Results of Operations\\n\\n&#160;\\n\\nGeneral\\n\\n&#160;\\n\\nADMIRAL FINANCIAL CORP.', 'respect\\nto the acquisition', 'Discussion and Analysis of Consolidated Financial Condition', 'Admiral', 'Capital', 'Haven Federal Savings', 'the Statements of Operations', 'Company'}"
MIRM,"{'the Shire Agreement', '\\n    Interest income\\n    &', 'Concentrations of Credit Risk and Off-Balance Sheet RiskFinancial', 'Shire and Satiogen', 'State', 'EMA', 'Intercept Pharmaceuticals', 'Note 6 &#x201c;Revenue Interest Purchase', 'Rights Agreement', 'Financial Instruments', 'currency.\\n  &', 'EU', 'currency.\\n  Critical Accounting Estimates\\n', 'Purchasers&#x2019', 'the Bile Acid Portfolio Acquisition', 'Licensing Agreement', 'x2022;a', 'the Shire License Agreement', 'Series A Preferred Stock', 'Pfizer Inc.', 'x201c;well', 'Shire International GmbH', 'UPC', 'CPRA', '\\n    Research', 'Office of Inspector General', 'PBC', 'RMP', 'the Bile Acid Medicines', 'Research', 'and\\n  &#x2022;improving', '58,954\\n          &#160;\\n', '\\n  &#x2022;prevent', 'Takeda Pharmaceutical Company Limited', 'Sanofi', 'and\\n  &', 'the Amended Agreement', 'compensation\\n    &', 'Canada&#x2019;s Personal Information Protection and Electronic Document Act', 'Oberland', 'FASB', '32,667\\n          &#160;\\n', 'Pfizer', 'management&#x2019;s', 'HHS', 'Shire', 'the U.S. False Claims Act', 'medicines;\\n  &#x2022;the', 'recognized\\n        &', 'CTX', 'x201c;Risk', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'Bile Acid Medicines', 'the U.S. Department of Justice', 'x2014;\\n        &', 'Mirum Pharmaceuticals, Inc.', 'FDA', '\\n  &#x2022;collaborations', 'National Association', 'The America Invents Act', 'and\\n  &#', 'Chenodal', 'the Medicaid Drug Rebate Program', 'including:\\n  &#x2022;identifying', '34,000\\n          &#160;\\n', 'HIPAA', 'REMS', '77\\n', 'activities\\n    &', 'Amount\\n          &', 'the Federal Communications Commission', 'Company', 'U.S. Bank Trust Company', 'Sanofi-Aventis Deutschland GmbH', 'this Quarterly Report on Form 10-Q.\\n  &#x2022;The', '\\n  &#x2022;salaries', 'USPTO', 'the EU Patent Package', '\\n    Interest expense\\n    &', 'profitably.\\n  &#x2022;If', 'commercial success.\\n  &#x2022;We', 'the Shire Agreement, Shire', 'thousands):16\\n       &', 'the &#x201c;Expanded Space&#x201d', 'ALGS', 'Results of Operations', 'and\\n  &#x2022;sufficient', 'EU&#x2019;s', 'decline.\\n  Raising', '\\n  &#160;\\n', '\\n  &#x2022;whether', 'Liability\\n        &', 'the Delaware General Corporation Law', 'Purchase Agreement', '\\n  &#x2022;cause', 'the European Commission', 'Cantor Fitzgerald &amp', 'the United Kingdom&#x2019;s General Data Protection Regulations', '62,107\\n          &', '32\\n', 'IBAT', 'the &#x201c;Initial', 'companies;\\n  &#x2022;a', 'events;\\n  &#x2022;research', '\\n  &#x2022;the', 'LiabilityThe', 'Stockholders&#x2019', 'the U.S. Department of Health and Human Services', 'the Contingent Milestone', 'Shire, Satiogen', '36,235\\n          &#160;\\n', 'x2022;a collaborator&#x2019;s', '\\n  &#', 'Satiogen', 'License Revenue\\n  License', 'the Initial Lease through March 2025', '\\n  &#x2022;collaborators', 'License Agreement with Shire International GmbH', 'Upfront', '\\n  &#x2022;require', '266,590\\n          &#160;\\n', 'Financial Overview\\n', 'plan\\n        &', '\\n          &', 'Thereafter\\n          &#', 'the Sarbanes-Oxley Act', 'ContingenciesThe Company', 'Research and Development Expenses \\n', 'AMP', 'Shire with Satiogen', 'Cholbam (&#x2265;1%', 'the Call Option', 'could:\\n  &#x2022;result', '\\n  &#x2022;our', 'NotesThe Company', 'Restricted Common Stock', 'the Cumulative Purchaser Payments', 'candidates.\\n  Selling', 'Form S-3', 'RIPA', 'California Privacy Protection Agency', 'the EMA Committee', 'BA', '\\n    Provision', '\\n  &', 'the &#x201c;Amended Agreement&#x201d', 'the Court of Chancery of the State of Delaware', 'CANbridge', 'China&#x2019;s Personal Information Protection Law', 'Livmarli, Cholbam', 'the Registrant&#x2019;s Quarterly Report on Form 10-Q', 'the Registrant&#x2019;s Registration Statement on Form S-1', 'ESPP', 'Ursodeoxycholic', 'Indenture', 'operations.\\n  Disruptions', 'Unified Patent Court', 'capabilities.\\n', 'European Commission', 'the Registrant&#x2019;s Current Report', 'the European Medicines Agency', 'viable.\\n  &#x2022;Our', '\\n        &', 'SEC', 'agreements.\\n', 'Liquidity and Capital Resources \\n', 'Nasdaq', '\\n    &', 'property.\\n', 'months)\\n          &#160;\\n'}"
MIRO,"{'the Merger Agreement', 'the University of Minnesota', 'Gross LossGross', 'September&#160;30,&#160;2022', '100.0&#8203;Total', 'Exclusive Patent License Agreement', 'Reprise Biomedical, Inc.', 'Contracts with Customers (&', 'income&#160;&#160', 'the Equity Distribution Agreement', 'LiquidityThe', 'InformationDuring', 'Co. (&', 'Transactions', 'the Mayo Clinic', 'ContentsComparison', 'ContentsItem&#160;6', 'PreparationThe', 'United Therapeutics Corporation', 'University', 'Baxter International Inc.', 'RevenueLicensing', 'ContentsUnder', 'Recent Accounting PronouncementsRecently Adopted Accounting PronouncementsThe FASB', 'Inc. (&', 'the Texas Heart Institute', 'DaVita Inc.Basis', 'Accounting Standards Codification', 'the University for the&#160;year ended December&#160;31', 'U.S. Treasury', 'Piper Sandler &amp', 'Form S-1', 'DevelopmentResearch', 'SEC', 'the University of $500,000', 'ContentsResearch', 'Contingent Value Rights Agreement', 'Company', 'herewith.32.1Certification of Chief Executive', 'StatementWe', 'Restated Bylaws of Miromatrix Medical Inc.', '8.9&#8203;Quality &', 'ProceduresDisclosure', 'Exhibit 3.2', 'the Sarbanes-Oxley Act', 'the Mount Sinai Health System', 'IPO', 'ContentsItem&#160;2', 'ExpenseInterest', 'Securities and Exchange Commission', 'ASU No', 'LossOur', 'the Registration Statement'}"
MIST,
MLEC,
MLTX,"{'ASC', 'OverviewWe', 'LLC', 'the Business Combination Agreement', 'Segment InformationThe Company', 'the Annual Report', 'ExhibitsThe', 'CompensationThe Company', 'Principal Executive Officer Pursuant to Securities Exchange Act', 'Principal Executive Officer Pursuant', 'MoonLake AG Common', 'No &#9744;Indicate', 'Principal Financial and Accounting Officer Pursuant to Securities Exchange Act', 'Note&#160;15 &', 'the &#8220;Business Combination Agreement&#8221;)', 'Helix Acquisition Corp.', 'Helix Holdings', 'SLK', 'Clinical Research Organizations (&#8220;CROs&#8221', 'Condensed Consolidated Financial Statements7Item 2', 'ProceduresWe', 'SVB Securities LLC', 'Internal Control', 'the Securities and Exchange Commission', 'SVB Securities', 'MoonLake Immunotherapeutics AG', 'Note 11 &', 'Cayman Islands', 'administrative(15,390,117)(17,685,152)2,295,035&#160;(13.0)%Total', 'each ML Party', 'Company', 'AcquisitionsThe Company', 'Net Loss', 'Research Cooperation Technologies, Inc. (&', 'ASU', 'Guggenheim Securities', 'ML Party', 'Merck Healthcare KGaA', 'Note 3 &#8212', 'OperationsComparison', 'MoonLake', 'Clinical Manufacturing Organizations (&#8220;CMOs&#8221', 'Financial ReportingThere', 'Determination of Fair Value &#8211', 'DevelopmentResearch', 'Pursuant', 'Leerink Partners', 'the Sarbanes-Oxley Act', 'MoonLake Immunotherapeutics Ltd.', 'Unipessoal Lda', 'Articles of Association of MoonLake Immunotherapeutics', 'AdoptedThe Company', 'Form S-3', 'Fair Value MeasurementsThe', 'Consolidated Balance Sheets2Condensed Consolidated Statements of Operations', 'this Quarterly Report', 'Basis of Presentation', 'ShareAs', 'Business Combination Agreement', 'MoonLake AG', 'the Accounting Standards Codification', 'ATM', 'Note 2 &#8212', 'the SLK Program', 'ESPP', 'IPR&amp;D', 'Immunotherapeutics 2022 Equity Incentive Plan408,171&#160;124,621&#160;721,155239,760Total', 'this Quarterly Report on Form 10-Q.No', '8220;In-License', 'Consolidated Statements of Changes In Equity', 'EquipmentProperty', 'Aktiengesellschaft', 'U.S. Dollar', 'In-License Agreement', 'respectively.24Item 2', 'RCT&#8217;s', 'SEC', 'AG', 'the Business Combination', 'MNLK Immunotherapeutics', 'ESOP'}"
MLYS,"{'FASB', 'Mitsubishi', 'ProceduresWe', 'CommitmentsUnder', 'this Quarterly Report', 'Contractual Obligations', 'BP', 'Mitsubishi TanabeIn', 'Preferred Stock OfferingsIn', 'Mitsubishi Tanabe', 'Internal Control', 'InformationDuring', 'the Private Securities Litigation Reform Act', 'Financial ReportingManagement', 'Mitsubishi Tanabe Pharmaceutical Company', 'ContingenciesLicense Agreement', 'the Mitsubishi License', 'Lorundrostat Products', 'Series A Preferred Stock', 'Administrative ExpensesGeneral', 'Sheet LocationOriginal MaturitiesAmortized CostEstimated Fair', 'Capital Resources.&#8221;License Agreement', 'U.S. Treasury', 'InflationInflation', 'Contentsmay', 'Conclusion Regarding the Effectiveness of Disclosure Controls', 'ProceduresUnder', 'the Series A Purchase Agreement', 'SEC', 'Milestone', 'Company', 'the Sarbanes-Oxley Act', 'COVID-19', 'IPO', 'Fair Value of Financial InstrumentsThe', 'Series B Preferred Stock', ': &#8226;the'}"
MMSI,
MNKD,
MNMD,
MNOV,
MNPR,"{'\\n       Financial Statements', 'ASC', 'Company&#x2019;s Validive', 'NUS', '\\n        &#', 'No &#x2610;\\n&#xa0;\\nIndicate', 'Board', 'Leases\\n   &', 'the Principal Investigator', 'operations.\\n   &#', 'operations.\\n  &#', 'Condensed Consolidated Statements of Operations and Comprehensive Loss', 'CSI Singapore', 'programs.\\n  &#', 'analogs)&#x37e', 'XOMA', 'agreement.\\n  &#xa0;\\n  Service Providers\\n  &#', 'Monopar&#x2019;s', 'this Quarterly Report on Form 10-Q', 'Concentration of Credit Risk\\n   &#', 'Prepaid Expenses\\n', 'assets.\\n   &', 'XOMA Ltd.', 'the Data Safety Monitoring Board', 'earned.\\n   &', '\\n   &#', 'Legal Contingencies\\n   &#', 'xa0;\\n     &#x2014;\\n     &#', 'FDA', 'ASTS', '\\n  &#', 'XOMA Ltd.\\n  &#', 'Variance \\n     &#', 'MNPR-202', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', 'November&#xa0;2024.\\n  &#', 'Research and Development (&#', 'the American Society of Hematology', 'U.S. Treasury', 'cash.\\n  &#', 'Legal Contingencies\\n  &#', '\\n        &', 'Condensed Consolidated Statements', 'Onxeo', 'RECIST', 'agreements.\\n', '\\n     &#', 'Condensed Consolidated Balance Sheets', 'personnel.\\n  &#', 'Company', 'Pursuant', 'Condensed Consolidated Statements of Cash Flows', 'Second Amended and Restated Certificate of Incorporation', 'Variance \\n     &#xa0;\\n     &#', 'Licensing Agreements\\n   &', 'Grupo Espa&#xf1;ol de Investigaci&#xf3;n en Sarcomas (&#x201c;GEIS&#x201d;)\\n  &#', 'Procedures\\n  &#', 'XOMA Ltd.\\n   &', 'certifications.\\n  &#', 'JonesTrading Institutional Services LLC', 'Office Lease\\n  &#', 'concern.\\n  &#xa0;\\n  &#', 'Comparison', 'Nasdaq', 'the U.S. Securities and Exchange Commission', '\\n    &#', 'agreement.\\n   &#', 'Condensed Consolidated Financial Statements'}"
MODD,
MODV,"{'Company\\', 'LLC', 'Credit Agreement', 'RPM', 'ContingenciesSurveys', 'PRF', 'JPMorgan Chase Bank', 'Deutsche Bank AG', 'PCS', 'net$485,951&#160;100.0%$459,796&#160;100.0%$1,452,389&#160;100.0%$1,309,449&#160;100.0%Service', 'Capital One', 'Truist Securities, Inc.', 'Intangible Assets', 'ESPP', 'the Compensation Committee', 'OtherTotalService', 'net$1,309,449&#160;$491,661&#160;$49,362&#160;$&#8212;&#160;$1,850,472&#160;Grant income(1)&#8212;&#160;4,587&#160;&#8212;&#160;&#8212;&#160;4,587&#160;Service expense1,100,801&#160;379,423&#160;17,884&#160;&#8212;&#160;1,498,108&#160;General', 'National Association', 'Truist Bank', 'Wells Fargo Bank', 'NEMT', 'PRSU Agreement', 'Credit Facility', 'GITC', 'Regions Bank', 'the Credit Agreement', 'Segment RevenueOperating ResultsService', 'Goodwill', 'SEC', 'SeasonalityOur NEMT', 'Restricted', 'the Department of the Treasury', 'Company', '8220;Financial Statements&#8221;.Credit Facility', 'Bank of America', 'New York Branch', 'SLFRF', 'COVID-19', 'Recent Accounting', 'YTD', 'Wells Fargo Securities', 'CODM', 'Bank of Montreal', '2023.Credit FacilityThe Company', 'Corporate', 'the Credit Facility', 'ARPA'}"
MOLN,"{'\\n  &#x2022;injury', 'years)\\n        &', 'LLC', 'AMD', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n    Interest income\\n    &', '\\n  &#x2022;variations', '\\n  Commission File Number 001-39782', '\\n', 'Medicaid Innovation (&#x201c;CMMI&#x201d;)', '\\n  &#x2022;expansion', 'the University of PennsylvaniaOn April 21, 2023', 'EMA', '\\n  &#x2022;disruptions', 'the Regents of the University of California', '\\n  &#x2022;an', 'Rights Agreement', 'Uneek Mehra\\n', '\\n  &#x2022;termination', 'this Quarterly Report on Form 10-Q', 'the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program', 'the University of California The Company', 'Jefferies LLC', '223,327\\n    &', '\\n  &#x2022;costs', 'B.V. (&#x201c;uniQure&#x201d', 'Molecular Therapeutics, Inc.', 'x2022;a', 'UNITED STATES', 'Effects of Inflation\\n', 'the &#x201c;License', '\\n    Research', 'AGT the Transferred Material', 'UC Agreements', 'ACA', 'Segment Information The Company', 'the Securities Exchange Act', '\\n  &#x2022;expenditures', 'the S-3 Registration Statement', 'COVID-19', 'the License Agreement).Aevitas Therapeutics, Inc.', 'the University of Pennsylvania', 'the Company&#x2019;s 2022 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'the Funding Agreement', 'Registration Statement on Form S-1', 'FASB', '2022\\n         \\n         \\n          &#160;Customer', '\\n  &#x2022;product', 'DirectorPrincipal Executive', '\\n  &#x2022;sufficient', 'the &#x201c;UC Agreements&#x201d', '\\n  &#x2022;publicity', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'CFF', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;general', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'Licensed Products', 'requirements.\\n  &#x2022;Our', 'parties)\\n    &', 'and\\n  &#', 'Registration Statement on Form S-3', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'Center for Medicare &', '\\n  &#x2022;others', 'the Medicaid Drug Rebate Program', 'the Amended uniQure Agreement', 'x201c;CFF', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;loss', '\\n  &#x2022;new', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '99%\\n          &#160;\\n', 'Catalent', 'USPTO', '\\n  &#x2022;impose', '\\n  &#x2022;seize', 'DME', '\\n    &#', 'Report', 'the Delaware General Corporation Law', '\\n  &#x2022;diligence', '\\n  ', 'Capital Requirements \\n', 'the UC Agreements', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD', 'UK Data Protection Act 2018', '\\n  &#x2022;future', 'the Program Advisory Group', '\\n  Interest Rate Sensitivity', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'the Sales Agreement', '497\\n        &', '\\n  &#x2022;coverage', 'Roche', '\\n  &#x2022;exhaustion', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;commencement', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;retention', 'Registrant', 'the UC Regents', '\\n          &', 'technologies.\\n  &#', 'Condensed Statements of Operations', '10\\n       &', '\\n  &#x2022;announcement', 'IPO', 'AWA', '\\n  &#x2022;The', 'companies&#x2019', 'ASU No', 'the Amended uniQure Agreement or the Second uniQure Agreement', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Therapeutic Vector Evolution', 'Form S-3', '\\n  &#x2022;convenience', 'the License Agreement', 'GA', '\\n  &#x2022;We', 'the Funding Agreement Product (&#x201c;Acceptance&#x201d;)', 'the &#x201c;August 2023', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '500\\n    &', 'harmed.\\n  &#x2022;Our', 'European Union', 'Condensed Statements of Comprehensive Loss', '99%\\n          &#', 'the State of Delaware', 'x2022;refuse', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', '\\n  &#x2022;suspend', 'frames.\\n  &', '\\n  &#x2022;the FDA', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Related Party Transactions', 'the Court of Chancery', 'Significant Accounting Policies', 'the &#x201c;Funding Agreement', '\\n        &', 'SEC', 'ATM Offering', 'agreements.\\n', 'Collaboration and License Agreement', 'BLA', 'The CFF Agreement', 'the Centers for Medicare &', 'the University of California and The Trustees of the University of Pennsylvania', '\\n  &#x2022;failure', 'Aevitas Therapeutics, Inc. (&#x201c;Aevitas&#x201d;)', '\\n  &#x2022;reduced', 'the European Union', '\\n  Litigation', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
MOR,
MORF,"{'the Delaware General Corporation Law', 'treasury', 'Schr&#246;dinger', 'CMS', 'NetInterest', 'OperationsComparison', 'Critical Accounting Policies', 'the Children&#8217;s Medical Center Corporation', 'EMA', 'ATM', 'the Court of Chancery of the State of Delaware', 'parties;&#8226;we', 'MMA', 'Medicaid', 'Medicare', 'European Council', 'IndemnificationsThe Company', 'CommercializationOur', 'ContingenciesGuarantees', 'GDPR', 'EU', 'Johnson &', 'FDA', 'PCT', 'ExpensesResearch', 'the UK Parliament', 'the Janssen Agreement', 'Consumer Data Protection Act', 'Jefferies LLC (&#8220;Jefferies&#8221', 'Contentsplanned', 'The U.S. Patent and Trademark Office', 'European Parliament', 'Clinical Trials Regulation', 'Pfizer Inc.', 'Bristol-Myers Squibb', 'The U.S. Treasury', 'Janssen Pharmaceuticals, Inc.', 'Risks Related', 'the Medicare Prescription Drug', 'the Medicaid Drug Rebate Program', 'HIPAA', 'ProceduresUnder', 'UCB', 'DevelopmentResearch', 'Restricted', 'SEC', 'ContentsWe', 'Financial Operations OverviewCollaboration RevenueWe', 'Company', 'ContentsOur', 'trial;&#8226;we', 'TCA', 'USPTO', 'Jefferies', 'COVID-19', 'the Schr&#246;dinger Agreement', 'BID', 'Placement Shares', 'the Pre-Funded Warrants', '2023.For', 'the General Data Protection Regulation', 'Takeda Pharmaceutical Company Limited', 'ContentsItem&#160;3', 'Biogen Inc.', 'the CMCC Agreement'}"
MOTS,"{'FASB', 'ASU', 'Form S-3', 'below.\\n\\n&#160;\\n\\nThe\\n2021 Shelf Registration Statement', 'Board', 'Financial Instruments-Credit Losses', 'the Placement Agent Warrants', 'Credit Losses&#8221', 'Co. Inc.', 'ASU No', 'Aegis\\nCapital Corp.', 'these Placement Agent Warrants', 'single\\ndigit', 'marketing&#160;\\n    &', 'the Certificate Holder Securities,\\nthe &#8220;Exchange', 'the Certificate Holders', 'the Shared Space Agreement', 'Pre-Funded Warrants', 'Loan', 'Oppenheimer', '\\n    &', 'executive\\nand', 'Distribution Agreement', 'the Private Placement', 'OBIO', 'Share', 'SEC', 'defer\\ntheir Board', 'Common Stock', 'Company', 'the Royalty Payment Rights Certificates', 'Equity Securities', 'Tranche', 'the Kreos Loan Agreement', 'Series A Convertible Preferred Stock', 'Oppenheimer &amp'}"
MOVE,"{'Yes &', 'the Nasdaq Capital Market', 'Registered Securities\\n\\n&#160;&#160;\\n\\nOn', 'Cover Page Interactive Data File', 'Board', 'the Preferred A Lead Investor\\nWarrants', 'eliminated\\nin', 'herewith)\\n', 'continuous\\nglucose monitoring (&', 'Restated Certificate of Incorporation of the Registrant', 'December&#160;31', 'the-Market Issuance Agreement', 'U.S.C Section 1350', 'WarrantsMember\\n', 'FDA', 'Company&#8217;s\\ncommon', 'B. Riley Securities, Inc.', 'April&#160;22', 'the Evie Ring', 'Principal Financial and Accounting', 'market&#8221', 'Principal Executive', 'Company', 'year.\\n\\n&#160;\\n\\nNote\\n9 &#8211', 'the Securities Exchange Act', 'purchase\\n201,613', 'December&#160;31,\\n2022', 'the indemnified party', 'the Issuance Agreement', 'Condensed Consolidated Financial', '\\n    &', 'FounderMember\\n', '\\n&#160;\\n\\nThe Company', 'the Sarbanes-Oxley Act of 2002'}"
MRAI,"{'FASB', 'ASU', 'the Nasdaq Capital Market', '\\n    Foreign exchange', 'Cover Page Interactive Data File', 'plan.\\n  &', 'Marpai Health and Marpai Administrators', 'Name:\\n', 'the Purchase Agreement (&', '2022.7\\n     &#160;MARPAI, INC.', 'the Board of Directors', '\\n  &', 'Exhibits.\\n  &#160;\\n', 'Yes &#9744', 'Notice', 'the Current Report on Form 8-K', 'ObligationsAll', 'No\\n  Indicate', 'Maestro', 'Market Value of Listed Securities (&#x201c;MVLS&#x201d;)', '\\n  &#', 'client&#x2019;s', 'Exhibit 10.2', 'the Bid Price Requirement', 'Marpai, Inc.', '+ Management', '\\n    Research', 'Depreciation', 'Principal Financial and Accounting', '\\n    Interest', 'SEC', 'Principal Executive', 'Interactive Data Files\\n', 'stakeholders.\\n  Research and Development Expenses\\n', 'Company', 'the Securities Exchange Act', 'Restricted CashRestricted', 'The Nasdaq Capital Market LLC (&#x201c;Nasdaq&#x201d', 'expense)\\n    &', 'indicated.\\n  &', '\\n    Interest expense\\n    &', 'Regulation S-K.\\n', 'Marpai', 'Comparison', 'management&#x2019;s current beliefs', 'Nasdaq', '\\n    &', 'ASU No', 'Nasdaq Listing Rule 5550(b)(2'}"
MREO,
MRKR,"{'LLC', 'Form S-3', 'net &', 'OperationsThe Purchased Assets', 'AML', 'the Work Direction', 'Danforth Advisors', 'Contracts', 'compensation&#8203', 'equivalents&#8203;$', 'ATM', 'the National Institutes of Health Small Business Innovation Research', 'THERAPEUTICS', 'the Securities and Exchange Commission', 'ASC Subtopic', 'ActivitiesNet', 'Section&#160;13', 'FDA', 'Lincoln Park', 'the Lincoln Park Purchase Agreement', 'Qualitative Disclosures About Market RiskWe', 'Bio-Techne Corporation', '25,118&#8203;&#8203', 'respectively.&#8203;National Institutes of Health Small Business Innovation ResearchIn', 'Estimates', 'Lincoln Park Capital Fund', 'AssumptionsThe', 'Entity&#8217;s Own Equity', 'FlowsThe', 'Working CapitalThe', 'Regulation S-K.', 'SEC', 'GeneMax Pharmaceuticals Canada', 'Principal Executive', 'Wilson WolfThe Company', 'Company', 'the Securities Exchange Act', 'Bio-Techne CorporationThe Company', 'the Manufacturing Facilities', 'number)&#8203;4551 Kennedy Commerce Drive', 'Marker Cell Therapy, Inc.', 'GeneMax Pharmaceuticals Inc.', 'FDIC', 'Interim Principal Financial and Accounting Officer&#8203;&#8203;&#8203;&#8203;31\\n\\n\\n\\n', 'compensation &', 'Nasdaq Stock Market', 'FactorsOur', 'BCM', 'LLC (&#8220;Lincoln', 'General Instruction I.B.6', 'the National Institutes of Health Small Business  Innovation Research', 'G-Rexes', 'the Wilson Wolf Agreement'}"
MRNA,"{'ASC', 'FASB', 'Cambridge CampusWe', 'Generation Bio Co.', 'LLC', 'RevenueThe', 'HHS', 'the U.S. Government', 'Principal Financial Officer', 'Melinda Gates Foundation', 'Merck', 'InformationDuring', 'RSV', 'Contents Recently Issued Accounting Standards Not', 'the National Institute of Allergy and Infectious Diseases', 'the Securities and Exchange Commission', 'Stock-Based Compensation and Share Repurchase ProgramsStock-Based Compensation  ', 'the U.S. Department of Health and Human Services', 'the Office of the Assistant', 'Contents 7', 'MTC', 'Performance Stock Units', 'GBIO', 'development40&#160;28&#160;115&#160;67&#160;Selling', 'DARPA', 'mRNA RiboTherapeutics, Inc.', 'CMV', 'No  &#9744;Indicate', 'TCR', 'ControlsOur', 'AI', 'SEC', 'Immatics', 'Response', 'Patented TechnologyWe', 'INT', 'Cellscript', 'Collaboration and License Agreement', 'Company', 'the Securities Exchange Act', 'Plant and Equipment, Net Property', 'the Defense Advanced Research Projects Agency', 'the Sarbanes-Oxley Act', 'COVID-19', 'Swiss Franc', 'TCER', 'Gates Foundation', 'Purchase OrdersWe', 'the Bill &', 'the Biomedical Advanced Research and Development Authority'}"
MRNS,
MRSN,"{'LLC', 'Synaffix B.V.', 'Oxford', 'Merck KGaA Supply Agreement', 'EMA', 'EstimatesOur', 'Principal Executive Officer', 'the GSK Agreement', 'EEA', 'this Quarterly Report on Form 10-Q', 'the ""Janssen Agreement', 'EU', 'Mersana Therapeutics, Inc.', 'Mersana Securities Corp.', 'the IRA&#8217;s Drug Price Negotiation Program for', 'Takeda Pharmaceuticals, Inc.', 'Chamber of Commerce', 'CPRA', 'Astellas Pharma Inc.', 'Option', 'ContentsWe', 'the Securities Exchange Act', 'Janssen Biotech Inc.', 'Need for Additional CapitalWe', 'COVID-19', 'FactorsOur', 'Principal Financial Officer Pursuant', 'ContentsIn', 'First-Citizens Bank &amp', 'FASB', 'GlaxoSmithKline Intellectual Property', 'HHS', 'EstimatesThe', 'Fifth Amended', 'Medicaid', 'the Securities and Exchange Commission', 'Congress', 'Medicare', 'ContentsAlternatively', 'GDPR', 'ContentsComparison', 'FDA', 'ContentsAny', 'the ""New Credit Facility', 'the Janssen Agreement', 'Licensed Products', 'Recepta Biopharma S.A.', 'Risks Related to Regulatory Approval', 'respectively.&#160;The Company', 'ADC', 'UPLIFT', 'Financial Position', 'Loan', 'Ludwig Institute for Cancer Research Ltd.', 'ContentsThe', 'Merck KGaA', 'Risks Related', 'HIPAA', 'Principal Executive Officer Pursuant to Rules', 'ContentsMersana', 'the FDA.The FDA', 'Martin Huber10.5*Letter Agreement', 'Silicon Valley Bank', 'ContentsMoreover', 'FDARA', 'FTC', 'Principal Financial Officer Pursuant to Rules', 'Company', 'ContentsIn December 2022', 'USPTO', 'Adopted Pursuant to Section 302', 'the California Privacy Rights Act', 'Cowen', 'SVB', 'Consolidated Statements of Operations', 'the European Commission', 'Ares Trading', 'CMS', 'ConsolidationThe', 'OperationsComparison', 'Oxford Finance', 'Merck', 'CandidatesOur', 'Consolidated Statements of Cash Flows', 'Trust Company', 'the Nasdaq Stock Market', 'the Research Collaboration and License Agreement', 'CMC', 'Lenders', 'LiabilitiesThe', 'ContentsOur', 'Restated Certificate of Incorporation', 'Liquidity and Capital Resources Sources', 'IRA', 'Genentech', 'the Sarbanes-Oxley Act', 'the Prior Credit Facility', 'the Roche Group', 'LiquidityWe', 'Consolidated Statements', 'CJEU', 'ATM', 'the Court of Chancery of the State of Delaware', 'Anna Protopapas.10.4*Offer Letter', 'the ""Development Activities', 'the New Credit Facility', 'European Union', 'the U.S. Food and Drug Administration', 'ContentsConfidentiality', 'the State of Delaware', 'Omnibus', ""Merck KGaA\\'s"", 'the Court of Chancery', 'ContentsGeneral Risk FactorsWe', 'Ares Trading S.A.', 'SEC', 'non-U.S.', 'BLA', 'the U.S.', 'AbbVie Inc.', 'Condensed Consolidated Financial Statements10Item&#160;2', 'Consolidated Balance Sheets', 'GSK', 'the European Union', 'ContentsThird'}"
MRTX,"{'OtherLongTermInvestmentsMember2023-09-300001576263us', 'Aadi Bioscience', 'LLC', 'document1.1Underwriting Agreement', 'Chargebacks', 'CDK4/6', 'Contents5.&#160;&#160;&#160;&#160;InventoryInventory', 'Manufacturing Supply', 'FairValueInputsLevel1Member2022-12-310001576263us-gaap', 'EMA', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001576263us-gaap', 'ProceduresAs', 'EstimatesOur', 'Legal ProceedingsThe Company', 'Mirati Therapeutics,&#160;Inc.&#8217;s Amended Registration Statement', 'ContentsProduct', 'Collaboration and License Agreement with Zai', 'EEA', 'Revenue RecognitionThe Company', 'Mirati Therapeutics, Inc.*', 'EU', 'netProduct', 'Pfizer Inc.', 'NSCLC', 'BMSWe', 'Array', 'ContentsWe', 'ACA', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'MaximumMember2023-08-012023-08-310001576263mrtx:AtTheMarketFacilityMember2020', 'Breakthrough Therapy Designation', 'International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use', 'Zai AgreementTerms', 'SOS1', 'ORIC Pharmaceuticals, Inc. (&#8220;ORIC&#8221', 'the BeiGene Agreement', 'ContentsIn', 'Mirati Therapeutics', 'ORIC.The', 'USTreasuryBillSecuritiesMember2023', 'the Merger Agreement', 'WarrantMember2023-07-012023-09-300001576263us-gaap', 'KRAZATI', 'Pfizer', 'Anti-Kickback Statute', 'AgreementOn August 3, 2020', 'Capital Requirements &', 'HHS', 'the BeiGene Licensed Territory', 'ClassOfWarrantsIssuedAugust112023Member2023-08-0100015762632023-08-0100015762632023-08-012023-08-310001576263srt', 'the ticker symbol &#8220;MRTX.&#8221;Agreement', 'Internal Control', 'less443,489&#160;65&#160;(811)442,743&#160;U.S. Agency', 'Medicare', 'Diluted', 'Medicaid', 'the Securities and Exchange Commission', 'CRC', 'Mirati Therapeutics,&#160;Inc.&#8217;s Registration Statement', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'USTreasuryBillSecuritiesMember2022-12-310001576263us-gaap', 'GMP', 'Clinical Research Organizations', 'Financial Position', 'Adagrasib Development in Collaboration with Zai Lab Ltd.', 'ContentsThe', 'Risks Related', 'ZaiCollaborationAndLicenseAgreementMember2023-01-012023-09-300001576263mrtx', 'Zai Lab Ltd.', 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR', 'less90,351&#160;22&#160;(434)89,939&#160;U.S. Treasury bills2', 'MRTX0902', 'BuildingMember2023-01-012023-09-300001576263mrtx:CurrentHeadquartersMember2020-06-300001576263mrtx', 'The Zai Agreement', 'the Swiss Federal Act', 'The Lease Term', 'ZaiCollaborationAndLicenseAgreementMember2023-07-012023-09-300001576263mrtx', 'Company', 'MTA', 'BID', 'the Nasdaq Capital Market', 'WarrantMember2022-01-012022-09-300001576263us', 'less244,277&#160;52&#160;(689)243,640&#160;U.S. Treasury', 'BMS', 'The BeiGene Agreement', 'Critical Accounting Policies', 'OperationsComparison', 'Contents&#8226;Our', 'the U.S. Patent and Trademark Office', 'Data Protection', 'Compensation Adjustment Letter', 'MilestonePaymentsFirstCommercialSaleOfKRAZATIMember2023', 'PrivatePlacementMember2023-09-300001576263mrtx:FutureHeadquartersMemberus-gaap', 'Mirati Therapeutics, Inc.', 'this Quarterly Report on Form&#160;10-Q', 'THE SECURITIES EXCHANGE ACT OF 1934&#160;For', 'MaximumMember2022-12-310001576263us-gaap', 'ZaiCollaborationAndLicenseAgreementMember2023-01-012023-09-300001576263us', 'CharlesMBaumMember2023-09-300001576263mrtx', 'KRAS G12C', 'net$16,400&#160;$&#8212;&#160;$16,400&#160;$36,056&#160;$&#8212;&#160;$36,056&#160;License', 'ZaiCollaborationAndLicenseAgreementMember2022-07-012022-09-300001576263us', 'ClassOfWarrantsIssuedAugust112023Member2023-09-300001576263us', 'Board of Directors', 'CMC', 'WarrantMember2022-07-012022-09-300001576263us-gaap', 'KRAS', 'KRAS G12C-mutated', 'PrivatePlacementMember2023-09-300001576263us', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001576263us', 'NDA', '2023MaturityAmortized', 'WarrantMember2023-01-012023-09-300001576263us-gaap', 'ContentsDiscovery', 'Vineyard Merger Sub Inc.', 'IRA', 'Restated Certificate of Incorporation', 'BeiGene', 'ZaiCollaborationAndLicenseAgreementMember2022-07-012022-09-300001576263mrtx', 'ProceduresEvaluation of Disclosure Controls', 'the Sarbanes-Oxley Act', 'Regulation S-K', 'Merger', 'Laurie Stelzer.10.4Consulting Agreement Amendment', 'ZaiCollaborationAndLicenseAgreementMember2022-01-012022-09-300001576263mrtx', 'Bristol-Myers Squibb Company', 'SDMA', 'ORIC Pharmaceuticals AgreementTerms', 'Sitravatinib Development in Collaboration', 'ZaiCollaborationAndLicenseAgreementMember2022-01-012022-09-300001576263us', 'Incyte', 'Goldman Sachs &', 'treasury', 'CharlesMBaumMember2023-07-012023-09-300001576263mrtx', 'USTreasuryBillSecuritiesMember2023-09-300001576263us-gaap', 'this Quarterly Report', 'PositionActionAdoption/', 'David Meek.10.2Consulting Agreement', 'Array BioPharma, Inc. (&#', 'BMS (&#8220;Merger', 'the International Trade Commission', 'Laurie Stelzer.10.3Consulting Agreement Amendment', 'ESPP', '2022Maturity', 'MAA', 'Laurie Stelzer.10.5Employment Agreement', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-3000015762632023-05-110001576263mrtx', 'Zai\\', 'the U.S. Treasury', 'INCB99280', 'Healthcare', 'BICR', 'the European Medicines Agency', 'the Pending Transaction', 'KRAZATIMembermrtx', 'BeiGene or Zai', 'SEC', 'Collaboration and License Agreement', 'the Zai Licensed Territory', 'Milestone Payments', 'the Zai Agreement', 'BI 1701963', 'Inc.&#8217;s Current Report', 'May&#160;10', 'ZaiCollaborationAndLicenseAgreementMember2023-07-012023-09-300001576263us', 'shares00015762632023-09-30iso4217:USD00015762632022-12-31iso4217', ': &#8226;salaries', 'ClassofWarrantsIssuedNovember202017Member2023-09-300001576263us-gaap'}"
MRUS,"{'LLC', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', 'x201c;global', 'harmed.\\n  &#x2022;Due', 'candidates;\\n  &#x2022;the', 'D;\\n  &#x2022;an', 'Kadans Science Partner XIII B.V.', '0.6\\n    &', 'EMA', 'EEA', 'this Quarterly Report on Form 10-Q', 'Betta', 'Jefferies LLC', 'intangibles\\n    &', 'Lilly', 'EU', 'IgG', 'x2022;a', 'Indicate', 'UNITED STATES', 'million/ &', 'NSCLC', 'The Sarbanes-Oxley Act of 2002', '\\n    Research', 'SOX', '\\n  Discussion and Analysis', 'ACA', 'Eli Lilly', 'the Financial Accounting Standards Board', 'Operations&#x201d;.New Accounting PronouncementsThe Company', 'antibody candidates;\\n  &#x2022;the', 'Jefferies', 'data)\\n  &#160;\\n', 'COVID-19', 'L.L.C.', 'Principal Financial Officer Pursuant', 'non-EEA', 'Accelerator', 'Betta Pharma', 'BofA Securities, Inc.', 'Anti-Kickback Statute', 'HHS', 'including:\\n  &#x2022;economic', 'QT', 'liability;\\n  &#x2022;expansion', 'the U.S. Congress', 'the Dutch Code of Civil Procedure', 'Keytruda', 'the Unaudited Condensed Consolidated Financial', 'Medicaid', 'Medicare', 'the Consulting Agreement', 'United Kingdom General Data Protection Regulation', 'GDPR', 'risks.\\n  Interest Rate', 'FDA', 'and\\n  &#x2022;establishment', 'approved.\\n  Risks Related to Intellectual Property and Information Technology\\n', 'Jefferies LLC (&#x201c;Jefferies&#x201d', 'letters;\\n  &#x2022;civil', 'collaborators&#x2019', 'the National Medical Products Administration', 'and\\n  &#', 'Risks Related to Regulatory', 'and\\n  &#x2022;imposition', 'Risks Related', 'the Medicaid Drug Rebate Program', 'HIPAA', 'the \\n  &#160;\\n', 'CONDENSED CONSOLIDATED', 'CRPC', 'injected;\\n  &#x2022;extension of a manufacturer&#x2019;s Medicaid', 'Eli Lilly and Company (&#x201c;Lilly&#x201d;)', 'activities\\n    &', 'Patient-Centered Outcomes Research Institute', 'Incyte Corporation', 'Company', '69\\n', 'the following:\\n  &#x2022;an', 'Material Changes in Financial Condition \\n', 'UK&#x2019;s', 'USPTO', 'markets;\\n  &#x2022;differing', 'profits.\\n', 'Association of Merus N.V.', 'and\\n  &#x2022;business', 'efficiencies;\\n', '\\n    &#', 'euro', 'Guggenheim Securities', 'the Public Health Service', 'AIA', 'CMS', 'candidates;\\n  &#', 'the U.S. Patent and Trademark Office', 'the &#x201c;Underwriting', 'regulations;\\n  &#x2022;changes', 'the Unaudited Condensed Consolidated Financial Statements', 'MERUS', 'x2022;injunctions;\\n  &#x2022;suspension', 'the Lilly Collaboration Agreement', 'U.S. Holder', 'The Hague Convention of 2', '\\n  &#', 'organizations;\\n  &#x2022;expansion', 'LiabilitiesThe', 'the Hague Convention on Choice of Court Agreements', 'partners.\\n  &#x2022;We', 'MeMo&#174', 'Betta Pharmaceuticals Co. Ltd.', 'United Kingdom&#x2019;s', 'the Sarbanes-Oxley Act', 'Comparison', 'EGFR', 'ADT', 'decline.\\n', 'Incyte', 'the Securities and Exchange Act', 'Form S-3', 'treasury', 'Merus', '\\n  &#x2022;We', 'Exon 21 (L858R', 'Medicaid Innovation', 'individuals.\\n  Most health care providers', 'Fast Track Designation', 'Tagrisso', 'European Union', 'CTR', 'Medicaid Services', 'the European Union General Data Protection Regulation', 'NRG1', 'Employee Matters', 'MCLA-145;\\n  &#x2022;the', '\\n        &', 'LeasesThe Company', 'Restricted', 'SEC', 'GCP', 'barriers;\\n  &#x2022;changes', 'the Centers for Medicare &', 'RESTRICTED', 'Nasdaq', '\\n    &'}"
MRVI,
MTEM,"{'\\n  &#x2022;injury', 'years)\\n        &', 'LLC', 'AMD', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n    Interest income\\n    &', '\\n  &#x2022;variations', '\\n  Commission File Number 001-39782', '\\n', 'Medicaid Innovation (&#x201c;CMMI&#x201d;)', '\\n  &#x2022;expansion', 'the University of PennsylvaniaOn April 21, 2023', 'EMA', '\\n  &#x2022;disruptions', 'the Regents of the University of California', '\\n  &#x2022;an', 'Rights Agreement', 'Uneek Mehra\\n', '\\n  &#x2022;termination', 'this Quarterly Report on Form 10-Q', 'the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program', 'the University of California The Company', 'Jefferies LLC', '223,327\\n    &', '\\n  &#x2022;costs', 'B.V. (&#x201c;uniQure&#x201d', 'Molecular Therapeutics, Inc.', 'x2022;a', 'UNITED STATES', 'Effects of Inflation\\n', 'the &#x201c;License', '\\n    Research', 'AGT the Transferred Material', 'UC Agreements', 'ACA', 'Segment Information The Company', 'the Securities Exchange Act', '\\n  &#x2022;expenditures', 'the S-3 Registration Statement', 'COVID-19', 'the License Agreement).Aevitas Therapeutics, Inc.', 'the University of Pennsylvania', 'the Company&#x2019;s 2022 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'the Funding Agreement', 'Registration Statement on Form S-1', 'FASB', '2022\\n         \\n         \\n          &#160;Customer', '\\n  &#x2022;product', 'DirectorPrincipal Executive', '\\n  &#x2022;sufficient', 'the &#x201c;UC Agreements&#x201d', '\\n  &#x2022;publicity', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'CFF', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;general', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'Licensed Products', 'requirements.\\n  &#x2022;Our', 'parties)\\n    &', 'and\\n  &#', 'Registration Statement on Form S-3', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'Center for Medicare &', '\\n  &#x2022;others', 'the Medicaid Drug Rebate Program', 'the Amended uniQure Agreement', 'x201c;CFF', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;loss', '\\n  &#x2022;new', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '99%\\n          &#160;\\n', 'Catalent', 'USPTO', '\\n  &#x2022;impose', '\\n  &#x2022;seize', 'DME', '\\n    &#', 'Report', 'the Delaware General Corporation Law', '\\n  &#x2022;diligence', '\\n  ', 'Capital Requirements \\n', 'the UC Agreements', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD', 'UK Data Protection Act 2018', '\\n  &#x2022;future', 'the Program Advisory Group', '\\n  Interest Rate Sensitivity', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'the Sales Agreement', '497\\n        &', '\\n  &#x2022;coverage', 'Roche', '\\n  &#x2022;exhaustion', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;commencement', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;retention', 'Registrant', 'the UC Regents', '\\n          &', 'technologies.\\n  &#', 'Condensed Statements of Operations', '10\\n       &', '\\n  &#x2022;announcement', 'IPO', 'AWA', '\\n  &#x2022;The', 'companies&#x2019', 'ASU No', 'the Amended uniQure Agreement or the Second uniQure Agreement', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Therapeutic Vector Evolution', 'Form S-3', '\\n  &#x2022;convenience', 'the License Agreement', 'GA', '\\n  &#x2022;We', 'the Funding Agreement Product (&#x201c;Acceptance&#x201d;)', 'the &#x201c;August 2023', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '500\\n    &', 'harmed.\\n  &#x2022;Our', 'European Union', 'Condensed Statements of Comprehensive Loss', '99%\\n          &#', 'the State of Delaware', 'x2022;refuse', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', '\\n  &#x2022;suspend', 'frames.\\n  &', '\\n  &#x2022;the FDA', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Related Party Transactions', 'the Court of Chancery', 'Significant Accounting Policies', 'the &#x201c;Funding Agreement', '\\n        &', 'SEC', 'ATM Offering', 'agreements.\\n', 'Collaboration and License Agreement', 'BLA', 'The CFF Agreement', 'the Centers for Medicare &', 'the University of California and The Trustees of the University of Pennsylvania', '\\n  &#x2022;failure', 'Aevitas Therapeutics, Inc. (&#x201c;Aevitas&#x201d;)', '\\n  &#x2022;reduced', 'the European Union', '\\n  Litigation', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
MXCT,
MYGN,
MYMD,"{'ASC', 'financial condition\\nand', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Conversion Price', 'Supera-CBD', 'the Fee Deferral Amount', 'this Quarterly Report on Form 10-Q', 'F Preferred Shares&#8221', 'SRQ Patent Holdings', 'Merger Sub, Inc. (', 'Court', 'MyMD Pharmaceuticals', 'Nasdaq Listing Rule', 'Merger Sub', 'the &#8220;August 2022', 'the Listing Qualifications Department', 'Nasdaq under\\nthe symbol &#8220;MYMD.&#8221;\\n\\n&#160;\\n\\nIn', 'Offering&#8221;).\\n\\n&#160;\\n\\nSeries\\nF Convertible Preferred Stock\\n\\n&#160;\\n\\nThe\\nPreferred Shares', 'MyMD', 'CBD', 'CECL', 'Certificate of Designation', 'The Conversion Price', 'Warrants', 'FASB', 'the Johns Hopkins University School of Medicine', 'Holdings', 'Supera', 'the Minimum\\nBid Price Requirement', 'Reverse Stock', 'the Securities and Exchange Commission', 'Diluted', 'Series F Preferred Stock', 'Stock Option Agreement', 'Financial Condition', 'Journal of Gerontology: Biological Sciences', 'the Certificate of Designation', 'the &#8220;Deferral', 'Common Stock', 'Company', 'Akers Biosciences, Inc.', 'MyMD Delaware', 'the Deferral Amount', 'Bout\\nTime Marketing Corporation', '2022.\\n\\n&#160;\\n\\nMIRA\\nPharmaceuticals Limited License', 'ASU', 'SRQ Patent Holdings II', 'CRO', 'Issued Accounting Pronouncements\\n\\n&#160;\\n\\nRecently\\nIssued Accounting Pronouncements', 'Value of Financial', 'Events\\n\\n&#160;\\n\\nNASDAQ Capital Market Notice of Delisting', 'the Series F Preferred Shares', 'separation.\\n\\n&#160;\\n\\nExecutive\\nOfficer Contract Amendments', 'the &#8220;Conversion Price&#8221', 'IL-6', 'the Common Stock', 'Entity&#8217;s Own Equity', 'Amended and Restated Confirmatory Patent Assignment', 'Executive', 'SRQ Patent Holdings II\\n\\n&#160;\\n\\nMyMD\\nis', 'Common\\nStock (the &#8220;Warrants&#8221', 'FASB ASC 730', 'the Minimum Bid', 'as\\nMyMD Pharmaceuticals, Inc. (&', 'the New Jersey Business Corporation\\nAct', 'MyMD Florida', 'Financial Instruments-Credit Losses', 'the Second Raymond Akers Action', 'the\\nlike', 'payment.\\n\\n&#160;\\n\\nVoting\\nRights\\n\\n&#160;\\n\\nThe\\nSeries F Preferred Stock', '\\n\\n&#160;\\n\\n(j)\\nRisk Management of Cash', 'the Certificate of Designations', 'CEPA', 'Akers Acquisition Sub, Inc.', 'Nasdaq', '\\n    &', 'the Superior Court of', 'Supera-CBD&#8482;\\nas'}"
MYNZ,
NAMS,
NAOV,"{'until\\nthe Centers for Medicare', 'the Securities Purchase Agreement', 'the International Chamber of Commerce', 'PainShield', 'GEOGRAPHIC INFORMATION', 'UNCERTAINTIES\\n\\n&#160;\\n\\nLiquidity\\nand Going', 'LIQUIDITY', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'the Board of Directors', 'Nasdaq Listing Rules', 'Markets and Markets', 'Nasdaq Listing Rule 5550(b)(1', 'the\\nInternational Court of Arbitration', 'controls\\nand', 'FDA', 'Medicaid Services', 'the Company.\\n\\n&#160;\\n\\nNOTE\\n11 &#8211', 'the Exclusive Distribution', 'RELATED PARTY TRANSACTION\\n\\n&#160;\\n\\nThe\\nfirm of FisherBroyles LLP', 'out\\n', 'respectively.\\n\\n&#160;\\n\\nSelling\\nand Marketing Expenses', 'Distribution Agreement', 'the Listing Qualifications Department', 'SEC', 'Company', '\\n    Stock Options &#8211', 'the dollar.\\n\\n&#160;\\n\\nResults\\nof Operations\\n\\n&#160;\\n\\nThree\\nMonths Ended September 30, 2023 Compared to', 'Nasdaq', 'Protrade Systems,', '\\n    &', 'The\\nterm &#8220;disclosure', 'Company&#8217;s\\nsecurities', 'the Exclusive Distribution Agreement'}"
NARI,"{'ASC', 'Purchase Agreement', 'LLC', 'Credit Agreement', 'Principal Financial Officer', 'this Quarterly Report', 'Restated Bylaws8-K001-392933.25/28/202010.1#Amended', 'the LC Facility', 'Exchange Act', 'Unaudited Condensed Consolidated Financial StatementsSublicense AgreementIn', 'Principal Executive Officer', 'this Quarterly Report on Form 10-Q', 'ESPP', 'Inari Medical, Inc.', 'ContentsINARI MEDICAL', 'ContentsComparison', 'a Letter of Credit', 'the Amended Credit Agreement', 'Board of Directors', 'Restated Employment Agreement', 'Unaudited Condensed Consolidated Financial Statementsthe', 'LimFlow, S.A.', 'No &#9744;Indicate', 'EXHIBITSExhibit NumberDescriptionIncorporated', 'Inceptus', 'the Bloomberg Short-Term Bank', 'the Statement of Operations', 'LimFlow Acquisition', 'Self-Insured Health PlanAs of January 1, 2023,', 'Company', 'LimFlow', 'The Amended Credit Agreement', 'Inceptus Medical', 'Bank of America', 'the Statements of Operations and Comprehensive Income', 'the Sarbanes-Oxley Act', 'IPO', 'Impairment', 'Mitchell Hill8-K001-3929310.29/22/202310.3#Amended'}"
NAUT,"{'Consolidated Statements of Operations', 'the FDA&#8217;s Quality System Regulations', 'StatementsCondensed Consolidated Financial Statements', 'ARYA Sciences Acquisition Corp. III', 'Board', '2021.Recent Accounting Pronouncements', 'Consolidated Statements', 'the Organisation for Economic Co-operation and', 'Business Combination Agreement', 'this Quarterly Report on Form 10-Q.', 'compromised.54If', 'the U.S. Congress', 'FDA&#8217;s', 'Medicaid', 'Medicare', 'Inc.&#8217;s (&#8220;Nautilus&#8221', 'this Quarterly Report on Form 10-Q', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'RUO', 'General Risk', 'Development ExpensesResearch', 'the UK Bribery Act', 'Consolidated Statements of Cash Flows', 'following:(in', 'FDA', 'Nautilus Subsidiary, Inc.', 'ExpensesResearch', 'Ag-Bio', 'the U.S. Foreign Corrupt Practices Act', 'ARYA (&', 'FDA &#8220;general', 'Risks Related', 'Discussion and Analysis of Financial Condition', 'Operations &', 'Condensed Consolidated Financial Statements', 'Nautilus Biotechnology, Inc.', 'LeasesThe Company', 'SOX', 'Consolidated Statements of Comprehensive Loss', 'non-U.S.', 'Common Stock', 'SEC', 'Equipment, Net Property', 'Company', 'the Securities Exchange Act', 'Condensed Consolidated Financial Statement Line ItemsProperty', 'The Nasdaq Stock Market LLC', 'USPTO', 'Consolidated Balance Sheets', 'COVID-19', 'the Foreign Corrupt Practices Act', 'the Health Insurance Portability', 'the European Union', 'This Quarterly Report on Form 10-Q', 'Nautilus Biotechnology', 'us;&#8226;a', 'the California Consumer Privacy Act', 'Accounting PronouncementsThe Company'}"
NBIX,
NBSE,"{'Placement', 'FASB', 'LLC', 'RNA', 'ASU', 'Consolidated Stock Incentive Plan', 'the Placement Agent Warrants', 'Condensed Consolidated Financial Statements(Unaudited)&#8203;Stock', '2023:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Weighted-&#8203;Weighted-&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Average&#8203;Average &', 'Rule&#160;12b-2', 'the Warrant Holder', 'the Series B Warrants', 'the &#8220;Registered Direct Offering&#8221;)', 'SEC.+All', 'ContentsNeuBase Therapeutics, Inc.', 'the Exchange Agreement', 'the Registered Direct Purchase Agreement', 'SubsidiariesNotes', 'the Equity Purchase Agreement', 'Pre-Funded Warrants', 'Condensed Consolidated Financial Statements(Unaudited)&#8203;measuring', 'September&#160;30,&#160;2023&#8203', 'Administrative ExpensesGeneral', 'OptionsBelow', 'the &#8220;Registered Direct Purchaser&#8221', 'The Nasdaq Capital Market', 'the Series A Warrants', 'the Common Stock', 'SEC', 'NeuBase Therapeutics, Inc.', 'Common Stock', 'Fair Value MeasurementsFair', 'Company', 'the Securities Exchange Act', 'Neubase Therapeutics, Inc. 2019', 'Condensed Consolidated Financial Statements(Unaudited)&#8203;On June&#160;28', 'the Sarbanes-Oxley Act', 'Held for SaleThe Company', 'Alumni Capital', '390,469&#8203;Common Stock Warrant Liabilities The Company', 'the &#8220;Registered Direct Purchase', 'ASU No', 'the Registered Direct Offering'}"
NBTX,
NCNA,
NDRA,"{'MaximumMember2023', 'FASB', 'LLC', 'UnderwritingAgreementMember2023-04-012023-04-270001681682ndra', 'Principal Financial Officer', 'ATM Agreement', '2023)31.1&#160;Certification of Periodic Report', 'TDBankLoanMember2023', 'Series B Preferred Stock or Series C Preferred Stock', 'CE mark', 'Restated Certificate of Incorporation of the Company', 'authorized.&#160;&#160;ENDRA LIFE SCIENCES INC.&#160;&#160;&#160;&#160;Date', 'EU', 'Underwritten Public Offering', 'THE SECURITIES EXCHANGE ACT', 'FDA', 'Warrant Agency Agreement', 'herewith)101.INS&#160;XBRL Instance Document', 'Series C Preferred Stock (&#8220;Series C Preferred Stock&#8221', 'Taxonomy Extension Definition Linkbase', 'OptionsToPurchaseCommonStockMember2023', 'Contents&#160;PART II - OTHER INFORMATION&#160;Item', 'Series A Preferred Stock', 'TAEUS', 'Ascendiant Capital Markets', 'Taxonomy Extension Label Linkbase', 'the Federal Deposit Insurance Corporation', 'U.S. Treasury', 'Company&#160;entered', 'Ascendiant', 'Silicon Valley Bank', 'OptionsToPurchaseCommonStockMember2022-01-012022-12-310001681682ndra', 'SEC', 'WarrantsToPurchaseCommonStockMember2022-01-012022-12-310001681682ndra', 'MaximumMember2023-01-010001681682srt', 'Chairman(Principal Executive Officer)&#160;&#160;&#160;ENDRA LIFE SCIENCES INC.&#160;&#160;&#160;&#160;&#160;Date', 'CT', 'Company', 'the Securities Exchange Act', 'MaximumMember2023-01-012023-09-300001681682ndra:', 'Compensation&#160;The', 'Finance(Principal Financial and Accounting', 'Taxonomy Extension Calculation Linkbase', 'Newbridge Securities Corporation', 'the American Institute of Certified Public Accountants', 'TDBankLoanMember2022-12-310001681682srt', 'the European Union', 'CE', 'the Sarbanes-Oxley Act of 2002'}"
NEO,
NEOG,
NEPH,
NEPT,
NERV,
NEXI,"{'AIM INJ.The', 'Adopted Accounting PronouncementsA', 'the Center for Discovery &', 'Board', 'Dissolution', 'Artificial Immune Modulation', 'this Quarterly Report', 'the Nasdaq Hearings Panel', 'Signal 2', 'AIM ACT', 'OPERATIONS', 'ActivitiesNet', 'the Sales Agreement', 'Initial Public OfferingIn', 'the State of Delaware', 'Unregistered Equity SecuritiesNone', 'WeaknessOur', 'Prospectus', 'Prospectus Supplement', 'AIM', 'Administrative ExpensesGeneral', 'EGC', 'the ""Board', 'Note 2', 'The Nasdaq Capital Market', 'InflationInflation', 'a Registration Statement on Form S-1', 'JHU', 'the Listing Qualifications Department', 'September&#160;30, 2023.The Company', 'SEC', 'the Certificate of Dissolution', 'Company', 'ContentsOur', ""the Company\\'s Board of Directors"", 'MBC', 'Equity Securities', 'IPO', 'Innovation at Hackensack Meridian Health', 'Final Candidate', 'CDI', 'JHU.12Table of ContentsThe Company', 'General Instruction I.B.6', 'Contentsallow', 'Nasdaq', 'the Capital Market'}"
NGM,"{'ASC', 'AMD', 'MHRA', 'net(15)78&#160;(93)(186)38&#160;(224)Net loss$(28,797)$(47,261)$18,464&#160;$(114,705)$(126,230)$11,525&#160;Related Party Revenue', 'ContingenciesOperating Leases and Lease', 'Exhibit 32.1', 'the Open Market Sales', 'EstimatesOur', 'EEA', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'development22,942&#160;46,106&#160;(23,164)96,150&#160;134,345&#160;(38,195)General', 'EU', 'Amended Collaboration Agreement with Merck', 'Lease Agreement', 'Related Party RevenueThe Company', 'No &#9744;Indicate', 'CashThe', 'HTA', 'UPC', 'CPRA', 'Office of Inspector General', 'ACA', 'CONSOLIDATED BALANCE SHEETS(In', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Regulation S-K.Chief Financial Officer', 'Jefferies', 'COVID-19', 'BD Arrangement', 'the Unitary Patent Court', 'Merck Revenue', 'NGM120', 'IndemnificationIn', 'FASB', 'Company\\', 'HHS', 'Merck Sharp &', 'NGM313', 'Business Development and Merck Collaboration UpdatesPursuing BD Arrangements', 'Director(Principal Executive', 'NGM Biopharmaceuticals, Inc.', 'Medicaid', 'Medicare', 'Congress', 'NGM Biopharmaceuticals, Inc.Date', 'FDA', 'Lonza Sales AG', 'NetProperty', 'Results of Operations-Overview of Our Business-Business Development and Merck Collaboration', 'Financial Operations OverviewRelated Party', 'the Lab Programs', 'Risks Related', 'Company', 'USPTO', 'KEYTRUDA&#174', ': &#8226;fees', 'Department of Justice', 'collaboration&#8212;&#160;7,580&#160;Prepaid', 'the Delaware General Corporation Law', 'the European Commission', 'Critical Accounting Policies', 'IndustryOur', 'CCPA', 'Merck', 'Horizon Discovery Ltd.', 'Success', 'Dohme', 'Registrant', 'Capital NeedsWe', '8220;Financial', 'NGM438', 'TCA', 'the Retained EU Law (Revocation and Reform', 'the Sarbanes-Oxley Act', 'DPA', 'the Letter Agreement', 'NATO', 'IPO', 'Financial HighlightsSince', 'Fair Value of Financial InstrumentsThe', 'the Amended Collaboration Agreement', 'CVM', '333 Oyster Point Blvd', 'Form S-3', 'NGM', 'UK Data Protection Act', 'the Court of Chancery of the State of Delaware', 'the Amended Sales Agreement', 'PINNACLES', 'the U.S. Food and Drug Administration', 'Our Business &#8211', 'Dear Healthcare Provider', 'BD Arrangements', 'amortization(44,323)(42,894)Total', 'Business Development and Merck Collaboration', 'NGM621', 'EquipmentProperty', 'NGM Bio', 'furniture3', 'SEC', 'Restricted', 'the United States Patent and Trademark Office', 'OperationsOur', '*&', 'Nasdaq'}"
NKGN,"{'ASC', 'Our Financial Position &', 'Factors &', 'Graf upon Closing', 'Contractual Obligations', 'FPA', 'NKMAX', 'the Public Warrants', 'Principal Executive Officer', 'Financial Instruments', 'this Quarterly Report on Form 10-Q', 'The Public Warrants', 'Affimed GmbH', 'Principal Executive Officer Pursuant to Securities Exchange Act', 'the PIPE Warrants', 'Working Capital Warrants', 'SNK01', 'ContentsEven', 'Indicate', 'Our Business and Industry &', 'NKGen', 'FlowsThe', 'Form S-1', 'ContentsWe', 'Securities Purchase Agreement', 'NKGen Biotech, Inc. (&', 'Principal Financial Officer Pursuant', 'the International Council for Harmonization; &#8226;disagreement', 'NKGen Biotech, Inc.', 'Licensed Technology', 'the Merger Agreement', 'the Intercompany License', 'Z.I de l&#8217;Ouriettaz (&', 'No &#9744', 'Pfizer', 'the Securities Purchase Agreement', 'HHS', 'Fair Value Option', 'LitigationThe Company', 'Pfizer, Inc. (&#8220;Pfizer&#8221;)', 'Private Placement', 'AresTrading S.A.', 'ContentsFurthermore', 'the U.S. Department of Justice', 'The SPA Warrants', 'Related Party Loan', ': &', 'FDA', 'Legacy Convertible Notes', 'The America Invents Act', 'NKMAX Co.', 'SNK01 with AFM24', 'Form S-4', 'Indemnification Agreement', 'ContentsThe', 'Risks Related', 'Merck KGaA', 'the Private Warrants', 'REMS', 'The East West Bank Loan Agreement', 'Common Stock', 'Company', 'the Prepayment Amount', 'the Working Capital Warrants', 'the U.S. DOJ', 'USPTO', 'the California Privacy Rights Act', 'Biotech, Inc. 2023 Equity Incentive', 'the U.S. Securities and Exchange Commission', 'the Private Placement Agreements', 'FPA Investors', 'CRO', 'SNK01 and SNK02', 'the Report of Independent Registered Public Accounting Firm', 'Plan.&#160;&#160;8-K&#160;001-40427&#160;&#160;10.25&#160;October 5', 'SPA Warrants', 'NKGen Operating Biotech, Inc.', 'Deferred Founder Shares', 'Plan.&#160;&#160;8-K&#160;001-40427&#160;&#160;10.24.2&#160;October', 'Graf Acquisition Corp.', 'GFAP', 'the State of Israel&#8217;s', 'SNK01, SNK02', 'The PIPE Warrants', 'PIPE Warrants', 'Inc.&#160;&#160;8-K&#160;001-40427&#160;10.23&#160;&#160;October 5', 'ContentsSIGNATURES Pursuant', 'ContentsOur', 'Pursuant', 'the Sarbanes-Oxley Act', 'Securities Exchange Act', 'administration; &#8226;the', 'the Forward Purchase Agreements', 'Hamas', 'the East West Bank Loan Agreement', 'Graf (&#8220;Merger', 'the Warrant Subscription Agreements', 'the SPA Warrants', 'CSF', 'Plan.&#160;&#160;8-K&#160;001-', 'the Warrant Investors', 'SNK', 'the FPA Investors', 'Restricted Stock Unit', 'Distinguishing Liabilities', 'Short Term Related Party', 'ContentsAs of September&#160;30', 'Related Party Transactions', 'Related Party', 'PIPE Warrants Prior', 'AresTrading', 'GCP', 'BLA', 'the Business Combination', '*&', 'ContentsThe East West Bank Loan Agreement', 'ContentsNet', 'the Legacy Convertible Notes', 'Nasdaq', 'Fair Value of Financial Instruments', 'Equity'}"
NKTR,
NKTX,"{'NKX101', '\\n  &#x2022;develop', 'LLC', '\\n  &#x2022;incur', 'candidates;\\n  &#x2022;interruptions', 'EEA', '\\n  &#x2022;education', 'and\\n  &#x2022;interruption', 'EU', '\\n  &#x2022;completing', 'the United States Food and Drug Administration', '\\n  &#x2022;compliance', 'National University of Singapore', 'the Internal Revenue Code', '\\n  &#x2022;foreign', 'The Sarbanes-Oxley Act of 2002', 'Form S-1', 'efforts.\\n  &#x2022;We', 'the National University of Singapore', 'approved.\\n  &#x2022;We', 'ACA', 'platform.\\n  &#x2022;If', '\\n  &#x2022;production', '\\n  &#x2022;establishing', 'Shelf Registration Statement on', 'COVID-19', 'Licensors', '\\n  &#x2022;recall', '\\n  &#x2022;workforce', 'the Registration Statement on Form S-3', '\\n  &#x2022;obtaining', '\\n  &#x2022;provide', '\\n  &#x2022;additional', '\\n  &#x2022;adverse', '\\n  &#x2022;product', '\\n  &#x2022;sufficient', '\\n  &#x2022;qualifying', 'the Tax Cuts and Jobs Act', 'Internal Control', 'manufacturers&#x2019', 'the Additional Lease Agreement', '\\n  &#x2022;refusal', 'the Securities and Exchange Commission', 'Medicaid', '\\n  &#x2022;any', 'Medicare', 'Congress', 'Form S-8', 'GDPR', '\\n  &#x2022;specify', 'FDA', 'and\\n  &#x2022;establishment', 'The America Invents Act', 'statements.\\n  &', 'national data protection authority', 'and\\n  &#x2022;increase', 'Warning Letters', '\\n  &#x2022;maintaining', 'injected;\\n  &#x2022;expansion', '\\n  &#x2022;relative', '\\n  Effective', '\\n  &#x2022;changes', '\\n  &#x2022;continue', '\\n  &#x2022;collaboration', 'Risks Related', 'the Medicaid Drug Rebate Program', '\\n  &#x2022;implementing', '\\n  &#x2022;requirements', '\\n  &#x2022;negotiating', 'REMS', '\\n  &#x2022;fines', 'liability;\\n  &#x2022;a new', 'Patient-Centered Outcomes Research Institute', 'Company', 'the ATM Offering Program', 'USPTO', '\\n  &#x2022;addressing', 'the California Privacy Rights Act', 'the Health Insurance Portability', '\\n  &#x2022;injunctions', '\\n  &#x2022;limitations', 'Financial Reporting \\n  Management', 'SVB', '\\n  &#x2022;unexpected', '50\\n', 'Additional Lease Agreement', 'The Prior Registration Statement', '\\n  &#x2022;avoiding', 'LN;\\n  &#x2022;delays', 'CMS', 'candidates;\\n  &#', 'The Shelf Registration Statement', 'this Quarterly Report on Form 10-Q.', '\\n  &#x2022;acquire', 'the Initial Lease Agreement', 'distribution;\\n  &#x2022;restrictions', '\\n  &#x2022;advance', '\\n  &#x2022;the', 'Initial Lease Agreement', 'The General Data Protection Regulation', '\\n  &#x2022;launching', '\\n  &#x2022;suspension', '\\n  &#', 'ATM Offering Program', '\\n  Outside', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;imposition', 'NKSTIM', 'the CRISPR Agreement', '\\n  &#x2022;different', 'the Lupus Research Alliance', 'St. Jude Children&#x2019;s Research Hospital, Inc.', '\\n  &#x2022;require', 'NKX019', 'the Sarbanes-Oxley Act', 'CRISPR Therapeutics AG', 'IPO', '47\\n', 'the Company&#x2019;s Registration Statement on', 'Cowen and Company', 'Contingencies Guarantee Agreement', 'Medicaid Innovation', '\\n  &#x2022;seeking', 'District Court', '\\n  &', '\\n  &#x2022;delays', 'revenues.\\n  &#x2022;If', '\\n  &#x2022;business', '\\n  &#x2022;interruption', 'the Coronavirus Aid, Relief and Economic Security Act', 'CRISPR', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'the U.S. Treasury', '\\n  &#x2022;withdrawal', 'SEC', 'healthcare programs;\\n  &#x2022;a', 'ATM Offering', '\\n  &#x2022;potential', 'the Budget Control Act', 'Nkarta\\', 'the Health Information Technology for Economic and Clinical Health Act', '\\n  &#x2022;reduced', 'Nasdaq', 'the Initial Lease Agreement and Additional Lease Agreement'}"
NLSP,
NLTX,"{'L.P.', 'the Merger Agreement', 'Neoleukin&#8217;s', 'the Delaware General Corporation Law', 'BofA Securities, Inc.', 'Our Financial Position', 'Form S-3', 'Board', 'Biologics License Applications', 'Project North Merger Sub, Inc.', 'Neoleukin', 'Employee Stock Purchase', 'ContentsFor', 'Neurogene Inc.', 'Neurogene&#8217;s board of directors', 'Medicaid', 'Medicare', 'ContentsSome', 'Baker Bros Advisory', 'the U.S. Food and Drug Administration', 'the Baker Entities', 'the Oncology Center of Excellence', 'FDA', 'ContentsRisks Related to Ownership of Our Common', 'Trust Company', 'expenses172&#160;1,058&#160;1,442&#160;3,501&#160;Total', 'Neurogene', 'The U.S. Patent and Trademark Office', 'Condensed Financial', 'United', 'company.&#8221', 'Capital NeedsWe', 'market&#8221', 'ATM &', 'LeasesThe Company', 'SEC', 'ContentsWe', 'Neoleukin and Neurogene', 'the Nasdaq Listing Qualifications Department', 'Company', 'ContentsOur', ""the Company\\'s Board of Directors"", 'USPTO', 'FDIC', 'the ""Supporting Stockholders""', 'COVID-19', 'ContentsRisks Related', 'Equity Offering Sales Agreement', 'Merger', 'SVB', 'Nasdaq', 'Neoleukin (&#8220;Merger', 'the ""Eastlake Lease', 'the European Union', 'First-Citizens Bank &amp'}"
NMRA,"{'Alairion', 'the GABA Program', 'tranche', 'the Syllable Merger Agreement', 'TwoThousandTwentyEquityIncentivePlanMember2023', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001885522us-gaap', 'EstimatesOur', 'this Quarterly Report on Form 10-Q', 'JSC', 'Prospectus', 'MaximumMember2023-01-012023-09-300001885522nmra', 'FlowsThe', 'x201c;Reverse Stock', 'Form S-1', 'License and Research and Collaboration Agreements', 'AwardsWithPerformanceConditionsMember2023-07-012023-07-310001885522us-gaap', 'the H1 Program', 'Syllable Life Sciences, Inc.', 'Sponsored Research Agreement', 'BlackThorn Milestones', 'MDD', 'CNS', 'Alairion Carveout PlanThe Alairion Merger Agreement', 'MarketableSecuritiesMember2022-01-012022-12-310001885522nmra', 'MarketableSecuritiesMember2022-12-310001885522nmra', 'Alairion, Inc. (Alairion', 'FASB', 'management&#x2019;s', 'the Syllable Milestones', 'Rule 424(b)(4', 'CompensationThe', 'the Amgen IPR&amp;D Assets', 'Harvard', 'FDA', 'THERAPEUTICS, INC.', 'the Amgen License Agreements', 'Company', 'AwardsWithPerformanceConditionsMember2023-01-012023-01-310001885522us-gaap', 'the Alairion Merger Agreement', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001885522nmra', '9746;\\n     QUARTERLY REPORT PURSUANT', 'Syllable', '389,534\\n         &', 'the Alairion Carveout Payments', 'MarketableSecuritiesMember2022-12-310001885522us-gaap', 'ContentsNEUMORA Therapeutics, Inc.Notes', 'the BlackThorn Merger Agreement', 'MarketAwardMember2023', 'ActivitiesNet', 'the BlackThorn Milestones', 'the following:&#160;\\n       \\n        \\n         \\n         \\n         \\n         \\n         \\n        \\n        \\n         &', 'Unaudited Condensed Consolidated Financial Statements &', '2022\\n         &', 'The BlackThorn Carveout Units', 'Alairion, Inc.', 'the Alairion Milestones', 'THE SECURITIES EXCHANGE ACT OF 1934\\n', 'Syllable Merger Agreement', 'Amgen', 'the Alairion Milestones).The Alairion Milestone', 'BlackThorn Milestone', 'Vanderbilt License Agreement', 'DevelopmentResearch', 'AwardModificationMember2023-08-012023-08-310001885522us-gaap', 'the Alairion Carveout Plan', 'FairValueMeasurementsRecurringMember2023', 'x201c;anticipate,&#x201d; &#', 'IPO', 'Alairion Milestone', 'GABA Program', 'compensation\\n         &', 'AdvisorsMember2023', 'the Amgen Milestones', 'Syllable Milestone', 'Amgen Inc.', 'MarketableSecuritiesMember2022-01-012022-12-310001885522us-gaap', 'IPR&amp;D', 'un', 'the Vanderbilt License Agreement', 'AwardsWithPerformanceConditionsMember2023-01-012023-09-3000018855222022-01-012022-12-3100018855222022-01-012022-03-310001885522us-gaap', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001885522us-gaap', 'SEC', 'the BlackThorn Carveout Units', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001885522nmra', 'BlackThorn', 'x201c;seek,&#x201d'}"
NMRD,"{'\\n    &#160;&#160;&#160;Total', 'Pursuant', 'Notes #3', 'RELATED PARTY', 'concern.\\n\\n&#160;\\n\\nIn', 'MySugarWatch Limited &', '\\n    &', 'upfront\\nfee of &', 'Company', 'Yes&#160;&#9746; &', 'DDL'}"
NMTC,
NNOX,
NOTV,
NPCE,"{'LLC', 'Physician Payments Sunshine Act', 'CEC', 'The Sarbanes-Oxley Act', 'Principal Executive Officer', 'Significant Accounting PoliciesBasis', 'this Quarterly Report on Form 10-Q', 'EU', 'the U.S. Foreign Corrupt Practices Act', 'Restated Bylaws of the Registrant', 'No &#9744;Indicate', 'CPRA', 'Form S-1', 'the FASB.Unaudited Interim Financial InformationThe', 'the Financial Accounting Standards Board', 'Lennox-Gastaut Syndrome', 'COVID-19', 'this Quarterly Report on Form 10-Q.DIXI Distribution AgreementIn', 'Fair Value Measurements(Level', 'Anti-Kickback Statute', 'the National Institutes of Health', 'the U.S. Congress', 'Restated Certificate of Incorporation of the Registrant', 'Form of Stock Option Agreement8-K001', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'GDPR', ': &', 'Unaudited Interim Condensed Financial StatementsDelaware', 'RNS System', 'FDA', 'NIH', 'COVID-19.The', 'the European Union&#8217;s General Data Protection Regulation', 'HIPAA', 'PresentationThe', 'Company', 'FDA&#8217;s Voluntary Improvement Program', 'USPTO', 'September&#160;30, 2023', 'the California Privacy Rights Act', 'FCA', 'Qualitative Disclosures About Market', 'the Delaware General Corporation Law', 'the FDA&#8217;s Quality System Regulation', ': &#8226;they', 'CMS', 'Principal Financial Officer', 'Unaudited Condensed Financial Statements6Item', 'DIXI Medical USA Corp.', 'Exchange Act', 'FCPA', 'ActivitiesNet', 'Micro Systems Technologies Management AG', 'Canada&#8217;s Personal Information Protection and Electronic Documents Act', 'Sales Agreement', 'Greatbatch Ltd', 'Value', 'Registrant', 'the Children&#8217;s Health Insurance Program', 'the Term Loan Agreement', 'DOJ', 'Leerink Partners', 'the Sarbanes-Oxley Act', 'DIXI', 'the Health Information Technology for Economic and Clinical Health', 'the Distribution Agreement', 'NeuroPace', 'ATM', 'a Term Loan Agreement', 'Medicaid Services', 'Healthcare', 'PMA', 'OIG', 'CRPA', 'the Centers for Medicare &', 'the Office of Inspector General', 'CRG', 'GAAP', 'Correction and Removal', 'the European Union', 'DIXI Medical'}"
NRBO,"{'ASC', 'Months Ended &', 'NASH', 'NB-02', 'YourChoice Therapeutics, Inc.', 'Months Ended &#8203;September&#160;30,&#160;&#8203;September&#160;30,&#160;&#8203;&#8203;2023&#8203;&#160;&#160;&#160;&#160;2022&#8203;&#8203;2023&#8203;&#160;&#160;&#160;&#160;2022General', 'the Nasdaq Capital Market', 'the YourChoice Agreement', 'Compensation &#8203;Stock', 'the Dong-A License Agreement', 'ANA', 'statements.&#8203;In', 'the Securities and Exchange Commission', '-Total', 'this Quarterly Report on Form 10-Q', 'Dong-A', 'Dong-A ST Co. Ltd.', 'Heon Kim&#8203;&#8203;&#8203;&#8203;President', 'the Shared Services Agreement', 'Dong-A ST Co., Ltd.', 'Related Party', 'NeuroBo', 'SEC', 'Company', 'the Financial Accounting Standards Board', 'Gemphire Therapeutics, Inc. (&', 'the Securities Exchange Act', 'NeuroBo Pharmaceuticals', 'Pfizer,&#160;Inc', 'PDN', 'OXM', 'Nasdaq', 'The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'Condensed Consolidated Financial Statements -continued(Dollar'}"
NRC,
NRIX,"{'LLC', 'Internal Control Over Financial ReportingThere', 'MHRA', 'the Accelerated Approval Program', 'the Equity Distribution Agreement', 'ContentsPART II &#8211', 'The Sarbanes-Oxley Act', 'EMA', 'Principal Executive Officer', 'the My Health My Data Act', ': &#8226;diversion', 'EU', 'The Accelerated Approval Program', 'Principal Executive Officer Pursuant', 'Piper Sandler', 'ContentsEven', 'HTA', 'DELigase', 'Accelerated Approval to &', 'ContentsAccrued Expenses and Other Current Liabilities Accrued', 'Piper Sandler &amp', 'Form S-1', 'market&#8221', 'ContentsWe', 'the Securities Exchange Act', 'an Organization for Economic Co-operation and', 'the RegistrantX10.3*&#8224;Collaboration and License Agreement', 'April&#160;30', 'ContentsIn', 'data.&#8221', 'ContentsFor', 'Sanofi', 'the Gilead License Option Exercise', 'Condensed Consolidated Balance Sheet Components Property and Equipment, Net Property', 'Trade Control Laws', 'Regulation (EC', 'Medicaid', 'Medicare', 'the Seagen Agreement', 'amortization(25,046)(19,670)Total', ': &', 'FDA', 'Seagen', 'Gilead License Option Exercise', 'Research and Development Expenses Research', 'fair', 'ContentsThe', 'Risks Related', 'HIPAA', 'REMS', 'Gilead and Sanofi', 'Gilead, Sanofi', 'Principal Financial Officer Pursuant to Rules', 'Company', 'the First Sanofi Amendment', 'USPTO', 'BeiGene, Ltd.', 'Adopted Pursuant to Section 302', 'Technology Forest PL', 'the Accelerated Approval Pathway', 'NIP', 'November&#160;30', 'the California Consumer Privacy Act', 'CMS', 'OperationsComparison', 'Senate', 'ILAP', 'Celgene Corporation', 'the Sanofi Agreement', 'Development Inclusive Framework', 'Sanofi Agreement', ': &#', 'Haisco Pharmaceutical Group Co.', 'European Parliament', 'the Northern Ireland Legislative Assembly', 'Registrant', 'NDA', 'CMO', 'Restated Certificate of Incorporation', 'the Sarbanes-Oxley Act', 'Gilead', 'ContentsProducts', 'Genzyme Corporation', 'Form S-3', 'The My Health My Data Act', 'Significant Accounting Policies&#8212;Recently Adopted Accounting', 'Accelerated Approval', 'ContentsCustomer', 'the Innovation Passport', 'Accelerated Approval Program', 'European Council', 'Owner', 'ContentsDespite', 'the Federal Food, Drug and Cosmetic Act', 'MAA', 'Risks Related to', 'the UK Parliament', 'Medicaid Services', 'Registered Direct OfferingsIn', 'SEC', 'ATM Offering', 'AbbVie Inc.', 'BTK', 'the Centers for Medicare', 'Equity Securities', 'the Gilead Agreement', 'ContentsIn January 2021', 'the Clinical Trials Regulation', 'the Northern Ireland Protocol', 'Registrant and Seagen Inc.X31.1Certification', 'Nasdaq', 'Principal Financial and Accounting Officer Pursuant'}"
NRSN,
NRXP,
NSPR,"{'FASB', 'MicroNet', 'ASU', 'Series C', 'Form S-3', 'Issued Accounting', 'commitments.\\n\\n&#160;\\n\\nRecently\\nAdopted', 'Financial Instruments-Credit Losses', 'the Series C Preferred Stock', 'CGuard', 'Series C Preferred Stock', 'the Quarterly Report on Form 10-Q', 'the Securities and Exchange Commission', 'to\\nbe', 'the Current Report on Form 8-K', 'Regulation S-K).\\n\\n&#160;\\n\\n\\n\\n    ', 'INSPIREMD,\\n', 'the State of Delaware', 'offices)\\n\\n(Zip\\nCode)\\n\\n&#160;\\n\\n(888)\\n776-6204\\n\\n(Registrant&#8217;s\\ntelephone', 'European Medical Device Regulation', 'Exhibit 3.17', 'May Affect Future', 'the Inline XBRL document)\\n  ', 'in\\nfull', 'Placement Offering', 'Piper Sandler &amp', 'SEC', 'Common Stock', 'Underwriter Warrants&#160;\\n    &', 'Company', 'the Securities Exchange Act', 'revenues\\nor', 'C-GUARDIANS', 'Health Research International Personal Medical Systems', 'Credit Losses', 'Item 408 of', '2022.\\n\\n&#160;\\n\\nNOTE\\n9 &#8211', 'Exhibit 3.2', 'the Series H Warrants', 'the Sarbanes-Oxley Act', 'Preferred Stock', 'the European Union', '\\n    &', 'micron', 'CE', 'the Registration Statement'}"
NSTG,"{'the Delaware General Corporation Law', 'OverviewWe', 'RNA', 'GeoMx', 'The IndentureThe Company', 'Financial Officer&#160;&#160;(Principal Financial and Accounting Officer)59\\n\\n\\n', 'Form S-3', 'HHS', 'Veracyte', 'amended.8-K001-35980August 3', '3.3%.The Company', 'HCL Technologies Limited of India', 'CJEU', 'the Exchange Transaction', 'Financial Statement Schedules', 'Item 408 of Regulation S-K.Item&#160;6.&#160;&#160;&#160;&#160;Exhibits', 'the Organic Change', 'the Securities and Exchange Commission', 'the Federal Food, Drug', 'Congress', 'ContentsConvertible Notes', 'European Union', 'RUO', 'the Registration Rights Agreement', 'Harvard', 'the Exchange Agreement', 'Genomics, Inc.', 'EU', 'Chief Executive Officer&#160;&#160;(Principal Executive', 'FDA', 'the 2023 Warrants (the &', 'National Association', 'RequirementsOur', 'AtoMx', 'the Condensed Consolidated Financial Statements', 'the U.S. Foreign Corrupt Practices Act', 'European Patent No', 'the Trans-Atlantic Data Privacy Framework', 'nCounter', 'the 2023 Warrant Registrable Securities', 'ContentsThe', 'UPC', 'the Court of Justice', 'Registrant', 'the 2023 Warrants', 'SEC', 'FundsSince', 'ContentsWe', 'Company', 'the Securities Exchange Act', 'U.S. Bank Trust Company', 'NanoString Technologies Germany GmbH', '*&', 'Amazon Web Services', 'CosMx', 'the Munich Regional Court', 'COVID-19', 'ContentsRisks Related', 'the Sarbanes-Oxley Act', 'the 928 Patent', 'ContentsIn', 'the European Union', 'ContentsFor', 'the United Kingdom&#8217;s Information Commissioner&#8217;s Office', 'Rule 16a-1', 'ConditionWe', 'Seattle BioSoftware Inc.', 'NanoString Technologies, Inc.'}"
NSYS,
NTBL,"{'contractual\\nduties', 'the Merger Agreement', 'GLP', 'Notable Ordinary', 'CMS', 'the License Fees', 'the symbol &#8220;VBLT.&#8221', 'research\\nor', 'Covered Products.\\nThe Asset Purchase Agreement', 'alleging\\nviolations of federal and state healthcare fraud', 'EMA', 'difficult.\\n\\n&#160;\\n\\nProvisions\\nin', 'Notable&#8217;s\\nbusiness', 'MMA', 'Medicaid', 'Medicare', 'the Asset Purchase Agreement', 'the U.S. Food and Drug Administration', 'EIC', 'reimbursement.\\n\\n&#160;\\n\\nEven\\nif', 'Immunewalk', 'EU', 'Nasdaq Listing Rule 5450(a)(1).\\nThe Nasdaq', 'FDA', 'PPMP', 'commercialization\\nat', 'Covered Products', 'Notable&#8217;s\\nability', 'discounts\\nin', 'development\\nin', 'letters;\\n  \\n    &', 'pursuant\\nto', 'United\\nStates', 'the Medicare Prescription Drug', 'corporation\\nand', 'Ordinary', 'NanoCarrier', 'REMS', 'NDA', 'the Listing Qualifications Department', 'SEC', 'Affiliates', 'ACA', 'and\\n  \\n    &', 'Company', 'a Merger Agreement', 'Notable Labs, Inc.', 'Pursuant', 'shares\\nto', 'BLA', 'candidates.\\n  \\n&#160;\\n\\nIf\\nNotable', 'Notable&#8217;s Incorporation', 'Notable Labs, Ltd.', 'Notable Labs', 'FDIC', 'employees.\\n  \\n&#160;\\n\\nNotable\\nis', '\\n\\n&#160;\\n\\n\\n\\nNotable\\nmay', 'Notable\\nintends', 'the\\n    European Medicines Agency', 'collaborators;\\n', 'Notable&#8217;s Reliance', 'memorandum of association', 'Volasertib', 'Nasdaq', 'the European Union', 'Medicare covers\\nand', '\\n    &', 'leads\\nto Notable', 'Notable', '\\n    &#'}"
NTLA,"{'\\n  Government', 'The Sarbanes-Oxley Act', 'EMA', 'AvenCell License', '\\n  &#x2022;an', '\\n  &#x2022;developments', 'the &#x201c;UC/Vienna/Charpentier', 'NTLA-3001;\\n  &#x2022;our', 'EEA', 'the AvenCell License', 'this Quarterly Report on Form 10-Q', 'European Data Protection Law', '\\n    External', 'NTLA-2001', 'SparingVision SAS', 'technology;\\n  &#x2022;our', 'programs.\\n', 'EU', '\\n  &#x2022;an $11.7 million', 'Phase 4', 'AvenCell Therapeutics, Inc. (&#x201c;AvenCell&#x201d;)', '\\n  &#x2022;a $5.7 million', 'employees.\\n  Risks Related', 'remediated;\\n  &#x2022;fines', '26\\n', 'Kyverna Therapeutics, Inc. (&', 'AvenCell Therapeutics, Inc.', 'ERS Genomics, Ltd.', 'ACA', 'and\\n  &#x2022;regulatory', 'Intellia', 'CRISPR/Cas9', 'Q3--12-31true0001652130falsehttp://fasb.org/us-gaap/2023#LicenseAndServiceMemberhttp://fasb.org/us-gaap/2023#LicenseAndServiceMemberhttp://fasb.org/us-gaap/2023#LicenseAndServiceMemberhttp://fasb.org/us-gaap/2023#LicenseAndServiceMember0001652130us-gaap:CorporateDebtSecuritiesMember2022-12-310001652130ntla:AvencellMember2022-12-310001652130ntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2023-09-300001652130us-gaap:RestrictedStockMember2023-01-012023-09-300001652130us-gaap:AssetBackedSecuritiesMember2023-09-300001652130us-gaap:AdditionalPaidInCapitalMember2023-06-300001652130ntla:AvencellCoCoAgreementMemberntla:AvencellMember2023-01-012023-09-300001652130us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130ntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2023-07-012023-09-3000016521302022-01-012022-12-310001652130ntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2016-04-012023-09-300001652130ntla:AvencellcocoMember2023-01-012023-09-300001652130ntla:JointVentureAvenCellMemberntla:AvencelllcaMember2023-09-300001652130us-gaap:FairValueInputsLevel2Memberntla:FinancialInstitutionDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-3000016521302023-07-012023-09-300001652130us-gaap:RetainedEarningsMember2022-01-012022-03-3100016521302023-01-012023-03-310001652130us-gaap:RetainedEarningsMember2022-04-012022-06-300001652130ntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2023-01-012023-09-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001652130ntla:AvencellMember2021-07-300001652130us-gaap:RelatedPartyMemberntla:AvencellMember2023-09-300001652130us-gaap:FairValueInputsLevel1Memberntla:USTreasuryAndOtherGovernmentBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130ntla:RewriteTherapeuticsDelawareCorporationMember2022-02-022022-02-020001652130us-gaap:RetainedEarningsMember2023-03-310001652130ntla:WinterStreetLeaseMember2022-02-012022-02-280001652130us-gaap:RetainedEarningsMember2023-09-3000016521302022-12-310001652130us-gaap:AdditionalPaidInCapitalMember2023-03-310001652130ntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2016-05-012016-05-310001652130ntla:RegulatoryApprovalMilestoneMemberntla:RewriteTherapeuticsDelawareCorporationMember2022-02-022022-02-020001652130us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001652130ntla:PreferredStockPurchaseAgreementMemberntla:CellexAndBxlsMemberntla:JointVentureAvenCellMember2021-07-300001652130ntla:TwoThousandNineteenSalesAgreementMember2022-01-012022-03-310001652130ntla:RewriteTherapeuticsDelawareCorporationMember2022-02-020001652130us-gaap:RetainedEarningsMember2023-07-012023-09-300001652130us-gaap:AdditionalPaidInCapitalMember2022-12-310001652130us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001652130us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100016521302022-01-012022-03-310001652130ntla:AvencellCoCoAgreementMemberntla:AvencellMember2022-07-012022-09-300001652130ntla:ResearchAndDevelopmentServicesMemberntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2023-01-012023-09-300001652130us-gaap:CorporateDebtSecuritiesMember2023-09-300001652130us-gaap:AdditionalPaidInCapitalMember2022-03-310001652130ntla:RegeneronPharmaceuticalsIncMemberus-gaap:RelatedPartyMember2022-12-310001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001652130ntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2022-01-012022-09-300001652130us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130us-gaap:AssetBackedSecuritiesMember2022-12-3100016521302023-11-030001652130us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001652130ntla:AvencellMember2023-07-012023-09-300001652130ntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2022-09-300001652130ntla:KyvernaTherapeuticsIncMember2022-01-012022-09-300001652130us-gaap:CashMember2023-01-012023-09-300001652130ntla:RewriteAcquisitionMemberntla:RewriteTherapeuticsDelawareCorporationMember2023-01-012023-01-310001652130us-gaap:RestrictedStockMember2023-09-300001652130us-gaap:CommonStockMember2023-03-310001652130ntla:KyvernaTherapeuticsIncMember2023-01-012023-09-300001652130ntla:TwoThousandTwentyTwoSalesAgreementMember2023-09-300001652130ntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2023-10-012023-10-310001652130ntla:AtTheMarketOfferingsMember2022-01-012022-03-310001652130us-gaap:CommonStockMember2023-01-012023-03-310001652130ntla:SparingVisionMember2021-10-310001652130ntla:AvencellCoCoAgreementMemberntla:AvencellMember2023-07-012023-09-300001652130ntla:USTreasuryAndOtherGovernmentBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130ntla:TwoThousandNineteenSalesAgreementMember2022-03-310001652130ntla:USTreasuryAndOtherGovernmentBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130ntla:RewriteAcquisitionMemberntla:RewriteTherapeuticsDelawareCorporationMember2023-02-280001652130ntla:FinancialInstitutionDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130ntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2022-07-012022-09-300001652130us-gaap:FairValueInputsLevel1Memberntla:USTreasuryAndOtherGovernmentBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130us-gaap:AdditionalPaidInCapitalMemberntla:AtTheMarketOfferingsMember2022-07-012022-09-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001652130us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-3000016521302022-04-012022-06-300001652130us-gaap:CommonStockMember2022-06-300001652130ntla:TwoThousandAndFifteenStockOptionAndIncentivePlanMember2023-01-012023-09-3000016521302022-03-012022-03-310001652130ntla:PreferredStockPurchaseAgreementMemberntla:JointVentureAvenCellMember2021-07-300001652130us-gaap:AdditionalPaidInCapitalMember2021-12-310001652130ntla:AtTheMarketOfferingsMember2023-03-310001652130us-gaap:AdditionalPaidInCapitalMember2022-06-300001652130ntla:HemophiliaCoCoAgreementsMemberntla:RegeneronPharmaceuticalsIncMember2023-07-012023-09-300001652130us-gaap:CommonStockMember2022-04-012022-06-300001652130us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-3000016521302023-09-300001652130srt:MaximumMemberntla:TwoThousandNineteenSalesAgreementMember2019-08-012019-08-310001652130ntla:AvencellcocoMember2022-01-012022-09-300001652130ntla:TwoThousandTwentyTwoSalesAgreementMemberus-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001652130ntla:SparingVisionMember2022-07-012022-09-300001652130us-gaap:AdditionalPaidInCapitalMemberntla:AtTheMarketOfferingsMember2023-01-012023-03-310001652130ntla:RegeneronPharmaceuticalsIncMember2023-09-300001652130us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100016521302023-04-012023-06-300001652130ntla:WinterStreetLeaseMember2023-01-012023-09-300001652130ntla:AtTheMarketOfferingsMember2022-12-310001652130ntla:FinancialInstitutionDebtSecuritiesMember2022-12-310001652130us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001652130ntla:SparingVisionMemberus-gaap:RelatedPartyMember2022-12-310001652130ntla:SparingVisionMember2023-09-300001652130us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001652130ntla:FinancialInstitutionDebtSecuritiesMember2023-09-300001652130us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130ntla:AtTheMarketOfferingsMember2022-01-012022-09-300001652130ntla:AtTheMarketOfferingsMember2023-01-012023-09-300001652130ntla:ResearchMaterialsShippmetServicesMemberntla:OnkTherapeuticsMember2023-01-012023-09-300001652130us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001652130us-gaap:CommonStockMember2023-04-012023-06-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001652130us-gaap:CommonStockMember2022-09-300001652130ntla:AvencellcocoMember2023-07-012023-09-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001652130us-gaap:IPOMember2023-01-012023-09-300001652130ntla:AtTheMarketOfferingsMemberus-gaap:CommonStockMember2023-01-012023-03-310001652130us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-3000016521302023-01-012023-09-300001652130ntla:SeriesA2PreferredStockMemberntla:SparingVisionMember2021-10-012021-10-310001652130us-gaap:CommonStockMember2021-12-310001652130ntla:ResearchMaterialsShippmetServicesMemberntla:OnkTherapeuticsMember2022-01-012022-09-3000016521302022-03-310001652130us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2022-03-012022-03-310001652130us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001652130us-gaap:CommonStockMember2022-01-012022-03-310001652130ntla:WinterStreetLeaseMember2022-02-282022-02-280001652130us-gaap:RestrictedStockUnitsRSUMember2022-07-012022-09-300001652130ntla:WinterStreetLeaseMember2022-02-280001652130ntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2023-07-012023-09-300001652130us-gaap:RetainedEarningsMember2022-06-300001652130ntla:KyvernaTherapeuticsIncMember2023-09-300001652130us-gaap:CommonStockMember2022-12-310001652130ntla:PerformanceStockUnitsMemberntla:NonExecutiveEmployeesMember2022-03-012022-03-310001652130ntla:TwoThousandTwentyTwoSalesAgreementMember2022-03-012022-03-310001652130ntla:ResearchMaterialsShippmetServicesMemberntla:OnkTherapeuticsMember2022-07-012022-09-300001652130us-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130us-gaap:CommonStockMember2023-09-300001652130ntla:MemorialDrive640Member2023-09-300001652130ntla:AvencellMember2023-01-012023-09-300001652130ntla:AvencellCoCoAgreementMemberntla:AvencellMember2022-01-012022-09-300001652130ntla:AtTheMarketOfferingsMemberus-gaap:CommonStockMember2022-07-012022-09-300001652130us-gaap:RetainedEarningsMember2022-09-300001652130us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001652130us-gaap:RetainedEarningsMember2021-12-310001652130ntla:SparingVisionMember2022-12-310001652130us-gaap:FairValueInputsLevel2Memberntla:FinancialInstitutionDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130ntla:KyvernaTherapeuticsIncMember2022-07-012022-09-300001652130us-gaap:FairValueInputsLevel2Memberntla:USTreasuryAndOtherGovernmentBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130us-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130us-gaap:RelatedPartyMemberntla:KyvernaTherapeuticsIncMember2022-12-310001652130ntla:AtTheMarketOfferingsMember2022-07-012022-09-300001652130us-gaap:RetainedEarningsMember2023-06-300001652130ntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2022-07-012022-09-300001652130us-gaap:CommonStockMember2022-07-012022-09-300001652130us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001652130us-gaap:RelatedPartyMemberntla:OnkTherapeuticsMember2023-09-300001652130ntla:CoDevelopmentAndCoFundingAgreementMemberntla:AvencellMember2022-01-012022-12-310001652130us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-3000016521302022-07-012022-09-300001652130ntla:AtTheMarketOfferingsMemberus-gaap:CommonStockMember2022-01-012022-03-310001652130us-gaap:RestrictedStockUnitsRSUMember2023-03-012023-03-310001652130us-gaap:RelatedPartyMemberntla:OnkTherapeuticsMember2022-12-310001652130us-gaap:RetainedEarningsMember2023-04-012023-06-300001652130us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001652130srt:ExecutiveOfficerMemberntla:PerformanceStockUnitsMember2023-03-012023-03-310001652130ntla:HemophiliaCoCoAgreementsMemberntla:RegeneronPharmaceuticalsIncMember2022-07-012022-09-300001652130us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001652130us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001652130ntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2022-01-012022-09-300001652130us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130ntla:RewriteTherapeuticsDelawareCorporationMemberntla:PrespecifiedResearchMilestonesMember2022-02-022022-02-020001652130ntla:AvencellMember2023-09-300001652130us-gaap:RelatedPartyMemberntla:AvencellMember2022-12-310001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001652130us-gaap:RelatedPartyMember2022-12-310001652130us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001652130ntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2023-01-012023-09-300001652130ntla:RegeneronPharmaceuticalsIncMember2022-12-310001652130ntla:AtTheMarketOfferingsMemberus-gaap:CommonStockMember2023-07-012023-09-300001652130ntla:RegeneronPharmaceuticalsIncMemberus-gaap:RelatedPartyMember2023-09-300001652130us-gaap:CommonStockMember2023-06-300001652130us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001652130ntla:KyvernaTherapeuticsIncMember2022-12-310001652130ntla:TwoThousandTwentyTwoSalesAgreementMember2022-09-3000016521302023-06-300001652130srt:MinimumMember2023-01-012023-09-300001652130srt:MinimumMember2023-09-300001652130us-gaap:CommonStockMember2022-03-310001652130us-gaap:RetainedEarningsMember2022-12-310001652130us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-3000016521302022-06-300001652130us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130ntla:SparingVisionMember2022-01-012022-09-300001652130us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001652130us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130ntla:HemophiliaCoCoAgreementsMemberntla:RegeneronPharmaceuticalsIncMember2023-01-012023-09-300001652130ntla:ResearchMaterialsShippmetServicesMemberntla:OnkTherapeuticsMember2023-07-012023-09-300001652130ntla:TwoThousandAndFifteenStockOptionAndIncentivePlanMember2023-09-300001652130us-gaap:FairValueInputsLevel2Memberntla:USTreasuryAndOtherGovernmentBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-09-300001652130us-gaap:AdditionalPaidInCapitalMemberntla:AtTheMarketOfferingsMember2022-01-012022-03-310001652130srt:MaximumMemberntla:TwoThousandAndSixteenEmployeeStockPurchasePlanMember2023-09-300001652130ntla:TwoThousandTwentyTwoSalesAgreementMember2023-01-012023-09-3000016521302022-01-012022-09-300001652130us-gaap:AdditionalPaidInCapitalMember2022-09-300001652130ntla:TwoThousandTwentyTwoSalesAgreementMember2022-01-012022-09-300001652130srt:MaximumMember2023-09-300001652130srt:MaximumMember2023-01-012023-09-300001652130ntla:AvencellcocoMember2022-07-012022-09-3000016521302022-09-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001652130srt:MaximumMemberntla:TwoThousandTwentyTwoSalesAgreementMember2022-03-012022-03-310001652130ntla:AtTheMarketOfferingsMember2023-07-012023-09-300001652130ntla:HemophiliaCoCoAgreementsMemberntla:RegeneronPharmaceuticalsIncMember2022-01-012022-09-300001652130ntla:KyvernaTherapeuticsIncMember2023-07-012023-09-3000016521302023-03-012023-03-310001652130us-gaap:CommonStockMember2023-07-012023-09-300001652130us-gaap:RelatedPartyMember2023-09-300001652130us-gaap:RetainedEarningsMember2023-01-012023-03-310001652130us-gaap:AdditionalPaidInCapitalMember2023-09-300001652130ntla:SparingVisionMember2023-07-012023-09-300001652130us-gaap:RetainedEarningsMember2022-07-012022-09-300001652130ntla:USTreasuryAndOtherGovernmentBackedSecuritiesMember2023-09-300001652130ntla:KyvernaTherapeuticsIncMember2023-03-012023-03-310001652130us-gaap:SeriesBPreferredStockMemberntla:KyvernaTherapeuticsIncMember2023-01-012023-09-300001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001652130us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001652130ntla:MemorialDrive640Member2023-01-012023-09-300001652130ntla:USTreasuryAndOtherGovernmentBackedSecuritiesMember2022-12-310001652130us-gaap:EmployeeStockOptionMember2022-07-012022-09-300001652130ntla:AtTheMarketOfferingsMember2023-01-012023-03-310001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001652130ntla:TwoThousandNineteenSalesAgreementMember2019-08-012019-08-310001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001652130ntla:TwoThousandTwentyTwoSalesAgreementMember2023-09-012023-09-300001652130us-gaap:AdditionalPaidInCapitalMemberntla:AtTheMarketOfferingsMember2023-07-012023-09-300001652130ntla:RegeneronArrangementMemberntla:RegeneronPharmaceuticalsIncMember2023-10-310001652130us-gaap:RelatedPartyMemberntla:KyvernaTherapeuticsIncMember2023-09-300001652130ntla:SparingVisionMember2023-01-012023-09-300001652130ntla:FinancialInstitutionDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-3000016521302021-12-310001652130ntla:SparingVisionMemberus-gaap:RelatedPartyMember2023-09-300001652130us-gaap:GeneralAndAdministrativeExpenseMemberntla:TwoThousandNineteenSalesAgreementMember2022-01-012022-03-310001652130us-gaap:RetainedEarningsMember2022-03-310001652130us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001652130ntla:RewriteTherapeuticsDelawareCorporationMember2023-01-012023-01-310001652130us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001652130us-gaap:EmployeeStockOptionMember2023-07-012023-09-300001652130ntla:AlbanyLeaseMember2023-01-012023-06-30iso4217:USDxbrli:sharesxbrli:pureutr:sqftxbrli:sharesntla:Productntla:USD_per_sqftntla:Targetcapntla:Trancheiso4217:USD\\n  &', 'AvenCell Co/Co', 'ATTR', 'Regeneron Agreement', 'NTLA-3001', '\\n  &#x2022;prevent', 'the SparingVision LCA', 'Recognition &#', '\\n  &#x2022;provide', 'and\\n  &', 'globally;\\n  &#x2022;improper', 'compensation\\n    &', 'Kyverna Therapeutics, Inc.', 'Caribou.\\n  &#x2022;We', 'the &#x201c;Kyverna', '\\n  &#x2022;product', 'Regeneron Agreements', 'the AvenCell Co/Co', 'manufacturers&#x2019', '\\n  &#x201c;Collaborations', '\\n  &#x2022;refusal', 'Medicaid', 'Medicare', 'Congress', 'the Securities and Exchange Commission', '2022.License AgreementsThe Company', '\\n  &#x2022;have', 'ATTR Co/Co', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'Regeneron&#x2019;s', '\\n  &#x2022;may', 'and\\n  &#', 'candidates;\\n  &#x2022;our', '\\n  &#x2022;could', 'Risks Related', '\\n  &#x2022;regulatory', '\\n  &#x2022;a $20.0 million', 'the ATTR Co/Co', 'REMS', '\\n  &#x2022;a $2.6 million', 'the &#x201c;ATTR Co/Co&#x201d;).In', 'AATD', 'Company', 'the Kyverna LCA', 'OSR', 'management&#x2019;s attention', '\\n  &#x2022;divide', 'federal and/or state breach notification laws', 'USPTO', 'Significant Accounting', 'Results of Operations', '\\n  &#x2022;injunctions', '\\n  &#160;\\n', 'Condensed Consolidated Financial', 'Charter)\\n  &#', '\\n  &#x2022;whether', '\\n    &#', 'contracted services;\\n  &', 'the Delaware General Corporation Law', 'the European Commission', 'Condensed Consolidated Statements of Operations', 'candidates;\\n  &#', 'Caribou', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', 'ONK Therapeutics, Ltd.', 'the U.S. Department of Health and Human Services', 'collaborators.\\n  Financial Overview\\n', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', '\\n  &#x2022;a $2.4 million', '\\n  &#x2022;experience', 'technologies.\\n  &#x2022;We', 'NTLA-5001', '\\n  &#', 'field.\\n  Disputes', 'SparingVision', 'the Regeneron Agreements', '\\n  &#x2022;require', 'Invention Management Agreement', 'Condensed Consolidated Balance Sheets', 'Intellia&#x2019;s', 'Cellex', 'the Hemophilia Co/Co', 'ONK', '840 Winter Street', 'CRISPR Therapeutics AG', 'death;\\n  &#x2022;transient', 'HAE', 'approved;\\n  &#x2022;estimates', 'Licensed Intellectual Property\\n  Third', 'Corporate', '\\n  &#x2022;our', '\\n  &#x2022;a $6.5 million', 'Blackstone Life Sciences Advisors L.L.C.', 'the &#x201c;Hemophilia Co', 'Novartis Institutes for BioMedical Research, Inc. (&', 'the CRISPR/Cas9', 'Regeneron', 'Collaboration Revenue', 'the Court of Chancery of the State of Delaware', 'General Counsel', 'AvenCell', 'Regeneron Pharmaceuticals, Inc. (&', 'Antitrypsin Deficiency', 'the U.S. Food and Drug Administration', 'jurisdictions.\\n  &#x2022;We', 'Condensed Consolidated Financial Statements\\n    ', 'the &#x201c;Delaware Forum', 'the U.K.&#x2019;s Data Protection Act', 'Medicaid Services', '\\n  &#x2022;restrictions', 'x2022;with', '\\n  &#x2022;obtain', 'Healthcare', 'the Company&#x2019;s Annual Report', '\\n  Risk Related', 'the Internal Revenue Service', 'ArrangementsTo', 'transthyretin (&#x201c;ATTR&#x201d', 'Development\\n  Research', 'the U.S. Treasury Department', '\\n  &#x2022;a $2.0 million', 'ATTR-CM', '\\n  &#x2022;an $8.5 million', 'Novartis', 'program:\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n', 'the Federal Trade Commission Act', 'the Centers for Medicare &', '\\n  &#x2022;manufacturing', 'Rewrite Therapeutics, Inc.', '\\n  Litigation', '\\n    &', 'the Rewrite Merger Agreement'}"
NTRA,"{'the Foundation Medicine Agreement', 'Credit Line', 'Guardant', 'BGI Genomics and Foundation Medicine', 'Prospera', 'ASU', 'ContingenciesLegal ProceedingsThe Company', 'Consolidated Statements of Operations and Comprehensive Loss', 'Months Ended &', 'SMART', 'UBS', 'Foundation Medicine, Inc.', 'the Clinical Laboratory Improvement Amendments', 'Financial Statements', '&quot;could,&quot', '5,903&#8203;$ &', 'Foundation', 'District Court', 'ContentsPursuant', '&quot;plan,&quot', 'the First Space and Second Space', 'Valuation of Stock Option Grants to Employees and Non-employeesThe Company', 'the Securities and Exchange Commission', 'Medicaid', 'Panorama, Horizon', 'Natera', '&quot;potential,&quot', 'FoundationOne', 'IPR&amp;D', 'Consolidated Statements of Cash Flows', 'expenses&#8203', 'ReferenceExhibit No.', 'Unaudited Interim Condensed Consolidated Financial Statements  &#', 'Foundation Medicine', 'expenses&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; &', 'Microdeletion', '&quot;estimate,&quot', 'ContentsProduct RevenuesDuring', 'ContentsInterest ExpenseInterest', 'Accounting PronouncementsWe', '&quot;expect,&quot', 'Inivata', 'NGS', '356,690)&#8203;&#8203', 'Panorama', 'ContentsAccumulated Other Comprehensive Income', 'The Foundation Medicine Agreement', 'SEC', 'Research and Development Research', 'IVD', 'Company', 'the Financial Accounting Standards Board', 'WilmerHale', '941&#8203;Total', '10,195&#8203;&#8203', 'the Securities Exchange Act', 'HCS', 'Panorama Non-Invasive Prenatal Test', 'New Accounting Pronouncements Not', 'the Qiagen LC (&#8220;Qiagen&#8221', 'the Sarbanes-Oxley Act', 'Consolidated Balance Sheets', 'Equity Securities', '&quot;predict,&quot', 'ConstellationThe', 'Credit Line&#8203;The', 'the UBS Credit Line', 'BGI Genomics Co. Ltd.', 'the BGI Genomics Agreement', 'Contentsplatform', 'the Credit Line', 'Critical Accounting PoliciesOur', 'RevenuesDuring', 'BGI Genomics'}"
NTRB,
NURO,"{'FASB', 'ASU', 'Form S-3', 'Financial Instruments &#8211', 'payments$324,662&#160;Discount', 'Accounting PronouncementsAccounting Standards Updates', 'Nasdaq Listing Rule 5505', 'HTM', 'Regulation S-K).&#160;20Item', 'Section&#160;13', 'Credit Losses: Measurement of Credit Losses on Financial Instruments', 'FDA', 'x &', 'registeredCommon Stock', 'The Nasdaq Capital Market', 'AFS', 'the Nasdaq Listing Qualifications Department', 'the Securities Exchange Act', 'Interactive Data File'}"
NUTX,"{'Nutex Health Holdco', 'the Office of Personnel Management', 'LLC', 'Administration', 'Form S-3', 'September&#160;30,&#160;2022', 'the Departments of HHS', 'Health Management Division', 'CMS', '-Payment', 'Determination Date', 'Restated Nutex Health Inc. 2022', 'the Center for Consumer Information and Insurance Oversight', 'Labor', 'Board of Directors.&#160;A', 'AHISP.All', 'the Securities and Exchange Commission', 'this Quarterly Report on Form 10-Q', 'AHP', 'basis&#8203;&#8203', 'Nutex Health Holdco LLC&#8217;s', 'Medicaid Services', 'stock &#', 'Federal IDR', 'the Sarbanes-Oxley Act of', 'Company Common Stock', 'ContentsThe', 'The Nasdaq Capital Market', 'AHP Health Management Services Inc.', 'net&#8203;&#8203', 'Apollo Medical Holdings', 'IDR', 'expenses&#8203;&#8203', 'Clinigence', 'Population Health Management', 'Treasury', 'the Contribution Agreements', 'NSA', 'Item I, &', '8220;Financial Statements&#8212;Note&#160;9 &#8211', 'the Texas Medical Association', 'Company', 'the Securities Exchange Act', 'Units', 'Advance Agreement', 'Debt&#8221', 'the Centers for Medicare &', 'the Sarbanes-Oxley Act', 'COVID-19', 'Regulation S-K', '-Deconsolidation of Real Estate', 'Nutex Health'}"
NUVL,"{'Shanghai Hengrui Pharmaceutical Co.', 'and\\n  &#x2022;requirements', 'the U.S.;\\n  &#x2022;potential', 'candidates;\\n  &#x2022;the', 'EMA', 'and\\n  17\\n', 'the Private Securities Litigation Reform Act', 'the Company&#x2019;s Annual Report on Form 10-K', 'EU', 'unsuccessful;\\n  &#x2022;Third', 'candidates;\\n  &#x2022;actual', 'the U.S. Foreign Corrupt Practices Act', 'HER2 Exon 20 Insertions', 'x2022;a', 'NVL-655', 'NSCLC', 'countries;\\n  &#x2022;developments', 'CPRA', '\\n    Research', 'the U.S.;\\n  &#x2022;production', 'Nuvalent, Inc.', 'Form S-1', 'stock\\n          &#160;\\n          &#160;\\n          ', 'the Securities Exchange Act', '\\n  Research', 'Research', 'CNS', 'losses;\\n  &#x2022;Our', 'affected;\\n  &#x2022;If', 'candidates;\\n  &#x2022;collaboration', 'No &#', 'capital commitments;\\n  &#x2022;actual', '\\n  &#x2022;expenses', 'G2032R', 'and\\n  &', 'our shares;\\n  &#x2022;announcement', 'sector;\\n  &#x2022;changes', 'HHS', 'Boehringer Ingelheim Pharmaceuticals', 'candidates;\\n  &#x2022;obtaining', 'candidates;\\n  &#x2022;collaborators', 'analysts;\\n  &#x2022;fluctuations', 'x201c;Risk', 'Medicaid', 'Medicare', 'x2014;\\n        &', 'GDPR', 'the National Comprehensive Cancer Network', 'a Committee for Medicinal Products for Human Use', 'FDA', 'letters;\\n  &#x2022;civil', 'and\\n  &#', 'others;\\n  &#x2022;collaborators', 'efforts;\\n  &#x2022;regulatory', 'commercialization;\\n  &#x2022;Our', 'affected;\\n  &#x2022;We', 'commitment.\\n  Co-development', 'HIPAA', 'Humana', 'REMS', 'FTC', 'Company', 'expense)\\n    &', 'payroll taxes;\\n  &#x2022;foreign', 'USPTO', 'profits.\\n', 'the California Privacy Rights Act', '\\n  &#160;\\n', 'Department of Justice', 'and\\n  &#x2022;business', 'Cowen', '70\\n', 'ASU', 'CMS', 'relationships;\\n  &#x2022;risks', 'matters;\\n  &', 'FCPA', 'and\\n  &#x2022;our', 'x2022;injunctions;\\n  &#x2022;suspension', 'the U.S. Department of Health and Human Services', 'Blue Cross Blue Shield', 'collaborators;\\n  &#x2022;We', 'x2022;a collaborator&#x2019;s', 'European Medicines Agency', '\\n  &#', 'ALK', 'production;\\n', 'IRA', 'interpretation;\\n  &#x2022;whether', 'stock.\\n  Pursuant', 'IPO', 'CNS progression.\\n  &#x2022;Lorlatinib-na&#xef;ve', 'Comparison', 'This Quarterly Report on Form 10-Q', 'EGFR', 'property.\\n', '\\n  &#x2022;our', 'Cowen and Company', 'approval;\\n  &#x2022;impact', 'oversight.\\n', 'this Quarterly Report', 'markets;\\n  &#x2022;compliance', 'including:\\n  &#x2022;the', '44\\n', 'and\\n  &#x2022;general', 'products;\\n  &#x2022;The', 'Medicaid Services', 'the Center for Medicare &', 'NVL-330', 'the Internal Revenue Service', '\\n  &#x2022;If', 'guidance;\\n  &#x2022;Our', 'Adopted Accounting Pronouncements\\n', 'products;\\n  &', 'the U.S. Treasury Department', '\\n        &', 'SEC', 'foreign countries;\\n  &#x2022;workforce', 'agreements.\\n', '\\n    &', 'No &#9744;\\n  Indicate', 'required;\\n  &#', 'See &#x201c;&#x2014;Liquidity'}"
NUWE,"{'Nuwellis, Inc.', 'No &#9744', 'the\\n          Company', 'ASU', 'ICU', 'the DaVita Warrant', 'State', 'Aquadex', 'F Convertible Preferred Stock:', 'Fourth Amended', 'PIK', 'the DaVita Supply Agreement', 'Stock-Based\\n        Compensation\\n\\n', 'Aquadex System', 'the U.S. Food and Drug', 'HDE', 'FOB', 'Internal Revenue Service', '9 &#', 'SeaStar', 'the State of Delaware a Certificate of Amendment', 'SeaStar Medical Holding Corporation', 'Company', 'Restated Certificate of Incorporation', 'the Aquadex System', 'Certificate of Incorporation', 'COVID-19', 'Nasdaq', 'the Series J Convertible Preferred Stock'}"
NVAX,
NVCR,"{'U.S. Food and Drug Administration', 'the Zai Agreement', 'NSCLC', 'Roche', 'TTFields', 'revenues$1,511&#160;$1,013&#160;$5,540&#160;$2,994&#160;Research', 'Company', 'the Consolidated Financial Statements'}"
NVCT,"{'liquidate.&#8203;&#8203;&#8203;8\\nNUVECTIS PHARMA,&#160;INC.Notes&#160;to', 'Form S-3', 'ProceduresOur', 'the Accounting Standards Codification', 'UoE', 'Finance', 'H. C. Wainwright &amp', 'Preferred Investment Options', 'the University of Edinburgh', 'the symbol &#8220;NVCT&#8221;.e', 'the CRT Pioneer Fund', 'Capital ResourcesThe Company', 'Financial ReportingThere', 'SEC', 'the Financial Accounting Standards Board', 'Income&#160;&#8203', 'Company', 'NASDAQ', 'Administrative&#160;&#8203', 'Development ExpensesThe', 'AdoptedManagement', 'the Registration Statement'}"
NVIV,
NVNO,"{'SAVVE', 'Components of Investments\\n\\n(In\\nthousands)\\n\\n&#160;\\n\\n\\n  ', 'enVVeno Medical Corporation.\\n\\n&#160;\\n\\nOverview\\n\\n&#160;\\n\\nenVVeno\\nMedical Corporation', '\\n    ', 'COVID-19', 'statements.\\n\\n&#160;\\n\\nNote\\n4 &#8211', 'Risk Factors\\n\\n&#160;\\n\\nAs\\na &', 'Item 10 of Regulation S-K', 'results\\nwill', '\\n    &'}"
NVOS,
NXGL,"{'ASC', 'Secured Convertible Promissory Notes', 'FASB', 'LLC', 'the RSU Grant', 'Bezalel Partners', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'the Board of Directors\\nin the current period.\\n\\n&#160;\\n\\nAdvertising', 'NXGL', 'Consumer Branded Products', 'Loan Authorization and Agreement', 'Amazon', 'the EIDL Loan', 'Reserved Common Stock For Issued Securities', 'White Label', 'Form S-1', 'SEC', 'Company', 'EXCHANGE', 'credit&#160;\\n    &', 'Custom &', 'Executive Employment Agreement', 'NexGel', '\\n    &'}"
NXL,"{'Joint Venture Agreement', 'ASC', 'FASB', 'The Incorporation Form (Company Limited', 'ASU', 'Panel', 'Factors &', 'SEC File', 'the Companies Registry', 'No\\n      &', 'Financial Instruments-Credit Losses', 'Stock Compensation (&', 'the Nasdaq Hearings Panel', 'NASDAQ Rule 5550(a)(2).\\nThe Company', 'this Quarterly Report', 'EDD', 'The University of Arizona\\n      &', 'Nexalin\\n      Technology, Inc.', 'the Board of Directors', 'the Securities and Exchange Commission', '9 &#8212', 'ROU', 'LLC (&#8220;U.S.\\n      ', 'the electrodes.\\n      &', 'Wider', 'Wider Come Limited', 'the University of Arizona', 'University', 'Prospectus', 'the\\nNasdaq Hearings Panel (&#8220;Panel&#8221', 'the University of Arizona\\n      ', 'this matter.\\n      &', 'disorders.\\n      &', 'Registrant', 'respectively.\\n      &', 'U.S. Asian Consulting Group', 'Quality, Regulatory and Clinical Affairs', 'RELATED PARTY', 'September&#160;30', 'Section&#160;2(a', 'Form S-1', 'RFID', 'SEC', 'the Nasdaq Listing Qualifications Department', 'Company', 'Compensation &#8212', 'NASDAQ', 'September&#160;25', 'Asian Consulting Group', 'net:&#160;\\n    &', 'the Sarbanes-Oxley Act', 'COVID-19', 'Total&#160;\\n    &', 'Wider Come Limited\\n      ', 'October&#160;13', 'Neuro-Health', 'the\\n      Company', 'Nasdaq', 'net&#160;\\n    &', 'revenues&#160;\\n    &', '\\n    &', 'reported.\\n      &', 'NV Nexalin', 'the Nasdaq Stock Market (&#8220;Nasdaq&#8221'}"
NXTC,"{'ASC', 'the Lilly Agreement', 'OverviewWe', 'Stock-Based CompensationEmployee Equity PlansThe NextCure, Inc.', 'ContentsNEXTCURE', 'this Quarterly Report', 'Omnibus Incentive Plan', 'the Private Securities Litigation Reform Act', 'ESPP', 'Development ExpensesResearch', 'Lilly', 'Issued Accounting PronouncementsThe Company', 'the SEC.Recent Accounting PronouncementsSee Note', 'OperationsThe', 'Company', 'The NextCure, Inc.', 'the &#8220;Effective', 'Leerink Partners', 'Plan&#8221', 'IPO', 'Results of Operations', 'Eli Lilly and Company', 'Yes &#9746;&#160;No &#9744;&#8203;Indicate'}"
NYXH,
OABI,"{'the Merger Agreement', 'OmniDeep&#8482', 'FASB', 'ProceduresWe', 'Consolidated and Combined Statements of Cash', 'Key Business MetricsWe', 'the Separation Agreement', 'Private Placement', 'the Amended and Restated Forward Purchase Agreement', 'Share-Based CompensationConversion and Modification of Equity Awards Outstanding at Separation DateIn connection', 'Backstop Warrants', 'Finance', 'Backstop Common Stock WarrantsThe Company', 'Condensed Consolidated and Combined Financial Statements', 'Distribution', 'OmniAb, Inc. (&', 'the Employee Matters Agreement', 'the Private Securities Litigation Reform Act', 'September&#160;30,', 'Consolidated and Combined Statements', 'The Public Warrants', 'equipment4', 'the Interactive Data File', 'Orwell Merger Sub Inc.', 'Trust Company', 'Ligand', 'CVR', 'OmniAb Operations, Inc.', 'Legacy OmniAb (the &#8220;Separation', 'ChangeResearch', 'NumberDate of FilingExhibit NumberFiled Herewith2.1+Agreement and Plan of Merger', '20222.12.2+Separation and Distribution Agreement', 'Share-Based Compensation', 'the Sarbanes-Oxley Act of', 'APAC', 'LifeLab', 'No &#9744;Indicate', 'Organization and Basis of PresentationSeparation and Business CombinationOn', 'OmniAb, Inc.S-4333-264525September 27', 'Incorporation of the Registrant10-K001-40720March', 'Continental Stock Transfer &amp', 'Significant Accounting Policies', 'ChangeActive', 'Regulation S-K.', 'SEC', 'Consolidated and Combined Balance Sheets3Condensed Consolidated and Combined Statements of Operations and Comprehensive', 'the Separation and Distribution Agreement', 'SeparationThe', 'Condensed Consolidated and Combined Financial Statements7ITEM', 'Company', 'Disaggregation of RevenueThe', 'the Securities Exchange Act', 'Avista Public Acquisition Corp. II', 'the Business Combination', '*&', 'InvestmentsShort', 'the Sarbanes-Oxley Act', 'Ligand Pharmaceuticals Incorporated', 'Cash Management and FinancingThe Company', 'GSK', 'Page Interactive Data File', 'OmniAb, Inc.', 'Computershare Trust Company', 'the Forward Purchase', 'Ligand (&#8220;Legacy OmniAb&#8221', 'Legacy OmniAb of $1.8 million'}"
OBIO,"{'ASC', 'compensation&#8203;$ 2,238&#8203;$', 'LLC', 'this Quarterly Report on Form&#160;10', '1,979&#160;&#8203', 'Security Agreement', 'Rule&#160;12b-2', '528&#8203;$ &', 'Financial Instruments', 'ContentsNet Cash Flows', 'SAB', 'Virtue SAB', 'Terumo Medical Corporation', 'Orchestra', 'Legacy Orchestra Preferred Stock', 'the Internal Revenue Code', 'Fair Value Adjustment', 'No &#9744;Indicate', 'the closing&#160;of&#160;the Business Combination', 'Business Combination(2)&#160', 'the Securities Exchange Act', 'the Series D-2 Financing', 'compensation&#8203;$ 1,001&#8203;$ 2,193&#8203;$', 'COVID-19', 'Consolidated Financial Statements', 'Vivasure', 'the Merger Agreement', '736&#8203;$ &#', 'FASB', 'July&#160;22', 'BACKBEAT', 'Legacy Orchestra Common Stock', 'fixed.&#8221', 'the Merger Agreement and Forward Purchase Agreements', 'the HSAC2 Trust Account', 'AVIM', 'FDA', 'Motus GI', 'Avenue Venture Opportunities', 'NetProperty', 'Results of Operations32Item', 'Forward Purchase Agreement', 'Loan', 'New Accounting', 'ISR', 'Company&#160;Common Stock', 'Company Common Stock', 'ContentsThe', 'Orchestra Common Stock', 'the Company Common Stock', 'November&#160;2024.&#160;Monthly', '528&#8203;$ &#8212;Debt', 'Silicon Valley Bank', 'Reverse Recapitalization', 'the Securities Exchange Act 47\\nTable', 'Financial Instruments&#160;&#8212;&#160;Credit Losses', 'Company', 'Note&#160;3.Defined Contribution PlanThe Company', 'the ISR indication.&#8203;The Company', 'the Legacy Orchestra Series&#160;D-2 Preferred Stock', 'November&#160;21', 'Backstop', 'Condensed Consolidated Financial', 'The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'Condensed Consolidated Financial Statements', 'Consolidated Statements of Operations', 'L.P. (&#8220;Avenue', 'the Final Milestone Event', 'development&#8203;$ 643&#8203;$ &#', 'OperationsComparison', 'BackBeat CNT and Virtue SAB', 'CommitmentsThe', 'ASC&#160;808, Collaborative Arrangements', 'Orchestra Warrants', 'the Medtronic Agreement', 'Orchestra stockholders &#8211', 'BackBeat Medical', 'Consolidated Statements of Cash Flows', 'Avenue Venture Opportunities Fund', 'Caliber', 'Note&#160;10', 'Medtronic plc', 'Collaborative Arrangements', 'the Sponsor Forfeiture', 'debt extinguishment&#8203;&#8203; &#8212;&#8203;&#8203', '2,018)Deferred Revenue &', 'Avenue Venture Opportunities Fund II', 'the Terumo Agreement', 'Business Combination:&#8203;&#8203;&#8203;&#8203;&#160;&#160;&#160;&#160;Number&#160;of&#8203;&#8203;SharesCommon', 'HSAC2 (&#8220;Merger', 'the Earnout Consideration', 'the Sarbanes-Oxley Act', 'Unaudited Condensed Consolidated Financial Statements6Item 2.Management&#8217;s', 'Financial Accounting Standards Board', 'Delaware Corporation', 'Revenue &', 'Contentspreclinical', 'the Consolidated Financial Statements.43\\nTable of ContentsRevenue RecognitionWe', 'Consolidated Statements', 'the Consolidated Financial Statements', 'compensation&#8203;$ 270&#8203;$ &#', 'the HSAC2 IPO', 'See Note&#160;4).BackBeatBackBeat Medical, Inc.', 'this Quarterly Report on Form&#160;10-Q.', 'Legacy Orchestra Common Stock (&#8220;Legacy Orchestra Options&#8221;)', 'Accounting Standards Codification', 'Medtronic', 'HSAC2 Ordinary Shares and/or Company Common Stock', '778)Total Property', 'ContentsOutstanding', 'Health Sciences Acquisitions Corporation 2', 'Significant Accounting Policies', 'Recognition', 'the Initial Milestone Event', 'Administrative ExpensesSelling', 'the Backstop Agreement', 'Regulation S-K.&#8203;&#8203;51\\nTable', 'the Business Combination', 'IDE', '643&#8203;$ &#8212;Selling', 'Consolidated Balance Sheets', 'BackBeat', 'Funding Requirements &', 'compensation;&#9679;Cost', 'equipment&#160;10 yearsOffice equipment&#160;3 &#8211', 'ContentsItem&#160;6'}"
OCEA,"{'L.P.', 'the Merger Agreement', 'Registration Statement on Form S-1', 'TNL Mediagene', 'the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition', 'ASU', 'the Working Capital Loans\\n(and', 'Class\\nB', 'Letter Agreement', 'Apollo SPAC Fund I', 'the Public Offering', 'the Extraordinary General Meeting', 'Name:\\n', 'Capital Resources and Going', 'this Quarterly Report on Form 10', 'Administrative Support Agreement', 'Internal Control', 'Private Placement Warrants', 'the Warrant Agreement', 'the Public Warrants', 'TNL (&#8220;Merger', 'Business Combination', 'in\\nthe Trust Account', 'this Quarterly Report on Form 10-Q', 'Transactions', 'TNL', 'The Public Warrants', 'Blue Ocean Acquisition Corp', 'Restated Memorandum', 'the &#', 'Trust Company', 'the Securities &amp', 'expire\\nor', 'the Trust Account.\\n\\n&#160;\\n\\nBusiness Combination\\n\\n&#160;\\n\\nOn June 6, 2023', 'Cayman Islands', 'the Registration\\nRights Agreement', 'Trust', 'Public Shares', 'Current Report', 'Memorandum', 'a Business Combination', 'Articles of Association', 'Merger Sub', 'Registrant', 'by\\nthe Public Company Accounting Oversight Board', 'The News Lens Co., Ltd.', 'the Additional\\nPrivate Placement Warrants', 'Principal Financial and Accounting', 'Item 303(a)(4)(ii)\\nof Regulation S-K', 'Apollo', 'SEC', 'Principal Executive', 'the Private Placement Warrants', 'the Founder Shares\\nand Private Placement Warrants', 'Company', 'concern.\\n\\n&#160;\\n\\nOff-Balance Sheet Financing', 'the Securities Exchange Act', 'Pursuant', 'Units', 'the\\nSecurities and Exchange Commission', 'the Additional\\nPrivate Placement', 'the Working Capital Loans', 'Founder Shares', 'See &#', 'the Sarbanes-Oxley Act', 'Exchange Commission', 'depositing\\ninto the Trust', 'Company&#8217;s\\nshareholders', 'pre-Business Combination', 'the Founder Shares', '\\n    &', 'Financial Accounting Standards Board'}"
OCGN,"{'ASC', 'Company\\', 'FASB', 'AMD', 'ProceduresWe', 'B Convertible Preferred Stock', 'the ""Canada Consulting Agreement', ""the Company\\'s Registration Statement on"", 'Development and Commercial Supply Agreement', 'Qualitative Disclosures', 'Adopted Accounting PronouncementsFor', 'the Canada Warrants', 'Bharat Biotech', 'Issuer Purchases of Equity Securities', 'Item&#160;4.&#160;&#160;&#160;&#160;Mine Safety', 'COVAXIN', 'this Quarterly Report on Form 10-Q', 'Bharat', 'the Canada Consulting Agreement', 'the Supply Agreement', 'Mucosal Vaccine PlatformThe Company', 'ContentsNot', 'The Nasdaq Capital Market (&#8220;Nasdaq&#8221', 'LCA', 'FDA', 'the ""Canada Warrants', 'the Covaxin Agreement', 'GMP', 'ObligationsWe', 'RSU', 'RP', 'Bharat Biotech International Limited', 'Cash EquivalentsThe Company', 'the Interim Chief Accounting Officer', 'EUA', 'ContentsThe', 'the ""Original Offering', 'the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock', 'Series B Convertible Preferred Stock', 'the EB-5 Loan Agreement', 'SEC', 'the ""OpCo Warrants', 'NeoCart', 'OpCo', 'the ""Preferred Stock Purchase Agreement', 'Company', 'the Sarbanes-Oxley Act', 'COVID-19', 'Equity Securities', '2022 Annual Report', 'Market Issuance Sales Agreement', 'Black-Scholes', 'Nasdaq', 'ASU No'}"
OCS,
OCUL,
OCUP,"{'ASC', 'the Viatris Territory', 'Part I &#', 'Note 2 &#8211', 'the\\n            Company', 'Rexahn', 'this Quarterly Report on Form 10-Q', 'BioSense', 'Lincoln Park', 'BioSense Global LLC (&#8220;BioSense&#8221;)\\n', 'Apexian Pharmaceuticals, Inc.', 'the Apexian Sublicense', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Rexahn Pharmaceuticals, Inc.', 'Item I &', '\\n               ', 'Consolidated Financial Statements', 'The Purchase Agreement', 'the Nyxol License Agreement.\\n\\n        \\n        \\n\\n        ', 'the Merger Agreement', 'FASB', 'BioSense License', 'See &#8220;Part', 'Review and Approval of Drugs', 'Diluted', 'The Series B Warrants', 'Note 11 &', 'FDA', 'Loan', 'Company', 'the Processa License Agreement', 'months.&#160;The', 'Viatris Inc.', 'the Waiver Agreements', 'Rexahn RX-3117', 'LLC (&#8220;Lincoln', 'Global Partners (&#8220;AGP&#8221', 'the Apexian Sublicense Agreement', 'Financial', 'Report', 'ASU', 'LDP', 'RDO Warrants', 'Contracts with Customers', 'APX3330', 'License', 'Value', 'the Series A Warrants', 'Lincoln Park Capital Fund', 'Entity&#8217;s Own Equity', 'Nyxol License', 'Conversion and Other Options', 'the Nyxol Products', 'NDA', 'the warrants.\\n\\n      &#160;\\n\\n', 'Form S-3.\\n\\n      &#160;\\n\\n', 'No &#9744;\\n\\n', 'The RDO Warrants', 'Clinical Development Plan &#8212;Potential', 'the Purchase Agreement', 'Processa Pharmaceuticals, Inc. (&#8220;Processa&#8221', 'license&#160;to', 'SPA', 'the Nyxol License Agreement', 'Rexahn (&#8220;Merger', '\\n                   ', 'Contracts', 'ATM', 'Note 12 &#8212', '\\nThe Company', 'Derivatives', 'DLD', 'Processa Pharmaceuticals, Inc.', 'the U.S. Food and Drug Administration', 'Series A Warrants and Series B Warrants', 'the &#8220;simplified', 'the Nyxol License', 'Condensed Financial', 'Business&#8212;APX3330 Clinical Experience Summary &', 'Accounting for Convertible Instruments', 'and\\n            \\n\\n', 'Rexahn Pharmaceuticals, Inc. (&#8220;Rexahn&#8221'}"
OCX,
OFIX,"{'ASU', 'Enabling Technologies', 'the License Agreement', 'ORTHOFIX MEDICAL INC', 'JPMorgan Chase Bank', 'Neo Medical', 'the Accounting Standards Codification', 'License and Distribution Agreement with CGBio Co.', 'Disclosure Update and Simplification Initiative', 'License and Distribution Agreement', 'tax\\n    &#160;\\n    &#160;\\n', 'The Financing Agreement', 'tax\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n    &#160;\\n', 'RecognitionThe Company', 'Medicare', 'CGBio Co., Ltd.', 'x2014;\\n        &', 'AccelStim', 'the Unaudited Condensed Consolidated Financial Statements', '\\n  &#x2022;Decrease', 'Neo Medical SA', 'IPR&amp;D', 'the Financing Agreement', 'CervicalStim', 'the &#x201c;Delayed', 'National Association', '\\n  &#', 'thousands)\\n        &', 'Wells Fargo Bank', '\\n    Effective', 'Evaluation\\n       \\n       \\n        Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions', 'Penalty Incurred', 'Exclusive License and Distribution Agreement', 'Equity \\n  &#160;\\n', 'Spinal Kinetics', 'the &#x201c;Credit', 'Indicate', 'Condensed Consolidated Statements of Changes', 'the &#x201c;Initial Term Loan&#x201d;)', 'Global Orthopedics', '26\\n', 'IMDP', 'the Prior Credit Agreement', '\\n    Research', '\\n    Interest', '\\n        &', 'the symbol &#34;OFIX&#34', 'Response', 'the Merger\\n        &', '\\n      &', 'SeaSpine', 'the Convertible Loan', 'Pro Forma Financial InformationDue', 'Company', 'Blue Torch Finance', 'NASDAQ', 'the &#x201c;Convertible', 'AccelStim\\n  &#x2022;Spinal Implants, Biologics', 'the Initial Term Loan', 'thousands)\\n    &', 'Supply Agreement with Wittenstein', 'Fair Value Measurement', 'Ltd.\\n  &', 'Exclusive License and Distribution Agreement \\n', 'the Orthofix Medical Inc.', 'the &#x201c;Merger', '\\n    &', 'the Delayed Draw Term Loan', 'property.\\n', 'Lattus'}"
OGI,
OKYO,
OLK,
OLMA,"{'ContentsIntellectual', 'OverviewWe', 'LLC', 'CDK4/6', 'Security Agreement', 'EMA', 'Adopted Pursuant', 'the Annual Report', 'EEA', 'EU', 'the Novartis Agreement', 'ContentsEven', 'Pfizer Inc.', 'the Sarbanes-Oxley Act of', 'Consolidated Statements of Cash Flows&#8203;6Notes&#160;to Unaudited', 'No &#9744;Indicate', 'Officer)Olema Pharmaceuticals, Inc.', 'Dropbox, Inc.', 'Board of Directors;&#9679;require', 'The Nasdaq Stock Market LLC', 'Note 11 &#', 'the Securities Exchange Act', 'COVID-19', 'December&#160;31,&#160;2022&#160;&#160;&#160;&#160;&#8203', 'IRBs;&#9679;IRBs', 'Value MeasurementThe Company', 'the Novartis Study Drugs', 'the Credit Facility', 'First-Citizens Bank &amp', 'HHS', 'the Pfizer Agreement', 'Aurigene Discovery Technologies Limited', 'Medicaid', 'the Bank.19\\nTable of Contents&#160;The Loan Agreement', 'Medicare', 'the Securities and Exchange Commission', 'GDPR', 'Principal Accounting', 'FDA', 'Credit Facility', 'Loan', 'Contentsmanufacturers', 'ContentsPIQRAY&#174', 'Concentration of Credit Risk and Other Risks', 'ContentsThe', 'HIPAA', 'AI', 'the Private Placement', 'Silicon Valley Bank', 'the Aurigene Agreement', 'Based Restricted Stock', 'REMS', 'Company', 'Initial Public Offering', 'The Novartis Agreement', 'The Novartis Amendment', 'USPTO', 'ContentsThe Company', 'Olema Pharmaceuticals', 'Department of Justice', 'Bank&#8217;s', 'the Delaware General Corporation Law', 'Fair Value Measurements', 'MandalMed, Inc.', 'Purchase Agreement', 'Consolidated Balance Sheets&#8203;3Condensed Consolidated Statements of Operations and Comprehensive', 'ContentsCosts', 'the Sarbanes-Oxley Act of 2002.&#8203;&#8203;&#8203;&#8203;32.1*#Certification', 'CMS', 'SecuritiesAll', 'CCPA', 'FCPA', 'the U.S. Department of Health and Human Services', 'the Maturity Date', 'Trust Company', 'UncertaintiesFinancial', 'Novartis Institutes for BioMedical Research, Inc.', 'Unregistered SecuritiesThere', 'Board of Directors', 'accelerated.&#160;The Loan Agreement', 'NDA', 'ContentsSince', 'IBRANCE&#174', 'the Loan Agreement 99\\nTable', 'IPO', 'deemed &#8220;filed&#8221', 'IPR', 'The Cambridge Redevelopment Authority', 'PGR', 'the Loan Agreement', 'Bank', 'Board', 'Consolidated Statements', 'Novartis Institutes for BioMedical Research, Inc. (&', 'UK Data Protection Act', 'ROU', 'the U.S. Food and Drug Administration', 'The Credit Facility', 'Medicaid Services', 'Contentswe', ';) Inhibitor', 'SEC', 'Financial Officer(Principal Financial Officer', 'GCP', 'Board of Directors;&#9679;limit', 'Clinical Collaboration and Supply Agreement', 'Data Safety Monitoring Board', 'Novartis', 'the Centers for Medicare &', 'Equity Securities'}"
OM,"{'FASB', 'this Quarterly Report', 'Second Revenue Milestone', 'the SLR Loan Agreement', 'Hemodialysis System', 'the Tablo System', 'operations.\\n  &#160;\\n  18\\n', 'Exhibits.\\n  &#160;\\n', 'SLR Credit Facility Agreement', 'the U.S. Food and Drug Administration', 'the SLR Revolving Credit Agreement', 'FDA', 'the Term A Loan', '\\n  &#', 'Board of Directors', 'SLR Revolving Credit Agreement', 'a Term C Loan', 'ABL Lender', 'TACNA Services', '\\n    Research', 'the Warning Letter', 'Prefiltration', 'agreements.\\n', 'TSR', 'the SLR Credit Facility Agreements', 'Company', 'the Financial Accounting Standards Board', 'Tablo', '\\n    Service', 'the Tablo Hemodialysis System', 'the SLR Credit Facilities', 'TabloCart', '\\n    Interest expense\\n    &', 'Significant Accounting PoliciesRecently Adopted Accounting', 'CRRT', 'Regulation S-K', 'the Sarbanes-Oxley Act', 'Principal Financial Officer Pursuant', 'Comparison', '\\n    &', 'TACNA', 'ASU No'}"
OMCL,
OMER,
OMGA,
OMIC,"{'additional markets;\\n  &#x2022;acquiring', 'LLC', 'customers;\\n  &#x2022;broader', '\\n  &#x2022;variations', 'lines;\\n  &#x2022;superior', 'and\\n  &#x2022;not', 'the future;\\n  &#x2022;citation', 'Principal Executive Officer', 'future products;\\n  &#x2022;scaling', 'RUO', 'portfolios;\\n  &#x2022;exclusive', 'EU', 'FDA &#', 'customers;\\n  &#x2022;market', 'recognition;\\n  &#x2022;greater', 'x2022;a', 'NGS', 'the &#x201c;License', 'Accounting Standards Update', 'OAS Lease', 'countries;\\n  &#x2022;volatility', 'the Minimum Bid Requirement', 'the Financial Accounting Standards Board', 'and\\n  &#x2022;financing', 'and\\n  &#x2022;market', 'COVID-19', 'x2022;scientists&#x2019', 'HHS', 'The License Agreement', 'the Clinical Laboratory Improvement Amendments', 'U.S. Food and Drug Administration', 'the G4;\\n  &#x2022;completing', 'PHI', 'the Securities and Exchange Commission', 'Congress', 'GDPR', 'FDA', 'the FDA&#x2019;s Quality System Regulations (&#x201c;QSRs&#x201d;)', 'costs;\\n  &#x2022;our', 'results;\\n  &#x2022;operating', '\\n  &#x2022;difficulties', 'and\\n  &#', 'Risks Related', 'this Shelf Registration Statement', 'Company', 'both;\\n  &#x2022;regulatory', 'management&#x2019;s attention', 'USPTO', 'x201c;Brexit&#x201d;);\\n  &#x2022;potentially', 'the Health Insurance Portability', 'The SVB Loan', 'Operations;\\n  &', 'expectations;\\n  &#x2022;the', 'companies;\\n  &#', 'SVB', 'the California Consumer Privacy Act', 'PX Instruments', 'the Delaware General Corporation Law', 'and\\n  &#x2022;advance', 'SVBB', 'the SVB Loan', 'the Nasdaq Capital Market', 'Exclusive License Agreement', 'PX', 'Principal Financial Officer', 'and\\n   ', 'capabilities;\\n  &#x2022;funding', 'Public Offering of Common Stock\\n', 'acquirer;\\n  &#x2022;the', 'and\\n  &#x2022;better', 'networks;\\n  &#x2022;substantial', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'enhancements;\\n  &#x2022;expanding', '\\n  &#x2022;the', 'ARE-SD Region', 'License Agreement', 'Alexandria Real Estate Equities, Inc. (&', 'License', 'Foreign Asset Control;\\n  &#x2022;export', 'companies;\\n  &#x2022;foreign currency', 'Capital ResourcesThe Company', 'pressures;\\n  &#x2022;litigation', 'the Public Readiness', 'The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d', 'directors;\\n  &#', 'the Sarbanes-Oxley Act', 'The Trustees of Columbia University (&#x201c;Columbia&#x201d', 'ECJ', 'IPO', 'customers;\\n  &#x2022;approvals', 'pricing;\\n  &#x2022;the', 'capabilities;\\n  &#x2022;greater', 'Cowen and Company', 'Our Financial Position', 'Form S-3', 'the License Agreement', 'the Standard Contractual Clauses', '44\\n', 'enhancements;\\n  &#x2022;actual', 'the &#x201c;Shelf Registration', 'the U.S. Food and Drug Administration', 'restrictions;\\n  &#x2022;laws', 'and\\n  &#x2022;general', 'LDTs', 'Columbia', 'capabilities.\\n', 'Patent Products and/or Other Products', 'SEC', 'the G4;\\n  &#x2022;the', 'Shelf Registration Statement and Sales Agreement', 'the Foreign Corrupt Practices Act', 'Equity Securities', 'timelines;\\n  &#x2022;changes', 'Series A Common Stock Equivalent Convertible Preferred Stock', 'the European Union', 'Nasdaq', 'consumables;\\n  &#x2022;our', '\\n    &', 'technologies;\\n  &#x2022;announcements', 'DebtSilicon Valley Bank'}"
ONCT,"{'\\n    &#160;&#160;&#160;&#160;31.2*\\n    &#160;\\n    Certification of Chief Financial Officer', 'FASB', 'the Georgetown License Agreement', 'LLC', 'ASU', 'DAARI', 'the Securities Purchase Agreement', 'Purchase Agreement&#x201d;)\\n    &', 'Exclusive License Agreement', 'LLC (&#x201c;H.C. Wainwright&#x201d', 'Cover Page Interactive Data File', 'EXHIBIT INDEX\\n  &', 'Related PartyIn', 'this Quarterly Report', '\\n', '\\n    &#', '3,411\\n          &', 'EWS-FLI1', 'The University of Tennessee Research Foundation', 'the Purchase Agreement', '\\n  &', 'Exhibits.\\n  &#160;\\n', 'Contractual Obligations and Commitments \\n', 'this Quarterly Report to &', 'Jefferies LLC', '\\n    &#160;&#160;&#160;&#160;101.LAB*\\n    &', 'the Interactive Data File', 'NIH', 'Financial Instruments &#', 'SPH USA', '\\n  &#', 'Oncternal Therapeutics, Inc.', 'Cash EquivalentsThe Company', 'Agreement\\n    &', 'Georgetown', 'the &#x201c;Exchange', 'Registrant', 'the Amended and Restated Underwriting Agreement', 'Restricted', 'the Minimum Bid Requirement', 'Company', 'the Securities Exchange Act', 'Credit Losses', 'Grant Revenue\\n  Grant', '\\n    &#160;&#160;&#160;&#160;4.3\\n    &', '\\n    &#160;&#160;&#160;&#160;101.SCH*\\n    &', 'the Regents License Agreement', 'Connell', 'stock\\n          &#160;\\n          &#160;\\n', 'Series B-2 Preferred Stock of Registrant\\n    &', 'Adopted Accounting', 'License and Development Agreement (&#x201c;LDA&#x201d', 'Nasdaq', 'This Quarterly Report', 'Series B-2 Preferred Stock of Private Oncternal\\n    &', '\\n    &', 'UTRF', 'Regents'}"
ONCY,
ONMD,"{'Convertible', 'FASB', 'ASU', 'Data Knights Acquisition', 'Black Scholes', 'and\\nhealth technology', 'the Company&#8217;s\\nSeries A-2 Preferred Stock', 'this Quarterly Report on Form 10-Q', 'Real World Data.\\n\\n&#160;\\n\\nOur\\nbusiness', 'PIPE', 'Trust Company', 'Principal Executive Officer Pursuant to Securities Exchange Act', 'Principal Executive Officer Pursuant', 'OneMedNet Corporation 2022 Equity Incentive Plan', 'method.\\n\\n&#160;\\n\\nRecent\\nAccounting Pronouncements\\n\\n&#160;\\n\\nIn\\nJune 2016', 'the Government of Canada', 'investment\\nin', 'Corporate Transaction', 'Continental Stock Transfer &amp', 'Exhibit 10.8', 'Form S-1', 'SEC', 'discounts\\nand', 'Commission', 'capital\\nthrough', 'Company', 'Pursuant', 'the Registration Statement on Form S-4', 'Measurement of Credit Losses on Financial Instruments', 'the Sarbanes-Oxley Act', 'Outstanding&#160;&#160;\\n    Weighted-Average\\n                                                                                ', 'Principal Financial Officer Pursuant to Securities Exchange Act', 'the Next Equity Financing,\\nat', 'this Quarterly Report on Form 10-Q.\\n\\n&#160;\\n\\n\\n', '\\n    &', 'Grand View Research'}"
ONTX,"{'Abemaciclib', 'FASB', 'K-Ras', 'ContentsOnconova', 'date.&#8203;The Company', 'Form S-3', 'CDK4/6', 'the Nasdaq Capital Market', 'formulation &amp', 'Interim Financial', 'the Equity Distribution Agreement', 'Rule&#160;405 of Regulation S-T', 'the Securities and Exchange Commission', 'Co. (&', 'Section&#160;13', 'RDEB', 'the Interactive Data File', 'Temple University', 'FDA', 'CDK', 'Monteverde', 'the National Medical Products Administration', 'Piper Sandler', 'the Chinese Investigational New Drug Application', 'HanX', 'Nasdaq Listing Rule', 'KRAS-Mutated Cancers &#8203;We', 'the Equity Distribution Agreement.&#8203;&#8203;15\\nTable of ContentsItem 2', 'ContentsThe', 'NSCLC', 'Internal Control Over Financial ReportingOur', 'Nasdaq Listing Rule 5550(a)(2', 'Principal Financial Officer32.1&#160;**Section&#160;1350 Certifications of Principal Executive Officer32.2&#160;**Section&#160;1350 Certifications', 'Piper Sandler &amp', 'Entity&#8217;s Own Equity', 'market&#8221', 'Principal Executive', 'price.&#8203', 'Company', 'Research Agreements&#8203;The Company', 'the Securities Exchange Act', 'Candidates / Compounds&#8203;Narazaciclib', 'RAS/RAF/PI3K', 'Temple University (&#', 'Oral Rigosertib', 'Principal Financial Officer&#8203;&#8203;&#8203;101.INS&#160;XBRL Instance &', 'U87', 'Page Interactive Data File', 'Interactive Data File', 'Nasdaq', 'The Equity Distribution Agreement', 'Condensed Consolidated Financial Statements'}"
ONVO,
OPCH,
OPGN,
OPK,"{'Underlying Equity in Net Assets &#xa0;\\n Equity', 'LLC', 'Chargebacks', 'Non-Invasive Monitoring Systems', 'Upfront License Fees', 'the &#x201c;Licensed', 'Total &#xa0;\\n Balance', 'the U.S. Government', '\\n', 'OPKO Health Europe SLU', 'xa0;$(37)&#xa0;$10&#xa0;&#xa0;$(27)&#xa0;$5&#xa0;\\n Forward', 'Consolidated Statement of Operations', 'services.\\n  &#', 'revenues.\\n   &', 'the Condensed Consolidated Balance Sheet', 'commitments.\\n   &', 'IPR&amp;D. Considering', 'Dravet', '\\n   &#', 'Development and License Agreement', 'uses.\\n   &', 'Academia Sinica.\\n   &#', 'LeaderMed Health Group Limited', 'Returns &#', 'net.\\n   &', 'Vaccines', '2023 &#xa0;$3,243&#xa0;&#xa0;$1,076&#xa0;\\n 2024 &', 'Item 408 of', 'Rayaldee', 'ModeX\\', 'COVID-19', 'investments &#xa0;$19,377&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;$28,080&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n\\n', 'the Merck Agreement', 'Losses', 'Directive', 'the Closing Shares', 'OPKO CURNA', 'unobservable &#', 'Regulation S-K.&#xa0;\\n   &#xa0;\\n   &', 'Fair', 'xa0;&#xa0;12,953&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;12,953&#xa0;\\n', 'FASB', 'LeaderMed', 'The Credit Agreement', 'Pfizer', 'the Restated Pfizer Agreement', 'x2014;\\n     &#', 'x201c;Nicoya Field&#x201d;).\\n', 'the Vifor Initial Indication', 'net &', 'NICOYA Macau Limited', 'the Pfizer Agreement', 'Operating &#xa0;&#xa0;', 'OPKO Health', 'Medicaid', 'Medicare', 'OPKO Chile &', 'balance.\\n   &', 'GeneDx Holdings', 'xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;28&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;28&#xa0;\\n Total', 'our Common Stock', 'FDA', 'RECENT ACCOUNTING PRONOUNCEMENTS\\n  &#', 'xa0;\\n     &#x2014;\\n     &#', 'xa0;&#xa0;7,057&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;(86)&#xa0;&#xa0;6,971&#xa0;\\n OPKO Mexico &#', 'inputs &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n', 'Foreign Currency Exchange Rate Risk &', 'Credit', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'ModeX &#xa0;\\n Cash', 'issue.\\n   &#', 'the &#x201c;Closing', 'Potential Products and Services', 'Limited\\n   &#', 'x201c;Common', 'Goodwill', 'Milestone', 'NICOYA Therapeutics', 'Company', 'Governmental &#xa0;&#xa0', 'Significant &#', 'geographies.\\n   &#', 'the Nicoya Territory', 'xa0;&#xa0;6.0%&#xa0;&#xa0;4.4%\\n Finance', 'the Condensed Consolidated Statement of Operations', '\\n    &#', 'notes.\\n  &#', 'BioReference', 'Vifor Fresenius Medical Care Renal Pharma Ltd.', 'Credit Agreement', 'acquisition:\\n   &#', 'period.\\n  &#', 'JPMorgan Chase Bank', 'the U.S. dollar.\\n   &', 'Israel&#x2019;s', 'them.\\n  &#', 'Alibaba Group Holding Limited&#xa0;Tmall Global', 'GHD', 'Underlying Equity in Net Assets &#', 'Merck', 'Diagnostics \\n  &#', 'xa0;&#xa0;80,432&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;(172)&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;80,260&#xa0;\\n OPKO Biologics &', '2022 &#', 'OPKO Diagnostics &', 'regions.\\n   &', 'Pfizer&#x2019;s', 'Zebra&#x2019;s Board', 'Condensed Consolidated Balance Sheet', 'the Chilean Peso', 'non-Dravet', 'LLC (&#x201c;BioReference&#x201d;)', 'xa0;\\n Investment type &#', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', '\\n  &#', 'Investments', 'Board of Directors', 'Chief Technical', 'It&#x2019;s', 'the Credit Agreement', 'Taxes', 'the &#x201c;Credit', 'method.&#x201d;\\n   &', 'EirGen', 'products.\\n   &', 'Assignment and Assumption Agreement', 'the GeneDx Holdings Shareholder Agreement', 'Condensed Consolidated Balance Sheets', 'inputs &#xa0;&#xa0', 'Nicoya', 'OPKO', 'the &#x201c;2033 Senior', 'xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;1,036&#xa0;&#xa0;&#xa0;1,036&#xa0;\\n Total liabilities &', 'E-Commerce Distribution Agreement with NextPlat Corp', 'Cocrystal Pharma, Inc. (&#x201c;COCP&#x201d;)', 'Xenetic Biosciences, Inc. (&#x201c;Xenetic&#x201d;)', 'Preferred Stock', 'xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;53%\\n\\n', 'operations.\\n  &#', 'Debt Issuance Cost &', 'ASU No', 'Property', 'ModeX Acquisition\\n   &#', 'xa0;\\n Healthcare', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Hamas', 'Rayaldee.\\n   &#', 'OPKO Renal', 'Amended and Restated Development and Commercialization License Agreement', 'xa0;&#xa0;4.7%&#xa0;&#xa0;3.8%\\n\\n', 'BioCardia', 'liabilities.\\n   &#', 'consolidation.\\n   &#', 'the Texas Medicaid Fraud Prevention Act', 'Texas Medicaid', 'xa0;&#xa0;195,000&#xa0;\\n Goodwill &', 'Investment Carrying Value &#xa0;&#xa0', 'the Euro.\\n  &#', '2022 &#xa0;\\n&#xa0;&#xa0', 'xa0;&#xa0;81,786&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;(962)&#xa0;&#xa0;80,824&#xa0;\\n FineTech &', 'CAMP4', 'Transition Services Agreement', 'IPR&amp;D', 'GeneDx Holdings Corp.', 'ModeX.&#xa0', 'the Nicoya Agreement', 'the Pfizer Transaction', '45,917\\n     &#', 'The Merck Agreement', 'Condensed Consolidated Statement of Operations', 'Quoted &#', 'the Mexican Peso', 'the Office of the Attorney General for the State of Texas (&#x201c;TX', '2022 &', 'Rayaldee.\\n  &#', 'Healthcare', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', 'Frost Holdings', 'equated&#xa0;to', 'the Vifor Agreement', 'ModeX', 'subsidiary.\\n   &#', 'xa0;\\n Assets &', '\\n     &#', '#xa0;&#xa0;727&#xa0;\\n Property', 'Rayaldee.\\n  &#xa0;\\n  Research', 'Factor', 'GeneDx Holdings Common Stock', 'Finance &#', 'BioCardia, Inc. (&#x201c;BioCardia&#x201d', 'CAMP4 Therapeutics\\n', 'xa0;&#xa0;3,767&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;&#x2014;&#xa0;&#xa0;&#xa0;(174)&#xa0;&#xa0;3,593&#xa0;\\n OPKO Health Europe &', 'BioReference Health', 'rates.\\n  &#', 'recoverable.\\n   &#', 'Academia Sinica&#xa0;in', 'Acquisitions', 'the European Union', 'x201c;GeneDx&#x201d;).\\n   &#', 'below.\\n  &#', 'Total &#xa0;\\n Assets: &', '\\n    &#xa0;&#xa0', 'component.\\n   &#'}"
OPRX,"{'customers\\nin', 'necessary\\nto', 'Healthy Offers, Inc.', '\\n    &', 'Business Combinations', 'Management Investor', 'the Securities and Exchange', 'period.\\n\\n&#160;\\n\\nWe', 'Accounting for Contract Assets and Contract Liabilities', 'contract\\nliabilities', 'the Subscription Agreement', 'Contracts with Customers', 'Company', 'Incorporation of OptimizeRx Corporation', 'OptimizeRx'}"
OPT,
OPTN,"{'Pharmakon Senior Secured Notes', 'ASU', 'BioPharma Credit PLC', 'the Note Purchase Agreement', 'Restated Certificate of Incorporation of OptiNose,&#160;Inc', 'OptiNose UK, Ltd.', 'the New Maturity Date', 'Note Purchase Agreement', 'PPN', 'the Accounting Standards Codification', 'the Pharmakon Senior Secured Notes;&#9642;maintain', 'the Pediatric Research Equity Act', 'the Securities and Exchange Commission', 'XHANCE', 'OptiNose AS', 'FASB).In', 'Unaudited Interim Consolidated Financial Statements(in', 'general &amp', 'FDA', 'the Pharmakon Senior Secured Notes', 'Financial Operations OverviewThe', 'ContentsProjected', 'OptiNose US, Inc.', 'The Effective Interest Rate', 'INS', 'Contracts with Customers (ASC 606', 'No&#160', 'Restated Certificate of Incorporation of OptiNose, Inc.', 'SEC', 'ContentsConsolidated Results of OperationsComparison', 'Company', 'the Financial Accounting Standards Board', 'The Pharmakon Senior Secured Notes', 'research &amp', 'Restated Bylaws of OptiNose,&#160;Inc', 'Results of Operations', 'The Note Purchase Agreement'}"
ORGO,"{'LLC', 'the Company&#x2019;s Registration Statement', 'the &#x201c;Acquisition Date&#x201d;)', 'Sports Medicine', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n    Legal', 'EPS', ': &', 'these actions.\\n  &#x2022;We', 'the United States Food and Drug Administration', '\\n  Selling', 'Advanced Wound Care', 'Dermagraft', 'the Acquisition Date', 'Indicate', '3,167\\n    &', 'Premarket Application', 'Surgical &', 'Bylaws of Organogenesis Holdings Inc.', 'PuraPly AM', 'NuShield', '\\n        &', 'SEC', '\\n    Interest', 'ERP', 'SOX', 'Regulation S-K. \\n', 'Company', 'reported.\\n  &#x2022;We', 'PuraPly', 'CPN Biosciences', 'Dan Road Associates', 'CPN', 'Results of Operations', 'SVB', 'necessary.\\n  &#', 'Concentration of Credit RiskFinancial', 'No  &#9744', '\\n    &', 'Note &#x201c;2'}"
ORGS,"{'LLC', 'Good Manufacturing Practices', 'Convertible Loan Agreement', 'the Orgenesis Mobile Processing Units &', 'SEGMENT', 'Lender', 'Therapies', 'Labs', 'Court', 'POCare Centers', 'November\\n2022', 'the Conversion Price', '2024.\\n\\n&#160;\\n\\n&#160;\\n\\nNOTE\\n8 &#8211', 'Euro', 'the Nir Convertible Loan Agreement', 'the Securities Exchange Act', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n9 &#8211', 'the Securities Exchange', 'Common Stock of the Company', '\\n    &#160;\\n\\n*\\nFiled', 'deconsolidation.\\n\\n&#160;\\n\\nBecause\\nthe Company', 'Warrants', 'the Initial Installment', 'FASB', 'Convertible\\nLoan Agreement', 'the NewTech Loan Amount', 'the JV partner&#8217;s\\nshare', 'Convertible Loan Extension Agreement', 'the Octomera Board', 'the European Innovation Council Pathfinder Challenge Program', 'the Convertible Loan Agreement', 'Metalmark Capital Partners (&#', 'Aharon Lukach', 'Company&#8217;s\\ninternally', 'POCare Services', 'the Borrower (&#8220;Acquisition&#8221', 'pursuant\\nto', 'Koligo Therapeutics Inc.', 'company&#160;\\n    &', 'principal\\nfinancial', 'the NewTech Convertible Loan Agreement', 'Common Stock', 'Company', 'Koligo', 'Yeda Research and Development Company Limited', 'net&#160;\\n    &', 'the Malik Lender', 'Convertible\\nLoan Extension Agreement', 'expenses\\n\\n\\n\\n&#160;\\n\\nNOTE\\n6 &#8211', 'the Malik Loan Agreement', 'fees\\nand', 'ASU', 'the Nasdaq Capital Market', 'POCare Therapies', 'POCare', 'the Securities and Exchange Commission\\n(the &', 'Loan Agreement', 'NewTech Investment Holdings', 'Tel Hashomer Medical Research', 'Unsecured Convertible Notes Extension', 'the Convertible Loan Agreements', '%&', 'Restated Limited Liability Company Agreement', 'Orgenesis Inc.', 'JVE', 'Infrastructure and Services Ltd.', 'assumptions\\nin', 'Common\\nStock (the &#8220;Warrants&#8221', 'Common Stock.\\n\\n&#160;\\n\\nThe Offering', 'the Sai Convertible Loan Agreement', 'the Metalmark Investment', 'the License Agreement', 'EQUITY', 'the Manufacturing and Service Agreement', '\\n    Financial Expenses', 'Owner', 'Complaint', 'the NewTech Lender', 'for\\nthe Nir Convertible Loan Agreement', 'SEC', 'Prof.', 'Principal Accounting Officer)\\n    &', 'the Koligo Convertible Loan Agreement', 'Credit Losses', 'Smaller Reporting Companies', 'Consolidated Balance', 'Nasdaq', '\\n    &', 'POCare Network', 'loan&#160;\\n    &'}"
ORIC,
ORMP,
ORTX,
OSA,"{'the Delaware General Corporation Law', 'FASB', 'ProSomnus Sleep Technologies', 'the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition', 'ASU', 'the Securities Purchase Agreement', 'the Transaction Warrants', 'the Indenture for Senior Secured Convertible Notes', '921,149&#8203', 'OperationsComparison', 'Contracts', 'LIQUIDITY', 'the Special Meeting', 'the Board of Directors', 'CPAP', '9,743,043)&#8203;n', 'the &', 'Medicaid', 'Medicare', 'Derivatives', 'operations.&#9679;The Company', 'Wilmington Trust', 'ContentsOther', 'the U.S. Food and Drug Administration', 'the Subordinated Secured Convertible Notes', 'ContentsConfidentiality', 'Indenture for Subordinated Secured Convertible Notes', 'FDA', 'National Association', 'Financing TransactionOn', 'the U.S. Foreign Corrupt Practices Act', 'the Business Combination.2022 Equity Incentive PlanDuring', 'ProSomnus', 'Board of Directors', 'Board of Directors;&#9679;the', 'Series A Preferred Stock', 'CAPITAL RESOURCESGoing Concern', 'United', 'PMA', 'ContentsThe', 'Risks Related', 'InflationInflation', 'the Financing Transaction', 'RegulationOur', 'the Common Stock', 'Entity&#8217;s Own Equity', 'Series A Preferred', 'Accounting for Convertible Instruments', 'Common Stock', 'Value ElectionThe Company', 'Company', 'the Securities Exchange Act', '2&#8212;Basis of Accounting', 'Risks Related to Government', 'ProSomnus Holdings', 'USPTO', 'the heading &#8220;Risk Factors,&#8221', 'the Sarbanes-Oxley Act', 'The Series A Preferred Stock', 'Preferred Stock', 'Subordinated Securities Purchase Agreement', 'Nasdaq', 'ProSomnus&#8217;s'}"
OSUR,
OTLK,
OTRK,"{'L.P.', 'the Delaware General Corporation Law', 'Company\\', 'Humanitario Capital LLC', 'Managed Behavioral Healthcare Organizations', 'the Note Purchase Agreement', 'ILevel IILevel', 'Motion for Class Certification', 'the Public Offering', 'LOC', 'The Stockholders Agreement', 'TO CONDENSED CONSOLIDATED FINANCIAL', 'the Original Keep Well Agreement', 'Note Documents', 'District Court', 'Qualified Financing', 'Medicaid', 'Medicare', 'PHI', 'EEA', 'Goldman Sachs Specialty Lending Group', 'The Patient Protection', 'Form S-3 &#8220;shelf&#8221', 'Ticking Warrants', 'the &#', 'Acuitas', 'Board of Directors', 'Court', 'the Internal Revenue Code', 'The Original Keep Well AgreementUnder', 'Series A Preferred Stock', 'the Health Care and Education Reconciliation Act', 'The National Securities Markets Improvement Act', 'the Department of Labor', 'the Series A Preferred Stock', 'Medicare Advantage', 'Form S-1', 'Condensed Consolidated Financial Statements', 'the Certificate of Designations', 'LeasesThe Company', 'SEC', 'the Public Offering Pre-Funded Warrants', 'the Trump Administration', 'Company', 'the Qualified Financing', 'The HIPAA Security Rule', 'the Public Offering Warrants', 'Acuitas Capital', 'the Stockholder Approval Matters', 'The Series A Preferred Stock', 'Independent Contractor Classification', 'the Health Care Reform Law', 'the California Privacy Rights Act', 'the Note Agreement', 'the Original Keep Well Notes', 'Nasdaq', 'the General Data Protection Regulation', 'the federal health care programs', 'the Anti-Kickback Law', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(unaudited)Financial', 'European Union Data Protection Directive', 'NotesThe Company'}"
OVID,"{'COMMITMENTS', 'LLC', 'the Graviton Agreement', 'The Sarbanes-Oxley Act', 'The Hudson Commons', 'The Marinus License Agreement', 'this Quarterly Report on Form 10-Q', 'EU', 'Dravet', 'Phase 4', 'Series A Preferred Stock', 'Healx', 'Commission', 'ContentsWe', 'Graviton', 'Lennox-Gastaut', 'NOL', 'the European Economic Area', 'CNS', 'Ligand Pharmaceuticals Incorporated', 'Takeda Pharmaceutical Company Limited', 'Our Business Operations', 'Hudson Commons', 'Recent Accounting PronouncementsThe Company', 'KCC2', 'NOTE 5 &#8211', 'International Council for Harmonization', 'PDP', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'GDPR', 'FDA', 'Ligand', 'Risks Related', 'REMS', 'AstraZeneca', 'CONTINGENCIESLicense AgreementsNorthwestern University', 'Company', 'Marinus (&#8220;Marinus License', 'USPTO', 'ContentsThe Company', 'the Ligand Agreement,', 'Significant Accounting', 'the Competent Authorities', 'Cowen', 'the U.S. Securities and Exchange Commission', 'Condensed Consolidated Financial Statements', 'GLP', 'the Delaware General Corporation Law', 'CRO', 'CCPA', 'ActivitiesNet', 'Gensaic', 'the Marinus License Agreement', 'ContentsSome', 'Good Clinical Practice', 'the Healx License and Option Agreement', 'Gensaic Collaboration and Option', 'IRB', 'LEASESDuring September 2021', 'Graviton License Agreement', 'ContentsRisks Related', 'ContentsIn August 2022', 'AstraZeneca AB', 'the RLT Agreement', 'Registration Statement', 'Cowen and Company', 'Northwestern', 'Form S-3', 'treasury', 'ATM', 'AstraZeneca AB License AgreementOn', 'the Northwestern Patent Rights', 'Graviton\\', 'the Ligand Agreement', 'United', 'Marinus Pharmaceuticals, Inc. (&', 'Employee Matters', 'U.S. Treasury', 'OperationsThe', 'SEC', 'GCP', 'BLA', 'the European Union', 'Northwestern University', 'the Opt-In Period', 'NOTE 2 &#8211'}"
PACB,
PAHC,
PALI,
PASG,"{'ASC', 'Reliance', 'FTD', 'Dr.&#160;Wilson', 'the University of Pennsylvania.&#8224', 'CMS.Outside the United States', 'NJ', 'qui tam', 'the Federal Food, Drug', 'Financial Instruments', 'EEA', 'Sublease Agreement B', 'ContentsGeneral', 'the University of Pennsylvania&#8217;s', 'Intellectual Property &', 'Note 9.LeasingThe Company', 'Principal Executive Officer Pursuant', 'BPCIA', 'Sublease B', 'the Penn Agreement', 'Physician Payment Sunshine Act', 'CPRA', 'Sublease Agreement B.', 'ContentsWe', 'ACA', 'Recent Accounting PronouncementsSee', 'the Securities Exchange Act', 'Unaudited Interim Financial StatementsSublease Agreement', 'Research', 'compensationThe Company', 'CNS', 'Principal Financial Officer Pursuant', 'No &#9723;Indicate', 'ICM', 'Unaudited Interim Financial StatementsThe', 'ContentsIn', 'ALS', 'equipment &', 'Anti-Kickback Statute', 'The Penn Agreement', 'Contentsunwillingness', 'Medicaid', 'Medicare', 'Unaudited Interim Financial StatementsThe Company', 'delay.&#8203;As', 'Lease Agreement&#8203;The Company', 'GDPR', 'FDA', 'PennsylvaniaWe', 'the following:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;(in thousands)&#160;&#160;&#160;&#160;September&#160;30,&#160;2023&#160;&#160;&#160;&#160;December&#160;31,&#160;2022Professional fees&#8203;$ 418&#8203;$ 602Compensation', 'PennThe Company', 'Principal Executive Officer Pursuant to Rules', 'ended &#8203;&#8203;&#8203;&#8203;&#8203;September&#160;30,&#160;&#8203;&#8203;&#8203;(in', 'HIPAA', 'The Laboratory Lease Agreement', 'initiatives.&#8203;As', 'Need for Additional Capital&#8203;We', 'Company', 'Principal Financial and Accounting Officer', 'Catalent', 'Sublease Agreement A.', 'USPTO', 'Adopted Pursuant to Section 302', 'GM1', 'candidates.&#8203;As', 'Restated Research, Collaboration and License Arrangement', 'the following:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;(in thousands)&#8203;September&#160;30,&#160;2023&#8203;December&#160;31,&#160;2022Laboratory', 'CMS', 'OperationsComparison', 'Financial Instruments&#8212;Credit Losses', 'License Agreement', 'the U.S. Department of Health and Human Services', 'this Quarterly Report on Form&#160;10-Q', 'ContentsFinancial Operations OverviewLicense AgreementUniversity', 'ContentsUnder the Penn Agreement', 'ContentsPassage Bio', 'the Laboratory Lease Agreement', 'Investigational New Drug', 'the Health Care and Education Reconciliation Act', 'the Letter Agreements', 'AAV', 'Registrant', 'the Children&#8217;s Health Insurance Program', 'DevelopmentResearch', 'PBGM01', 'the Sarbanes-Oxley Act', 'ex-U.S.', 'EstimatesDuring', 'the U.K.&#8217;s Information Commissioner&#8217;s Officer', 'ProgramsWe', 'the Health Information Technology for Economic and Clinical Health', 'September&#160;30,&#160;2022', 'Program', 'this Quarterly Report', 'pathway&#8203;The Patient Protection', 'Health Insurance Portability', 'Unaudited Interim Financial StatementsLetter', 'the American Medical Association', 'Sublease Agreement A', 'Sublease Agreement', 'ESPP', 'GTP', 'the State of Delaware', 'Medicaid Services', 'ContingenciesAmended', 'Catalent of $6.0 million', 'netProperty', 'the &#8220;simplified', 'Administrative ExpensesGeneral', 'control.&#8203;As', 'Employment AgreementsThe Company', 'ContentsRisks Related to', 'SEC', 'fixtures&#8203', 'TLE', 'the Biologics Price Competition and Innovation Act', 'Nasdaq', 'the Principal Executive Officer', 'Catalent of'}"
PAVM,"{'ASC', 'the Lucid Diagnostics 2018 Equity Plan', 'the Amended CWRU License Agreement', 'loss.\\n\\n&#160;\\n\\nRecently\\nAdopted Accounting Pronouncements\\n\\n&#160;\\n\\nIn\\nJune 2016', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'equity &#8211', 'Long-Term Incentive Equity', 'this Quarterly Report on Form 10-Q', 'ResearchDx Inc.', 'Agreement and Management Services Agreement - ResearchDx Inc.\\n\\n&#160;\\n\\nLucidDx\\nLabs', 'Restricted Stock Awards&#160;&#160;\\n    Weighted\\n', 'VerisBox', 'Stock-Based Compensation - continued\\n\\n&#160;\\n\\nLucid\\nDiagnostics Stock Options\\n\\n&#160;\\n\\nLucid\\nDiagnostics', 'Company\\nconsiders', 'the Listing\\nQualifications Department of Nasdaq', 'NCI', 'Lucid Test Centers', 'the Listing Qualifications Department', 'the financing\\nterms the Company', 'the Securities Exchange Act', 'the Veris Cancer Care Platform', 'Physician Inventors', 'classified\\nas', 'EsoGuard Esophageal DNA Test', 'the &#8220;PAVmed Inc.', 'operations.\\n\\n&#160;\\n\\nCost\\nof', 'FASB', 'Summarizes Information About Stock Options\\n\\n\\n  \\n    &', 'interests.\\n\\n&#160;\\n\\nOther\\nRelated Party', 'Stock-Based Compensation', 'Company&#8217;s\\nunaudited', 'the EsoGuard Commercialization Agreement', 'Intangible Assets', 'the separate &', 'statements.\\n\\n&#160;\\n\\nNote\\n3 &', 'LucidDx Labs Inc.', 'Lucid Diagnostics', 'Asset Purchase Agreement and Management Services Agreement\\n\\n&#160;\\n\\nAsset\\nPurchase', 'CLIA-certified,\\nCAP-accredited clinical laboratory', 'Lucid Clinical Trials', 'Company', 'Principal Financial and Accounting Officer', 'Management Services Agreement and Modification of Other Payment Obligations - ResearchDx', 'Diagnostics Inc 2018 Long-Term Incentive Equity Plan&#8221', 'PAVmed holds\\n31,302,420', 'Restricted Stock Award', 'Administrative Expense&#160;\\n    &', 'ASU', '2022.\\n\\n&#160;\\n\\nNote\\n4 &#8212', 'Prepaid Expenses', 'Contracts with Customers', 'Internal Controls Over Financial', 'the Lucid Diagnostics Inc 2018 Equity Plan', 'CWRU', 'net&#8221', 'APA', 'License Agreement - reimbursement', 'Exchange', 'Prepaid Expenses and Other Current Assets\\n\\n\\n  ', 'the Lucid Diagnostics', 'the Sarbanes-Oxley Act', 'EsoCheck', 'Granted(1)&#160;\\n    &', '\\n\\n\\n\\n&#160;\\n\\nNote\\n4 &', 'Lucid Series A-1 Convertible Preferred Stock', 'Capital Resources &', 'Veris Health', 'SPA', 'the Lucid Diagnostics\\nInc 2018 Equity Plan', 'Contracts', 'respect\\nto the Amended CWRU License Agreement', 'ATM', 'Co.', 'Contracts with Customers - continued\\n\\n&#160;\\n\\nRevenue\\nRecognized\\n\\n&#160;\\n\\nIn\\nthe three and nine months ended September 30, 2023', 'Cantor', 'ResearchDx, Inc. (&', 'Asset Purchase Agreement and Management Services', 'the Lucid Test Centers', 'Related Party Transactions', 'date.\\n\\n&#160;\\n\\nNote\\n14 &#8212', 'PAVmed', 'Related Party Transactions\\n\\n&#160;\\n\\nCase\\nWestern Reserve University', 'agreements&#160;\\n    &', 'monthly\\nfee of', 'Lucid Diagnostics Inc.', 'termination.\\n\\n&#160;\\n\\nNote\\n6', 'quarters.\\n\\n\\n&#160;\\n\\nLucid\\nDiagnostics Restricted Stock Awards\\n\\n&#160;\\n\\nLucid\\nDiagnostics', '\\n    &', 'EsoGuard'}"
PBLA,"{'x201c;plans,&#x201d;&#x201d', 'the words &#x201c;anticipates,&#x201d; &#x201c;intends,&#x201d', 'the Nasdaq Capital Market', 'Form S-3', 'US World', 'Internal Control Over Financial Reporting\\n\\n&#xa0;\\n\\nWe', 'the Aspire Trial', 'State', 'Johns Hopkins University School of Medicine', 'Adopted Pursuant', 'x201c;expects,&#x201d', 'Panbela', 'the Arizona Board of Regents of the University of Arizona', 'Indiana University', 'Filing\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t3.1\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\tRestated Certificate of Incorporation', 'the Inducement Warrants Shares', 'FDA', 'costs\\n\\n&#xa0;\\n\\nResearch', 'ASPIRE', 'Board of Directors', 'Southwest Oncology Group', 'CPP&#x2019;s', 'the Juvenile Diabetes Research Foundation', 'the Children&#x2019;s Oncology Group', 'Nasdaq Listing Rule 5550(a)(2', 'the Inducement Warrants', 'the Listing Qualifications Department', 'SEC', 'adenomas &gt;/=', 'Sucampo Note', 'the Inducement Letters', 'Company', 'the Arizona Board of Regents of the University of Arizona.\\n\\n&#xa0;\\n\\n&#xa0;\\n\\nAs Panbela', 'the Securities Exchange Act', 'CPP', 'loss\\n\\n&#xa0;\\n\\nComprehensive', 'the National Cancer Institute (&#x201c;NCI&#x201d', 'Certificate of Incorporation', 'the Sarbanes-Oxley Act', 'Tillotts Pharma AG', 'The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;).&#xa0;As', 'the &#x201c;Resale Registration', 'Nasdaq', 'Restated Bylaws', 'II &#'}"
PBYI,
PCRX,"{'ASC', 'Eurofarma Laboratories S.A.', 'The 340B Drug Discount Program', 'the United States Securities and Exchange Commission', 'PIT', 'NetThe', 'ANDA', 'the Notice Letter', 'JPMorgan Chase Bank', 'EXPAREL', 'District Court', 'the &#8220;TLB Credit', '+&#160;Effective', 'Black-Scholes Weighted', 'SkyePharma Holding, Inc.', 'TA', 'the U.S. Dollar', 'TLB Term Loan', 'ProceduresAs', 'Internal Control', 'Financial Instruments', 'the Research Development Foundation', 'September&#160;30,', 'ESPP', 'U.S. Patent Nos', 'PLGA', 'GQ Bio Therapeutics GmbH', 'Global ExpansionIn', 'eVenus Pharmaceutical Laboratories', 'Restructuring Charges and Other', 'eVenus', 'FDA', 'the Flexion Acquisition', 'Complaint', 'ASA', 'Clinical Development', 'MyoScience Acquisition', 'Science Center Campus', 'ContentsItem&#160;4', 'GeneQuine Biotherapeutics GmbH', 'Financial ReportingThere', 'Accounting Standards Codification', 'Society', 'ContentsThe', 'Pacira Pharmaceuticals, Inc.', 'ControlsOur', 'iovera&#176', 'Significant Accounting Policies', 'Notice Letter', 'the U.S. District Court', 'the Alternate Base Rate', 'Skyepharma', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'Company', 'ZILRETTA', 'the Securities Exchange Act', 'Verve Medical Products, Inc.', 'MyoScience', 'Vectura Group plc', 'the MyoScience Merger Agreement', 'Abbreviated New Drug Application', 'mg/10 mL', 'BioSciences, Inc.', 'IIIChief Financial Officer(Principal Financial Officer)Pacira BioSciences', 'RDF', 'Flexion Therapeutics, Inc.', 'the TLB Term Loan Credit Agreement', 'Regulation S-K', 'the TLA Term Loan', 'Paragraph IV Certification', 'ContentsIn', 'ContentsOther Expense'}"
PCSA,"{'Placement', 'Elion Oncology, Inc. (&', '5-Fluorouracil', 'commissions.\\n\\n&#160;\\n\\nLincoln\\nPark Capital Fund', 'Next Generation', 'Stock Unit Award Agreement', 'Co. Inc.', 'Internal Control', 'controls\\nand', 'Processa Pharmaceuticals, Inc.', 'this Quarterly Report on Form 10-Q', 'DPD', 'agreements.\\n\\n&#160;\\n\\nItem\\n6', 'FDA', 'Lincoln Park', 'products\\nin', 'FDA&#8217;s Project Optimus Oncology', 'ended.\\n\\n&#160;\\n\\nNote\\n5 &#8211', 'Next Generation Chemotherapy', 'NGC', '\\n\\n\\n\\n\\n\\n\\n&#160;\\n\\nRevenues.\\n\\n&#160;\\n\\nWe\\ndo', 'share:&#160;\\n    &', '\\n    Research', 'Company\\nundertakes', 'CorLyst', 'Company', 'the Securities Exchange Act', 'NGC-Cap', 'Results of Operations', 'compensation.\\n\\n&#160;\\n\\nGoing\\nConcern', 'classified\\nas', 'operations.\\n\\n&#160;\\n\\nItem\\n3', 'FDA Draft Guidance', 'net&#160;\\n    &', '\\n    &', 'Oppenheimer &amp', 'report\\nare', 'Accounting'}"
PCVX,"{'ASC', '\\n  &#x2022;Expanded Collaboration with Lonza for Global Commercial Manufacturing', 'Vaxcyte Switzerland GmbH', '\\n  &#x2022;injury', 'candidates.\\n  &#x2022;If', '\\n  &#x2022;an annual', '\\n', 'Item 408 of Regulation S-K', 'the Sutro Biopharma Supply Agreement', '\\n  &#x2022;expansion', '\\n  &#x2022;an', 'the Option Agreement', 'Biologics License Application', 'the Advisory Committee on Immunization Practices', '\\n  &#x2022;costs', 'EU', 'The Sutro Biopharma License Agreement', 'ACIP', '\\n    Laboratory', '\\n  &#x2022;compliance', 'the U.S. Foreign Corrupt Practices Act', 'x2022;a', '\\n  &#x2022;differing', '\\n  &#x2022;conditions', 'Sensitive Information', '\\n  &#x2022;foreign', 'Lonza (the &#x201c;2023 Lonza DMSA&#x201d', '\\n    Research', 'Germany&#x2019;s Federal Ministry of Education', 'Option', 'ACA', 'Form Definitive Agreement', '\\n  &#x2022;harmful', 'The Nasdaq Stock Market LLC', 'costs.\\n  Research', 'Research', '\\n  &#x2022;production', 'pay&#x201d', '\\n  &#x2022;adding', '\\n  &#x2022;workforce', '\\n  &#x2022;prohibit', '\\n  &#x2022;obtaining', 'CDC', '\\n  &#x2022;unfavorable FDA', 'Products', 'the &#x201c;Option Agreement&#x201d', '\\n  &#x2022;improving', 'HHS', '\\n  &#x2022;product', '\\n  &#x2022;substantial', '\\n  &#x2022;inadequate', '\\n  &#x2022;initiation', 'Sutro Biopharma', 'manufacturers&#x2019', '\\n  &#x2022;a', 'Medicaid', 'Medicare', '\\n  &#x2022;extension', '\\n  &#x2022;allow', 'the &#x201c;Initial Cash', ': &', 'Sutro', 'FDA', 'NIH', '\\n  &#x2022;clinical', 'RSU', '\\n  &#x2022;difficulties', 'the Trustees of Boston University', 'the Commercial Manufacturing and Supply Agreement', 'the Repurposing Fee', 'The Sutro Biopharma Supply Agreement', '\\n  &#x2022;changes', '\\n  &#x2022;loss', '77\\n', 'the Medicaid Drug Rebate Program', '\\n  &#x2022;occurrence', 'activities\\n    &', 'Patient-Centered Outcomes Research Institute', '\\n    &#160;&#160;4.1\\n    &', 'Company', 'the Term Sheet', 'USPTO', '\\n  &#x2022;import', '\\n  &#x2022;addressing', '\\n  &#x2022;challenges', 'Lonza (the &#x201c;Lonza Letter', 'Sutro Biopharma&#x2019;s', '\\n  &#x2022;unexpected', '\\n  &#x2022;authorize our Board', '\\n    &#', 'the University of Maryland', 'the Delaware General Corporation Law', 'the Public Health Service', 'ESG', 'Codexis, Inc.', 'CMS', 'the U.S. Patent and Trademark Office', '\\n  &#x2022;recruiting', '\\n  &#x2022;establishment', '\\n  &#x2022;subjects', 'PCV', 'Contractual Obligations and Commitments \\n', 'the Commercial Manufacturing and Supply Agreement, Lonza', '\\n  &#x2022;the', 'Supply Agreement', 'the U.S. Internal Revenue Code', 'restrictions;\\n  &#x2022;differing', '\\n  &#x2022;exhaustion', 'Response/Biomedical Advanced Research and Development Authority', 'Wellcome Trust', 'IRB', '\\n  &#', 'Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator', 'Lonza', 'CMC', '\\n  &#x2022;managing', 'IPD', '\\n  &#x2022;varying', '\\n  &#x2022;imposition', 'Investigational New Drug', 'The Lonza Letter Agreement', '\\n  &#x2022;difficulty', '\\n  &#x2022;decreased', '\\n  &#x2022;require', 'the Company&#x2019;s Amended', 'CMO', '\\n  &#x2022;reaching', 'the Form Definitive Agreement', 'New General Application Intellectual Property', 'INC', 'National Institutes of Health', 'the Sarbanes-Oxley Act', '\\n  &#x2022;inability', 'Economy,&#x201d', 'IPO', '\\n    &#160;&#160;4.4\\n    &', 'VAXCYTE', 'New Customer Intellectual Property', 'Development and Manufacturing Services', 'Comparison', 'companies&#x2019', 'Vaxcyte', '\\n  &#x2022;increased', 'the Company&#x2019;s Board of Directors', 'the CMS Innovation Center', '\\n  &#x2022;limit', 'Board', 'Melinda Gates Foundation', 'Medicaid Innovation', 'the Lonza Letter Agreement', '\\n  &#x2022;delays', 'Lonza Ltd.', 'ROU', 'the United Kingdom Global Antimicrobial Resistance Innovation Fund', '\\n  &#x2022;transfer', 'the Sutro Biopharma License Agreement', '\\n  &#x2022;business', '\\n  Components of Results of Operations \\n', 'the &#x201c;Repurposing Fee&#x201d;)', 'Restricted Stock Unit', 'Healthcare', '\\n  &#x2022;identifying', 'Lonza (the &#x201c;2018 Lonza DMSA&#x201d;)', '\\n  &#x2022;withdrawal', '\\n    ', 'U.S. Treasury', 'Vaxcyte GmbH', '80\\n', 'SEC', 'Restricted', 'the Shelf Registration Statement', 'GCP', '\\n  &#x2022;potential', 'BLA', 'presented.\\n  &#', 'Lonza (the &#x201c;2022 Lonza DMSA&#x201d', '\\n  &#x2022;manufacturing', '\\n  &#x2022;failure', 'Nasdaq', 'the European Union', '\\n    &'}"
PDCO,
PDEX,
PDSB,
PEPG,"{'EXCEPT SHARE AND PER SHARE AMOUNTS)\\n', '\\n  &#x2022;injury', 'LLC', 'PepGen Limited', '\\n    Interest income\\n    &', 'MRC', '\\n  &#x2022;satisfying', 'Restriction Agreements', 'The Sarbanes-Oxley Act', 'State', 'EMA', 'Reorganization', 'Exhibits.\\n  &#160;\\n', 'Standard Contractual Clauses', 'EEA', '\\n  &#x2022;termination', 'the Federal Reserve', 'EU', 'PCT', 'Wave Life Sciences Ltd.', 'AOC', '\\n  &#x2022;compliance', 'the Public Company Accounting Oversight Board', 'Discovery, Development, Preclinical and Clinical Testing \\n', '\\n    Research', 'the Organization for Economic Co-Operation', 'efforts.\\n  &#x2022;We', 'Related Party Transactions Technology', 'United Kingdom Research and Innovation', 'the Securities Exchange Act', '\\n  &#x2022;coordination', '\\n  &#x2022;not', 'Licensors', '\\n  &#x2022;misappropriation', 'PGN-EDODM1', 'Future Funding Requirements \\n', '\\n  &#x2022;obtaining', '\\n  &#x2022;litigation', '\\n  &#x2022;additional', 'Company, Incorporated', 'Anti-Kickback Statute', '\\n  &#x2022;diminished', 'DYNE-251', 'BioMarin Pharmaceutical Inc.', '\\n  &#x2022;significant', 'Base Erosion and Profit Shifting', 'WVE-N531', '\\n  &#x2022;substantial', '\\n  &#x2022;exemptions', '\\n  &#x2022;issued', '\\n  Research and Development Expenses \\n  Research', 'U.K. NOL', 'the Securities and Exchange Commission', '\\n  &#x2022;allow', '\\n  &#x2022;any', 'IP', 'Stock Purchase Agreement (Note 8)', 'PGN', 'GDPR', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', '\\n  &#x2022;collaborations', 'Prospectus Supplement', 'the U.K. International Data Transfer Agreement/Addendum', 'EGC', 'EDO', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'tax\\n    &#', '\\n  &#x2022;loss', 'HIPAA', '\\n  &#x2022;others', '\\n  Commission File Number', '\\n  &#x2022;third', 'Company', 'the Department of the Treasury', 'PepGen', 'management&#x2019;s attention', 'expense)\\n    &', 'USPTO', 'federal and/or state breach notification laws', 'PepGen Limited to PepGen Inc.', 'Charter)\\n  &#', '\\n  &#x2022;achieving', 'SVB', ""PGN-EDODM1\\'s"", '\\n    &#', '\\n  &#x2022;breach', 'Signature Bank', 'the Delaware General Corporation Law', 'Common Stock Subject to Repurchase', 'the Company&#x2019;s Registration Statement on Form S-1', 'the European Commission', 'NHP', 'BEPS', '\\n  &#x2022;liability', '\\n  &#x2022;the', 'Stockholders&#x2019', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'STOCKHOLDERS&#x2019', 'Majesty&#x2019;s Revenue &', 'the Harrison Lease', '\\n  &#', 'Sales Agreement', '\\n  &#x2022;collaborators', 'OECD', 'Avidity Biosciences, Inc.', '\\n  &#x2022;retention', 'PGN-EDO44', '\\n  &#x2022;diversion', 'Duchenne', 'Customs', 'Registrant', '\\n  &#x2022;decreased', '\\n  &#x2022;require', 'NDA', 'plan\\n        &', 'Restated Certificate of Incorporation', '\\n  &#x2022;cultural', 'FDIC', 'PEPGEN INC', 'Oxford University Innovation Limited', 'the indemnified party', 'IPO', 'Comparison', '\\n  &#x2022;our', 'Entrada Therapeutics, Inc.', 'DMD', 'Form S-3', '\\n  &#x2022;limit', 'the License Agreement', 'the Third Amended and Restated Certificate of Incorporation', 'the University of Oxford', '2022.The Company', '\\n  &', 'European Union', 'OUI', '\\n  &#x2022;unanticipated', '\\n  &#x2022;disputes', 'Stock Purchase Agreement', '\\n  &#x2022;foreign exchange', 'PepGen Inc.', 'thousands)\\n        &', 'MRC License', 'institute a &#x201c;poison pill&#x201d', 'Healthcare', 'HSALR mice.\\n  &', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', '\\n  &#x2022;authorize', 'the Company&#x2019;s Restated Certificate of Incorporation', 'U.S. Treasury', 'PMO', '\\n        &', 'Stifel, Nicolaus &amp', 'SEC', 'Restricted', 'the Services Agreement', 'the Restriction Agreements', 'the Medical Research Council', 'the University of Massachusetts', 'IRS', '\\n  &#x2022;manufacturing', 'the Health Information Technology for Economic and Clinical Health Act', 'the future;\\n  &#', '\\n  &#x2022;failure', '\\n  &#x2022;reduced', 'Stock\\n    &', 'the European Union', '\\n    &'}"
PETQ,"{'the Condensed Consolidated Statements', 'Secured Overnight Financing Rate', 'LLC (&#8220;OpCo&#8221', 'Consolidated', 'the ABL.Senior Secured Term Loan Facility - Term Loan', 'April&#160;13', 'Intangible Assets', 'other33,239&#160;33,239&#160;In', 'the U.S. Dollar', 'PetIQ Holdings', 'Net SalesConsolidated', 'PetIQ', 'Financial Condition', 'LLC (&#8220;HoldCo&#8221;)', 'sales$642,981&#160;$94,453&#160;Segment', 'Indenture', 'KeyBank National Association', 'Loan', 'SegmentServices', 'GoodwillGoodwill', 'OperationsThe', 'Capital ResourcesHistorically', 'Jefferies Finance', 'ABL', 'Company', 'the Securities Exchange Act', 'See &#', 'processes5-10 years14,731&#160;14,634&#160;Brand names5-15', 'Results of Operations', 'Acadia Investor Relations', 'DebtSenior Secured Asset-Based Revolving Credit FacilityOn', 'Products'}"
PETS,
PETV,"{'Consolidated Statements of Operations', 'FASB', 'ASU', 'Accounting Pronouncements\\n\\n&#160;\\n\\nThe\\nCompany', 'cost&#160;\\n    &', 'EQUIPMENT&#160;\\n\\n\\n', '\\n\\n&#160;\\n\\nNOTE\\n3 &#8211', 'Common Stock\\n    &', 'Goods&#160;\\n', 'fees.\\n\\n&#160;\\n\\nNOTE\\n4 &#8211', 'Technology', 'furniture&#160;\\n    &', 'the Maturity Date', 'Convertible Debenture Conversion Agreements', 'OsteoCushion&#8482', 'the Black Scholes', 'the Consolidated Balance', '2023&#160;\\n    &', 'Distribution Services Agreement', 'FINRA', 'The Nasdaq Capital Market', 'elastin', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n6 &#8211', 'MWI Veterinary Supply Co.', 'the Condensed Consolidated Statements of Operations', 'Gel-Del Technologies, Inc.', 'Company', 'the Debenture Holders', 'PetVivo Holdings, Inc.', 'ISO', 'Masters', 'applicable.\\n\\n&#160;\\n\\nNOTE\\n2 &#8211', 'Nasdaq', '\\n    &', 'Colorado State University'}"
PGEN,
PGNY,"{'the Delaware General Corporation Law', 'FASB', 'Smart Cycles', 'follows:&#8226;Utilization Component', 'ESG', 'HHS', 'The Employee Retirement Income Security Act', 'IVF', 'provider clinics', 'ERISA', 'Progyny', 'The Sarbanes-Oxley Act', 'Data Protection', 'PBM', 'Adopted Accounting PronouncementsFor', 'Note 2 &#8211', 'ServicesPharmacy', 'Related to Government Regulation', 'Congress', 'OCR', 'Inc.8-K001-391003.110/31/20193.2Amended', 'Risks Related to Government Regulation', 'the State of Delaware', 'NY', 'Covered Entities', 'the Smart Cycle', 'the Nasdaq Stock Market', 'Smart Cycle', '2 &#8211', 'Business and Basis of Presentation', 'Progyny Rx', 'PEPM', 'Board of Directors', 'Note 1 &#8211', 'contentsPART I &#8211', 'Board of Directors;&#8226;establish', 'Office for Civil Rights', 'the Department of Labor', 'Patient Care Advocates (&#8220;PCAs&#8221', 'Provider Relations and Claims Processing', 'HIPAA', 'Significant Accounting Policies', 'the Business Associate', 'Taft-Hartley', 'ExpensesOur', 'Business Associate Agreement', 'Supreme', 'SOX', 'Form S-1', 'ACA', 'SEC', 'Silicon Valley Bank', 'Company', 'Net Settlement of Equity Awards Our', 'litigation and/or regulatory action', 'Restated Certificate of Incorporation of Progyny', 'Purchase Stock', 'See &#', 'DOL', 'IRS', 'COVID-19', 'Business Associates', 'the Covered Entity or Business Associate', 'IPO', 'CAA', 'Adopted Accounting', 'Progyny, Inc.', 'Nasdaq', 'this Quarterly Report on Form 10-Q.In', 'ASU No', 'Progyny Rx&#8217;s PBM'}"
PHAR,
PHAT,"{'the Approval Milestone', 'years)\\n        &', '\\n    Interest income\\n    &', 'the Approval Additional Funding', 'the Additional Investor', 'Sarbanes-Oxley', '26\\n', '\\n    Research', 'PHALCON-HP', 'patients;\\n  &#x2022;potential', 'The Commercial Supply Agreement', 'the Interest Rate', 'COVID-19', 'the Initial Investors', 'Revenue Interest Financing Agreement', 'the Wall Street Journal', 'Cover Page Interactive Data File', 'CO Finance LVS XXXVII LLC', 'the Second Loan Amendment', '\\n  &#x2022;per', 'x2014;\\n        &', 'FDA', 'the Revenue Interest Financing Agreement', 'Loan', 'the Performance Covenants', 'and\\n  &#', 'the Revised Warrant Agreement', '30\\n', 'Silicon Valley Bank', 'Company', 'the Prime Rate', '\\n  Research and Development Expenses', 'the Second Performance Milestone', 'the Hercules Loan Agreement', 'The Initial Investors', '\\n    Interest expense\\n    &', 'Results of Operations', 'the Joinder Agreement', 'Non-Erosive GERD', 'L.P.', 'the Takeda License', 'costs;\\n  &#x2022;the', 'Loan Agreement', '32\\n', 'the &#x201c;Investment', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Third Loan Amendment', 'The Loan Agreement', 'fee\\n        &', 'the Additional Investor Funding', '\\n  &#', 'Lenders', 'Registrant', 'the Inline XBRL document)\\n    &', 'the Common Stock', 'Initial Investors NQ', 'Takeda', 'the Sarbanes-Oxley Act', 'IPO', 'Comparison', 'Form S-3', 'the Loan Agreement', 'the Commercial Supply Agreement', 'Hercules Capital, Inc.', 'Organization, Basis of Presentation and Summary of Significant Accounting Policies', 'WestRiver Innovation Lending Fund VIII', 'Hercules Capital', 'the State of Delaware', 'the Interactive Data File', 'stock.\\n  Contractual Obligations', '\\n    ', 'the Temporary Services Agreement', '\\n        &', 'SEC', 'ATM Offering', 'Phathom Pharmaceuticals, Inc.', '\\n    &'}"
PHIO,"{'the Clinical Co-Development Agreement.\\n\\n&#160;\\n\\nPH-894\\n\\n&#160;\\n\\nPH-894', 'DP TIL technology.\\n\\n&#160;\\n\\nThe Company', 'DP TIL', 'Phio Pharmaceuticals', 'Company&#8217;s\\ncorporate', 'this Quarterly Report', '\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n    &', 'liabilities\\nat', 'INTASYL compound\\nthat', 'Under\\nthe Clinical Co-Development Agreement', 'the Securities and Exchange Commission', 'the Private Securities Litigation Reform Act', 'this Quarterly Report on Form 10-Q', 'Company&#8217;s\\nstockholders', 'forced\\nto', 'approximately\\n$606,000', 'AgonOx', 'Value of Financial Instruments\\n\\n&#160;\\n\\nThe Company', 'Long-Term Incentive Plan', 'the Clinical Co-Development Agreement', 'payments&#160;\\n    &', 'Accounting Standards Codification', 'of\\n$5.40', 'Registrant', 'Principal Executive', 'another company.\\n\\n&#160;\\n\\nThe Company', 'Co-Development', 'Company', 'the Financial Accounting Standards Board', 'Section', 'the April\\n2023 Financing', 'AgonOx, Inc. (&#8220;AgonOx&#8221;)', 'Significant Accounting', '\\n    &', '1 &#8211'}"
PHVS,
PHXM,
PIII,
PINC,
PIRS,
PLRX,
PLSE,"{'ASC', 'disclosures\\nof', 'demand.\\n\\n&#160;\\n\\nNOTE\\n16 &#8211;&#160;SUBSEQUENT', 'RRA', 'EQUITY', 'the Amended Equity Financing Agreement', 'Registration Rights Agreement', 'TJM subsidiaries.\\n\\n&#160;\\n\\nThe Company&#8217;s\\nfuture', 'the GHS Registration Rights Agreement', 'Common Stock.\\n\\n&#160;&#160;&#160;\\n\\nThe', 'Neural Signals Inc', 'net&#160;\\n', 'products\\nand', 'the U.S. Dollar', 'GHS', 'habitat', 'DPTI', '\\n    &#160;Schedule', 'University', 'Credit', 'the United States\\nof America (&', 'NSI', 'the GHS Registration Statement', '\\n    Office', 'the 2023\\nEquity', 'Accounting Standards Codification', 'U.S. Dollar', 'Optilan', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n8 &#', 'of\\n$1,775,869', 'Form S-1', 'Optilan UK Liquidation.\\n\\n&#160;\\n\\nRevenue\\nRecognition\\n\\n&#160;\\n\\nThe Company&#8217;s\\nrevenues', 'SEC', 'Company&#8217;s\\nForm', 'Big Data', 'Common Stock', 'and\\n  \\n    &', 'Interim Financial Information\\n\\n&#160;\\n\\nThe', 'Company', 'August\\n31', 'Certificate of Incorporation', 'the Second\\nAmended Equity Financing Agreement', 'L.P. (&#8220;Carebourn&#8221', 'EFA', 'Purchase', 'Carebourn Capital', 'filed.\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'into\\na Joint Venture Agreement', '\\n    &', 'the U.S Securities and Exchange Commission for Interim Financial\\nInformation', 'Common Stock.\\n\\n&#160;\\n\\nThe 2023', 'the Optilan Liquidation'}"
PLUR,"{'PLX', 'Tnuva Food-Tech Incubator', 'Form S-3', 'e. New Accounting Pronouncements', 'USUHS', 'the European Investment Bank\\n    ', '\\n\\n&#160;\\n\\nPLURI INC.', 'Limited Partnership', 'the Additional Compliance Period', 'The Nasdaq Capital', 'the symbol &#8220;PLUR.&#8221', 'respectively&#160;\\n    &', 'the Board of Directors', 'Qualitative Disclosures', 'the Uniformed Services University of Health Sciences', 'Development Expenses', 'the European Union\\ngrant', 'Hematopoietic Acute Radiation Syndrome', 'Armed Forces Radiobiology Research\\nInstitute', 'Net\\n\\n&#160;\\n\\nResearch', 'Agricultural', 'Pluri Inc.', 'operations.\\n\\n&#160;\\n\\nWe', 'Form\\nS-3', 'CLI', '\\n\\n&#160;\\n\\n  &', 'CONDENSED CONSOLIDATED STATEMENTS OF\\nOPERATIONS', 'activities.\\n\\n&#160;\\n\\nWe', 'The Nasdaq Capital Market', 'NIAID', 'PLX-R18', 'the Listing Qualifications Department', 'SEC', 'IIA', 'financial\\nreporting.\\n\\n&#160;\\n\\n\\n\\n', 'Company', 'the Securities Exchange Act', 'pay&#160;\\n    &', 'the U.S. Department', 'Jefferies', 'Tnuva Food Industries &', 'Israel Ltd.', 'Interactive Data File', 'CFO', 'Rule 405 of Regulation S-T', 'Nasdaq', '\\n    &', 'Controls\\nand Procedures.\\n\\n&#160;\\n\\nEvaluation of Disclosure\\nControls and Procedures', 'Jefferies LLC (&#8220;Jefferies&#8221;),\\npursuant'}"
PMCB,
PMD,
PMN,"{'ASC', 'Contentsour', 'FASB', 'IIOTHER', 'ASU', 'Consolidated Statements of Cash', 'the Vancouver Coastal Health Authority', 'RedemptionThe Preferred Shares', 'this Quarterly Report', 'Contracts', 'the Accounting Standards Codification', 'ContentsTable', 'University Health Network AgreementIn', 'Internal Control', 'PART&#160;IIItem&#160;1', 'Post-Effective Amendment No', 'the Securities and Exchange Commission', 'VotingThe Preferred', 'the UHN License Agreement', 'Development ExpensesResearch', 'Yes &#160;&#9744', 'ExpensesResearch', 'the heading &#8220;Risk Factors', 'Daniel Geffken&#8203;&#8203;&#8203;Daniel', 'Conversion and Other Options (&', 'Financial ReportingThere', 'the University Health Network', 'Credit RiskFinancial', 'Registrant', 'ProMIS Neurosciences Inc.', 'SEC', 'Accounting for Convertible Instruments', 'United States dollars', 'UHN', 'ContentsWe', 'Financial Officer&#8203;&#8203;&#8203;(principal', 'Company', 'Unaudited Condensed Consolidated Financial Statements8Item 2.Management&#8217;s Discussion and Analysis of Financial Condition', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Consolidated Statements of Operations and', 'Derivatives and Hedging Contracts', 'Consolidated Statements of Changes', 'ASU No.&#160;2020-06', 'CRA', 'Note&#160;9 Related Party Transactions', 'Consolidated Balance', 'CODM', 'Consolidated Financial Statements', 'ASU No', 'Equity', 'the Vancouver Coastal Health Authority AgreementIn April&#160;2016', 'ALS'}"
PMVP,"{'LLC', 'Cover Page Interactive Data File', 'Continental Stock Transfer &', 'the Public Offering', 'UBS', 'PMV Consumer Delaware Management Partners', 'LaPenta', 'negotiate\\nand', 'TO CONDENSED FINANCIAL STATEMENTS\\n\\nSEPTEMBER 30', 'the Investment Company', 'the Court of Chancery of the State of Delaware', 'PMV Consumer Acquisition Holding Company', 'the Sarbanes-Oxley Act\\n    ', 'the Public Warrants', 'Initial Public\\nOffering', 'the Initial Public Offering', 'vote\\non', '\\n\\n\\n&#160;\\n\\nThe Company', 'the Initial\\nPublic Offering', 'Trust Company', 'the Interactive Data File', 'Co-Principal Executive', 'VALUE MEASUREMENTS\\n\\n&#160;\\n\\nThe', 'the Company&#8217;s\\nInitial Public Offering', 'Trust', 'CONT', 'Co-Principal Executive Officers', 'Administrative Services Agreement', 'Continental Stock Transfer &amp', 'the Private Warrants', 'will\\nbe', 'of\\nthe State of Delaware', 'the Court of Chancery', 'Form S-1', 'Principal Financial and Accounting', 'SEC', 'remaining\\nin the Trust Account', 'the IPO Trust', 'Company', 'Pursuant', 'UBS Securities', 'PMV Consumer Acquisition', 'IPO', 'The Trust Account', 'PMV Consumer Acquisition Company', 'the Court of Chancery\\nin the State of Delaware', 'BTIG', 'this Quarterly Report on Form 10-Q.\\n\\n&#160;\\n\\n\\n', '\\n    &', 'Growth Company\\n\\n&#160;\\n\\nThe Company', 'the Certificate of Incorporation'}"
PNT,
PNTG,"{'\\n  &#x2022;injury', 'years)\\n        &', 'LLC', 'AMD', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n    Interest income\\n    &', '\\n  &#x2022;variations', '\\n  Commission File Number 001-39782', '\\n', 'Medicaid Innovation (&#x201c;CMMI&#x201d;)', '\\n  &#x2022;expansion', 'the University of PennsylvaniaOn April 21, 2023', 'EMA', '\\n  &#x2022;disruptions', 'the Regents of the University of California', '\\n  &#x2022;an', 'Rights Agreement', 'Uneek Mehra\\n', '\\n  &#x2022;termination', 'this Quarterly Report on Form 10-Q', 'the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program', 'the University of California The Company', 'Jefferies LLC', '223,327\\n    &', '\\n  &#x2022;costs', 'B.V. (&#x201c;uniQure&#x201d', 'Molecular Therapeutics, Inc.', 'x2022;a', 'UNITED STATES', 'Effects of Inflation\\n', 'the &#x201c;License', '\\n    Research', 'AGT the Transferred Material', 'UC Agreements', 'ACA', 'Segment Information The Company', 'the Securities Exchange Act', '\\n  &#x2022;expenditures', 'the S-3 Registration Statement', 'COVID-19', 'the License Agreement).Aevitas Therapeutics, Inc.', 'the University of Pennsylvania', 'the Company&#x2019;s 2022 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'the Funding Agreement', 'Registration Statement on Form S-1', 'FASB', '2022\\n         \\n         \\n          &#160;Customer', '\\n  &#x2022;product', 'DirectorPrincipal Executive', '\\n  &#x2022;sufficient', 'the &#x201c;UC Agreements&#x201d', '\\n  &#x2022;publicity', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'CFF', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;general', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'Licensed Products', 'requirements.\\n  &#x2022;Our', 'parties)\\n    &', 'and\\n  &#', 'Registration Statement on Form S-3', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'Center for Medicare &', '\\n  &#x2022;others', 'the Medicaid Drug Rebate Program', 'the Amended uniQure Agreement', 'x201c;CFF', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;loss', '\\n  &#x2022;new', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '99%\\n          &#160;\\n', 'Catalent', 'USPTO', '\\n  &#x2022;impose', '\\n  &#x2022;seize', 'DME', '\\n    &#', 'Report', 'the Delaware General Corporation Law', '\\n  &#x2022;diligence', '\\n  ', 'Capital Requirements \\n', 'the UC Agreements', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD', 'UK Data Protection Act 2018', '\\n  &#x2022;future', 'the Program Advisory Group', '\\n  Interest Rate Sensitivity', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'the Sales Agreement', '497\\n        &', '\\n  &#x2022;coverage', 'Roche', '\\n  &#x2022;exhaustion', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;commencement', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;retention', 'Registrant', 'the UC Regents', '\\n          &', 'technologies.\\n  &#', 'Condensed Statements of Operations', '10\\n       &', '\\n  &#x2022;announcement', 'IPO', 'AWA', '\\n  &#x2022;The', 'companies&#x2019', 'ASU No', 'the Amended uniQure Agreement or the Second uniQure Agreement', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Therapeutic Vector Evolution', 'Form S-3', '\\n  &#x2022;convenience', 'the License Agreement', 'GA', '\\n  &#x2022;We', 'the Funding Agreement Product (&#x201c;Acceptance&#x201d;)', 'the &#x201c;August 2023', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '500\\n    &', 'harmed.\\n  &#x2022;Our', 'European Union', 'Condensed Statements of Comprehensive Loss', '99%\\n          &#', 'the State of Delaware', 'x2022;refuse', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', '\\n  &#x2022;suspend', 'frames.\\n  &', '\\n  &#x2022;the FDA', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Related Party Transactions', 'the Court of Chancery', 'Significant Accounting Policies', 'the &#x201c;Funding Agreement', '\\n        &', 'SEC', 'ATM Offering', 'agreements.\\n', 'Collaboration and License Agreement', 'BLA', 'The CFF Agreement', 'the Centers for Medicare &', 'the University of California and The Trustees of the University of Pennsylvania', '\\n  &#x2022;failure', 'Aevitas Therapeutics, Inc. (&#x201c;Aevitas&#x201d;)', '\\n  &#x2022;reduced', 'the European Union', '\\n  Litigation', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
POAI,"{'ASC', 'the STREAMWAY System', 'the Company&#x2019;s Board of Directors', 'FASB', 'ASU', '% &#', 'Terms and Conditions', 'EQUITY', 'the Board of Directors', 'Contracts with Customers', 'Company.\\n\\n&#xa0;\\n\\nCustomers', 'zPREDICTA Inc.', 'Medicare', 'Series F Preferred Stock', 'this Quarterly Report on Form 10-Q', 'the Company.\\n\\n&#xa0;\\n\\nRecently Adopted Accounting Standards\\n\\n&#xa0;\\n\\nIn', 'dividend yield\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t0.0%\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t0.0%\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tExpected stock price', 'STOCKHOLDERS&#x2019', 'the United States Food and Drug Administration', 'the Company&#x2019;s Certificate of Incorporation', 'the Audit Committee', 'NOTE', 'Reverse Stock Split\\n\\n&#xa0;\\n\\nOn', 'x201c;Financial Instruments &#', 'AI', 'F Preferred Stock Dividend', 'Company', 'rate\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t0%\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t2.96% &#', 'point of sale.\\n\\n&#xa0;\\n\\nValuation and Accounting for Stock Options', 'Predictive Oncology Inc.'}"
POCI,
PODD,
PPBT,"{'ASC', 'LLC', 'Class\\nB Units', 'CCM', 'Condensed Consolidated Financial Statements\\n(unaudited)\\n\\n&#160;\\n\\nThe Company', 'Paired Securities', 'Consolidated Financial Statements\\nfor Correction of Immaterial Misstatements\\n\\n&#160;\\n\\nThis Management&#8217;s Discussion\\nand', 'net&#160;\\n', 'the Term Loan Lenders', 'CDF', 'the Term Loan', 'Court', 'Coliseum', 'the Condensed Consolidated Statement of Cash Flows', '\\n    Research', 'the Third Amended and Restated Limited Liability\\nCompany Agreement', 'Purple Innovation, Inc.', 'a Monte Carlo Simulation', 'TNT Holdings', 'the Merger Agreement', 'FASB', 'Blackwell', 'Condensed Consolidated Financial Statements\\n(unaudited)\\n\\n&#160;\\n\\nRecent\\nAccounting', 'Warrant Liabilities', 'Cease', 'the Securities and Exchange Commission', 'Blackwell Partners LLC &#8211', 'Warrant Liabilities\\n\\n&#160;\\n\\nUnexercised\\nsponsor', 'ReST', 'PRPLS', 'Credit', 'CCP', 'Loan', 'debt&#160;\\n    &', 'Capital Management', 'Warrant Liabilities\\n\\n&#160;\\n\\nThe\\nCompany', 'pursuant\\nto', 'Purple Inc.', 'Company\\nregularly', 'Purple', 'Common Stock', 'Company', 'IRS\\nCode', 'Respondents', 'Results of Operations', 'Condensed Consolidated Financial', 'net&#160;\\n    &', 'Condensed Consolidated Financial Statements\\n(unaudited)\\n\\n&#160;\\n\\nAggregate\\nNon-Cash Stock-Based Compensation\\n\\n&#160;\\n\\nThe\\nCompany', 'fees\\nand', 'ITC', 'Credit Agreement', 'a\\nresult', 'the ABL Agreement', 'Loan Agreement', 'required\\nto', 'the Subject Events of Default', 'Series A (&#8220;Blackwell&#8221', 'controls\\nand', 'Capital Resources\\n\\n&#160;Our\\nprincipal', 'all.\\n\\n&#160;\\n\\nResearch\\nand Development\\n\\n&#160;\\n\\nResearch\\nand', 'Master Professional Services Agreement with Photon', 'Photon', 'the Second Amended\\nand Restated Limited Liability Company Agreement', 'Purple Innovation LLC&#8217;s', 'PROCEDURES\\n\\n&#160;\\n\\nEvaluation\\nof Disclosure Controls', 'Intellibed', 'the Term Loan Agreement', 'Sealy Mattress', 'Equity\\n\\n&#160;\\n\\nClass\\nA Common Stock\\n\\n&#160;\\n\\nThe\\nCompany', 'Sealy Technology', 'Net &', 'our\\nTax Receivable Agreement', 'Photon Interactive UK Limited', 'the Coliseum Investors', 'the Bank of Montreal', 'ASU No', 'Fair Value &#8211', 'Purple LLC.\\n\\n&#160;\\n\\nThe\\naccompanying', 'ABL Agreement', 'Alpine', 'Form S-3', 'Board', 'the Master Professional Services Agreement', 'Internal Controls Over Financial Reporting.\\n\\n&#160;\\n\\n\\n\\nOur', 'Purple Innovation', 'Voting Securities', 'sufficient\\ncapital', 'August\\n7', 'InnoHold', 'Principal', 'Callodine Commercial Finance', 'Coliseum Capital Management', 'Tempur Sealy International, Inc.', 'forced\\nto', 'First Amended and Restated Limited Liability Company Agreement', 'payments&#160;\\n    &', 'the Special Committee', 'LLC (&#8220;InnoHold&#8221', 'Paired Security', 'credit.\\n\\n&#160;\\n\\nUnder\\nthe Term Loan Agreement', 'Related Party', 'Exhibit 10.8', 'the U.S. District Court', 'SEC', 'SOFR', 'ABL', 'data.\\n\\n&#160;\\n\\nIn', 'the Business Combination', 'Coliseum Capital\\nPartners (&#8220;CCP&#8221;)', 'GPAC', '\\n    &', 'Coliseum Capital', 'center\\nis'}"
PRAX,"{'ASC', 'FASB', 'OperationsComparison', 'Development ExpenseThe', 'Adopted Accounting PronouncementsOn', 'Contracts', 'the Accounting Standards Codification', 'Ionis Pharmaceuticals, Inc.', 'IP', 'Administrative ExpenseThe', 'FASB.The', 'RogCon', 'Capital Resources.&#8221;Financial Operations', 'Cooperation and License Agreement', 'Consolidated Financial InformationThe', 'ShareThe', 'Entity&#8217;s Own Equity', 'Related Party TransactionsOn', 'Company', 'the Financial Accounting Standards Board', 'Ionis', 'RogCon Inc.', 'ASO', '2022 Annual Report', 'ASU No', 'ESPP161,713&#160;48,182&#160;161,713&#160;48,182&#160;10,671,584&#160;9,997,016&#160;10,671,584&#160;9,997,016&#160;Common'}"
PRCT,"{'Aquablation', 'Significant Accounting Policies Basis of Presentation', 'the United States Securities and Exchange Commission', 'IIOTHER', 'the Loan Agreement', 'the Black-Scholes', 'the AquaBeam Robotic System', 'this Quarterly Report', 'Consolidated Statements', 'Unaudited Interim Financial Statements', 'Canadian Imperial Bank of Commerce', 'Item 408 of Regulation S-K).31Item&#160;6', 'U.S. Food and Drug Administration', 'QUARTERLY REPORT For', 'Internal Control', 'InformationDuring', 'Recent Accounting PronouncementsThe', 'AquaBeam Robotic Systems', 'ContingenciesGuarantees', 'Customer ConcentrationThe Company', 'Consolidated Statements of Cash Flows8Notes to', 'U.S.8&#160;%8&#160;%9&#160;%10&#160;%We', '13.&#160;&#160;&#160;&#160;Defined Contribution PlanThe Company', 'value$11.28&#160;Total', 'ShareNet', 'TURP', 'Condensed Consolidated Financial Statements9Item 2.Management&#8217;s Discussion and Analysis of Financial Condition', 'Financial ReportingThere', 'the Quarterly Report on Form 10-Q.', 'SEC', 'SOFR', 'The Initial Interest-Only Period', 'Company', 'ESPP.The', '10-Q &#8211', 'consumables1,651&#160;791&#160;3,826&#160;2,369&#160;Service298&#160;177&#160;860&#160;511&#160;Total', 'Geographical', 'Qualitative Disclosure About Market', 'AquaBeam Robotic System', 'CONTENTS PagePart', 'Accounting PronouncementsNo', 'Consolidated Financial Statements', 'BPH', 'the Term Loan Facility', 'Consolidated Balance Sheets4Condensed Consolidated Statements of Operations and Comprehensive'}"
PRE,
PRFX,
PRLD,
PRME,
PROC,
PROF,
PROK,
PRPH,"{'ASC', 'BE-Smart Esophageal Pre-Cancer', 'PMI', 'Stella', 'ReconciliationIn', '8220;Financial Instruments - Credit Losses', 'Significant Accounting PoliciesBasis', 'Consolidated Statements of Operations and Comprehensive Income', 'the Manufacturing Agreement', 'Lease Agreement', 'Issuer Purchases of Equity SecuritiesPeriodTotal', 'PBIO', 'Clinical Laboratory Improvement Amendments', 'H.C. Wainwright &amp', 'Confucius Plaza Medical Laboratory Corp.', 'Rule 405 of Regulation S', 'HRSA', 'COVID-19', 'PIM', 'a New Drug Application', 'Asset', 'Mylan Inc.', 'non-GMO', 'FASB', 'Company\\', 'Meda Consumer Healthcare Inc.', 'Compound&#8221', 'FASB ASC', 'First Floor Lease&#8221', 'the Office of Management and Budget', 'the Securities and Exchange Commission', 'Diluted', 'Medicare', 'Medicaid', 'FDA', 'Mylan', 'PresentationThe', 'Company', 'TK', 'Business Combinations', 'CODM', 'The Second Floor Lease Amendment', 'ASU', 'BRG Office', 'GRDG Sciences', 'AgreementsLinebacker', 'Condensed Consolidated Financial Statements11Item', 'Pharmaloz Manufacturing, Inc. (&', 'Exchange Act', 'License Agreement', 'the ""Second Equipment Lease', 'Consolidated Statements of Cash Flows', 'ProPhase Diagnostics, Inc. (&#8220;ProPhase', 'MCH, &#8220;Mylan&#8221', 'LB-2', 'Inc. (&', 'the Adjusted Gross Margin', 'NDA', 'the ""Third Equipment Lease', 'Mylan Consumer Healthcare Inc.', 'the Stella Purchase Agreement', 'Restated Bylaws of Prophase Labs, Inc.', 'Nurya Brands', 'LLC (&#8220;GRDG&#8221', 'the License Agreement', 'InventoriesInventory', 'Consolidated Statements', 'Qualitative Disclosures', 'the White House Coordinator', 'Nurya', 'the Linebacker Effective Date', 'Global BioLife, Inc.', 'Linebacker LB-1', 'SEC', 'The Milestone Stock', 'ProgramsApproximate Dollar Value of Shares', 'Equity Securities', 'Co. (&#8220;Wainwright&#8221;)', 'ThinkEquity', 'Interactive Data File', 'the Commercialization Event', '10 - Segment InformationThe Company', 'ProPhase BioPharma'}"
PRPO,"{'FASB', 'Contentsappropriate', 'ASU', 'Form S-3', 'The Purchase Agreement', 'this Quarterly Report on Form 10-Q.', 'Contractual Obligations', 'Contracts', 'Global Partners', 'Rule&#160;12b-2', 'CommitmentsNo', 'the 2023 Registration Statement', 'ATM', 'the Financial Advisor Agreement', 'Third Amended', 'ContentsStock Compensation', 'Medicaid', 'Credit Losses on Financial Instruments&#8221', 'Medicare', 'the &#8220;Registered Direct Offering&#8221;)', 'expense&#8203;$ &#8212;&#8203;&#160;&#160;&#160;Total', 'the Securities and Exchange Commission', 'ROU', 'ReceivableThe Company', 'Unaudited Condensed Consolidated Financial Statements', 'Contentsa', 'the Offering.&#160;The Registered Direct Offering', 'Nasdaq Listing Rule', 'the 2023 Registration Statement on Form S-3', 'ContentsThe', 'InflationInflation', 'EQUITYCommon Stock', 'Form S-1', 'the Nasdaq Capital Market (&#8220;Nasdaq&#8221', 'Joint Venture', 'SEC', 'Common Stock', 'Company', 'CustomersThe', 'Restated Certificate of Incorporation', 'the Securities Exchange Act', 'results.&#8203;The Company', 'the Joint Venture', 'ContentsThe Company', 'ThermoFisher', 'the Company&#8217;s Board of Directors', 'Significant Accounting', 'Stock Options', 'Securities', 'Adopted Accounting Pronouncements', 'Nasdaq', 'Note&#160;2&#160;- &#8220;Summary', 'the Purchase Agreement', 'the Registered Direct Offering'}"
PRQR,
PRTA,
PRTC,
PRTG,
PRVA,"{'ASC', 'FFS', 'LLC', 'PH Group Holdings Corp.', 'the Non-Owned Medical Group', 'PQN-CT', 'the Revolving Loan', 'Privia Medical Group &#8211', 'Privia Providers', 'the Privia Technology Solution', 'Capital Resources GeneralTo', 'Beebe Healthcare', 'ProceduresUnder', 'Management Services Agreement', 'AccumulatedAmortization IntangibleAssets AccumulatedAmortization Trade', 'the Securities Exchange Act', 'ContentsResults of Operations', 'Variable Interest Entities Management', 'Washington Friendly Medical Group', 'ContentsIndebtedness', 'Medical Group', 'Privia', 'Activities Net', 'Implemented Providers', 'Non-Owned Medical Group', 'Non-Owned Medical Groups', 'the Original Credit Agreement to &#8220;springing&#8221', 'Friendly Medical Groups', 'ChoiceHealth', 'the Securities and Exchange Commission', 'Privia Health Group, Inc.', 'the Privia Platform', 'Care Margin', 'Provider', 'Novant Sub', 'Friendly WTX', 'the Revolving Loan Facility', 'Silicon Valley Bank', 'Goodwill', 'the Affiliated Practices', 'Common Stock', 'Practice Collections', 'Company', 'Medical Groups', 'the Original Credit Agreement', 'the Health Insurance Portability', 'SVB', 'the &#8220;Administrative', 'Segment Reporting', 'the Term Loan Facility', 'the Credit Facilities', 'Novant Health Enterprises', 'Credit Agreement', 'Related-Party Transactions', 'The Equity Alignment Agreement', 'athenahealth, Inc.', 'Restriction Agreement', 'EquityNovant Health Private Placement', 'September&#160;30,', 'the Non-Owned Medical Groups', 'Novant Health, Inc. (&#8220;Novant', 'Privia Health Group', 'the Credit Agreement', 'PaidCurrent', 'Privia Health', 'IPO', 'MSA', 'VBC', 'ContentsContract Asset', 'Novant Health', 'Administrative', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'the Equity Alignment Agreement', 'Privia Medical Group &', '2022Balances&#160;for&#160;contracts&#160;with&#160;customersAccounts', 'Owned Medical Groups', 'Washington Nominee PC', 'WA)6,660&#160;69&#160;&#8212;&#160;&#8212;&#160;Payer', 'Privia Physicians', 'ACO', 'the &#8220;Effective'}"
PSNL,"{'The Federal Food, Drug and Cosmetic Act', 'Cancer Research', 'Foresight Diagnostics Inc.', 'programs.\\n  &#', 'the Francis Crick Institute', 'GHR', 'EEA', 'this Quarterly Report on Form 10-Q', ""Vall d\\'Hebron Institute of Oncology"", 'program.\\n  Components of Operating Results\\n', 'EU', 'the New York State Department of Health', 'the Internal Revenue Code', 'non-FDA', '\\n    Research', 'unsuccessful;\\n  &#x2022;collaborators', 'MapKure', 'ACA', 'Personal&#x2019;s', 'COVID-19', 'LiabilitiesContract', 'the Department of Justice', 'the Tax Cuts and Jobs Act', 'Criterium', 'PHI', 'Canada&#x2019;s Anti-Spam Legislation (&#', 'Medicare', 'Medicaid', 'the Regulation on In-Vitro Diagnostic Devices (Regulation (', 'Congress', 'x2014;\\n        &', 'the Federal Trade Commission', 'future.\\n', 'the Academic Breast Cancer Consortium', 'The &#x2018;783 Patent', 'FDA', 'the VA MVP', 'C.F.R.', 'and\\n  &#', 'the Physician Fee Schedule', 'the District Court', 'others;\\n  &#x2022;collaborators', 'the HHS Office of Inspector General (the &#x201c;OIG&#x201d;)', 'collaborations;\\n  &#x2022;collaborators', 'HIPAA', 'AI', 'See &#x201c;&#x2014;We', 'Duke University', 'LDT', 'products;\\n  &#x2022;collaborators', 'Company', 'USPTO', 'NeXT Personal', 'California Business and Professions Code Section', 'liability;\\n  &#x2022;disputes', 'the California Privacy Rights Act', 'costs.\\n  Specific', 'CMS', 'the Personal Information Protection and Electronic Documents Act', 'University Medical Center Hamburg-Eppendorf', 'the U.S. Supreme Court', 'IVDR', 'decline.\\n  Holders', 'University College London', '98/79/EC', 'manufacturer&#x2019;s', 'the Protecting Access to', 'scale.\\n  Research and Development Expenses\\n  Research', 'stock.\\n  Pursuant', 'the Sarbanes-Oxley Act', 'MVP', 'CFO', 'the Academic Breast Cancer', 'Loans\\n  Equipment', 'EKRA;\\n  &#x2022;other', 'the Business and Professions Code', 'The &#x2018;033 Patent', 'ATM', 'China&#x2019;s Personal Information Protection Law', 'ACE', 'Natera', 'KOLS', 'Dana-Farber Cancer Institute', 'and\\n  &#x2022;similar', 'PMA', 'OIG', 'BC Cancer', 'the Genetic Information Nondisclosure Act', 'the U.S. District Court', '\\n        &', 'the Budget Control Act', 'PAMA', 'the FDA&#x2019;s Quality System Regulation', '\\n    &'}"
PSTV,
PSTX,"{'ASC', 'RNA', 'LLC', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001661460us-gaap', 'x201c;Amended Loan', 'tax\\n    &', 'Oxford', 'Security Agreement', 'EMA', 'Collaboration Programs', 'Principal Executive Officer', 'the heading &#x201c;Special Note Regarding Forward-Looking', 'the &#x201c;Roche Collaboration', 'EquipmentMember2023', 'Hoffmann-La Roche Inc.', 'the Internal Revenue Code', 'x2022;a', 'the &#x201c;Takeda Collaboration', '26\\n', 'CPRA', '\\n    Research', 'above;\\n  &#x2022;lack', 'the Roche Collaboration Agreement', 'the Securities Exchange Act', 'PurchaseAgreementMember2023-08-042023-08', 'NOL', 'Roche (&#x201c;Licensed', 'results.\\n  &#x2022;We', 'Accounting Standard Update', 'Adopted Accounting', 'licensed;\\n  &', 'property;\\n  &#x2022;collaborators', 'FASB', 'HHS', 'MaximumMember2022-02-280001661460us-gaap', 'Internal Control Over Financial Reporting\\n', 'recalls;\\n  &#x2022;fines', 'Medicaid', 'Medicare', 'the &#x201c;Maturity Date&#x201d', 'Diluted', 'Loan Agreement \\n  ', 'prices;\\n  &#x2022;convenience', 'design;\\n  &#x2022;delays', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'the Data Safety Monitoring Board', 'TeneoBio&#x2019;s', 'Licensed Products', 'CollaborationRevenueMember2022', 'Loan', '\\n        Laboratory equipment\\n', 'Financial Position', 'and\\n  &#', 'Collaboration Program', 'PublicOfferingMember2022-07-012022-09-300001661460pstx', 'TwoThousandTwentyEmployeeStockPurchasePlanMember2022-01-012022-09-300001661460pstx', 'strategy.\\n  &#x2022;We', '77\\n', 'Poseida Therapeutics', '\\n  Commission File Number', 'Company', 'USPTO', 'Measurement of Credit Losses on Financial Instruments', 'Genus Oncology', '\\n    Interest expense\\n    &', '\\n    &#160;&#160;&#160;&#160;4.3\\n    &', 'the Leahy-Smith Act', 'the California Privacy Rights Act', 'the Amended Loan Agreement', 'FCA', 'Charter)\\n  &#', '\\n    &#', 'and\\n  &#x2022;advance', 'Purchase Agreement', 'infringed;\\n  &#', 'LicensedProductsMember2022-07-012022-07-310001661460pstx', 'Strategic Rights Letter AgreementOn', 'Cantor Fitzgerald &amp', 'property;\\n  &#', 'the Delaware General Corporation Law', 'WarrantMember2022-01-012022-09-300001661460pstx', 'candidates;\\n  &#', 'Principal Financial Officer', 'P-PAH-101', 'Oxford Finance', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001661460pstx', 'WarrantMember2023-01-012023-09-300001661460pstx', 'this Quarterly Report on Form 10-Q.', '32\\n', 'litigation;\\n  &#x2022;collaborators', 'acquirer;\\n  &#x2022;the', 'Takeda Pharmaceuticals USA, Inc. (&', 'candidates;\\n  &#x2022;loss', 'the Xyone Agreement', 'CAR', 'Our Industry and Business Operations\\n', 'candidates.\\n  &#x2022;License Agreement with Xyone Therapeutics, Inc.', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'CIRM', 'Roche', 'the Nasdaq Stock Market', 'IRB', 'Cas-CLOVER', 'MarketFacilityMember2021-08-012021-08', 'Capital ResourcesThe Company', 'characteristics;\\n  &#x2022;to', 'Registrant', 'a Program Transaction', 'TwoThousandAndTwentyTwoLoanAgreementMember2022-02-012022-02-280001661460us-gaap', 'RocheLtdAndTakedaPharmaceuticalsUSAIncMember2023', 'P-CD19CD20-ALLO1', 'Equity &', 'candidates.\\n  Risks Related', 'terminated;\\n  &#x2022;collaborators', '\\n  &#x2022;2017 Commercial License Agreement', 'the 2022 Loan Agreement', 'directors;\\n  &#', 'FairValueMeasurementsRecurringMember2023', 'the Sarbanes-Oxley Act', 'TeneoBio, Inc.', 'Economy,&#x201d', 'reporting.\\n', 'Comparison', 'collaborators.\\n  Collaborations', 'LiborMemberpstx', 'candidates.\\n  Manufacturing', 'LLC (&#x201c;Astellas&#x201d', 'and\\n  &#x2022;injunctions', 'TeneoBio', 'candidates.\\n  Regulatory', 'California Privacy Protection Agency', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001661460us', 'including:\\n  &#x2022;the', 'the Court of Chancery of the State of Delaware', 'P-BCMA-ALLO1', 'Amgen Inc.', 'lose;\\n  &#', 'the Registrant&#x2019;s Registration Statement on Form S-1', 'ESPP', 'the State of Delaware', 'candidates.\\n  &#x2022;We', 'Cantor', 'profitably.\\n  Obtaining', 'Stockholders&#x2019;', 'PublicOfferingMember2022-07-012022-09-300001661460us-gaap', 'the Registrant&#x2019;s Current Report', 'patents;\\n  &#x2022;issued', 'x201c;Private', 'U.S. Dollar', 'the Collaboration Programs', 'and\\n  &#x2022;in', 'Financial Instruments - Credit Losses', 'U.S. Treasury', 'the Court of Chancery', 'including:\\n  &#x2022;efficacy', 'SEC', 'SOFR', 'GCP', 'Amended Loan Agreement', 'the Federal Trade Commission Act', 'Tier 2 Programs', 'the Registrant&#x2019;s Registration Statement', '\\n    &', 'the Principal Executive Officer', 'No &#9744;\\n  Indicate', 'TeneoBio Agreement', 'litigation;\\n  &#x2022;distraction'}"
PTCT,
PTGX,"{'the Delaware General Corporation Law', 'ASU', 'PASI', 'Warrant Shares', 'Condensed Consolidated Statements of Cash', 'Months Ended &#8203;&#8203;&#8203;&#8203;&#8203;&#8203;September&#160;30,&#160;&#8203;Dollar&#8203;%&#8203;&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;Change&#160;&#160;&#160;&#160;Change&#8203;&#8203;(Dollars', 'CMS', 'The Restated Agreement', 'Collaboration Revenue License', 'the Restated Agreement with Janssen', 'EMA', 'ATM', 'Internal Control', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'ContentsRisks Related to Clinical Development', 'Biologics License Application', 'the U.S. Food and Drug Administration', 'ICONIC', ': &', 'FDA', 'the Restated Agreement with Janssen, Janssen', 'the Financial Accounting Standard Board', 'net&#8203;&#160; &', 'Intellectual Property', '2022 &', 'the Internal Revenue Code', 'Pre-Funded Warrants', 'IL-23R', 'Financial Position', 'Healthcare', 'Protagonist Australia', 'Original', 'United', 'the European Medicines Agency', 'funds&#8203;$ 70,470&#8203;$ &#8212;&#8203;$&#8212;&#160;$ 70,470Certificates', 'Months Ended &#8203;&#8203;September&#160;30,&#160;&#8203;September&#160;30,&#160;&#8203;&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022Research', 'Risks Related', 'the Federal Deposit Insurance Corporation', 'Months Ended &#', 'Significant Accounting Policies', 'NDA', 'Development Expenses &', 'liabilities:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203', 'the Original Agreement', 'ContentsResearch', 'PharmaEssentia Corporation', 'Company', 'ContentsOur', 'the Securities Exchange Act', 'ContentsTotal', 'NetOther', 'and&#9679;we', 'COVID-19', 'Janssen, &', '51)&#8203;$ &#', '*&#', 'a New Drug Application', 'Adopted Accounting', 'Ended &#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;September&#160;30,&#160;&#8203;Dollar&#8203;%&#8203;&#160;&#160;&#160;&#160;2023&#8203;2022&#8203;Change&#8203;Change&#8203;&#8203;(Dollars', 'the European Union', 'the Restated Agreement', 'Warrants'}"
PTIX,"{'Company', 'FASB', 'exclusive\\nlicense', 'the New Research Agreement', 'Food and Drug Administration', 'the U.S. Dollar', 'the License Agreement', 'this Quarterly Report on Form 10-Q.', 'University', 'to\\nthe U.S. Dollar', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n10 &#8211', 'ASU No', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Technologies'}"
PTPI,"{'ASC', 'API', 'avanafil', 'Conversion Price', 'Principal Executive Officer', 'Tissue-Specific Oxygenation Sensor Technology Strategies', 'ApprovalOur', 'this Quarterly Report on Form 10-Q', 'the Series A Preferred Shares', 'Liability Maturity Analysis&#160;&#160;&#160;&#160;Operating&#160;Leases2023', 'Thermo Fisher Scientific', 'the Conversion Price', 'Accounting Standards Update', 'Contentsroyalty', 'Principal Executive', 'Vivus (&', 'Fair Value MeasurementsCertain', 'PDE-5', 'the Securities Exchange Act', 'InformationThe Company', 'The Conversion Price', 'Medical Devices segment.39\\nTable of', 'ContentsIn', 'Consolidated Financial Statements', 'MTPC', 'Warrants', 'U.S. Food and Drug Administration', 'the Effectiveness Date', 'Active Pharmaceutical Ingredient (&#8220;API&#8221', 'Principal Financial', 'FDA', 'Health Canada', 'the Conversion Shares', 'the Private Placement', 'Principal Financial Officer&#8203;&#8203;&#8203;&#8203;51\\n\\n\\n\\n', 'Common Stock', 'Company', 'the Security Agreement', 'the Vivus Settlement Agreement', 'Principal Financial Officer', 'Exchange Act', 'Medical Devices', 'Neurotrope', 'the Financial Accounting Standard Board', 'a Technology Transfer Service Agreement', 'the Common Stock', 'Conversion Shares', 'The Private Placement', 'Restated Petros Pharmaceuticals', 'Recent Accounting', 'Patheon Pharmaceuticals Inc.', 'This Quarterly Report on Form 10-Q', 'Corporate', 'portion&#8203;$ 7,248,635&#8203;&#8203;9)&#160;&#160;&#160;&#160;Operating LeasesThe Company', 'Form S-3', 'the License Agreement', 'a Fundamental Transaction', 'this Quarterly Report', 'ArrangementsWe', '2022.The Company', 'Acerus Pharmaceuticals Corporation', 'Finance', 'the Registration Rights Agreement', 'ContentsThe Private Placement', 'authorized.&#8203;&#8203;Petros Pharmaceuticals,&#160;Inc.&#8203;&#8203;&#8203;Date', 'Contentsone', 'DistributionThe Company', 'Public Company Accounting Oversight Board', '2023).10.1&#8203;Securities Purchase Agreement', '2023.Vivus Settlement Agreement', 'ContentsPrescription Medicines', 'the Certificate of Designations', 'SEC', 'Fair Value MeasurementsFair', 'the Food and Drug Administration', 'the Vivus Supply Agreement', 'GAAP', 'the Registration Statement'}"
PULM,"{'ASC', 'Form S-3', 'of\\nthe Securities and Exchange Commission', 'Tmax', 'Value of Financial Instruments\\n\\n&#160;\\n\\nAs\\nof', 'the Amended Cipla Agreement', 'the Company&#8217;s\\nAnnual Report on Form 10-K', 'DHE', 'JSC', 'LLC for\\nits', 'the Assigned Assets', 'PUR1800.\\n', 'Compensation Expenses&#160;\\n\\n\\n', 'costs.\\n\\n&#160;\\n\\nLiquidity\\nand Capital', 'Collaborative Arrangements', 'Significant Accounting Policies', 'Cobalt Propco', 'SEC', 'Pulmatrix, Inc.', 'ATM Offering', 'and\\n  \\n    &', 'Company', 'the Financial Accounting Standards Board', 'H.C. Wainwright and Co.', 'Cipla', 'the Cipla Agreement', '\\n    &', 'Cipla Agreement', 'this Quarterly Report on Form 10-Q to &#'}"
PXMD,"{'ASC', 'FASB', 'LLC', 'Registration Statement', 'the Company&#8217;s Annual Report on Form 10-K', 'HAT', 'Our Financial Position', 'PaxMedica, Inc.', 'Stock-Based Compensation&#8203;The Company', 'New Drug Application', 'the Minimum Market Value Requirement', 'the Reverse Stock Split', 'the Listing Qualification Department of The Nasdaq Stock', 'the Quarterly Report on Form 10-Q', 'No &#9744;&#8203;Indicate', 'LLC (&#8220;Vox Nova&#8221;)', 'LPC', 'TardiMed Sciences', 'LLC (&#8220;TardiMed&#8221;)', 'Vox Nova', 'Principal Executive Officer', 'Restricted Stock Units', 'ContentsTo', 'Topic&#160;326,&#160;Financial Instruments-Credit Losses', 'FDA', 'the Rent and Administrative Services', 'Prospectus', 'Lind', 'the Reserve Stock Split', 'the U.S. Food and Drug', 'Corporate Communications', 'Instruments-Credit Losses', 'ASD', 'Lincoln Park Capital Fund', 'Lincoln Park CapitalDuring', 'the Listing Qualifications Department', 'DevelopmentResearch', 'RLS', 'Regulation S-K Item', 'Simple Agreement For Equity', 'Vox Nova Exclusive Pharmacy Distribution AgreementOn June 30, 2023', 'Company', 'the Securities Exchange Act', 'Lind Global Fund II LP', 'Principal Financial and Accounting Officer', 'Certificate of Incorporation', 'the Sarbanes-Oxley Act', 'Adopted Pursuant to Section 302', 'ContentsOperating', 'Trypanosome', 'Listing Rule&#160;5550(a)(2)&#160;(the &#', 'Nasdaq', 'the Current Report on Form&#160;8-K', 'Consulting Services', 'the Registration Statement on Form S-1'}"
PYPD,
PYXS,
QDEL,"{'Grifols Diagnostic Solutions, Inc. (&', 'LLC', 'Credit Agreement', 'Capital ResourcesAs', 'ProceedingsThe', 'treasury', 'Exchange Act Rule', 'revenues$744.0&#160;$783.8&#160;$2,255.2&#160;$2,399.5&#160;In', 'L/C issuers party', 'NetInterest', 'this Quarterly Report', 'urgent care clinics', 'Ortho-Clinical Diagnostics US FinanceCo', 'the Consolidated Financial Statements', 'Ortho Clinical Diagnostics Holdings plc', 'Exchange Act', 'EPS', 'Significant Accounting PoliciesBasis', 'Sofia SARS Antigen', 'QuickVue SARS Antigen', 'Revolving Credit Facility', 'BorrowingsThe', 'follows:&#8226;Total revenues &', 'Combinations', 'a Business Combination Agreement', 'Consolidated Financial', 'current$511.3&#160;$568.1&#160;As of October&#160;1', 'Quidel Corporation', 'Labs, Transfusion Medicine', 'Wells Fargo Bank', 'the Term Loan', 'costs(8.7)(10.6)Total', 'Ortho', 'Ortho-Clinical Diagnostics, Inc.', 'the Consolidated Balance Sheets', 'Operations.&#8221;&#8226;Adjusted EBITDA &#8212', 'QuidelOrtho', 'Grifols', 'ProceduresEvaluation', 'QuickVue', 'Laguna Merger Sub, Inc.', 'Company', 'ExpensesInterest Expense', 'FactorsThere', 'ProgramsApproximate Dollar Value of Shares', 'BCA', 'Joint Business with Grifols', 'Bank of America', 'Foreign Currency Exchange', 'Point of Care', 'Equity Securities', 'for:&#8226;incremental', 'Quidel', 'QuidelOrtho Corporation', 'SecuritiesThe', 'Ortho Inc.', 'Consolidated Financial Statements', 'Labs and Transfusion Medicine', 'Corporate', 'Orca Holdco'}"
QIPT,
QLGN,"{'the University of Louisville Research\\nFoundation (&#8220;ULRF&#8221', 'ULRF', 'LLC', 'Series C', 'RAS', 'this Quarterly Report', 'G4s against &#', 'Chembio Diagnostics', 'Clinigen Clinical Supplies Management, Inc. (&', 'a Securities Purchase Agreement', 'Yes &#9744', 'Orphan Drug', 'UCL Business Limited', 'NanoSynex Ltd.', 'MLM for\\nthe', 'University College', 'the Original Registration Statement', 'Master Laboratory Services Agreement', 'this Master Laboratory Services', 'FDA', 'un', 'PDAC', 'Clinigen', 'MLM Medical Labs', 'LICENSE', 'S.A. (&#8220;Biosynex&#8221', 'last\\nto', 'respectively\\n(of', 'the Alpha Warrant', 'this Master Clinical Research Services', 'the Debenture (the &#8220;Monthly Redemption', 'Qualigen, Inc.', 'Alpha Capital', 'SEC', 'NanoSynex', 'paid.\\n\\n&#160;\\n\\nNOTE\\n11 &', 'Company', 'RAS-F', 'Pan-RAS Inhibitor', 'COVID-19', '2022.\\nThe Debenture', 'Alpha Capital&#8217;s'}"
QLI,
QNCX,"{'regulators;\\n  &#x2022;costs', 'LLC', 'control;\\n  &#x2022;prohibiting', 'The EryDel Acquisition', '\\n    Interest income\\n    &', 'the &#x201c;Separation', 'and\\n  &#x2022;enrollment', 'Reliance', 'Novosteo', 'Contractual Obligations', 'candidates;\\n  &#x2022;the', 'this Quarterly Report on Form 10-Q', 'Jefferies LLC', 'or\\n  &#x2022;require', 'the &#', 'candidates;\\n  &#x2022;actual', 'management;\\n  &#x2022;cause', 'x2022;a', 'Philip Low', 'Note 13 Subsequent', 'results;\\n  &#x2022;announcement', 'the Financial Accounting Standards Board', 'EryDel Italy', 'the Securities Exchange Act', 'thousands):&#160;20\\n       &', 'compensation)\\n    &', 'Research', 'Except', 'things:\\n  &#', 'candidates;\\n  &#x2022;withdrawal', 'consequences.\\n  &#', 'law;\\n  &#x2022;require', 'Certificate of Incorporation', 'Company, Novosteo', 'the EIB Facility', 'licensed;\\n  &', 'Morphimmune', 'us;\\n  &#x2022;impose', 'Risks Relating to Owning Our Common Stock\\n', 'and\\n  &', 'FASB', 'others:\\n  &#x2022;our', 'management&#x2019;s', 'our shares;\\n  &#x2022;market', 'HHS', 'reference.\\n  &', 'candidates;\\n  &#x2022;collaborators', 'analysts;\\n  &#x2022;fluctuations', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'Purdue', 'patents.\\n  ', 'property;\\n  &#x2022;require', 'strategic alternatives;\\n  &#x2022;changes', 'x2014;\\n        &', 'procedures.\\n  Under', 'force;\\n  &#x2022;announcements', 'and\\n  &#x2022;requiring', 'candidates;\\n  &#x2022;a', 'EryDex', 'FDA', 'NetProperty', 'EquivalentsThe Company', 'consent;\\n  &#', 'Morphimmune Inc.', 'and\\n  &#', 'years.&#160;Stock-Based Compensation ExpenseThe', 'others;\\n  &#x2022;collaborators', 'depreciation\\n        &', 'the Novosteo Acquisition', 'operations.\\n  Failure', 'collaborations;\\n  &#x2022;collaborators', 'payors;\\n  &#x2022;the', 'EryDel S.p.A.', 'Goodwill', 'candidates;\\n  &#x2022;regulatory', 'Shareholder Representative Services', 'Company', 'general;\\n  &#x2022;the', 'the Patent and Trademark Law Amendments Act', 'Novosteo Plan', 'Risks Relating to Our Intellectual Property\\n', 'American Stock Transfer &amp', 'approvals;\\n  &#x2022;suspend', 'liability;\\n  &#x2022;disputes', 'Purdue Research Foundation', 'the Listing Qualifications Staff', 'Department of Justice', 'Quince Therapeutics, Inc.', 'capital commitments;\\n  &#x2022;additions', 'healthcare practitioners;\\n  &#x2022;require', 'structure.\\n  &', 'candidates;\\n  &#', 'Principal Financial Officer', 'FCPA', 'revenue;\\n  &#x2022;exhaustion', 'AdoptedThe', 'License Agreement', 'x2022;we', 'the goodwill.9\\n     &#160;Cash', 'EIB Facility', 'NEAT', 'noncompliance;\\n  &#x2022;withdraw', 'Trust Company', 'x2022;a collaborator&#x2019;s', 'Research and Development Expenses', '\\n  &#', 'Novosteo, Inc.', 'law;\\n  &#', 'NDA', 'Assets.&#x201d', 'Ataxia-Telangiectasia', 'directors;\\n  &#', 'and\\n  &#x2022;unforeseen', 'Fortis Advisors LLC', 'x201c;anticipate,&#x201d; &#', 'Economy,&#x201d', 'IPO', 'EryDel Italy, Inc.', '47\\n', 'Schedule II', 'ASU No', 'could:\\n  &#x2022;result', '\\n  &#x2022;our', 'the &#x201c;Purdue', 'Board', 'SPA', 'own;\\n  &', 'x201c;held', '\\n  &', 'including:\\n  &#x2022;the', 'Finance', 'approved.\\n  &', 'included.7\\n       &', 'the Stock Purchase Agreement', 'Sublease Agreement', 'Novosteo\\', 'IPR&amp;D', 'x2022;refuse', 'SaleAssets', 'the Purdue Agreement', 'Stock Purchase Agreement', 'patents;\\n  &#x2022;issued', 'Accounting Standards Codification', '\\n        &', 'the &#x201c;Purchase', 'candidates;\\n  &#x2022;inability', 'facilities;\\n  &#x2022;seize', 'DSP', 'EryDel', 'Nasdaq Listing Rule 5450(a)(1', 'Nasdaq', '\\n  Interest Income\\n  Interest', '\\n    &'}"
QNRX,"{'ProceduresWe', 'The License Agreement', 'ContentsResults of Operations &', 'Restated Articles of Association of Quoin Pharmaceuticals Ltd.', 'Quoin Pharmaceuticals Ltd.', 'RESEARCH', 'IR', 'No &#9744;&#8203;Indicate', 'the Securities and Exchange Commission', 'European Union', 'the Current Report on Form 8-K', 'Consolidated Financial StatementsSeptember', 'Skinvisible, see &#8220;Research', 'Quoin&#160;Inc.', 'Annex', 'FDA', 'PHARMACEUTICALS', 'COMMITMENTSResearch', 'the Acquisition Agreement', 'the February Offering', 'US Treasury', 'Distribution Agreement', 'NDA', 'Quoin Inc.', 'SEC', 'Queensland University of Technology', 'Company', 'IN-LICENSED TECHNOLOGYPolytherapeutics', 'Therapeutics Inc.', 'the February Purchase Agreement'}"
QSI,"{'Form S-3', 'QUANTUM', 'Exhibit 32.1', 'CONDENSED', '\\n                   ', 'respectively.&#160', 'the Technology and Services Exchange\\n', 'the New Collaboration', 'Next-Generation Protein', 'the &#8220;Shelf Registration', 'the Securities and Exchange Commission', '\\nThe Company', 'the Technology and Services Exchange', 'The New Collaboration', 'The\\n              Company', 'Carbon&#8482', '\\n              ', 'Dividend income\\n\\n    &', 'Majelac', 'the Interactive Data File', 'RELATED PARTY TRANSACTIONS\\n\\n        \\n&#160;\\n\\n        \\n          \\nThe Company', 'Quantum-Si Incorporated', 'RSU', 'Protein Evolution, Inc. (&#8220;PEI&#8221', 'PEI', 'The Private Warrants', 'liabilities\\n\\n    &#160;\\n\\n    &#160;\\n\\n', 'Quantum-Si\\n\\n\\n\\n\\n\\n\\n      Incorporated', 'EDA', 'the Shelf Registration Statement', 'Q-SI Operations Inc.', 'Company', 'Evercore Group', 'the Securities Exchange Act', 'QUANTUM-SI', 'securities\\n\\n    &#160;\\n\\n    &#160;\\n\\n', 'the Sarbanes-Oxley Act', 'compensation\\n\\n    &#160;\\n\\n    &#160;\\n\\n', 'Significant Accounting', 'Protein Engineering Collaboration', 'ARTSA', '\\n              Management', 'Weighted', 'Protein Evolution,\\n        Inc.'}"
QTRX,"{'ASC', 'bonds&#8203', 'the Abbott License Agreement', 'thousands):&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;As', 'the &#8220;UltraDx Agreement', 'costs&#8203', 'years)&#8203;5.1&#8203;&#8203;5.5 &', 'the Consolidated Balance', 'the Harvard License Agreement', 'the Sarbanes-Oxley Act of', 'the Consolidated Balance Sheets', 'Simoa', 'the Tufts License Agreement', 'Harvard University', 'Financial Officer&#8203;&#8203;&#8203;(principal', 'the Securities Exchange Act', 'UltraDx Limited', 'NetOther', 'Consolidated Financial Statements', 'Economic Security Act', '1,234&#8203;$ &#', '% - 3.9%&#8203;&#8203;5.2% - 5.5%&#8203;&#8203;0.7% - 3.9%', 'AdministrativeSelling', 'Tufts', '30,857&#160;$', 'Vandana Sriram', 'Related Matters', 'Capital ResourcesOur', '% &#8722', 'Harvard', 'ContentsSet', 'NIH', 'the Coronavirus Aid, Relief, and', 'Note 3 &#8722', 'Abbott License Agreement', 'Company', '56,874&#8203;&#8203; &', 'LeasesOperating', '357&#8203;$ &#8212;&#8203;$ &', '126,449&#8203;&#8203; &#8212;&#8203;&#8203', 'Principal Financial Officer', 'CommitmentsThe', 'this Quarterly Report on Form 10-Q.', 'the Stratec Supply Agreement', 'Restated Certificate of Incorporation.&#8203;&#8203;&#8203;8-K&#8203;12/15/2017&#8203;001', 'Vandana Sriram&#8203;&#8203;&#8203;Vandana', 'the U.S. Department of Health and Human Services', 'NetIncome', 'Mass General Brigham', 'ContentsService', 'the Consolidated Statements of Operations', 'the UltraDx Agreement', 'Tufts University', 'UltraDx', '35,587&#8203;&#8203; &#8212;Total', 'Abbott', 'RevenueThe Company', 'Note 2 &#8722', 'ARCH Venture Partners', 'the Sarbanes-Oxley Act', 'Research services &', 'September&#160;30,&#160;2022', 'Note 13 &#8722', 'the Consolidated Financial Statements', 'ESPP', 'the Interactive Data File', '499&#8203;$ &', 'Rapid Acceleration of Diagnostics (&#8220;RADx&#8221', '126,449&#8203;&#8203; &#8212;Total financial assets$ 305,032&#8203;$', 'Related Party Transactions', 'Fair Value of Financial InstrumentsRecurring Fair Value MeasurementsThe', 'Related Party', 'Significant Accounting Policies', '7,6412028&#8203;&#8203', 'SEC', '35,587&#8203;&#8203; &#8212;&#8203;&#8203', 'the Company&#8217;s Board of Directors.&#8203;Cost', 'liabilities&#8203;As', 'Page Interactive Data File', 'the Principal Executive Officer', 'Related Matters Disaggregated'}"
QURE,"{'candidates;&#9679;a', 'HemB SPV', 'ContentsThe U.S.', 'Reorganization', 'Principal Executive Officer', 'the Private Securities Litigation Reform Act', 'the Annual Report', 'AMT Therapeutics Holding N.V.', 'this Quarterly Report on Form 10-Q', 'Amyotrophic Lateral Sclerosis', 'EU', 'EUR', 'Sarbanes-Oxley', 'net&#8203;&#8203', 'the CSL Behring Agreement', 'the Securities Exchange Act', 'B.V.', 'the Royalty Financing Agreement the Company', 'ContentsFor', 'Consolidated Financial Statements', 'Medicare', 'Congress', 'the Securities and Exchange Commission', '34,801&#8203;&#8203', 'GDPR', 'ContentsComparison', 'FDA', 'ContentsThe', 'Risks Related', 'ContentsMoreover', 'Company', 'HEMGENIX&#174', 'CSL', '9Royalty Financing Agreement &', 'IBC', 'ContentsRegulatory', 'CSL Behring LLC (&#8220;CSL Behring&#8221', 'SAS', 'Consolidated Statements of Operations', 'ESG', 'BMS', 'Principal Financial Officer', 'this Quarterly Report on Form&#160;10-Q', 'CandidatesOur', '7,608&#8203;&#8203; &#8212;&#8203;&#8203', 'Consolidated Statements of Cash Flows', 'Good Clinical Practice', 'License', 'IRB', 'B.V. (&#', 'the Development of Our Product', 'EUR 10.0 million', '2022&#8203;&#8203;(in', 'ContentsOur', 'plans&#8203;&#8203', '1,290&#8203;$ &', 'the EU Clinical Trials Regulation', 'the Sarbanes-Oxley Act', 'the CSL Behring Agreement.&#8203;Financing&#8203;Royalty Financing', 'asset&#8203;As', '6,596&#8203;$ &#', 'StatementsuniQure', 'the Royalty Financing Agreement', 'the Securities and Exchange Act', 'Results of Operations (&#8220;MD&amp;A&#8221', 'DSMBs', 'CSL Behring', 'CSL Behring LLC (&', 'L.P. (the &#8220;Purchaser&#8221', 'Consolidated Statements', 'Qualitative Disclosures', 'Liability', 'Regulation S-K.&#8203;Item 6.Exhibits&#8203;See', 'the Commercialization and License Agreement', 'the Royalty Financing Agreement &', 'Bristol-Myers Squibb', 'ContentsCommitments', 'Employee Matters', 'expenses&#8203;&#8203', 'EUR 87.0 million', 'Issuer Purchases of Equity', 'Inline Extensible Business Reporting Language', 'SEC', 'BLA', 'respectively&#8203;&#8203', 'ContentsEXHIBIT INDEX&#8203;&#8203;&#8203;10.1* tTermination and Consulting Agreement', 'Consolidated Balance Sheets', 'the Foreign Corrupt Practices Act', 'effects&#8203', 'FINANCIAL INFORMATION&#8203;Item', 'provisions.&#8203'}"
RAIN,
RANI,"{'LLC', 'Quality System Regulations (&#34;QSRs&#34', 'the RMS-ICL Service Agreement', 'Contractual Obligations', 'Rani Therapeutics Holdings', 'ExhibitsThe', 'Rani Management Systems', 'TRA', 'H.C. Wainwright &amp', 'License and Supply Agreement with Celltrion', 'ProceduresUnder', 'the Securities Exchange Act', 'LLC-ICL Service Agreement&#34', '32.1*&#134;\\n     &', ': &#x2022;expenses', 'Principal Financial Officer Pursuant', 'InCube Labs', 'or39\\n   &', 'BKM South Bay 240', 'The European Patent Office', 'months&#x2019', 'The Registration Rights Agreement', 'ICL', 'the &#x201c;Rani', 'the Securities and Exchange Commission', 'the &#x201c;Maturity Date&#x201d', 'Rani Management Services, Inc. (&#x201c;RMS&#x201d', 'Organizational TransactionsThe Company', 'FDA', 'Tax Receivable', 'the &#x201c;Organizational Transactions&#x201d;):&#x2022;Amended', 'Rani Therapeutics', 'the Amended and Restated Employment Agreement', 'Novo Nordisk', 'Company', 'the Rani LLC Agreement', 'Celltrion&#x2019;s', 'the Sales Agreement (&#', 'Adopted Pursuant to Section 302', '29,323\\n         &', 'GLP', 'Cantor Fitzgerald &amp', 'RaniPill HC', 'Organizational Transactions', 'this Quarterly Report on Form 10-Q.', 'The Loan Agreement', 'The Non-Exclusive License Agreement', 'Avenue Venture Opportunities Fund', 'Rani LLC', '2022\\n         &', 'the Mir Agreement', 'The Mir Agreement', 'These Tax Receivable Agreement', 'LLC (&#x201c;Rani LLC&#x201d', 'the Continuing LLC Owners (Note 2', 'the &#x201c;Exchange', 'Registrant', '26\\n   &', 'The Tax Receivable Agreement', 'the Sarbanes-Oxley Act', 'IPO', 'Agents', 'Organization and Nature of Business Description of Business Rani Therapeutics Holdings, Inc. (&#x201c;Rani', 'party.&#160;Tax Receivable AgreementCertain', 'Celltrion', 'Rani Management Services, Inc. (&#', 'Form S-3', 'RaniPill', 'the Amended and Restated Exclusive License Agreement', 'the Loan Agreement', 'ATM', 'CommitmentsExcept', 'LLCService Agreements', 'the Registration Rights Agreement', 'European Patent No', 'the Intellectual Property Agreement', 'the Tax Receivable Agreement', 'LeasesThe Company', 'SEC', 'x201c;Loan', 'to:&#x2022;seek', 'License and Supply Agreement', 'RMS', 'the Registrant&#x2019;s Registration Statement', 'the 43\\n   &', 'the Continuing LLC Owners'}"
RAPT,"{'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n  &#x2022;variations', '\\n', 'premiums.\\n', 'EEA', '\\n  &#x2022;having', '\\n    External', 'Personal Information Protection Act', 'programs.\\n', 'Financial Instruments&#x2014;Credit Losses', '\\n  &#x2022;conditions', 'Indicate', 'UNITED STATES', 'Codification Improvements to Topic 326', 'CPRA', '\\n    Research', 'the Financial Accounting Standards Board', 'Thailand&#x2019;s Personal Data Protection Act', 'RAPT Therapeutics, Inc.', 'Taiwan&#x2019;s Personal Data Protection Act', 'AbbVie', '0001673772Q3--12-31falsehttp://fasb.org/us-gaap/2023#AccountingStandardsUpdate201613Member0001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMember2023-09-300001673772rapt:AtTheMarketMember2022-01-012022-09-300001673772us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001673772us-gaap:RetainedEarningsMember2023-07-012023-09-300001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001673772us-gaap:EmployeeStockOptionMemberrapt:TwoThousandNineteenEquityIncentivePlanMember2023-09-300001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMember2023-07-012023-09-300001673772us-gaap:AdditionalPaidInCapitalMember2022-12-310001673772us-gaap:EquipmentMember2022-12-310001673772us-gaap:CommonStockMember2023-04-012023-06-3000016737722022-04-012022-06-300001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMember2020-04-300001673772us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000016737722022-07-012022-09-300001673772us-gaap:RetainedEarningsMember2023-04-012023-06-300001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001673772us-gaap:FurnitureAndFixturesMember2023-09-300001673772rapt:PreFundedWarrantsIssuedAndOutstandingMember2023-09-300001673772us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-3100016737722022-11-3000016737722023-09-300001673772us-gaap:AdditionalPaidInCapitalMember2023-09-300001673772rapt:SalesAgreementMemberrapt:AtTheMarketMember2023-07-012023-09-300001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMembersrt:MaximumMember2019-12-310001673772us-gaap:RetainedEarningsMember2023-09-3000016737722018-04-300001673772rapt:SouthSanFranciscoAndCaliforniaMember2022-11-3000016737722022-09-300001673772rapt:TwoThousandNineteenEquityIncentivePlanMemberrapt:SharesAvailableForFutureGrantsMember2023-09-300001673772us-gaap:RetainedEarningsMember2022-09-300001673772us-gaap:CommonStockMember2022-01-012022-03-3100016737722022-12-310001673772us-gaap:LeaseholdImprovementsMember2023-09-300001673772rapt:TwoThousandNineteenEquityIncentivePlanMemberrapt:RestrictedStockUnitsIssuedAndOutstandingMember2023-09-300001673772us-gaap:EquipmentMember2023-09-300001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000016737722023-01-012023-09-3000016737722018-04-012018-04-3000016737722015-05-012015-05-310001673772us-gaap:RetainedEarningsMember2023-03-310001673772us-gaap:CommonStockMember2021-12-310001673772us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001673772us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001673772us-gaap:EmployeeStockOptionMemberrapt:TwoThousandNineteenEquityIncentivePlanMember2022-01-012022-12-310001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMember2023-01-012023-09-300001673772srt:MaximumMemberrapt:AtTheMarketMember2023-01-012023-09-300001673772us-gaap:CommonStockMember2022-07-012022-09-300001673772rapt:AtTheMarketMember2023-01-012023-09-300001673772rapt:OptionsIssuedAndOutstandingMemberrapt:TwoThousandNineteenEquityIncentivePlanAndTwoThousandFifteenStockPlanMember2023-09-300001673772rapt:CommonStockOptionsIssuedAndOutstandingMember2023-01-012023-09-300001673772us-gaap:CommonStockMember2023-09-300001673772us-gaap:AdditionalPaidInCapitalMember2023-03-310001673772rapt:TwoThousandNineteenEmployeeStockPurchasePlanMember2023-09-3000016737722023-01-012023-03-310001673772us-gaap:ComputerEquipmentMember2023-09-300001673772us-gaap:CommonStockMember2022-03-310001673772rapt:SalesAgreementMemberrapt:AtTheMarketMember2023-01-012023-09-300001673772us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001673772us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001673772us-gaap:CommonStockMember2022-04-012022-06-3000016737722022-01-012022-09-300001673772us-gaap:CommonStockMember2022-09-300001673772us-gaap:RetainedEarningsMember2022-04-012022-06-300001673772rapt:TwoThousandNineteenEquityIncentivePlanMember2023-09-300001673772rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember2022-01-012022-09-300001673772us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-09-300001673772us-gaap:EmployeeStockOptionMemberrapt:TwoThousandNineteenEquityIncentivePlanMember2023-01-012023-09-300001673772us-gaap:RetainedEarningsMember2021-12-310001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMember2019-12-3100016737722015-05-310001673772us-gaap:AdditionalPaidInCapitalMemberrapt:AtTheMarketMember2022-07-012022-09-300001673772rapt:AtTheMarketMember2022-07-012022-09-300001673772us-gaap:RetainedEarningsMember2022-03-3100016737722022-03-310001673772us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001673772us-gaap:ComputerEquipmentMember2022-12-310001673772us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310001673772us-gaap:CommonStockMember2023-01-012023-03-310001673772rapt:SouthSanFranciscoAndCaliforniaMember2015-05-310001673772us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2023-09-300001673772us-gaap:RetainedEarningsMember2022-07-012022-09-300001673772us-gaap:EmployeeStockMember2022-01-012022-09-3000016737722023-03-310001673772us-gaap:EmployeeStockOptionMemberrapt:TwoThousandNineteenEquityIncentivePlanMember2022-12-310001673772us-gaap:CommonStockMember2022-06-300001673772srt:MaximumMemberrapt:AtTheMarketMember2023-08-172023-08-1700016737722022-11-302022-11-300001673772us-gaap:RetainedEarningsMember2023-01-012023-03-310001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001673772us-gaap:FurnitureAndFixturesMember2022-12-3100016737722022-01-012022-03-310001673772us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMember2022-12-3100016737722023-06-300001673772us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-09-300001673772rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember2022-01-012022-09-300001673772us-gaap:AdditionalPaidInCapitalMember2022-03-310001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001673772us-gaap:AdditionalPaidInCapitalMember2022-06-300001673772us-gaap:LeaseholdImprovementsMember2022-12-310001673772us-gaap:EmployeeStockMember2023-07-012023-09-300001673772us-gaap:CommonStockMember2023-06-300001673772us-gaap:AdditionalPaidInCapitalMember2022-09-300001673772rapt:EstimatedSharesIssuableUnderEmployeeStockPurchasePlanMember2023-01-012023-09-300001673772us-gaap:RetainedEarningsMember2022-12-310001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMember2022-07-012022-09-300001673772us-gaap:AdditionalPaidInCapitalMember2021-12-3100016737722022-06-3000016737722021-12-310001673772rapt:CommonStockOptionsIssuedAndOutstandingMember2022-01-012022-09-300001673772us-gaap:EmployeeStockMember2023-01-012023-09-300001673772us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001673772us-gaap:RestrictedStockUnitsRSUMemberrapt:TwoThousandNineteenEquityIncentivePlanMember2022-12-310001673772us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-3000016737722023-07-012023-09-300001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001673772us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001673772rapt:CollaborationAndLicenseAgreementMemberrapt:HanmiPharmaceuticalCompanyLimitedMember2022-01-012022-09-300001673772us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001673772us-gaap:CommonStockMember2023-03-310001673772us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001673772us-gaap:EmployeeStockMember2022-07-012022-09-300001673772us-gaap:RetainedEarningsMember2022-01-012022-03-310001673772us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001673772us-gaap:CommonStockMember2022-12-310001673772us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001673772us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001673772rapt:AtTheMarketMemberus-gaap:CommonStockMember2022-07-012022-09-300001673772us-gaap:RetainedEarningsMember2023-06-300001673772us-gaap:RestrictedStockUnitsRSUMemberrapt:TwoThousandNineteenEquityIncentivePlanMember2023-01-012023-09-300001673772us-gaap:AdditionalPaidInCapitalMember2023-06-300001673772us-gaap:RetainedEarningsMember2022-06-300001673772us-gaap:RestrictedStockUnitsRSUMemberrapt:TwoThousandNineteenEquityIncentivePlanMember2023-09-300001673772srt:MaximumMemberrapt:SalesAgreementMemberus-gaap:CommonStockMemberrapt:AtTheMarketMember2023-08-172023-08-170001673772rapt:RestrictedStockUnitsRSUsSubjectToFutureVestingMember2023-01-012023-09-300001673772us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-09-3000016737722023-11-070001673772us-gaap:CommonStockMember2023-07-012023-09-3000016737722023-04-012023-06-300001673772us-gaap:FairValueInputsLevel2Memberus-gaap:AssetBackedSecuritiesMember2022-12-310001673772us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001673772rapt:AtTheMarketMember2023-08-17xbrli:pureiso4217:USDxbrli:sharesutr:sqftxbrli:sharesiso4217:USD\\n  &', '\\n  &#x2022;adding', '\\n  &#x2022;obtaining', '\\n  &#x2022;unfavorable FDA', 'Property and Equipment Property', 'No &#9744', 'x2022;high', 'Pfizer', 'Hong Kong&#x2019;s Personal Data (Privacy) Ordinance', '\\n  &#x2022;inadequate', 'x201c;Risk', 'Medicaid', 'Medicare', '\\n  &#x2022;any', 'FDA', '\\n  &#x2022;clinical', '\\n        Laboratory equipment\\n', 'the Hanmi Agreement', '30\\n', '\\n  &#x2022;changes', 'Roche/Genentech', '\\n  &#x2022;regulatory', 'AstraZeneca', 'Company', 'management&#x2019;s attention', 'USPTO', 'UK&#x2019;s', 'Co. (&#x201c;Cantor&#x201d;)', '\\n    &#', 'the Delaware General Corporation Law', 'Cantor Fitzgerald &amp', 'ASU', '\\n  ', 'UK&#x2019;s International Data Transfer Agreement / Addendum', '\\n  &#x2022;recruiting', 'Item 10 of Regulation S-K', 'Merck', '\\n  &#x2022;the', '\\n  &#x2022;disruption', 'Hanmi Pharmaceutical Ltd.', 'Company, Incorporated (', '\\n  &#', 'pandemics.\\n  &#x2022;If', '\\n  Outside', 'the Hanmi Territory', 'Amgen', 'Kyowa Hakko Kirin', '\\n  &#x2022;difficulty', '\\n  &#x2022;additions', '\\n  &#x2022;negative', 'Leerink Partners', 'Research and Development Expenses \\n', '47\\n', 'Equity Incentive Plan\\n        &', 'Comparison', '\\n  &#x2022;impairment', '\\n  &#x2022;our', 'products.\\n  &#x2022;Our', 'Form S-3', 'FLX475)\\n    &', '\\n  &', 'ATM', 'Investigational New Drug Applications', '\\n  &#x2022;delays', '44\\n', 'Cantor', 'retain.\\n  Components of Operating Results \\n', 'RPT193)\\n    $', 'Healthcare', 'Plan\\n        &', 'Bristol-Myers Squibb', '\\n        &', 'SEC', 'Stifel, Nicolaus &amp', 'Collaboration and License Agreement', 'Novartis', 'Sanofi/Regeneron', '\\n  &#x2022;manufacturing', '\\n  &#x2022;exposure', '\\n  &#x2022;failure', 'Hanmi', '\\n  &#x2022;strategic', 'the European Union', '\\n    Internal', '\\n    &'}"
RARE,"{'ASC', 'UX701', 'Reliance', 'License and Technology Access Agreement', 'KKC', 'candidates;\\n  &#x2022;the', 'Crysvita globally.\\n  &#', 'Principal Executive Officer', 'IOI Oleo', 'the Annual Report', 'LC-FAOD', 'Haupt Pharma AG', 'EU', 'Indicate', 'Rentschler', 'CPRA', 'Solid and Arcturus Therapeutics Holdings', 'HoFH', 'the Securities Exchange Act', 'NOL', '\\n    &#160;&#160;&#160;&#160;Gene', 'Jefferies', 'candidates;\\n  &#x2022;KKC', 'COVID-19', '\\n  &#x2022;prohibit', 'Amended &', '\\n  &#x2022;provide', 'compensation\\n    &', 'Arcturus and Solid', 'REGENXBIO', 'Latin America.15\\n', 'KHK', 'AAV9', 'Anti-Kickback Statute', 'Deferred Compensation Plan The Company', '\\n  &#x2022;sufficient', '\\n  &#x2022;publicity', 'Director(Principal Executive', 'manufacturers&#x2019', 'distributors;\\n  &#x2022;our', 'Diluted', 'OMERS', 'Crysvita', 'the future;\\n  &#x2022;the', 'Regeneron Pharmaceuticals', 'GDPR', 'Business &#x2013; Government', '\\n  &#x2022;specify', 'FDA', 'others.\\n  The', 'GMP', 'ArrangementsThe Company', 'and\\n  &#', '\\n  &#x2022;relative', 'HIPAA', 'MPS', 'Company', 'Daiichi Sankyo Co., Ltd.', 'management&#x2019;s attention', 'and\\n  &#x2022;the', 'USPTO', 'the Unitholder Option Agreement', 'OI', '\\n  &#x2022;impose', 'Evkeeza for HoFH', 'the U.S. Evkeeza', 'the California Privacy Rights Act', '70\\n', '\\n  &#x2022;seize', '\\n  &#x2022;KKC', 'Arcturus', 'the California Consumer Privacy Act', 'the Delaware General Corporation Law', 'the European Commission', 'ESG', 'CMS', 'Principal Financial Officer', 'Pinnacle PCL Platform', 'Contracts with Customers', 'the Condensed Consolidated Balance Sheets', '\\n  &#x2022;the', 'Mereo&#x2019;s', 'strategy;\\n  &#x2022;our', 'processes;\\n  &#x2022;developments', 'Dojolvi', '\\n  &#', 'Kyowa Kirin Co., Ltd.', 'REGENX', 'Upfront', 'Registrant', '\\n  &#x2022;require', 'plan\\n        &', 'Liabilities for Sales of', 'Kyowa Hakko Kirin Co., Ltd.', 'candidates.\\n  Risks Related', 'Europe;\\n  &#x2022;the', 'Orphan Drug Designation', 'DTX401;\\n  &#', 'XLH', 'the Sarbanes-Oxley Act', 'Regulation S-K', 'reporting.\\n', 'Pinnacle', '\\n  &#x2022;The', '\\n  &#x2022;our', 'operations.\\n  Risks', 'Wilson', 'the License Agreement', 'ULTRAGENYX PHARMACEUTICAL INC', '\\n  &#x2022;We', 'this Quarterly Report', 'Health Insurance Portability', 'Fast Track Designation', 'Regeneron', 'ATM', 'UX053;\\n  &#', 'Cybersecurity', 'UX143', '\\n    Infrastructure\\n    &', 'the Investigational New Drug Application', 'x2022;refuse', 'MAA', 'Daiichi Sankyo', '\\n  &#x2022;suspend', 'Osteogenesis Imperfecta', 'PayableThe Company', 'Pinnacle PCLTM', '\\n  &#x2022;estimates', 'Collaboration and Royalty Revenue', 'Abeona Therapeutics', 'the Condensed Consolidated Statements of Operations', '\\n        &', 'ERP', 'SEC', '\\n  &#x2022;authorize &#x201c;blank', 'TerritoryThe Company', 'UX111', 'efforts;\\n  &#', 'GC', 'the Health Information Technology for Economic and Clinical Health Act', 'the European Union', 'Nasdaq', 'RPI', '\\n    &', 'the Sublicense Agreement', 'Earthquakes'}"
RCEL,"{'ASC', 'LLC', 'Credit Agreement', 'ASU', 'the Lender for an', 'fee.\\n  &#160;\\n', 'this Quarterly Report on Form 10-Q.', 'Release Agreement&#160;The Company', 'TONE', 'the FASB ASC', 'the RECELL System', 'ESPP', 'Plant and Equipment &', '\\n        Laboratory', 'the U.S. Food and Drug Administration', 'EU', 'FDA', 'Performance Obligations &', 'the Condensed Consolidated Financial Statements', 'OrbiMed Advisors', '\\n  &#', 'RSU', 'the Consolidated Statement of Operations', 'the Credit Agreement', 'PMA', 'Indicate', 'depreciation\\n        &', '30\\n', 'Accounting Standards Update', '\\n    Research', 'x201c;Cybersecurity Risk Management', '\\n        &', 'SEC', 'Company', 'RECELL', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Financial Information \\n', 'agreement.\\n  &', 'FDIC', '\\n    Interest expense\\n    &', 'indebtedness.\\n  &', 'M3 Group', '160;In', 'RECELL System', '\\n  &#160;\\n', 'the European Union', '\\n    &', 'COSMOTEC Company Ltd (&#34;COSMOTEC&#34', 'the &#x201c;Warrant&#x201d'}"
RCKT,
RCM,
RDHL,
RDNT,"{'the Truist Term Loan', 'LLC', 'ContentsPART II &#8211', 'ExpensesTotal', 'Los Angeles Imaging Group', 'RADNET', 'Truist Term', 'NOTE 3 &#8211', 'Accounting PronouncementsWe', 'First Lien Net Leverage RatioTerm', 'the Barclays Revolving Credit Facility', 'Eurodollar Rate', 'the Securities Exchange Act', 'RadNet, Inc.', 'COVID-19', 'the Restated Credit Agreement', 'the Truist Restated Credit Agreement', 'DeepHealth', 'Barclays Revolving Credit Facility', 'FASB', 'interestLos Angeles Imaging Group', 'EstimatesThe', 'Internal Control', 'Capital ResourcesThe', 'Medicaid', 'thousands):&#160;As', 'Medicare', 'liabilities)230,919&#160;(41,932)Stockholders\\', 'the Truist Revolving Credit Facility', 'OperationsImaging Centers$44,743&#160;$13,752&#160;$90,541&#160;$43,880&#160;AI(1,492)(6,828)(16,178)(19,119)Total', 'AI Segment2,499&#160;4,462&#160;10,283&#160;12,253&#160;Adjusted EBITDA', 'Group', 'the World Health Organization', 'ContentsThe', 'AI', 'the Alternate Base Rate', 'PSOs', 'Company', 'Montclair Radiological Associates', 'the Second Amended and Restated Guaranty and Security Agreement', 'TO RADNET, INC', 'Second Amended and Restated First Lien Credit', 'Consolidated Statements of Operations', 'Truist Term Loan$&#8212;&#160;$850,405&#160;$&#8212;&#160;$850,405&#160;$853,063&#160;&#160;As', 'Center Segment Revenue399,081&#160;349,144&#160;1,188,849&#160;11888490001,043,129&#160;AI Segment Revenue2,887&#160;900&#160;7,398&#160;3,056&#160;Total', 'the Restated Credit and Term Loan Agreement', 'Heart Lung Imaging Limited', 'the Truist Restated Credit and Term Loan Agreement', 'AI Segment$57,920&#160;$45,772&#160;$166,531&#160;$135,241&#160;EBITDA Losses', 'Credit Facilities', 'the Credit Agreement', 'First Lien Term Loans(9,563)(11,127)Truist Term Loan Agreement', 'Registrant', 'ContentsStaffing', 'ContentsIn ThousandsThree Months Ended September 30,Salaries', 'Alternate Base Rate', 'Truist Revolving Credit Facility', 'the Second Amended and Restated Credit and Term Loan Agreement', 'The Barclays Revolving Credit Facility', 'Recent Accounting', 'Capital', 'ScriptSender', 'RevenuesOur', 'it\\', 'Compensation388&#160;713&#160;1,897&#160;2,119&#160;Depreciation &amp', 'ContentsImaging Center SegmentWe', 'RECENT ACCOUNTING', 'IPR&amp;D', 'Pricing Level IV', 'OperationsThe', 'CREDIT FACILITIES', 'SOFR', 'Revolving Credit FacilityThe Barclays Revolving Credit Facility', 'the Truist Restated Credit and Agreement', 'Second Amended and Restated Revolving Credit and Term Loan AgreementOn', 'Financial Reporting&#160;There', 'Revolving Credit FacilitiesAssociated', 'ContentsAdjusted EBITDA', 'GOODWILL - Goodwill at September&#160;30'}"
REGN,
RENB,
REPL,"{'ASC', 'current$1,138&#160;$1,118&#160;Finance', 'a Master Clinical Trial Collaboration and Supply Agreement', 'Contentscontract', 'Unrestricted Cash', 'Biologics License Application', 'the Company.2017 Equity Compensation', 'ContentsIn February 2018', 'CPRA', 'ReferenceNumberExhibit DescriptionFormDateNumber10.1&#8224;*Employment Agreement', 'Treasury', 'U.S. Government Agency', 'ARTACUS', 'Regeneron Pharmaceuticals,&#160;Inc', 'AmgenIn August 2023 the Company', 'ContentsWe', 'COVID-19', 'the Registrant.10.3&#8224;*Restricted Stock Unit Agreement', 'HCC', 'SVB Securities LLC', 'the Securities and Exchange Commission', 'Medicare', 'CRC', 'FDA', '1A &#8220;Risk Factors&#8221', 'Loan', 'ContentsThe', 'REMS', 'ContentsMoreover', 'Incyte Corporation', 'Company', 'the Hercules Loan Agreement', 'the California Privacy Rights Act', 'Replimune Limited', 'the Term Loan Facility', 'Amgen\\', 'CRO', 'Replimune Group, Inc.', 'BMS', 'pronouncementsA', 'Loan Agreement', 'Employment Agreement', 'The Loan Agreement', 'Roche Holding AG', 'the Securities Exchange Commission', 'Roche', 'yield0&#160;%0&#160;%0&#160;%0&#160;%Stock', 'Bristol Myers Squibb Company', 'Collaborative Arrangements', 'Amgen', 'Lease CostsResearch', 'the Settlement Agreement', 'Omnibus Incentive Compensation', 'investmentsUS Government Agency', 'Plan&#8221', 'the Sarbanes-Oxley Act', 'Leerink Partners', 'Inctye', 'ContentsNumber', 'the Sarbanes-Oxley Act of 2002', 'Incyte', 'the Loan Agreement', 'ContentsAdditionally', 'this Quarterly Report', 'Hercules Capital, Inc.', 'Regeneron', 'European Union', 'Regeneron Pharmaceuticals, Inc.', 'Good Manufacturing Practice', 'the Risk Factor captioned &#8220;We', 'INCB99280', 'Contentswe', 'U.S. Treasury', 'IGNYTE', 'SEC', 'the ""2023 Sales Agreement', 'BLA', 'the European Union'}"
REVB,
RGC,
RGEN,
RGLS,"{'RNA', 'LLC', 'PROCEDURESDisclosure Controls', 'ProceduresWe', 'the Loan Agreement', 'HHS', 'Therapeutics Inc.Date', 'Oxford Finance', 'Alnylam', 'Loan Agreement', 'Amendment of Amended and Restated Certificate of Incorporation', 'Restated Certificate of Incorporation of the Registrant', 'Medicare', 'ARE-SD Region', 'EEA', 'Significant Accounting PoliciesBasis', 'The Loan Agreement', 'the ""Term Loan', 'LeasesRemaining 2023$196&#160;2024800&#160;2025824&#160;2026277&#160;Total', 'deoxyribonucleic', 'MAD', 'EU', 'the Stock Sales Agreement', 'the Sanofi Agreement', 'FDA', 'the Term Loan', 'the U.S. Treasury', 'Internal Control Over Financial Reporting Our', 'the Campus Point Premises', 'Financial Instruments-Credit', 'The Nasdaq Capital Market', 'CPRA', 'U.S. Treasury', 'Registrant', 'NDA', 'SEC', 'Designation of Preferences, Rights and Limitations', 'OPERATIONSComparison', 'the Securities Exchange Act', 'the Certificate of Designation of Preferences, Rights and Limitations', 'the European Economic Area', 'GDPR;&#8226;the California Consumer Privacy Act', 'InvestmentsHistorically', 'the FASB issued&#160;ASU&#160;2018-19', 'trials;&#8226;we', 'the Sarbanes-Oxley Act', 'Cris Calsada&#160;Cris Calsada&#160;Chief Financial Officer&#160;(Principal Financial Officer)60\\n\\n\\n', 'the ""Eleventh Amendment', 'Results of Operations', 'the California Privacy Rights Act', 'collaboration;&#8226;a', 'Amendment of Amended and Restated Certificate of Incorporation of the Registrant', 'Sanofi', ': &#8226;the'}"
RGNX,"{'REGENXBIO', 'BofA Securities, Inc.', 'The Settlement Agreement', '\\n  Commission File', '9804 Medical Center Drive', 'LLC', 'the Penn Letter Agreement', 'Related Party TransactionsFOXKISER', 'the Company&#x2019;s Board of Directors', 'AMD', 'NAV Technology', 'capacity;\\n  &#x2022;the', 'REGENXBIO Inc.\\n    &', '\\n      &#', 'AveXis, Inc.', 'technologies.\\n  Many', 'NAV Technology Licensees', 'this Quarterly Report on Form 10-Q.', 'candidates;\\n  &#x2022;the', '\\n    &#', 'recognized\\n        &', 'AAV8 vector', 'x2014;\\n        &', 'Biologics License Application', 'HCR', 'the future;\\n  &#x2022;the', 'ATM Equity OfferingSM', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'the Royalty Purchase Agreement', 'non-current:\\n        &', 'SMA', 'Healthcare Royalty Management', 'of:\\n  &#x2022;salaries', 'and\\n  &#', 'VEGF', 'AbbVie Global Enterprises Ltd.', 'Charter)\\n  &#160;\\n', 'candidates;\\n  &#x2022;our', 'The Penn Letter Agreement', 'period.\\n  Research and Development Expense\\n', 'the Settlement Agreement', '\\n        &', 'SEC', 'collaborations;\\n  &#x2022;the', 'Company', 'the following:\\n  &#x2022;an', 'Restricted CashRestricted', 'The Private Placement', 'AbbVie Inc.', 'the Pledged Royalties', 'AbbVie', 'Novartis Gene Therapies', 'Additional Capital Requirements\\n', 'the Sarbanes-Oxley Act', 'organization)\\n    &#160;\\n', 'the Novartis License', 'NAV', '6,636\\n        &', 'and\\n  &#x2022;direct', 'Interest Expense\\n  Interest', 'the Penn License', 'SecuritiesThe', 'the University of Pennsylvania', '\\n    &', 'and\\n  &'}"
RIGL,"{'ASC', 'If\\nand', 'LLC', 'May&#160;9', 'value:\\n      &', 'Option Units', 'the Special Meeting', 'operations.\\n      &#160;\\n', 'Fair Value Hierarchy', 'the Initial Public Offering.\\n      &', 'the Private Placement Warrants\\nand Forward Purchase Agreement', 'Private Placement Warrants', 'the Public Warrants', 'For\\nfurther', 'this Quarterly Report on Form 10-Q.\\n      &', 'The Public Warrants', 'Liabilities Measured at Fair Value', 'Rigel Resource Acquisition Holding', 'operations.\\n      &', 'the Initial Public Offering', 'Initial Business\\n      Combination', 'the Initial Public Offering\\n      ', 'the Forward Purchase Agreement', 'agreement.\\n      &', 'national securities exchange', 'Trust', 'August&#160;9,\\n2023', 'a Business Combination', 'the Redemption Limitation', 'Articles of Association', 'warrants:\\n      &', 'SEC', 'the Public and Private Warrants', 'the\\n      Initial Public Offering', 'the reclassification.\\n      &', 'Company', 'the Private Placement Warrants', 'Units', 'realized.\\n      &', 'Founder Shares', 'Articles of Association of the Company', 'the Second Extension Loan', 'ASC Topic', 'Public Warrants', 'Public Warrants:\\n      &', '\\n    &', 'and\\n         \\n      \\n      &', 'operations.\\n      &#'}"
RLAY,"{'Certificate of Incorporation and Bylaws', 'API', 'EC&#x2019;s', 'LLC', 'D.E.', 'EC', 'and\\n  &#x2022;Collaborations', 'Exhibits.\\n  &#160;\\n', 'Contingent Milestone Payments\\n        &', 'the Private Securities Litigation Reform Act', 'programs.\\n', 'Phase 4', 'expensive;\\n  &#', 'Genentech.&#34', 'operations.\\n  Obtaining', '\\n    Research', 'See &#34;Risks Related', 'charges;\\n  &#', 'Interim Financial InformationThe', 'ZebiAI Therapeutics, Inc.', 'Our Collaborations &#', 'the Merger Agreement', 'FASB', 'Company\\', 'and\\n  &#x2022;risks', '\\n  &#x2022;product', 'Genentech, Inc.', '\\n  &#x2022;issued', 'Restated Certificate of Incorporation of Relay Therapeutics, Inc.', '\\n  &#x2022;refusal', 'Medicaid', 'candidate;\\n  &#', 'Medicare', 'the Delaware General Corporate Law', 'x2014;\\n        &', 'GDPR', 'companies;\\n  &#x2022;claims', 'FDA', '\\n  &#x2022;clinical', 'ArrangementsThe Company', '\\n  &#x2022;others', 'Amended and Restated Collaboration and License Agreement', 'Risks Related', 'HIPAA', 'Genentech Milestones Paid', 'Company', 'Genentech&#x2019;s', 'Shaw Research', '\\n  &#x2022;injunctions', 'Cowen', 'the Genentech Agreement', 'Our Intellectual Property &', '50\\n', 'Strategic Collaborations &', 'CMS', 'candidates;\\n  &#', 'the DESRES Agreement', 'Contingent Milestone Payments', 'This Quarterly Report on Form 10', '\\n  &#x2022;the', 'the U.S. Department of Health and Human Services', 'policies;\\n  &#x2022;the', '\\n  &#', 'implied &', 'the Trans-Atlantic Data Privacy Framework', 'Registrant', 'RLY-2608', 'CMO', 'D. E. Shaw Research', 'Genentech', 'holds;\\n  &#x2022;fines', '34;Trans-Atlantic Data', 'the Sarbanes-Oxley Act', 'companies&#x2019', 'the Roche Group', '\\n  &#x2022;our', 'Genentech Agreement', 'IDTA', 'Cowen and Company', '\\n  &#x2022;reliance', '\\n  &#x2022;We', 'Other Government Regulations &', 'Fair Value of Contingent ConsiderationIn', 'iii\\n', '\\n  &', 'Genentech, Inc. (&', 'the International Data Transfer Agreement or International Data', 'companies;\\n  &#x2022;assumption', 'Medicaid Services', '\\n  &#x2022;restrictions', 'Healthcare', '\\n  &#x2022;If', 'Adopted Accounting Pronouncements\\n', 'the Collaboration and License Agreement', 'General Risk Factors\\n  Risks Related', '\\n        &', 'SEC', 'Collaboration and License Agreement', 'Our Financial Position and Ability to Raise Additional Capital \\n', 'the Centers for Medicare &', 'operations:\\n  &#x2022;difficulties', '\\n  Litigation', 'Nasdaq', '\\n    &', 'property.\\n', 'Government Regulation &'}"
RLMD,
RLYB,"{'GLP', 'Contentsmilestones', 'Exscientia Limited', 'EyePoint Pharmaceuticals, Inc.', 'LLC', 'Sanofi', 'ContentsOperating Expenses Research and Development Expenses', 'Good Laboratory Practice', 'CMOs', 'administrative20,200&#160;20,897&#160;(697)Total', 'PTE', 'HPP', 'Form S-3', 'Prophylix AS', 'The Sarbanes-Oxley Act', 'EMA', 'Medicaid', 'ContentsLoss On Investment In Joint Venture Loss', 'Medicare', 'Rallybio', 'EEA', 'Rallybio Corporation', 'the U.S. Internal Revenue Code', 'GDPR', 'IPR&amp;D', 'a Committee for Medicinal Products for Human Use', 'EU', 'supply and/or transport materials', 'FDA', '2023).10.2Second Amended', 'EyePoint', 'the Public Company Accounting Oversight Board', 'Good Manufacturing Practice', 'Restated Employment Agreement', 'AbCellera Biologics Inc.', 'FNAIT', 'the Internal Revenue Service', 'EGC', 'others;&#9642;we', 'Condensed Consolidated Statements of Changes', 'ContentsAccordingly', 'Risks Related', 'HIPAA', 'Swedish Orphan Biovitrum AB', 'the U.S. Treasury Department', 'Form S-1', 'SEC', 'REV', 'GCP', 'Company', 'CMO', 'Contentstechnologies', 'IRA', 'Contentsand', 'Amended and Restated Employment Agreement', 'expire;&#9642;we', 'USPTO', 'Condensed Consolidated Balance', 'the Sarbanes-Oxley Act', 'COVID-19', 'AbCellera;&#9642;continue', 'Unaudited Condensed Consolidated Financial Statements11Item', 'Ectonucleotide Pyrophosphatase/Phosphodiesterase 1', 'Affibody AB', 'IPO', 'Form S-1MEF', 'CTA', 'ContentsIn', 'This Quarterly Report on Form 10-Q', 'Cowen', 'ContentsOur OperationsSince', 'Metabolic DisordersIn', 'Qualitative Disclosures About Market'}"
RMTI,
RNA,"{'the Lilly Agreement', 'FASB', 'LLC', 'Cowen and Company', 'ASU', 'ProceduresWe', 'Form S-3', 'Financial Instruments-Credit Losses', 'OperationsComparison', 'SoldExpiration', 'Item 408 of Regulation S-K', 'Research Collaboration and License Agreement', 'the Securities and Exchange Commission', 'Eli Lilly and Company (Lilly', 'AOC 1001', 'Financial Instruments', 'ActivitiesNet', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'the U.S. Food and Drug Administration', 'ContentsContractual ObligationsThe Company', '10203,840&#160;3,036&#160;804&#160;12,957&#160;8,499&#160;4,458&#160;AOC', 'Contentsdate', 'MyoKardia, Inc.', 'Lilly', 'FDA', 'AOC', 'AdministrativeGeneral', 'EquityAmended', 'Bristol Myers Squibb', 'ArrangementTotal Shares', 'MARINA', 'the Quantitative Muscle Testing', 'FlowsThe', 'SEC', 'the Shelf Registration Statement', 'Scientist', 'Eli Lilly', 'ContentsResearch', 'Company', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'MyoKardia', 'the MyoKardia Agreement', 'License and Research AgreementsResearch Collaboration and License Agreement', 'respectively.7.&#160;&#160;&#160;&#160;Commitments', 'IPO', 'Eli Lilly and Company', 'Adopted Accounting'}"
RNAC,"{'ASC', 'Working Capital Loans', 'CONDENSED FINANCIAL STATEMENTSSEPTEMBER&#160;30', 'liability &#8211', '2023&#8203;$ &#', 'Critical Accounting PoliciesThe', 'Private Placement', 'Private Placement Warrants', 'any Sponsor Loan Warrants', 'ExhibitsThe', 'ii)&#160;and', 'the Initial Public Offering', 'Restated Memorandum', 'the Sponsor Loan', 'UncertaintiesManagement', 'inception)&#8203;$ &#8212;&#8203;$ &', 'FAIR VALUE', 'Cayman Islands', 'Principal Executive Officer Pursuant', 'the At-Risk Funds', 'a Business Combination', 'this Quarterly Report.&#8203;&#8203;&#8203;No.&#160;&#160;&#160;&#160;Description of Exhibit&#8203;&#8203;&#8203;3.1&#8203;Amended and', 'Principal Executive Officer Pursuant to Rules', 'SEC', 'the Private Placement Warrants', 'Company', 'Pursuant', 'the Securities Exchange Act', 'ProceduresDisclosure', 'Articles of Association of the Company', 'the Sarbanes-Oxley Act', 'COVID-19', 'the Trust Account', 'Principal Financial Officer Pursuant', 'October&#160;13', '2022&#8203;$ &#', '2023&#8203;$ &', 'Provider AgreementsThe Company'}"
RNAZ,
RNLX,
RNXT,"{'FASB', 'ASU', 'Form S-3', 'the American Recovery and Reinvestment Act', 'the Center for Drug Evaluation and Research', 'RenovoGem', 'the U.S. Small Business', 'us\\nor', 'Dodd-Frank Wall Street Reform', 'SBRT', 'Protection Program (&#8220;PPP&#8221', 'FDA&#8217;s', 'the Court of Chancery of the State of Delaware', 'Financial Instruments&#8212;Credit Losses', 'Medicare', 'Congress', 'the Common Warrants', 'the Consulting Agreement', 'Administrative\\n\\n&#160;\\n\\nGeneral\\nand', 'the State of Delaware', 'The Sarbanes-Oxley Act of', 'FDA', 'collaborator\\nin', 'PPP', 'Company&#8217;s\\ncommon', 'IRB', 'SAP', 'Court', 'study\\nis', 'when\\n', 'Form\\nS-3', 'RenovoCath', 'the State of Delaware.\\n\\n&#160;\\n\\nThe\\nexclusive', 'the Unaudited Condensed Interim Financial Statements\\n    ', 'cover\\nour', 'Direct Offering', 'compensation.\\n\\n&#160;\\n\\nRecently\\nIssued', 'approximately\\n$5 million', 'HIPAA', 'Form S-1', 'SOX', 'Pre-Funded\\nCommon Warrants', 'SEC', 'Common Stock', 'and\\n  \\n    &', 'Company', 'the Securities Exchange Act', 'Financial and Accounting Officer', 'CECL', 'COVID-19', '\\n&#160;\\n\\n\\n\\n\\n\\n    &', 'the Securities Act,\\nand Section', 'factors\\nour', 'IPO', 'Adopted Accounting', 'the European Union', 'Silicon\\nValley Bank', 'Nasdaq', '\\n    &', 'the Registered Direct Offering'}"
ROIV,"{'Fully Diluted', 'API', 'Samsung Biologics Co., Ltd.', 'LLC', 'EC', '397 Public Warrants', 'State', 'decline.\\n\\n      &#160;\\n\\n      ', 'individual.\\n\\n      &#160;\\n\\n      Intellectual', 'the Warrant Agreement', 'MMA', 'the Public Warrants', 'GlaxoSmithKline Intellectual Property Development Ltd.', 'the GSK Agreement', 'EEA', 'the Federal Circuit', 'the Roche Transaction', 'EU', 'PCT', 'the United States Food and Drug Administration', 'the Pfizer Action', 'the Patent Trial and Appeal Board', 'milestones.\\n\\n      &#160;\\n\\n', 'Genevant Sciences Ltd.', 'Pfizer Inc.', 'BPCIA', 'XYQ', 'G (&#8220;IgG&#8221', 'the NovaQuest Agreement', 'Treasury', 'ACA', 'the Securities Exchange Act', 'the Warrant Assumption Agreement', 'Genevant Sciences GmbH', 'OPM', 'the United Kingdom Bribery Act 2010', 'NovaQuest Co-Investment Fund XVII', 'COVID-19', 'NovaQuest', 'us.\\n\\n      &#160;\\n\\n', 'Vants', 'Roivant Sciences Ltd.', 'the Credit Facility', 'Warrants', 'FASB', 'IRB/EC', 'the following:\\n\\n      &#160;\\n\\n', 'Telavant', 'key\\n                personnel.\\n            \\n\\n  \\n\\n\\n\\n       \\n      ', 'Merck Sharp &', 'harmed.\\n\\n      &#160;\\n\\n      Following', 'Medicaid', 'Medicare', 'Congress', 'the ACA.\\n\\n      &#160;\\n\\n      ', 'GDPR', 'the Windsor Agreement', 'FDA', 'the Patent Cooperation Treaty', 'including:\\n\\n      &#160;\\n\\n', 'Welichem Biotech Inc.', 'Japan Tobacco Inc.', 'HIPAA', 'AI', 'Arbutus Biopharma Corp.', 'REMS', 'property.\\n\\n      &#160;\\n\\n', 'the Acuitas\\n        Action', 'FTC', 'Genevant', 'the Private Placement Warrants', 'Company', 'U.S. Bank National Association', 'PHSA', 'USPTO', 'Section', 'Adopted Pursuant to Section 302', 'Ciox Parent', 'Results of\\n        Operations', 'Department of Justice', 'Roche Holdings, Inc. (&', 'L.P.', 'Telavant Holdings, Inc. (&#8220;Telavant&#8221', 'NovaQuest Capital Management', 'the European Commission', 'the future.\\n\\n      &#160;\\n\\n', 'CMS', 'Pipeline', 'it.\\n\\n      &#160;\\n\\n', 'Please see\\n        &#8220;Cautionary', 'Palantir Technologies Inc.', 'the Code.\\n\\n      &#160;\\n\\n', 'Roivant and the Vants', 'Roche', 'Good Clinical Practice', 'Trust Company', 'IRB', 'MG', 'the Earn-Out', '\\n        &#8226;&#160;Telavant', 'FDA&#8217;s Form-483', 'NDA', 'Telavant Holdings, Inc.', 'CMO', 'IRA', 'Rule 144', 'the Sarbanes-Oxley Act', 'Regulation S-K', 'RSL', 'MAM Tapir Lender', 'the Datavant Merger', 'fees.\\n\\n      &#160;\\n\\n      Cost of revenues\\n\\n      &#160;\\n\\n', 'Form S-3', 'the 20,475,875 Public Warrants', 'Glaxo Group Limited', 'VTAMA', 'Acuitas Therapeutics Inc.', 'this Quarterly Report', 'the Montes Archimedes Acquisition Corp.', 'and\\n            \\n\\n  \\n\\n\\n\\n      &#160;\\n\\n', 'Arbutus', 'Roche Holdings, Inc.', 'Marathon Asset Management', 'IPR&amp;D', 'Welichem', 'the United States\\n        Court of Appeals', 'revenue\\n\\n      &#160;\\n\\n      License', 'Immunovant, Inc. (&', 'Moderna Therapeutics, Inc. (&', 'Continental Stock Transfer &amp', 'the U.S. District Court', 'Dermavant', 'SEC', 'GCP', 'known.\\n\\n      &', 'Dohme Corporation', 'Bermuda', 'the Business Combination', 'the Federal Register', 'expenses\\n\\n      &', 'time.\\n\\n      &#160;\\n\\n', 'IRS', 'Samsung', 'GSK', 'the United States Foreign Corrupt Practices Act', 'Telavant\\n              Holdings, Inc. (&#8220;Telavant&#8221', 'property.\\n'}"
RPHM,"{'API', '\\n  &#x2022;injury', 'LLC', '\\n', 'LC-FAOD', '\\n  &#x2022;costs', 'EU', '\\n  &#x2022;result', '\\n  &#x2022;compliance', 'the U.S. Foreign Corrupt Practices Act', '\\n  &#x2022;publications', 'x2022;a', '\\n  &#x2022;differing', '\\n  &#x2022;foreign', 'the Office of Inspector General of the U.S. Department of Health and Human Services', 'CPRA', 'Form S-1', 'concern.\\n  &#x2022;We', 'The Nasdaq Stock Market LLC', 'Therapeutics', '\\n  &#x2022;production', 'COVID-19', '\\n  &#x2022;workforce', '\\n  &#x2022;prevent', 'a Common Stock Repurchase Agreement', 'Consolidated Financial Statements', 'convenience.\\n  ', '\\n  &#x2022;improving', 'FASB', '\\n  &#x2022;identification', 'HHS', 'the condition.\\n  Generally', '\\n  &#x2022;product', 'the U.S. Congress', '\\n  &#x2022;substantial', 'the Department of Justice', 'x201c;Risk', '\\n  &#x2022;initiation', 'Medicaid', 'Medicare', 'mavodelpar.\\n  &#x2022;We', ': &', 'FDA', '\\n  &#x2022;collaborations', 'prospects.\\n  &#x2022;The', '\\n  &#x2022;difficulties', 'commercialization.\\t\\n  &#x2022;Preclinical', 'candidates.\\n  Composition', '\\n  &#x2022;loss', '\\n  &#x2022;regulatory', 'AI', 'the Private Placement', 'REMS', 'the Trade and Cooperation Agreement', 'mavodelpar', '\\n  &#x2022;patent', 'activities\\n    &', 'Company', 'LCHAD', 'management&#x2019;s attention', 'UK&#x2019;s', 'USPTO', '\\n  &#x2022;challenges', 'the California Privacy Rights Act', '\\n  &#x2022;seize', '\\n  &#x2022;whether', '\\n  &#x2022;unexpected', 'the California Consumer Privacy Act', 'New Zealand&#x2019;s Privacy Act', 'this Quarterly Report on Form', '\\n  &#x2022;cause', 'ASU', 'the European Commission', 'CRO', 'Cooley LLP', 'EXHIBIT INDEX\\n  &', 'this Quarterly Report on Form 10-Q.', '\\n  &#x2022;the', 'License Agreement', 'technologies.\\n  &#x2022;We', '\\n  &#x2022;exhaustion', 'x2022;a collaborator&#x2019;s', 'the Nasdaq Stock Market', '\\n  &#', 'Recent Accounting Pronouncements\\n', '\\n  &#x2022;managing', '\\n  &#x2022;collaborators', 'Registrant', '\\n  &#x2022;require', '\\n  &#x2022;decreased', 'the European Union&#x2019;s General Data Protection Regulation', 'PPAR&#x3b4', 'PMM', 'Leerink Partners', 'IPO', '\\n  &#x2022;mandate', '\\n  &#x2022;some', '\\n  &#x2022;our', 'Form S-3', 'the U.S. Federal Trade Commission', '\\n  &', 'ATM', '44\\n', 'harmed.\\n  &#x2022;Our', 'the Registrant&#x2019;s Registration Statement on Form S-1', 'ESPP', 'results.\\n  &#x2022;If', 'Canada&#x2019;s Personal Information Protection and Electronic Documents Act', '\\n  &#x2022;business', 'x2022;refuse', 'the EU Single Market', '\\n  &#x2022;disputes', 'operations.\\n  Disruptions', '\\n  &#x2022;suspend', 'the Registrant&#x2019;s Current Report', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', '80\\n', 'SEC', '\\n  &#x2022;potential', 'ATM Offering', 'IRS', 'Equity Securities', 'the Registrant&#x2019;s Registration Statement', 'Fair Value Measurement', 'CEO&#x2019;s', 'Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions', '\\n    &', 'Brexit', 'property.\\n'}"
RPID,
RPRX,
RPTX,"{'ASC', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001808158us-gaap', 'CDK4/6', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001808158rptx', 'TwoThousandTwentyEquityIncentivePlanMember2023', '\\n  &#x2022;expansion', 'OnoPharmaceuticalCompanyLimitedMember2023', 'HoffmannLaRocheIncAndFHoffmannLaRocheLtdMember2023-04-012023-06-300001808158us', 'Repare Therapeutics Inc.', 'the Annual Report', 'Lease\\n  &', 'Bristol Myers Squibb', 'the Ono Agreement', 'x2022;a', 'OnoPharmaceuticalCompanyLimitedMember2022', 'ACA', 'OptionsToPurchaseCommonSharesMember2023-07-012023-09-300001808158rptx', 'satisfied\\n        &', 'the Securities Exchange Act', 'NCT05601440).\\n  &#', 'and\\n  &', 'the Ono Agreement\\n        &', 'CCTG', 'satisfied\\n    &', 'Bristol-Myers Squibb Collaboration', 'HHS', 'Medicaid', 'Medicare', 'Bristol-Myers Squibb Company (&#x201c;Bristol Myers', 'Congress', 'x2014;\\n        &', 'THE SECURITIES EXCHANGE ACT OF', 'and\\n  &#x2022;establishment', 'the Licensed Products', 'OnoPharmaceuticalCompanyLimitedMember2023-04-012023-06-300001808158rptx', 'Canadian Cancer Trials Group', 'TwoThousandTwentyEmployeeSharePurchasePlanMember2023-07-012023-09-300001808158rptx', 'the Repare Trials', 'the Research Term', 'Center for Medicare &', 'the Medicaid Drug Rebate Program', 'activities\\n    &', '\\n  Commission File Number', 'Patient-Centered Outcomes Research Institute', 'Company', 'Filer', 'the following:\\n  &#x2022;an', 'Charter)\\n  &#', 'TwoThousandTwentyEmployeeSharePurchasePlanMember2023-07-012023-09-300001808158rptx:', 'TAPISTRY', 'Roche Agreement\\n        &', 'CMS', 'the Roche Agreement', 'Contracts with Customers', 'the Department of Treasury', 'TwoThousandTwentyEmployeeSharePurchasePlanMember2023-01-012023-09-300001808158us-gaap', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'Bristol', 'Roche', '\\n  &#', 'the Canadian Cancer Trials Group', '\\n    Increase', 'FairValueMeasurementsRecurringMember2023', 'the Sarbanes-Oxley Act', 'Economy,&#x201d', 'Comparison', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001808158rptx', 'the Continuing Trials', 'The BMS Agreement', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001808158us-gaap', 'Form S-3', 'Medicaid Innovation', 'Montr&#xe9;al, Qu&#xe9;bec', 'ATM', 'TwoThousandTwentyEmployeeSharePurchasePlanMember2023-01-012023-03', 'European Union', 'ESPP', 'the Association of Southeast Asian Nations', 'Research and Development Expenses, Net of Tax Credits\\n  Research', 'The Roche Agreement', 'the Internal Revenue Service', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001808158rptx', 'OptionsToPurchaseCommonSharesMember2023-01-012023-09-300001808158us-gaap', '\\n        &', 'OnoPharmaceuticalCompanyLimitedMember2023-01-012023-09-300001808158rptx', 'agreements.\\n', 'the BMS Agreement', '\\n    &', 'RP-3500 / RG6526'}"
RSLS,"{'FASB', 'the Condensed Consolidated Statements', 'Condensed Consolidated Financial Statements.&#8203;&#8203;&#8203;104&#8203;Cover Page Interactive Data File', 'Black Scholes', 'the Condensed Consolidated Statements of Cash Flows', 'ContentsResults', 'this Quarterly Report on Form 10-Q.', 'COSO', 'the Quarterly Report on Form 10-Q', 'the Committee of Sponsoring Organizations of the Treadway Commission', 'the Condensed Consolidated Balance Sheets', '2022.&#160;Recent Accounting', 'ContentsNet Cash', 'the Supreme Court', 'expenses&#8203', 'ContentsThe', 'Months Ended &#', '6.5%&#8203;&#8203', 'ShareThe', 'OperationsThe', '23&#8203', '33)&#8203;&#8203; &#', 'Operating Capital', 'Obalon', 'Cowen &', 'the Condensed Consolidated Statements of Operations', 'Company', 'Securities Purchase Agreement', 'net&#8203', '30,069)&#8203', 'ReShape Lifesciences Inc.', '2,798&#8203;$6,696 &#8203;$8,130 &#', 'the Sarbanes-Oxley Act', 'Internal Control - Integrated Framework', 'Cowen', '4.7%Total', 'Capital Expenditure Requirements', 'Capital Resources'}"
RVMD,
RVNC,"{'ASC', 'GL Approval&#8221', 'NotesPayableOtherPayablesMember2022', 'Consolidated RevenueThree Months Ended September 30,Nine Months Ended September 30,(in', 'the RHA&#174; Collection of dermal fillers.&#8220;Product Segment&#8221', 'the Note Purchase Agreement', 'operations$(139,293)$(77,484)$(262,824)$(197,547)(1)For the three and nine months ended September 30, 2023', 'the Fosun License', 'CostOfProductRevenueMember2022', 'RevenueOur', 'Consolidated Teoxane Distribution Net Product Sales', 'the Viatris Territory', 'Ajinomoto Bio-Pharma Services', 'NMPA', 'SegmentOur Service Segment', 'Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd.', 'ProductMember2023', 'ContentsOperating ExpensesThree Months Ended September 30,Nine Months Ended September', 'Equity (Deficit)4Condensed', 'ContentsDAXXIFY&#174', 'ServiceMember2022', 'OliviaWareMember2023-09-30UNITED', 'the Fosun License Agreement', 'Hint, Inc.', 'platform.&#8220;Indenture&#8221', 'Operations', 'Botulinum Toxin Research Associates', 'ViatrisMember2022', 'the United States Food and Drug', 'the Expansion Premises', 'COVID-19', 'the Second Tranche', 'GL Approval PSUs&#8221', 'National Medical Products Administration.&#8220;Note Purchase', 'Pipeline Products', 'Consolidated Financial Statements', 'OliviaWareMember2023-07-012023-09-300001479290rvnc', 'the PCI Supply Agreement', 'ContentsFor', 'CostOfProductRevenueMember2023', 'Products', 'the Notes Payable', 'DAXXIFY&#174', 'MarkFoleyMember2023-07-012023-09-300001479290rvnc', 'ATM Agreement', 'LeaseOperating', 'PCI', 'PCI Pharma Services', 'Capital 31Table', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'Second Tranche', 'FDA', 'GL', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001479290us', 'GL Approval', 'CollaborationRevenueMember2022', 'OperatingSegmentsMember2023-07-012023-09-300001479290rvnc', 'ContentsSummary of Risk FactorsInvesting', 'ABPS', 'Common Stock', 'OperatingSegmentsMember2022-01-012022-09-300001479290us', 'Company', 'Lyophilization Services of', 'Viatris$4,973&#160;$6,162&#160;Total', 'ExpensesCorporate', 'the U.S. Securities Exchange Act', 'U.S. Bank National Association', 'the Teoxane Agreement', 'Viatris Inc.', 'the RHA&#174; Collection of dermal fillers', 'principles.&#8220;Viatris&#8221', 'Report', 'Condensed Consolidated Financial Statements', 'Shanghai Fosun Pharmaceutical (Group) Co.', 'the First Tranche', 'A2017EquityIncentivePlanHintMDPlanMember2023-01-012023-09-300001479290rvnc', 'DebtThe', 'OperatingSegmentsMember2022-07-012022-09-300001479290rvnc', 'the Financial Accounting Standards Board.&#8220;Athyrium&#8221', 'OperatingSegmentsMember2023-01-012023-09-300001479290rvnc', 'TransferredAtPointInTimeMember2022-07-012022-09-300001479290us-gaap', 'Ajinomoto Althaea, Inc.', 'Purchasers', 'THE SECURITIES EXCHANGE ACT OF 1934 For', 'DAXXIFY&#174;.&#8220;Products&#8221', 'RevenueWe', 'ContentsTo', 'the Hint, Inc. 2017', 'Stock-Based Compensation ExpenseThe', 'The PCI Supply Agreement', 'the RHA&#174', 'compensation358&#160;&#8212;&#160;$358&#160;N/M1,306&#160;&#8212;&#160;$1,306&#160;N/MTotal', 'USTreasurySecuritiesMember2022-12-310001479290us-gaap', 'Intangible Asset ImpairmentFor', 'ProductMember2022', 'the Note Purchase Agreement.&#8220;Teoxane&#8221', 'September&#160;18', 'RHACollectionOfDermalFillersMember2023-01-012023-09-300001479290rvnc', 'FairValueMeasurementsRecurringMember2023', 'Plan&#8221', 'Tranche', 'the indemnified party', 'ViatrisMember2023', 'the Technology Transfer', 'SegmentOur Product Segment', 'the Service Segment (Note 13', 'RHACollectionOfDermalFillersMember2023-07-012023-09-300001479290rvnc', 'FairValueInputsLevel1Member2022-12-310001479290us-gaap', 'Assets AmortizationAmortization', 'Teoxane', 'OtherSoftwareMember2023', 'Cowen and Company', 'the Service Segment', 'the License Agreement', 'ViatrisMember2023-09-300001479290rvnc', 'Commercial Fill/Finish Services Agreement', 'Consolidated Balance Sheets2Condensed Consolidated Statements of Operations', 'the Commercial Supply Agreement', 'Consolidated Statements', 'resources.&#8226;As', 'Qualitative Disclosures', 'the Accounting Standards Codification', 'Viatris Agreement', 'Collection of Dermal FillersFor', 'the RHA&#174; Collection of dermal fillers.', 'ATM', 'IndemnificationWe', 'ESPP', 'Condensed Consolidated Financial Statements &', 'RevenueThree Months Ended September 30,Nine', 'Indenture', 'revenue&#8212;&#160;970&#160;970&#160;&#8212;&#160;6,197&#160;6,197&#160;Total', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001479290us', 'Relational Commerce', 'Condensed Consolidated Financial Statements7Item', 'Second Expansion Premises', 'the Collaboration and License Agreement', 'ABPS Services Agreement', 'TransferredAtPointInTimeMember2022-01-012022-09-300001479290us', 'SEC', 'non-current &#8212', 'The Teoxane Agreement', 'PreferredStockMember2022-09-300001479290us', 'BLA', 'the Product Segment', 'Consolidated Loss', 'Commission File No.&#160;001-36297', 'recognized(139)Billings', 'The Note Purchase Agreement', 'Revance'}"
RVPH,
RWLK,"{'SCI Products', 'Hamas', 'the Nasdaq Capital Market', 'RRG', 'the License Agreement', 'the National Spinal Cord Injury Statistical Center (&#8220;NSCISC&#8221;)\\nreported', 'CMS', 'Principal Financial Officer', 'Earn', 'Internal Control over', 'Rental \\n    &', 'Medicaid', 'Medicare', '\\n    Represents', 'ReWalk operations.\\n\\n&#160;\\n\\nOur\\nIsraeli', 'the SCI Products', 'ReWalk Rehabilitation', 'Harvard', 'DAP', '\\n\\n\\n\\n&#160;\\n\\n\\n\\n\\n\\n15\\n\\n&#160;\\n\\nREWALK\\nROBOTICS LTD', 'FDA', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS', 'LLC,\\nRRI', 'Health Insurer (&', 'the Principal Financial Officer', 'ReWalk Personal', 'Merger Sub', 'ReBoot', 'MediTouch', '\\n        &', 'SEC', 'RRI', 'The Harvard License Agreement', 'Shareholder Representative Services', 'CE Clearance', 'Company', 'Net \\n    &', 'Private Securities Litigation Reform Act', 'acquired\\nentity', 'combined\\ncompany', 'Nasdaq', '\\n    &', 'the License Agreement.\\nThe Company', 'AGI'}"
RXRX,
RXST,"{'years)\\n        &', 'regulators;\\n  &#x2022;costs', 'effective;\\n  &#x2022;product changes;\\n  &', 'investments; &#x2022;intention', 'and\\n  &#x2022;exemptions', 'operations.\\n  &#160;\\n', 'Oxford', 'Security Agreement', 'procedures.\\n  Changes', 'EU', 'the &#', 'operations.\\n  Environmental', 'the Public Company Accounting Oversight Board', 'the Medical Devices Directive (&#x201c;MDD&#x201d;)', 'x2022;a', 'countries;\\n  &#x2022;developments', 'CPRA', 'LiquidityShelf Registration Statement', 'the Organisation for Economic Co-operation and Development', 'sources.\\n  &#160;\\n', 'the Securities Exchange Act', 'OfferingAs', 'LeasesLease', 'capital commitments;\\n  &#x2022;actual', 'and\\n  &', '\\n       &', 'our shares;\\n  &#x2022;announcement', 'BofA Securities, Inc.', 'Company\\', 'analysts;\\n  &#x2022;fluctuations', 'sanctions:\\n  &#x2022;adverse', 'Internal Control', 'x2022;post', 'Medicaid', 'Medicare', 'x2014;\\n        &', 'GDPR', 'FDA', 'The America Invents Act', 'Weighted Average\\n        &', 'Loan', 'and\\n  &#', 'others;\\n  &#x2022;collaborators', 'efforts;\\n  &#x2022;regulatory', 'collaborations;\\n  &#x2022;collaborators', 'the \\n  &#160;\\n', 'the Sarbanes-Oxley Act;\\n  &#x2022;not', 'Company', 'LAL', 'ISO 13485', 'management&#x2019;s attention', 'and\\n  &#x2022;the', 'payroll taxes;\\n  &#x2022;foreign', 'USPTO', 'the ATM Facility', 'Adopted Pursuant to Section 302', 'liability;\\n  &#x2022;disputes', 'Significant Accounting', 'including:\\n  &#x2022;not', '\\n  &#160;\\n', 'and\\n  &#x2022;business', 'products;\\n  &#x2022;withdrawal', 'Oxford Finance', 'FCPA', 'the Condensed Consolidated Balance Sheets', 'revenue;\\n  &#x2022;exhaustion', 'production;\\n  &#x2022;denial', 'x2022;a collaborator&#x2019;s', 'distribution;\\n  &#x2022;premarketing', '\\n  &#', 'StockEach', 'Lenders', 'the Sarbanes-Oxley Act', 'the indemnified party', 'IPO', 'reporting.\\n', 'MDR', 'and\\n  &#x2022;criminal', 'First Amendment to Loan', 'products;\\n  &#x2022;actual', '7,932\\n          &', 'Form S-3', 'Board', 'enforce;\\n  &#', 'the United States;\\n  &#x2022;production', 'markets;\\n  &#x2022;compliance', 'regulations;\\n  &#160;\\n', 'ATM', 'and\\n  &#x2022;general', '\\n         &', '\\n          &#160;\\n', 'Healthcare', '8,909\\n        &', 'LDD', 'patents;\\n  &#x2022;issued', 'PMA', 'RxSight', '4,826\\n        &', 'OIG', 'fair value\\n        &#160;\\n        ', '\\n        &', 'LeasesThe Company', 'SEC', 'CA', 'Concentration of Credit Risk and Other Risks and Uncertainties Financial', 'the future;\\n  &#', 'the Equity Plans\\n        &', 'include:\\n  &#x2022;the', '\\n    &', 'property.\\n'}"
RYTM,
RYZB,"{'the PeptiDream Agreement', 'API', 'MHRA', 'CMOs', 'Contractual Obligations', 'Collaboration and Supply Agreement with Niowave, Inc.', 'The Indianapolis Lease', 'the UK Medicines', 'ContentsRestricted', 'Principal Executive Officer', 'EEA', 'the PeptiDream Amendment', ': &#8226;timing', 'EU', 'ContentsLicense Agreement', 'Phase 4', 'Prospectus', 'HTA', 'the Ablaze Agreement', 'the Niowave Agreement', 'ContentsWe', 'ACA', 'the Securities Exchange Act', 'Principal Financial Officer Pursuant', 'ContentsIn', 'S-1/A9/11/202310.310.3+The', 'Anti-Kickback Statute', 'HHS', 'PeptiDream, Inc. (&#8220;PeptiDream&#8221', 'Medicaid', 'Medicare', 'Risks Related to Government Regulation', 'GDPR', ': &', 'FDA', 'ContentsAny', 'Rule 701', 'GMP', 'RSU', 'PeptiDream, Inc.', 'Principal Executive Officer Pursuant to Rules', 'AI', 'Ablaze, Nimble', 'Niowave the Actinium 225', 'Company', 'this Quarterly Report on Form 10-Q.Critical Accounting Policies', 'USPTO', 'Adopted Pursuant to Section 302', 'RPT', 'FCA', 'Health Technology Assessment', 'the U.S. Securities and Exchange Commission', 'the Delaware General Corporation Law', 'the &#8220;Niowave', 'this Quarterly Report on Form 10-Q.', ': &#8226;delays', 'ContentsIn February 2022', 'IRB', 'MSCE.S-1/A9/11/202310.710.7+Employment Agreement', ': &#', 'Research Collaboration Agreement', 'Registrant', 'the Nimble Agreement', 'RYZ101', 'NDA', 'the Sarbanes-Oxley Act', 'Regulation Fair Disclosure', 'Contingencies and Collaboration and License', 'IPO', 'the U.S. Department of Energy', 'the General Data Protection Regulation', 'SSTR2', 'PGR', 'PeptiDream', 'ESPP', 'ContentsDespite', 'Issuer Repurchases of Equity', 'Nimble Therapeutics, Inc.', 'Healthcare', 'Condensed Financial', 'Ablaze Pharmaceuticals Inc.', 'SEC', 'GCP', 'the Budget Control Act'}"
RZLT,"{'the XOMA License Agreement', 'LLC', 'this Quarterly Report on Form 10-Q:Exhibit Number&#160;&#160;&#160;&#160;Description&#160;of&#160;Exhibits31.1*&#8203;Certification of Chief Executive', 'the Loan Agreement', 'PKI', 'Regulatory Authorities', 'Principal Financial Officer', 'Unaudited Condensed Consolidated Financial Statements5Item 2', 'EMBEDDED', 'Condensed Consolidated Statements of Cash Flows &#8211', 'ContentsPART II &#8211', 'XOMA', 'SLR Investment Corp.', 'expenses.&#160;General', 'The ActiveSite License Agreement', 'XOMA Corporation', 'Report', 'the Private Securities Litigation Reform Act', 'years)&#160;&#8203', 'Consolidated Financial StatementsShare', 'this Quarterly Report on Form 10-Q', 'the New Restrictions', '7 &#8212', 'FDA', 'Handok, Inc. (&#8220;Handok&#8221', 'Equity &#8211', 'LICENSE AGREEMENTSXOMA License AgreementIn', 'Loan', 'Development and License Agreement', 'Registrant', 'Condensed Consolidated Statements of Operations and Comprehensive Loss &#8211', 'Condensed Consolidated Statements', 'Company', 'the Securities Exchange Act', 'Exit Fee Agreement', 'Financial Officer)&#8203;&#8203;27\\n\\n\\n\\n', 'Contentsrelated', 'ActiveSite Pharmaceuticals, Inc. (&#8220;ActiveSite&#8221', 'the Sarbanes-Oxley Act', 'Results of Operations', 'RELATED PARTY TRANSACTIONSRelated Party Licensing AgreementOn', 'ActiveSite', 'the ActiveSite License Agreement', 'Condensed Consolidated Balance Sheets &', 'Consolidated Financial StatementsNOTE'}"
SABS,
SAGE,
SANA,
SAVA,
SBFM,
SCLX,"{'\\n  &#x2022;injury', 'the &#x201c;Standby Equity', 'Hudson Bay Capital Management LP', 'the Romeg License Agreement', 'The Closing Penny Warrant', 'eCapital Health Corp.', 'Lender', 'Subordination', 'Form S-1', 'pain.\\n  &', 'the Securities Exchange Act', 'Repurchase', 'AmerisourceBergen Corporation', 'the Wall Street Journal Prime Rate', 'COVID-19', 'Developers', 'ZTLido', '\\n  &#x2022;improving', 'the Subordination Agreement', 'the Junior DIP Loan Agreement', 'the DIP Assignment Agreement', 'FDA', 'The Securities Purchase Agreement', 'reporting.\\n  &', 'Cayman Islands', 'Riley Purchase', '\\n  &#x2022;difficulties', '\\n  &#x2022;regulatory', '\\n    &#160;&#160;&#160;&#160;2.3#\\n    ', 'FASB ASC 260', 'Semnur Pharmaceuticals', 'Scilex Holding', 'the Oramed Note\\n', 'Department of Justice', 'x201c;reverse', 'ELYXYB', 'CMS', 'Release Agreement', 'Intangible Amortization\\n  &', 'the Product Development Agreement.&#160;Litigation', 'Scilex Pharmaceuticals, Inc.', 'The Yorkville Registration Statement', '\\n    &#160;&#160;&#160;&#160;4.3\\n', 'PTO', 'Sorrento', 'Fortis Advisors', 'Vickers', 'Senior Secured', 'Acquiom Agency Services', 'the &#x201c;Purchased', 'the eCapital Credit Agreement.&#160;As', 'DIP Loan', 'the Original Purchase Agreement', 'Exhibit 3.2', 'the DIP Documents', 'the Delaware Court of Chancery', 'the &#x201c;B. Riley Commitment', 'Vickers&#x2019;s Current Report', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Scintilla Pharmaceuticals, Inc.', 'Form S-3', 'treasury', 'HBC Investments LLC', 'The Subordination Agreement', '\\n  &', '\\n  &#x2022;delays', 'LLC (&#x201c;B.', 'Federal Drug Administration', 'the Product Development Agreement and Commercial Supply Agreement', 'ELYXYB Royalties\\n  &', 'VWAP', '\\n  &#x2022;restrictions', 'the &#x201c;Yorkville Commitment', 'Healthcare', '&#x201c;Convertible', '\\n  &#x2022;lack', 'the B. Riley Registration Statement', 'LLC', 'operations.\\n  &#160;\\n', 'State', 'the DIP Loans', 'the Closing Penny Warrant', 'RxOmeg Therapeutics', 'Exhibit 10.7', 'x2022;a', '\\n    &#160;&#160;10.13+*\\n    Severance and Change of Control Agreement', 'notice.&#160;&#160;23\\n     &', 'Products', 'Oishi Koseido Co., Ltd.', 'Cover Page Interactive Data File', 'B. Riley Principal Capital II', 'between Sorrento Therapeutics, Inc.', '\\n  &#x2022;substantial', 'Internal Control', '\\n  &#x2022;a', 'Oramed Note', 'HBC', 'Risks Related to Government Regulations', 'GDPR', 'our Common Stock', 'the Junior DIP Facility', '\\n  &#x2022;complexities', 'the Medicaid Drug Rebate Program', 'Oramed Pharmaceuticals Inc.', 'eCapital Credit Agreement', '\\n  &#x2022;occurrence', 'Company', 'The Product Development Agreement', 'sciatica (&#', 'the Required Holders', 'the eCapital Credit Agreement', 'x201c;Scilex Holding', 'SPAC Warrants', '\\n  &#x2022;subjects', 'the Pay-Off Letter', '\\n  &#x2022;the', 'LLC (&#x201c;Cove Lane&#x201d', 'YA II, Ltd.', '\\n  &#', 'the &#x201c;Mandatory Prepayment Sweep&#x201d;).\\n', 'the Romeg Agreement', '\\n  &#x2022;managing', 'Exhibit 2.4', 'Registrant', 'McKesson Corporation', 'Virpax', 'Assignment and Assumption Agreement', 'the Settlement Agreement', 'NDA', 'Vickers&#x2019;s', 'Preferred Stock', 'the Letter Agreement', 'adults.\\n  &', 'Virpax Pharmaceuticals, Inc. (&', 'the Revolving Facility and Convertible Debentures', 'capital.\\n  &#', '\\n  &#160;\\n  ', 'Nasdaq&#x2019;s', 'the State of Delaware', 'statements.&#x201d', 'Recent Accounting Pronouncements\\n  &', 'Sorrento Therapeutics, Inc.', 'the Legal Fee Assumption', 'The B. Riley Registration Statement', 'Oramed', '\\n  &#x2022;natural', 'Affiliates', 'GCP', 'the Product Development Agreement', 'the Acceptable Indebtedness', 'Equity Securities', 'Exhibit 10.3', '\\n    &#160;&#160;10.10#\\n', 'the Oramed Note', 'ZTlido', 'the Public Warrants', 'the \\n  &#', 'x201c;Dodd-Frank Act&#x201d;)', 'EU', 'the ABL Lender', 'the Penny Warrants', '\\n  &#x2022;selection', 'the Revolving Facility', 'eCapital Healthcare Corp.', 'cash.\\n  &#', 'ACA', 'the &#x201c;Convertible', 'the Merger Agreement', 'USP', 'the Transferred Warrants', 'the Securities Purchase Agreement', 'Romeg&#x2019;s', 'Legal Fee Assumption Letter Agreement\\n  &', '\\n  &#x2022;initiation', 'DIP', 'Medicare', 'the Federal Trade Commission', 'the Medicaid Drug Rebate', 'B. Riley Purchase Agreement', 'the Purchased Securities', 'Scilex Pharmaceuticals Inc.', 'SCLX DRE Holdings', 'Development Milestones Payment', 'the DIP Commitments', '77\\n', 'Scilex, Inc.', 'activities\\n    &', 'Common Stock', 'operations.\\n  &#160;\\n  Failure', 'the Development Milestone Payment', 'Scilex Holding Company, Sorrento Therapeutics, Inc.', '\\n    &#', 'Cove Lane Onshore Fund', 'the Security Agreement', 'this Quarterly Report on Form', 'Super-Priority Debtor-In-Possession Loan', 'the European Commission', 'the Lifecore Master Services Agreement', 'YA II PN, Ltd.', 'Romeg', 'Restricted Cash&#160;The Company', 'x201c;Legacy', '\\n    &#160;&#160;10.14+*\\n    Severance and Change of Control Agreement', 'Trust Company', 'SCLX JV', 'between Scilex Holding Company', 'B. Riley', 'HBC Investments LLC (&#', 'the &#x201c;Exchange', '\\n  &#x2022;decreased', 'Financial Reporting \\n  &#', 'Vickers Venture Fund VI Pte Ltd', 'between Scilex Holding Company and Sorrento Therapeutics, Inc.', '\\n  &#x2022;cost', 'Junior DIP Facility and Sorrento Stock Purchase', 'the Sarbanes-Oxley Act', 'the Bankruptcy Court', '47\\n', '\\n    &#160;&#160;&#160;&#160;2.1#\\n    Agreement and Plan of Merger', 'the Sorrento SPA', 'Credit and Security Agreement', 'below.\\n  &', 'the Loan Agreement', 'Bloomberg L.P.', 'the Security Agreement and Subsidiary Guarantee', 'the Registration Rights Agreement', 'No\\n  Indicate', 'Stock Purchase Agreement', 'Aardvark Therapeutics, Inc.', 'the &#x201c;B.', 'the Subsidiaries of the Company party', 'Continental', 'the Business Combination', 'Itochu', 'the &#x201c;Product Development', '\\n  &#x2022;failure', '\\n    &', 'Sorrento&#x2019;s Chapter 11 Cases', 'L.P. (the &#x201c;CNH Revolving', 'Oishi', 'Intellectual Property \\n  &#', 'Exhibits.\\n  &#160;\\n', 'Vickers Vantage Corp.', 'Principal Executive Officer', 'this Quarterly Report on Form 10-Q', 'Vickers Venture Fund VI', '\\n  &#x2022;costs', 'Shares &', 'Court', 'The Tennessee Information Protection Act', '\\n  &#x2022;foreign', 'the &#x201c;Supply', 'Loan Document', 'known.\\n  &#', 'GLOPERBA', 'HRSA', 'the &#x201c;Public', 'the &#x201c;Yorkville Registration', 'PHN', 'the Certificate of Incorporation', 'Scilex Holding Company', 'Yorkville Purchase Agreement', 'Letter Agreement', 'Critical Accounting Estimates\\n  &', 'Lifecore', 'the &#x201c;Former Employee', 'the Oramed Closing Date', 'Medicaid', 'Exhibit 10.5', '\\n  &#x2022;any', 'the Licensed Products', '\\n  &#x2022;clinical', '\\n  &#x2022;changes', 'the Private Warrants', 'x201c;Common', 'Capital II', 'the &#x201c;Settlement Agreement&#x201d;).\\n', 'CNH Finance Fund I', 'The Certificate of Incorporation', 'Intellectual Property Security Agreement', 'plans.\\n  &', 'the Medicaid Drug Rebate Agreement', '\\n  &#160;\\n', 'this Quarterly Report on Form 10-Q.', '\\n  &#94', 'The Junior DIP Facility', 'License Agreement', 'Riley Purchase Agreement Pursuant', '\\n  &#x2022;imposition', 'the Common Stock', 'the Annual Report on Form 10-K', 'the Senior DIP Facility', 'CNH Revolving', 'Aardvark', 'Regulation S-K', 'reporting.\\n', 'the B. Riley Purchase Agreement', 'companies&#x2019', 'Yorkville', 'costs.\\n  &', 'the Mandatory Prepayment Sweep', 'the Scilex Pharma Notes', 'cash.\\n  &#160;\\n', 'Board', '\\n  &#x2022;We', 'the Nasdaq Listing Rules', 'Debtors&#x2019', 'SPAC', '\\n    &#160;&#160;10.6\\n', 'the Lender and Acquiom Agency Services', '\\n  &#x2022;withdrawal', 'the &#x201c;Oramed', 'SEC', 'Sorrento&#x2019;s', 'the Convertible Debentures', 'pronouncements.\\n  &#160;\\n  &#160;\\n  48\\n  ', 'the Annual Report on Form 10-K.', 'Hudson Bay Parties &', 'citizen&#x2019;s', 'Nasdaq'}"
SCNI,
SCPH,"{'LLC', 'between scPharmaceuticals Inc.', 'Silicon Valley Bank Term', '\\n    Interest income\\n    &', 'studies.\\n  &', 'this Quarterly Report', 'Investigational New Drug Application', 'Loan Agreement', 'Contracts', 'SLR Investment Corp.', 'Rights Agreement', 'Sublease Agreement', 'x2014;\\n        &', 'Credit Agreement and Guaranty', 'ContingenciesOperating LeasesThe Company', 'FUROSCIX', 'the Oaktree Agreement', '\\n  Selling', '\\n  &#', 'Customer (&#x201c;Topic 606&#x201d;)', 'the ESPP.The Company', 'Solar Capital Ltd.', 'the Registrant&#x2019;s Current Report', 'the Exit Agreement', 'Accounting Standards Codification', '\\n    Research', 'Exit Agreement', 'Silicon Valley Bank', '\\n        &', '7,109\\n        &', '\\n    &#160;&#160;4.1\\n    &', 'Company', '\\n    Interest expense\\n    &', 'the Registrant&#x2019;s Registration Statement', 'Comparison of Nine Months Ended September 30,', 'InventoryInventory', 'Comparison', 'companies&#x2019', '\\n    &', 'Oaktree Fund Administration'}"
SCTL,"{'\\n      &#160;Contract', 'Credit Agreement', '1,461,529\\n          &#160;\\n         \\n         \\n          Stock options\\n          &#160;\\n', 'Lannett', 'treasury', '\\n    Interest income\\n    &', 'Athyrium Opportunities III Acquisition LP', 'this Quarterly Report', 'goods\\n        &', 'respectively.\\n  Interest', 'Societal CDMO, Inc.', 'x2014;\\n        &', '\\n  &#', 'RSU', 'capabilities.\\n', 'the Credit Agreement', 'depreciation\\n        &', '\\n    &', '\\n        &', 'AthyriumThe Company', 'Restricted', 'x201c;Athyrium Credit', 'Royal Bank of Canada', 'satisfied\\n        &', 'Company', 'the Securities Exchange Act', '7,331,963\\n          &', 'agreement.\\n  &', '\\n    Interest expense\\n    &', 'Comparison of third quarters 2023', 'Nasdaq Listing Rule 5635(c)(4).Other informationThe', 'Series A Convertible Preferred Stock', 'No &#9744;\\n  Indicate', 'WarrantsThe', 'Warrants\\n          &#160;\\n'}"
SCYX,"{'ASC', 'MaximumMember2023', 'WarrantMember2022-07-012022-09-3000011782532022-01-012022-09-300001178253us', 'ProductRecallMember2023-01-012023-09-300001178253scyx', 'Good Manufacturing Practices', '\\n', 'respectively.4\\n     Table of Contents&#160;The Company', 'Security Agreement', 'NetNet', 'Warrant Liabilities Fair Value Adjustment', 'WarrantMember2022-01-012022-09-300001178253us', 'December2020PublicOfferingMember2022-12-310001178253scyx', 'ProductMember2023', 'WarrantMemberscyx', 'WarrantMember2023-07-012023-09-300001178253scyx', 'Description of Business and Basis of PreparationOrganizationSCYNEXIS, Inc. (&#x201c;SCYNEXIS&#x201d', 'the Financial Accounting Standards Board', 'Candida and Aspergillus', 'the Common Stock Purchase Agreement', 'the Securities Exchange Act', 'WarrantMember2022-12-310001178253us-gaap', 'Waterstone', 'First Citizens Bank', 'WarrantsAssociatedWithApril2022PublicOfferingMember2023-09-3000011782532022-07-012022-09-300001178253us', 'The Common Stock Purchase Agreement', 'CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember2022-01-012022-09-300001178253us', 'WarrantMember2023-07-012023-09-300001178253us-gaap', 'BorrowingsLoan', 'FASB', 'GlaxoSmithKline Intellectual Property', 'RevenueProduct', 'April2022PublicOfferingMember2023-09-300001178253scyx', 'Cover Page Interactive Data File', 'WarrantMember2022-07-012022-09-300001178253scyx', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001178253scyx', 'Merck Sharp &', 'WarrantMember2022-07-012022-09-3000011782532022-06-300001178253scyx', 'SCYNEXIS', 'commercialization.\\n  Components of Operating Results\\n', 'SeniorConvertibleNotePurchaseAgreementMember2022-07-012022-09-300001178253us', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'SEC File No', 'USDscyx', 'Loan', 'x201c;Common', 'MaximumMemberscyx', 'activities\\n    &', 'Company', 'Aspire Capital', 'SuccessfulCompletionOfMarioStudyMember2023', 'WarrantMember2023-01-012023-09-300001178253scyx', 'BREXAFEMME', 'April2022PublicOfferingMember2023-01-012023-09-300001178253scyx', 'FairValueInputsLevel1Memberscyx', 'WarrantMember2022-01-012022-09-300001178253scyx', 'cyclophilin', 'DanforthMember2022', 'SVB', 'SeniorConvertibleNotePurchaseAgreementMember2022-01-012022-09-300001178253scyx', 'DerivativeMember2023', 'ASU', 'Loan Agreement', 'Ibrexafungerp', 'CantorFitzgeraldCoAndLadenburgThalmannCoIncMember2023', 'Merck', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001178253scyx:ExclusiveLicenseAndCollaborationAgreementMember2023-01-012023-09-300001178253scyx', 'License Agreement', 'DerivativeMember2022', 'ProductRecallMember2021-12-310001178253us-gaap', 'CommonStockAssociatedWithMarchTwoThousandNineteenNotesMember2022', 'WarrantMember2023-07-012023-09-300001178253scyx:', 'License', '\\n  &#', 'Dohme', 'SeniorConvertibleNotePurchaseAgreementMember2022-12-3100011782532018-03-012018-03-010001178253scyx', 'Lenders', 'December2020PublicOfferingMember2022-09-300001178253us', 'ProductMember2022', 'Consolidated Financial InformationThe', 'RestrictedStockUnitsRSUMember2023-09-300001178253us', 'WarrantMember2022-01-012022-09-3000011782532023-07-012023-09-300001178253scyx', 'Amplity', 'the GSK Territory', 'WarrantMember2023-01-012023-09-300001178253us-gaap', 'FairValueMeasurementsRecurringMember2023', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001178253us', 'CJSC', 'Dohme Corp.', 'organization)\\n    &#160;\\n', 'Hercules Capital, Inc. (&', 'ShortTermDebtMember2022-12-310001178253us-gaap', 'charter)\\n  &#', 'ASU No', 'See &#x201c;Liquidity', 'WarrantMember2023-09-300001178253scyx', 'LoanAgreementAmendmentMember2023-05-310001178253scyx', 'Silicon Valley Bridge Bank', 'the Loan Agreement', 'the License Agreement', 'WarrantMember2023-01-012023-09-300001178253srt', 'LoanAndSecurityAgreementMemberscyx:InitialTrancheOfTermLoanMember2021-05-1300011782532021-', 'WarrantMember2022-07-012022-09-300001178253us', 'CantorFitzgeraldCoAndLadenburgThalmannCoIncMember2022', 'District Court', 'ATM', 'ShortTermDebtMember2022-12-310001178253scyx', 'Hercules Capital', 'AccountingStandardsUpdate201613Member2023-09-300001178253us', 'Cantor', 'UNITED', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001178253us', 'LoanAgreementAmendmentMember2023-03-300001178253scyx', '2,067\\n        &', '\\n        &', 'SEC', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001178253us', 'Territory', 'the &#x201c;Company&#x201d;)', 'ProductRecallMember2023-09-300001178253us', 'Factors&#34', 'PrefundedWarrantsMemberscyx', 'GSK', 'Cypralis Limited', '\\n    &', 'ProductReturnsMember2021'}"
SDGR,
SEEL,
SEER,"{'ASC', 'PrognomiQ', 'Financial ReportingWe', 'the FDA&#8217;s Quality System Regulations', 'the Delaware General Corporation Law', 'LLC', 'Capital ResourcesSince', 'HHS', ': &#8226;decreases', 'EstimatesThe', 'this Quarterly Report', 'development2,242&#160;2,395&#160;7,523&#160;6,788&#160;Selling', 'the U.S. Congress', 'the Instrument Control Software', 'the Board of Directors', 'the California Privacy Protection Agency', 'the PrognomiQ, Inc.', 'U.S. Food and Drug Administration', 'FDA&#8217;s', 'BWH', 'PrognomiQ, Inc. (', 'the Securities and Exchange Commission', 'Contracts With Customers', 'CompensationThe', 'the Market Price Milestone', 'Instrument Control Software', ': &#8226;estimates', 'RUO', 'the Department of Health and Human Services', ': &', 'GDPR', 'Proteograph', 'FDA', 'Unaudited Condensed Consolidated Financial Statements', 'LDTs', 'the Nasdaq Stock Market', 'the U.S. Foreign Corrupt Practices Act', 'Inherent Limitations on Effectiveness of', 'Indicate', 'Accounting Standards Codification', 'FDA &#8220;general', 'Risks Related', 'EUA', 'UPC', 'U.S. Treasury', 'ControlsOur', 'CPRA', 'ProceduresUnder', 'HIPAA', 'SEC', 'NP', 'SOX', 'LDT', 'Company', 'the Securities Exchange Act', 'Hamilton Company', 'USPTO', 'COVID-19', 'the Foreign Corrupt Practices Act', 'the Health Insurance Portability', 'CFO', 'the European Union', 'No  &#9744', 'this Quarterly Report of Form'}"
SERA,
SGEN,"{'EC', 'RAS', 'Merck for TUKYSA', 'EMA', 'Seagen Inc.', 'Standard Contractual Clauses', 'the Baker Entities', 'EU', 'ESMO', 'PADCEV', 'Pfizer Inc.', 'ContentsMerck', 'Merger Sub', 'the National Medical Products Administration of China', 'PIPL', 'ContentsWhile', 'ContentsWe', 'the Securities Exchange Act', 'ContentsDuring', 'Restated Certificate of Incorporation of Seagen Inc.8-K000', 'AbbVie', 'Data Bridge', 'cisplatin', 'the American Arbitration Association', 'Takeda Pharmaceutical Company Limited', 'Sanofi', 'Pending Transaction', 'ADCETRIS', 'the Merger Agreement', 'Pfizer', 'HHS', 'TIVDAK', 'PartiesOur', 'gastric', 'Medicaid Drug Rebate Agreement', 'Genentech, Inc.', 'the EU&#8217;s General Data Protection Regulation', 'TUKYSA', 'GlaxoSmithKline', 'Medicare', 'Medicaid', 'the Securities and Exchange Commission', 'SEAGEN', 'The U.K. Extension', 'the Federal Trade Commission', 'GDPR', 'FDA', 'the Physician Payments Sunshine Act', 'Seagen', 'Recent Accounting PronouncementsWe', 'KEYNOTE-B15', 'ADC', 'ContentsThe', 'Risks Related', 'REMS', 'AstraZeneca', 'FTC', 'Ventana Medical Systems, Inc.', 'Restated Certificate of Incorporation of Seagen Inc.8-K000-324053.35/26/20113.3Certificate', 'Global Stock Unit', 'Antibody-Drug Conjugate Technology License AgreementsGenentech', 'SGN', 'ProceedingsThe', 'Restated Bylaws of Seagen Inc.8-K000', 'Merck', 'ZN-A-1041', 'Good Clinical Practice', 'RequirementsOur', 'IRB', 'Global Performance Stock Unit', 'Risks Related to Regulatory Oversight', 'the Data Bridge', 'LAVA', 'Amendment of Fourth Amended', 'Polivy', 'Upfront', 'Registrant', 'the Children&#8217;s Health Insurance Program', 'Rule 13a-14(a).&#8212;&#8212;&#8212;&#8212;32.1+Certification', 'Genentech', 'ContentsMaterial', 'EGFR', 'the Roche Group', 'netInvestment', 'Baker Bros. Advisors LP', 'development$449,047&#160;$384,605&#160;17&#160;%$1,204,930&#160;$986,518&#160;22&#160;%Research', 'Aris Merger Sub, Inc.', 'District Court', 'ContentsClinical Development and Regulatory StatusADCETRIS', 'Aris Merger Sub', 'MDRA', 'Daiichi Sankyo', 'LAVA Therapeutics', 'Medicaid Services', 'Personal Information Protection Law', 'Schedule A', 'compensationThe', 'Healthcare', 'Zion Pharma', 'GSK plc', 'the U.S. District Court', 'SEC', 'GCP', 'ContentsIn April 2020', 'LAVA Therapeutics N.V.', 'RemeGen', 'FSS', 'Array BioPharma, Inc.', 'the Centers for Medicare &', 'CI', 'ContentsSupplemental', 'GSK'}"
SGHT,
SGMO,
SGMT,"{'ASC', 'FASB', 'ASU', 'FASN', 'ContentsRevenue recognitionThe Company', 'this Quarterly Report', 'Gannex Pharma Co., Ltd.', 'Internal Control', 'GBM', 'Financial Instruments', 'March&#160;12', 'Ascletis', 'Ascletis Pharma&#160;Inc', 'ContentsRecently', 'the Public Company Accounting Oversight Board', 'Ascletis BioScience Co. Ltd.', 'Contentsgranted Ascletis', 'Accounting Standards Codification', 'Instruments-Credit Losses', 'ContentsThe', 'Form S-1', 'SEC', 'ContentsWe', 'Company', 'Assignment and Assumption Agreement with Ascletis', 'Contracts with Customers (ASC', 'COVID-19', 'IPO', 'No &#9723;Indicate', 'Ascletis BioScience', 'Financial', 'Financial Accounting Standards Board'}"
SGRY,
SHC,"{'Consolidated Financial StatementsOn', 'activities(3,353)(1,452)Net', 'LLC', 'EO', 'Sterigenics', 'the Credit Agreement (&', 'the Willowbrook Term Sheets', 'Georgia EO', 'this Quarterly Report on Form 10-Q', 'Nordion Nordion', 'BioScience Labs', 'LiabilitiesAccrued', 'Consolidated Statements of Operations and Comprehensive Income', 'the Term Loan', 'Cobb Counties', 'Nordion', 'CashThe', 'the Willowbrook Covered Claims', 'the Consolidated Balance Sheets', 'Consolidated Financial Statements1.Basis of PresentationPrinciples of Consolidation &#8211', 'the Securities Exchange Act', 'SPO', 'Regulatory Compliance Associates', 'Consolidated Financial StatementsCapital', 'the Senior Secured Credit Facilities', 'Consolidated Financial Statements', 'the Settling Defendants', 'LossForeign', 'Consolidated', 'the State Court of Cobb County', 'Sterigenics, Nordion', 'the Securities and Exchange Commission', 'Revolving Credit Facility', 'Georgia EO Litigation', 'the Illinois Joint Contribution Among Tortfeasors Act', 'the Consolidated Statements of Operations and Comprehensive Income', 'the Non-Settling Willowbrook Claimants', 'compensation$29,361&#160;$32,936&#160;Georgia EO', 'Company', 'Defend', 'Medical Isotopes', 'Consolidated Financial Statements9.Long-Term', 'the State Court of Cobb Country', 'the State Court', 'EPA', 'RCA', 'Cobb Counties Settlement', 'revenues341,974&#160;336,813&#160;5,161&#160;1.5&#160;%Total', 'the Delaware Superior Court', 'FacilitiesSenior Secured', 'Sotera Health Holdings', 'this Quarterly Report on Form 10-Q.', 'Incremental Facility Amendment', 'the Quarterly Report on Form 10-Q', 'AmountUnamortized Debt Issuance CostsUnamortized Debt DiscountNet', 'LLC (&#8220;SHH&#8221;)', 'net&#8221', 'the Illinois Contribution Among Joint Tortfeasors Act', 'the &#8220;Past', 'BenefitsThe Company', 'Non-Settling Willowbrook', 'the Revolving Credit Facility', 'Nelson Labs', 'Eligible Claimants', 'Sections 11', 'Regulation S-K', 'IPO', 'CFO', 'ContentsSotera Health Company Consolidated Statements', 'the Willowbrook Settlement Agreements', 'Consolidated Financial StatementsThe', 'Insurance Coverage for Environmental LiabilitiesOur', 'the Defendant Subsidiaries', 'treasury', 'ContentsPart', 'follows:(thousands of U.S. dollars)For', 'LIQUIDITY', 'Sotera Health Company', 'net(a)30,464&#160;20,080&#160;82,275&#160;53,974&#160;Depreciation', 'the Circuit Court', 'PEC', 'the Settling Claimants', 'Note 2', 'ContentsSotera Health Company Notes', 'SOFR', 'assets(4,171)(4,259)Net', 'SCAQMD', '2022Accrued', 'the Covered Claims', 'Internal ControlDuring', 'Willowbrook', 'Consolidated Balance Sheets', 'SegmentSterigenics', 'the Amended Complaint', 'ContentsSotera Health Company Consolidated Statements of Equity', 'the Willowbrook Settlement', 'Consolidated Financial Statementsinformation', 'Post-Settlement Willowbrook Cases', 'Illinois EO'}"
SHCR,"{'Unaudited Interim Financial InformationThe', 'ShareAdjusted', 'Credit Agreement', 'ASU', 'New Accounting PronouncementsSee', 'Principal Financial Officer', 'PaymentsStock', 'ContentsFinancing ArrangementsSenior Secured', 'Consolidated Statement of Operations', 'Procedures35Part II', 'ProceduresAs', 'Segment InformationThe Company', 'Unaudited Consolidated Financial', 'Principal Executive Officer', 'the Consolidated Statements of Operations and Comprehensive Loss', 'Consolidated Statements of Cash Flows', 'ContentsComparison', 'marketing43,858&#160;40,698&#160;3,160&#160;8&#160;%Product', 'Sharecare', 'AmortizationDepreciation', 'Senior Secured Credit Agreement', 'the Senior Secured Credit Agreement', 'the Consolidated Statement of Redeemable Convertible Preferred Stock', 'AdministrativeGeneral', 'EBITDAAdjusted EBITDA', 'MarketingSales', 'the Consolidated Statement of Operations', 'the Consolidated Statements of Operations', 'Administrative ExpensesGeneral', 'the Consolidated Balance Sheets', 'Consolidated Balance Sheet', 'Discussion and Analysis of Financial Condition', 'SEC', 'ContentsWe', 'Company', 'technology53,112&#160;54,237&#160;(1,125)(2)%General', 'ContentsSharecare', 'The Senior Secured Credit Agreement', 'Sharecare, Inc.', 'Consolidated Statements of Redeemable Convertible Preferred Stock', 'Consolidated Financial Statements', 'Years)AggregateIntrinsic Value(in thousands)Number of Plan'}"
SHLT,
SHPH,"{'LLC', '\\n\\n&#160;\\n\\nNote\\n7 &#8211', 'the License Agreement', 'Black Scholes', 'SPA', 'the University of Virginia', 'LOC', 'Use Asset and Lease Information', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'the Intellectual Property', 'Shuttle Pharmaceuticals Holdings', 'Georgetown University Medical School', 'Restricted Stock Units', 'FDA', 'name\\nto Shuttle Pharmaceuticals, Inc. (&#8220;Shuttle&#8221', 'CAM', 'the Licensed Products', 'cost&#160;\\n    $', 'RSU', 'payments&#160;\\n    &', '27,120.\\n\\n&#160;\\n\\nLegal\\nand Professional Expenses', 'Licensed\\nProduct', 'the Restricted Stock Units', '\\n\\n&#160;\\n\\nNote\\n4 &#8211', 'First Republic Bank', 'agreement.\\n\\n&#160;\\n\\nBoustead\\nSecurities', 'the Alto Convertible Note\\nis', 'under\\nthe circumstances.\\n\\n&#160;\\n\\nNote\\n3 &#8211', 'Company', 'Restated Certificate of Incorporation', 'Sublease income&#160;\\n    &', 'LLC (&#8220;Boustead&#8221', '\\n    &', 'the Registration Statement on Form S-1', 'the &#8220;Springing\\nDACA&#8221'}"
SIBN,"{'ASC', 'Trust Company (&', 'Security Agreement', 'Contracts with Customers (&#', 'Principal Executive Officer', 'the Original Loan Agreement', 'EEA', 'the ""Term Loan', 'the Compensation Committee', 'the First-Citizens Term Loan', 'iFuse', 'ContingenciesOperating LeasesThe Company', 'EU', 'Notified Body', 'Sarbanes-Oxley', 'Principal Financial and Accounting', 'FlowsThe', 'SeaSpine', 'the Securities Exchange Act', 'NOL', 'an Organization for Economic Co-operation and', 'IndemnificationThe Company', 'COVID-19', 'MaheshwariAnshul MaheshwariChief Financial Officer(Duly Authorized Officer', 'First-Citizens Bank &amp', 'First-Citizens', 'the U.S. Congress', 'the Revolving Line of Credit', 'the Department of Justice', 'Medicaid', 'Medicare', 'the Medical Device Directive', 'the U.S. Department of Justice', 'FDA', 'Loan', 'Risks Related', 'Silicon Valley Bank', 'Company', 'the Median Peer Companies', 'the Amended Loan Agreement', 'SVB', 'Report', 'TORQ.We', 'the iFuse Implant System', 'FCPA', 'the Development Agreement', 'Allowance for Credit Losses', 'Development Inclusive Framework', 'CE Certificates of Conformity', 'Orthofix Medical, Inc.', 'SeaSpine Orthopedics Corporation', 'Registrant', 'Our Amended Loan Agreement', 'Revolver', 'SIGNATURES Pursuant', 'FDIC', 'The Amended Loan Agreement', 'First-Citizens Term Loan', 'the indemnified party', 'CFO', 'Revolver Maturity Date', 'the United States Federal Food, Drug', 'CE', 'Silicon Valley Bridge Bank', 'SI-BONE SImulator', 'healthcare', 'Good Clinical Practices', 'patients;&#8226;&#160;&#160;&#160;&#160;we', 'CFR Parts', 'iFuse-Bone', 'Bedrock', 'PMA', 'Related Party Transaction', 'Amended Loan Agreement', 'HCT/Ps', 'Cosmetic Act', 'CE Certificate of Conformity', 'the European Union'}"
SIEN,"{'years)\\n        &', 'SimpliDerm', '\\n    Interest income\\n    &', 'the &#x201c;Restated', 'ReserveThe', 'TSA', 'the Annual Report', 'Breast Products', 'net\\n  &#160;\\n  Other (expense', 'the Company&#x2019;s Common Stock', 'the American Society of Plastic Surgeons', 'the Temporary Waiver and Exchange Agreement', 'the Original Note', 'the Specified Event of Default', '\\n    Research', 'Operations &', 'COVID-19', 'The Purchase Agreement', 'Warrants', 'FASB', 'management&#x2019;s', 'the Securities and Exchange Commission', 'x2014;\\n        &', 'concern.&#160;To', '\\n  Research and Development Expenses\\n', 'Revolving Credit', 'operations.&#160;The Company', 'Aziyo Biologics, Inc. (&#x201c;Aziyo&#x201d', 'Second Amended and Restated Credit and Security Agreement', '7,341\\n        &', 'x201c;Common', 'Adopted Accounting Standards  &#', 'Common Stock', 'Company', 'Facility Document', '\\n    Interest expense\\n    &', 'Results of Operations', 'Amended and Restated Credit and Security Agreement', 'miraDry Acquisition Company, Inc.', 'Elutia Inc.', 'L.P.', 'Deerfield of', 'operations.\\n  &#160;\\n  17\\n', 'ASU', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Amended and Restated Facility Agreement', 'financial condition.\\n  &#160;\\n', '\\n  &#', 'concern.\\n  &', 'Viality', 'Exchange', 'the Common Stock', 'Conversion and Other Options', 'the Platinum20 Limited Warranty Program', 'Entity&#x2019;s Own Equity', 'the &#x201c;Specified Event', 'Elutia\\', 'Temporary Waiver and Exchange Agreement', 'Restated Agreement', 'the Financial Accounting Standards Board&#x2019;s Accounting Standards Codification', 'CFO', 'Comparison', 'the Restated Agreement', 'The Restated Agreement', 'this Quarterly Report', 'Deerfield Partners', 'Contracts', '\\n  &', 'Deerfield', 'Derivatives', 'The Temporary Waiver and Exchange Agreement', 'MidCap Financial Trust', 'Pre-Funded Warrants', 'MidCap Funding IV Trust', '\\n    ', '\\n        &', 'SEC', 'Accounting for Convertible Instruments', 'Default Interest', 'ADM', 'GAAP', 'Nasdaq', '\\n    &'}"
SIGA,"{'ASC', 'satisfied.&#xa0;The Company', 'International Promotion Agreement', 'CDND', 'the Loan Agreement', 'Department of Health and Human', 'the U.S. Government', 'the United States&#xa0;(the &#x201c;Territory&#x201d;)', 'Condensed Consolidated Financial Statements\\n   &#', 'SIGA Technologies, Inc.', 'this Loan Agreement', 'the Securities and Exchange', 'Internal Control', 'Financial Instruments\\n   &#', 'Yes&#xa0;&#x2612', 'the Current Report on Form 8-K', 'or&#xa0;the &#x201c;Company&#x201d', 'thereunder.\\n   &#', 'the International Promotion', 'the International Promotion Agreement', 'the Company and MacAndrews &', '\\n   &#', 'SIGA Technologies, Inc. (&#x201c;we,&#x201d', '\\n  International Promotion Agreement\\n  &#', '\\n  &#', 'No &#x2610;.\\n&#xa0;\\nIndicate', 'Related Party', 'procedures.\\n  &#', '\\n     &#', 'factors.\\n  &#', 'factors.\\n   &#', 'IV FDP', 'x201c;Loan', 'Company', 'Territory', 'LLC (&#x201c;Lender&#x201d;)', 'the New HQ Lease', 'the ""Canadian Military Contract', 'the Sarbanes-Oxley Act', 'BDS', 'revenue&#xa0;in', 'Financial Reporting\\n  &#', 'material consumed.&#xa0;\\n   &#', 'the International Promotion Agreement with&#xa0;Meridian', 'the Biomedical Advanced Research and Development Authority'}"
SILK,"{'ASC', 'Clinical, Regulatory Affairs', 'Silk Road Medical, Inc.', 'Condensed Financial Statements(unaudited', 'Contractual Obligations', 'this Quarterly Report on Form 10', 'Stifel Bank', 'this Quarterly Report on Form 10-Q', 'Percutaneous Transluminal Angioplasty', 'IRC', 'the Internal Revenue Code', 'the Index Rate', 'QSR', 'net&#8212;&#160', 'the Securities Exchange Act', 'Accumulated Accumulated &', 'SEC Regulation S-K', 'Cordis', 'ISO', 'TCAR', 'the Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis', 'the National Institutes of Health', 'net &', 'CAS', 'Medicaid', 'Medicare', 'FDA', 'ENROUTE', 'Loan', 'Amount2023', 'The Company Silk Road Medical, Inc.', 'Company', 'ISO 13485', 'First Citizens Bank &amp', 'USPTO', 'Contents&#160;Silk Road Medical, Inc.Notes', 'CTA', 'CMS&#8217;s', 'the Delaware General Corporation Law', 'CMS', 'the U.S. Patent and Trademark Office', 'Oxford Finance', 'Loan Agreement', 'FCPA', 'The Loan Agreement', 'September&#160;30,(in thousands)2023 2022', 'Trust Company', 'the Organization for Economic Cooperation and Development', 'Board of Directors', 'The Index Rate', '343,712)Total stockholders&apos', 'TSR', 'Contents&#160;\\n     &#160;Results', 'FDIC', '\\n    &#160;12Table', 'artery stenosis &', 'Hamas', 'the Loan Agreement', 'the Court of Chancery of the State of Delaware', 'CEA', 'Contents&#160;\\n    Silk Road Medical, Inc.', 'ESPP', 'Quality Assurance', 'the State of Delaware', 'the SVS&#8217;s Patient Safety Organization', 'Risks Related to Government RegulationHealthcare', 'value  &#8212', 'this Quarterly Report on Form&#160;10-Q.', 'PMA', 'Accounting Standards Codification', 'data)Common Stock Additional &#', 'the Court of Chancery', 'SEC', 'SOFR', 'Contents&#160;\\n     Silk Road Medical, Inc.', 'Risks Related to Ownership of Our Common', 'MRA', 'compensation &', 'the Multispecialty Carotid Alliance', '\\n    &', 'Condensed Financial Statements&#160;Silk Road Medical, Inc.'}"
SILO,"{'ASC', 'LLC', 'Venture', 'negotiate\\nand', 'the July\\n2021 Sponsored Research Agreement', 'pursuant\\nto the', 'into\\nthe Master License Agreement (&', 'UMB', 'UMB Master License Agreement.&#160;\\n\\n\\n\\n\\n\\n\\n', 'Aikido Pharma Inc.', 'the Compensation Committee', 'the License Agreement (&#8220;Amended License', 'Asset Purchase Agreement', 'a Patent License Agreement', 'The Regents of the University of California', 'Pharma, Inc.', 'The Aikido License Agreement', 'the License Agreement to', 'the Securities Exchange Act', 'customers\\nin', 'Therapeutics', 'Aikido pursuant\\nto', 'Certificate of Incorporation', 'CNS', 'the JV Agreement', 'classified\\nas', 'the Master License Agreement.\\nThe Company', 'Research &', 'operations.\\n\\n&#160;\\n\\nCost\\nof', 'Use&#8221;).\\n\\n&#160;\\n\\nThe\\nLicense Agreement', 'ZTI', 'University of Maryland', 'the Ryweck Employment Agreement', 'the Weisblum Severance', 'Baltimore - License Agreement for Development and Use of Joint-Homing', 'import\\nthe Licensed Products', 'Daniel Ryweck\\ndated', 'The Employment Agreement', 'yet.\\n\\n&#160;\\n\\nFurthermore,\\npursuant', 'the University of Texas (&#8220;University&#8221', 'Series C Convertible', 'UMB pursuant\\nto', 'Fair Value of Financial', 'CONSOLIDATED FINANCIAL STATEMENTS\\nSeptember', 'the Company and University of Maryland', '2023\\n(UNAUDITED)\\n\\n&#160;\\n\\nNOTE\\n3 &#8211', 'the Series M Convertible Preferred Stock', 'the Joint Venture Agreement,&#160;(A', 'Laidlaw &amp;\\nCompany', 'Baltimore - License Agreement for Development and Use of Central Nervous System-Homing', 'FAIR VALUE OF FINANCIAL INSTRUMENTS', 'SUBSEQUENT', 'the Amended Service Agreement', 'Company', 'Multiple Sclerosis (&#8220;MS&#8221;)', 'Company and University of Maryland', 'Silo Pharma, Inc.', 'the Master License Agreement', 'Reprocell Europe Ltd.', 'ASC 718 &#8211', 'net&#160;\\n    &', 'Company\\nvalued', 'the University of Maryland', 'LLC (&#8220;Joint', 'Joint Venture Agreement', 'UK) Ltd.', 'operations.\\n\\n&#160;\\n\\nNOTE\\n8 &', 'ASU', 'the Patent Rights.\\n\\n&#160;\\n\\nPursuant\\nto', 'committed\\nto', 'the &#8220;Customer&#8221;)', 'Agreement with Columbia University', 'Reprocell', 'License Agreement', 'the Weisblum Employment Agreement', 'tax&#160;\\n    &', 'the Series C Convertible', 'the Amended License Agreement', 'License', 'the Weisblum Payments', 'the UMB License', 'an Employment Agreement', 'PROCEDURES\\n\\n&#160;\\n\\nEvaluation\\nof Disclosure Controls', 'of\\nthe Compensation Committee of the Board of Directors of the Company (the &#', 'the Patented Technology', 'ketamine,\\n(3', 'the Sponsored Research Agreement.\\n\\n&#160;\\n\\nInvestigator-Sponsored\\nStudy Agreement', 'UMB License Agreement', 'Aikido Pharma, Inc.', 'the Sponsored Study Agreement', 'the Company&#8217;s Board of Directors', 'Zyl&#246;\\nTherapeutics, Inc. (&#8220;ZTI&#8221', 'the Sponsored Research Agreement', 'the Employment Agreement', 'Financial Accounting Standards Board', 'the Company.\\nThe Company', 'the &#8220;Effective Date&#8221;)', 'NFID', 'Multiple Sclerosis.\\n\\n&#160;\\n\\nCommercial\\nEvaluation License and Option Agreement', 'Weisblum Employment Agreement&#8221;)\\npursuant', 'the Columbia Agreement', 'Ryweck Employment Agreement', 'the License Agreement', 'Sponsored\\nStudy Agreement with University of Maryland', 'the Joint Venture Agreement', 'Contracts with Customers (&', 'this Quarterly Report', 'the Master License\\nAgreement', 'realized.\\n\\n&#160;\\n\\nThe\\nCompany', 'The Kuo Employment Agreement', 'the Series M Convertible', 'Stress Projects', 'Columbia University', 'UMB Arising IP', 'the Reprocell Research Agreement', 'the Patent Rights', 'Columbia', 'CNS Homing', 'the Sponsored Study\\nAgreement', 'Cause', 'Columbia University (&#8220;Columbia&#8221', 'sheets.\\n\\n&#160;\\n\\nSponsored\\nResearch Agreement', 'UCSF', 'The Regents of the University of California\\n\\n&#160;\\n\\nOn\\nJune 1, 2021 (', 'Albert Einstein College of Medicine', 'the Certificate of Designations', 'the Joint Venture', 'The Regents of\\nthe University of California', 'the &#8220;License\\nAgreement&#8221', '\\n    &', 'the Employment Agreement,\\neffective', 'the Kuo Employment Agreement at'}"
SINT,"{'CTL Medical', 'ASU', 'the Nasdaq Capital Market', 'Form S-3', 'Maxim.\\n\\n&#160;\\n\\nNASDAQ Notification\\n\\n\\n&#160;\\n\\nOn\\nOctober 20, 2023', 'Commission&#8217;s\\nrules', 'the Financial Statement Accounting Board', 'ATM', 'the &#8220;Shelf Registration', 'Nasdaq Listing Qualifications', 'controls\\nand', 'Maxim Group', 'the The Nasdaq Capital Market', 'marketing&#160;\\n    &', 'NIH', 'The Nasdaq Capital Market', '\\n    Research', 'Industrial Lease Agreement', 'Company&#8217;s\\ninitial', 'SEC', 'the Shelf Registration Statement', 'Company', 'Unrecognized\\n    Stock-Based&#160;&#160;\\n    Remaining of\\n                                                                                                                                                                                                                                                                     Recognition&#160;\\n  \\n    &', 'the Securities Exchange Act', 'TA&amp;T', 'the Securities Exchange', 'COVID-19', 'Unrecognized Stock', 'requires\\nenhanced', 'Amedica Corporation', '\\n    &'}"
SLDB,"{'the Health Insurance Marketplace', 'LLC', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', 'principles:\\n  &#x2022;identify', 'Fair Value of Financial Assets', 'candidates;\\n  &#x2022;difficulty', 'Mayo Collaborative Services', 'Ultragenyx Pharmaceutical Inc.', 'EMA', 'biosimilar applicants;\\n  &#', 'Board of Directors;\\n  &#x2022;require', 'MaximumMembersldb', 'Maugeri\\', 'EEA', 'November2022WorkforceReductionPlanMember2022-01-012022-12-310001707502us-gaap', 'Ultragenyx', 'Solid Biosciences Inc.', 'EU', '\\n  &#x2022;bring', 'AavantiBio', 'EquipmentMember2023', 'phenotype;\\n  &#x2022;failure', 'x2022;a', 'the Agreement, Maugeri', 'Indicate', 'UNITED STATES', 'BPCIA', 'AccruedExpensesAndOtherMember2022-12-310001707502sldb', 'CPRA', '\\n    Research', 'Form S-1', 'the Securities Exchange Act', 'Research', '\\n  &#x2022;recall', 'COVID-19', 'and\\n  &', 'Property and Equipment Property', '\\n  &#x2022;litigation', 'OneTimeTerminationBenefitsMember2022', 'the University of Missouri', 'AtTheMarketOfferingSalesAgreementMember2023-01-012023-09-3000017075022022-07-012022-09-3000017075022022-10-2800017075022022-12-310001707502sldb', 'dose escalation;\\n  &#x2022;delays', '\\n  &#x2022;product', 'UltragenyxMember2022', 'Private Placement', '\\n  &#x2022;publicity', 'x201c;Risk', 'manufacturers&#x2019', 'and\\n  &#x2022;require', '\\n  &#x2022;refusal', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'x2014;\\n        &', ': &', 'design;\\n  &#x2022;delays', 'a Committee for Medicinal Products for Human Use', 'FDA', '\\n  &#x2022;collaborations', 'the Licensed Products', 'requirements.\\n  &#x2022;Our', '\\n        Laboratory equipment\\n', '\\n  &#x2022;disagreements', 'and\\n  &#', 'Prometheus Laboratories', 'EGC', '\\n  &#x2022;relative', 'depreciation\\n        &', '\\n  &#x2022;warning', '77\\n', 'HIPAA', 'the Hatch-Waxman Amendments', '\\n  &#x2022;requirements', 'AtTheMarketOfferingSalesAgreementMember2023', 'SGT-001', '\\n  &#x2022;fines', 'follows:&#160;\\n        \\n         \\n', 'the European Union Data Protection Directive', 'activities\\n    &', 'and\\n  &#x2022;disruptions', 'Company', 'LeaseholdImprovementsMember2022-12-310001707502sldb', 'requirements;\\n  &#x2022;economic', 'the board;\\n  &#', 'Adopted Pursuant to Section 302', 'the Health Care Reform Law', 'the California Privacy Rights Act', '\\n  &#x2022;injunctions', '\\n  &#160;\\n', 'and\\n  &#x2022;business', 'Candidates', '\\n    External expenses\\n    &', 'April2022PlanMember2022-04-012022-04', 'including:\\n  &#x2022;reduced', 'the Delaware General Corporation Law', 'the European Commission', 'Candidates;\\n  &#x2022;obtain', 'UltragenyxMember2023-09-30iso4217:', 'CMS', 'relationships;\\n  &#x2022;risks', 'ICS Maugeri S.p.A. SB', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'collaboration;\\n  &#x2022;retention', 'the U.S. Department of Health and Human Services', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001707502sldb', '49,037\\n          &', 'IRB', '\\n  &#', '\\n  &#x2022;suspension', 'Board of Directors', '\\n  &#x2022;collaborators', 'This Executive Order', 'the U.S. Supreme Court', '\\n  Designation', 'the University of Washington', 'patentable;\\n  &#x2022;the', 'consent;\\n  &#x2022;limit', 'Contractual', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n  &#', 'the Listing Qualifications Department of The Nasdaq Stock Market', 'the Sarbanes-Oxley Act', 'otherwise;\\n  &#x2022;occurrence', 'the collaboration;\\n  &#x2022;collaborators', 'organization)\\n    &#160;\\n', 'Comparison', 'activities;\\n  &#x2022;the', 'DMD', 'SOLID Ventures Management', 'Board of Directors;\\n  &#x2022;limit', 'CJEU', 'Health Insurance Portability', 'markets;\\n  &#x2022;compliance', '\\n  &#9744;\\tTRANSITION', '\\n  &', 'November2022WorkforceReductionPlanMember2022-12-310001707502us-gaap', 'the Court of Chancery of the State of Delaware', '\\n  &#x2022;delays', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09', 'RestrictedStockUnitsRSUMember2023-01-012023-09', 'European Union', '\\n  &#x2022;favorable', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', '\\n  &#x2022;unfavorable', 'the Drug Price Competition and Patent Term Restoration Act', 'patents;\\n  &#x2022;issued', '\\n  &#x2022;withdrawal', '\\n        &', 'SOLID BIOSCIENCES INC', 'Restricted', 'SEC', 'Trade Control', '\\n  &#x2022;damage', 'SoftwareAndSoftwareDevelopmentCostsMember2022-12-310001707502us-gaap', '42\\n  \\n  &#', '\\n  &#x2022;failure', 'may:\\n  &#', 'the European Union', 'Nasdaq', '\\n    &', 'property.\\n'}"
SLGC,"{'ASC', 'Value LevelWarrant', 'KOLs', 'the Merger Agreement', 'SaleThe', 'CMLS II', 'RevenueThe', 'United&#160;States', 'NEC Solution Innovators, Ltd.', 'NEC Corporation', 'SoftwareThe Company', 'EstimatesThe', 'OperationsComparison', 'controls&#8226;As', 'COSO', 'The Nasdaq Stock Market', 'RevenueOther', 'NEB', 'the Palamedrix Acquisition', 'Development ActivitiesWe', 'the Securities and Exchange Commission', 'ROU', 'assessment:&#8226;As', 'Compensation - Nonretirement Postemployment', 'SSP', 'SomaLogic', 'the Joint Development &', 'NEC', 'SPAC', 'Condensed Consolidated Financial StatementsUnauditedLiabilities', 'value:(in', 'Standard BioTools&#8217', 'ActivitiesPurchases', 'No &#9744;Indicate', 'the Standard BioTools Stock Issuance', 'NES', 'SEC', 'Common Stock', 'Company', 'Condensed Consolidated Financial StatementsUnauditedAs of September&#160;30', 'the Securities Exchange Act', 'Financial Information - Item 1', 'Commercialization Agreement', 'Standard BioTools', 'I.', 'ContentsPART 1 &#8211', 'LeasesWe', 'Leases', 'the Illumina Agreement', 'The Merger Agreement', 'October&#160;13', 'Merger', 'SAA', 'Marketed', 'Condensed Consolidated Financial', 'Condensed Consolidated Financial StatementsUnauditedof', 'SomaLogic Operating Co. Inc.', 'U.S. Treasuries', 'Warrants'}"
SLGL,
SLN,
SLNO,
SLP,
SLRN,
SLRX,"{'FASB', 'ASU', 'the University of Utah', 'Qualitative Disclosures', 'the University of Utah Research FoundationIn 2011', 'Financial Instruments', 'September&#160;30,', 'FDA', 'national securities exchange', 'Financial Instruments - Credit Losses', 'EquivalentsSalarius', 'OperationsThe', 'SEC', 'Common Stock', 'the Minimum Bid Requirement', 'Company', 'the Securities Exchange Act', 'the unaudited financial information', 'Results of Operations', 'Hearings Panel', 'Nasdaq'}"
SLS,"{'GenFleet Therapeutics', 'Fast Track Designation for AML', ': &#8226;expenses', 'Cantor Fitzgerald &amp', 'Form S-3', 'ODD', 'AML', 'Keytruda', 'EMA', 'GPS', 'revenue&#8212;&#160;100&#160;(100)Research', 'Internal Control', 'development5,813&#160;4,282&#160;1,531&#160;General', 'the Securities and Exchange Commission', 'REGAL', 'Biologics License Application', 'the U.S. Food and Drug Administration', 'a Clinical Trial Collaboration and Supply Agreement', 'MPM', 'MM', 'this Quarterly Report on Form 10-Q', 'FDA', 'II - OTHER INFORMATIONITEM&#160;1', 'CR2', 'this Quarterly Report on Form 10-Q:(a)our', 'the European Medicines Agency', 'NCI', '3D Medicines Inc.', 'Orphan Drug Product Designations', 'SEC', 'Merck &', 'DevelopmentResearch', 'myeloid', 'In-Process Research', 'BLA', 'Company', 'CDK9', 'the Securities Exchange Act', 'MSK', 'IncomeNon', 'Results of Operations', 'Nasdaq', 'this Quarterly Report on Form 10-Q.23Results of', 'GenFleet'}"
SMLR,
SMMT,
SMTI,"{'ASC', 'eliminated\\non', 'LLC', 'Direct Dermatology Inc.', 'as\\nan independent contractor', 'into\\nthe Loan Agreement', 'Applied', 'indicated\\non', 'Rochal Industries', 'the Board of Directors of the Company or SMAT', 'Phillips', 'SMAT.\\n\\n&#160;\\n\\nThe\\nLoan Agreement', 'RELATED PARTIES\\n\\n&#160;\\n\\nCellerateRX\\nSurgical Sublicense Agreement\\n\\n&#160;\\n\\nThe\\nCompany', 'consideration&#160;\\n    &#160;&#160;&#160;&#160;\\n    $16,581,783&#160;\\n', 'BioStructures', 'flows.\\n\\n&#160;\\n\\nNOTE\\n3 &#8211', 'the Audit Committee', 'LLC (&', 'the Federal Reserve Bank', 'The Catalyst Group', 'Catalyst Services Agreement', 'the Applied Asset Purchase.\\nDepreciation', 'Regulation S-K.', 'options&#160;\\n    &', 'the term\\nof the Sublicense Agreement', 'pursuant\\nto the Sales Agreement', 'Products &#8211', 'warrants&#160;\\n    &', 'Operations', 'the True-Up Payment', 'the Petito Services', 'the Maximum Rate', 'Series A Convertible Preferred Stock', 'Rochal', 'Catalyst', 'DirectDerm', 'Consolidated', 'goods\\nsold', 'the Catalyst Services Agreement', 'SMTI', 'Precision Healing', 'products.\\n\\n&#160;\\n\\nDepreciation\\nand', 'the Securities and Exchange Commission', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n13 &#8211', 'Precision Healing, Inc. (&#8220;Precision', 'Loan', 'WCS', 'pursuant\\nto', 'the Applied Asset', 'Transaction Advisory Services Agreement', '\\n\\n&#160;\\n\\nNOTE\\n9 &#8211', 'consideration&#160;\\n    &#160;&#160;&#160;&#160;\\n    &', 'the Sublicense Agreement.\\n\\n&#160;\\n\\nSelling,\\ngeneral', 'The\\nSeries A Stock', 'Company', 'Catalyst Services', 'LLC (&#8220;Rochal&#8221;)', 'Business Combinations', 'Indemnity Holdback', 'Applied Asset Purchase', '\\n    &#', 'Catalyst.\\n\\n&#160;\\n\\n\\n\\n    &', 'Cantor Fitzgerald &amp', 'the Applied Earnout', 'Business Combinations (&', 'Loan Agreement', 'required\\nto', 'HYCOL', 'purchase\\n(i', 'underlying\\nasset', 'The Catalyst Group, Inc. (&#8220;Catalyst&#8221', 'Convertible Preferred Stock', 'Precision Healing&#160;\\n    &', 'earned\\nat', 'Precision Healing.\\n\\n&#160;\\n\\nScendia\\nPurchase Agreement\\n\\n&#160;\\n\\nIn\\nJuly', 'Board of Directors', 'Owner &#8220;For', 'The Nasdaq Capital Market', 'Cadence Bank', 'the Debrider License Agreement include:\\n\\n&#160;\\n\\n\\n&#9679;Upon\\n                                            FDA', 'Applied Earnout', 'payable.\\nPursuant', 'purposes.\\n\\n&#160;\\n\\nPursuant\\nto', 'Executive', 'defined\\nin the Sublicense Agreement', 'Healing technology.\\n\\n&#160;\\n\\n&#9679;\\nVirtual Consult Services', 'Rochal.\\n\\n&#160;\\n\\nCatalyst\\nTransaction Advisory Services', 'the Company&#8217;s Board of Directors', 'LLC (&#8220;Sanara', 'SMAT', 'Flow Leverage', '2023.\\n\\n&#160;\\n\\nThe\\nLoan Agreement', 'Scendia.\\n\\n&#160;\\n\\nApplied\\nAsset', 'Bank', 'the Loan Agreement', 'Furneaux Capital Holdco', 'Contracts with Customers (&', 'Consolidated Statements', 'disadvantage.\\n', 'Company\\nand', 'securities&#160;\\n    &', 'the Board of Directors', 'investors\\nin', 'Scendia', 'the Petito Services Agreement', 'the Precision Healing\\nPlan', 'all\\ncollected Net Sales', 'Owner', 'United Wound', 'agreement\\nwith CGI Cellerate RX', 'the Precision Healing Plan', 'Cantor', 'LFA', 'Ms.', 'the Applied Asset Purchase', 'the Applied Purchase Agreement', 'CGI Cellerate RX', 'respectively.\\n\\n&#160;\\n\\nNOTE\\n10 &#8211', 'into\\na professional services', 'us,\\nand', 'Minimum Development Efforts', 'Wound Care Solutions,', 'Company&#8217;s\\nconsolidated', '\\n    &', 'the Sublicense Agreement'}"
SNCE,"{'LLC', 'Tyche Capital', 'Reliance', 'programs.\\n\\n&#160;\\n\\nWe', 'the Reverse Stock Split', 'Note 2 &#8211', 'Covered Officer engaged\\nin', 'this Quarterly Report on Form 10-Q', 'Court', 'Compensation Committee\\nand Board', 'Third-Party Complaint', 'the Oxford University Studentship Program', 'Principal Financial and Accounting', 'Commission', 'the Securities Exchange Act', 'the Sarbanes-Oxley Act\\n    &', 'COVID-19', 'the Clawback Policy', 'Oxford University', 'The Alpha Warrants', 'the Private SPAC Warrants', 'Therapeutics L.P.', 'Diluted', 'IP', 'Consolidated Financial', 'Going Concern', 'the Individual Company Defendants', 'revenues.\\n\\n&#160;\\n\\nWe', 'Termination Letter', 'value.\\n\\n&#160;\\n\\nAs', 'Clawback Policy', 'KBL\\nHealthcare Management, Inc.', 'Company', 'the Chancery Court', 'Freedom Specialty Insurance Company (&#8220;Freedom&#8221', 'the Restricted Stock Shares\\nwere', 'agreements\\non', 'the Public SPAC Warrants', 'clinical\\nproduct', 'the Company&#8217;s\\nCannBioRex Pharmaceuticals Corp.', 'Report', 'Life Sciences Corp. Policy', 'the Hebrew University of Jerusalem, Ltd.', 'the Nasdaq Capital Market', 'the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'Tyche with\\nregards', 'Omnibus Incentive Plan\\n    &', 'Clawback Policy,\\na', 'the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;)\\nindicating', 'the Supreme Court of New York', 'Yissum Research\\nDevelopment Company', 'Life Sciences Corp.', 'the Securities and Exchange Commission.\\n\\n&#160;\\n\\nSignificant\\nFinancial Statement Components\\n\\n&#160;\\n\\nResearch\\nand', '2023.\\n\\n&#160;\\n\\nRecently\\nIssued Accounting', 'Order', 'the\\nIP', 'The Nasdaq Capital Market', 'the Stanford License\\nAgreement', 'the AGP Warrants', 'Rule 144', 'another national securities exchange', 'Public Warrants', 'Company&#8217;s\\nformer', 'Equity, under &#8220;Part I &#8211', '2022,\\nunder &#', 'Opposition', 'the University of Oxford', 'December\\n2022', 'Tyche Capital LLC\\n\\n&#160;\\n\\nThe\\nCompany', 'Delaware Law\\n\\n&#160;\\n\\n\\n&#9679;Our\\nCertificate of Incorporation', 'Incorporation', 'Complaint', 'the Interactive Data File', 'the Subject Guarantee', 'Pre-Funded Warrants', 'Third-Party', 'Freedom\\nwill', 'First Amended and Restated', 'Oxford University\\nand Yissum', 'Yes &#9746;&#160;No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'Nasdaq', '\\n    &'}"
SNDX,"{'Incyte;\\n  &#x2022;the', 'LLC', 'Menin&#x2013;KMT2A', 'AML', '\\n', 'candidates;\\n  &#x2022;the', 'ATM Program', '\\n  &#x2022;costs', 'Indicate', 'countries;\\n  &#x2022;developments', 'CR/CRh', 'Unless', 'technologies;\\n  &#x2022;the', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'and\\n  &#x2022;unfavorable', 'AbbVie', 'data)\\n        &', 'Future Funding Requirements \\n', 'Adopted Accounting Pronouncements', '\\n  &#x2022;expenses', 'our shares;\\n  &#x2022;announcement', 'RESTRICTED CASH &#x2014;end', 'compensation\\n    &', 'FASB', 'x201c;Risk', 'Internal Control', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'the Allergan License Agreement', 'x2014;\\n        &', 'products;\\n  &#', '27\\n', 'FDA', 'UncertaintiesWe', 'and\\n  &#', 'UCB', 'REMS', '\\n  &#x2022;license', 'activities\\n    &', 'equipment.\\n  Net Cash Provided by Financing Activities \\n  ', 'Company', 'letters;\\n  &#x2022;mandate', 'Bayer Schering Pharma AG', 'analysts;\\n  &#x2022;variations', 'the unaudited financial information', 'USPTO', '\\n  &#160;\\n', 'NR', 'and\\n  &#x2022;business', 'Incyte Share Purchase Agreement', 'healthcare practitioners;\\n  &#x2022;require', 'the Delaware General Corporation Law', 'capital commitments;\\n  &#', 'candidates;\\n  &#', 'New Drug Application', 'events;\\n  &#x2022;the', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Bayer', 'the UCB License Agreement', 'Stockholders&#x2019', 'technologies;\\n  &#x2022;regulatory', 'UCB6352', 'Oncology Review', 'Financial Reporting\\n  Controls', '\\n  &#', 'Recent Accounting Pronouncements\\n', 'NDA', 'CONDENSED CONSOLIDATED BALANCE SHEETS \\n', 'the&#x202f;Leukemia &amp', 'INC', 'Economy,&#x201d', 'Results of Operations \\n', 'Vitae Pharmaceuticals', 'products;\\n  &#x2022;actual', 'Incyte', 'Cowen and Company', 'iii\\n', 'ATM', 'Bayer Pharma AG', 'development programs;\\n  &#', 'x2022;strategic', 'x2022;refuse', 'and\\n  &#x2022;general', 'PHARMACEUTICALS', 'us;\\n  &#x2022;suspend', 'litigation;\\n  &#x2022;business', 'Significant Accounting Policies', 'candidates;\\n  &#x2022;termination', '\\n  &#x2022;consulting', '\\n        &', 'SEC', 'noncompliance;\\n  &#', '\\n  &#x2022;allocated', '\\n  &#x2022;manufacturing', '17\\n', 'RESTRICTED', 'may:\\n  &#', 'Nasdaq', '\\n    &'}"
SNGX,
SNOA,"{'L.P.', 'FASB', 'LLC', 'Internal Control&#160;&#8212', 'the Natural Products', 'Brill International', 'Sonoma Pharmaceuticals', 'Ladenburg Thalmann &amp', 'concern.\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'the Board of Directors', 'Co. Inc.', 'Sonoma Pharmaceuticals, Inc.', 'Petagon Limited', 'Maxim Group', 'distributors.\\n\\n&#160;\\n\\nTo', 'net&#160;\\n', 'Nasdaq&#8217;s\\nletter', 'goods&#160;\\n    &', 'the Compensation Committee', 'Maxim', 'the Compensation Committee of\\nthe Board of Directors', 'Dyamed Biotech Pte Ltd.', 'Daewoong Pharmaceutical Co., Ltd.', 'Integrated Framework&#160;issued', 'S.A. de C.V.', 'de C.V.', 'Microdacyn60&#174; Eye Care', 'reference).\\n\\n', 'S.L.', 'Definitive Proxy Statement', 'procedures.\\n  \\n    &', 'SEC', 'Exclusive License and Distribution Agreement', 'circumstances.\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'Company', 'positions.\\n', 'the Committee of Sponsoring\\nOrganizations of', 'Montreux Equity Partners V', 'Petagon', 'MicroSafe Group', 'Computershare, Inc.', 'Anlicare International', 'the Sarbanes-Oxley Act', 'Jerome Dvonch Consulting', 'the Treadway Commission', 'Limited', 'Nasdaq', 'life.\\n\\n&#160;\\n\\nIn', 'Computershare Trust Company', '\\n    &', 'products.\\n\\n&#160;\\n\\nThe Company', '\\n    &#', 'Westland Development Services'}"
SNPX,"{'ASC', 'Synaptogenix', 'LLC', 'ConsultingAgreementWithSmCapitalManagementLlcMember2023-01-012023-09-300001571934snpx:', 'Multiple Sclerosis', 'WCT 2022 Study', 'The Certificate of Designations', 'CRE', 'Stanford', 'the Icahn School of Medicine', 'State', 'Blanchette Rockefeller Neurosciences Institute', 'GPN', 'Conversion Price', 'November2022PrivatePlacementMember2022-11-170001571934snpx:MeasurementInputEstimatedEquityVolatilityMemberus-gaap', 'Katalyst Securities LLC (&#8220;Katalyst&#8221', 'NRV II', 'Financial Instruments', 'Nemours A.I.', 'this Quarterly Report on Form 10-Q', 'November2022PrivatePlacementMember2022-11-170001571934us-gaap', 'the Supply Agreement', 'the Katalyst Agreement', 'November2022PrivatePlacementMember2022-12-310001571934us-gaap', 'the November Investors', 'November2022PrivatePlacementMember2022-11-170001571934snpx:', 'NCI', 'WarrantMember2022-01-012022-09-300001571934us', 'SMCM', 'SeriesBPreferredStockMember2022-01-012022-12-310001571934snpx:', 'WarrantMember2022-01-012022-12-310001571934us-gaap', 'Integrated Framework', 'Cooperative Research and Development Agreement', 'WarrantMember2023-09-300001571934us-gaap', 'the National Cancer Institute of the National Institutes of Health (&#8220;NCI&#8221;)', 'CECL', 'Synaptogenix, Inc.', 'The Conversion Price', 'Series B Preferred Stock', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001571934snpx:', 'November2022PrivatePlacementMember2022-01-012022-09-300001571934us', 'LicenseMembersnpx', 'ConsultingAgreementWithSmCapitalManagementLlcMember2022-01-012022-09-300001571934snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember2022-01-012022-09-300001571934snpx:ConsultingAgreementWithGpNurmenkariIncMember2022-01-012022-09-300001571934snpx:StanfordLicenseAgreementsMember2017-01-192017-01-190001571934snpx', 'PreferredStockMember2022-06-300001571934us', 'FASB', 'the Transfer Agreement', 'The Common Stock', '&quot;floor price&quot', 'FASB ASC', 'the Stanford Agreement', 'WarrantMember2022-07-012022-09-300001571934us', 'Private Placement', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'the Consulting Agreement', 'FDA', 'Niemann-Pick Type C', 'the Cleveland Clinic', 'WarrantMember2023-07-012023-09-300001571934us-gaap', 'ContentsThe', 'ContentsEffective', 'Loss)The Company', 'the Private Placement', 'Fragile X', 'Common Stock', 'PreferredStockMember2022-01-012022-09-300001571934us', 'Company', 'Multiple Sclerosis (&#8220;MS&#8221;)', 'ServicesAgreement2020Member2020-04-012020-04-300001571934snpx', 'BryoLogyx', 'November2022PrivatePlacementMember2022-11-170001571934snpx:AdvisoryAgreementsMember2022-11-220001571934snpx:PlacementAgentsMembersnpx:November2022PrivatePlacementMember2022-11-170001571934snpx:SeriesGWarrantsMember2022-09-300001571934snpx:SeriesEWarrantsMember2022-09-300001571934us-gaap', 'WarrantMember2023-01-012023-09-300001571934us-gaap', 'The Broker Warrants', 'WCT', 'November&#160;10', 'Form&#160;10-K', 'the November Warrants and the Company', 'ContentsCognitive Research', 'NemoursAgreementMember2023-01-012023-09-300001571934snpx:ServicesAgreement2020Member2022-02-102022-02-1000015719342023-09-3000015719342022-12-310001571934us', 'Cleveland ClinicOn', 'Purchase Agreement', 'ASU', 'the CRE License Agreement', 'Exclusive License Agreement', 'OperationsComparison', 'the Certificate of Designations for the Series B Preferred Stock', 'the Committee of Sponsoring Organizations of the Treadway Commission', 'October&#160;2016', 'the U.S. Department of Health and Human Services', 'Neurotrope', 'THE SECURITIES EXCHANGE ACT', 'WarrantMember2023-01-012023-09-300001571934us', 'Internal Controls', 'Protein Kinase C Epsilon', 'November2022PrivatePlacementMember2022-11-172022-11-170001571934srt:', 'Stanford University', 'The Board of Trustees of The Leland Stanford Junior University', 'Neurotrope Bioscience, Inc.', 'November2022PrivatePlacementMember2023-01-012023-09-300001571934us', 'the Company', 'the Annual Report on Form 10-K', 'the November Warrants on any national securities exchange', 'ConsultingAgreementWithSmCapitalManagementLlcMember2022-07-012022-09-300001571934snpx:ConsultingAgreementWithKatalystSecuritiesLlcMember2022-07-012022-09-300001571934snpx:ConsultingAgreementWithGpNurmenkariIncMember2022-07-012022-09-300001571934snpx:', 'November2022PrivatePlacementMember2022-11-170001571934snpx:MeasurementInputEstimatedTradedVolatilityMemberus-gaap', 'November2022PrivatePlacementMember2023', 'November2022PrivatePlacementMember2022-11-172022-11-170001571934snpx:', 'AgreementsWithBryologyxMember2023-01-012023-09-300001571934us-gaap', 'the Stanford License Agreement', 'November2022PrivatePlacementMember2022-11-172022-11-170001571934snpx:AgreementsWithBryologyxMember2020-06-090001571934us-gaap', 'FairValueMeasurementsRecurringMember2023', 'PreferredStockMember2022-12-310001571934us-gaap', 'Katalyst Securities', 'ServicesAgreement2022Member2023-09-300001571934snpx:', 'Bryostatin-1&#8217;s', 'November2022PrivatePlacementMember2022', 'TLSA', 'the Offer Letter', 'Fragile X syndrome', 'Black Scholes', 'Board', 'Financial Instruments-Credit Losses', 'a Fundamental Transaction', 'Cognitive Research Enterprises, Inc.', 'the Blanchette Rockefeller Neurosciences Institute', 'GP Nurmenkari, Inc. (&#8220;GPN&#8221', 'Cleveland Clinic', 'Mount Sinai Agreement', 'ASC 480.The Warrants', 'this Quarterly Report on Form 10-Q.Changes', 'November2022PrivatePlacementMember2022-12-310001571934snpx:', 'CRADA', 'the State of Delaware', 'SM Capital Management', '4.7%.Common Stock WarrantsPursuant', 'Related Party Transactions', 'November2022PrivatePlacementMember2022-01-012022-12-310001571934srt', 'the Tax Matters Agreement', 'ConsultingAgreementWithSmCapitalManagementLlcMember2023', 'November2022PrivatePlacementMember2022-11-172022-11-170001571934srt', 'the Certificate of Designations', 'SEC', 'WarrantMember2022-12-310001571934us-gaap', 'MaximumMember2023-09-300001571934us-gaap', 'the Series B Preferred Shares', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001571934snpx:', 'the Series B Preferred Stock', 'a Technology License and Services Agreement', 'EquityIncentivePlan2020Member2021-04-0700015719342021-04-070001571934snpx:EquityIncentivePlan2020Member2020-12-070001571934snpx', 'Stanford License AgreementsOn May&#160;12', 'the CRE License', 'Cognitive Research'}"
SNSE,"{'ASC', 'API', 'years)\\n        &', 'Treasury Regulations', 'Hope Farms', 'The Sarbanes-Oxley Act', 'the Hope Farms Services Agreement', 'the &#', 'Phase 4', 'the Internal Revenue Code', 'Altarius Asset Management Ltd.', 'CPRA', '\\n    Research', 'Principal Financial and Accounting', 'the BSP Service Agreement', '\\n      &', 'the Securities Exchange Act', 'L.L.C.', 'Property and Equipment Property', '\\n  &#x2022;adverse', 'HHS', '\\n  &#x2022;assimilation', 'the Apeiron Purchase Agreement', '\\n  Research and Development Expenses \\n  Research', 'the Trade Control laws.\\n', 'Purchase Agreement - Apeiron Investment Group', 'x201c;Risk', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'x2014;\\n        &', '\\n  &#x2022;general', 'FDA', 'FAIR VALUE', 'Agreement - Binney Street Partners During', 'EGC', '\\n  &#x2022;changes', '\\n  &#x2022;regulatory', 'the Cambrian Purchase Agreement', 'REMS', 'Company', 'RELATED-PARTY TRANSACTIONS Service Agreement - Hope Farms During', 'Binney Street Partners', 'USPTO', '\\n  &#160;\\n', 'Immunoglobulin Domain Containing 4', 'VISTA', 'Report', 'L.P.', 'CMS', 'Item 10 of Regulation S-K', '32\\n', 'Financial Position\\n  &#x2022;We', 'x2022;concerns', 'CCPA', 'Sublease', 'FCPA', 'the Hope Farms Service', '\\n  &#x2022;the', '\\n  &#x2022;positive', '\\n  &#x2022;sales', '\\n  &#', 'Principal Executive Officer\\n', 'and\\n  &#x2022;termination', '\\n  &#x2022;retention', 'Registrant', 'the University of Washington', 'CMO', 'the &#x201c;Apeiron', 'Economy,&#x201d', '47\\n', 'Comparison', 'Presight Sensei Co-Invest Fund', '\\n  &#x2022;our', '\\n  &#x2022;announcements', '\\n        &#', '2022.The Company', 'the &#x201c;BSP Service', 'The Anti-Kickback Statute', '44\\n', '\\n  &#x2022;stock', '\\n  &#x2022;risks', 'Trump', 'the Registrant&#x2019;s Current Report', 'Apeiron SICAV Ltd.', '\\n        &', 'Trade Control', 'SEC', '\\n  &#x2022;potential', 'agreements.\\n', 'BLA', 'the Registrant&#x2019;s Registration Statement', '\\n  &#x2022;actual', 'the European Union', 'Nasdaq', 'all;\\n  &#x2022;production', '\\n    &', 'No &#9744;\\n  Indicate', 'Apeiron Investment Group Ltd.'}"
SNTI,
SNY,
SONN,
SOPH,
SPOK,
SPRB,
SPRC,
SPRO,"{'ASC', 'AP', 'LLC', 'Collaboration and Service Agreements&#160;The Company', '\\n  &#x2022;payments', '\\n    Interest income\\n    &', 'Reliance', 'Pro Bono Bio PLC', 'License, Collaboration and Service Agreements', 'Our United States Government Contracts', 'this Quarterly Report on Form 10-Q', '\\n  &#x2022;mandatory', '\\n  &#x2022;costs', 'probable.&#160;The Company', 'x2022;a', 'Everest.\\n  Research and Development Expenses \\n', 'Consolidated Appropriations Act', 'Indicate', 'the &#x201c;Cantab', 'Accounting Standards Update', '\\n    Research', 'the Listing Qualifications Department', 'Everest Medicines II Limited', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Congressionally Directed Medical Research Programs', 'compensation)\\n    &', 'country.&#160;The Company', 'the Nasdaq GS', '\\n  &#x2022;claim', 'Marti', 'TB', 'services.&#160;The Company', 'Recognition &#', '\\n  &#x2022;acceptance', '\\n  &#x2022;expenses', 'GlaxoSmithKline Intellectual Property', 'No &#9744', 'Pfizer', '\\n  &#x2022;adverse', 'the GSK Closing Date', '\\n  &#x2022;product', 'Nasdaq GS', '\\n  Research and Development Expenses \\n  Research', 'include:\\n  &#', 'Medicaid', 'Congress', 'Medicare', 'Joint Warfighter Medical Research Program', 'x2014;\\n        &', 'Spero Potentiator, Inc.', 'incurred.&#160;The Company', 'FDA', '\\n  &#x2022;collaborations', 'Cantab Anti-Infectives Ltd.', 'Collaboration Revenue &', 'RSU', 'Biomedical Advanced Research and Development Authority', '\\n  &#x2022;disagreements', 'and\\n  &#', '\\n  &#x2022;relative', '77\\n', 'REMS', 'GGL', 'Company', '\\n          Office', 'Massachusetts.&#160;Indemnification Agreements &', '\\n  &#x2022;facilities', 'GSK.\\n  &#x2022;Analyses', 'USPTO', 'FAR', 'SRC', '10\\n         &', '\\n  &#x2022;impose', 'Melinda Gates Research Institute', '\\n  &#x2022;limitations', '\\n  &#x2022;seize', '\\n  &#x2022;whether', 'Co. (&#x201c;Cantor&#x201d;)', 'GSK License Agreement', '\\n    &#', '2022.&#160;Vertex License Agreement &', 'milestones)\\n       \\n       \\n        Total', 'Tebipenem HBr\\n    &', 'the Delaware General Corporation Law', 'Cantor Fitzgerald &amp', 'ASU', 'the Pfizer License Agreement', 'CCPA', 'Contracts with Customers', 'the &#x201c;Pfizer License', 'Management&#x2019;s Discussion and Analysis of Financial Condition', '\\n  &#x2022;the', 'License Agreement', 'PBB Distributions Limited', 'Vertex Pharmaceuticals Incorporated', 'Tebipenem HBr)\\n    &', 'the Sales Agreement', 'The Federal Trade Commission', 'SSP', 'License', 'The Original Everest License Agreement', '\\n  &#', 'Vertex', 'Impairment of Long-Term Asset\\n', '\\n  &#x2022;collaborators', 'the Meiji License', 'the Bid Price Requirement', '\\n  &#x2022;require', 'NDA', 'U.S. REIF Central Plaza', 'The Amended Everest License Agreement', 'the Savior Lifetec Corporation', 'Vertex Pharmaceuticals', 'Global Pharma', 'another national securities exchange', '\\n  &#x2022;public', 'the Sarbanes-Oxley Act', 'MDR', 'Research and Development Expenses \\n', '\\n  &#x2022;mandate', 'New Pharma License Holdings Limited', 'respectively.&#160;U.S. Department of Defense &', 'Grant', 'Amended Everest License', 'Form S-3', 'Glaxo Group Limited', 'SPA', 'and\\n  &#x2022;laws', 'the Original Everest License Agreement', 'the Meiji Territory', 'The Amended Complaint', '44\\n', 'DHHS', 'SPR741', '\\n  Collaboration Revenue \\n  Collaboration', 'the U.S. Food and Drug Administration', 'the Bronchoalveolar Lavage (&#', 'the U.S. Department of Defense (&#x201c;DoD&#x201d', 'the Pfizer Purchase Agreement', 'x2022;refuse', '\\n    &#160;&#160;32*\\n    Certification', 'Cantor', 'commercialization.\\n  ', 'Gates', '\\n  &#x2022;suspend', '\\n  &#x2022;If', 'Grant Revenue \\n', 'the Anti-Kickback Statute', 'NIAID', 'the Foreign Corrupt Practices', '\\n        &', 'the GSK License Agreement', '\\n    Interest', 'SEC', 'the New Drug Application', 'Medicines License Agreement &', 'Meiji', '\\n  &#x2022;audit', 'the &#x201c;Gates MRI&#x201d', 'SPR720', 'GSK', 'Nasdaq Listing Rule 5450(a)(1', 'the European Union', 'Nasdaq', '\\n    &', '\\n          Laboratory equipment\\n          &#160;\\n'}"
SPRY,
SRDX,
SRPT,"{'API', 'LLC', 'Nationwide Children&#x2019;s Hospital', 'the Unvested Tranche', '\\n  &#x2022;$42.6 million', 'Exonics Therapeutics', 'EMA', 'us;\\n  &#x2022;changes', 'EXONDYS 51', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'the Leahy-Smith America Invents Act', 'EU', 'the UWA Patents', 'Court', 'our investments;\\n  &#x2022;difficulties', 'Notes Exchange', 'the Thermo Agreement', 'and\\n  &#x2022;$3.2 million', 'Editas Medicine', 'Eli Lilly', 'and\\n  &#x2022;difficulties', 'manner;\\n  &#x2022;uncertainties', 'Option AgreementsThe Company', 'appeals;\\n  &#x2022;public', 'Myonexus Therapeutics, Inc. (&', 'healthcare practitioners;\\n  &#x2022;suspend', 'goods;\\n  &#x2022;receive', 'COVID-19', 'regiments.\\n  &#160;\\n', 'Oxford University', 'Ionis, Alexion Pharmaceuticals', 'Catalyst', 'process;\\n  &#x2022;developments', 'the Capped Call Transactions', 'compensation\\n    &', '1A', 'Company\\', 'litigation matters;\\n  &#x2022;$63.8 million', 'control laws;\\n  &#x2022;restrictions', 'the &#x201c;Roche', 'Contingencies', '149,891\\n        &', 'Medicaid', 'Akashi', 'EPS', 'Sarepta&#x2019;s', 'transactions;\\n  &#x2022;comments', 'GDPR', 'Dyno Therapeutics', 'VYONDYS', 'FDA', 'x201c;Thermo', 'and\\n  &#', 'letters;\\n  &#', 'the &#x201c;Bedford Lease&#x201d', '\\n  &#x2022;changes', 'NS', 'CRIPSR', 'Alnylam Pharmaceuticals, Inc.', 'drugs;\\n  &#x2022;caps', 'Hoffman-La Roche Ltd.', '\\n  &#x2022;$9.9 million', 'Duke University', 'Company', '\\n  Regulatory', 'Indebtedness', 'analysts;\\n  &#x2022;developments', 'U.S. Bank National Association', 'companies.\\n  &#160;\\n  2', 'USPTO', 'liability;\\n  &#x2022;disputes', 'Genethon, University of Florida,', 'candidates;\\n  &#x2022;delays', 'Thermo', 'the U.S. Securities and Exchange Commission', 'Fisher Scientific', 'the &#x201c;Exchange Date&#x201d', 'the Delaware General Corporation Law', 'the Exchange Date', 'Henogen SA', 'CMT', 'the Roche Agreement', 'stock.\\n  Future', '\\n  &#x2022;liability', '\\n  &#x2022;the', ""Nationwide Children\\'s"", 'agreements.\\n  &#160;\\n', 'marketing;\\n  &#x2022;develop', 'Roche', 'Compensation ExpenseFor', 'commercial insurance;\\n  &', 'Genevant Sciences', '\\n  &#', 'and\\n  &#x2022;prohibition', 'additional capital;\\n  &#x2022;failure', 'Moderna Therapeutics, Inc.', '\\n  &#x2022;$3.4 million', 'ELEVIDYS;\\n  &#x2022;our', 'the &#x201c;Exchange', '\\n  &#x2022;$7.3 million', 'Thermo Fisher Scientific, Inc. (&', 'NDA', 'plan\\n        &', 'PMO Products', 'Vertex Pharmaceuticals', 'decline.\\n  Provisions', 'the Sarbanes-Oxley Act', 'quickly;\\n  &#x2022;have', 'Walker Process', '\\n  &#x2022;our', 'Biogen Inc.', 'Nippon Shinyaku', 'requirements;\\n  &#x2022;expansion', 'positions.\\n  &', '\\n  &', 'the U.S. Food and Drug Administration', 'x2022;refuse', 'MAA', 'litigation matters;\\n  &#x2022;$6.6 million', 'the U.S.;\\n  &#x2022;the', 'Arrowhead Pharmaceuticals', 'us;\\n  &#x2022;suspend', 'ELEVIDYS', 'the European Medicines Agency', 'Nationwide', 'Lacerta Therapeutics, Inc. (&', 'The Capped Call Transactions', 'UWA', 'PMO', '\\n        &', 'SEC', 'agreements.\\n', 'the Food and Drug Administration', 'candidates.\\n  &', 'BLA', 'the &#x201c;Company&#x201d;)', 'noncompliance;\\n  &#', 'activity.\\n  &#160;\\n', 'BioMarin', 'the Foreign Corrupt Practices Act', 'governmental controls;\\n  &#x2022;less', '\\n    &', 'PMO (&#34;PPMO&#34;)'}"
SRRK,
SRTS,"{'ASC', 'FASB', 'incurred.\\n\\n&#160;\\n\\nShipping\\nand', 'in):&#160;\\n    &', 'Income Taxes\\n\\n&#160;\\n\\nThe Company', 'Critical Accounting Policies', 'Identification No.', 'Regulation S-K. None.\\n\\n&#160;\\n\\n\\n\\n\\n    17\\n', 'Medicare', '7 &#8212', 'written\\nnotice.\\n\\n&#160;\\n\\nThe Company', 'Weighted-\\n Average\\n Remaining\\n', 'respectively.\\n\\n&#160;\\n\\nSegment\\nand Geographical', 'Lease Agreements\\n\\n&#160;\\n\\nThe Company', 'Organization and Summary of Significant Accounting Policies', 'the period&#160;\\n    &', 'Company', 'maturities.\\n\\n&#160;\\n\\nFair\\nValue Measurements\\n\\n&#160;\\n\\nThe\\nCompany', '\\n    Maturity of Operating Lease', 'Total&#160;\\n    ', 'Results of Operations', 'payments&#160;\\n    $', 'Justice', '\\n    &', 'ASU No'}"
SRZN,"{'ASC', 'LLC', 'Treasury Regulations', 'technologies;\\n  &#x2022;incurrence', 'AH', '\\n    Interest income\\n    &', 'EC', 'Stanford', 'SWAP', '4,752\\n          &', 'the Public Warrants', 'BI', 'the Company&#x2019;s Annual Report on Form 10-K', 'decline.\\n  Clinical', 'collaborators;\\n  &#x2022;suspension', 'EU', 'Lincoln Park', 'reputation.\\n', 'the Internal Revenue Code', 'events;\\n  &#x2022;certain', 'licenses;\\n  &#x2022;failure', 'Bio Subscription', 'injected;\\n  &#x2022;extension', 'CPRA', '\\n    Research', 'healthcare programs;\\n  &#x2022;an', 'ACA', 'stock\\n          &#160;\\n          &#160;\\n          ', 'and\\n  &#x2022;regulatory', 'patents;\\n  &#', 'the Registration Statement on Form S-1', 'and\\n  &', 'the assets.&#160;The Public Warrants', 'Charles River Laboratories International, Inc.', 'Letter Agreement', 'SZN-413', 'Charles River Laboratories', 'the PIPE Warrant Agreement', 'and\\n  &#x2022;implementation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'Stanford Agreement', 'GDPR', 'FDA', 'the Data Safety Monitoring Board', 'Surrozen Operating, Inc.', 'litigation;\\n  &#x2022;Collaborations', 'and\\n  &#', 'fluctuations;\\n  &#x2022;natural', 'the Medicaid Drug Rebate Program', 'AMP;\\n  &#x2022;a', 'Distributed Bio', 'activities\\n    &', 'and\\n  &#x2022;Collaboration', 'Patient-Centered Outcomes Research Institute', 'Company', 'management&#x2019;s attention', 'USPTO', 'License Agreements&#160;Stanford License', 'legal challenges;\\n  &#x2022;our', 'and\\n  &#x2022;diminished', '\\n  &#160;\\n', 'dates.\\n  &', 'Report', 'control;\\n  &#', 'the UCSF Agreements', 'Guggenheim Securities', 'CMS', 'CCPA', 'the Unaudited Condensed Consolidated Financial Statements', 'the Current Report on Form 8-K', 'Surrozen Inc.', 'Boehringer Ingelheim International', 'x2022;we', 'Trust Company', 'Guggenheim', 'Center for Medicare Innovation', 'IRB', '\\n  &#', 'Intellectual Property', 'law;\\n  &#', 'organizations;\\n  &#x2022;expansion', 'candidates.\\n  &#x2022;Collaborations', 'Stanford University', 'PIPE Warrants', 'Lincoln Park Capital Fund', 'Surrozen, Inc.', 'the Annual Report on Form 10-K', 'Company &', 'Boehringer Ingelheim International GmbH', 'factors.\\n  &', 'reporting.\\n', 'costs;\\n  &#', 'CLA', 'Comparison', 'Public Warrants', 'and\\n  &#x2022;injunctions', 'liability;\\n  &#x2022;a', 'Form S-3', 'securities.\\n  &', 'commercialization.\\n  &#', 'ATM', '\\n  &', 'including:\\n  &#x2022;the', 'Distributed Bio, Inc.', 'approvals;\\n  &#x2022;product', 'Nasdaq&#x2019;s', 'Healthcare', 'the Distributed Bio Agreement', '\\n  &#x2022;the FDA', 'programs.\\n  &#160;\\n', 'Continental Stock Transfer &amp', 'UCSF', 'the Public Health program;\\n  &#', 'SEC', 'Interest Income\\n  &', 'prospects.\\n  Obtaining', 'Antibody Library Subscription Agreement', 'Equity Securities', 'the European Union', 'Nasdaq', '\\n    &', 'property.\\n'}"
SSIC,
SSKN,"{'Credit and Security Agreement', 'FASB', 'ASU', 'the Nasdaq Capital Market', 'Theravant', 'devices.\\n\\n      \\n\\n      Introduction, Outlook, Overview of Business Operations', 'STRATA Skin Sciences, Inc.', 'Unaudited Condensed Consolidated Financial', 'Restated Certificate of Incorporation of the Company (Incorporated', 'Regulation S-K).\\n\\n      \\n\\n\\n\\n', 'coronavirus (&#8220;COVID-19&#8221', 'the Listing Department of Nasdaq', 'MidCap Funding XXVII', '\\nThe Pharos', 'Pharos', 'the Development Agreement', 'EPS', 'Financial Instruments', 'extinguishment\\n\\n    &#160;\\n\\n    &#160;\\n\\n    &#', 'Rate Reform', 'FDA', 'MidCap', 'Exhibit 3.1', 'MidCap Financial Trust', 'Credit Facility', 'Nasdaq Listing Rule', 'TheraClear', 'SEC', 'XTRAC', 'Company', 'the Financial Accounting Standards Board', 'the Senior Term Facility', 'Exhibit 3.2', 'Credit Losses', 'The Senior Term Facility', 'COVID-19', 'Accounting Standard Update', 'Equity Securities', 'Nasdaq Capital', 'c)&#160;the Amended and Restated Registration Rights Agreement', 'Instruments &#8211', 'Report'}"
STAA,"{'years)\\n        &', '2022.The Condensed Consolidated Financial Statements', 'Income TaxesThe Company', '\\n  &', 'Prepayments', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'the Company&#x2019;s Annual Report on Form 10-K', 'x2014;\\n        &', 'Condensed Consolidated Statements of Income', '\\n    Investments', 'thousands):11\\n     STAAR SURGICAL COMPANYNOTES', '\\n  &#', 'the term &#x201c;disclosure', 'depreciation\\n        &', '\\n  Research and Development Expense\\n', '\\n    Research', '\\n        &', 'Company', 'the Securities Exchange Act', 'Nine Months\\n    &', '\\n  Research', 'ii)Any &#x201c;non-Rule 10b5-1', 'indicated.\\n  &', 'COVID-19', '2022\\n    &', 'Results of Operations', '\\n    &'}"
STIM,"{'LLC', 'Interim Financial Statements', 'Success TMS (&#8220;Success', 'September&#160;30,&#160;2022', 'ContentsNEURONETICS,&#160;INC.Notes&#160;to Interim Financial', 'Regulation S-K.Chief', 'EQUIPMENT', 'Security Agreement', 'NeuroStar Advanced Therapy Systems', 'benefits&#8203;$', 'SLR Investment Corp.', 'the Company&#8217;s Annual Report on Form&#160;10-K', 'Success', 'the Solar Facility', 'The Term A Loan', 'ContentsNEURONETICS,&#160;INC.Notes&#160;to Interim Financial Statements(Unaudited)On', 'the Term A Loan', 'Part I &#8211', 'Loan', 'Solar Capital Ltd.', 'FINANCIAL INFORMATION', 'No &#9744;Indicate', 'RECEIVABLEGreenbrook TMS Inc.', 'Months Ended &#', 'TMS Neurohealth Centers Inc.', 'SEC', 'SOFR', 'Company', 'the Securities Exchange Act', 'Check Five', 'Neuronetics, Inc.', 'TMS', 'MDD', 'the Sarbanes-Oxley Act', 'Greenbrook TMS Inc.', 'Significant Accounting', 'ContentsNet', 'Teijin Pharma Limited', 'Madryn Fund Administration', 'Code)(610'}"
STOK,
STRM,
STRO,
STRR,
STRRP,
STSS,
STTK,
SUPN,
SVRA,"{'and\\n  &#x2022;internal', 'API', '\\n  Research and Development \\n  Research', 'x201c;Amended Loan', 'The Wall Street Journal', 'Modifications and Extinguishments', 'Silicon Valley Bank.\\n  &', 'the Loan Agreement', 'Financial Operations Overview \\n  Research and Development Expenses \\n', 'The Common Stock', 'this Quarterly Report', 'Comparison of Nine Months Ended September 30, 2023', 'Aravas Inc.', 'Subsidiaries \\n  Notes', 'the Registration Statement', 'the Committee of Sponsoring Organizations of the Treadway Commission', 'CFR &', 'First Citizens BancShares, Inc.', 'European Union', 'FCNCA', 'Lender', 'OtherThe Company', 'Debt &', '\\n  &#', 'Pre-Funded Warrants', 'Loan', 'the &#x201c;Amended Loan', 'Indicate', 'the Federal Deposit Insurance Corporation', '\\n    Research', 'Savara Inc.', 'Silicon Valley Bank', 'SEC', 'Significant Accounting Policies &', 'x201c;Loan', 'Company', 'Amended Loan Agreement', 'Integrated Framework', 'Unaudited)\\n  &#160;\\n  1', 'FASB ASC Topic', 'FDIC', '\\n  &#x2022;expenses', 'Results of Operations &', 'The Amended Loan Agreement', '\\n  &#x2022;laboratory', 'Standard &', 'Internal Control &#', 'Future Funding Requirements \\n', 'the Amended Loan Agreement', '\\n    &', 'a Common Stock Sales Agreement with Evercore Group L.L.C.', 'stock\\n        &', 'Condensed Consolidated Financial Statements'}"
SWAV,"{'Bunker Hill', 'LLC', 'Credit Agreement', 'The Credit Agreement', 'MEDICAL', 'the License Agreement', 'NetUseful LifeEstimated RemainingUseful LifeCustomer', 'Condensed Consolidated Financial Statementsissued', 'Restricted Cash The Company', 'CAD', 'Condensed Consolidated Financial Statements4', 'Medical, Inc.', 'IVL', 'the Securities and Exchange Commission', 'the Private Securities Litigation Reform Act', 'Bunker Hill Lease&#8221', 'Unaudited Condensed Consolidated Financial Statements9Item 2.Management&#8217;s Discussion and Analysis of Financial Condition', 'this Quarterly Report on Form 10-Q', 'Condensed Consolidated Financial StatementsThe', 'ASC 360', 'InterestAs of September&#160;30', 'October&#160;19', 'PAD', 'Neovasc', 'National Association', 'Indenture', 'Results of Operations32Item', 'Wells Fargo Bank', ': &#', 'Business Combination Neovasc Inc.', 'The Capped Call Transactions', 'IVL System', 'Information53Item 6.Exhibits54Signatures55SPECIAL', 'the Shockwave License Agreement', 'Silicon Valley Bank', 'Condensed Consolidated Financial StatementsActual', 'Goodwill', 'SEC', 'Note 10 &#8220;Convertible Debt&#8221', 'Company', 'the Securities Exchange Act', 'U.S. Bank Trust Company', 'Equity Securities', 'Genesis', 'Consolidated Balance Sheets3Condensed', 'Wells Fargo Securities', 'Capital ResourcesTo', 'Property', 'the Capped Call Transactions'}"
SWTX,"{'Glaxo Group Limited', 'the Fred Hutchinson Cancer Research Center', 'EstimatesThe', 'BRAF', 'Critical Accounting Policies', 'the Stock Purchase Agreement', 'the Securities and Exchange Commission', 'BeiGene Ltd.', 'this Quarterly Report on Form 10-Q', 'MEK', 'PDUFA', 'FDA', 'the Hellenic Society of Haematology', 'AdministrativeGeneral', 'ReNeu', 'ADC', 'us;&#8226;costs', 'Registrant', 'ExpensesAccrued', 'the Common Stock', 'NDA', 'MapKure', 'the GSK License Agreement', 'DevelopmentResearch', 'GGL', 'CT', 'Company', 'Restated Certificate of Incorporation', 'BCMA', 'ContentsEXHIBIT INDEXExhibit NumberDescription3.1Amended', 'SpringWorks', 'BeiGene', 'BeiGene, Ltd.', 'ContingenciesThe Company', 'GSK', 'Adopted Accounting Pronouncements', 'MapKure LLC'}"
SXTC,
SXTP,
SY,
SYBX,
SYRA,"{'ASC', 'LLC (&#8220;STVentures&#8221;),\\nan', 'Citizens State Bank of New', 'FASB', 'Citizens State Bank of New Castle', 'Sahasra Technologies Corp.', 'CONDENSED FINANCIAL STATEMENTS\\n\\n(Unaudited)\\n\\n&#160;\\n\\nCost\\nof', 'Maricopa County Department of Public', 'including\\nour', 'Collateral', 'Under\\nthe Tax Cuts and Jobs Act', 'Castle', 'Company&#8217;s\\ntax', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'the Revolving Line of Credit', 'Citizens State Bank of New Castle&#8217;s\\nrequest', 'ASC Topic 360', 'Company&#8217;s\\ncontract', 'consisting\\nof', 'this Quarterly Report on Form 10-Q', 'CONDENSED FINANCIAL STATEMENTS\\n\\n(Unaudited)\\n\\n&#160;\\n\\nNote\\n8 &#8211', 'closed.\\n\\n&#160;\\n\\nNote\\n10 &#8211', 'NeuroDiagnostic Institute and Division of Mental Health and Addiction', 'STLogics', 'STVentures', 'FSSA', 'nationwide.\\n\\n&#160;\\n\\nWe', 'the Internal Revenue Code', 'capabilities.\\n', '95,582\\n', 'Citizens State Bank\\nof New Castle', 'Line of Credit\\n\\n&#160;\\n\\nOn\\nFebruary 7,', 'payments&#160;\\n    &', 'undergoes\\nan &#8220;ownership', 'pursuant\\nto', 'The Nasdaq Capital Market', 'Related Party', 'the Revolving Line', 'the Indiana Family and Social\\nServices Administration (&#8220;FSSA&#8221', 'SEC', 'county.\\n\\n&#160;\\n\\nTrue\\nto', 'and\\n  \\n    &', 'Company', 'Indebtedness', 'Units', 'expense)\\n    &', 'pursuant\\nto the Revolving Line of Credit', 'CONDENSED FINANCIAL STATEMENTS\\n\\n(Unaudited)\\n\\n&#160;\\n\\nNote\\n9 &#8211', 'Citizens State Bank', 'digital health services revenue', 'the Over-Allotment', 'Nasdaq', 'cost:&#160;\\n    &', 'Citizens State\\nBank', '\\n    &', 'digital health services', 'statements\\nare', 'defined\\nin'}"
SYRE,
SYRS,"{'ASC', 'years)\\n        &', 'LLC', 'Target Discovery, Research Collaboration and Option Agreement', '\\n    Interest income\\n    &', 'AML', 'Qiagen Manchester Limited', 'Oxford', 'EMA', 'All-Trans-Retinoic-Acid', 'Financial Instruments', 'equipment.\\n  Net Cash Provided by Financing Activities\\n  Net', 'CR/CRi', 'Orsenix', 'stock.\\n  Comparison', '\\n    Research', 'The 2023 Registration Statement', '\\n  &#x2022;development', 'costs.\\n  Research', 'SY-2101.License AgreementTMRC Co. Ltd.', 'COVID-19', 'arrangements;\\n  &#', 'compensation\\n    &', 'the Merger Agreement', 'FASB', 'the HQ Lease', 'EstimatesThe', 'include:\\n  &#', 'x2014;\\n        &', 'Note 3).Recently Adopted Accounting', 'FDA', 'x201c;Stock Purchase', 'benefits;\\n  &#x2022;stock', 'periods.\\n  Expenses\\n  Research and Development Expenses\\n  Research', 'TMRC', 'Loan', 'and\\n  &#', 'AgreementOrsenix', 'Warrants*\\n          &', 'the &#x201c;Asset Purchase', 'Company', 'SELECT-MDS-1', 'the 2022 Warrants', '\\n    Interest expense\\n    &', 'TMRC Co. Ltd.', 'Cowen', 'Orsenix&#x2019;s', 'GBT', 'Tyme', 'the &#x201c;Research', 'the Merger Sub', 'ASU', 'Oxford Finance', 'the 2023 Registration Statement', 'Tack Acquisition Corp.', 'Tyme Technologies, Inc.', '\\n  &#x2022;the', 'The Loan Agreement', 'CR', 'the Maturity Date', '\\n  &#', '2022 Warrants', 'the 2020 Warrants', 'Collaborative Arrangements', '\\n  &#x2022;revenue', 'and\\n  &#x2022;facilities', 'Comparison', 'SY-5609', '\\n  &#x2022;our', 'Incyte', 'Cowen and Company', 'Form S-3', 'RARA', 'the Loan Agreement', 'Financial Instruments-Credit Losses', 'MDS', 'this Quarterly Report', '\\n  &', 'the Stock Purchase Agreement', 'the Loan Amendment', 'ESPP', 'PDAC', 'No  &#9744;\\n  Indicate', 'Pre-Funded Warrants', '\\n    ', 'U.S. Treasury', '\\n        &', 'SEC', 'Qiagen', 'x201c;Loan', 'SELECT', 'Note 8)', 'The HQ Lease', '\\n    &'}"
TALK,"{'refunds.&#160;The', 'LLC', 'costs.\\n  Sales and Marketing Expenses \\n', 'the Derivative Action', 'this Quarterly Report', 'District Court', 'x201c;Risk', 'Internal Control Over Financial Reporting\\n  Other', 'serve.\\n  &', 'the Company&#x2019;s Annual Report on Form 10-K', 'C.A.', 'costs.\\n  Sales', 'statements.\\n  &', '\\n  &#', 'client&#x2019;s', 'Talkspace', 'Allowance for Credit LossesAccounts', '\\n        &', 'profitability.\\n  Research', 'Company', 'reporting.\\n', 'Adopted Accounting PronouncementsThe Company', 'the Delaware Court of Chancery', 'early.\\n  &', 'Hudson Executive Investment Corp.', 'DTE'}"
TARA,"{'API', 'FASB', '\\n\\n&#160;\\n\\nProtara Therapeutics, Inc.', 'ASU', 'agreement\\nwith Chugai Pharmaceutical', 'Series 1 Convertible Preferred Stock', 'achieved.\\n\\n&#160;\\n\\nWe', 'cost&#160;\\n    &', 'a Security Incident', 'campaign.\\n\\n&#160;\\n\\nWe', 'Data Protection', 'impaired.\\n\\n&#160;\\n\\nWe', 'candidates.\\n\\n&#160;\\n\\nWe', 'IV Choline Chloride', 'Medicaid', 'Medicare', 'acceptance.\\n\\n&#160;\\n\\nWe', 'Company&#8217;s\\naccrued', 'Nasdaq.\\n\\n&#160;\\n\\nWe', 'Klinische Einheit', 'FDA', 'date\\nif Chugai Pharmaceutical', 'Company&#8217;s\\ncommon', 'Chugai Pharmaceutical', 'RISKS AFFECTING OUR', 'Picibanil', 'Phase 4', 'cost&#160;\\n    $', 'KE', 'capital\\non', 'Prepaid software&#160;\\n    &', 'Capital Resources and Management Plans\\n\\n&#160;\\n\\nThe Company', 'NMIBC', 'payments&#160;\\n    &', 'Financial Instruments\\n\\n&#160;\\n\\nThe Company', 'manner.\\n\\n&#160;\\n\\nWe', 'Sensitive Information', '\\n    Research', 'protection\\nto', 'per\\nshare data)\\n\\nRecently Adopted Accounting', 'SEC', 'Unaudited Condensed Consolidated Financial\\nStatements\\n\\n(amounts', 'successful\\nin', 'Company', 'impact.\\n\\n&#160;\\n\\nWe', 'Dividend income&#160;\\n    &', 'Data Protection Requirements', 'future.\\n\\n&#160;&#160;\\n\\nHealthcare\\nreform', 'COVID-19', 'products.\\n\\n&#160;\\n\\nWe', 'customers.\\n\\n&#160;\\n\\nAs', 'which\\n11,364,903', 'property.\\n\\n&#160;\\n\\nWe', 'net&#160;\\n    &', 'Company&#8217;s\\nprepaid', '\\n&#160;\\n\\nCommon Stock', '\\n    &', 'Nasdaq', 'parties.\\n\\n&#160;\\n\\nIf', 'the Financial\\nAccounting Standards Board'}"
TARS,"{'tranche', 'Upfront License Fees', 'Galatea', 'CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-12-012022-12-310001819790tars', 'CostOfSalesMember2022', 'XDEMVY;&#8226;our', 'ProductMember2023', 'Jefferies LLC', 'License Fees and Collaboration RevenueFor', 'Condensed Statements of Operations and Comprehensive Loss', 'Meibomian Gland Disease', 'RestrictedStockUnitsRSUMember2023-01-012023-03-310001819790us-gaap', 'Internal Control Over Financial Reporting', 'Food and Drug Administration', 'No &#9744;Indicate', 'Condensed Statement of Operations', 'LianBio', 'Treasury', 'Condensed Balance Sheets', 'Shelf Registration Statement', 'License Fees and Collaboration Revenue For', 'ContentsFor', 'the Credit Facility', 'CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2023', 'the ""China Territory', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'the Securities and Exchange Commission', 'Intangible Assets', 'CreditFacilityTrancheOneMember2023-09-300001819790tars', 'Lyme', 'noncurrent1,667&#160;Total', 'RestrictedStockUnitsRSUMember2023-07-012023-09-300001819790us-gaap', 'FDA', 'Research and Development Services', 'AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-09-300001819790srt', 'Credit Facility', 'FAIR VALUE', 'Inherent Limitations on Effectiveness of Controls', 'the China Territory', 'the Federal Deposit Insurance Corporation', 'this Shelf Registration Statement', 'LineOfCreditSVBMember2023-09-152023-09-150001819790us-gaap', 'ShareBasedPaymentArrangementEquityInstrumentsOtherThanOptionsRestrictedStockUnitsUnvestedMember2023-01-012023-09-300001819790tars', 'Silicon Valley Bank', 'Company', 'Initial Public Offering', 'AvailableForSaleDebtSecuritiesContractualMaturityLessThan12MonthsMember2023-09-300001819790tars', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001819790us-gaap', 'LeaseholdImprovementsMember2022-12-31tars', 'AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-3000018197902023-06-300001819790us-gaap', 'FairValueInputsLevel1Member2022-12-310001819790us-gaap', 'the Condensed Statements of Operations', 'ContentsNine Months Ended', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001819790us-gaap', 'the Company F-25Table of ContentsTARSUS PHARMACEUTICALS', 'Out-LicenseThe Company', 'SVB', 'the China Out-License', 'Elanco Tiergesundheit AG', 'warrant00018197902022-01-012022-12-31tars', 'Critical Accounting Policies', 'Contractual Terms for Receipt', 'RELATED PARTY TRANSACTIONSConsulting AgreementsThe Company', 'the All Human Uses Elanco Agreement', 'LianBio Ophthalmology Limited', 'NetDuring', 'ActivitiesNet', 'XDEMVY', 'Dividend Yield &', 'Registrant', 'ProductMember2022', 'NDA', 'ContentsOur', 'years)(Unaudited)update', 'Condensed Statements of Operations', 'FDIC', 'Financial OverviewWe', 'the ""Eye and Derm Elanco Agreement', 'years)(Unaudited)Risk-Free Interest Rate &', 'the U.S. Department of Treasury', 'Condensed Financial Statements', 'Form S-3', 'treasury', 'Hercules Capital, Inc.', 'the Phase 2a Carpo', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001819790us-gaap', 'XDEMVY&#174', 'PHARMACEUTICALS', 'License Fees and Collaboration Revenue35Table', 'U.S. Treasury', 'this Credit Facility', 'SEC', 'CustomerOneMember2023-07-012023-09-30xbrli', 'Demodex', 'NetIntangible', 'RestrictedStockUnitsRSUMember2023-04-012023-06-300001819790us-gaap', 'Administrative ExpensesSelling', 'funds(1)$64,685&#160;$&#8212;&#160;$&#8212;&#160;$64,685&#160;U.S. Treasury', 'This Consulting Agreement'}"
TBIO,"{'ASC', 'The Long-Term Warrants', 'Credit, Security and Guaranty Agreement', '\\n', 'Contractual Obligations', 'capital stock;\\n  &#x25aa;our', 'x25aa;our', 'the Annual Report', 'Financial Instruments', 'the Company&#x2019;s Annual Report on Form 10-K', 'RUO', 'FDA &#', 'Lender', 'The Short-Term Warrants', 'BioXp 9600', 'BioXp', 'Pfizer Inc.', 'the Redeemable Convertible Preferred Stock', 'the Accrued Value', 'CPRA', '\\n    Research', 'capital stock;\\n  &#x25aa;certain', 'matter;\\n  &#x25aa;vacancies', 'reagents;\\n  &#', 'the Financial Accounting Standards Board', 'the Redeemable Convertible Preferred Stock and/or', 'the Securities Exchange Act', 'the Preferred Warrant', 'the 2022 Revolving Credit Agreement', 'Delaware;\\n', 'COVID-19', 'ISO', 'EtonBio, Inc.', 'the Centers for Disease Control and Prevention', 'SGI', 'regulations;\\n  &#x25aa;changes', 'Warrants', 'Pfizer', 'and\\n  &#x25aa;difficulties', 'the Revolving Credit Agreement', 'the Pfizer Agreement', 'Financial Statements', 'the FDA&#x2019;s Quality System Regulations', 'manufacturers&#x2019', 'the Securities and Exchange Commission', 'the Short-Term Warrants', 'The Company&#x2019;s Board of Directors', 'Redeemable Convertible Preferred Stock and Warrants', 'The 2022 Loan Agreements', 'The 2022 Term Loan Agreement', 'the United States;\\n  &#', 'Redeemable Convertible Preferred Stock', 'FDA', 'the Agreement (Additional Warrants', 'Credit', 'Loan', 'and\\n  &#', 'Years\\n    &', 'the Office of Foreign Asset Control;\\n  &#x25aa;export', 'the Private Placement', 'Silicon Valley Bank', 'Deemed Liquidation Event or Liquidation Event', 'EtonBio', 'Research and License Agreement', 'Company', 'management&#x2019;s attention', 'Additional Warrants', 'CONTINGENCIESLitigationThe Company', 'losses.\\n  &', 'the 2022 Revolving Loan Agreement', 'SVB', 'the Delaware General Corporation Law', 'Revolver Loan', 'Condensed Consolidated Statements of Operations', 'Oxford Finance', 'Item 10 of Regulation S-K', 'the California Privacy Protection Agency', 'Contracts with Customers', 'the U.S. Department of Commerce&#x2019;s Export Administration Regulations', 'FCPA', 'Ukraine;\\n  &#x2022;our', 'lender&#x2019;s', 'Pfizer, Inc.', 'MidCap', 'the Nasdaq Stock Market', '\\n  &#', 'restrictions;\\n  &#', 'the ESPP.The Company', 'Telesis Bio Inc.\\n', 'Condensed Consolidated Statements of Redeemable Convertible Preferred Stock', 'capital stock;\\n  &#', 'plan\\n        &', 'Revolving Loan', 'kits.\\n  Components', 'x201c;anticipate,&#x201d; &#', 'the U.S. Treasury Department&#x2019;s Office of Foreign Assets Control.\\n', 'Tranche Three', 'and\\n  &#x25aa;advance', 'IPO', '47\\n', 'CFO', 'Comparison', 'FSAP', '\\n    Service revenue\\n    &', 'regulation;\\n  &#x2022;our', 'Financial Instruments-Credit Losses', 'The Preferred Warrant', 'this Quarterly Report', 'Inherent Limitations on Effectiveness', 'the Accounting Standards Codification', 'ESPP', 'the U.S. Food and Drug Administration', 'Condensed Consolidated Financial Statements\\n    ', 'Loan AgreementsOn', 'LDTs', 'MidCap Financial Trust', 'companies;\\n  &#x25aa;foreign currency', 'MidCap Funding IV Trust', 'trends;\\n  &#x2022;our', 'Short-Term Warrants', 'International Organization for Standardization', 'effectively;\\n  &#x2022;our', '\\n        &', 'SEC', '\\n    Interest', 'the 2022 Revolving Loan', '2022 Revolving Loan', 'Long-Term Warrants', 'Eton', 'the European Union', 'Nasdaq', '\\n    &', 'No &#9744;\\n  Indicate', 'concern.\\n  &#', 'x201c;seek,&#x201d'}"
TBPH,"{'ASC', 'the YUPELRI Peak Inspiratory Flow Rate', 'DevelopmentOur', 'the Ongoing Economic Interest', 'net&#8203;&#8203; &#8212;&#8203;&#8203', 'below:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Three&#160;Months&#160;Ended &#', 'programs.&#8203;As', 'The Budget Control Act', 'Irenic Capital Management LP', 'the Viatris Development and Commercialization Agreement', 'the General Data Protection Regulation (&#8220;GDPR&#8221', 'pan-JAK', 'EstimatesOur', 'COPD', 'the Federal Food, Drug', 'Program &#', 'EEA', 'EU', 'CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)&#8203;1', 'Consolidated Statements of Operations and Comprehensive Income', 'the Internal Revenue Code', 'Pfizer Inc.', 'ContingenciesWe', 'the TRELEGY Royalty Transaction', 'TRC Transaction', 'VIBATIV', '53)&#8203;&#8203; &#8212;&#8203;&#8203', 'Theravance Respiratory Company', 'Mylan Ireland Limited', 'the Securities Exchange Act', 'COVID-19', 'the Grand Court', 'ContentsIn April 2022', 'Condensed Consolidated Financial Statements7Item 2', 'AdministrativeSelling', 'Rule&#160;13a-15(e', 'Pfizer', 'ProceduresWe', 'sublease&#8203;$ 6,490&#8203;$ &#8212;&#8203;See', 'Assigned Collaboration Products', 'net &', 'Mylan Specialty L.P.', 'the Pfizer Agreement', 'The Federal Food, Drug', 'Teva Pharmaceuticals', 'Medicaid', 'Medicare', 'liabilities &#8203;&#160', 'GDPR', 'FDA', 'operations &', 'Cayman Islands', 'Orange Book', 'Collaborative Arrangements &', 'the Sarbanes-Oxley', '12.35&#8203;$ &', 'the Assigned Collaboration Products', 'ContentsSelling', 'Velusetrag&#8203;&#8203', 'Company', 'interest&#8203;$ &#', 'Viatris Inc.', 'cash&#8203;&#8203', 'Months Ended &#8203;&#8203;September&#160;30,&#160;&#8203;September&#160;30,&#160;(In', 'section&#160;505(j', '3,034)&#8203;&#8203; &#8212;&#8203;&#8203', '2023&#8203;$ &', 'the California Consumer Privacy Act', 'Innoviva', 'the Public Health Service', 'Royalty Pharma Investments', 'YUPELRI&#174', 'Contentsmonotherapy', 'The Patient Protection', 'Consolidated Statements of Cash Flows', 'Contentscommon', 'the Contingent Consideration', 'Months Ended &#', 'the Settlement Agreement', 'development &', '12,838Total expenses &', 'the Sarbanes-Oxley Act', 'TRELEGY Royalty Transaction', 'the Purchase Agreement', 'deficit &', 'Months Ended &', 'YUPELRI.Under the Drug Price Competition and Patent Term Restoration Act', 'the Medicare Drug Rebate', 'Board', 'Consolidated Statements', 'Cumberland', 'MSA', 'FDA&#8217;s', 'diluted&#8203;$ &#', 'the Standard Contractual Clauses', 'PAF', 'TRC', '711&#8203;&#8203', 'ESPP', 'a Settlement Agreement (&#8220;Settlement', 'the Public Health Service Act', 'Viatris', 'the TRC Transaction', 'the Effectiveness of ControlsOur', '16,277&#8203;&#8203', 'expenses&#8203;&#8203', 'SEC', 'Restricted', 'ContentsResearch', 'Contentsand', 'the US Food and Drug Administration', 'Consolidated Balance Sheets', 'GSK', 'REGULATORY UNCERTAINTY &', 'Licensing', 'the Milestone Payments', 'LLC (&#8220;TRC&#8221'}"
TCBP,
TCMD,
TCON,
TCRT,"{'AdditionalPaidInCapitalCommonStockMember2022', 'LicenseAgreementWithTheNationalCancerInstituteMember2023-07-012023-09-300001107421tcrt', 'the MD Anderson Cancer Center', 'the Surgery Branch', 'Based CompensationThe Company', '\\n  &#x2022;Injury', 'candidates;\\n  &#x2022;Approval', 'the Equity Distribution Agreement', 'Security Agreement', 'CantorMember2022', 'the Annual Report', 'regulators;\\n  &#x2022;Withdrawal', '\\n  &#x2022;Loss', 'Transaction', 'Trademark Office', 'the Term B Tranche', 'Piper Sandler', 'AdditionalPaidInCapitalCommonStockMember2022-01-012022-09-300001107421tcrt', 'CantorMember2023', 'the Lackey Transition Period', 'NSCLC', 'Anderson Cancer Center', 'NCI', 'Piper Sandler &amp', 'the Listing Qualifications Department', 'ACA', 'Property and Equipment', 'The Nasdaq Stock Market LLC', 'the Securities Exchange Act', 'NOL', 'Cause&#34', 'Cooperative Research and Development Agreement', 'KBI', 'Licensors', 'Legal and Administration', 'The Deniger Retention Agreement', 'WarrantMember2021-12-280001107421tcrt', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001107421tcrt', '165th Judicial District', '\\n  &#x2022;Initiation', 'Melinda', 'KBI Biopharma, Inc.', 'the KBI Agreement', 'Platform\\n  &', 'Retention Agreements', 'CONDENSED FINANCIAL STATEMENTS(unaudited)License Agreement', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'TriArm', 'x2014;\\n        &', 'the OTC Bulletin Board', 'IntrexonCorporationMember2018', 'LicenseAgreementWithTheNationalCancerInstituteMember2023-01-012023-09-300001107421us-gaap', 'Technology License Agreement&#x2014;The University of Texas', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'the District Court of', 'Loan', 'Security Agreement\\n        &', 'and\\n  &#', '\\n  Effective', 'the Retention Agreement', 'Research and Development Agreement &#x2014;The University of Texas', 'the National Cancer Institute', 'Intrexon', 'REMS', 'Silicon Valley Bank', 'below).\\n  &#', 'Common Stock', 'use;\\n  &#x2022;Such', 'Company', 'the Lackey Retention Agreement', 'MaximumMember2022', 'The SVB Facility', 'USPTO', 'the Deniger Retention Agreement', 'CONDENSED FINANCIAL', '\\n    Interest expense\\n    &', 'Security AgreementOn', 'WarrantMember2023-01-012023-09-300001107421us-gaap', '\\n  &#x2022;whether', 'SVB', 'the SVB Facility', '\\n    &#', 'the Delaware General Corporation Law', 'the Cooperative Research and Development Agreement', 'Panel', 'the Nasdaq Capital Market', 'ZiopharmMember2019-07-050001107421tcrt', 'Principal Financial Officer', 'New Drug Application', 'Value of Non-Financial InstrumentsThe Company', 'RoyaltyMembertcrt', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'License Agreement', 'the Patent License', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'NonVestedStockMember2023', 'the Texas A&amp;M University System', 'License', '\\n  &#', 'Board of Directors', 'the Texas A&amp;M University', 'KRAS', 'These &#x201c;penny', 'TCR', 'Registrant', 'the Deniger Transition Period', 'stock.\\n  2022 Equity Distribution Agreement\\n', 'FairValueMeasurementsRecurringMember2023', 'the Sarbanes-Oxley Act', 'the Term A Tranche', 'safety risks;\\n  &#x2022;We', '\\n  &#x2022;The', 'The Framework Agreement and Share Subscription Agreements', 'charter)\\n  &#', 'hunTR', 'PGEN', '\\n  &#x2022;our', 'WarrantMember2022-01-012022-09-300001107421tcrt', 'the License Agreement', 'MaximumMember2023-01-012023-09-300001107421us-gaap', 'AtTheMarketOfferingMember2022-11-292022-11-290001107421us-gaap', 'Intrexon Corporation', 'MaMember2023-04-012023-06-300001107421tcrt', '\\n  &#x2022;Withdrawal', 'AdditionalPaidInCapitalCommonStockMember2023-01-012023-09-300001107421us', 'The Patent License', 'CRADA', 'the Biden Administration', 'MD Anderson.2019 Research and Development Agreement&#x2014;The University of Texas', 'Cantor', 'operations.\\n  &', 'Precigen', 'candidates;\\n  &#x2022;Such', 'TheUniversityOfTexasMDAndersonCancerCenterAndTheTexasAAndMUniversitySystemMember2023', 'PMA', 'Accounting Standards Codification', 'AdditionalPaidInCapitalCommonStockMember2022-12-310001107421srt', 'Research and Development', 'AdditionalPaidInCapitalCommonStockMember2023-09-300001107421us-gaap', 'MinimumMember2015', 'SEC', 'CONDENSED FINANCIAL STATEMENTS(unaudited)Cooperative Research and Development Agreement', 'the United States;\\n  &#x2022;We', 'BLA', 'The Lackey Retention Agreement', 'AdditionalPaidInCapitalCommonStockMember2023-07-012023-09-300001107421us-gaap', 'CONDENSED FINANCIAL STATEMENTS(unaudited)Distribution Agreement', 'PGEN Therapeutics, Inc.', 'Nasdaq', 'CONDENSED FINANCIAL STATEMENTS(unaudited)Following', '\\n    &'}"
TCRX,"{'additional capital.&#x201d;18\\n   &', 'the UK Medicines', 'organization)\\n     &#160;\\n', 'the Federal Reserve', 'EEA', 'K2HealthVenturesMember2023-01-012023-09-300001783328tcrx', 'EU', 'PCT', 'Unregistered Equity SecuritiesNot ApplicableUse', 'USTreasurySecuritiesMember2022-12-310001783328us-gaap', 'the Novartis Agreement', 'the Public Company Accounting Oversight Board', 'x2022;a', 'CPRA', 'the Amgen Agreement', 'the Securities Exchange Act', 'the Development of Our Product Candidates &#', '48\\n   &', 'COVID-19', 'PPF', 'x2022;a court', 'fee\\n         &#160;\\n         1,800\\n         &', 'HHS', 'x2022;if', 'Item 408 of Regulation S-K).On', 'compensation)\\n     &#160;\\n     &#160;\\n', ': &#x2022;collaborators', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'fee\\n         &', 'GDPR', ': &', 'FDA', 'the Conversion Shares', 'Contingencies LeasesThe Company', 'Loan', ': &#x2022;our', 'Unaudited Condensed Consolidated Financial Statements\\n     ', 'THERAPEUTICS, INC.', 'UNITED STATESSECURITIES', 'Company', 'the Department of the Treasury', 'The Novartis Agreement', 'USPTO', 'the world.&#x201d;&#x2019;Third party', 'the California Privacy Rights Act', '9746;\\n     QUARTERLY REPORT PURSUANT', '55\\n   ', '\\n     &', 'SVB', 'NovartisMember2020-03-012020-03-310001783328tcrx', 'Our Intellectual Property &', ': &#x2022;decreased', 'the California Consumer Privacy Act', 'Signature Bank', 'L.P.', ': &#x2022;identifying', 'the Delaware General Corporation Law', 'the European Commission', 'TScan Therapeutics', 'CMS', 'Loan Agreement', 'BWH', '&#x2022;collaborations', 'NovartisMember2023', 'the U.S. Department of Health and Human Services', 'Loan Agreement\\n         &', 'MinimumMembertcrx', 'IRB', 'Novartis Institutes for BioMedical Research, Inc.', 'compensation)\\n     &#160;\\n     &#160;\\n     19,164\\n     &#160;\\n     &#160;\\n     &#160;\\n     14,672\\n     &', 'THE SECURITIES EXCHANGE ACT OF 1934\\n', 'Novartis Institutes For Biomedical Research, Inc.', 'Amgen', 'TCR', 'K2HealthVenturesMember2022-09-092022-09-0900017833282021-12-310001783328us-gaap', '80\\n   &', 'Centers for Medicare &', 'FDIC', 'the Sarbanes-Oxley Act', '79\\n   &', 'this Quarterly Report to &#x201c;us,&#x201d', 'companies&#x2019', 'FairValueInputsLevel1Member2022-12-310001783328us-gaap', 'Hamas', 'the Loan Agreement', 'Baker Brothers Life Sciences', 'Business &#', 'this Quarterly Report', 'FairValueInputsLevel1Member2022-12-310001783328tcrx', 'K2HealthVenturesMember2022-09-092022-09-090001783328us-gaap', 'K2HealthVenturesMember2023', 'Medicaid Services', '63\\n   &', 'Healthcare', 'the European Medicines Agency', 'SEC', 'The Brigham and Women&#x2019;s Hospital, Inc.', 'Collaboration and License Agreement', 'BLA', 'K2HealthVenturesMember2022-09-090001783328tcrx', 'Novartis', 'Equity Securities', 'stock\\n         &#160;\\n         &#160;\\n         10,518,779\\n         &#160;\\n         &#160;\\n         &#160;\\n         5,258,027\\n         &'}"
TECH,
TELA,"{'compensation&#8203;$ 1,369&#8203;$', 'Credit and Security Agreement', 'FASB', 'OverviewWe', 'ASU', 'repurchase)&#8203', 'the OrbiMed Credit Facility', 'this Quarterly Report', 'Co', 'the Securities and Exchange', 'OptionsThe', 'Co.', 'Yes &#9723', 'Piper Sandler &', 'MidCap Financial Trust', 'the Lease Amendment', 'RevenueCost', 'OrbiMed', 'Internal Control Over Financial', 'ContentsGross MarginGross', 'Aroa', 'End of Term Charge', 'Registration 32\\nTable', 'Issued Accounting PronouncementsThe Company', '13,063&#8203;&#8203', 'Piper Sandler &amp', 'The OrbiMed Term Loan', 'SEC', 'FINANCIAL INFORMATIONItem&#160;1', 'Company', 'Advanced Medical Solutions Limited', 'the Securities Exchange Act', 'Measurement of Credit Losses on Financial Instruments', 'COVID-19', 'the MidCap Credit Agreement', 'The Lease Amendment', 'ExpenseInterest', 'Restated Bylaws', 'No  &#8203;Indicate', 'marketing&#8203;$', 'the Sarbanes-Oxley Act of 2002', 'the Registration Statement'}"
TENX,
TERN,"{'392\\n          &', 'FASB', 'LLC', 'Cowen and Company', 'Form S-3', '\\n    Interest income\\n    &', 'Board', 'SAD', '\\n    &#160;10.1#\\n', '\\n  &', 'the Underwriting Agreement', 'Terns, Inc.', 'include:\\n  &#x2022;expenses', 'the Securities and Exchange Commission', 'thousands)\\n          &#160;\\n', 'The Quirk Agreement', 'the Quirk Agreement', 'ESPP', 'the Quirk Retention Award', 'the Employment Agreements', ': &', 'and\\n  &#x2022;expenses', 'each Employment Agreement', 'MAD', 'the Quigley Agreement', 'Vintagence Biotechnology Ltd.', 'Terns Pharmaceutical HongKong Limited', 'Underwriters', '\\n  &#', '8,055\\n          &', 'the Compensation Committee of the Board', 'Hansoh&#x2019;s', 'DUET', 'consultants;\\n  &#x2022;the', 'Registrant', 'Healthtech Co., Ltd.', 'Hansoh Healthtech', '\\n    Research', 'the Condensed Consolidated Statements of Operations', 'SEC', 'collaborators.\\n  External', 'Company', '\\n  Research', 'x201c;anticipate,&#x201d; &#', 'Jiangsu Hansoh Pharmaceutical Group Company Ltd.', 'Cowen', 'Quigley Agreement', '\\n    &', '6,162\\n          &', '\\n    &#', 'x201c;seek,&#x201d'}"
TFFP,"{'ASU', 'TFF', 'Augmenta Bioworks, Inc.', 'cost&#160;\\n    Research', 'the Australian Taxation Office', 'ATM', 'the Australian\\nTax Incentive', 'Medicare', 'FDA', 'candidates;\\n\\n&#160;\\n\\n\\n&#9679;the\\n                                            ', 'us.\\n\\n&#160;\\n\\n\\n\\n\\n', 'VORI', 'candidates\\nand', 'the Health Care and Education Affordability Reconciliation Act', 'the United States Patent', 'NDA', 'Certificate', 'Tax Incentive Program', 'Company', 'restrictions;\\n\\n&#160;\\n\\n\\n&#9679;the\\n                                            ', 'the U.S. PTO', 'COVID-19', 'the Health Care Reform Law', 'TAC', 'INC.\\n\\nNOTES\\nTO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL', 'Company\\nfirst', '\\n    &', 'the Australian Tax Incentive'}"
TGTX,
THAR,"{'LLC', 'Target', 'Collaboration Patent', 'target.\\n\\n&#160;\\n\\nApplied\\nBiomedical Research Institute Research and Development Collaboration and License', 'Commercial License Agreement\\nwith Taurus Biosciences', 'Developed', 'the Company&#8217;s\\nRegistration Statement on Form S-1', 'Applied Biomedical Science Institute', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'The Avior Patent License Agreement', 'the &#8220;Avior Patent License', 'the ticker symbol &#', 'PD-1.\\n\\n&#160;\\n\\nThe\\nMinotaur Agreement', 'Licensed Patent Rights', 'the &#8220;Avior Patent License\\nAgreement&#8221', 'Develop', 'financial\\nstatements.\\n\\n&#160;\\n\\n\\n\\n    &', 'the Minotaur Agreement,\\nthe Company', 'the Minotaur Agreement', 'the Maturity Date', 'Development Milestone Payment', 'Company&#8217;s\\ncommon', 'HB', 'Challenge Proceeding', 'paid.\\n\\n&#160;\\n\\nEffective\\nJanuary 1, 2021,', 'the Avior Patent License Agreement', 'Form\\nS-3', 'activities.\\n\\n&#160;\\n\\nRecently\\nAdopted Accounting Pronouncements', 'Research and Development Collaboration and License Agreement\\n(the &#', 'Minotaur Therapeutics, Inc. (&#8220;Minotaur&#8221', 'pursuant\\nto', 'The Nasdaq Capital Market', 'Accounting Standards Update', 'the ticker symbol &#8220;HILS&#8221;\\nand', '\\n&#160;\\n\\nChanges\\nin Internal', 'Entity&#8217;s Own Equity', 'SEC', 'discounts\\nand', 'the Licensed Patent Rights and Licensed Technology to Develop', 'the Amended and Restated Employment Agreement', 'financial\\nreporting.\\n\\n&#160;\\n\\n\\n\\n', 'Company', 'the Securities Exchange Act', 'Development Milestone', 'Development Expenses\\n\\n&#160;\\n\\nResearch\\nand', 'Amended and Restated Employment Agreement', 'Applied Biomedical Science Institute (&#8220;ABSI&#8221', 'Certificate of Incorporation', 'the Next Equity Financing', 'the Sarbanes-Oxley Act', 'Adopted Pursuant to Section 302', 'Applied Biomedical Science', 'IPO', 'the Avior\\nPatent License Agreement', 'the Securities Act.\\n\\n&#160;\\n\\nITEM\\n3', 'and\\n  \\n    &#', 'Farrington', '\\n    &', 'MINT Patent', 'Avior Inc.', 'statements\\nare', 'Licensed Technology', 'Accounting for Convertible Instruments\\nand Contracts'}"
THMO,"{'Boyalife Group (USA)', 'L.P.', 'LLC', 'Credit Agreement', 'ASU', 'Board', 'License and Technology Access Agreement', 'Restated Bylaws of ThermoGenesis Holdings', 'Common Warrant (Incorporated', 'ImmuneCyte, Inc.', 'share.\\n\\n\\n&#xa0;\\n\\n&#xa0;\\n\\n\\n\\n\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t2.\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tGoing Concern\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nThe Company', 'the Market Offering Agreement', 'Capital Resources\\n\\n&#xa0;\\n\\nThe Company', 'First Amended and Restated Revolving Credit Agreement', 'Regulation S-K).\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\n\\n23\\n\\n\\n&#xa0;\\n\\n\\n&#xa0;\\n\\n&#xa0;\\n\\n\\n\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tITEM', 'ThermoGenesis Holdings', 'rate\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t4.20\\n\\t\\t\\t%\\n\\t\\t\\n\\n\\n\\n\\n&#xa0;\\n\\nThe Company', 'Boyalife Genomics', 'Bay City Capital Fund V Co-Investment Fund', 'China.\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\n\\n15\\n\\n\\n&#xa0;\\n\\n\\n&#xa0;\\n\\n\\n&#xa0;\\n\\n\\n\\n\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t9.\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tConcentrations\\n\\t\\t\\t\\n\\t\\t\\n\\n\\n\\n&#xa0;\\n\\nThe Company', 'Lease Agreement', 'Board of Directors', 'between ThermoGenesis Holdings, Inc.', 'Bay City Capital Fund V', 'the Offering Agreement', 'H.C. Wainwright &amp', 'CARTXpress Bio, Inc.', 'No &#x2610;\\n\\n&#xa0;\\n\\nIndicate', 'Form S-1', 'SEC', 'Common Stock', 'Company', 'the Securities Exchange Act', 'Boyalife Genomics.\\n\\n\\n&#xa0;\\n\\n&#xa0;\\n\\n\\n\\n\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t5.\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tRelated', 'Item 408 of', 'Genomics Tianjin Ltd.', 'Equity Securities', 'Restated Certificate of Incorporation of ThermoGenesis Holdings', 'the Registration Statement on Form S-3', 'Boyalife Group Inc.', 'ReadyStart'}"
THRD,
THRX,"{'FASB', 'LeasesThe', 'Form S-3', 'the License Agreement', 'Exhibit 32.1', 'this Quarterly Report', 'the Accounting Standards Codification', 'Release Agreement', 'ARIAD Pharmaceuticals, Inc. (&#8220;ARIAD&#8221', 'the Securities and Exchange Commission', 'ATM Program', 'NetTotal', 'Theseus Pharmaceuticals', 'Development ExpensesResearch', 'the State of Delaware', 'KIT', 'Principal Executive Officer Pursuant to Securities Exchange Act', 'ExpensesResearch', 'Principal Executive Officer Pursuant', 'the Internal Revenue Service', 'Adopted Accounting PronouncementsFrom', 'the ""Board', 'BCR-ABL', 'Registrant', 'Accounting Standards Update', 'PlanThe Company', 'SEC', 'Company', 'the Financial Accounting Standards Board', 'AgreementsThe Company', 'the ARIAD License Agreement', 'Restated Certificate of Incorporation', 'the Securities Exchange Act', 'the Sarbanes-Oxley Act', 'the indemnified party', 'RightsEach', 'IPO', 'Restated Bylaws', 'Exhibit 101).X*Management Contract', 'EGFR', 'compensation)$14,358&#160;11,908&#160;2,450&#160;Other$1,585&#160;1,166&#160;419&#160;Total'}"
THTX,
TIL,"{'MHRA', 'the Condensed Consolidated Statements', 'the Nasdaq Capital Market', 'Note 10).Legal Proceedings', 'HHS', 'the Condensed Consolidated Financial Statements.104Cover Page Interactive Data File', 'Reliance', 'the Condensed Consolidated Statements of Cash Flows', 'Consolidated Statements of Cash', 'CMS', 'Consolidated Balance Sheets2Condensed Consolidated Statements of Operations', 'Plan', 'Consolidated Statements', 'Item 10 of Regulation S-K', 'Financial Statements', 'Adopted Pursuant to Section 906', 'The Sarbanes-Oxley Act', 'Principal Financial Officer', 'EMA', 'FDA&#8217;s GCP', 'FCPA', 'Medicaid', 'Medicare', 'ActivityThe', 'the Condensed Consolidated Balance Sheets', 'European Union', 'the U.S. Department of Health and Human Services', 'Development ExpensesResearch', 'Sandeep LaumasSandeep LaumasChief Financial Officer', 'MAA', 'EU', 'FDA', 'Immetacyte', 'the Data Safety Monitoring Board', 'Status', 'PTO', 'the Nasdaq Stock Market', 'IRB', 'Medicaid Services', 'post-Transition Period', 'Board of Directors', 'Financial Position', 'Inherent Limitations on Effectiveness of', 'Healthcare', 'Immetacyte Ltd.', 'Public CompanyAn', 'Risks Related', 'the Hatch-Waxman Amendments', 'ControlsOur', 'Capital NeedsWe', 'TIL', 'the Trade and Cooperation Agreement', 'the Condensed Consolidated Statements of Operations', 'SEC', 'Inline XBRL (Extensible Business Reporting Language', 'Company', 'Administrative Expenses General', 'BLA', 'the United States Patent and Trademark Office', 'Plant and Equipment, Net Property', 'the Securities Exchange Act', 'the Centers for Medicare &', 'the Sarbanes-Oxley Act', 'COVID-19', 'Held for SaleThe Company', 'Marketable SecuritiesThe Company', 'the Company&#8217;s Board of Directors', 'the Leahy-Smith Act', 'Department of Justice', 'the European Union', 'Nasdaq', 'deemed &#8220;filed&#8221', 'Condensed Consolidated Financial Statements7Item 2', 'INC.November&#160;13'}"
TIVC,"{'the Company&#x2019;s Board of Directors', 'FASB', 'the Nasdaq Capital Market', 'Form S-3', 'Issued Accounting Pronouncements &', '\\n  &#x2022;We', 'Walmart.com', 'The Shelf Registration Statement', 'ASU No', 'Reverse Stock', 'Amazon.com', 'the &#x201c;Shelf Registration', 'IP', 'CompensationThe Company', 'Maxim', 'year.\\n  &', 'FDA', '\\n  &#', 'Cash EquivalentsThe Company', 'Indicate', 'The Nasdaq Capital Market', 'Form S-1', 'Amerisource Bergen', 'SEC', 'the Microart Agreement', 'Company', 'The Feinstein Institute', 'Feinstein', 'factors.\\n  &', 'Nasdaq', 'of Q4.\\n  &#x2022;We'}"
TKNO,
TLIS,"{'L.P.', 'ASC', 'the Retention Award Agreement', 'the University of Massachusetts Medical School for Phase 1', 'LLC', 'None.\\n  &', 'Offer Letter', '\\n  Components', 'Form S-3', 'Initial Public Offering of Common Stock\\n  &', 'Baker Brothers Life Sciences', 'Talis One', 'LOC', 'this Quarterly Report', 'The Registration Rights Agreement', 'securities\\n  &#', 'the Securities and Exchange', '\\n  &#x2022;an', 'L.P. (the Baker Funds', 'Exhibits.\\n  &#160;\\n', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'NIH Rapid Acceleration of Diagnostics', 'the Company&#x2019;s Annual Report on Form 10-K', 'this Quarterly Report on Form 10-Q', 'Illinois (IL).LiquidityThe Company', 'the Registration Rights Agreement', 'Microtechnology AG', 'the State of Delaware', 'NIH', 'Phenotypic Antibiotic Susceptibility Testing of Pathogens', '\\n  Selling', 'the Public Company Accounting Oversight Board', 'Exhibit 10.7', '\\n  &#', 'the Retention Agreement', '\\n    &', 'EUA', 'Diagnostics via Rapid Enrichment', 'Interim CFO', 'Identification', '\\n        &', 'SEC', 'CA', 'Company', 'the Securities Exchange Act', 'Kriya Therapeutics, Inc.', '\\n  &#x2022;not', 'the Baker Funds', 'the Sarbanes-Oxley Act', 'COVID-19', 'Adopted Pursuant to Section 302', 'Talis Biomedical Corporation', 'IPO', 'Results of Operations', '\\n  &#x2022;reduced', 'Diagnostics - Advanced Technology Platforms'}"
TLRY,"{'knowhow &amp', 'AOR', 'xa0;&#xa0;73,414&#xa0;\\n 2028 &', 'liability.\\n   ', 'liability &', '2023 &', 'x201c;Non', '2023 &#', 'Amortization &#xa0;\\n 2024', 'LLC&#xa0;(the &#x201c;Share', 'Level 3 &#', 'market.\\n  &#', 'HTI Share Consideration&#x2019;s', 'HEXO&#xa0;Corp', '\\n   &#', 'xa0;&#xa0;2,128&#xa0;&#xa0;&#xa0;2,104&#xa0;\\n Term loan &', 'xa0;&#xa0;(1,098)&#xa0;&#xa0;(738)\\n Net', 'Court', 'IRI', 'HEXO Corp.', 'ABG', 'Treasury', 'the 420 Term Loan', 'Ontario Limited', 'items:\\n   &#', 'margin.\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#xa0;\\n  &#', 'Intangible Assets\\n   &#', 'EURIBOR', '5,106\\n     &#xa0;\\n     &#xa0;\\n     &#', 'the Fall of&#xa0;2023.&#xa0;The Company', 'Initial Measurement (&', 'xa0;$93,521&#xa0;&#xa0;$82,192&#xa0;\\n EMEA &#', 'Tilray Brands', 'ColCanna S.A.S.', 'FASB', 'SH Acquisition', 'xa0;\\n Credit', 'DDH', 'Internal Control', 'Adjusted EBITDA\\n  &#', 'xa0;&#xa0;73,414&#xa0;\\n 2026 &', 'resources.\\n   &#', 'activities\\n  &#', 'the High Park License', 'xa0;\\n Cannabis &', 'xa0;\\n     &#x2014;\\n     &#', 'Four Twenty Corporation', 'Superior Court', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Breckenridge', 'Wellness', 'North America &', 'Docklight&#x2019;s', '58,570\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Company', 'World &#xa0;&#xa0;3,724&#xa0;&#xa0;&#xa0;4,978&#xa0;\\n Total &', 'IFRS', 'the U.S. Department', 'RNDC', 'xa0;&#xa0;434,357&#xa0;\\n Total &#', 'Results of Operations', '\\n    &#', 'Defendants', 'of&#xa0;70', 'the Company&#xa0;and HEXO Corp.', 'this Court decision.\\n   &#', 'the Company&#xa0;and HEXO', 'Level 1 &#', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'P.A.', 'the TLRY&#xa0;27 Notes', 'Double Diamond Holdings Ltd.', 'xa0;\\n Customer', 'xa0;&#xa0;2023&#xa0;\\n Financial', 'CC Pharma Nordic ApS', 'results.\\n  &#', '\\n  &#', 'Tilray&#x2019;s Application for Summary Judgment', 'TLRY&#xa0;27&#xa0;Notes&#xa0;to', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Authentic Brands Group', '\\n    &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;August 31,&#xa0;\\n&#xa0;&#xa0', 'Montauk Brewing Company, Inc.', 'inflation.&#xa0;\\n  &#', '8,766\\n     &#xa0;\\n     &#xa0;\\n     &#', '2021&#xa0;Docklight Brands, Inc. (&', 'a&#xa0;2018&#xa0;license', '\\n \\n \\n \\n', 'xa0;$384,091&#xa0;&#xa0;$319,173&#xa0;\\n EMEA &', '\\n    &#xa0;&#xa0;August', 'channel &', '47\\n', 'Financial Reporting\\n  &#', 'liabilities &#xa0;&#xa0;(13,489)&#xa0;&#xa0;(24,080)\\n', 'adjustments.\\n  &#', 'value:\\n   &#', '\\n        &#', 'The MedMen Convertible Note', 'World &#xa0;&#xa0;3,767&#xa0;&#xa0;&#xa0;3,363&#xa0;\\n Total &#', 'this Quarterly Report', 'High Park Holdings, Ltd.', 'respectively.\\n   &#', 'HEXO', 'Level 2 &#', 'Docklight Litigation \\n', 'xa0;&#xa0;7,689&#xa0;&#xa0;&#xa0;5,601&#xa0;\\n Beverage', 'Office', '2022 &', '50,517\\n     &#xa0;\\n     &#xa0;\\n     &#', 'xa0;\\n     &#', 'Tilray', '\\n     &#xa0;\\n     &#', 'Docklight', 'the U.S. District Court', '\\n     &#', 'SEC', 'SOFR', 'the 420 Secured Credit Agreement', 'disclosure.\\n  &#xa0;\\n  Consistent', 'Revenue\\n   &#', 'Equity Securities', 'HTI', 'the HEXO Convertible Note', 'Unregistered Equity', 'items:\\n  &#'}"
TLSA,
TLSI,"{'ASC', 'API', 'MTAC Warrants', 'LLC', 'Good Manufacturing Practices', 'The Sarbanes-Oxley Act', 'Financial Instruments', 'this Quarterly Report on Form 10-Q', 'The Dynavax Agreement', 'The Public Warrants', 'the Amended and Restated Registration Rights Agreement', 'EU', 'Our Public Warrants and Private Placement Warrants', 'ExpensesResearch', 'Phase 4', 'the Public Company Accounting Oversight Board', 'Sarbanes-Oxley', 'Form S-1', 'Series&#160;A-1', 'the Sarbanes Oxley Act.&#8226;Our', 'ACA', 'TriSalus).Proceeds', 'the Financial Accounting Standards Board', 'Series&#160;A-2', 'the Private Placement Warrants or Conversion Warrants', 'Series B-1', 'concern.&#8226;The Asset Purchase Agreement', 'Yorkville Advisors Global, LP', 'MTAC Public Warrants', 'COVID-19', 'Series A Convertible Preferred Stock', 'PEDD', 'TriSalus', 'the Merger Agreement', 'Combined Company Common Stock', 'Financial Statements', 'Executive Orders', 'Private Placement Warrants', 'Advanced Critical Devices', 'Medicaid', 'Medicare', 'Congress', 'Warrant LiabilitiesThe', 'the Initial Preferred Stock Financing', 'Series&#160;A-5', 'FDA', 'Audit Committee', 'the Yorkville Purchase Agreement', 'Cayman Islands', '31,2022Public Warrants8,333,272&#160;&#8212;&#160;Private', 'the Sponsor Support Agreement', 'Risks Related', 'September&#160;30', 'Common Stock', 'Company', 'Certificate of Incorporation or Bylaws', 'Gross MarginGross', 'Gross Profit', 'USPTO', 'Series B-3', 'Series&#160;B-1', 'TriNav', 'ASU', 'TriSalus Life Sciences, Inc.', 'CMS', 'MTAC', 'Dynavax', 'the Condensed Consolidated Balance Sheets', 'the Sarbanes Oxley Act', 'the Series A Convertible Preferred Stock', 'Fair Value of Tranche', 'the Asset Purchase Agreement', 'the Dynavax Agreement', 'RequirementsOur', 'Trust Company', 'the Nasdaq Stock Market', 'IRB', 'ReportingWe', ': &#', 'the Subscription Agreements', 'TPT', 'Dynavax Technologies Corporation', 'the B-2 Preferred Stock Financing', 'the Common Stock', 'NDA', 'Series&#160;A-6', 'Series&#160;B-2', 'the Consolidated Appropriations Act', 'a Statement of Comprehensive Income', 'Preferred Stock', 'Tranche', 'the Delaware Court of Chancery', 'Our Certificate of Incorporation', 'Yorkville', 'Board', 'Issuer Purchases of Equity SecuritiesSubscription AgreementsIn', 'ACD', 'the Court of Chancery of the State of Delaware', 'Series&#160;A-4', 'Contents&#160;&#160;&#160;&#160;stockholders', 'the Publicly Traded Warrants', 'MedTech Acquisition', 'the Legacy TriSalus Preferred Stock', 'the State of Delaware', 'Trump', 'the U.S. Treasury', 'Administrative ExpensesGeneral', 'YA II PN, LTD.', 'Financial Instruments - Credit Losses', 'the Series&#160;B-2 Tranche Rights', 'Continental Stock Transfer &amp', 'OperationsThe', 'ExpensesOur', 'SEC', 'WeaknessesOur', 'PreferencesThe', 'MTAC Warrants and Level 2', 'the Business Combination', 'the Preferred Stock PIPE Investors', 'Equity Securities', 'Series&#160;A-3', 'the European Union', 'Nasdaq'}"
TMCI,
TMDX,"{'\\n    Service revenue\\n    &', 'Company\\', 'LLC', 'OrbiMed Royalty Opportunities II', '\\n  Research, Development and Clinical Trials Expenses \\n  Research', 'National OCS Program (&#x201c;NOP&#x201d;)', 'management&#x2019;s', 'OCS Perfusion Sets', 'OCS Consoles', 'OPTN', 'Acquisitions\\n  &#', 'realized.\\n', 'Federal Aviation Administration', 'Whitney', 'Canadian Imperial Bank of Commerce', 'National OCS Program', '\\n  &', 'TRANSMEDICS GROUP', 'x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#', 'CIBC', '\\n  &#x2022;the', 'the Organ Care System', 'and\\n  &#x2022;our', 'European Union', 'Pratt &', '\\n  &#x2022;attacks', 'guarantor&#x2019;s', 'IPR&amp;D', 'FDA', 'the OrbiMed Credit Agreement', 'of:\\n  &#160;\\n', 'Material Contractual Obligations\\n', 'National Association', '\\n  Economic Impacts', '\\n  &#', 'OCS', 'OrbiMed', 'NOP', 'i\\n', 'Summit Aviation, Inc.', 'Indicate', '\\n  &#x2022;that', 'The Capped Call Transactions', 'OCS Solutions', 'In-Process Research and Development Expenses\\n', '\\n  &#x2022;regulatory', '\\n    Research', '\\n        &', 'Need for Additional', 'the Food and Drug Administration', 'United States\\n    &', 'Company', 'Stock-Based Compensation The Company', 'Acquired Intangible Assets\\n  Recently Issued Accounting Pronouncements \\n', 'Restated TransMedics Group', '\\n  &#x2022;facilities', 'the CIBC Credit Agreement', 'U.S. Bank Trust Company', 'Gross Profit', 'INC', 'OCS technology platform.\\n', '\\n  Management', '\\n  &#x2022;laboratory', '\\n    Interest expense\\n    &', 'strategic investments;\\n  &#x2022;our', 'Summit\\', 'FAA Qualification Standards', 'Northside Property Group', 'Comparison', 'FAA', '\\n    &', '\\n  &#x2022;expenses', 'Organ Procurement and Transplantation Network Act', '\\n  &#x2022;our', 'the Capped Call Transactions'}"
TNDM,
TNGX,
TNON,
TNXP,"{'the Current\\n                                    Report on Form 8-K', 'LLC', 'ASU', 'the License Agreement', 'the National Institutes of Health', 'Procedures\\n    &', 'Brookline Capital Markets', 'ASSET', 'mAbs', 'ATM', 'Cooperative Agreement', 'Exchange Act', 'Medicaid', 'Medicare', 'UNIVERSITY OF', 'to\\nbe', 'the Securities and Exchange Commission', 'License Agreement', 'LEASES \\n\\n&#160;\\n\\nThe Company', 'this uncertainty.\\n\\n&#160;\\n\\nNOTE 2 &#8211', 'Articles of Incorporation', 'Transition Services Agreement', 'the Current Report on Form 8-K', 'Tri-Care', 'compensation\\n\\n&#160;\\n\\nAll', 'Tonix Pharmaceuticals Holding Corp.', 'murine\\nmAbs', 'FDA', 'Zembrace and Tosymra', 'the National Institute on Drug\\nAbuse (&#8220;NIDA&#8221', 'Lincoln Park', 'Pre-Funded Warrant', 'Arcadia Securities', 'Tamandare Explorations Inc.', 'Columbia', 'FINANCIAL INFORMATION\\n\\nITEM\\n1', 'USL', 'University of Alberta', 'Orange Book', 'Upsher-Smith Laboratories', 'antiviral\\ndrugs', 'A.G.P./Alliance\\nGlobal Partners', 'Registrant', 'LICENSE AGREEMENT WITH', 'Regulation S-X.', 'Lincoln Park Capital Fund', 'the Annual Report on Form 10-K', 'to\\na', 'Company&#8217;s\\nauthorized', 'Commission', 'the Healion Purchase Agreement', 'Company', 'Lincoln', 'measured\\nat', 'reference.\\n\\n    \\n    &', 'the University of Alberta', 'Preferred Stock', 'reference.\\n\\n    &', 'LLC (&#8220;Lincoln', 'Nasdaq', 'Restated Bylaws', '\\n    &', 'the Registration Statement on Form S-1'}"
TNYA,"{'API', 'LLC', 'the U.S.;\\n  &#x2022;potential', '\\n', 'the Shelf Registration', 'UTSW License', 'EMA', 'this Quarterly Report on Form 10-Q', '42\\n  \\n  &#160;\\n', 'programs.\\n', 'EU', 'facilities;\\n  &#x2022;the', 'Need for Additional Capital and Limited', 'x2022;a', 'the UTSW License', 'the U.S.;\\n  &#x2022;production', 'Form S-1', 'products.\\n  Regulatory', 'approved.\\n  &#x2022;We', 'candidates;\\n  &#x2022;FDA', 'all;\\n  &#x2022;collaborators', 'candidates;\\n  &#x2022;collaboration', 'and\\n  &', 'HHS', 'the Gladstone License Agreement', 'disease;\\n  &#', 'candidates;\\n  &#x2022;collaborators', 'UTSW', 'U.S. Food and Drug Administration', 'x201c;Risk', 'Medicaid', 'CompensationThe', 'Congress', 'Medicare', 'Obtaining', 'x2014;\\n        &', 'stockholders&#x2019', 'the University of Texas Southwestern', 'SVB Securities', 'GDPR', 'FDA', 'letters;\\n  &#x2022;civil', 'the Securities Market and Ownership of Our Common Stock\\n  An', 'and\\n  &#', 'others;\\n  &#x2022;collaborators', 'candidates;\\n  &#x2022;our', 'them;\\n  &#x2022;the', 'and\\n  &#x2022;imposition', 'business;\\n  &#x2022;collaborators', 'Company', 'Gladstone', 'management&#x2019;s attention', 'and\\n  &#x2022;the', 'payroll taxes;\\n  &#x2022;foreign', 'USPTO', 'profits.\\n', 'Department of Justice', 'and\\n  &#x2022;business', 'operations.\\n  Emerging Growth Company', 'University of Texas Southwestern License AgreementsIn', 'CAT', 'CMS', 'candidates;\\n  &#', 'relationships;\\n  &#x2022;risks', 'jurisdictions;\\n  &#x2022;our', 'FCPA', 'Gladstone License Agreement', 'revenue;\\n  &#x2022;exhaustion', 'and\\n  &#x2022;our', 'x2022;injunctions;\\n  &#x2022;suspension', 'targeting;\\n  &#x2022;our', 'the U.S. Department of Health and Human Services', 'stock.\\n  Risk Factors Summary\\n', 'CDMOs', 'strategy;\\n  &#x2022;our', 'performance;\\n  &#x2022;our', 'CommitmentsThe Company', 'x2022;a collaborator&#x2019;s', '\\n  &#', 'the Nasdaq Stock Market LLC', 'the Union City Facility', 'the Data Protection', 'reporting.\\n', 'IPO', 'Privacy and Electronic Communications', 'products.\\n  Risks Related to Regulatory Approval', '\\n  &#x2022;our', 'them;\\n  &#', 'Our Financial Position', 'the J. David Gladstone Institute', 'Form S-3', 'oversight.\\n', 'this Quarterly Report', 'resources.\\n  Regardless of the merits', 'markets;\\n  &#x2022;compliance', 'ATM', '\\n  &', '\\n  &#x2022;delays', 'cGMP;\\n  &#', 'ESPP', 'activities;\\n  &#x2022;retention', 'Equity &#', 'Medicaid Services', 'No  &#9744;\\n  Indicate', 'products;\\n  &', '\\n        &', 'SEC', 'Equity Offering16\\n     &', 'the Shelf Registration Statement', 'GCP', 'the Centers for Medicare &', 'the European Union', 'collaborator&#x2019;s'}"
TOI,"{'\\n  &#x2022;injury', 'years)\\n        &', 'LLC', 'AMD', 'THE SECURITIES EXCHANGE ACT OF 1934 \\n', '\\n    Interest income\\n    &', '\\n  &#x2022;variations', '\\n  Commission File Number 001-39782', '\\n', 'Medicaid Innovation (&#x201c;CMMI&#x201d;)', '\\n  &#x2022;expansion', 'the University of PennsylvaniaOn April 21, 2023', 'EMA', '\\n  &#x2022;disruptions', 'the Regents of the University of California', '\\n  &#x2022;an', 'Rights Agreement', 'Uneek Mehra\\n', '\\n  &#x2022;termination', 'this Quarterly Report on Form 10-Q', 'the Optimized Adeno-Associated Virus for Lung Epithelia Gene Delivery Development Program', 'the University of California The Company', 'Jefferies LLC', '223,327\\n    &', '\\n  &#x2022;costs', 'B.V. (&#x201c;uniQure&#x201d', 'Molecular Therapeutics, Inc.', 'x2022;a', 'UNITED STATES', 'Effects of Inflation\\n', 'the &#x201c;License', '\\n    Research', 'AGT the Transferred Material', 'UC Agreements', 'ACA', 'Segment Information The Company', 'the Securities Exchange Act', '\\n  &#x2022;expenditures', 'the S-3 Registration Statement', 'COVID-19', 'the License Agreement).Aevitas Therapeutics, Inc.', 'the University of Pennsylvania', 'the Company&#x2019;s 2022 Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'the Funding Agreement', 'Registration Statement on Form S-1', 'FASB', '2022\\n         \\n         \\n          &#160;Customer', '\\n  &#x2022;product', 'DirectorPrincipal Executive', '\\n  &#x2022;sufficient', 'the &#x201c;UC Agreements&#x201d', '\\n  &#x2022;publicity', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;issued', 'x201c;Risk', '\\n  &#x2022;initiation', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'CFF', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;general', '\\n  &#x2022;expanding', 'FDA', '\\n  &#x2022;collaborations', 'Licensed Products', 'requirements.\\n  &#x2022;Our', 'parties)\\n    &', 'and\\n  &#', 'Registration Statement on Form S-3', '\\n  &#x2022;changes', '\\n  &#x2022;collaboration', 'Center for Medicare &', '\\n  &#x2022;others', 'the Medicaid Drug Rebate Program', 'the Amended uniQure Agreement', 'x201c;CFF', '\\n  &#x2022;regulatory', 'REMS', '\\n  &#x2022;loss', '\\n  &#x2022;new', 'activities\\n    &', 'Concentration of Credit Risk Financial', 'Patient-Centered Outcomes Research Institute', 'Company', '\\n  Regulatory', '99%\\n          &#160;\\n', 'Catalent', 'USPTO', '\\n  &#x2022;impose', '\\n  &#x2022;seize', 'DME', '\\n    &#', 'Report', 'the Delaware General Corporation Law', '\\n  &#x2022;diligence', '\\n  ', 'Capital Requirements \\n', 'the UC Agreements', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD', 'UK Data Protection Act 2018', '\\n  &#x2022;future', 'the Program Advisory Group', '\\n  Interest Rate Sensitivity', '\\n  &#x2022;the', 'and\\n  &#x2022;our', 'the Sales Agreement', '497\\n        &', '\\n  &#x2022;coverage', 'Roche', '\\n  &#x2022;exhaustion', '\\n  &#x2022;timing', 'x2022;a collaborator&#x2019;s', '\\n  &#x2022;commencement', '\\n  &#', '\\n  &#x2022;managing', '\\n  &#x2022;market', '\\n  &#x2022;collaborators', 'Investigational New Drug', '\\n  &#x2022;retention', 'Registrant', 'the UC Regents', '\\n          &', 'technologies.\\n  &#', 'Condensed Statements of Operations', '10\\n       &', '\\n  &#x2022;announcement', 'IPO', 'AWA', '\\n  &#x2022;The', 'companies&#x2019', 'ASU No', 'the Amended uniQure Agreement or the Second uniQure Agreement', '\\n  &#x2022;our', '\\n  &#x2022;key', 'Therapeutic Vector Evolution', 'Form S-3', '\\n  &#x2022;convenience', 'the License Agreement', 'GA', '\\n  &#x2022;We', 'the Funding Agreement Product (&#x201c;Acceptance&#x201d;)', 'the &#x201c;August 2023', 'ATM', '\\n  &', 'the Court of Chancery of the State of Delaware', '500\\n    &', 'harmed.\\n  &#x2022;Our', 'European Union', 'Condensed Statements of Comprehensive Loss', '99%\\n          &#', 'the State of Delaware', 'x2022;refuse', '\\n  &#x2022;risks', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Medicaid Services', '\\n  &#x2022;suspend', 'frames.\\n  &', '\\n  &#x2022;the FDA', '\\n  &#x2022;identifying', '\\n  &#x2022;withdrawal', 'Related Party Transactions', 'the Court of Chancery', 'Significant Accounting Policies', 'the &#x201c;Funding Agreement', '\\n        &', 'SEC', 'ATM Offering', 'agreements.\\n', 'Collaboration and License Agreement', 'BLA', 'The CFF Agreement', 'the Centers for Medicare &', 'the University of California and The Trustees of the University of Pennsylvania', '\\n  &#x2022;failure', 'Aevitas Therapeutics, Inc. (&#x201c;Aevitas&#x201d;)', '\\n  &#x2022;reduced', 'the European Union', '\\n  Litigation', '\\n    &', '\\n  &#x2022;sales', 'collaborator&#x2019;s'}"
TPST,
TRDA,"{'ASC', 'RevenueCollaboration', 'RNA', 'LLC', 'ProceedsSet', 'Incentive Plan', 'EMA', 'Principal Executive Officer', 'the EU Commission', 'the Private Securities Litigation Reform Act', 'Pompe', 'EEA', 'ExhibitsThe', 'this Quarterly Report on Form 10-Q', 'Development ExpensesResearch', 'EU', 'the Vertex Agreement', 'ExpensesResearch', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS', 'the Public Company Accounting Oversight Board', 'Nexviazyme', 'Development ExpensesNine Months Ended', 'Vertex Agreement', 'Form S-1', 'ContentsWe', 'ACA', 'Privacy Shield Framework', 'CONSOLIDATED BALANCE SHEETS(In', 'Amicus Therapeutics Inc.', 'the Securities Exchange Act', 'the Pierrepont Agreement', 'Entrada', 'Expansion Therapeutics, Inc.', 'ASO', 'Principal Financial Officer Pursuant', 'Adopted Accounting', 'ContentsCollaboration RevenueCollaboration', 'ContentsIn', 'the Registration Statement on Form S-1', 'FASB', 'Company\\', 'LeasesThe', 'linear', 'Anti-Kickback Statute', 'HHS', 'Rule 424(b)(4', 'Contingencies', 'Restated Certificate of Incorporation of the Registrant', 'Medicaid', 'the Securities and Exchange Commission', 'IDB Lease', 'Arrangements&#160;(ASC', 'Design Therapeutics, Inc.', 'Medicare', 'CUG', ': &', 'compensation&#8212;&#160;&#8212;&#160;2,512&#160;&#8212;&#160;&#8212;&#160;2,512&#160;Other comprehensive loss&#8212;&#160;&#8212;&#160;&#8212;&#160;(730)&#8212;&#160;(730)Net loss&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;(23,179)(23,179)Balances', 'GDPR', 'FDA', 'the Data Safety Monitoring Board', 'NetProperty', 'national data protection authority', 'the Physician Payments Sunshine Act', 'amounts)(unaudited)Common StockAdditionalPaid&#8209;inCapitalAccumulated Other Comprehensive LossAccumulated DeficitTotal', 'OSIF', 'the IDB Lease', 'EGC', 'Ohio State Innovation Foundation', 'the Court of Justice', 'ContentsThe', 'Risks Related', 'HIPAA', 'GTG', 'Company', 'compensation&#8212;&#160;&#8212;&#160;2,755&#160;&#8212;&#160;&#8212;&#160;2,755&#160;Other', 'compensation&#8212;&#160;$&#8212;&#160;$3,396&#160;$&#8212;&#160;$&#8212;&#160;$3,396&#160;Other', 'USPTO', 'Adopted Pursuant to Section 302', 'ERT', 'SecuritiesThe', 'company.&#8221', 'GLP', 'Maximillian Schrems', 'CMS', 'OperationsComparison', 'Endosomal Escape Vehicle', 'Data Protection', 'Contracts with Customers', 'Amicus', 'RecognitionThe Company', 'Avidity', 'the Current Report on Form 8-K', 'the U.S. Department of Health and Human Services', 'September&#160;30,', 'SSP', 'OSIF License Agreement', 'License', 'IRB', ': &#', 'Vertex', 'Tide Street LeaseThe Company', 'The Vertex Agreement', 'Upfront', 'GDPR\\', 'Registrant', 'the Children&#8217;s Health Insurance Program', 'the Vertex Agreement and Sublicense Agreement', ""ContingenciesThe Company\\'s"", 'CTA/IND', 'NDA', 'The Ohio State University&#8221', 'The IDB Lease', 'receivable5,025&#8212;Prepaid', 'the United Kingdom Medicines', 'the Sarbanes-Oxley Act', 'IPO', 'AMO Pharma Ltd.', 'Capital Resources.&#8221', 'ASU No', 'DMD', 'Cowen and Company', 'Form S-3', 'Vertex Agreement - Accounting AnalysisThe Company', 'this Quarterly Report', 'EQUITY', 'CJEU', 'the International Data Transfer Agreement and International Data', 'Locana, Inc.', 'Premises', 'Income TaxesThe Company', 'the UK Information Commissioner&#8217;s Office', 'ATM', 'ASC 842$&#8212;$32,991Transfer', 'Healthcare Products Regulatory Agency', 'December&#160;31', 'PepGen, Inc.', 'the State of Delaware', 'ContentsThe Company and Vertex', 'Medicaid Services', 'EEV', 'Pierrepont Therapeutics, Inc.', 'Discussion and Analysis of Financial Condition', 'Significant Accounting Policies', ': &#8226;such', 'SEC', 'Research Ethics Committee', 'BLA', 'Development ExpensesThree Months Ended', '31,2022Laboratory equipment$11,661$8,335Furniture', 'the Federal Trade Commission Act', 'Drydock Limited Partnership', 'the Centers for Medicare &', 'U.S.C &', 'Equity Securities', 'programs2,3898721,517&#160;&#160;&#160;Other', 'DM1', 'March&#160;31', 'ASC Topic', 'the European Union', 'Nasdaq', 'the Sublicense Agreement'}"
TRIB,
TRML,"{'Boston Lease', 'Fair Value of Financial Assets', 'the Stockholder Litigation', 'European Data Protection Laws', 'ImmunoFree, Inc. (&#8220;ImmunoFree&#8221;)', 'EEA', 'this Quarterly Report on Form 10-Q', 'New York Blood Center, Inc. (&#8220;NYBC&#8221', 'EU', 'expenses\\n&#160;&#160;\\n$\\n267\\n&#160;\\n&#160;&#160;\\n$\\n14,981\\n&#160;\\n&#160;&#160;\\n$\\n(14,714\\n)&#160;\\n\\n\\n&#160;&#160;\\n &#', 'the Boston Lease', 'Terrain Merger Sub, Inc.', 'the Internal Revenue Code', 'Note 10).&#160;The Company', '\\n &#160', 'HTA', 'the Lonza License Agreement, Lonza', 'Research and Development Expenses  Research', 'ACA', 'the Securities Exchange Act', 'Strategic Advisor Agreement', 'BD Arrangement', 'October&#160;19', 'the Merger Agreement', 'FASB', 'Pfizer', 'ImmunoFree', 'HHS', '\\n &', 'net\\n&#160;&#160;\\n&#160;\\n5,262\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,286\\n&#160;\\n&#160;&#160;\\n&#160;\\n3,976\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'September&#160;30,\\n&#160;\\n\\n&#160;\\n&#160;&#160;\\n2023\\n&#160;\\n&#160;&#160;\\n2022\\n&#160;\\n&#160;&#160;\\nChange\\n&#160;\\n\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#160;\\n&#160;&#160;\\n(in&#160;thousands)\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#160;\\n\\n\\n\\n Direct', 'Concentration of Credit Risk  Financial', 'Restated Certificate of Incorporation of the Registrant', 'Facilitated', 'expenses\\n&#160;&#160;\\n$\\n17,770\\n&#160;\\n&#160;&#160;\\n$\\n42,364\\n&#160;\\n&#160;&#160;\\n$\\n(24,594\\n)&#160;\\n\\n\\n&#160;&#160;\\n &', 'programs\\n&#160;&#160;\\n$\\n(324\\n)&#160;\\n&#160;&#160;\\n$\\n4,294\\n&#160;\\n&#160;&#160;\\n$\\n(4,618\\n)&#160;\\n\\n\\n&#160;&#160;\\n &#', 'Medicaid', 'the ImmunoFree Demand Letter', 'the Securities and Exchange Commission', 'Medicare', 'Congress', 'September&#160;30,\\n&#160;\\n\\n&#160;\\n&#160;&#160;\\n2023\\n&#160;\\n&#160;&#160;\\n2022\\n&#160;\\n&#160;&#160;\\nChange\\n&#160;\\n\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#160;\\n&#160;&#160;\\n(in&#160;thousands)\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#160;\\n\\n\\n\\n Operating expenses\\n&#160;&#160;\\n\\n\\n\\n&#160;&#160;\\n\\n\\n\\n&#160;&#160;\\n\\n\\n\\n\\n Research', 'FDA', 'compensation)\\n&#160;&#160;\\n&#160;\\n8,564\\n&#160;\\n&#160;&#160;\\n&#160;\\n21,366\\n&#160;\\n&#160;&#160;\\n&#160;\\n(12,802\\n)&#160;\\n\\n Facilities', 'Indemnification Agreement', 'costs\\n&#160;&#160;\\n&#160;\\n543\\n&#160;\\n&#160;&#160;\\n&#160;\\n3,386\\n&#160;\\n&#160;&#160;\\n&#160;\\n(2,843\\n)&#160;\\n\\n\\n&#160;&#160;\\n &#', 'REMS', 'Company', 'USPTO', 'CTA', 'administrative\\n&#160;&#160;\\n&#160;\\n21,322\\n&#160;\\n&#160;&#160;\\n&#160;\\n14,288\\n&#160;\\n&#160;&#160;\\n&#160;\\n7,034\\n&#160;\\n\\n Restructuring costs\\n&#160;&#160;\\n&#160;\\n10,958\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#160;&#160;\\n&#160;\\n&#160;&#160;\\n&#160;\\n10,958\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'ULRF', 'ASU', 'CRO', 'the European Commission', 'the Pfizer License Agreement', 'Offer Letter and Severance Plan', 'CCPA', 'net\\n&#160;&#160;\\n&#160;\\n1,917\\n&#160;\\n&#160;&#160;\\n&#160;\\n812\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,105\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'Reference\\n\\n Exhibit No.\\n&#160;&#160;\\nDescription\\n&#160;&#160;\\nForm\\n&#160;&#160;\\nFile No.\\n&#160;&#160;\\nExhibit\\n&#160;&#160;\\nFiling Date\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n', 'the U.S. Department of Health and Human Services', 'Bio, Inc.', 'CMC', 'the Lonza License Agreement', 'IL-6', 'ImmunoFree, Inc.', 'EXHIBITS  &#160;\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#160;&#160;\\nIncorporated', 'Registrant', 'operations\\n&#160;&#160;\\n&#160;\\n(8,932\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(19,823\\n)&#160;\\n&#160;&#160;\\n&#160;\\n10,891\\n&#160;\\n\\n\\n&#160;&#160;\\n &#160;\\n &#160;\\n&#160;\\n&#160;&#160;\\n &', 'the Settlement Agreement', 'the Louisville Lease', 'IRA', 'Note 10 &#8220;Commitments', 'the Sarbanes-Oxley Act', 'DPA', 'sale\\n&#160;&#160;\\n&#160;\\n538\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#160;&#160;\\n&#160;\\n&#160;&#160;\\n&#160;\\n538\\n&#160;\\n\\n\\n&#160;&#160;\\n &#160;\\n &#160;\\n&#160;\\n&#160;&#160;\\n &', 'IPO', 'This Quarterly Report on Form 10-Q', 'Form S-3', 'the Severance Period', 'UK Data Protection Act', 'operations\\n&#160;&#160;\\n&#160;\\n(49,512\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(56,652\\n)&#160;\\n&#160;&#160;\\n&#160;\\n7,140\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'the Company (&#8220;Merger', 'Dear Healthcare Provider', 'BD Arrangements', 'June&#160;22', 'Medicaid Services', 'Restricted Stock Unit', 'Novartis, Inc.', 'asset sale\\n&#160;&#160;\\n&#160;\\n538\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#160;&#160;\\n&#160;\\n&#160;&#160;\\n&#160;\\n538\\n&#160;\\n\\n\\n&#160;&#160;\\n &#160;\\n &#160;\\n&#160;\\n&#160;&#160;\\n &', 'the Proxy Statement', 'SEC', 'the &#8220;Settlement', 'the Side Letter', 'Talaris Therapeutics, Inc.', 'costs\\n&#160;&#160;\\n&#160;\\n4,152\\n&#160;\\n&#160;&#160;\\n&#160;\\n9,593\\n&#160;\\n&#160;&#160;\\n&#160;\\n(5,441\\n)&#160;\\n\\n\\n&#160;&#160;\\n &', 'Contingencies&#8212;Legal', 'the &#8220;say', 'IL-6R'}"
TRVI,
TRVN,
TSBX,"{'ASC', '\\n  &#x2022;injury', 'the Underlying Agreements', 'MHRA', '\\n  Government', 'the Myst Holders', '\\n', '\\n  &#x2022;publication', 'the UK Medicines', '\\n  &#x2022;volatility', 'Takeda (&#x201c;Takeda', 'EU Patent Package', 'Carleton University', 'the Federal Reserve', 'EEA', 'Condensed Consolidated Statements of Operations and Comprehensive', '\\n  &#x2022;having', '\\n  &#x2022;costs', 'EU', 'Phase 4', '\\n  &#x2022;conditions', 'Indicate', 'Selected TIL', 'UPC', '\\n    Research', 'Piper Sandler &amp', 'the Securities Exchange Act', 'the European Economic Area', 'OPM', 'Selected Discovery Candidates', 'AbbVie', 'COVID-19', '160;18\\n     &', '\\n  &#x2022;prohibit', '\\n  &#x2022;obtaining', 'Adopted Accounting Pronouncements', 'Takeda Pharmaceutical Company Limited', '\\n  &#x2022;expenses', '\\n  &#x2022;provide', 'BofA Securities, Inc.', 'FASB', 'x2022;high', '\\n  &#x2022;adverse', 'Anti-Kickback Statute', 'AbbVie Biotechnology Ltd.', 'x2022;if', 'HHS', '\\n  &#x2022;significant', '\\n  &#x2022;product', 'Rule 424(b)(4', 'the Alliance Agreement', '\\n  &#x2022;assimilation', '\\n  &#x2022;substantial', '\\n  &#x2022;inadequate', 'x201c;Risk', '\\n  &#x2022;initiation', 'the Myst Merger Agreement', 'Medicaid', 'Medicare', '\\n  &#x2022;refusal', '\\n  &#x2022;any', 'x2014;\\n        &', 'GDPR', '\\n  &#x2022;there', 'Millennium Pharmaceuticals, Inc.', '\\n  &#x2022;specify', 'FDA', '\\n  &#x2022;collaborations', 'the EMA&#x2019;s Committee for Medicinal Products for Human Use', '\\n  &#x2022;clinical', '\\n  &#x2022;disagreements', '\\n  &#x2022;changes', '\\n  &#x2022;others', '\\n  &#x2022;loss', 'HIPAA', 'REMS', 'Silicon Valley Bank', 'TIL Products', '\\n  &#x2022;fines', 'Company', 'the Department of the Treasury', 'management&#x2019;s attention', '\\n  &#x2022;overall', 'The Moffitt Agreement', 'USPTO', 'General Risk Factors \\n', 'the Takeda Agreement', '\\n  &#x2022;addressing', '\\n  &#x2022;injunctions', 'FCA', '\\n  &#x2022;whether', '\\n  Takeda Pharmaceutical Company Limited \\n', 'Signature Bank', 'the Delaware General Corporation Law', '\\n  &#x2022;recruiting', '\\n  &#x2022;decline', 'Development Opt-Down Right', '\\n  &#x2022;the', 'Underlying Agreements', '\\n  &#x2022;exhaustion', 'Turnstone Biologics Corp.', 'IRB', '\\n  &#', 'Individual EU', '\\n  &#x2022;varying', '\\n  &#x2022;collaborators', '\\n  &#x2022;retention', '\\n  &#x2022;diversion', '\\n  &#x2022;decreased', '\\n  &#x2022;require', '\\n  &#x2022;additions', '\\n  &#x2022;introduction', '\\n  &#x2022;negative', '\\n  &#x2022;reaching', 'Moffitt Alliance Agreement', 'FDIC', 'Leerink Partners', 'Turnstone Biologics Inc.', '\\n  &#x2022;inability', 'Economy,&#x201d', 'Moffitt Alliance Agreement \\n', 'IPO', 'Comparison', 'General Data Protection Regulations', 'the Moffitt Agreement', 'the &#x201c;Alliance', 'the Development Program', 'ASU No', '\\n  &#x2022;our', '\\n  &#x2022;global', '\\n  &#x2022;announcements', 'Moffitt', '\\n  &#x2022;convenience', '\\n  &', '\\n  &#x2022;delays', '\\n  &#x2022;risks', 'CTR', '\\n  &#x2022;unanticipated', '\\n  &#x2022;restrictions', '\\n  &#x2022;unfavorable', '\\n  &#x2022;efficacy', 'Healthcare', '\\n  Critical Accounting Polices and Estimates \\n', '\\n  &#x2022;withdrawal', '\\n  &#x2022;authorize', 'Significant Accounting Policies', 'Takeda&#x2019;s', 'TIL', '\\n        &', 'SEC', '\\n  &#x2022;potential', 'GCP', 'CA', 'BLA', 'Liquidity and Capital Resources \\n', '\\n  &#x2022;unsuccessful', 'Alliance Funding Amount', '\\n  &#x2022;manufacturing', '\\n  &#x2022;failure', '\\n  &#x2022;actual', 'Nasdaq', '\\n    &', '\\n  &#x2022;sales', '\\n  &#x2022;expiration'}"
TSHA,"{'ASC', 'Dallas Lease', 'years)\\n        &', 'LLC', 'hierarchy.&#160;The Company', 'the Black-Scholes-Merton', 'Astellas Securities Purchase Agreement', '\\n    Interest income\\n    &', 'Fragile X (Fmr1 KO', 'activities\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n         \\n         \\n          ', 'UT Southwestern', '\\n', 'Rett Syndrome, Stage', 'Abeona', 'the Trinity Term Loan', 'the Option Agreement', 'this Quarterly Report on Form 10-Q', '\\n  &#x2022;costs', 'the Public Company Accounting Oversight Board', 'the Term Loan', 'the GAN Agreement', 'Giant Axonal Neuropathy\\n', 'The University of Texas Southwestern Medical Center \\n', 'flows.8\\n       &#160;The', 'the &#x201c;Office', '\\n    Research', 'type;\\n  &#x2022;license', 'Option', 'Financial Information', 'the Securities Exchange Act', 'The Term Loan Agreement', 'CNS', 'ASO', 'ICV', 'the 2020 Stock Incentive Plan (&#x201c;New Plan&#x201d', 'Trinity', 'Adopted Accounting', 'The Board of Regents of the University of Texas System', 'General Instruction I.B.6', 'University of North Carolina', 'GAN', 'FASB', 'AAV9', 'Rett Products', 'liabilities:\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n         \\n         \\n          &#160;&#160;Accrued', 'convenience.\\n  &', '\\n  &#x2022;exemptions', 'Private Placement', 'Internal Control Over Financial Reporting\\n', 'the Underwriting Agreement', 'the Securities and Exchange Commission', 'the Trinity Term Loan Agreement', 'x2014;\\n        &', 'GAN Products', 'debt;\\n  &#x2022;merge', 'the Astellas Transactions', 'FDA', 'Health Canada', 'Trinity Lenders', 'the Rett Option Period', 'RSU', 'the SSI Warrants', 'Loan', 'and\\n  &#', 'the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;)', 'Trinity Capital Inc.', 'the National Institutes of Health (&#x201c;NIH&#x201d', 'the Private Placement', 'Silicon Valley Bank', 'Audentes Therapeutics, Inc.', 'the Trinity Lenders (&#x201c;Trinity&#x201d;)', 'Fragile X', '\\n  &#x2022;license', 'Company', 'the Board of Regents of the University of Texas System', '\\n  &#x2022;facilities', '\\n  &#x2022;laboratory', '\\n    Interest expense\\n    &', 'Results of Operations', 'Trinity Term Loans', 'the Pre-Funded Warrants', 'Hannah&#x2019;s Hope Fund for Giant Axonal Neuropathy', 'the Rett Option', 'the Lenders (&#x201c;Agent&#x201d;)', 'the Trinity Closing Date', 'Change of Control', 'the European Commission', 'Restricted Stock', 'Purchase Common Stock', 'patient.\\n  &', 'Upfront Payment', 'Critical Accounting Policies', 'the Abeona Rett Agreement', 'the University of North Carolina', 'the Abeona CLN1 Agreement', 'Contracts with Customers', 'Batten Disease', 'affiliates.\\n  &#', '383\\n          &#160;\\n          &#160;\\n', 'License Agreement', 'Purchasers', 'the Sales Agreement', 'the Maturity Date', '810\\n          &', 'the &#x201c;Abeona License', 'Trinity Term Loans \\n', '\\n  &#', 'the GAN Option', 'Lenders', 'the Abeona License Agreement', 'the Trinity Lenders', 'Rett', '\\n          &', 'The Trinity Term Loan Agreement', 'the Term Loan Agreement', 'satisfied.\\n  &', 'a Change of Control', 'the &#x201c;Trinity Term', 'IPO', '47\\n', 'the Upfront Payment', 'Astellas Private Placement', 'Wells Fargo Securities', 'RSBQ Total Score', 'License Agreements \\n  Research, Collaboration and License Agreement', 'ASU No', 'below.\\n  &', 'Form S-3', '\\n        &#', 'Goldman Sachs &', ""Hannah\\'s Hope Foundation"", 'the &#x201c;August 2023', 'Tauopathies', 'the &#x201c;Abeona Rett', 'the &#x201c;Shelf Registration', 'the U.S. Food and Drug Administration', 'ESPP', 'Compensation ExpenseThe', 'Worldwide Rights', 'The University of Texas Southwestern Medical Center (&#x201c;UT Southwestern&#x201d', 'Abeona Therapeutics Inc.', 'the University of Edinburgh', 'the &#x201c;Maturity', 'Company and Board of Directors', '\\n        &', 'LeasesThe Company', 'the Shelf Registration Statement', 'FMRP', 'SEC', 'the &#x201c;Dallas', 'Adjustments\\n          &', 'Inherent Limitations on Effectiveness of Internal', 'the UT Southwestern Agreement', 'Condensed Consolidated Statement of Cash Flows\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n          &#160;\\n         \\n         \\n          Adjustments', '\\n  &#x2022;reduced', '\\n    &', 'patents.\\n  The UT Southwestern Agreement'}"
TSVT,
TTNP,
TTOO,
TVTX,"{'ASC', 'API', 'Physician Payments Sunshine Act', 'Mission Pharmacal', 'EMA', 'TSA', 'Adopted Accounting PronouncementsIn', 'Jefferies LLC', 'EU', 'the Ligand License Agreement', 'the Drug Supply Chain Security Act', 'Chenodal and Cholbam', 'the Consolidated Balance Sheets', 'CPRA', 'EDA', 'UPCR) &', 'the Financial Accounting Standards Board', 'tHcy', 'NOL', 'Cooperative Research and Development Agreement', 'Mission Pharmacal Company', 'Consolidated Financial Statements', 'Products', 'The U.S. Foreign Corrupt Practices Act', 'FASB', 'Thiola EC', 'ProceduresWe', 'Social Security Act', 'Anti-Kickback Statute', 'HHS', 'cystinuria', 'Medicaid', 'Medicare', 'Congress', 'HCU', 'Issued Accounting PronouncementsSee Note', 'The Drug Price Competition and Patent Term Restoration Act', 'FDA', 'SHARE-BASED COMPENSATIONStock OptionsThe', 'Ligand', 'SEC Rule 13a-15(b', 'ContentsThe', 'HIPAA', 'AI', 'REMS', 'the Trade and Cooperation Agreement', 'Company', 'MattersAdoption of New Accounting StandardsSee Note', 'the National Institutes of Health&#8217;s National Center for Advancing Translational Sciences', 'ALGS', 'INTANGIBLE ASSETSLigand License AgreementIn 2012', 'Consolidated Statements of Operations', 'ProceedingsThe', 'revenues33,932&#160;25,369&#160;8,563&#160;87,621&#160;72,154&#160;15,467&#160;License', 'New Drug Application', 'Contracts with Customers', 'CSL Vifor', 'UPCR', 'CBS', 'the Nasdaq Stock Market', 'Alagille Syndrome Alliance', 'the Committee for Medicinal Products for Human Use', 'the Thiola Intangible', 'FILSPARI', 'ContentsIntangible Assets', 'NDA', 'InformationTrading', 'EFTA', 'FSGS', 'Orphan Technologies Limited', 'DUPLEX', 'Orphan Drug Designation', 'ProceduresEvaluation of Disclosure Controls', 'Kolbam', 'Bristol-Myers Squibb Company', 'FILSPARI and/or', 'ASU No', 'the Purchase Agreement', 'Consolidation Financial Statements', 'the United States;&#8226;variations', 'Form S-3', 'the License Agreement', 'ContentsAdditionally', 'California Privacy Protection Agency', 'VIE', 'the Stock Purchase Agreement', 'ACE', 'Critical Accounting EstimatesOur', 'ContentsAssets', 'administrative67,801&#160;52,420&#160;15,381&#160;201,954&#160;140,434&#160;61,520&#160;Total', 'the European Medicines Agency', 'Accounting Standards Codification', 'FILSPARI.The', 'the Unaudited Consolidated Financial Statements', 'SEC', 'ContentsCongressional', 'the Federal Trade Commission Act', 'Preclinical Programs', 'the European Union', 'Mirum Pharmaceuticals, Inc. (&#8220;Mirum&#8221', 'Ligand Pharmaceuticals, Inc.', 'this Quarterly Report on Form 10-Q.Item'}"
TWST,
TXG,"{'net$285,008&#160;$289,328&#160;Accrued Compensation', 'LitigationThe Company', 'Contents10x Genomics, Inc.Notes', 'Director(Principal Executive', 'the NanoString Action', 'Unaudited Condensed Consolidated Financial StatementsInventoryInventory', 'RecognitionThe Company', 'costs$5,584&#160;$3,102&#160;Accrued', 'United States)2,917&#160;2,236&#160;8,581&#160;5,997&#160;Total', 'GeoMx Digital Spatial Profiler', 'ContentsLiquidity', 'NetProperty', 'net&#8221', 'NanoString Technologies, Inc. (&', 'CosMx Spatial Molecular Imager', 'Significant Accounting Policies', 'replacements(4,368)(2,616)End of period$6,435&#160;$1,968&#160;Revenue', 'Unaudited Condensed Consolidated Financial StatementsThe', '9Table of Contents10x Genomics, Inc.Notes', 'the U.S. District Court', 'Company', 'the Securities Exchange Act', 'authorized.10x Genomics, Inc.', '*&', 'the Munich Regional Court', 'Serge SaxonovSerge SaxonovChief Executive Officer', 'Unaudited Condensed Consolidated Financial Statementsprices', 'Unaudited Condensed Consolidated Financial StatementsAccrued Expenses and Other Current LiabilitiesAccrued'}"
TXMD,"{'BocaGreenMD&#174', 'Granted \\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160', 'IMVEXXY', 'Principal Financial Officer', '\\n &', 'Rubric Capital Management LP', 'Knight', 'the Mayne License Agreement Amendment', 'Teva', 'Notice', 'see &#', 'the Population Council License Agreement', 'Theramex', 'Knight Therapeutics Inc.', 'JZ Advisory Group', 'the Financing Agreement', 'Interim Co-Chief Executive Officers', 'the Population Council', 'FDA', 'the Condensed Consolidated Financial Statements', 'the Licensed Products', 'the Mayne Transaction', 'the Knight License Agreement', 'Rubric', 'ANNOVERA', 'Years)\\n&#160;\\n&#160;&#160;\\nOptions Awards\\n&#160;\\n&#160;\\nWeighted Average Exercise Price\\n&#160;\\n&#160;&#160;\\nAggregate', 'Series A Preferred Stock', 'the District Court', 'Population Council License Agreement', 'the Federal Deposit Insurance Corporation', 'the &#8220;Population Council License', 'Cancelled/Forfeited', 'Unvested', 'SEC', 'GoodRx, Inc.', 'Subscription Agreement with Rubric Capital Management LP', 'Common Stock', 'the New Drug Application', '\\n\\n&#160;\\n&#160;&#160;\\n &#160', 'Company', 'the Securities Exchange Act', 'Subsidiaries  Notes', 'Expired', 'Sixth Street Specialty Lending, Inc.', 'the Transaction Agreement', '\\n&#160', '\\n&#160;\\n&#160;&#160;\\n &#160', 'Common Stock to Rubric', 'COVID-19', 'Regulation S-K', '\\n&#160;\\n&#160;\\n &#160', 'the heading &#8220;Risk Factors,&#8221', 'Disclosure Controls and Procedures  Disclosure', '10-K Report', 'Securities and Exchange Commission', 'the Subscription Agreement', 'the Population Council, Inc.', 'the FDA&#8217;s Orange Book', 'the Mayne License Agreement'}"
TYRA,"{'Fibroblast Growth Factor Receptor', 'FASB', 'LLC', 'the Original Lease', 'Critical Accounting Policies', 'Expansion Lease', 'Adopted Accounting Pronouncements See Note', 'the Private Securities Litigation Reform Act', 'Simple Agreements for Future Equity', 'the following:&#160;\\n       \\n        \\n         \\n         \\n         \\n         \\n         \\n         \\n         \\n         \\n         \\n        \\n        \\n         &', 'ESPP', ': &', 'the Expansion Lease', 'Original Lease or the Expansion Lease', 'the Imagine Institute', 'Stock-Based Compensation Expense The Company', 'SEC Rule 13a-15(b', 'Initial Public OfferingOn', 'Virtu Americas', 'Form S-1', ': &#x2022;external', 'Stock Purchase Plan\\n         &', 'Company', 'Restricted CashRestricted', 'van den Boom &amp', 'and&#x2022', 'Equity Securities', 'Associates', 'IPO'}"
UBX,
UFPT,"{'ASC', 'Note&#160;F, &#8220;Business Combinations&#8221', '0.1&#160; &', 'Palets Suller Group', 'UFP Transportation Ltd.', 'Contingencies', 'Time', 'Exchange Act', 'the Securities and Exchange Commission', 'the Unaudited Condensed Consolidated Financial Statements', 'UFP Industries,&#160;Inc', 'Section&#160;13', 'the U.S. Dollar', 'ContentsUFP INDUSTRIES', 'Deckorators', 'Unaudited Consolidated Condensed Financial Statements', '30,422&#8203;&#8203', 'UFP Real Estate, Inc.', 'UFP Retail Solutions', 'UFP Palets', 'UFP Packaging (&', '9.4&#160', 'Company', 'the Lumber Market', 'the Securities Exchange Act', 'Organic', 'ProWood', 'a Southern Yellow Pine', 'No &#9723;Indicate', 'UFP Industries, Inc.', 'UFP Construction (&#8220;Construction&#8221', 'Random Lengths', 'Corporate'}"
UNCY,"{'ASC', 'Unicycive', 'Purchase Agreement', 'the Series A-1 Preferred Stock', 'the Company&#8217;s Board of Directors.\\n\\n&#160;\\n\\nOn the', 'stockholders.\\n\\n&#160;\\n\\nAt', 'Syneos', 'Globavir Biosciences, Inc. (&#8220;Globavir&#8221', 'Customers', 'Inotiv', 'the Board of Directors', 'the Stockholder Approval', 'exclusive\\nlicense', 'the agreements.\\n\\n&#160;\\n\\nRevenue Recognition\\n\\n&#160;\\n\\nThe Company', 'A-5 Preferred', 'and\\nA-5 Preferred Stock', 'Shilpa Medicare Ltd', 'Series\\nA-2 Convertible Preferred Stock', 'IP', 'the Tranche A Warrant\\nand the Tranche B Warrant', 'processes.\\n\\n&#160;\\n\\nWe', 'FDA', 'Syneos Health LLC (&', 'Series A-1 Preferred Stock', 'dilutive.\\nCommon', 'the Preferred Stock Offering', 'Pharmaceutical (HK) Limited', 'the Company&#8217;s future financial\\nposition', 'the Certificate of Designation', 'Series A-4 Convertible Preferred Stock', 'Series A-1 Preferred', 'and\\n  \\n&#160;\\n\\n\\n  \\n    &', 'Information\\n\\n&#160;\\n\\nThe Company', 'NDA', 'Series A-1 Convertible Preferred\\nStock', 'share\\nof Series A-2 Preferred Stock', 'Series A-3 Convertible Preferred Stock', 'Lotus', 'Common Stock', 'Company', 'the Financial Accounting Standards Board', 'Series A-2 Preferred Stock', 'A-5 Preferred Stock', 'the &#8220;Service', 'the Series\\nA-1 Preferred Stock', 'Lotus International Pte Ltd.', 'Preferred Stock', 'the indemnified party', 'IPO', 'Sphaera', 'Series A-5 Convertible Preferred Stock', 'the Spectrum Agreement', 'Capital', 'Lotus\\nInternational Pte Ltd.', '\\n    &', 'Oxylanthanum Carbonate product.\\nThe Company', 'number\\nof'}"
UPC,
URGN,"{'ASC', 'the Organisation for Economic Co-Operation', 'expense.\\n  &#', 'Prepaid Forward Contract', 'xa0;3 - 6.5&#xa0;\\n Furniture &#xa0;5 - 16.5&#xa0;\\n Manufacturing equipment &', 'Contractual Obligations', 'reputation.\\n  &#xa0;\\n  ', 'NJ', 'UroGen Pharma Ltd.', 'March 7,&#xa0;2022,&#xa0;the Company', '2023 &#', 'premium.\\n  &#', 'U.S. Department of Justice', 'services.\\n  &#', 'The Journal of Urology', 'BCG', 'interrupt healthcare services', 'UTUC', 'Unaudited Condensed Consolidated Financial Statements', 'RTW.\\n  &#', 'Phase 4', 'indebtedness.\\n  &#', 'the U.S. Foreign Corrupt Practices Act', 'CPRA', 'Pharmakon Advisors', 'property.\\n  &#', 'of:\\n  &#', 'the Financial Accounting Standards Board', 'assets.\\n  &#', 'time.\\n  &#', 'UPI', 'Agenus Inc.', 'UroGen Pharma, Inc.', 'ASC Topic 260, &#x201c;Earnings', 'prospects.\\n  &#', 'Operations', 'Adopted Issued Pronouncements &#xa0', 'BCG.\\n  &#', 'Administrative Expenses &#', 'efforts.\\n  &#', 'Foreign Currency Exchange', 'Products', 'Company\\', 'Jelmyto.\\n  &#', 'owed.\\n  &#', 'xa0;\\n Accounts', 'L.P. (&#x201c;Pharmakon&#x201d;)', 'HHS', 'Capital Requirements \\n  &#', 'obligation.\\n\\n&#xa0;\\n\\nLong-Term Debt &#xa0', 'Guarantor', 'RTGel', 'the Product Collateral', 'manufacturers&#x2019', 'Medicaid', 'Medicare', 'collaborators.\\n  &#', 'CIS', 'Risks Related to Government Regulation', 'MD Anderson.&#xa0;&#xa0;\\n  &#', 'the Federal Trade Commission', 'employees.\\n  &#', 'March&#xa0;2022 (&#x201c;Tranche', 'OPTIMA II', 'FDA', 'candidates.\\n  &#', 'xa0;\\n &', 'and\\n    \\n\\n', 'RTW', 'NMIBC', 'Risks Related', 'products.\\n  &#', 'HIPAA', 'AI', 'impaired.\\n  &#', 'Condensed Consolidated Statements', 'Company', 'xa0;\\n Interest', 'Our Business and Strategy \\n  &#', 'management&#x2019;s attention', 'rights.\\n  &#', 'the California Privacy Rights Act', 'Shareholders', 'Warrants &#xa0', '\\n    &#', 'L.P.', 'trading.\\n  &#', 'compliance.\\n  &#', 'ESG', 'BioPharma Credit Investments V', 'Condensed Consolidated Statements of Operations', 'CMS', 'revenues.\\n  &#', 'Loan Agreement', 'harmed.\\n  &#', 'Condensed Consolidated Statements of Cash Flows \\n       ', '2022 &#', 'Useful Lives &#', 'CR', 'Good Clinical Practice', 'License', 'OPTIMA', '\\n  &#', 'us.\\n  &#', 'Lenders', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', 'initiatives.\\n  &#', 'we:\\n  &#', 'Orphan Drug Designation', 'delayed.\\n  &#', 'Financial Information\\n&#xa0;\\nAccounts Payable', 'predict.\\n  &#', '\\n \\n \\n \\n', 'xa0;\\n Raw', 'benefits.\\n  &#', 'Economy,&#x201d', 'Comparison', 'operations.\\n  &#', 'recordkeeping.\\n  &#', 'Revenue\\n  &#', 'Property', '\\n       Financial Statements', 'BioPharma Credit PLC', 'Form S-3', 'xa0;3&#xa0;\\n Laboratory equipment &', 'the Loan Agreement', 'securities.\\n  &#', 'Health Insurance Portability', 'California Privacy Protection Agency', 'the U.S. Internal Revenue Service', 'fulguration.\\n  &#', 'ATM', 'Condensed Consolidated Balance Sheets \\n', 'BPCR Limited Partnership', 'receive&#xa0;regulatory', 'care.\\n  &#', 'UGN-101.&#xa0;\\n  &#', '2023.&#xa0;\\n  &#', 'the Accounting Standards Updates', 'abroad.\\n  &#', 'edition.\\n  &#', '2022 &', 'the U.S. Treasury', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', 'demands.\\n  &#', 'Exhibits.\\n  &#', '\\n     &#', 'SEC', 'factors.\\n  &#', 'use.\\n  &#', 'services.&#xa0;&#xa0;\\n  &#', 'GCP', 'x201c;Loan', 'CA', 'candidates.\\n  &', 'the Federal Reserve Bank of New', 'the New Israeli Shekel', 'to:\\n  &#', 'Credit Parties&#x2019', 'the Health Information Technology for Economic and Clinical Health Act', 'the European Union', 'Teva Pharmaceuticals Industries', 'method.\\n\\n&#xa0;\\n\\nFunctional Currency &#'}"
UTHR,"{'ASC', 'ISDA', 'ASU', 'LTV', 'Exchange Act Rule', 'Bank', 'SBA', 'ACL', 'CRE', 'SecuritiesInvestment', 'agreementsThe Company', 'Sub-Market        ', 'Tri', 'deposits(311,637)Adjusted', 'Unregistered Sales of Equity Securities', 'CollateralAmortized CostExtent', 'InformationDuring', 'Derivatives', 'September&#160;30,', 'Contingencies&#160;The Company', 'September&#160;30, 2023 (dollars', 'FRB', 'Quarterly HighlightsMacro-Environmental Factors of Note', 'Domestic ProductGNMAGovernment National Mortgage AssociationISDAInternational Swaps', 'Which Secured', 'defaultPinnaclePinnacle Public Finance', 'QualityCommercial LoansWe', 'capital$3,291,844&#160;13.17&#160;%$1,624,717&#160;6.50&#160;%$1,124,804&#160;4.50&#160;%$1,749,695&#160;7.00&#160;%Tier&#160;1', 'Consolidated Balance SheetsContractual', 'FICO', 'ConsideredAdequatelyCapitalized Including Capital Conservation', 'SEC', 'CostExtent', 'Company', 'FHLB', 'Regulation S-K.65Item', 'FDIC', 'Item 408 of', 'September&#160;30, 2023', 'CET1', 'the Sarbanes-Oxley Act', '2022 Annual Report', 'Estate Investment TrustRPARisk', 'Sub-MarketFlorida', 'CCAR', 'Pinnacle', 'FCA', ""Geographic ConcentrationsThe Company\\'s"", 'New Accounting Pronouncements Adopted', 'capital$2,861,887&#160;11.42&#160;%$1,628,267&#160;6.50&#160;%$1,127,261&#160;4.50&#160;%$1,753,518&#160;7.00&#160;%Tier&#160;1 risk-based'}"
UTMD,
UTRS,
VALN,
VANI,"{'TFSSA', 'Board', 'the National Institutes of Health', 'controls.\\n\\n&#160;\\n\\nInherent\\nLimitations on Effectiveness of Controls\\n\\n&#160;\\n\\nBecause\\nof', 'GLP-1', 'GBM', 'entering\\ninto', 'the Funding Support Term', 'Cortigent&#8217;s\\ninitial', 'the State of Delaware', 'FDA', 'Nano Precision Medical, Inc. (&', 'month.\\n\\n&#160;\\n\\nVivani\\nentered', 'MOU', 'Second Sight', 'Board of Directors', 'NPM', 'Pixium', 'Second Sight Medical Products, Inc.', 'and\\n\\n    &', 'Second Sight Medical Products', 'Nano Precision Medical', 'U.S. FDA', 'the Company and Cortigent', 'SEC', 'Argus II', 'the Transition Funding, Support and Services Agreement', 'Company', 'Chemistry, Manufacturing', 'Cortigent', 'Recent Accounting', 'LIBERATE-1', 'Services Agreement', 'Controls (&#8220;CMC&#8221', 'Orion', 'the U.S. Securities and Exchange Commission'}"
VAXX,"{'ASC', 'the Platform License Agreement', 'Registration Statement on Form S-1', 'Yes &#9746;&#160;No &#9744;Indicate', 'HSE', 'THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS &', 'MSA', 'United&#160;Biomedical, Inc. (&', 'CEPI', 'the CEPI Funding Agreement', 'reorganizing&#160;and', 'Internal Control', 'revenue.&#160;\\n\\n\\n\\n&#160;23 Research and Development', 'UBP', 'COVAXX', 'Restated Certificate of Incorporation of Vaxxinity,&#160;Inc', 'CMOs&#160;to', 'Contingencies Contractual Obligations&#160;The Company', 'that&#160;may arise&#160;by reason&#160;of their&#160;status or&#160;service as&#160;directors', 'the Coalition for Epidemic Preparedness', 'respect&#160;to', 'Corp. (&', 'UNS', 'in&#160;Item 1A', 'SEC', 'UBI-Asia&#160;provides&#160;research,&#160;development,&#160;testing&#160;and&#160;manufacturing&#160;services&#160;to&#160;the&#160;Company&#160;and&#160;UBP&#160;provides&#160;contract development', 'Company', 'the &#8220;Platform&#160;License', 'Immunoglobulin', 'COVID-19', 'filed&#160;as', 'UBI', 'Vaxxinity', 'raising&#160;new capital', 'UBI&#160;Warrant.&#160;The majority&#160;of', 'Report'}"
VBIV,"{'respect\\nto the advancement', 'K2HV Extension Agreements\\nand Forbearance', 'EC', 'financial condition\\nand', 'VBI Vaccines Inc.', 'GBM', 'September\\n14', 'Lender&#8217;s\\ninvestment committee approval.\\n\\n&#160;\\n\\nPursuant\\nto', 'ATM Program', 'net&#160;\\n', 'Process Research &', 'the Loan Agreement.\\nAccordingly', 'the Condensed Consolidated Financial Statements', 'the Several Underwriters', 'VBI-2601 (&', 'the Brii Collaboration and License Agreement', 'Forbearance', 'Guaranty Agreement', 'the Securities Exchange Act', 'additional\\ndebt', 'Agenus Inc.', 'as\\na', 'classified\\nas', 'CDC', 'PreHevbri', 'FASB', 'VBI-2601', 'Sources of Liquidity &', 'IPR&amp;D. See Note', 'VBI Cda', 'Ferring License Agreement', 'FDA', 'the Contribution Agreement', 'Jefferies LLC (&#8220;Jefferies&#8221', 'Loan', 'the District Court', 'any Event of Default', 'Company', 'Principal Financial and Accounting Officer', 'VBI Equity Incentive Plan', 'the Reverse Stock Split\\nthat', 'the European Commission', 'as\\nan', 'VBI', 'CEPI', 'Licensed Territory', 'Recent Developments &#8211', 'The Loan Agreement', 'UPMC', 'HBV', 'Collaboration Agreements', 'the Forbearance Agreement', 'the ATM Program', 'the Liquidity Requirement', 'Lenders', '\\n    &', 'SciVac', 'Associates, Inc.', 'Equity Incentive', '\\n\\n&#160;\\n\\nBrii\\nCollaboration Agreements &', 'Secured', 'facilities.\\n\\n&#160;\\n\\n3.\\nNEW ACCOUNTING PRONOUNCEMENTS\\n\\n&#160;\\n\\nRecently\\nAdopted Accounting Pronouncements\\n\\n&#160;\\n\\nIn\\nJune 2016', 'Raymond James &amp', 'ASU No', 'Results of Operations &', 'the Government of Canada.\\n\\n&#160;\\n\\n\\n\\n    35\\n', 'the Loan Documents', 'Hamas', 'Form S-3', 'the Loan Agreement', 'the Project Completion Date', 'Development (&#8220;IPR&amp;D&#8221', 'NET', 'the Licensed Territory', 'IPR&amp;D', 'the Extension Agreement', 'Default', 'payments&#160;\\n    &', 'CMV', 'the Brii Second Amendment Collaboration', 'Research and Development', 'the &#8220;Supply', 'the Brii Collaboration Agreements', 'will\\nbe', 'Variation Biotechnologies Inc.', 'SEC', 'the Specified Default', 'and\\n  \\n    &', 'Collaboration and License Agreement', 'VBI-2601 and/or PreHevbri', 'FDS Pharm LLP', 'Nasdaq', 'SciGen Ltd.'}"
VCEL,"{'the Periods Ended September&#160;30', 'the FDA&#8217;s BLA', 'JPMorgan Chase Bank', 'the Revolving Credit Agreement', 'XBRL Taxonomy Extension Definition', 'MediWound', 'The Revolving Credit Agreement', 'ContentsResults', 'Critical Accounting PoliciesThe', 'Item 408 of Regulation S-K', 'Premises', 'ATM', 'Represents', 'ExpenseNon', 'Matricel GmbH', 'Principal Accounting Officer', 'New Hire Incentive Stock Option Agreement', 'EU', 'NumberExhibitFiling Date3.1Restated Articles of Incorporation', 'NexoBrid', 'FDA', 'ACI-Maix', 'the Matricel Supply Agreement', 'NexoBrid&#8217;s', 'Burlington', 'ActivitiesOur', 'the Restated Articles of Incorporation of the Company', '21%-26%', 'HDE', 'the Sarbanes-Oxley Act of', 'HUD', 'the Revolving Loans', 'ContentsThe', 'ContentsIn May 2019', 'Non-Qualified Stock Option Award Agreement for Non-Employee Directors', 'the Construction Escrow Agreement', 'OperationsThe', 'SEC', 'this Quarterly Report on Form&#160;10-Q.EXHIBIT&#160;INDEX Incorporated', 'our Statement of Company Policy', 'Revolving Commitments', 'BLA', 'Company', 'OrganizationVericel Corporation', 'The Matricel Supply Agreement', 'TBSA', 'ContentsIn April 2023', 'Current Employee Incentive Stock Option Agreement', 'November&#160;21', 'the Burlington Lease', 'Leerink Partners', 'ReferenceExhibit NumberDescription', 'COVID-19', 'the Sarbanes-Oxley Act', 'Page Interactive Data File', 'Revolving Credit Agreement', 'the European Union', 'Accounting PronouncementsNo', 'the Vericel Corporation Board', 'the &#8220;Revolving Credit'}"
VCNX,
VCYT,
VERA,
VERO,
VERU,
VERV,"{'the Company and Beam Therapeutics Inc.', 'ASC', '1,879\\n        &', 'years)\\n        &', 'RNA', 'LLC', '\\n  &#x2022;injury', 'MHRA', '\\n  &#x2022;variations', '20\\n', 'Good Laboratory Practices', 'Innovative Licensing', 'The Sarbanes-Oxley Act', 'the Research and Collaboration Agreement', 'EMA', 'Precision&#x2019;s', '\\n  &#x2022;developments', 'Endcadia, Inc.', 'the Company&#x2019;s Annual Report on Form 10-K', '\\n  &#x2022;termination', 'Congress&#x2019', '\\n    External', 'CVC', 'criteria.&#160;The Company', 'Sigma-Aldrich Co.', 'Lilly', 'EU', 'the Vertex Agreement', 'Acuitas', 'the Public Company Accounting Oversight Board', 'the Novartis Agreement', 'x2022;a', 'the Amended Beam Agreement', 'The Broad Institute, Inc. (&', 'Lilly Agreement', 'CPRA', '\\n    Research', 'Vertex Agreement', 'The Biden Administration', '\\n  &#x2022;coordination', '\\n  &#x2022;not', 'the Lilly Research and Development Plan', 'Research', 'Jefferies', 'COVID-19', 'affected;\\n  &#x2022;If', 'the Acuitas Agreement', 'Eli Lilly and Company', 'Research and Collaboration Agreement', '\\n  &#x2022;litigation', 'the Lilly Agreement', 'FASB', 'LeasesThe', 'Company\\', '\\n  &#x2022;adverse', 'HHS', '\\n  &#x2022;significant', '\\n  &#x2022;product', 'Toolgen, Inc.', '\\n  &#x2022;substantial', 'MIT', '\\n  &#x2022;exemptions', '\\n  &#x2022;issued', 'x201c;Risk', 'Internal Control', 'Medicaid', 'Broad', 'Medicare', '\\n  &#x2022;any', 'Congress', '\\n  &#x2022;allow', 'Harvard', ': &', '\\n  &#x2022;general', 'LNP', 'FDA', '\\n  &#x2022;collaborations', 'Regenerative Medicine Advanced Therapy', 'Jefferies LLC (&#x201c;Jefferies&#x201d', 'the &#34;Vertex', '\\n  &#x2022;disagreements', 'the Hatch-Waxman Act', '\\n  &#x2022;Our', 'EGC', 'depreciation\\n        &', '\\n  &#x2022;changes', '\\n  &#x2022;others', '\\n  &#x2022;loss', '\\n  &#x2022;effective', '77\\n', 'Harvard/Broad License Agreement', 'HIPAA', '\\n  &#x2022;regulatory', 'FDARA', 'FTC', 'the &#x201c;Amended', 'Company', 'the Boston Licensing Parties&#x2019', 'USPTO', 'Harvard/Broad', 'the California Privacy Rights Act', '\\n  &#160;\\n', 'the &#x201c;Lilly Stock Purchase', 'depreciation)\\n    &', '50\\n', 'Beam', 'the Delaware General Corporation Law', 'the Lilly Option', '\\n  ', 'CROs\\n    &', 'Fellows of Harvard College (&#34;Harvard&#34', 'CMS', '\\n  &#x2022;establishment', 'The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d', 'ARCLA', '\\n  &#x2022;liability', 'Success', '\\n  &#x2022;the', 'Stockholders&#x2019', 'the Research and Development Plan', 'Vertex Pharmaceuticals Incorporated', 'Verve Therapeutics, Inc.', 'Verve Therapeutics', '\\n  &#x2022;sales', '\\n  &#x2022;timing', 'FH', '\\n  &#', 'Accounting Analysis&#160;The Company', 'CVD', 'Vertex', 'The Vertex Agreement', '\\n  &#x2022;collaborators', '\\n  &#x2022;market', '\\n  &#x2022;retention', '\\n  &#x2022;diversion', '\\n  &#x2022;decreased', 'Note 8', 'accordingly.&#160;The Company', '\\n  &#x2022;require', 'IRA', '\\n  &#x2022;cultural', 'the Company and Beam', 'the Sarbanes-Oxley Act', 'IPO', 'ANGPTL3', '\\n  &#x2022;The', '\\n  &#x2022;delay', 'ASU No', 'Property', '\\n  &#x2022;our', 'Form S-3', '\\n  &#x2022;limit', 'Organization Verve Therapeutics, Inc.', '\\n  &#x2022;reliance', '\\n  &#x2022;We', 'the Initial Vertex Research Services', '\\n  &#x2022;commercial', 'the Lilly Research Services', 'Beam Therapeutics Inc.', '\\n  &', 'ATM', 'thousands)\\n          &#160;\\n', 'European Union', 'the Biden Administration', 'Omnibus', '\\n  &#x2022;unanticipated', 'Sigma-Aldrich', '\\n  &#x2022;disputes', 'and\\n  &#x2022;We', 'the Boston Licensing Parties', 'institute a &#x201c;poison pill&#x201d', ""the United Kingdom\\'s"", 'x201c;Private', '\\n  &#x2022;successful', '\\n    ', '\\n  &#x2022;withdrawal', '\\n  &#x2022;authorize', '\\n    Interest', '\\n        &', 'SEC', 'the Cas9 License Agreement', 'agreements.\\n', 'Novartis', 'Factors&#34', '277,019\\n          &', 'the Beam Agreement', '\\n  &#x2022;reduced', 'ASC Topic', 'the European Union', '\\n  &#x2022;actual', 'the Sublicense Option Agreement', '\\n    &', '\\n  &#x2022;receipt', 'Boston Licensing Parties'}"
VIGL,"{'\\n  &#x2022;competition', '\\n  &#x2022;develop', 'LLC', 'The Series A Preferred Stock Tranche Obligation', 'Liechtenstein', '\\n    Interest income\\n    &', 'Good Laboratory Practices', '\\n  &#x2022;incur', '\\n  &#x2022;expand', 'EMA', 'the EMA&#x2019;s Committee Medicinal Products for Human Use', 'Jefferies LLC', '\\n  &#x2022;attract', 'EU', 'the Series A Preferred Stock Tranche Obligation', 'The Amgen Agreement', '\\n  &#x2022;demonstration', 'The University of Oxford', '26\\n', '\\n  &#x2022;selection', '\\n    Research', 'Form S-1', '\\n  Legally', '\\n  &#x2022;development', 'the Amgen Agreement', 'the Securities Exchange Act', '\\n          &#', '\\n  &#x2022;expenditures', 'CNS', 'Fair Value Measurements and Financial InstrumentsThe', '\\n  &#x2022;obtaining', 'satisfactorily.\\n  &#x2022;If', 'FASB', 'x2022;if', 'policies;\\n  &#', '\\n  &#x2022;product', 'Restated Certificate of Incorporation of the Registrant', '56,794\\n          &#160;\\n          &#160;\\n', '\\n  &#x2022;refusal', 'Medicaid', 'Medicare', '\\n  &#x2022;patient', '\\n  &#x2022;any', 'Grant Plan', 'Risks Related to Government Regulation', 'x2014;\\n        &', 'FDA', '\\n  &#x2022;collaborations', 'the Data Safety Monitoring Board', '\\n  &#x2022;maintaining', 'Research and Development Expenses \\n  Research', 'and\\n  &#', 'follows:\\n  &#x2022;VGL101', '\\n  &#x2022;changes', '\\n  &#x2022;continue', '\\n  &#x2022;approval', '\\n  &#x2022;effective', 'HIPAA', 'chapter).\\n  &', '\\n  &#x2022;requirements', '\\n  &#x2022;serious', 'REMS', '\\n  &#x2022;occurrence', '\\n  &#x2022;fines', 'AL002', 'Company', '\\n  &#x2022;sufficiency', 'USPTO', '\\n  &#x2022;challenges', '\\n  &#x2022;injunctions', '\\n  &#160;\\n', '\\n  &#x2022;whether', 'L.P.', 'ASU', 'the European Commission', '\\n  &#x2022;invest', 'Related Party Transactions Atlas The Company', 'MA LeaseIn', '\\n  &#x2022;establishment', 'AbbVie, Inc.', '\\n  &#x2022;patient recruitment', '\\n  &#x2022;future', '\\n  &#x2022;initiate', '\\n  &#x2022;acquire', 'mAb TREM2', '\\n  &#x2022;the', 'and\\n  &#x2022;our', '\\n  &#x2022;positive', 'ALSP', 'European Medicines Agency', '\\n  &#x2022;launching', 'IRB', 'License', '\\n  &#', 'the Sale Agreement', '\\n  &#x2022;suspension', '\\n  &#x2022;imposition', '\\n  &#x2022;collaborators', '\\n  &#x2022;issuance', 'Amgen', 'TREM2', 'NDA', 'Atlas Venture Fund XII', '\\n  &#x2022;negative', 'the Sarbanes-Oxley Act', '\\n  &#x2022;inability', 'IPO', '203,863\\n          &#160;\\n         \\n         \\n', 'This Quarterly Report', '\\n  &#x2022;our', 'VGL101', 'Janssen Pharmaceutica NV', '\\n  &#x2022;add', 'Board', '\\n  &#x2022;We', '\\n  &#x2022;commercial', '\\n  &#x2022;issues', 'the Registration Statement', 'the European Economic Area (Iceland,', '\\n  &#x2022;delays', 'Amgen Inc.', 'non-current)\\n        &', 'Alector', 'the State of Delaware', '\\n  &#x2022;disputes', '\\n  &#x2022;restrictions', 'Good Manufacturing Practice', 'the Internal Revenue Service', '\\n  &#x2022;the FDA', '\\n  &#x2022;successful', 'the U.S. Treasury Department', '\\n        &', 'SEC', 'Restricted', '\\n  &#x2022;potential', 'GCP', 'BLA', '\\n  &#x2022;lack', 'the Federal Trade Commission Act', 'U.S.C &', 'Equity Securities', 'FUJIFILM Diosynth Biotechnologies Texas', 'Smaller Reporting Companies', '\\n  &#x2022;failure', 'Nasdaq', '\\n    &', '\\n  &#x2022;receipt', 'FTCA', '\\n  &#x2022;such'}"
VINC,"{'the Merger Agreement', 'expense)\\n&#160;&#160;\\n&#160;\\n230\\n&#160;\\n&#160;&#160;\\n&#160;\\n(103\\n)&#160;\\n&#160;&#160;\\n&#160;\\n333\\n&#160;\\n\\n\\n&#160;&#160;\\n &#', 'LLC', 'LifeSci Acquisition Merger Sub, Inc.', 'the Bayer License Agreement', 'Restricted Stock', 'development\\n&#160;&#160;\\n&#160;\\n6,800\\n&#160;\\n&#160;&#160;\\n&#160;\\n11,066\\n&#160;\\n&#160;&#160;\\n&#160;\\n(4,266\\n)&#160;\\n\\n Restructuring\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;&#160;\\n&#160;\\n1,310\\n&#160;\\n&#160;&#160;\\n&#160;\\n(1,310\\n)&#160;\\n\\n\\n&#160;&#160;\\n &', '\\n &', 'EQUITY', 'expenses\\n&#160;&#160;\\n&#160;\\n37,076\\n&#160;\\n&#160;&#160;\\n&#160;\\n58,151\\n&#160;\\n&#160;&#160;\\n&#160;\\n(21,075\\n)&#160;\\n\\n\\n&#160;&#160;\\n &', 'expense)\\n&#160;&#160;\\n&#160;\\n804\\n&#160;\\n&#160;&#160;\\n&#160;\\n(111\\n)&#160;\\n&#160;&#160;\\n&#160;\\n915\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'Merger Agreement', 'the Court of Chancery of the State of Delaware', 'CDK9&#8221', 'Medicaid', 'Medicare', 'LifeSci Holdings', 'Bayer', 'License Agreement', 'the Current Report on Form 8-K', 'December&#160;23', 'the State of Delaware', 'the Continental Stock Transfer&#160;&amp', 'development\\n&#160;&#160;\\n&#160;\\n25,260\\n&#160;\\n&#160;&#160;\\n&#160;\\n40,779\\n&#160;\\n&#160;&#160;\\n&#160;\\n(15,519\\n)&#160;\\n\\n Restructuring\\n&#160;&#160;\\n&#160;\\n&#8212;&#8194;\\n&#160;\\n&#160;&#160;\\n&#160;\\n2,469\\n&#160;\\n&#160;&#160;\\n&#160;\\n(2,469\\n)&#160;\\n\\n\\n&#160;&#160;\\n &', 'FDA', 'LSAC', 'Trust Company', 'expenses\\n&#160;&#160;\\n&#160;\\n10,317\\n&#160;\\n&#160;&#160;\\n&#160;\\n16,901\\n&#160;\\n&#160;&#160;\\n&#160;\\n(6,584\\n)&#160;\\n\\n\\n&#160;&#160;\\n &#160;\\n &#160;\\n&#160;\\n&#160;&#160;\\n &', 'ADC', 'Bayer AG', 'The Foreign Corrupt Practices Act', 'operations\\n&#160;&#160;\\n&#160;\\n(37,076\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(58,151\\n)&#160;\\n&#160;&#160;\\n&#160;\\n21,075\\n&#160;\\n\\n\\n&#160;&#160;\\n &#', 'Contents\\n\\n\\n\\n\\n\\n\\n&#160;\\n&#8226;\\n&#160;\\n', 'administrative\\n&#160;&#160;\\n$\\n3,517\\n&#160;\\n&#160;&#160;\\n$\\n4,525\\n&#160;\\n&#160;&#160;\\n$\\n(1,008\\n)&#160;\\n\\n Research', 'The Nasdaq Capital Market', 'Accounting Standards Update', 'Uncertainties', 'the Court of Chancery', 'expense)\\n&#160;&#160;\\n&#160;\\n602\\n&#160;\\n&#160;&#160;\\n&#160;\\n22\\n&#160;\\n&#160;&#160;\\n&#160;\\n580\\n&#160;\\n\\n\\n&#160;&#160;\\n &#', 'operations\\n&#160;&#160;\\n&#160;\\n(10,317\\n)&#160;\\n&#160;&#160;\\n&#160;\\n(16,901\\n)&#160;\\n&#160;&#160;\\n&#160;\\n6,584\\n&#160;\\n\\n\\n&#160;&#160;\\n &', 'the Certificate of Amendment', 'SEC', 'The Bayer License Agreement', 'Contents\\n\\n\\n\\n Research and Development  Research', 'Company', 'Restated Certificate of Incorporation', 'Grant Date Fair Value', 'September&#160;25', 'the Business Combination', '\\n&#160;\\n&#160;&#160;\\n &#160', '\\n&#160', 'USPTO', 'Certificate of Incorporation', '\\n&#160;&#160;\\n&#160;\\n182,686\\n&#160;\\n&#160;&#160;\\n$\\n0.045\\n&#160', 'COVID-19', 'Warrant Agreement', 'Capital Resources.&#8221', 'Nasdaq', 'Restated Bylaws', '\\n\\n\\n&#160;&#160;\\n &#160', 'the Registration Statement on Form S-1', 'Institutional Review Board'}"
VIR,"{'Development', 'Purchase Agreement', 'LLC', 'Credit Agreement', 'the Securities and Exchange Act', 'use.&#8203;The Company', 'ERISA', 'California.10.2&#8203;Joinder Agreement', 'expenses.&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;Three Months Ended October&#160;28', 'this Quarterly Report on Form 10', 'Windward Performance, Ltd.', 'the California Labor Code', 'Internal Control', 'No &#9744;&#8203;Indicate', 'this Quarterly Report on Form 10-Q', 'UMS', 'Jefferies LLC', 'payable.&#8203;The First Amendment to Credit Agreement', 'Accounting Policies', 'Chief Accounting', 'Credit Facility', 'Fair Value Measurements&#8203;Fair', 'AeroVironment', 'the Credit Agreement', 'Lenders', 'Planck', 'BCORE Defender CA1W01', 'Inc.3.2(3)&#8203;Fourth Amended', 'the Revolving Facility', 'AeroVironment, Inc.', 'net&#8203;&#8203', 'Planck Aerosystems, Inc. (&#8220;Planck&#8221', 'the Revolving Credit Facility', 'the Consolidated Fixed Charge Coverage Ratio', 'Tropic Merger Sub, Inc.', 'Definitive Proxy Statement', 'Note 5&#8212;Equity Method Investments', 'MUAS', 'Restated Certificate of Incorporation of AeroVironment', 'Shareholder Representative Services', 'Company', 'the Securities Exchange Act', 'ContentsThe Credit Agreement', 'respectively&#8203;&#8203', 'Bank of America', 'Months Ended &#8203;&#8203;October&#160;28,&#8203;October&#160;29,&#8203;&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022Balance', 'Results of Operations', 'April&#160;30', 'the Consolidated Leverage Ratio', 'Regulation S-K.&#8203;46\\nTable', 'ContentsIn', 'Wahid Nawabi&#8203;&#8203;Wahid Nawabi&#8203;&#8203;Chairman', 'deemed &#8220;filed&#8221', 'the Term Loan Facility', 'California Superior Court', 'Arcturus'}"
VIRI,"{'the Sarbanes-Oxley Act of 2002&#8203;32.1&#8224;&#8203;Certification', 'LLC', 'Months Ended &', 'Form S-3', 'the Agreement, UA', 'the Second Amended and Restated Operating Agreement the &#8220;Amended', 'ExhibitsSee', 'fibromyalgia (&#8220;FM&#8221', 'Ended &#8203;September&#160;30,&#160;&#160;September&#160;30,&#160;&#8203;2023&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022Operating expenses:(Unaudited)&#160;(Unaudited)Research', 'OperationsBelow', 'Section&#160;13', 'Development ExpensesResearch', 'Principal Executive Offices)(866', 'Virios Therapeutics,&#160;LLC.The Company', 'AgreementThe Company', 'Exhibit 3.1', 'EmployerIdentification', 'the President Options', 'celecoxib (&#', 'Innovative Med Concepts', 'BHC', 'SEC', '2020)&#8203;&#8203;&#8203;3.2&#8203;Bylaws of Virios Therapeutics, Inc.', 'Company', 'the Securities Exchange Act', 'Exhibit 3.2', 'the Listing Qualifications Department of The Nasdaq Stock Market', 'the Sarbanes-Oxley Act', 'the University of Alabama (&#8220;UA&#8221', 'IPO', 'ThinkEquity', 'IMC-2', 'Incorporation of Virios Therapeutics, Inc.', 'Nasdaq Rules'}"
VIRX,"{'API', 'RNA', 'LLC', 'Oxford', 'EMA', 'Viracta Therapeutics, Inc. (&#x201c;Private', 'Jefferies LLC', 'federal and/or', 'EU', 'Qualitative Disclosure', 'Nana-val;\\n  &#x2022;the', 'and\\n  &#x2022;analogous', 'x2022;a', 'Principal Financial and Accounting', 'Principal Executive', 'the Securities Exchange Act', 'NOL', 'COVID-19', 'all;\\n  &#x2022;collaborators', 'candidates;\\n  &#x2022;collaboration', 'the Amended Lease', 'the &#x201c;NK License', 'and\\n  &', 'ImmunityBio, Inc.', 'Anti-Kickback Statute', 'the California Department of Financial Protection and Innovation', 'HHS', 'candidates;\\n  &#x2022;collaborators', 'NantKwest, Inc. (&', 'Medicaid', 'Medicare', 'the U.S. Department of Justice', 'the Securities Markets and Ownership', 'management&#x2019;s equity and/or', 'GDPR', 'efforts.\\n  Efforts', 'FDA', 'letters;\\n  &#x2022;civil', 'RSU', 'and\\n  &#', 'Nana', 'SEC Rule 13a-15(b', 'the World Health Organization', 'others;\\n  &#x2022;collaborators', 'the Federal Deposit Insurance Corporation', 'and\\n  &#x2022;imposition', 'Risks Related', 'the Medicaid Drug Rebate Program', 'HIPAA', 'private &#', 'ImmunityBio', 'REMS', 'Silicon Valley Bank', 'RPI Finance Trust', 'Company', 'payroll taxes;\\n  &#x2022;foreign', 'USPTO', 'DOT', 'profits.\\n', 'Viracta', 'cGMPs;\\n  &#x2022;the', 'and\\n  &#x2022;business', 'SVB', 'CMS', 'Critical Accounting Policies', 'relationships;\\n  &#x2022;risks', 'Oxford Finance', 'EBV', 'the NK License Agreement', 'FCPA', 'Oxford Loan', 'and\\n  &#x2022;our', 'x2022;injunctions;\\n  &#x2022;suspension', 'Stockholders&#x2019', 'NK Covered Products', 'x2022;a collaborator&#x2019;s', 'Nana-val;\\n  30\\n', '\\n  &#', 'Day One Biopharmaceuticals, Inc.', 'size;\\n  &#x2022;there', 'the Company (&#x201c;Merger', 'patentable;\\n  &#x2022;the', 'DOJ', 'the NK Covered Products', 'the Sarbanes-Oxley Act', 'required;\\n  &#x2022;maintaining', '47\\n', 'the &#x201c;Merger', 'companies&#x2019', 'First-Citizens Bank and Trust Company (&#', 'PGR', 'Denovo Biopharma', 'periods.\\n  Forward-Looking Statements\\n', 'them;\\n  &#', 'Form S-3', 'oversight.\\n', 'the United States;\\n  &#x2022;production', 'markets;\\n  &#x2022;compliance', 'XOMA', '\\n  &', 'including:\\n  &#x2022;the', 'European Union', 'Nana-val.\\n  &', 'Sunesis Pharmaceuticals, Inc.', 'HDAC', 'initiation;\\n  &#x2022;maintaining', 'patents;\\n  &#x2022;issued', 'employees.\\n  Patent', 'candidates.\\n  Intellectual', 'products;\\n  &', 'SEC', 'Nana-val;\\n  &#x2022;obtaining', 'the Office of Inspector General', 'EquityCommon StockThe', 'the European Union', 'Nasdaq', '\\n    &', 'property.\\n'}"
VKTX,
VMD,
VNDA,
VOR,
VRAX,
VRCA,"{'API', 'years)\\n        &', 'OneYearAnniversaryMember2023', '\\n    Interest income\\n    &', 'the Initial Commitment Amount', 'Credit Opportunities IV, LP', 'PBM', 'the Term B1 Loan', '9746;\\n    &', 'NewDrugApplicationMember2023', 'ProductMember2023', 'Torii Pharmaceutical Co., Ltd.', 'CollaborationMember2023-07-012023-09-300001660334vrca', 'Torii Agreement', 'Loan Facility', 'MaximumMembervrca', 'VP-102\\n    &', '\\n    Research', 'Treasury', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001660334us', 'the Securities Exchange Act', '9744;\\n    &', 'LeaseholdImprovementsMember2022-12-3100016603342023-01-012023-09-300001660334us-gaap', 'ToriiAgreementMembervrca', 'PbmCapitalGroupLlcMember2022-07-012022-09-300001660334vrca', 'RestrictedStockUnitsRSUMember2019-11-012019-11-300001660334us', 'compensation\\n    &', 'The Credit Agreement', 'management&#x2019;s', 'the Torii Clinical Supply', 'RestrictedStockUnitsRSUMember2019-11-012019-11-300001660334vrca', '\\n    &#160;Exercise', '\\n  Interest Expense\\n  Interest', 'RestrictedStockUnitsRSUMember2023-01-012023-03-310001660334us-gaap', 'Verrica Pharmaceuticals', 'x201c;anticipate,&#x201d; &#x201c;intend,&#x201d; &#x201c;believe,&#x201d;', 'Medicaid', 'the Securities and Exchange Commission', 'Torii of $0.5 million', 'GTN', 'Expired\\n        &', 'FDA', 'THE SECURITIES EXCHANGE ACT OF', 'the OrbiMed Credit Agreement', 'Unaudited)\\n  &#160;\\n', 'GMP', 'and\\n  &#', 'WarrantMember2023-01-012023-09-300001660334vrca', 'the words &', 'WarrantMember2023-07-262023-07-260001660334us-gaap', 'Silicon Valley Bank', 'activities\\n    &', 'Company', 'expense)\\n    &', 'SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001660334us', '\\n    Interest expense\\n    &', 'the Clinical Supply Agreement', 'Results of Operations', 'the Torii Agreement', 'Charter)\\n  &#', '\\n    &#', 'WarrantsThe', 'ASC Topic 606 &#', 'the Company&#x2019;s Registration Statement on Form S-1', 'Gorlamari v. Verrica Pharmaceuticals Inc.', 'Credit Agreement', 'Net&#160;The Company', 'The Torii Agreement', 'RestrictedStockUnitsRSUMember2023-07-012023-09-3000016603342023-06-300001660334vrca', 'Contracts with Customers', 'YcanthMember2023', 'the &#x201c;Initial', 'Stockholders&#x2019', 'NewDrugApplicationMember2023-08-242023-08-240001660334vrca', 'UNITED STATES\\n  SECURITIES AND EXCHANGE COMMISSION\\n  ', 'CONDENSED BALANCE', '\\n    &#160;Issuance', 'SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001660334us', '\\n  &#', 'OrbiMed', 'the Credit Agreement', 'Lenders', 'RestrictedStockUnitsRSUMember2023-09-3000016603342022-04-012022-06-300001660334vrca', 'the &#x201c;Exchange', 'Registrant', 'ProductMember2022', '\\n  &#x2022;decreased', 'the Loan Facility', 'OrbiMed Royalty &', 'the &#x201c;Administrative', 'Lytix Biopharma AS', 'PbmCapitalGroupLlcMember2023', 'Regulation S-K', 'IPO', 'the Initial Lender', 'the Company&#x2019;s Board of Directors', 'RestrictedStockUnitsRSUMember2023-08-242023-08-240001660334us-gaap', 'the Mezzanine Loan Agreement', 'YCANTH', '\\n  &', 'Lytix', 'CollaborationMember2023-01-012023-09-300001660334us', 'the U.S. Food and Drug Administration', 'revenue;\\n  &#x2022;reduced', 'end\\n    &', 'FFF', 'the Term A Loan', 'Condensed Financial', 'costs.\\n  &#160;\\n', '\\n    ', 'the U.S. District Court', '\\n        &', 'SEC', 'Restricted', 'Clinical Enrollment', 'agreements.\\n', 'stock.\\n  &', 'WarrantMember2022-01-012022-09-3000016603342022-01-012022-09-300001660334vrca', ""the Company\\'s Board of Directors"", 'BusinessVerrica Pharmaceuticals Inc.', 'Lytix Biopharma AS (&#x201c;Lytix&#x201d;)', '\\n    &'}"
VRDN,"{'ASC', 'The Hercules Amendment', 'Contractual Obligations', 'USE OF', 'Security Agreement', 'the Xencor License Agreement', 'Segment InformationThe Company', 'Principal Executive Officer', 'Office SpaceThe Company', 'Development and License Agreement', 'Series A Preferred Stock', 'CostsDebt', 'UPC', 'the Series A Preferred Stock', 'the ImmunoGen License Agreement', 'the Financial Accounting Standards Board', 'ContentsDuring', 'Paragon Therapeutics, Inc. (&', 'COVID-19', 'the Zenas Agreements', 'Viridian Therapeutics, Inc.', 'FASB', 'Activities Net', 'ProceduresWe', 'ATM Agreement', 'Restated Certificate of Incorporation of the Registrant', 'Contingencies - Lease Obligations', 'the Delaware General Corporate Law', 'VRDN-002', 'FDA', 'ContentsAt', 'Jefferies LLC (&#8220;Jefferies&#8221', 'the Certificate of Designation', 'the Aspire Common Stock Purchase Agreement', 'Xencor, Inc. (&', 'the Viridian Therapeutics, Inc.', 'Risks Related', 'REMS', 'Company', 'Aspire Capital', 'the Hercules Loan', 'USPTO', 'ObligationsColorado', 'Fairmount Funds Management', 'the Enable License Agreement', 'the &#8220;Massachusetts Lease&#8221', 'License Agreement with Enable', 'The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221', 'Xencor License Agreement', 'Evercore Group L.L.C.', 'Aspire Capital Fund', 'the 2022 Public Offering', 'DEBTLoan', 'Principal Financial Officer', 'Paragon', 'the Aspire Stock Purchase Agreement', 'the Paragon License Agreement', 'Zenas', 'License Agreement', 'September&#160;30,', 'Lenders', 'Collaborative Arrangements', 'Capital RequirementsWe', 'the Paragon Agreement', 'Office and Lab SpaceThe Company', 'See &#8220;Business&#8212;Coverage', 'ReferenceExhibit', 'Fairmount', 'Agreement - Aspire Capital Fund', 'Regulation S-K', 'Recent Accounting Pronouncements &#8211', 'the Hercules Amendment', 'European Unified Patent Court', 'Mahoney Employment Agreement', 'ASU No', 'the Securities and Exchange Act', 'this Quarterly Report', 'Enable Injections, Inc. (&', 'Hercules Capital, Inc.', '2022.The Company', 'the Accounting Standards Codification', '2023x31.1Certification of Principal Executive Officer', 'Hercules Loan', 'CONTROLS AND PROCEDURESEvaluation of Disclosure Controls', 'the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221', 'Healthcare', 'Zenas BioPharma', 'Accounting Standards Codification', 'SEC', 'Immunogen, Inc. (&#8220;ImmunoGen&#8221', 'LLC (&#8220;Aspire Capital&#8221;)', 'The Term Loan', 'Contentsexercise', 'Paragon Therapeutics, Inc.', 'Beetham Employment Agreement', 'The Hercules Loan', 'FairJourney Biologics', 'the European Union', 'Nasdaq'}"
VREX,
VRNA,"{'CRO', 'the Loan Agreement', 'HHS', 'AIA', 'CMS', 'the Condensed Consolidated Statement of Operations', 'Medicaid Innovation', 'the U.S. Patent and Trademark Office', 'Quality of Life (&#8220;QOL&#8221;)14&#8226;In', 'Oxford', 'R.L.', 'The Sarbanes-Oxley Act', 'Oxford Finance Luxembourg', 'EMA', 'the UK Medicines', 'Nuance Pharma Limited', 'COPD', 'Medicare', 'Medicaid', 'Macau).The Nuance Agreement', 'non-EU', 'the Center for Medicare', 'EEA', 'GDPR', 'U.S. Holder', 'EU', 'FDA', 'a Center for Medicare', 'PCT', 'Medicaid Services', 'Ligand', 'compensationThe', 'DPI', 'Healthcare', 'the U.S. Supreme Court', 'Employee Matters', 'Risks Related', 'the Medicaid Drug Rebate Program', 'Condensed Consolidated Financial Statements(unaudited)Note', 'HIPAA', 'the Oxford Term Loan Advances', 'NDA', 'REMS', 'the UK International Data Transfer Agreement', 'the Data Review Committee', 'the FDA.Nuance PharmaIn 2021', 'Regulatory Agency', 'GCP', 'ACA', 'Patient-Centered Outcomes Research Institute', 'Trade Control', 'Company', 'CMO', 'Data Safety Monitoring Board', 'USPTO', 'the &#8220;Effective', 'the Nuance Agreement', 'CF', 'the Centers for Medicare', 'COVID-19', 'NCFB', 'the Health Information Technology for Economic and Clinical Health Act', 'the European Union', 'the Nuance Licensed Products', 'SME', 'Ligand UK Development Limited', 'Nasdaq', 'Nuance Pharma'}"
VRPX,"{'Amended Nanomerics License Agreement', 'see &#8220;Part', 'TO CONDENSED CONSOLIDATED FINANCIAL', 'Compound (&#', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n(UNAUDITED)\\n\\n&#160;&#160;\\n\\nOn', 'Lipocure RX, Ltd.', 'The Nanomerics Collaboration\\nAgreement', 'Dravet', 'Nasdaq Listing', 'Asia/Pacific', 'the Public Company Accounting Oversight Board', 'the Company&#8217;s\\nexercise of the MedPharm Option', 'Nanomerics&#8217', 'this Lipocure\\nagreement.\\n\\n&#160;\\n\\nNanomerics Ltd.\\n\\n&#160;\\n\\nNanomerics Collaboration', 'Agreement\\nfor Rendering of Research Services', 'Diclofenac Epolamine', '\\n    Research', 'Virpax Pharmaceuticals', 'the &#8220;Lipocure', 'notified\\nthe Board of Directors of the Company', 'Lennox-Gastaut', 'Novvae Pharmaceuticals', 'the Company&#8217;s Board', 'additional\\ndebt', 'Estimates&#160;&#8212', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n(UNAUDITED)\\n\\n\\n&#160;\\n\\nStock', 'Lipocure Research Agreement', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n(UNAUDITED)\\n\\n&#160;\\n\\nLipocureRx', 'required.\\n\\n&#160;\\n\\nWe', 'Compound&#8221', 'the Nanomerics License Agreement', 'September\\n2024', 'Chemistry, Manufacturing and Controls (&#8220;CMC&#8221', 'the Securities and Exchange Commission', 'certain\\ndevelopment &#', 'FDA', 'NIH', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n(UNAUDITED)\\n\\n&#160;\\n\\nNanomerics License Agreement', 'panel.\\n\\n&#160;\\n\\nOn', 'the Nanomerics Collaboration\\nAgreement', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS\\n\\n(UNAUDITED)\\n\\n&#160;\\n\\nNCATS-NIH Cooperative Research', 'Company', 'the Chancery Court', 'the\\nSecurities and Exchange Commission', 'Nanomerics Ltd.', 'Plaintiffs', 'models.\\n\\n&#160;\\n\\nWe', 'the Amended Nanomerics License Agreement', 'the Listing Qualifications Department of The Nasdaq Stock Market (&#8220;Nasdaq&#8221', 'the Restrictive Covenants\\nAgreement', 'the Nanomerics Collaboration Agreement,\\nthe Company', 'Condensed Consolidated Financial Statements', '2023.\\n\\n&#160;\\n\\nThe Company', 'Agreement for Rendering\\nof Research Services', 'Restrictive Covenants Agreement', 'expressed\\nor', 'the Counter (&#8220;OTC&#8221', 'Employment Agreement', 'The Amended Nanomerics License Agreement', 'the MedPharm Research\\nand Option Agreement', 'the &#8220;MedPharm Research and Option', 'the Bruce Employment Agreement', 'Employment, Proprietary Information and Inventions Agreement', 'date.\\n\\n&#160;\\n\\nIn', 'Virpax', 'The Nasdaq Capital Market', 'the National Institute of Neurological Disorders and Stroke (&#8220;NINDS&#8221;)', 'Financial\\nInformation&#8221', 'LipocureRx, Ltd.', 'the National Center for Advancing Translational Science (&#', 'Item 1A &#8211', 'the Employment Agreement', 'MedPharm', 'the Middle East.\\n\\n&#160;\\n\\nYissum Research Agreements\\n\\n&#160;\\n\\nOn', 'MedPharm Limited', 'Board', 'United&#160;States', 'a\\nSecond Amended Complaint', 'this Quarterly Report', 'the MedPharm Research and Option', 'CRADA', 'Nanomerics', 'Research and Development Agreement (&', 'nature\\nof', 'the MedPharm Research and Option Agreement,\\nthe Company', 'Lipocure', 'Nasdaq Listing Rule 5250(c)(1', 'the MedPharm Research and\\nOption Agreement', 'Rendering of Research Services', 'the Nanomerics License Agreement - NobrXiol', 'the MedPharm Research and Option Agreement', 'The\\nNasdaq Capital Market', 'MedPharm Limited,\\na', 'Research and Option Agreement', 'the European Union', 'Nasdaq', '\\n    &'}"
VRTX,"{'the Heartland Assets and Operations', 'LLC', 'Renewable Identification Numbers', 'Ruddy Gregory', 'GFL Environmental Inc.', 'LLC (&#8220;Vertex LA&#8221;)', 'RFS', 'Metal(s', 'Internal ControlsManagement', 'Consolidated Statement of Operations', 'the Warrant Agreement', 'Vertex Energy, Inc.', 'Cantor Fitzgerald Securities', 'the Initial Warrants and Additional Warrants', 'the Penthol Agreement', 'Offtake Agreement (&#8220;Amendment 1&#8221', 'Mobile', 'VGO', 'the Company (&#8220;Vertex', 'the Term Loan', 'the Consolidated Balance Sheets', 'Vertex Recovery Management LA', 'FlowsThe', 'Regulation S-K.', 'Supply', 'Warrant Exchange AgreementOn', 'Commission', 'the Securities Exchange Act', 'the heading &#8220;Risk Factors&#8221', 'Brent Complex', 'the Clawback Policy', 'Consolidated Financial Statements', 'Warrants', 'HPRM', 'the &#8220;Commission&#8221', 'MarketingTotal Refining', 'MarketingGross', 'Capital ResourcesOur', 'the Securities and Exchange Commission', 'Chris CarlsonChris', 'Penthol Agreement', 'LLC (&#8220;Vertex', 'Penthol', 'FAIR VALUE', 'GFL', 'Loan', 'New Accounting PronouncementsThe Company', 'the Federal Deposit Insurance Corporation', 'Company', 'Vertex Recovery Management', 'and&#9679', 'Clawback and Forfeiture Policy', 'Macquarie, Vertex Refining', 'Vertex Refining LA', 'Report', 'the Company&#8217;s Annual Report on Form 10-K', 'the General Counsel', 'OperationsSet', 'NV', 'PLLC', 'Vertex Refining', 'Martin Energy Services', 'the Additional Warrants', 'revenues9,477&#160;5,338&#160;14,815&#160;574&#160;15,389&#160;5,944&#160;395&#160;6,339&#160;RFS', 'Trust Company', 'the Sale Agreement', 'Vertex', 'Lenders', 'Shell', 'the Refining and Marketing', 'The Nasdaq Capital Market', 'relations104,778&#160;4,624&#160;154&#160;4,778&#160;4,575&#160;203&#160;Trademark/Trade name15887&#160;645&#160;242&#160;887&#160;608&#160;279&#160;TCEP Technology/Patent1513,287&#160;9,502&#160;3,785&#160;13,287&#160;8,838&#160;4,449&#160;Non-compete3197&#160;197&#160;&#8212;&#160;197&#160;197&#160;&#8212;&#160;Software39,344&#160;4,783&#160;4,561&#160;9,387&#160;2,495&#160;6,892&#160;Licensing', 'the Inventory Financing Agreement', 'ReferenceExhibit NumberDescription', 'Non-U.S. GAAP Financial Measures', 'Penthol LLC&#8217;s', 'Macquarie Energy North America Trading Inc (&#8220;Macquarie&#8221', 'UMO Business', 'the New York Mercantile Exchange', 'GFL Environmental', 'COD', 'Macquarie', 'Mobile Refinery', 'the United States Securities and Exchange Commission', 'Results of Operations (&#8220;MD&amp;A&#8221', 'Non-U.S.', 'Idemitsu Apollo Renewable Corp.', 'the Board of Directors', 'Macquarie Energy North America Trading, Inc (&#8220;Macquarie&#8221', 'Offtake Agreements', 'Vertex Renewables', 'Vertex Energy', 'Consolidated Results', 'the Mobile Refinery', 'Industrial Pipe, Inc.', 'Adjusted Gross Margin', 'NON-CONTROLLING INTERESTSVertex Recovery Management LA', 'Continental Stock Transfer &amp', 'RD', 'Restricted', 'the Offtake Agreement', 'Offtake Agreement'}"
VSTM,"{'Value of Financial InstrumentsThe', 'AFCO', 'GenFleet Therapeutics', 'ASU', 'the Nasdaq Capital Market', 'the Securities Purchase Agreement', 'Sanofi', 'the Loan Agreement', 'ContentsPART I&#8212;FINANCIAL INFORMATIONItem&#160;1', 'CRO', 'the U.S. Food &amp', 'ContentsEXHIBIT&#160;INDEX&#8203;c&#8203;&#8203;3.1&#8203;Restated Certificate of Incorporation of the Registrant', 'Verastem Europe GmbH', 'the Term Loans', 'Oxford', 'Balance Sheet Information - Operating', 'the GenFleet Agreement', 'the Underwriting Agreement', 'Oxford Finance Credit Fund III LP', 'CSPC Pharmaceutical Group Limited', 'this Quarterly Report on Form&#160;10-Q', 'assets&#8203;$ &#', '2682024&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203', 'Verastem Securities Company', 'FDA', 'ContentsComparison', 'Secura APA.The', 'areas.&#160;The Company', 'the Regulatory Milestone Payment', 'License', 'Analysis&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;2023&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203', 'Underwriters', 'KRAS G12V NSCLC', 'Pre-Funded Warrants', 'Loan', 'GenFleet Options', 'Lenders', 'Notes Payable', 'KRAS', 'ContentsThe', 'Yakult Honsha Co., Ltd.', 'the Reverse Stock', 'Series B Convertible Preferred Stock', 'the Annual Report on Form 10-K', 'the Term B Loan', 'the Registration Statement on Form S-1', 'the Conversion Blocker', 'Company', 'the Series B Convertible Preferred Stock', 'Secura Bio, Inc.', 'LGSOC', 'June&#160;16', 'RAMP', 'NotesIn', 'CME Secured', 'the European Union', 'COPIKTRA', 'GenFleet', 'Drug Administration', 'FAK'}"
VTGN,"{'the T1 Warrants', 'API', 'LLC', 'others:\\n  &#', 'Good Manufacturing Practices', 'CMOs', 'The Nasdaq Stock Market', '\\n      &#', '\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#xa0;\\n       &#', 'Financial Operations Overview', 'EMA', 'all.\\n  &#xa0;\\n  Research and Development Expense\\n  &#xa0;\\n  Research and Development', 'THERAPEUTICS', 'General Company-Related', 'the Patient Protection', 'Jefferies LLC', 'Improvement\\n  &#', 'SublicenseMember2022-04-012022-09-30\\n0001411685vtgn', 'LicenseMember2023-04-012023-09-30\\n0001411685us-gaap', '\\n   &#', 'expenditures.\\n  &#', 'appetite.\\n  &#', 'the Internal Revenue Code', 'conclusion.\\n  &#', 'purpose.\\n  &', 'the &#x201c;Sunshine', 'revenue.\\n  &#', 'the Children&#x2019;s Health Insurance Program', 'WarrantMember2022-04-012022-09-30\\n0001411685vtgn', 'WarrantMember2023-04-012023-09-30\\n0001411685us-gaap', 'gain.\\n  &#', 'MDD', 'Jefferies', 'L.L.C.', 'prospects.\\n  &#', 'CNS', 'COVID-19', 'candidate.\\n  &#', 'resources.\\n  &#', 'efforts.\\n  &#', 'Company, Incorporated', 'Bionomics', 'jurisdictions.\\n  &#', 'Collaborative Agreements\\n   &', 'the T2 Warrants', 'protection.\\n  &#', 'agency.\\n  &#', 'PH284 Nasal Spray', 'function.\\n  &#', 'Reverse Stock', 'the Underwriting Agreement', 'Medicaid', 'the Securities and Exchange Commission', 'collaborators.\\n  &#', 'Medicare', '383\\n     &#', 'employees.\\n  &#', 'the Purchase Price', 'AffaMed Therapeutics, Inc.', 'FDA', 'NIH', 'candidates.\\n  &#', 'Potential Definitive Agreement', 'The Purchase Price', '\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#xa0;\\n     &#', '\\n       &#xa0;\\n       &#', 'Responders', 'Sales\\n  &#', 'therapies.\\n  &#', 'in&#xa0;Mayo Collaborative Services', 'U. S. New Drug Application', 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR', 'REMS', 'Exhibit 4.3', 'stock.\\n  &#', 'DBA Mayo Medical Laboratories', 'the FitzPatrick Co Consulting Agreement', 'EquityLineMember2023-04-012023-09-30\\n0001411685vtgn', 'Company', 'the S-3 Shelf Registration Statement', 'menopause.\\n  &#', 'Artemis', 'USPTO', 'rights.\\n  &#', 'VistaStem Canada', 'the Pre-Funded Warrants', 'Itruvone \\n     &#xa0;\\n     &#', '\\n    &#', 'Report', 'Artemis Neuroscience, Inc.', 'ClassOfWarrantOrRightOutstandingExpirationPeriodJuly252025Member2023-09-30\\n0001411685vtgn', 'the Nasdaq Capital Market', '420\\n     &#xa0;\\n     &#xa0;\\n     &#', 'Capital Stock', 'the PGI-C. Responders', 'them.\\n  &#', 'migraine.\\n  &#', 'General and Administrative Expense\\n  &#', 'GeneralAndAdministrativeExpenseMember2022-04-012022-09-30\\n0001411685us-gaap', 'SAD', 'Liquidity\\n   &', 'prosecution.\\n  &#', 'Phase 2', 'requirements.\\n  &#', 'The Negotiation Agreement', 'the U.S. National Institute of Health', 'designs.\\n  &#', '3,028,900\\n       &#', 'CMO&#x2019;s', 'MOA', 'Fasedienol', 'collaborations.&#xa0;\\n  &#', 'the Department of Health and Human Services', 'including:\\n  &#', 'penalties.\\n  &#', '\\n  &#', 'CMC', 'the FitzPatrick Co Amendment', 'Investigational New Drug', 'FitzPatrick Co.', 'NDA', 'the Managing Partner', 'NP', 'substances.\\n  &#', 'Fuji Pharma Co., Ltd.', 'the Warrant Registration Statement', 'FairValueMeasurementsRecurringMember2023', 'Tokyo Stock Exchange', 'commercialized.\\n  &#', 'operations.\\n  &#', 'THE SECURITIES EXCHANGE ACT OF 1934', 'Consulting Agreement', 'Form S-3', '\\n        &#', 'Board', '2,573,600\\n       &#xa0;\\n       &#xa0;\\n       &#', 'impacted.\\n  &#', 'ATM', '\\n  &', 'respectively.\\n   &#', 'Purchase Price', 'Nasdaq&#x2019;s', 'the U.S. Food and Drug Administration', 'DEA', 'collaborators:\\n  &#', 'Pre-Funded Warrants', 'Fuji Pharma\\n  &#', 'the Potential Definitive Agreement', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', 'Vistagen Therapeutics, Inc.', '9,815\\n     &#xa0;\\n     &#xa0;\\n     &#', 'agreements.\\n  &#', '\\n     &#', 'SEC', 'Stifel, Nicolaus &amp', 'ATMFacilityMember2022-04-012022-09-30\\n0001411685vtgn', 'the U.S.\\n  &#', 'the U.S. Drug Enforcement Administration', 'entities.\\n  &#', '\\n       &#', 'Nasal Spray for Cognitive', 'AffaMed', 'limits.\\n  &#', 'institution.\\n  &#', 'SublicenseMember2022', 'Nasdaq', '\\n    &', '284,700\\n       &', 'decline.\\n  &#', 'NMDAR'}"
VTRS,"{'ASC', 'API', 'Finance Programs', 'GUK', 'FINANCIAL INFORMATION VIATRIS INC.', 'SUBSIDIARIESCondensed Consolidated Statements', 'ContentsPurchase Accounting Amortization', 'Business Combination AgreementBusiness Combination Agreement', 'Securities and Exchange CommissionSecurities ActSecurities Act', 'SubUtah Acquisition Sub Inc.', 'TSA', 'Biocon Biologics', 'ViatrisUpjohn', 'Condensed Consolidated Financial Statements8Table', 'EU', 'KingdomU.S.United', 'relationships186.8&#160;376.7&#160;107.8&#160;962.4&#160;Net', '2023BiogenBiogen MA Inc.', 'Emerging Markets', 'Biogen International GmbH', 'EpiPen&#174', 'Combination', 'the Biocon Agreement', 'Treasury', 'ContentsWe', 'the State of New York', 'the Securities Exchange Act', 'the Upjohn Distributor Markets', 'Item 408 of', 'ViatrisUtah U.S. Dollar', 'U.K.] Limited (&#8220;GUK&#8221', 'Skandia Litigation', 'Mylan Inc.', 'FASB', 'SUBSIDIARIESCondensed Consolidated Statements of Operations (Unaudited', 'the Announced Divestitures', 'Pfizer', 'NetThe', 'Mylan II B.V.ViatrisViatris Inc.', 'the Utah U.S. Dollar Notes', 'Global Systemically Important Banks', 'Condensed Consolidated Financial Statements9Table', 'Mylan N.V. (&', 'Wales', 'Mylan Inc. Debt', 'Capital ResourcesOur', 'Insud Pharma', 'Distribution', 'Auto-Injector', 'Mylan N.V.', ': &', 'EDPA', 'FDA', 'SUBSIDIARIESCondensed Consolidated Statements of Comprehensive Earnings', 'U.S. GAAP.The', 'Mylan', 'Merck KGaA', 'the Medicaid Drug Rebate Program', 'Senior U.S. Dollar Notes', 'Upjohn Business', 'VIATRIS INC.', 'Instruments and Risk Management The Company', 'Triggering Indebtedness', 'Company', 'CCPS', 'Viatris Inc.', 'Condensed Consolidated Financial', 'DevelopmentsPlanned', 'the Business Combination Agreement and Separation and Distribution Agreement', 'Condensed Consolidated Financial Statements', 'the Senior U.S. Dollar Notes', 'Reverse Morris Trust', 'the Biocon Biologics Transaction', 'the European Commission', 'net$(36.5)$13.2&#160;Interest ExpenseInterest', 'Famy Life Sciences', 'liabilities27,877.0&#160;28,949.9&#160;EquityViatris Inc.', 'Mizuho Bank, Ltd.', 'the Public Employees Retirement System', 'Transaction Agreement', 'net$(26.1)$(3.9)Interest ExpenseInterest', 'Teva', 'ActivitiesNet', 'Yupelri&#174', 'costCommon stock', 'Board of Directors', 'net$3,738.5&#160;$3,814.5&#160;Accounts Receivable Factoring ArrangementsWe', 'the Northern District Court of Ohio.49Table', 'Securities Related Litigation Purported', 'Upjohn Inc.', 'Condensed Consolidated Financial Statements7Table', 'Sections 11', 'Note 4 Acquisitions', 'DOJ', 'Mylan II B.V.&#8217;s', 'Announced Divestitures', 'Regulation S-K.ITEM 6', 'SUBSIDIARIESCondensed Consolidated Balance Sheets', 'deemed &#8220;filed&#8221', 'the Receivables Facility and Note Securitization Facility', 'GA Depot', 'Upjohn Distributor Markets', 'ItemsThe', 'NotesUnsecured', 'the Civil Division of the DOJ', 'the Board of Directors', 'District Court', 'net3,738.5&#160;3,814.5&#160;Inventories3,671.9&#160;3,519.5&#160;Prepaid', 'Utah Acquisition Sub Inc.UpjohnUpjohn Inc.', 'the Mylan Inc.', 'Complaint', 'ContentsUpjohn BusinessPfizer&#8217;s', 'England &', 'Utah Acquisition Sub Inc.Utah Acquisition', 'net$3,231.0&#160;$3,243.8&#160;Other receivables507.5&#160;570.7&#160;Accounts', 'Utah Acquisition Sub Inc.', 'Mylan II B.V.', 'SARsTevaTeva Pharmaceutical Industries Ltd.TSATransition', 'NotesSenior', 'Significant Accounting Policies', 'the U.S. District Court', 'SEC', 'IRS', 'NotesThe Upjohn', 'the OTC Transaction', 'ContentsVIATRIS INC.', 'the U.K. Competition Appeals Tribunal', 'Prepaid Expenses and Other Current Assets'}"
VTVT,"{'ASC', 'LLC', 'Forbes Incorporated', 'CommonClassAMember2022-01-012022-09-300001641489us-gaap', 'MacAndrews &', 'Lincoln Park', 'the Condensed Consolidated Financial Statements', 'AAA', 'the Sarbanes-Oxley Act of', 'NonrelatedPartyMember2022-07-012022-09-300001641489us-gaap', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'WarrantMember2022-01-012022-09-300001641489us-gaap', 'NetOther', 'NonrelatedPartyMember2023-01-012023-09-300001641489us-gaap', 'Reneo Pharmaceuticals', 'Therapeutics LLC (&#8220;vTv', 'Liquidation and Dissolution', 'a Common Stock Repurchase Agreement', 'FASB', 'Anteris Bio, Inc. (&#8220;Anteris&#8221', 'G42InvestmentsMember2022-05-310001641489vtvt', 'SGLT2', 'the Partner Territory', 'HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2021', 'ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember2023-01-012023-09-300001641489us-gaap', 'M&amp;F', 'THE SECURITIES EXCHANGE ACT OF 1934For', 'IP', 'the CinRx Purchase Agreement', 'G42 Investments 10,386,274', 'the Exchange Agreement', 'T1D.', 'the LPC Purchase Agreement', 'charter)_____________________________Delaware47-3916571(State', 'Silicon Valley Bank', 'the Company to M&amp;F', 'Novo Nordisk', 'Company', 'LLC (&#8220;G42 Healthcare&#8221', 'Anteris', 'MaximumMember2022-12-310001641489srt', 'Units', 'LPCPurchaseAgreementMember2022-01-012022-09-300001641489us-gaap', 'the Venture Loan', 'ReneoPharmaceuticalsIncMember2022', 'Horizon Technology Finance Corporation', 'Cogna Technology Solutions', 'Significant Accounting', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001641489vtvt', 'LLC (&#8220;Lincoln', 'the First Huadong Amendment', 'G42InvestmentsMember2022-05-312022-05-310001641489vtvt', 'The Exchange Agreement', 'Letter AgreementsThe Company', 'Tax Receivable AgreementThe Company', 'LetterAgreementWarrantsMember2023-09-300001641489srt', 'ASU', 'Cantor Fitzgerald &amp', 'Novo Nordisk A/S', 'this Quarterly Report on Form 10-Q.', 'Lincoln Park Capital TransactionOn November&#160;24', 'the Condensed Consolidated Balance Sheets', 'MacAndrews', 'Huadong License AgreementThe Company', 'G42 Healthcare Research Technology Projects', 'the G42 Promissory Note', 'Therapeutics Holdings', 'Collaborative Arrangements', 'the CinRx Purchase Agreement the Company and CinRx', 'Lincoln Park Capital Fund', 'ShareBasic', 'Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.', 'FairValueMeasurementsRecurringMember2023', 'the Sarbanes-Oxley Act', 'the &#8220;Cogna', 'affiliates &', 'ExpenseInterest', 'RiskOur', 'Forbes Group', 'LetterAgreementWarrantsMember2023-09-300001641489us-gaap', 'the Letter Agreement Warrants and CinRx Warrants', 'Form S-3', 'the Anteris License Agreement', 'WarrantMember2023-01-012023-09-300001641489us-gaap', 'the CinRx Warrants', 'Co. (&#8220;Cantor', 'the Board of Directors', 'MacAndrewsAndForbesIncorporatedMember2023-01-012023-09-300001641489us-gaap', 'G42 Investments', 'Issued Accounting PronouncementsFair Value Measurements', 'the Tax Receivable Agreement', 'Note 2', 'MFTTPHoldingsLLCMember2023-01-012023-09-300001641489us-gaap', 'NonrelatedPartyMember2022-01-012022-09-300001641489us-gaap', 'the Condensed Consolidated Statements of Operations', 'MacAndrewsAndForbesIncorporatedMember2023-09-300001641489us-gaap', 'Contents(TTP399', 'the Cogna Agreement', 'LLC (&#8220;vTv Therapeutics Holdings&#8221;)', 'SEC', 'G42 Healthcare Technology Solutions', 'TTP Holdings', 'ConsolidationvTv Therapeutics Inc.', 'Therapeutics Inc.', 'NonrelatedPartyMember2023-07-012023-09-300001641489us-gaap', 'the Huadong License Agreement'}"
VTYX,"{'\\n  &#x25aa;our', 'years)\\n        &', 'LLC', 'commercially;\\n  &#x25aa;It', 'controls;\\n  &#', '\\n  Government', 'the Organisation for Economic Co-operation and', 'EU Data Protection Directive', 'the Open Market Sales', '\\n  &#x25aa;countries', 'Exhibits.\\n  &#160;\\n', '\\n  &#x25aa;a', '\\n  &#x25aa;manufacturers', 'EU', 'the U.S. Foreign Corrupt Practices Act', '26\\n', 'Accounting Standards Update', '\\n    Research', '\\n  &#x25aa;substantial', 'Form S-1', 'Jefferies LLC (&#x201c;Jefferies&#x201d;)', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', '\\n  &#x25aa;difficulties', 'Jefferies', 'COVID-19', 'the Centers for Disease Control and Prevention', '\\n  &#x25aa;product', '\\n  Assumptions', '\\n  &#x25aa;issued', '\\n  &#x25aa;injury', 'FASB', '\\n  &#x25aa;exhaustion', 'Consolidated Balance Sheet DetailsProperty', 'Medicaid', 'the Securities and Exchange Commission', 'Medicare', 'Congress', 'x2014;\\n        &', 'FDA', 'Processing', '\\n        Laboratory equipment\\n', '\\n  &#x25aa;we', 'and\\n  &#', '\\n  &#x25aa;acquisition', 'depreciation\\n        &', 'HIPAA', 'REMS', 'Company', 'Bayside', '\\n  &#x25aa;others', 'management&#x2019;s attention', 'Risks Related to Government', 'USPTO', 'Adopted Pursuant to Section 302', 'and\\n  &#x25aa;Our', 'the Health Insurance Portability', 'FCA', 'Deferred Offering CostsThe Company', '\\n  &#x25aa;it', 'the Delaware General Corporation Law', 'ASU', '\\n  ', 'x25aa;other', '\\n  &#x25aa;The', 'Research and Development Support Services Agreement', '32\\n', 'Sublease', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Form', 'IRB', '\\n  &#', 'OECD', 'contractors;\\n  &#x25aa;changes', 'x25aa;We', '\\n  &#x25aa;business', 'NDA', 'contractors.\\n  We', 'risk.\\n  Obtaining', 'the EU Clinical Trials Directive', '7\\n       &#160;changes', 'the EU Clinical Trials Regulation', 'the Sarbanes-Oxley Act', '47\\n', 'Comparison', 'This Quarterly Report', '\\n  &#x25aa;the', 'national and/or international data protection laws', 'ASU No', '\\n  &#x25aa;production', 'PGR', 'Recent Accounting PronouncementsRecently Issued Accounting Pronouncements Not', 'this Quarterly Report', 'outstanding.\\n  &#', '\\n  &', 'Unaudited Condensed Consolidated Financial Statements\\n    ', 'Sublease Agreement', 'the Registrant&#x2019;s Quarterly Report on Form 10-Q', 'ROU', 'ESPP', '\\n  Other Company Information\\n', '\\n  &#x25aa;We', 'CTR', 'the Company&#x2019;s Annual Report', 'the Registrant&#x2019;s Current Report', '\\n  &#x25aa;The FDA', '\\n    ', 'Related Party', 'Significant Accounting Policies', '\\n        &', 'SEC', 'GCP', '\\n  &#x25aa;unexpected', 'Nasdaq', '\\n  &#x25aa;delays', '\\n    &', 'and\\n  &#x25aa;delays', 'collaborator&#x2019;s', 'S1P1R'}"
VVOS,"{'ASC', 'ASU', 'BSM', 'Dividend yield&#160;\\n    &', 'Vivos Therapeutics, Inc. (&', 'the Black-Scholes', 'Ortho-Tain&#8217;s', 'Vivos Therapeutics, Inc.', 'this Quarterly Report on Form 10-Q.', 'Orders', 'Private Placement', 'CPAP', 'Financial Instruments - Credit', 'reimbursement),\\n(v', 'October\\n25', 'Arbitration', 'Ortho-Tain', 'Financial Instruments', 'MyoCorrect', 'the Asset Purchase Agreement', 'DDS', 'Lincare', 'controls\\nare', 'Financial Condition', 'FDA', 'the Company&#8217;s Medical Integration Division (&#8220;MID&#8221;)', 'the Nasdaq Listing Rules.\\n\\n&#160;\\n\\n\\n\\nLincare Distribution', 'PPP', 'the Audit Committee', 'Recent Accounting Pronouncements\\nunder', 'Board of Directors', 'fees.\\n\\n&#160;\\n\\nSales\\nand Marketing\\n\\n&#160;\\n\\nSales\\nand', 'Performance Obligations\\n\\n&#160;\\n\\nThe\\nCompany', 'Company&#8217;s\\nproducts', 'the Financial Accounting\\nStandards Board (&#', 'United', 'These\\nare', 'First Vivos,\\nInc', 'Research and Development', '\\n    &', 'Airway Intelligence Service', 'the Reverse Stock\\nSplit.\\n\\n&#160;\\n\\nAmong\\nother', 'SOT', 'found\\nin the Accounting Standards Codification', 'BIS', 'Goodwill', 'Administrative Expenses\\n\\n&#160;\\n\\nGeneral\\nand', 'Common Stock', 'revenue\\nis', 'Company', 'the Financial Accounting Standards Board', 'NOUM', 'dentist.\\n\\n&#160;\\n\\nNews\\nof', 'IRS', 'accordingly.\\n\\n&#160;\\n\\nForeign\\nCurrency Risk', 'COVID-19', 'NO &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'the &#8220;Risk Factors&#8221;\\nsection of this Quarterly Report on Form 10-Q', 'Preferred Stock', 'shares\\n(each a &#8220;Share&#8221', 'BioModeling', 'Unregistered Oral Appliance Publicity', 'the Pre-Funded Warrants', 'Arbitrator', 'Benco', 'VivoScore', 'YES &#9746', 'the Employment Agreement', 'Billing Intelligence Services', 'DME', 'the &#8220;SEA&#8221'}"
VXRT,"{'Amount &#xa0;\\n 2023', 'Other Information\\n  &#', 'stock &#xa0;&#xa0;227,434&#xa0;&#xa0;&#xa0;227,434&#xa0;&#xa0;&#xa0;227,434&#xa0;&#xa0;&#xa0;229,156&#xa0;\\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Employee', 'Expected volatility &#x2013', '\\n      &#x25cf', '2023 &#', 'Recent Accounting Pronouncements\\n  &#', 'Condensed Consolidated Statements of Operations and Comprehensive', '\\n   &#', 'the Condensed Consolidated Financial Statements', 'the &#x201c;License', 'statements.\\n  &#xa0;\\n  &#', 'the Securities Exchange Act', 'consulting services &', 'Accrued Liabilities', 'its&#xa0;common', 'Fair', 'management&#x2019;s', 'HCRP', 'Internal Control', 'Item&#xa0;6.&#xa0;&#xa0;Exhibits\\n  &#', 'Recent&#xa0;Accounting Pronouncements\\n   &#', 'candidates.\\n  &#', 'xa0;\\n     &#x2014;\\n     &#', 'significant.\\n  &#', 'Goodwill', 'Condensed Consolidated Statements', 'Company', 'the  &#x201c;June 2023', 'costs.\\n  &#', '\\n    &#', 'the Japanese Ministry of Health and Welfare', 'Principal Financial Officer', 'xa0;&#xa0;1,365&#xa0;\\n Total &', 'General and Administrative Expense\\n  &#', 'Aviragen', 'the following&#xa0;(in thousands):\\n   &#', 'the Putative Class Action', 'Altesa', 'requirements.\\n  &#', '2022 &#', 'xa0;\\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Net loss &#', 'stock &#xa0;&#xa0;3,629,741&#xa0;&#xa0;&#xa0;660,660&#xa0;&#xa0;&#xa0;2,840,178&#xa0;&#xa0;&#xa0;353,738&#xa0;\\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Warrants', '\\n  &#xa0;\\n  &#', 'xa0;&#xa0;152,026,112&#xa0;&#xa0;&#xa0;126,889,718&#xa0;&#xa0;&#xa0;145,810,175&#xa0;&#xa0;&#xa0;126,374,424&#xa0;\\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Net', '\\n  &#', 'net &#xa0;$4,472&#xa0;&#xa0;$5,020&#xa0;\\n\\n', 'This&#xa0;is', 'The Nasdaq Capital Market', 'x201c;Recent Accounting', 'xa0;\\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Accrued', 'Condensed Consolidated Balance Sheets&#xa0;as', 'Daiichi Sankyo Company, Limited (&#x201c;Daiichi', 'Altesa Biosciences, Inc. (&', 'the Listing Qualifications Department of The Nasdaq Stock Market', 'the Sarbanes-Oxley Act', 'reporting.\\n', 'Financial Reporting\\n  &#', 'Royalty Interest Acquisition Agreement', 'Vaxart, Inc.', 'stock &#xa0;&#xa0;18,151,747&#xa0;&#xa0;&#xa0;14,735,710&#xa0;&#xa0;&#xa0;17,019,217&#xa0;&#xa0;&#xa0;13,170,959&#xa0;\\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Restricted', 'Goodwill \\n\\n   &', '\\n       Financial Statements', 'Inavir', 'Condensed Consolidated Statements of Cash Flows&#xa0;for', 'Form S-3', 'decrease.\\n  &#', 'securities.\\n  &#', 'xa0;\\n&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;\\n Developed technology &', 'with&#xa0;HealthCare&#xa0;Royalty&#xa0;Partners&#xa0;III,&#xa0;L.P. (&#x201c;HCRP&#x201d;)', 'Nasdaq&#x2019;s', 'ESPP', 'Daiichi Sankyo', 'Dividend yield &#xa0;&#xa0;&#x2014;%&#xa0;&#xa0;&#x2014;%\\n\\n', 'Item&#xa0;1 for information', '2022 &', 'xa0;\\n     &#', '\\n     &#xa0;\\n     &#', 'the Condensed&#xa0;Consolidated Financial Statements', '\\n     &#', 'SEC', 'Accrued Research and Development Expenses \\n  &#', 'Value of Financial Instruments \\n', 'NOTE&#xa0;5.&#xa0;&#xa0;Revenue\\n', 'Equity Securities', 'xa0;$5,000&#xa0;&#xa0;$5,000&#xa0;\\n Intellectual', 'Nasdaq', '\\n    &#xa0;&#xa0', 'officers\\'}"
VYGR,
VYNE,"{'ASC', 'the Delaware General Corporation Law', 'Company\\', 'ASU', 'Mutual Fund Series Trust', 'the Securities Purchase Agreement', 'Chargebacks', 'Adopted Accounting PronouncementsSee &', 'Tay', 'Contingencies', 'the Molecule Stabilizing Technology', 'the VYN201 License Agreement', 'Sublease Agreement', 'the Securities and Exchange Commission', 'Purchase Price', 'the Option Agreement', 'Note&#160;2, &', 'the Purchase Price', 'Asset Purchase Agreement', 'Molecule Stabilizing Technology', 'Journey', 'the MST Franchise:(in thousands)Nine Months Ended September 30', 'the Oral Option', 'the Equity Purchase Agreement', 'FCD105', 'Accounting Standards Codification', 'Upfront', 'Journey Medical Corporation', 'the Second Letter Agreement', 'the Private Placement', 'ExpensesOur', 'Series A Preferred', 'SEC', 'ASC Topic 808', 'Company', 'Cutia Therapeutics (HK) Limited (&#8220;Cutia&#8221', ""the Company\\'s Board of Directors"", 'AlphaCentric LifeSci Healthcare Fund', 'VYNE', 'The Series A Preferred', 'Basis of PresentationThe', 'Nasdaq', 'Series A Convertible Preferred Stock', 'the Series A Preferred', 'the Purchase Agreement'}"
WBA,
WGS,"{'ASC', 'the Tranche B Loan', 'Security Instruments', 'LLC', 'Internal Control Over Financial ReportingThere', 'ExhibitsThe', 'this Quarterly Report on Form 10-Q', 'maturities$6,052&#160;Connecticut Department of Economic and Community Development Funding Commitment', 'Principal Executive Officer Pursuant to Securities Exchange Act', 'Principal Executive Officer Pursuant', 'Intangible Assets&#8221;.For', 'Amended DECD Loan', 'ContentsNine', 'the &#8220;SVB', 'Financial Information', 'the Securities Exchange Act', 'NetOther', 'Contentsrelated', 'Restated Certificate of Incorporation of GeneDx Holdings Corp.8-K3.101/09/20233.3Second Certificate of Amendment', 'COVID-19', 'Adjusted Gross Profit', 'Restricted Stock Units (&', 'ContentsFor', 'the Perceptive Term Loan Facility', 'Perceptive', 'the Genetic Sequencing Laboratory Project', 'PRF', 'the &#8220;Business Combination Merger', 'OPKO Health, Inc. (&', 'Sema4', 'Loan', 'CMLS Holdings', 'a Business Combination', 'costs$3,087&#160;$2,800&#160;$8,350&#160;$8,219&#160;On', 'Silicon Valley Bank', 'ERC', 'Restated Certificate of Incorporation of GeneDx Holdings Corp.8-K3.104/17/20233.4Third Certificate of Amendment', 'Company', 'Impairment LossThe', 'Legacy GeneDx', 'SVB', 'the Disputed Claims', 'GeneDx, Inc.', 'ASU', 'ISMMS', 'the Tranche A Loan', 'the Quarterly Report on Form 10-Q', 'ActivityThe Company', 'OpCo, Inc.', 'Perceptive Credit Holdings IV', 'September&#160;30,', 'the Maturity Date', 'Board of Directors', 'the Credit Agreement', 'the OPKO Transition Services Agreement', 'DevelopmentResearch', 'PlanOur', 'Pursuant', 'OPKO', 'the Sarbanes-Oxley Act', 'the DECD Loan Agreement', 'OPKO 2.4&#160;million', 'the Effectiveness of Internal ControlOur', 'Property', 'Milestone Payment', 'Payor', 'Icahn School of Medicine', 'the Milestone Payments as zero', 'this Quarterly Report', 'the SVB Agreement', 'the U.S. Food and Drug Administration', 'Letters of Credit', 'Restated Certificate of Incorporation of GeneDx Holdings Corp.8-K3.104/28/20233.5Amended and Restated Bylaws of GeneDx Holdings Corp.8-K3.201/09/202331.1Certification', 'the Acquisition Merger Agreement', 'PrepaymentPrior', 'DECD', 'Issuer Purchases of Equity', 'The DECD Loan Agreement', 'CT', 'ContentsResearch', 'the Business Combination', 'Equity Securities'}"
WINT,
WORX,"{'Yes &', '\\n    Commitment', 'FASB', 'WORX &#160', 'Consolidated Statements of Cash', 'warrants\\nto', 'The\\nwords &#', 'Clinical (&#8220;EMR&#8221', 'Consolidated Statements', 'this Quarterly Report on Form 10-Q.', 'respectively&#160;\\n    &', 'SCWorx Corp.', 'customer\\nis', 'activities:&#160;\\n    &', 'RackSpace', 'American Environmental', 'Credit and Other Risks\\n\\n&#160;\\n\\nFinancial', 'the Committee of Sponsoring Organizations of the Treadway Commission', 'SCWorx', 'the Private Securities Litigation Reform Act', 'information:&#160;\\n    &', 'Nasdaq Capital Market \\n&#160;\\n\\nIndicate', 'the customer.\\n\\n&#160;\\n\\nThe Company', 'compensation\\nis', 'Amazon', 'Ms.', 'PPP loan&#160;\\n    &', 'the Proposed Transaction', 'systems.\\nSCWorx&#8217;s', 'liabilities:&#160;\\n    &', 'AI', 'will\\nbe', 'Charge', 'SEC', 'Item Master File', 'Company', 'the Securities Exchange Act', 'quickly\\nand', 'credit&#160;\\n    &', 'warrants&#160;\\n    &', 'Data Normalization\\nand Professional Services', 'Bank of America', 'Total&#160;\\n', 'COVID-19', 'the American Arbitration Association', 'Consolidated Balance', 'compensation&#160;\\n    &', 'Condensed Consolidated Financial', '\\n    &', '\\n&#160;\\n\\nThe Company'}"
WVE,
XAIR,"{'L.P.', 'Delaware limited\\npartnership', 'AIT Therapeutics, Inc.', 'Dividend yield&#160;\\n    &', 'the Loan Agreement', 'Stanford School of Medicine\\nand', 'BA Ltd.', 'EQUITY', 'No &#9744;\\n\\n&#160;\\n\\nIndicate\\nby', 'ATM', '\\n    Maturity of Long-Term Loan', 'Truist Securities, Inc.', 'to\\nbe', 'The Loan Agreement', 'the Agreement,\\nthe &#8220;Loan', 'the Company (&#8220;BA', 'SITC', 'EU', 'UNO', 'FDA', 'Oppenheimer &amp;\\nCo, Inc. (', 'Avenue Venture Opportunities Fund', 'SECURITY', 'University', 'the Interactive Data File', 'NitricGen, Inc. (&#8220;NitricGen&#8221;)\\nto', 'NTM', 'the Suzy Yuan-Huey Hung Endowed Professor of Medical Oncology', 'the Beyond\\nCancer Scientific Advisory Board (&#8220;SAB&#8221', 'Loan', 'Empery Asset Master, Ltd.', 'Yissum Research Development Company', 'Lenders', 'Avenue', 'Hebrew University', 'Stanford School of Medicine,\\nand', 'Beyond Air', 'Avenue Venture Opportunities Fund II', 'ASD', 'Pulmonox', 'continued)\\n\\n&#160;\\n\\nThe\\nCompany', 'Cancer Cell International', 'Restricted', 'the &#8220;Settlement', 'SEC', 'NitricGen', 'the American College of Chest Physicians (&#8220;CHEST&#8221', 'NitricGen agreement&#160;\\n    &', 'Company', 'LungFit PH', 'the Securities Exchange Act', 'Beyond Cancer', 'the Hebrew', 'the NitricGen Agreement', '\\n\\n&#160;\\n\\nWarrants\\nto', 'the Stanford School of Medicine', 'Total&#160;\\n    &', 'Beyond Air, Inc.', 'Beyond Air Ltd.', 'the Sarbanes-Oxley Act', 'Purchase', 'Avenue Capital Management II', 'unrestricted\\ncash', 'the European Union', 'the U.S. Securities and Exchange Commission', '\\n    &', 'CE'}"
XBIO,"{'the Company&#8217;s\\nCo-Development Agreement with Pharmsynthez', 'platform,\\nPolyXen', 'ASU', 'the Agreement.\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'Scripps Research', 'Serum Institute', 'Capital Resources\\n\\n&#160;\\n\\nWe', 'Sublicense Agreement', 'disorders.\\n\\n&#160;\\n\\nWe', 'TSRI Technology', 'Volition.\\n\\n&#160;\\n\\nCatalent Pharma Solutions', 'met.\\n\\n&#160;\\n\\n&#160;\\n\\n&#160;\\n\\n\\n\\n\\n    &', 'the Bid Price Requirement', 'Related Party', 'the Listing Qualifications Department', 'Company', 'Pharmaceutical Co. Ltd.', 'Catalent', 'PolyXen', 'Pharmsynthez', 'Nasdaq', '\\n&#160;\\n\\nThe Company', 'the Nasdaq Stock Market (&#8220;Nasdaq&#8221'}"
XBIT,"{'Consolidated Statements of Operations', 'XBiotech Inc.', 'ASC', 'FASB', 'LLC', '\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t6,940\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t5,701\\n\\t\\t\\t&#xa0;\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tShareholders&#x2019', 'XBiotech Germany GmbH', 'March&#xa0;22', 'Finance', 'Management&#x2019;s Discussion and Analysis of Financial Condition', 'Shares\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\tCommon Stock and Additional Paid', 'ASC Topic 360', 'Long-Lived Assets \\n\\n&#xa0;\\n\\nThe Company', 'Principal Financial', 'Inline Extensive Business Reporting Language', 'Trust Company', 'statements.&#xa0;\\n\\n&#xa0;\\n\\n\\n\\n\\n6\\n\\n\\n\\n\\n\\n\\n&#xa0;\\n\\n\\n\\n\\n&#xa0;\\n\\n&#xa0;\\n\\nXBiotech Inc.', 'XBiotech USA, Inc.', 'the Condensed Consolidated Statements of Operations', 'Principal Executive', 'Consolidated Statements of Comprehensive Loss', 'Company', 'the Securities Exchange Act', 'Consolidated Balance Sheets\\n\\n(in', 'American Stock Transfer &amp', '2023\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tXBIOTECH INC.\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\n\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\tBy:\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t&#xa0;\\n\\t\\t\\t\\n\\t\\t\\t\\n\\t\\t\\t/S/', 'XBiotech', 'Results of Operations', 'ASC Topic', 'ASU No', 'Capital Resources'}"
XCUR,
XENE,
XERS,"{'API', 'LLC', 'Oxford', 'EMA', 'Financial Instruments', 'EEA', 'this Quarterly Report on Form 10-Q', 'EU', 'Dravet', 'the Public Company Accounting Oversight Board', 'Horizon', 'the United States Department of Health and Human Services', 'QSR', 'the ""Oxford Loan Agreement', 'SHL Pharma', 'the European Economic Area', 'ProductsOur', 'Credit LossesFor', 'XeriSol', 'Fair', 'FASB', 'Consolidated Statements of Cash Flow', 'Guarantor', 'Restated Certificate of Incorporation of the Registrant', 'Medicaid', 'Medicare', 'the Securities and Exchange Commission', 'GDPR', 'FDA', 'national data protection authority', 'the Oxford Loan Agreement', 'the Hatch-Waxman Act', '20298,268,258The Company', 'Risks Related', 'Silicon Valley Bank', 'The Hayfin Loan Agreement', 'Quarterly Report on Form 10-QPagePart I.', 'Company', 'the Hayfin Loan Agreement', 'USPTO', 'Hayfin Loan Agreement', 'CHI', 'FCA', 'Flows &', 'Consolidated Statements of Operations', 'Xeris Biopharma Holdings', 'UnrealizedGainsGross Unrealized LossesTotalFair', 'ASU', 'the European Commission', 'SBA', 'CMS', 'Congenital Hyperinsulinism', 'Hayfin Services LLP', 'Oxford Finance', 'Condensed Consolidated Financial Statements9Item 2', 'FCPA', 'Credit Agreement and Guaranty', 'PBH', 'NIPHS', 'PPP', 'Intellectual Property', 'Bachem Americas', 'Lenders', 'Xeris Pharmaceuticals, Inc.', 'Registrant', 'the Commercialization and Marketing', 'NDA', 'BylawsProvisions', 'ContentsXERIS BIOPHARMA HOLDINGS', 'Armistice', 'Recorlev', 'CMO', 'DOJ', 'the Sarbanes-Oxley Act', 'IPO', 'NotesIn', 'Keveyis, Recorlev', 'The Oxford Loan Agreement', 'Hamas', 'Warrant Shares', 'Form S-3', 'the Quality System Regulation', 'Consolidated Statements', 'FDA&#8217;s', 'Credit and Guaranty Agreement', 'T3', 'the ""Hayfin Loan Agreement', 'Medicaid Services', 'Oxford Loan Agreement', 'Market AcceptanceOur', 'Good Manufacturing Practice', 'Pyramid Laboratories Inc.', '340B', 'The Nasdaq Global Select Market', 'MarketingOur', 'Financial Instruments - Credit Losses', 'Hayfin Loan', 'LeasesThe Company', 'SEC', 'the United States', 'Gvoke', 'the Centers for Medicare &', 'Cushing\\', 'CRG', 'HypothyroidismThe', 'reference.70XERIS BIOPHARMA HOLDINGS', 'Avenue Capital'}"
XFOR,"{'Internal Control Over Financial ReportingThere', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)Stock OptionsThe', 'Hercules Capital Inc.', 'Security Agreement', 'TO CONDENSED CONSOLIDATED FINANCIAL', 'EstimatesOur', 'Lincoln Park', 'Georgetown University', 'Genzyme', 'X4 Pharmaceuticals', 'Accounting Standards Update', 'Lincoln Park Capital Fund LLC (&', 'the Securities Exchange Act', 'the &#8220;Conversion', 'the Q2 2023', 'COVID-19', 'Hercules Capital Funding IV', 'Company\\', 'Restricted Stock Units&#8212', 'the Wall Street Journal', 'HHS', 'the Amended Loan Agreement or &#9702;(ii', 'Contingencies', 'Trade Control Laws', 'Private Placement', 'Medicaid', 'Medicare', 'Level 3 inputs:(in', 'FDA', 'the Data Safety Monitoring Board', 'Risks Related', 'Trademark Office (&#8220;USPTO&#8221', 'Company', 'the Registrable Securities', 'LiquidityTo', 'USPTO', 'the Hercules Loan Agreement', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)Unaudited Interim', 'Condensed Consolidated Financial', 'DFCI', 'The Nasdaq Stock Market (&#8220;Nasdaq&#8221', 'the Delaware General Corporation Law', 'New Drug Application', 'TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited)The Company', 'FCPA', 'net&#8221', 'Hercules Capital Funding Trust', 'The Nasdaq Capital Market', 'The Hercules Loan Agreement', 'Second Amended and Restated Loan', 'Restated Certificate of Incorporation', 'Dana-Farber Cancer Institute (&', 'No.&#160;2014-15', 'the Sarbanes-Oxley Act', 'Hercules Loan Agreement', 'Investors', 'the Investors (the &#8220;Registrable', 'this Quarterly Report', 'Hercules Capital, Inc.', 'healthcare', 'Beth Israel Deaconess Medical Center', 'X4 Therapeutics, Inc.', 'ATM', 'the Court of Chancery of the State of Delaware', 'the U.S. Food and Drug Administration', 'Hercules Loan Agreement &', 'PHARMACEUTICALS', 'Dana-Farber Cancer Institute', 'the Performance Covenant', 'Austria) GmbH', 'Georgetown', 'United', 'Accounting Standards Codification', 'SEC', 'GCP', 'Risks Related to Ownership of Our Common', 'the European Union', 'Nasdaq'}"
XGN,
XLO,
XNCR,"{'ASC', 'LLC', 'MorphoSys AG', 'the Vir Agreement', 'Gilead Sciences, Inc.', 'the Securities and Exchange', 'ProceduresAs', 'XmAb306/RG6323', 'this Quarterly Report on Form 10-Q', 'XmAb', 'PartnersPlamotamab', 'a Patent License Agreement', 'Alexion Pharmaceuticals, Inc. (Alexion', 'the Zenas Agreement', 'the Omeros Agreement', 'Astellas Pharma Inc.', 'Xencor', 'the Securities Exchange Act', 'the XmAb 2+1', 'XBRL Instance Document &#8211', 'COVID-19', 'CollaborationsWe', 'ContentsIn', 'Viridian Therapeutics, Inc.', 'OCM Life Sciences Portfolio LP', '2022.Alexion Pharmaceuticals, Inc.', 'Company\\', 'Cytotoxic Fc and Xtend Fc', 'Cover Page Interactive Data File', 'INmune Bio, Inc.', 'Genentech, Inc.', 'the Securities and Exchange Commission', 'Congress', 'Restated Certificate of Incorporation of the Company', 'ContentsIn December', 'SVB Securities', 'ContentsComparison', 'FDA', 'the Janssen Agreement', 'ContentsThe', 'the Alexion Agreement', 'Research and License Agreement', 'Royalty Agreements', 'Company', 'Omeros Corporation', 'ContentsThe Company', 'CTA', 'the Genentech Agreement', 'Fc technologies', 'OperationsComparison', 'MorphoSys Agreement', 'the Second Zenas Agreement', 'the Balance Sheets', 'License Agreement', 'MorphoSys', 'the ""Ultomiris Agreement', 'Board of Directors', 'the Second Janssen Agreement', 'XmAb306/RG6323 programs*9.8&#160;11.9&#160;(2.1)XmAb56418.7&#160;11.3&#160;7.4&#160;XmAb662', 'Genentech', 'Fc', 'Leerink Partners', 'Gilead', 'the Roche Group', 'the ""Monjuvi Agreement', 'Exchange Act Rule 13a-15(b', 'ContentsGenentech, Inc.', 'General Counsel', 'Sublease Agreement', 'the Employment Agreement Addendums', 'the Second Vir Agreement', 'the European Society for Medical Oncology', 'the Interactive Data File', 'Vir Biotechnology, Inc.', 'The Second Janssen Agreement', 'ContentsOmeros CorporationIn', 'LicensesProduct', 'Alexion', 'LeasesThe Company', 'Xtend', 'SEC', 'ContentsResearch', 'Collaboration and License Agreement', 'the Gilead Agreement', '2022 Annual Report', 'INmune', 'March&#160;31', 'Principal Financial Officer.32.1Section 1350 Certification', 'Vir'}"
XOMA,"{'ASC', 'LLC', 'The Nasdaq Stock Market', 'StockOptionInducementAwardOneMember2023-01-032023-01-030000791908xoma', 'Milestone PaymentsThe Company', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2022', 'Rule&#160;12b-2', 'EMA', 'AffimedMemberxoma', 'March&#160;9', 'Kuros', 'Principal Executive Officer', 'AssignmentAndAssumptionAgreementMember2023-06-210000791908xoma', 'HCRP.R&amp;D Expenses', 'AldoxorubicinMemberxoma', 'AptevoMemberxoma', 'XOMA Ltd.', 'the Organon License Agreement', 'August&#160;24', 'the Second Bioasis RPA', 'AAA', 'LiabilitiesAccrued', '27)&#8203;&#8203', 'SeriesAPreferredStockMember2022-07-012022-09', 'Yes&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;Indicate', 'the Palo Licensed Products', 'Contentsagainst', 'the U.S. Foreign Corrupt Practices Act', 'LicenseAgreementMember2019-08-012019-08-310000791908xoma', 'NIR178', 'the Biosis RPA', 'Series A Preferred Stock', 'IL-1', 'ContentsArbitration Settlement CostsArbitration', 'to__________Commission File No.&#160;001-39801XOMA', 'the Series A Preferred Stock', 'CPRA', 'Prothena Biosciences Limited', 'SOX', 'Designation of Preferences, Rights and Limitations', 'CommonStockWarrantExercisePrice14.71Member2022', 'the Securities Exchange Act', 'NOL', 'Common Stock Certificate &', 'PreferredStockMember2022-12-310000791908us', 'the Rezolute License Agreement', 'ObsEva Sales Milestones', 'the Bioasis Contingent Consideration', 'Dyax Corp.', 'Second Bioasis RPA', 'Amendment of Certificate of Incorporation of XOMA Corporation8-K000-147103.105/31/2012&#160;3.3&#8203;Certificate', 'Correction of the Certificate of Designation', 'Series B Preferred Stock', 'RezoluteIncMember2023-07-012023-09-300000791908xoma', 'ObsevaMemberxoma', 'EURxoma', 'FASB', 'Pfizer', 'ProceduresWe', 'HHS', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-01-012017-12-310000791908xoma', 'Shire', 'StockOptionInducementAwardOneMember2023-01-012023-03-310000791908xoma', 'StockOptionInducementAwardOneMember2023-01-012023-09', 'StockOptionInducementAwardOneMember2023-01-012023-09-300000791908xoma:', 'the Bioasis RPA', 'the Kuros Sales Milestones', 'HCRP', 'Ended &', 'WarrantMember2022-01-012022-09', 'LadRx', 'SeriesAPreferredStockMember2022-12-310000791908us', 'Medicaid', 'Medicare', 'the Initial Period', 'the Securities and Exchange Commission', 'IP', 'ContentsSale of Future Revenue StreamsOn December&#160;21', 'Principal Financial', 'Chapter&#160;63 of Title 18', 'FDA', 'WarrantMember2022-07-012022-09', 'XOMA Corporation.&#8203;79\\nTable of ContentsITEM&#160;6.&#160;EXHIBITS&#8203;&#8203;&#8203;&#8203;Incorporation By ReferenceExhibitNumber&#160;&#160;&#160;&#160;Exhibit&#160;Description&#160;&#160;&#160;&#160;Form&#160;&#160;&#160;&#160;SEC', 'PreferredStockMember2022-09', 'ASC 450.The Company', 'Loan', 'the symbol &#8220;XOMA&#8220', 'Rezolute', 'ContentsThe', 'Merck KGaA', 'PreferredStockMember2022-03-310000791908us', 'Wyeth Pharmaceuticals', 'Risks Related', 'ImmunityBio', 'Royalties', 'TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023', 'LicenseAgreementMember2019-01-012019-12-310000791908xoma', 'Company', 'AdrMemberxoma', 'American Stock Transfer &amp', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma', 'Measurement of Credit Losses on Financial Instruments', 'Internal ControlThere', 'Janssen BiotechThe Company', 'Viracta', 'SVB', 'WarrantMember2023-01-012023-09-300000791908us-gaap', 'Rule&#160;13a-14(b', 'ASU', 'ContentsIn June 2023', 'the Affitech CPPA', 'WarrantMember2023-07-012023-09-300000791908us-gaap', 'ContentsMilestone paymentsAt', 'Contentsintangible', 'thousands):&#8203;&#8203;&#8203;&#8203;&#8203', 'ObsEva', 'LadRx Agreements', 'Bioasis', 'Merck', 'thereunder&#8203;8-K &#', 'SeriesAPreferredStockMember2022-10-262022-10-260000791908srt', 'Second Bioasis', 'XOMA Corporation', 'Bayer', 'this Quarterly Report on Form&#160;10-Q', 'the U.S. Internal Revenue Code', 'the Aronora RPA', 'Rule&#160;15d-14(a)&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;31.2+Certification of Chief Financial Officer', 'Second Bioasis RPA.In', 'THE SECURITIES EXCHANGE ACT', 'Trust Company', 'LitigationThe', 'B. Riley', 'Board of Directors', 'The Bioasis Contingent Consideration', 'CurrentEmployeesExcludingChiefExecutiveOfficerMember2022-11-012022-11-010000791908srt', 'the LadRx Agreements', 'Checkmate Pharmaceuticals', 'the Aptevo Contingent Consideration', 'Registrant', 'ArimoclomolMemberxoma', 'NDA', 'Equity SecuritiesThe Company', 'the Investment Company Act', 'FairValueMeasurementsRecurringMember2023', 'BurnsSenior', 'December&#160;31, 2015.The Company', 'the Aronora Contingent Consideration', 'the ObsEva Non-Sales Milestones', 'RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember2022-12-310000791908xoma', 'the American Arbitration Association/International Centre for Dispute Resolution', 'StockOptionInducementAwardOneMember2023-07-012023-09-300000791908xoma:', 'Financial Instruments-Credit Losses', 'Medexus', 'Aptevo the Company', 'the Merck KGaA License Agreement', 'the Board of Directors', 'XOMA', 'Finance', 'PreferredStockMember2022-06-300000791908us-gaap', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09', 'ContentsNet Loss Per Share Attributable', 'collected.&#160;The Company', 'SeriesBPreferredStockMember2022-01-012022-09', 'the Gevokizumab License Agreement', 'the Aronora Royalty Milestones', 'SeriesBPreferredStockMember2022-01-012022-12-310000791908us', 'SeriesAPreferredStockMember2022-01-012022-12-310000791908us', 'ContentsIntangible', 'the ObsEva IP Acquisition Agreement', 'Trade Control', 'SEC', 'LeasesThe Company', 'SeriesAPreferredStockMember2022-01-012022-09', 'ContentsUnder the Gevokizumab License Agreement', 'BLA', 'the IL-1 Target License Agreement', 'Novartis', 'follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; &#8203', 'the Budget Control Act', 'Antibody License Agreement', 'Page Interactive Data File', 'the Aptevo CPPA', 'HCW', 'Continuity Incentive', 'Principal Accounting Officer)&#8203;&#8203;&#8203;&#8203;82\\n\\n\\n\\n', 'LadrxMemberxoma', 'compensation&#8203;&#8203'}"
XOMAO,"{'ASC', 'LLC', 'The Nasdaq Stock Market', 'StockOptionInducementAwardOneMember2023-01-032023-01-030000791908xoma', 'Milestone PaymentsThe Company', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2022', 'Rule&#160;12b-2', 'EMA', 'AffimedMemberxoma', 'March&#160;9', 'Kuros', 'Principal Executive Officer', 'AssignmentAndAssumptionAgreementMember2023-06-210000791908xoma', 'HCRP.R&amp;D Expenses', 'AldoxorubicinMemberxoma', 'AptevoMemberxoma', 'XOMA Ltd.', 'the Organon License Agreement', 'August&#160;24', 'the Second Bioasis RPA', 'AAA', 'LiabilitiesAccrued', '27)&#8203;&#8203', 'SeriesAPreferredStockMember2022-07-012022-09', 'Yes&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;Indicate', 'the Palo Licensed Products', 'Contentsagainst', 'the U.S. Foreign Corrupt Practices Act', 'LicenseAgreementMember2019-08-012019-08-310000791908xoma', 'NIR178', 'the Biosis RPA', 'Series A Preferred Stock', 'IL-1', 'ContentsArbitration Settlement CostsArbitration', 'to__________Commission File No.&#160;001-39801XOMA', 'the Series A Preferred Stock', 'CPRA', 'Prothena Biosciences Limited', 'SOX', 'Designation of Preferences, Rights and Limitations', 'CommonStockWarrantExercisePrice14.71Member2022', 'the Securities Exchange Act', 'NOL', 'Common Stock Certificate &', 'PreferredStockMember2022-12-310000791908us', 'the Rezolute License Agreement', 'ObsEva Sales Milestones', 'the Bioasis Contingent Consideration', 'Dyax Corp.', 'Second Bioasis RPA', 'Amendment of Certificate of Incorporation of XOMA Corporation8-K000-147103.105/31/2012&#160;3.3&#8203;Certificate', 'Correction of the Certificate of Designation', 'Series B Preferred Stock', 'RezoluteIncMember2023-07-012023-09-300000791908xoma', 'ObsevaMemberxoma', 'EURxoma', 'FASB', 'Pfizer', 'ProceduresWe', 'HHS', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-01-012017-12-310000791908xoma', 'Shire', 'StockOptionInducementAwardOneMember2023-01-012023-03-310000791908xoma', 'StockOptionInducementAwardOneMember2023-01-012023-09', 'StockOptionInducementAwardOneMember2023-01-012023-09-300000791908xoma:', 'the Bioasis RPA', 'the Kuros Sales Milestones', 'HCRP', 'Ended &', 'WarrantMember2022-01-012022-09', 'LadRx', 'SeriesAPreferredStockMember2022-12-310000791908us', 'Medicaid', 'Medicare', 'the Initial Period', 'the Securities and Exchange Commission', 'IP', 'ContentsSale of Future Revenue StreamsOn December&#160;21', 'Principal Financial', 'Chapter&#160;63 of Title 18', 'FDA', 'WarrantMember2022-07-012022-09', 'XOMA Corporation.&#8203;79\\nTable of ContentsITEM&#160;6.&#160;EXHIBITS&#8203;&#8203;&#8203;&#8203;Incorporation By ReferenceExhibitNumber&#160;&#160;&#160;&#160;Exhibit&#160;Description&#160;&#160;&#160;&#160;Form&#160;&#160;&#160;&#160;SEC', 'PreferredStockMember2022-09', 'ASC 450.The Company', 'Loan', 'the symbol &#8220;XOMA&#8220', 'Rezolute', 'ContentsThe', 'Merck KGaA', 'PreferredStockMember2022-03-310000791908us', 'Wyeth Pharmaceuticals', 'Risks Related', 'ImmunityBio', 'Royalties', 'TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023', 'LicenseAgreementMember2019-01-012019-12-310000791908xoma', 'Company', 'AdrMemberxoma', 'American Stock Transfer &amp', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma', 'Measurement of Credit Losses on Financial Instruments', 'Internal ControlThere', 'Janssen BiotechThe Company', 'Viracta', 'SVB', 'WarrantMember2023-01-012023-09-300000791908us-gaap', 'Rule&#160;13a-14(b', 'ASU', 'ContentsIn June 2023', 'the Affitech CPPA', 'WarrantMember2023-07-012023-09-300000791908us-gaap', 'ContentsMilestone paymentsAt', 'Contentsintangible', 'thousands):&#8203;&#8203;&#8203;&#8203;&#8203', 'ObsEva', 'LadRx Agreements', 'Bioasis', 'Merck', 'thereunder&#8203;8-K &#', 'SeriesAPreferredStockMember2022-10-262022-10-260000791908srt', 'Second Bioasis', 'XOMA Corporation', 'Bayer', 'this Quarterly Report on Form&#160;10-Q', 'the U.S. Internal Revenue Code', 'the Aronora RPA', 'Rule&#160;15d-14(a)&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;31.2+Certification of Chief Financial Officer', 'Second Bioasis RPA.In', 'THE SECURITIES EXCHANGE ACT', 'Trust Company', 'LitigationThe', 'B. Riley', 'Board of Directors', 'The Bioasis Contingent Consideration', 'CurrentEmployeesExcludingChiefExecutiveOfficerMember2022-11-012022-11-010000791908srt', 'the LadRx Agreements', 'Checkmate Pharmaceuticals', 'the Aptevo Contingent Consideration', 'Registrant', 'ArimoclomolMemberxoma', 'NDA', 'Equity SecuritiesThe Company', 'the Investment Company Act', 'FairValueMeasurementsRecurringMember2023', 'BurnsSenior', 'December&#160;31, 2015.The Company', 'the Aronora Contingent Consideration', 'the ObsEva Non-Sales Milestones', 'RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember2022-12-310000791908xoma', 'the American Arbitration Association/International Centre for Dispute Resolution', 'StockOptionInducementAwardOneMember2023-07-012023-09-300000791908xoma:', 'Financial Instruments-Credit Losses', 'Medexus', 'Aptevo the Company', 'the Merck KGaA License Agreement', 'the Board of Directors', 'XOMA', 'Finance', 'PreferredStockMember2022-06-300000791908us-gaap', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09', 'ContentsNet Loss Per Share Attributable', 'collected.&#160;The Company', 'SeriesBPreferredStockMember2022-01-012022-09', 'the Gevokizumab License Agreement', 'the Aronora Royalty Milestones', 'SeriesBPreferredStockMember2022-01-012022-12-310000791908us', 'SeriesAPreferredStockMember2022-01-012022-12-310000791908us', 'ContentsIntangible', 'the ObsEva IP Acquisition Agreement', 'Trade Control', 'SEC', 'LeasesThe Company', 'SeriesAPreferredStockMember2022-01-012022-09', 'ContentsUnder the Gevokizumab License Agreement', 'BLA', 'the IL-1 Target License Agreement', 'Novartis', 'follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; &#8203', 'the Budget Control Act', 'Antibody License Agreement', 'Page Interactive Data File', 'the Aptevo CPPA', 'HCW', 'Continuity Incentive', 'Principal Accounting Officer)&#8203;&#8203;&#8203;&#8203;82\\n\\n\\n\\n', 'LadrxMemberxoma', 'compensation&#8203;&#8203'}"
XOMAP,"{'ASC', 'LLC', 'The Nasdaq Stock Market', 'StockOptionInducementAwardOneMember2023-01-032023-01-030000791908xoma', 'Milestone PaymentsThe Company', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2022', 'Rule&#160;12b-2', 'EMA', 'AffimedMemberxoma', 'March&#160;9', 'Kuros', 'Principal Executive Officer', 'AssignmentAndAssumptionAgreementMember2023-06-210000791908xoma', 'HCRP.R&amp;D Expenses', 'AldoxorubicinMemberxoma', 'AptevoMemberxoma', 'XOMA Ltd.', 'the Organon License Agreement', 'August&#160;24', 'the Second Bioasis RPA', 'AAA', 'LiabilitiesAccrued', '27)&#8203;&#8203', 'SeriesAPreferredStockMember2022-07-012022-09', 'Yes&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;Indicate', 'the Palo Licensed Products', 'Contentsagainst', 'the U.S. Foreign Corrupt Practices Act', 'LicenseAgreementMember2019-08-012019-08-310000791908xoma', 'NIR178', 'the Biosis RPA', 'Series A Preferred Stock', 'IL-1', 'ContentsArbitration Settlement CostsArbitration', 'to__________Commission File No.&#160;001-39801XOMA', 'the Series A Preferred Stock', 'CPRA', 'Prothena Biosciences Limited', 'SOX', 'Designation of Preferences, Rights and Limitations', 'CommonStockWarrantExercisePrice14.71Member2022', 'the Securities Exchange Act', 'NOL', 'Common Stock Certificate &', 'PreferredStockMember2022-12-310000791908us', 'the Rezolute License Agreement', 'ObsEva Sales Milestones', 'the Bioasis Contingent Consideration', 'Dyax Corp.', 'Second Bioasis RPA', 'Amendment of Certificate of Incorporation of XOMA Corporation8-K000-147103.105/31/2012&#160;3.3&#8203;Certificate', 'Correction of the Certificate of Designation', 'Series B Preferred Stock', 'RezoluteIncMember2023-07-012023-09-300000791908xoma', 'ObsevaMemberxoma', 'EURxoma', 'FASB', 'Pfizer', 'ProceduresWe', 'HHS', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-01-012017-12-310000791908xoma', 'Shire', 'StockOptionInducementAwardOneMember2023-01-012023-03-310000791908xoma', 'StockOptionInducementAwardOneMember2023-01-012023-09', 'StockOptionInducementAwardOneMember2023-01-012023-09-300000791908xoma:', 'the Bioasis RPA', 'the Kuros Sales Milestones', 'HCRP', 'Ended &', 'WarrantMember2022-01-012022-09', 'LadRx', 'SeriesAPreferredStockMember2022-12-310000791908us', 'Medicaid', 'Medicare', 'the Initial Period', 'the Securities and Exchange Commission', 'IP', 'ContentsSale of Future Revenue StreamsOn December&#160;21', 'Principal Financial', 'Chapter&#160;63 of Title 18', 'FDA', 'WarrantMember2022-07-012022-09', 'XOMA Corporation.&#8203;79\\nTable of ContentsITEM&#160;6.&#160;EXHIBITS&#8203;&#8203;&#8203;&#8203;Incorporation By ReferenceExhibitNumber&#160;&#160;&#160;&#160;Exhibit&#160;Description&#160;&#160;&#160;&#160;Form&#160;&#160;&#160;&#160;SEC', 'PreferredStockMember2022-09', 'ASC 450.The Company', 'Loan', 'the symbol &#8220;XOMA&#8220', 'Rezolute', 'ContentsThe', 'Merck KGaA', 'PreferredStockMember2022-03-310000791908us', 'Wyeth Pharmaceuticals', 'Risks Related', 'ImmunityBio', 'Royalties', 'TwoThousandTenLongTermIncentiveAndStockAwardPlanMember2023', 'LicenseAgreementMember2019-01-012019-12-310000791908xoma', 'Company', 'AdrMemberxoma', 'American Stock Transfer &amp', 'Xoma052LicenseAgreementAndIL1TargetLicenseAgreementMember2017-08-242017-08-240000791908xoma', 'Measurement of Credit Losses on Financial Instruments', 'Internal ControlThere', 'Janssen BiotechThe Company', 'Viracta', 'SVB', 'WarrantMember2023-01-012023-09-300000791908us-gaap', 'Rule&#160;13a-14(b', 'ASU', 'ContentsIn June 2023', 'the Affitech CPPA', 'WarrantMember2023-07-012023-09-300000791908us-gaap', 'ContentsMilestone paymentsAt', 'Contentsintangible', 'thousands):&#8203;&#8203;&#8203;&#8203;&#8203', 'ObsEva', 'LadRx Agreements', 'Bioasis', 'Merck', 'thereunder&#8203;8-K &#', 'SeriesAPreferredStockMember2022-10-262022-10-260000791908srt', 'Second Bioasis', 'XOMA Corporation', 'Bayer', 'this Quarterly Report on Form&#160;10-Q', 'the U.S. Internal Revenue Code', 'the Aronora RPA', 'Rule&#160;15d-14(a)&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;31.2+Certification of Chief Financial Officer', 'Second Bioasis RPA.In', 'THE SECURITIES EXCHANGE ACT', 'Trust Company', 'LitigationThe', 'B. Riley', 'Board of Directors', 'The Bioasis Contingent Consideration', 'CurrentEmployeesExcludingChiefExecutiveOfficerMember2022-11-012022-11-010000791908srt', 'the LadRx Agreements', 'Checkmate Pharmaceuticals', 'the Aptevo Contingent Consideration', 'Registrant', 'ArimoclomolMemberxoma', 'NDA', 'Equity SecuritiesThe Company', 'the Investment Company Act', 'FairValueMeasurementsRecurringMember2023', 'BurnsSenior', 'December&#160;31, 2015.The Company', 'the Aronora Contingent Consideration', 'the ObsEva Non-Sales Milestones', 'RoyaltyPurchaseAgreementAndSecondRoyaltyPurchaseAgreementMember2022-12-310000791908xoma', 'the American Arbitration Association/International Centre for Dispute Resolution', 'StockOptionInducementAwardOneMember2023-07-012023-09-300000791908xoma:', 'Financial Instruments-Credit Losses', 'Medexus', 'Aptevo the Company', 'the Merck KGaA License Agreement', 'the Board of Directors', 'XOMA', 'Finance', 'PreferredStockMember2022-06-300000791908us-gaap', 'GeneralAndAdministrativeExpenseMember2022-01-012022-09', 'ContentsNet Loss Per Share Attributable', 'collected.&#160;The Company', 'SeriesBPreferredStockMember2022-01-012022-09', 'the Gevokizumab License Agreement', 'the Aronora Royalty Milestones', 'SeriesBPreferredStockMember2022-01-012022-12-310000791908us', 'SeriesAPreferredStockMember2022-01-012022-12-310000791908us', 'ContentsIntangible', 'the ObsEva IP Acquisition Agreement', 'Trade Control', 'SEC', 'LeasesThe Company', 'SeriesAPreferredStockMember2022-01-012022-09', 'ContentsUnder the Gevokizumab License Agreement', 'BLA', 'the IL-1 Target License Agreement', 'Novartis', 'follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203; &#8203', 'the Budget Control Act', 'Antibody License Agreement', 'Page Interactive Data File', 'the Aptevo CPPA', 'HCW', 'Continuity Incentive', 'Principal Accounting Officer)&#8203;&#8203;&#8203;&#8203;82\\n\\n\\n\\n', 'LadrxMemberxoma', 'compensation&#8203;&#8203'}"
XRAY,"{'ASC', 'the Equipment &', 'Company\\', 'FASB', 'losses(4,080)&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;&#8212;&#160;(4,080)Goodwill', 'the Consolidated Statements of Cash Flows', 'EquipmentConsumablesConnected Technology SolutionsEssential Dental SolutionsOrthodontic', 'SPA', 'SegmentConnected Technology SolutionsNet', 'Sirona Dental Systems', 'Code of Ethics and Business Conduct.b', 'Internal Control Over Financial ReportingAs', 'CAD', 'ASU No', 'netInterest', 'Essential Dental Solutions', 'OPERATIONS', 'Financial Instruments', 'Unaudited Consolidated Financial Statements', 'platform.19Orthodontics The Orthodontics', 'Digital Dental Group and Equipment &', 'the ""Amended Complaint', 'Wellspect Healthcare', 'the Interactive Data File', 'CAM', 'Connected Technology Solutions', 'the Results of Operations', 'Prosthetics', 'Business and Basis of Presentation', 'Change% ChangeNet', 'SalesThe Company', 'RegionUnited StatesNet', 'Technologies &', 'c.The Company', 'Change% ChangeInterest', 'pronouncements.61Item 3 &#8211', 'HealthcareThe', 'SureSmile', 'HealthcareNet', 'the Connected Technology Solutions and Orthodontic and Implant Solutions', 'Sirona Dental Systems, Inc.', 'the Unaudited Consolidated Financial Statements', 'Regulation S-K.', 'goodwill$(1,831)$(870)$293&#160;$835&#160;$1,303&#160;$270&#160;$&#8212;&#160;Translation&#8212;&#160;&#8212;&#160;&#8212;&#160;1&#160;(5)6&#160;2&#160;Goodwill', 'DENTSPLY SIRONA Inc./s/Simon D. CampionNovember 2', 'Yes&#160;&#160;x &#160;No&#160;&#9744;Indicate', 'the Orthodontic and Implant Solutions', 'Company', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'Orthodontics', 'Swiss franc foreign exchange', 'Instruments', 'XRAY.Material Weaknesses', 'Change% ChangeNet sales$276&#160;$286&#160;$(10)(3.8&#160;%)Foreign exchange', 'PerformanceThe', 'MHT S.p.A.', 'Technology &', 'ExhibitsExhibit', 'the Connected Technology Solutions', 'Page Interactive Data File', 'Adopted Accounting', 'Change% ChangeNet sales$212&#160;$208&#160;$4&#160;2.3&#160;%Foreign exchange', 'millions)Technologies &', 'Nasdaq', 'Prosthetics The Implants &', 'Implants &', 'DI', 'Connected Technology', 'Byte', 'the ASR Agreement'}"
XRTX,
XTLB,
XWEL,
YI,
YMAB,"{'ASC', 'Y-mAbs Sublicense Agreement', 'ContentsSummary', 'API', 'candidates;&#9679;a', 'inventors;&#9679;we', 'Bosnia &', 'Swixx BioPharma AG', 'Contractual Obligations', 'EMA', 'Adium', 'NMPA', 'Swixx Biopharma AG', 'ExhibitsThe', 'this Quarterly Report on Form 10-Q', 'EU', 'MabVax/MSK Agreement', 'United Therapeutics Corporation', 'DisAssembly-Bispecific DOTA-Engaging', 'Lease Agreement', 'ContentsProduct Revenue', 'the Consolidated Balance Sheets', 'SADA', 'PIPL', 'the Financial Accounting Standards Board', 'the Securities Exchange Act', 'institute a &#8220;poison', 'Contentspursue', 'CNS', 'the Congress of the FDA&#8217;s', 'COVID-19', 'Advisory Committee Meeting', 'ContentsCurrent', 'the Sponsored Research Agreements', 'ContentsIn', 'Contentsproduct', 'Takeda Pharmaceutical Company Limited', 'ContentsIn April 2022', 'FASB', 'MabVax Therapeutics, Inc.', 'DANYELZA', 'the Settlement and Assumption', 'HHS', 'the Consolidated Statements of Cash Flows', 'control;&#9679;we', '4,125&#8203;&#8203; &#8212;&#8203;&#8203', 'the U.S. Congress', '82,964Total&#8203;$ &', 'Level 3.Operating Lease', 'MIT', 'the Department of Justice', 'Restated Certificate of Incorporation of the Registrant', 'FDCA', 'SADA License', 'WEP Clinical Ltd.', 'Medicaid', 'Medicare', 'Form S-8', 'the Securities and Exchange Commission', 'SciClone Pharmaceuticals International&#160;Ltd', 'BeiGene Ltd.', 'Y-mAbs Sublicense', 'FDA BLA Dossier', 'SciClone', 'Principal Financial', 'ContentsThe FDA', 'FDA', 'Adium Pharma S.A. (&#8220;Adium&#8221', 'Cash EquivalentsThe Company', 'Biologics License', 'ContentsThe', 'ContentsOmburtamab BLA', 'REMS', 'the MabVax Agreement', 'the United States;&#9679;the', 'Anti-Money Laundering Program', 'Company', 'the State of Israel', 'Investigator-Sponsored Master Clinical Trial Agreement', 'MSK License Agreements', 'SciClone Pharmaceuticals International Ltd.', 'Non-EmployeesIn', 'NB', 'MSK License', 'Contentsformer', 'Related CommitmentsThe Company', 'the European Commission', 'the MabVax Sublicense', 'ODD', 'the SADA Technology', 'MabVax Therapeutics Holdings', 'EUSA', '86,965Total&#8203;$ &#', 'SADA Technology License Agreement', 'Adium Pharma S.A.', 'FCPA', 'Success', 'License Agreement', 'follows:&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#8203;&#160;&#160;&#160;&#160;&#8203;&#8203;Contractual &', 'SciClone International Pharmaceuticals Ltd.', 'Core Facility Service Agreements', 'MCTA', 'SADA-BiDE', 'License', 'the China National Medical Products Administration', 'Registrant', 'Memorial Sloan Kettering Cancer Center', 'ContentsDANYELZA', 'NDA', 'funds&#8203;$ &#8212;&#8203;$', 'Orphan Drug Designation', 'ContentsOur', 'DOJ', 'BeiGene', 'MabVax', 'United Therapeutics', 'SADA License Agreement', '82,964&#8203;$ &', 'the Paris Agreement', 'Hamas', 'EVP', 'Administrative', 'the SADA License Agreement', 'Master Data Services Agreement', 'the State of Delaware', 'the Federal Food, Drug and Cosmetic Act', 'MAA', 'the Bank Secrecy Act', 'CNS/LM', 'WEP', 'the Takeda Licensing Agreement', 'Contentsconflict', 'United', 'Self-Assembly', 'SEC', 'BLA', 'the General Corporation Law', 'funds&#8203;$ &#8212;&#8203;$86,965&#8203;$ &', 'MSK', 'Operating Lease LiabilitiesThe Company', 'the Massachusetts Institute of Technology', 'the MSK License', 'national and/or international', 'the MSK License Agreement', 'The Securities and Exchange Commission', 'the European Union', ': &#9679;differing', 'ContentsItem&#160;3'}"
YS,
ZCMD,
ZIMV,"{'Credit Agreement', 'treasury', 'Consolidated Financial Statements,&#34', 'Interest Rate Risk\\n  &#', 'the Transition Services Agreement', 'Israeli Shekels', 'healthcare', 'x201c;Risk', 'Internal Control', 'goods\\n        &', 'The Separation Agreement', 'the Employee Matters Agreement', 'Dental', 'European Union', 'x2014;\\n        &', 'Financial Reporting\\n  &', 'the U.S. Food and Drug Administration', 'Procedures\\n  &', 'general &amp', '\\n  &#', 'the Term Loan', 'the Credit Agreement', 'the Internal Revenue Service', 'JP Morgan Chase Bank', 'the &#x201c;Credit', 'NPI', 'recur.\\n  &', 'New Taiwan Dollars', 'the Tax Matters Agreement', 'SEC', 'the Securities Exchange Act', 'Research', 'COVID-19', 'Zimmer Biomet', 'reporting.\\n', 'flows.\\n  &'}"
ZJYL,
ZLAB,
ZNTL,"{'ASC', 'OverviewWe', 'Physician Payments Sunshine Act', 'BRAF', 'the Collaboration and License Agreements with', 'Kalyra Pharmaceuticals', 'EEA', 'the &#8220;Share Purchase', 'EU', 'Recurium IP', 'The Recurium Agreement', 'K-Group Alpha, Inc.', 'COVID-19', 'the Board of Directors of Zentera', 'Fair', 'PLD', 'Pfizer', 'Anti-Kickback Statute', 'HHS', 'ZMI', 'Recurium IP Holdings', 'Medicaid', 'Medicare', 'the U.S. Department of Justice', 'GSK\\', 'the Recurium Agreement', 'GDPR', 'Refractory Light Chain Amyloidosis', ': &', 'FDA', 'interest&#160;(12)(99)87&#160;Net', 'Recurium', 'Zeno Management, Inc. (&', 'Risks Related', 'REMS', 'the UK International Data Transfer Agreement', 'UncertaintiesEffect if Actual Results Differ', 'the Resignation Effective Date', 'Company', 'USPTO', 'Organization and BusinessOrganizationZentalis Pharmaceuticals, Inc. (&#8220;Zentalis,&#8221', ': &#8226;our', 'Results of Operations', 'LiquiditySubstantial', 'AE', 'GlaxoSmithKline Clinical Trial Collaboration and Supply Agreement', 'the &#8220;Recurium', 'USC', 'Strategic CollaborationsRecurium IP Holdings', 'CMS', 'ValueDue', 'New Drug Application', 'UK Data Protection Act 2018', 'FCPA', 'the U.S. Department of Health and Human Services', ': &#', 'Pfizer Development Agreement', 'Taxes', 'Ex-U.S.', 'the Children&#8217;s Health Insurance Program', 'NDA', 'IRA', 'ZN-d5', 'LLC (&#8220;Recurium IP&#8221;)', 'ATM ProgramIn', 'Leerink Partners', 'PGR', 'the Resignation Effective Date through March 31', 'this Quarterly Report', 'ATM', 'Recurium Agreement', 'IPR&amp;D', 'the Zentera Collaboration Products', 'CTR', 'K-Group Beta, Inc.', 'Medicaid Services', 'Equity Method InvestmentThe', 'Research and Development', 'SEC', 'GCP', 'Critical Accounting Estimates', 'GSK', 'the European Union', 'Nasdaq', 'Development Expenses Research', 'Zeno Pharmaceuticals, Inc.'}"
ZTEK,
ZURA,"{'ASC', 'ContentsShare', 'LLC', 'the Business Combination Agreement', 'the New York Stock Exchange', 'the Public Warrants', 'this Quarterly Report on Form 10-Q', 'THE SECURITIES EXCHANGE ACT OF 1934 &', 'Life Sciences/Biotech', 'Lilly', 'Zura Bio Limited', 'the Public Company Accounting Oversight Board', 'RightsThe', 'March&#160;20', 'Principal Executive Officer Pursuant', 'PWERM', 'van Amstel', 'MaximumMemberzura', 'PrivatePlacementMember2023-01-012023-09-300001855644us-gaap', 'Zb17LlcMember2023-04-260001855644zura', 'the &#8220;Business Combination Agreement&#8221;)', 'Zura', 'Financial Information', 'Compensation ExpenseShare', 'the Securities Exchange Act', 'JATT Merger Sub', 'JATT', 'the &quot;Cell Line License Agreement&quot;)', 'Incentive PlanShare OptionsThe', 'L.P. (the &#8220;Sponsor&#8221', 'Principal Financial Officer Pursuant', 'No &#', 'ContentsIn', 'Z33 Bio Inc.', 'the Lonza License', 'Amended Forward Purchase Agreement', 'Products', 'costs&#8203;&#160;&#8212;&#8203;&#160', 'the 2022 Lilly License', 'Pfizer', 'ProceduresWe', 'WuXi Biologics LicenseIn', 'Adopted Pursuant to Section 906', 'the Pfizer Agreement', 'Private Placement', 'the Business Combination, Holdco', 'Series&#160;A-1 Subscription and Shareholder&#8217;s Agreement', 'Zb17LlcMember2023-04-262023-04-260001855644zura', 'Severance Agreement', 'WarrantMember2023-01-012023-09-300001855644us-gaap', 'PIPE', 'Organization and Description of Business', 'Lonza Sales AG', 'WuXi Biologics', 'the Forward Purchase Agreement', 'the &#8220;Cell Line License', 'Principal Executive Officer Pursuant to Rules', 'Zura Bio Holdings Ltd.', 'Company', 'Lilly LicenseOn', 'Adopted Pursuant to Section 302', 'CombinationOn', 'Results of Operations', 'this Quarterly Report on Form 10-Q:&#8203;ExhibitNumber&#160;&#160;&#160;&#160;Description31.1*&#8203;Certification', 'the Series Seed Preferred Shares', 'THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM &', 'DirectorTo', '2023&#8203;$ &#8212;&#8203;The Company', 'The Pfizer Agreement', 'RestrictedStockUnitsRSUMember2023-01-012023-09-300001855644us-gaap', 'the PIPE Subscription Agreements', 'The WuXi Biologics MSA', 'Z33SeriesSeedPreferredSharesMember2023-04-242023-04-240001855644zura', 'Board of Directors', 'JATT Ventures', 'The Pre-Funded Warrants', 'Registrant', 'PrivatePlacementMember2023-01-012023-09-300001855644zura', 'Lilly License', 'COO', 'the Sarbanes-Oxley Act', 'Stone Peach', 'the 2023 Lilly License', 'Zura&#8217;s', 'Contents5.Accounts Payable', 'CompensationIn', 'Stone Peach Properties', 'Z33SeriesSeedPreferredSharesMember2022-12-310001855644zura', 'EquityIncentivePlan2023Member2022-01-012022-12-310001855644zura', 'BAFF (&#8220;ZB-106&#8221;) in exchange', 'Pre-Funded Warrants', 'Yes &#160;&#9746', 'InvestmentConcurrently', 'expenses&#8203;&#8203', 'Share', 'Affiliates', 'SEC', '12.8%PIPE', 'ContentsResearch', 'the Business Combination', '30,&#8203;&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022&#160;&#160;&#160;&#160;2023&#160;&#160;&#160;&#160;2022Research and development&#8203;$ &#8212;&#8203;$ &', 'Equity Securities', 'Nasdaq'}"
ZVRA,
ZVSA,"{'the Company of $351,579', 'LLC', 'ZyVersa Therapeutics', 'effectively.\\n\\n&#160;\\n\\nChanges\\nin Internal Control', 'Black Scholes', 'performance.\\n\\n&#160;\\n\\nNote\\n4 &#8211', 'covered\\nthe Private Investment in Public Equity', 'The Nasdaq Stock Market', 'the Business Combination Agreement', 'Outstanding&#160;&#160;\\n    &', 'Ended &', 'Larkspur (&', 'the Business Combination with ZyVersa Therapeutics, Inc.', 'LLC (&#8220;Nasdaq&#8221;)\\nindicating', 'Principal Executive Officer', 'Information Related', 'the Securities and Exchange Commission', 'Business Combination', 'Notice', 'ZyVersa Therapeutics, Inc.', 'liability.\\n\\n&#160;\\n\\nNote\\n8 &#8211', 'the First Milestone Payment', 'this Quarterly Report on Form 10-Q', 'Predecessor&#160;&#160;\\n    &', 'Securities Excluded from Calculation of Diluted Net Loss Per', 'controls\\nare', 'the &#8220;Operating\\nCompany&#8221', 'Nine &#', 'Financial Condition', 'the PIPE Warrants', 'Series A Convertible Preferred Stock', 'Note 1 &#8211', 'Nasdaq Listing Rule', 'Goodwill', 'SEC', 'Administrative Expenses\\n\\n&#160;\\n\\nGeneral\\nand', 'Successor', 'Business Organization,\\nNature of Operations and Basis of Presentation', 'In-Process Research', 'the Operating Company', 'Company', 'Fair Value of Stock Warrants', 'sublicensable\\nlicense', 'prepared\\nin', 'the Business Combination', 'the New Parent', 'Variant Pharmaceuticals, Inc.', 'Successor options&#160;\\n    &', 'Amendment and Restatement Agreement', 'Results of Operations', 'the &#8220;PIPE Subscription Agreements&#8221;)', 'Series A Convertible Preferred Stock\\n(the &#8220;PIPE Shares&#8221', 'the Listing Qualifications Staff', 'ZyVersa Therapeutics Operating', 'Nasdaq', ': &#9746', '\\n    &', 'Expenses\\n\\n&#160;\\n\\nGeneral\\nand'}"
ZYME,"{'CollaborationsOur', 'ContentsSpecifically', 'the &#8220;Restated and Amended Transaction', 'The Budget Control Act', 'EMA', 'BTC', 'Zymeworks CallCo ULC', 'the Scientific Research', 'EEA', 'ExchangeCo', 'this Quarterly Report on Form 10-Q', 'Post-Arrangement Transactions', 'EU', 'IND', 'FlowsThe', 'the Collaboration and Cross License Agreement', 'ContentsWe', 'Zymeworks Zanidatamab Inc.', 'The Nasdaq Stock Market LLC', 'the U.S. Congress of the FDA&#8217;s', 'HSR Clearance', 'HERIZON', 'Operations', 'Exchangeable Shares', 'COVID-19', 'HCC', 'ZBI', 'Amendment of BeiGene License and Collaboration Agreement Regarding Zanidatamab', 'the Annual Report on Form 10-K.As', 'the Transfer Agreement', 'ContentsCompany', 'LiquiditySince', 'Medicaid', 'Medicare', 'Congress', 'FDA', 'EFECT', 'CallCo', 'HIPAA', 'Common Stock', 'Company', 'LEO Pharma A/S (&#8220;LEO&#8221;)', 'Zymeworks ExchangeCo Ltd.', 'USPTO', 'Jazz Pharmaceuticals, Inc. (&', 'the California Privacy Rights Act', 'the Health Insurance Portability', 'the California Consumer Privacy Act', 'the License and Collaboration Agreement', 'Azymetric', 'the FDA&#8217;s Oncology Center of Excellence', 'the Office for Civil Rights of the U.S. Department of Health and Human Services', 'BMS', 'this Quarterly Report on Form 10-Q.', 'Zymeworks BC', 'Recent Accounting PronouncementsRecent', 'Termination of BeiGene License and Collaboration Agreement Regarding', 'LEO', 'Zymeworks BC Inc.', 'The General Data Protection Regulation', 'License', 'IRB', 'Fab', 'the Research and License Agreement', 'Orphan Drug Designation', 'the Final Omnibus Rule', 'BeiGene License and Collaboration Agreement Regarding Zanidatamab ZovodotinOn', 'BeiGene', 'Jazz Collaboration Agreement', 'ContentsOperating', 'IPO', 'the Redomicile Transactions', 'Jazz, BeiGene', 'the U.S. Patent and Trademark Office (&#8220;USPTO&#8221', 'this Quarterly Report on Form 10-Q to &#', 'the Canada Business Corporations Act', 'Jazz Inc.', 'California Privacy Protection Agency', 'Termination and License Agreement', 'FDA&#8217;s', 'the Termination and License Agreement', 'HITECH', 'New Plan and Inducement PlanOn April&#160;10', 'Experimental Development (&', 'Daiichi Sankyo', 'Janssen, Iconic, Merck', 'SEC', 'Zymeworks Inc.', 'BLA', 'Computershare Trust Company of Canada', 'the Share Trustee', '30,2023202220232022Jazz Pharmaceuticals Ireland Limited', 'June&#160;16', 'the Company, Zymeworks Biopharmaceuticals Inc.', 'the Health Information Technology for Economic and Clinical Health Act', 'GSK', 'GPC3', 'the European Union', 'ContentsThird', 'the Transfer Agreement, Jazz'}"
ZYXI,
